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As one class of the most important steroid hormones, glucocorticoids have long been 
recognised and their therapeutic benefits have been widely used in clinical treatment, 
especially in anti-inflammation cases. Glucocorticoids regulate various processes 
in the body including the mobilization of energy stores, immune functions, gene 
expression, and maintenance of the homeostasis as well as the stress response, this is 
not surprising that the concept of “glucocorticoids” is mentioned in almost all medical 
text books that focus on specific organs or systems such as the cardiovascular system, 
the immune system, and the neuroendocrine system. The book of Glucocorticoids - 
New Recognition of Our Familiar Friend aims to introduce the latest findings relating 
to glucocorticoids, either freshly from the laboratory or from clinical case studies, and 
to open up a new angle of looking at the issue of balancing the therapeutic benefits and 
side effects brought up by glucocorticoids.
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Preface 
Unlike many other laborious professional names and terms that are used by scientists 
in the academic world, the word “glucocorticoids” is not that unfamiliar to the general
public. The clinical use of glucocorticoids is widely covering treatment for various 
diseases, ranging from as common as an inhaled asthma spray to after-surgery anti-
inflammation treatment. The most commonly mentioned roles of glucocorticoids are 
their metabolism-mediating and anti-inflammatory effects, meanwhile the occurrence 
of side effects and resistance during glucocorticoid treatment is not ignorable. 
However, the therapeutic effects of glucocorticoids in many diseases have yet been 
replaced by any other compounds, which has made this type of steroids still unique.
How much do we really understand about glucocorticoids? Have we thoroughly 
unveiled the curtain behind the effects of glucocorticoids in either physiological or 
pathological processes? Why instead of designing a replacing compound to be safely
used in clinic, physicians still have to prescribe glucocorticoids to patients but at the
same time pay great attention to the dosage and duration of treatment to avoid side 
effects or glucocorticoid-resistance? Although glucocorticoids have been known for 
more than a century, the aforementioned questions remain obscure. 
As a class of steroid hormones secreted by the adrenal gland and circulating in the 
blood, glucocorticoids spread almost all over the essential organs of the body. 
Therefore, it is hard to avoid mentioning glucocorticoids when discussing one 
particular system. For example, glucocorticoids regulate many processes in the body 
including the mobilization of energy stores, immune functions, gene expression, and
maintenance of the homeostasis as well as the stress response. Furthermore, 
glucocorticoids play key roles in consolidation of memories of a stressful event.
Consequently in a typical medical text book, glucocorticoids and their use in clinical
therapy against specific disease have been described in various chapters themed “the 
cardiovascular system”, “the central nervous system”, “the immune system” and so 
on. However, there has been lack of reference that systemically gives a relatively
thorough introduction of glucocorticoids as a specific topic. It is really influential of 
InTech publisher to endeavour to invite scientists from worldwide, sharing their 
unique specialties and knowledge to fill in the gap and I feel extremely honoured to 
contribute my part in the processing of this book. 
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Around the world, exciting research programmes on mechanisms of glucocorticoids’ 
effects on specific system are underway, especially combining modern molecular 
technologies, we are building up more understanding of glucocorticoids. The first part 
of the book Glucocorticoids - New Recognition of Our Familiar Friend aims to cover 
the main systems that are influenced by glucocorticoids. How glucocorticoids mediate 
the gene expression of key molecules that are heavily involved in the function of 
hypothalamus-pituitary-adrenal axis has been reviewed, which gives implication on 
how glucocorticoids affect the neuroendocrine system. The mechanisms of how 
glucocorticoids influence tumour development, osteoporosis process, 
cardioprotection, and intestinal environment are also reviewed and discussed. The 
second part of the book introduces the animal models that are commonly used in 
recent studies of glucocorticoids. In the third part, the glucocorticoids’ role in 
regulating the metabolism balance and energy homeostasis is reviewed, the recently 
found molecular pathways that are involved in physiopathology of Addison’s and 
Cushing’s diseases are discussed. Part Four focuses on how prenatal glucocorticoids 
affect the placental development and the consequent long-term impacts on the 
adulthood.    
As mentioned earlier, although endocrinologists have been searching for the 
replacement for glucocorticoid therapy in order to eliminate unwanted side effects, 
glucocorticoids are still widely used clinically for various diseases. In Part Five, 
comprehensive overview is carried out, focusing on the clinical use of glucocorticoids 
in the treatment for systemic lupus erythematosus, acute asthma, rheumatic 
inflammatory disorders and oral/maxillofacial surgery. Using latest clinical case 
studies and reports, the chapters in this part systemically review the background of 
the disease, therapeutic effects introduced by glucocorticoids as well as side effects, 
recommended dosage and duration of the treatment, and the cause of the 
glucocorticoid resistance.  
In summary, as one type of the most important steroid hormones, undoubtedly 
glucocorticoids’ role in mediating physiology of multiple organs and systems is well 
recognised and has been widely introduced into clinical practice. However, using 
glucocorticoids is similar to holding a double-edged sword - while benefiting from the 
therapeutic effects brought in by glucocorticoids, patients also suffer from painful side 
effects produced by glucocorticoids. Certainly replacement compounds or medical 
treatment can supply new alternatives to the glucocorticoid treatment, however it is 
equally essential for endocrinologists and scientists to build up more knowledge, 
based on the tremendous findings about glucocorticoids over the last few decades, 
about the mechanisms that underlie the phenomenons and finally achieve the ideal 
balance between the beneficial therapeutic effects and side effects of glucocorticoids. 
Finally, I would like to acknowledge all of the authors who have contributed 
tremendously to the publishing of this book. Their kindness of sharing their expertise 
and knowledge in the relevant field is truly appreciated. Also, I would like to express 
        Preface XI 
 
my appreciation to Ms. Tanja Skorupan, the Publishing Process Manager at InTech 
(Europe), for her diligent coordination work that guarantees the publication of this 
book. 
 
Dr. Xiaoxiao Qian 
Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, 
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1. Introduction 
Normal physiologic functioning is dependent on the maintenance of homeostasis in the face 
of numerous stressors. Responses to stress include the fight or flight reaction and activation 
of the sympathetic nervous and endocrine systems. The central component of the endocrine 
response is the hypothalamic-pituitary-adrenal (HPA) axis, which when activated leads to 
increased levels of circulating glucocorticoids. Indeed, an increase in glucocorticoids has 
been used as an operational definition of stress. 
The HPA axis is activated by a wide range of stimuli which includes perception of danger, 
pain, sepsis, and others. These stimuli are integrated at points throughout the central 
nervous system and ultimately impinge on the HPA axis motor neurons in the 
paraventricular nucleus of the hypothalamus (PVH). HPA neurons synthesize and secrete 
corticotropin releasing factors (crfs), the best known of which is the 41 amino acid peptide 
corticotropin releasing hormone (CRH);(Vale et al 1981)). CRH travels through the 
hypothalamic portal circulation to the anterior pituitary where it binds CRH receptors. This 
in turn leads to adrenocorticotrophic hormone (ACTH) secretion into the systemic 
circulation which stimulates the adrenal cortex to secrete glucocorticoids. 
Glucocorticoids elicit gluconeogenesis, which increases circulating levels of glucose. 
Although this mechanism is adaptive in the face of a homeostatic challenge, glucocorticoids 
can also have deleterious effects. Dysregulation of the HPA axis underlies classic endocrine 
disorders, such as Cushing’s disease, and is highly correlated with a number of psychiatric 
disorders, including post-traumatic stress disorder, anorexia nervosa, and depression. In 
addition, high circulating levels of glucocorticoids lead to osteopenia and 
immunosuppression. Thus, regulation of the HPA axis must be exquisitely controlled.  
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There are numerous components to HPA axis down-regulation;  one of the most significant 
of these is the end product of HPA axis regulation itself – glucocorticoids. Glucocorticoids 
down-regulate axis activity by acting at numerous loci in the HPA axis and in extra-
hypothalamic regions of the brain, such as the hippocampus(de Kloet et al 2005, (Sapolsky et 
al 1984). Glucocorticoid regulation in the hippocampus, extra-hypothalamic sites and 
pituitary are reviewed below. 
1.1. Glucocorticoidregulation of the hippocampal-hypothalamic pathway 
Glucocorticoid receptors (GRs) are most densely concentrated in the hippocampus of the 
central nervous system (CNS), and in fact it is in the hippocampus where glucocorticoid 
binding sites were first detected(McEwen et al 1979). GRs were first classified by their 
binding characteristics. Two types were identified, distinguished in part by their binding 
characteristics to corticosterone and the synthetic glucocorticoid dexamethasone (Dex) (de 
Kloet et al 1975). After steroid receptor cloning it became apparent that the two receptors 
correlate to the mineralocorticoid receptor (MR) and the GR. The GR is recruited in the 
presence of high levels of circulating glucocorticoids elicited in the face of stress (de Kloet et 
al 2005).  
Down-regulatory signals from the hippocampus are processed through a multisynaptic 
pathway. Hippocampal projections to the subiculum elicit excititory signals in the form of 
glutamatergic synapses in the basal nucleus of the stria terminalis (BNST). These stimulate 
inhibitory output from the BNST, which in turn down regulates the HPA axis. Thus, damage 
to the hippocampus leads to loss of HPA axis inhibition (Choi et al 2007, Herman et al 2003).  
1.2. Glucocorticoid regulation at the level of the pituitary 
One of the best studied components of glucocorticoid down-regulation of the HPA axis is 
ligand-bound GR-mediated down-regulation of the gene that codes for the ACTH precursor, 
pre-pro-opiomenlanocortin (POMC)(Bicknell 2008). As is the case  in other cells, 
glucocorticoids gain entry to the cyptoplasm and bind the cytoplasmic GR. Ligand binding 
activates the receptor, a process that includes dissociation from the heat shock protein 90 
(hsp90) as reviewed by Pratt and Dittmar(Pratt & Dittmar 1998). The ligand-bound receptor is 
transported into the nucleus where it interacts with numerous nuclear proteins and chromatin 
to regulate transcription. Prototypically, the GR binds to glucocorticoid response elements that 
are inverted palindromes; however, the regulatory region of pomc does not have such 
elements. Rather, it has a negative glucocorticoid response elements (nGREs) – hybrid 
elements also called composite elements. GRs bind these sites as monomers and interact with 
monomers of other transcription factors to down-regulate pomc transcription. GRs also repress 
transcription in the absence of direct DNA binding by modulating the activity of other 
transcription factors. In these aspects pomc regulation is similar to regulation of crh. 
A significant difference between the synthesis of CRH and ACTH is the relative contribution 
of post-translational enzymatic processing. In the case of CRH synthesis, one peptide is 
produced, thus, the majority of regulatory steps are pre-translational. Conversely, numerous 
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peptides are generated from pomc. These include ACTH, beta-endorphin, and alpha-
melanocyte stimulating hormone. Thus, pre-pro-POMC enzymatic processing plays a major 
role in determining levels of functional ACTH. 
1.3. Hypothalamic crfs 
CRH-expressing parvocellular neurons are the final common integrators of humeral and 
synaptic input. Located in the mpPVH, they receive inputs from numerous sites in the CNS:  
the hippocampus, brainstem, amygdala, intrahypothalamic sites, and PVH interneurons. 
(Swanson & Sawchenko 1980).  
Although CRH is the most potent and best known crf, it is only one of several. Prior to the 
biochemical characterization  of CRH(Vale et al 1981), arginine vasopressin (AVP) and 
oxytocin were also known to have crf properties(Gibbs 1986). Perhaps the most studied of 
these is AVP, best known for its activity as an anti-diuretic hormone. AVP arises from PVH 
magnocellular neurons whose terminals secrete AVP directly into the systemic 
circulation.The AVP that acts as a crf is synthesized in parvocellular neurons of the PVH. 
Interestingly, all parvocellular neurons that express AVP also express CRH. Furthermore, all 
of these express GRs(Cintra et al 1987, Uht et al 1988), and their function is measured by the 
ability to translocate into the nucleus in the presence of Dex(Uht et al 1988). 
2. Glucocorticoid receptors 
Many biochemical and pharmacologic properties of GRs were characterized prior to cloning 
(Gustafsson et al 1987). The existence of the MR and the GR was determined 
pharmacologically. In the absence of ligand the GR was present in a cytoplasmic complex. In 
the presence of ligand, the GR was present in the nucleus. Furthermore, ligand bound GR had 
been shown to bind specific sites in DNA, which came to be known as glucocorticoid response 
elements (GREs). Thus, before cloning, the fundamental differences between a steroid receptor 
and receptors for other hormones had been determined. The GR was an intracellular receptor 
rather than a plasma membrane bound receptor and its mechanism of action involved binding 
DNA. Hence the term that evolved -- ligand activated nuclear receptors. 
2.1. Glucocorticoid receptor cloning and identification of functional domain  
The initial cloning of the GR revealed two GRs: alpha and beta. Oakley et al discovered that 
GR beta did not bind ligand(Oakley et al. 1996) --  biological functions of GR-beta are still in 
the early stages of discovery(Yudt & Cidlowski 2002). This review focuses on GR-alpha, 
which will be referred to as GR.  
2.2. GR as a founding member of the nuclear receptor (NR) superfamily 
The GR and the estrogen receptor (ER) are founding members of the NR superfamily, and 
were cloned within the same time period(Green et al 1986, Greene et al 1986). They are 
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elements also called composite elements. GRs bind these sites as monomers and interact with 
monomers of other transcription factors to down-regulate pomc transcription. GRs also repress 
transcription in the absence of direct DNA binding by modulating the activity of other 
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peptides are generated from pomc. These include ACTH, beta-endorphin, and alpha-
melanocyte stimulating hormone. Thus, pre-pro-POMC enzymatic processing plays a major 
role in determining levels of functional ACTH. 
1.3. Hypothalamic crfs 
CRH-expressing parvocellular neurons are the final common integrators of humeral and 
synaptic input. Located in the mpPVH, they receive inputs from numerous sites in the CNS:  
the hippocampus, brainstem, amygdala, intrahypothalamic sites, and PVH interneurons. 
(Swanson & Sawchenko 1980).  
Although CRH is the most potent and best known crf, it is only one of several. Prior to the 
biochemical characterization  of CRH(Vale et al 1981), arginine vasopressin (AVP) and 
oxytocin were also known to have crf properties(Gibbs 1986). Perhaps the most studied of 
these is AVP, best known for its activity as an anti-diuretic hormone. AVP arises from PVH 
magnocellular neurons whose terminals secrete AVP directly into the systemic 
circulation.The AVP that acts as a crf is synthesized in parvocellular neurons of the PVH. 
Interestingly, all parvocellular neurons that express AVP also express CRH. Furthermore, all 
of these express GRs(Cintra et al 1987, Uht et al 1988), and their function is measured by the 
ability to translocate into the nucleus in the presence of Dex(Uht et al 1988). 
2. Glucocorticoid receptors 
Many biochemical and pharmacologic properties of GRs were characterized prior to cloning 
(Gustafsson et al 1987). The existence of the MR and the GR was determined 
pharmacologically. In the absence of ligand the GR was present in a cytoplasmic complex. In 
the presence of ligand, the GR was present in the nucleus. Furthermore, ligand bound GR had 
been shown to bind specific sites in DNA, which came to be known as glucocorticoid response 
elements (GREs). Thus, before cloning, the fundamental differences between a steroid receptor 
and receptors for other hormones had been determined. The GR was an intracellular receptor 
rather than a plasma membrane bound receptor and its mechanism of action involved binding 
DNA. Hence the term that evolved -- ligand activated nuclear receptors. 
2.1. Glucocorticoid receptor cloning and identification of functional domain  
The initial cloning of the GR revealed two GRs: alpha and beta. Oakley et al discovered that 
GR beta did not bind ligand(Oakley et al. 1996) --  biological functions of GR-beta are still in 
the early stages of discovery(Yudt & Cidlowski 2002). This review focuses on GR-alpha, 
which will be referred to as GR.  
2.2. GR as a founding member of the nuclear receptor (NR) superfamily 
The GR and the estrogen receptor (ER) are founding members of the NR superfamily, and 
were cloned within the same time period(Green et al 1986, Greene et al 1986). They are 
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highly homologous and are composed of domains that retain much of their function when 
dissociated from each other. Both GR and ER have three major domains, the NTD, DBD and 
LBD, as do all steroid receptors (Fig 1). The domains are dissociable and for certain 
functions are also interchangeable. For example, an ER chimera, which contains a GR 
binding domain, activates transcription in the presence of estradiol but does so by binding a 
GRE(Green & Chambon 1987). 
 
Figure 1. Domains of the GR and ER. (hGR) human glucocorticoid receptor, (hER) human estrogen 
receptor, (AF-1 and AF-2) activation functions 1 and 2, respectively 
3. GR-regulated gene repression: response elements 
Prior to the late 1980s, a prevailing view of GR-mediated repression was that it would 
require a palindromic DNA binding site. This assumption could not explain the fact that 
glucocorticoids repress a number of genes in the absence of a prototypic GRE. The discovery 
of composite elements and the discovery that elements for other transcription factors could 
sustain GR-mediated inhibition of gene activation were major advances in the 
understanding of GR-mediated repression. 
3.1. Repression mediated by composite elements  
 Composite elements are hybrids (Lefstin & Yamamoto 1998). In the case of GR regulation 
they consist of half sites, one for a GR monomer and one for a monomer of a distinct 
transcription factor -- e.g. a monomer of an activator protein-1 (AP-1) family member. They 
are found in numerous genes, including those directly involved in regulating the HPA-axis -
- crh and pomc. 
Much of the initial molecular analysis of composite elements was performed using the 
proliferin gene (proliferin).The proliferin composite element consists of half sites for GRE and 
AP-1 binding and confers both activation and repression, dictated by the specific AP-1 family 
member bound (Diamond et al 1990, Pearce et al 1998). AP-1 family members include c-Jun, 
cFos and similar proteins. A GR monomer bound in the presence of a c-Jun monomer will 
stimulate activation from the proliferin element, whereas high levels of c-Fos inhibit 
activation(Diamond et al 1990). Like the proliferin element, the crh nGRE is composed of GRE 
and AP-1 half sites. In addition, the extent to which the nGRE directs repression is dependent 
on the AP-1 family member bound to the composite element (Malkoski & Dorin 1999). 
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3.2. Repression mediated through other transcription factors and components of 
the basal transcriptional activity 
Three papers published simultaneously in 1990 reported that glucocorticoid-bound GR could 
down-regulate AP-1 stimulated gene expression (Jonat et al 1990, Schule et al 1990, Yang-Yen 
et al 1990). Mechanisms by which the GR down-regulates AP-1 activity and activity of other 
transcription factors are still being elucidated -- some interact with coregulators and others 
interact directly with components of the general transcription machinery. An example of the 
latter is GR down-regulation of nuclear factor-kappa B (NF-kB) activity. In the context of the 
interleukin-8 gene(il-8), GR is a physical and functional intermediary between the RelA (p65) 
component of NF-kB and the C’-terminal domain of polymerase II (pol II). GR alters the 
phosphorylation state of the C’-terminal domain of pol II and thus regulates its activity(Nissen 
& Yamamoto 2000). The GR also down-regulates il-8 expression by interfering with the activity 
of the transcription elongation factor-b (Luecke & Yamamoto 2005). Thus, GR targets both 
initiation and elongation steps in the context of the il-8 promoter. It is unknown whether or not 
GR works through either of these mechanisms in the context of crh. 
4. Identification of NR coregulators 
By the 1990s it was clear that NRs required additional factors to regulate gene expression. 
The discovery of NR co-regulators — coactivators and corepressors — permitted a quantum 
leap in the elucidation of NR mechanisms of gene regulation.  
4.1. NR coactivators 
Although there are numerous coactivators, this review focuses on the three members of the 
p160 family commonly referred to as SRCs-1, -2, and -3. In addition, a nomenclature group 
has codified the names of these coactivators as NCoA 1-3. Here they will be referred to 
collectively as the p160 family and individually the names first reported will be used with 
the agreed upon nomenclature indicated, e.g. SRC-1 (NCoA 1). 
The first p160 was discovered by O’Malley as a coactivator for a progesterone receptor -- the 
steroid receptor co-activator-1, SRC-1 (NCoA 1)(Onate et al 1995). Subsequently, Stallcup 
reported a p160 coactivator for the mouse GR, Glucocorticoid Receptor Interacting Protein 1 
GRIP1(Hong et al 1997, Hong et al 1996), also designated NCoA 2. The third p160, reported 
by several investigators, bears many names, including AIB1(Anzick et al 1997) and RAC3(Li 
et al 1997) but  it is often referred to as SRC-3 (NCoA 3).  
Each p160 contains two highly conserved regions. In the center of the protein is a cluster of 
three Leucine-X-X-Leucine-Leucine (LXXLL) motifs, in which X denotes any amino 
acid(Ding et al 1998, Heery et al 1997). These are also referred to as NR-boxes. The motifs are 
a requisite site of interaction with nuclear receptors; mutations of these sites abrogate NR 
activation functions (Feng et al 1998). p160s also contain a domain that binds to histone 
acetylases, e.g. the cAMP regulatory element binding protein (CREB)-binding protein (CBP), 
which remodel chromatin by acetylating specific lysines in histones(Marmorstein 2001). 
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AP-1 binding and confers both activation and repression, dictated by the specific AP-1 family 
member bound (Diamond et al 1990, Pearce et al 1998). AP-1 family members include c-Jun, 
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3.2. Repression mediated through other transcription factors and components of 
the basal transcriptional activity 
Three papers published simultaneously in 1990 reported that glucocorticoid-bound GR could 
down-regulate AP-1 stimulated gene expression (Jonat et al 1990, Schule et al 1990, Yang-Yen 
et al 1990). Mechanisms by which the GR down-regulates AP-1 activity and activity of other 
transcription factors are still being elucidated -- some interact with coregulators and others 
interact directly with components of the general transcription machinery. An example of the 
latter is GR down-regulation of nuclear factor-kappa B (NF-kB) activity. In the context of the 
interleukin-8 gene(il-8), GR is a physical and functional intermediary between the RelA (p65) 
component of NF-kB and the C’-terminal domain of polymerase II (pol II). GR alters the 
phosphorylation state of the C’-terminal domain of pol II and thus regulates its activity(Nissen 
& Yamamoto 2000). The GR also down-regulates il-8 expression by interfering with the activity 
of the transcription elongation factor-b (Luecke & Yamamoto 2005). Thus, GR targets both 
initiation and elongation steps in the context of the il-8 promoter. It is unknown whether or not 
GR works through either of these mechanisms in the context of crh. 
4. Identification of NR coregulators 
By the 1990s it was clear that NRs required additional factors to regulate gene expression. 
The discovery of NR co-regulators — coactivators and corepressors — permitted a quantum 
leap in the elucidation of NR mechanisms of gene regulation.  
4.1. NR coactivators 
Although there are numerous coactivators, this review focuses on the three members of the 
p160 family commonly referred to as SRCs-1, -2, and -3. In addition, a nomenclature group 
has codified the names of these coactivators as NCoA 1-3. Here they will be referred to 
collectively as the p160 family and individually the names first reported will be used with 
the agreed upon nomenclature indicated, e.g. SRC-1 (NCoA 1). 
The first p160 was discovered by O’Malley as a coactivator for a progesterone receptor -- the 
steroid receptor co-activator-1, SRC-1 (NCoA 1)(Onate et al 1995). Subsequently, Stallcup 
reported a p160 coactivator for the mouse GR, Glucocorticoid Receptor Interacting Protein 1 
GRIP1(Hong et al 1997, Hong et al 1996), also designated NCoA 2. The third p160, reported 
by several investigators, bears many names, including AIB1(Anzick et al 1997) and RAC3(Li 
et al 1997) but  it is often referred to as SRC-3 (NCoA 3).  
Each p160 contains two highly conserved regions. In the center of the protein is a cluster of 
three Leucine-X-X-Leucine-Leucine (LXXLL) motifs, in which X denotes any amino 
acid(Ding et al 1998, Heery et al 1997). These are also referred to as NR-boxes. The motifs are 
a requisite site of interaction with nuclear receptors; mutations of these sites abrogate NR 
activation functions (Feng et al 1998). p160s also contain a domain that binds to histone 
acetylases, e.g. the cAMP regulatory element binding protein (CREB)-binding protein (CBP), 
which remodel chromatin by acetylating specific lysines in histones(Marmorstein 2001). 
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Mechanisms by which p160s regulate crh expression are not well understood. The best studied 
of these is SRC-1. The SRC-1a isoform mRNA has been mapped to the PVH, and CRH mRNA 
levels have been evaluated in SRC-1 knockout mice (Lachize et al 2009). Paradoxically, SRC-1 
is associated with crh repression(van der Laan et al 2008). There is precedent for this --  
Rogatsky and colleagues reported that GRIP1 has a repressive function(Rogatsky et al 2001). 
The GRIP1 domain that supports this function, however, is unique to the GRIP1 p160. Thus, 
the mechanisms of SRC-1a down-regulation have yet to be identified. 
4.1.1. Coactivator interaction with histone acetyl transferases (HATs) 
The discovery of the p160s and the discovery of a coactivator for the cAMP regulatory 
element binding protein (CREB) - binding protein (CBP) and its homologue p300 occurred 
contemporaneously. In addition to a p160 binding domain the two coactivators contain a 
histone acetylase domain. CBP is a coactivator for numerous transcription factors that 
include a number of nuclear receptors and factors involved in inflammation, e.g. STAT1 
(Horvai et al 1997). In addition to CBP and p300, other acetylases such as the p300/CBP-
associated factor (p/CAF;(Yang et al 1996)play a role in nuclear receptor regulation; 
however, their role in GR regulated crh expression is poorly understood. 
4.2. Nuclear receptor co-repressors 
Some members of the NR family, such as the thyroid hormone receptor (TR), maintain a 
constitutively silent state of gene expression. The search for a co-repressor for TR led to the 
discovery of the Nuclear Receptor Corepressor (NCoR), whose homologue is known as the 
silencing mediator of retinoic acid receptor and the thyroid receptor (SMRT). The NR 
interaction site in NCoR is remarkably similar to the NR-boxes in the p160 coactivator 
family. The corepressor motif is L/I XXI/V-I, compared to the p160 coactivator motif, LXXLL. 
The corepressor motif is referred to as a CoRNR box. These features of coactivator and 





























Table 1. The chain of events for activation parallels that for repression. 
The mechanisms by which co-repressors interact with GR to down-regulate crh expression 
are largely uncharacterized. Using transient transfection/reporter assays, van der Laan et al. 
reported that cotransfection of NCoR and SMRT did not accentuate glucocorticoid mediated 
crh repression. Instead, these repressors accentuated corticosterone inhibition of forskolin-
stimulated expression(van der Laan et al 2008). 
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The corepressors NCoR and SMRT bind to histone deacetylases (HDACs). The specificity of 
an HDAC for a given receptor has been elucidated in some studies. An early report revealed 
that HDAC3 but not HDAC1 is involved in TR repression (Guenther et al 2001). Given the 
conserved nature of many functions across nuclear receptors one might predict that like the 
TR, GR- repressed transcription of crh expression would involve HDAC3 but not HDAC1. In 
the context of the crh promoter, however, the reverse is true(Miller et al 2011). 
5. Structural analysis of GR 
Structural analysis of GR permits identification not only of a single protein structure but 
also of protein interfaces involved in specific inter-molecular interactions.  
5.1. The DNA binding domain  
Crystallographic analysis of a GR dimer bound to its DNA recognition site revealed that GR 
zinc fingers intercalate with DNA (Freedman et al 1988, Luisi et al 1991). Subsequent NMR 
analysis of the DBD structure revealed inherent stability in the absence of DNA (Berglund et 
al 1992). The DBD is now known to have several functions in addition to binding DNA, and 
it may be that the inherent structure supports these functions. 
5.2. The ligand binding domain  
A characteristic of all NRs is that the LBD is longer and less structured than the DBD. This 
partially explains why the crystal structure of two smaller nuclear receptors, RXR-alpha and 
TR were the first to be solved (Bourguet et al 1995, Wagner et al 1995). The TR was the first 
ligand-bound NR to be crystallized; even so, it took years to optimize LBD purification in 
sufficient quantities to permit crystallization (Apriletti et al 1995, Apriletti et al 1988) 
(McGrath et al 1994). This process was facilitated by use of a radioactively labeled ligand 
(Apriletti et al 1995, Apriletti et al 1988), which allowed LBD to be tracked throughout 
purification. The discovery of NR boxes was taking place simultaneously with efforts to 
crystalize the TR LBD. Thus, crystallization of the ligand-bound TR bound to a GRIP1NR 
box followed shortly thereafter (Darimont et al 1998, Wagner et al 1995). 
The next LBD structure to be solved was ER-alpha, again bound to ligand and an NR box. 
As a member of the steroid receptor branch of the NR superfamily it has a longer, more 
complex LBD than the TR. Thus, the protein is inherently more difficult to crystalize, and its 
crystal structure more difficult to solve. Coordinates used to solve the TR structure 
permitted ER modeling (Shiau et al 1998). Indeed, in the absence of TR crystal structure 
coordinates, solution of the ER crystal structure may have been intractable at the time. 
The GR LBD is even less structured than either TR or ER-alpha. In fact, a mutation in the GR 
LBD was required to generate crystals. Co-crystallization of GR LBD bound to Dex and to an 
NR box revealed that the overall structure of the receptor LBD is the same as the TR and ER-
alpha with three key differences: an additional dimerization function, a second set of charge 
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Mechanisms by which p160s regulate crh expression are not well understood. The best studied 
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The mechanisms by which co-repressors interact with GR to down-regulate crh expression 
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reported that cotransfection of NCoR and SMRT did not accentuate glucocorticoid mediated 
crh repression. Instead, these repressors accentuated corticosterone inhibition of forskolin-
stimulated expression(van der Laan et al 2008). 
 
Mechanisms of Glucocorticoid Receptor (GR) Mediated Corticotropin Releasing Hormone Gene Expression 9 
The corepressors NCoR and SMRT bind to histone deacetylases (HDACs). The specificity of 
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sufficient quantities to permit crystallization (Apriletti et al 1995, Apriletti et al 1988) 
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(Apriletti et al 1995, Apriletti et al 1988), which allowed LBD to be tracked throughout 
purification. The discovery of NR boxes was taking place simultaneously with efforts to 
crystalize the TR LBD. Thus, crystallization of the ligand-bound TR bound to a GRIP1NR 
box followed shortly thereafter (Darimont et al 1998, Wagner et al 1995). 
The next LBD structure to be solved was ER-alpha, again bound to ligand and an NR box. 
As a member of the steroid receptor branch of the NR superfamily it has a longer, more 
complex LBD than the TR. Thus, the protein is inherently more difficult to crystalize, and its 
crystal structure more difficult to solve. Coordinates used to solve the TR structure 
permitted ER modeling (Shiau et al 1998). Indeed, in the absence of TR crystal structure 
coordinates, solution of the ER crystal structure may have been intractable at the time. 
The GR LBD is even less structured than either TR or ER-alpha. In fact, a mutation in the GR 
LBD was required to generate crystals. Co-crystallization of GR LBD bound to Dex and to an 
NR box revealed that the overall structure of the receptor LBD is the same as the TR and ER-
alpha with three key differences: an additional dimerization function, a second set of charge 
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clamps, and an additional pocket (Bledsoe et al 2002, Bledsoe et al 2004). These distinctive 
features underscore the complexity of GR (Bledsoe et al 2004). 
6. Epigenetics and chromatin modification 
Strictly defined, the term epigenetics refers to an inheritable factor composed of something 
other than unmodified genomic DNA— this is distinct from chromatin modifications that 
regulate processes that are not inherited. Thus, most of the processes referred to here are not 
truly epigenetic, but rather consist of chromatin modifications that modulate gene 
expression. 
6.1. Histone acetylation  
Although typically associated with transcriptional activation, histone acetylation  is also 
associated with repressed states of gene expression (Shahbazian & Grunstein 2007). The 
initial focus of study in this field was on chromatin acetylation via recruitment of histone 
acetyl transferases (HATs). The addition of an acetyl to a lysine (Lys) neutralizes the acid-
base interaction with DNA. This neutralization, as well as the steric hindrance conferred by 
Lys acetylation, destabilizes histone:DNA interactions, and allows proteins such as 
transcription factors, transcription initiators, and elongation factors access to DNA binding 
sites.  
6.2. Histone Deacetylation 
Deacetylation is the counterpart to acetylation. Histone Deacetylases (HDACs) are 
comprised of a family of enzymes with three subdivisions. The nomenclature of mammalian 
HDACs is somewhat confounding, having arisen from sequential numbering as the 
enzymes were discovered. Class I includes HDAC 1-3, 8 and 11. They have one catalytic 
domain and for the most part are nuclear. Class II HDACs are larger than Class I and are 
divided into two subclasses, IIa and IIb. Class IIa HDACs include HDAC 4, 5, 7and have an 
N’-terminal domain unique to this class. In addition, Class IIa HDACs shuttle between the 
nucleus and cytoplasm. Class IIb HDACs, 6 and 10, have two HDAC domains instead of a 
unique N’-terminus, and are predominantly found in the cytoplasm (Verdin et al 2003). 
Class III HDACs are distinguished by their requirement for NAD+. They are named sirtuins 
due to similarity to the yeast Sir2. Like Sir2, they are targets of intense study given their 
association with aging and neurodegenerative processes. Because HDACs are tightly 
correlated with repression they have been examined in the context of GR-repressed crh 
expression (Miller et al 2011). 
7. Corticotropin Releasing Hormone (CRH)   
Although CRH is widely expressed in the mammalian CNS, the focus here is on regulation 
of crh in the medial parvocellular region of the PVH (mpPVH).  
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7.1. CRH cloning  
In 1983, a fragment of the human crh was cloned that contained the proximal promoter and 
coding region. The predicted amino acid sequence differs from the ovine by seven residues 
(Shibahara et al 1983). Cloning the rat cDNA and a portion of the promoter were reported in 
1987(Thompson et al 1987). The rat cDNA has high sequence homology to human cDNA, 
and in fact the peptide sequences are identical. Rat and human proximal promoter 
sequences are also highly conserved (Thompson et al 1987).  
7.2. crh regulation 
A cAMP regulatory element (CRE) at approximately -200 in the proximal promoter plays a 
pivotal role in activating crh expression by recruitment of (CREB)(Seasholtz et al 1988, 
Thompson et al 1987). Interestingty this site not only mediates activation but also mediates 
repression by recruiting the inducible cAMP early repressor(Aguilera & Liu 2012). In 
addition, a negative GRE in the 200 base span contributes to crh down-regulation (Malkoski 
& Dorin 1999,(Malkoski et al 1997). Indeed the entire first 200 bases of the proximal 
promoter are highly conserved, underscoring the importance of this region to regulation of 
the stress response(Yao et al 2007). 
Specific mechanisms of GR-mediated crh down-regulation have been difficult to parse, as is 
case for most glucocorticoid down-regulated genes. At the most basic level it is unclear 
whether glucocorticoids suppress crh-activated expression only, or if they also suppress 
basal levels of expression. This distinction is important in that recruitment of signal-specific 
co-activators would be required prior to GR inhibition. Repressionof basal activity, 
however, would entail recruiting a corepressor. 
Most studies of inhibited crh regulation have used transient transfection assays or isolated 
DNA. In neither case is DNA in its natural state of chromatinization. More recent studies of 
crh expression underscore the importance of considering the chromatin environment. 
8. Impact of chromatin modifications on analysis of GR-mediated crh 
down-regulation  
A number of factors regulate the crh chromatin environment. Inhibition of activated crh 
expression involves both the CRE and the nGRE, and maintenance of basal activity involves 
histone acetylation and DNA methylation. Numerous steps in mechanisms of inhibition and 
repression have yet to be elucidated.  
8.1.1. Repression of cAMP activated crh expression 
CRE is required for regulation of crh expression through signal transduction. 
Phosphorylated CREB (pCREB) can interact with an inhibitory member of the CREB family, 
the inducible cAMP early repressor (ICER). ICER is a dominant negative of pCREB and 
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decreases cAMP activated expression. Further details on the role of pCREB and its family 
members in regulating crh expression can be found in the Aguilera and Liu review(Aguilera 
& Liu 2012). 
8.1.2. Regulation through the nGRE 
Repression mediated through the nGRE in the proximal crh promoter is similar to repression 
mediated through the proliferin nGRE. A monomer of GR and a monomer of the AP-1 family 
bind the composite element. The prototypic coactivator for pCREB is CBP, which is also a 
coactivator for AP-1(Bannister & Kouzarides 1995, Bannister et al 1995). Thus, in the context 
of crh, CBP might permit a functional interaction between the GR:AP-1 dimer and a dimer of 
CREB family members bound to the CRE. 
8.2. Maintenance of basal levels of activation 
Basal levels of activation involve a balance of activation and repression. There are numerous 
ways in which this balance may be maintained -- one is to maintain a constant state of 
chromatin modification. Two modification types that play a role in crh regulation are 
histone acetylation and methylation of CpG islands. 
8.2.1. Histone acetylation 
Activated crh expression involves CBP recruitment to the proximal promoter. CBP is a HAT 
coactivator for both pCREB and c-Jun, so activation of either the pKA pathway or the pKC 
pathway could be involved in CBP recruitment. 
Analysis of global histone 3 and 4 (H3 and H4) acetylation in the context of estradiol-
regulated crh expression has been reported(Lalmansingh & Uht 2008). As is the case in 
estradiol regulation, Dex regulates H3 and H4 acetylation differentially, as measured by 
chromatin immunoprecipitation followed by PCR amplification(Miller et al 2011). Dex 
increases H4 acetylation, a finding that underscores the fact that acetylation may be 
associated a state of repression as well as activation. 
The level of histone acetylation is a function of the presence of enzymatically active  
HATs and HDACs. In the case of Dex-regulated crh expression, the amount of ligand  
bound GR is increased in the region of the promoter(Miller et al 2011). When measured at 
the same time, HDAC levels are also increased. Furthermore, GR binds HDAC1 in a Dex-
dependent manner, suggesting the possibility that GR recruits HDAC1 to the crh promoter 
(Figure 2).  
Like the differential acetylation of H3 and H4, the Dex associated increase in HDACs 
displays a degree of specificity — although HDAC1 is increased at the promoter, HDAC3 is 
not (Miller et al 2011). The mechanisms by which these enzymes leave and are recruited to 
chromatin are poorly understood and merit further study. 
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Figure 2. Dex treatment leads to increased HDAC1:GR complexes and increased HDAC1 at the crh 
promoter. (A) Co-immunoprecipitation analysis; nuclear extract was immunoprecipitated with a 
polyclonal antibody against GR. Western blot analysis of the immune-precipitate revealed an increase 
in the co-immunoprecipitation of HDAC1. n=3; Bars represent the mean ± SEM and are represented as 
the fold difference of the Veh *, P < 0.05. (B) ChIP analysis of the CRH promoter; cells were treated with 
Dex and chromatin was immune-precipitated with an anti HDAC1 antibody. Quantitative RT-PCR 
analysis of the immune-precipitated DNA indicates enrichment of HDAC1 at the promoter. n=3; Bars 
represent the mean ± SEM and are represented as the fold difference of the Veh *, P < 0.05.  
8.2.2. DNA methylation 
Methylation of CpG islands of the GR promoter was one of the earliest reported true 
epigenetic phenomena in that it was associated with inheritance -- in this case a behavioral 
phenotype(Weaver et al 2004). More recently, CpG island methylated crh has been described 
in the context of social defeat(Elliott et al 2010). 
The first report of CpG island methylation in the context of crh regulation was an offshoot 
from a study of a mouse model of Rett Syndrome. This syndrome occurs in girls and 
manifests as diminished intelligence, repetitive motor movements, and anxiety — all of 
which have variable penetrance. The genetic lesion in Rett Syndrome is a mutation in the 
methyl CpG (meCpG) binding protein 2 (MeCP2). This protein binds to meCpG islands and 
represses the expression of bound genes. McGill and colleagues found that one of these 
genes is crh. Remarkably, mice bearing the MeCP2 mutation have a hyperactive HPA axis 
associated with elevated levels of CRH mRNA in the PVH, central amygdala, and BNST— 
all regions that express GRs and which are associated with HPA axis regulation. In addition, 
meCpG sites have been mapped in the crh proximal promoter region and were found to be 
present in the same region as the CRE and nGRE(McGill et al 2006). These findings 
underscore the importance of this region in crh regulation. 
9. A role for bioinformatics in GR-regulated crh expression 
Dalwadi and Uht recently investigated expression patterns of two neuronal cell lines, which 
were derived from embryonic PVH and amygdala. Paradoxically, even though neurons in 
these populations express CRH and contain GRs, they differ in the response to 
glucocorticoid treatment. In the mpPVH, glucocorticoids down-regulate crh expression 
whereas in the amygdala they up-regulate it. Expression microarrays are currently being 
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analyzed using the expression pattern of two neuronal cell lines, amygdalar AR-5 and 
hypothalamic IVB - both differentially express crh in response to Dex treatment. The number 
of genes associated with development of projections is similar between the two cell lines, 
whereas the number of genes involved in steroid hormone responsiveness is two-fold 
greater in the hypothalamic line compared to the amygdalar line. Given the importance of 
the hypothalamus relative to amygdala in regulation of steroid hormone physiology, these 
results are not unexpected. However, the two lines also differ in the relative expression of 
genes associated with response to oxidative stress and to DNA binding, as categorized in 
the Gene Ontology database (GO; Figure 3). These differences are intriguing and have 
spurred further investigation.  
GO Term AR-5 IVB
DNA Binding 36 21
Neuron Projection Development 9 8
Response to Oxidative Stress 10 6
Response to Steroid Hormone Stimulus 6 12
 
Figure 3. Hierarchal cluster showing relative abundance of genes between the AR-5 and IVB cell lines 
(red - abundant, green - less abundant). (GO) Gene Ontology as defined by the DAVID analysis 
program. (AR-5) Amygdalar cell line, (IVB) Hypothalamic cell line. 
More refined techniques are now available for bioinformatics analysis of gene expression. 
One of those is the combination of chromatin immunoprecipitation and microarray assays 
(ChIP-chip). In this approach, DNA isolated from ChIPs is used to probe a genomic 
microarray. ChIP-chip has been used to analyze GR binding sites. So and colleagues used a 
combination of conventional expression array analysis followed by ChIP-chip. When 
glucocorticoid-induced genes were compared to glucocorticoid-repressed genes, analysis 
revealed that the GR-holoreceptor induced all genes that were regulated via a conventional 
palindrome. In distinction, none of the genes repressed contained such an element (So et al 
2007). Such a clear-cut distinction is rare in biology.  
A second example of a bioinformatics approach useful in the analysis of NR mediated gene 
regulation is global run-on and sequencing (GRO-seq)(Core et al 2008). This technique 
permits unbiased analysis of all RNA transcripts, which allows detection of both mRNA and 
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non-coding RNAs. It has been used in a number of biological systems, including use of this 
technique to determine the nature of transcripts induced by 17estradiol treatment of MCF-7 
cells, a prototypic breast cancer cell line. To date, however, there are no reports of GRO-seq 
analysis of glucocorticoid regulated genes. 
10. Summary 
In the last fifteen years an explosion of new information has facilitated novel ways of 
looking at GR mediated gene expression. The seminal findings by Yamamoto in the early 
1980s —that GRs bind to specific palindromic glucocorticoid response elements(Payvar et al 
1983)— is now frequently referred to as the classic mechanism of gene regulation. At 
present, numerous alternate mechanisms of gene regulation are being elucidated. Many of 
these involve interactions with coregulatory factors. Such interactions have helped bridge 
the gap between transcription and chromatin remodeling, which in turn has resulted in the 
intersection of the NR field with the field of epigenetics. 
This review has focused on glucocorticoid regulation of genomic effects via the GR. Other 
areas currently being investigated include the actions of GR splice variants, and the role of 
glucocorticoid regulation of heat shock proteins. Lastly, the effects of glucocorticoids at the 
cell membrane (non-genomic events), mechanisms of cell membrane transport of 
glucocorticoids, and nuclear import of the GR holoreceptors are all steps in regulation that 
merit further analysis. 
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intersection of the NR field with the field of epigenetics. 
This review has focused on glucocorticoid regulation of genomic effects via the GR. Other 
areas currently being investigated include the actions of GR splice variants, and the role of 
glucocorticoid regulation of heat shock proteins. Lastly, the effects of glucocorticoids at the 
cell membrane (non-genomic events), mechanisms of cell membrane transport of 
glucocorticoids, and nuclear import of the GR holoreceptors are all steps in regulation that 
merit further analysis. 
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1. Introduction 
Early-life exposure to adverse experience or stress, simply termed early-life stress (ELS), is a 
worldwide problem that has a significantly negative impact in human health [1, 2]. In the 
United States, about 50% of adults had experienced some kind of stress before age 18 [3], 
and up to 15-25% of adults had traumatic ELS such as sexual abuse [4]. Most ELS is parents-
originated, such as neglect, maltreatment, and abuse [5, 6]. In addition to the immediate, 
dreadful, and destructive effects on a child’s life, ELS may produce a series of mental [7, 8], 
cardiovascular [9, 10], metabolic [11, 12], and many other types of disease [13, 14], at a later 
life stage. For example, adults who were sexually abused during childhood have a 5.7-fold 
increase in risk for drug abuse over those without ELS [7], and the prevalence of 
posttraumatic stress disorder (PTSD), a predominant form of anxiety disorders (ADs), is 
highly associated with ELS, with a 4-5 fold difference between adults with ELS and those 
without ELS [15]. Moreover, cognitive dysfunctions [16-18] such as learning and memory 
impairment [19-21] are also highly associated with ELS. Given that children, especially early 
adolescents, have a higher possibility to expose to a traumatic insult [22], adolescent trauma 
(AT) is an important risk factor for these post-ELS disorders.  
Over the past decades, considerable insights have been gained into the molecular/neuronal 
mechanisms regarding how ELS impacts brain function and behavior [23-26]. Generally, it is 
now accepted that ELS can produce changes, most permanently, at multiple levels [25, 27]. 
Following ELS, for example, the overall volume of the hippocampus [28-30], corpus 
callosum [31-33], and cortex [34-36] all becomes smaller, compared to that of those brain 
regions in age-matched subjects. Besides these neuroanatomical changes, the neuronal 
activity and the synaptic function in the brain in ELS-victims are impaired [37-39], and most 
neurotransmitter systems are significantly affected too. By using positron emission 
tomography or fMRI, it has been found that a significantly increased release of dopamine in 
the ventral striatum is associated to ELS [40, 41]. The turnover rate of the serotonin (5-HT) 
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1. Introduction 
Early-life exposure to adverse experience or stress, simply termed early-life stress (ELS), is a 
worldwide problem that has a significantly negative impact in human health [1, 2]. In the 
United States, about 50% of adults had experienced some kind of stress before age 18 [3], 
and up to 15-25% of adults had traumatic ELS such as sexual abuse [4]. Most ELS is parents-
originated, such as neglect, maltreatment, and abuse [5, 6]. In addition to the immediate, 
dreadful, and destructive effects on a child’s life, ELS may produce a series of mental [7, 8], 
cardiovascular [9, 10], metabolic [11, 12], and many other types of disease [13, 14], at a later 
life stage. For example, adults who were sexually abused during childhood have a 5.7-fold 
increase in risk for drug abuse over those without ELS [7], and the prevalence of 
posttraumatic stress disorder (PTSD), a predominant form of anxiety disorders (ADs), is 
highly associated with ELS, with a 4-5 fold difference between adults with ELS and those 
without ELS [15]. Moreover, cognitive dysfunctions [16-18] such as learning and memory 
impairment [19-21] are also highly associated with ELS. Given that children, especially early 
adolescents, have a higher possibility to expose to a traumatic insult [22], adolescent trauma 
(AT) is an important risk factor for these post-ELS disorders.  
Over the past decades, considerable insights have been gained into the molecular/neuronal 
mechanisms regarding how ELS impacts brain function and behavior [23-26]. Generally, it is 
now accepted that ELS can produce changes, most permanently, at multiple levels [25, 27]. 
Following ELS, for example, the overall volume of the hippocampus [28-30], corpus 
callosum [31-33], and cortex [34-36] all becomes smaller, compared to that of those brain 
regions in age-matched subjects. Besides these neuroanatomical changes, the neuronal 
activity and the synaptic function in the brain in ELS-victims are impaired [37-39], and most 
neurotransmitter systems are significantly affected too. By using positron emission 
tomography or fMRI, it has been found that a significantly increased release of dopamine in 
the ventral striatum is associated to ELS [40, 41]. The turnover rate of the serotonin (5-HT) 
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metabolism or the 5-HT receptor density [42, 43] is altered following ELS. Similarly, the 
activity of the glutamatergic system [44, 45] and the cholinergic system [46, 47] are also altered 
in the brain of individuals following ELS. However, it should be emphasized that the changes 
in the hypothalamic-pituitary-adrenal (HPA) axis activity is of the most interest [48-52]. 
As the most important stress-related neuroendocrine system in the body, the HPA axis is 
anatomically and functionally composed of three major structures: the paraventricular 
nucleus of the hypothalamus (PVN), the anterior lobe of the pituitary gland, and the adrenal 
gland [53, 54]. The PVN contains magnocellular neurosecretory neurons that synthesize and 
release a corticotropin-releasing factor (CRF). CRF is a 41 amino acid peptide [55, 56], and can 
bind to three types of G-protein-coupled receptors: CRFR1, CRFR2, and CRFR3 [57-59]. In the 
mammalian brain, both CRF and CRFR1 are mainly distributed in the limbic system, while 
CRFR-2 is in the hypothalamus [60-62]. The essential role for the CRF system is to maintain the 
basal HPA axis activity as well as to trigger the HPA axis in response to stresses. After released 
from the PVN, the CRF binds to CRFR1 at the anterior pituitary and increase the release of 
adrenocorticotropic hormone (ACTH). The ACTH consequently stimulates the release of 
glucocorticoids from the adrenal gland [63]. Once released, glucocorticoids bind both high-
affinity mineralocorticoid receptors and lower-affinity glucocorticoid receptors. The 
glucocorticoids, or cortisol in humans and corticosterone in rodents, play an essential role in 
energy metabolism, growth processes, immune function, and brain functions [63, 64].  
In response to stress, CRF system plays an essential role in modifying peripheral 
physiological response to support “fight or flight” reactions, such as mobilizing energy 
stores, increasing blood sugar and heart rate, inhibiting digestive functions etc [65,66]. In 
addition, CRF itself may act on CRFR2 in the brain to directly regulate adaptive behavioral 
changes encountering stress [67-69]. Taken together, the CRF/HPA system plays a primary 
role in coordinating the endocrine, autonomic, immune, and behavioral response to stress. 
As stress, either real or imaged, is a necessary inducer for ADs, the CRF/HPA system must 
play a unique role in anxiety-related behaviors. Indeed, a huge body of evidence has 
documented this notion. For example, administration of CRF [70-72] or CRFR1 agonists 
[69,73,74] or overexpression of the CRF gene [75-77] produces Anxiety-like behaviors (ALBs) 
in the animals. On the other hand, CRFR1 antagonists exert significantly anxiolytic effects 
[78-80]. Knockout of CRF or CRFR1 in mice significantly reduces ALBs to stress and 
dramatically blunts stress-induced HPA axis activity [61,81,82]. Remarkably, previous 
chronic stress is able to enhance HPA axis activity in response to a novel acute stress, 
despite the negative feedback effects of increased glucocorticoids produced by the chronic 
stress [83-85]. For example, CCK-4-induced panic status in healthy volunteers significantly 
increases HPA axis activities [86]. Even the effects of early-life stress on HPA axis function 
are found to be associated with CCK sensitivity 130. Most interestingly, interactions between 
the CCKergic system and the CRF/HPA system exist [88-90]. For example, the CCKergic 
system was found to be involved in this chronic stress-enhanced responsiveness, since 
chronic stress can specifically facilitate the release of CCK into the PVN, which directly 
projects to the pituitary, in response to acute stress 125. All these findings have not only 
established the role of the CRF/HPA system in initiating behavioral responses to stresses, 
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but also indicate that a significant interaction may exist between the CRF/HPA system and 
CCKergic system to regulate stress-related behaviors. 
However, the vulnerability among different individuals to AT is different. This variability 
may at least partially attribute to a genetic variability [91]. A twin study of Vietnam veterans 
revealed that about 37.9% of vulnerability to PTSD was genetically related [92]. Further 
genetic evidence comes from clinical association studies, by which several candidate genes 
for ADs including PTSD have been associated, although a causative gene has not been yet 
established [91]. Among those candidate genes, cholecystokinin (CCK) receptor-2 (CCKR-2) 
has been linked to panic disorder, another major form of ADs [93,94]. 
As the most abundant neuropeptides, CCK distributes broadly in the brain and mainly in 
the limbic system [95,96]. CCK binds to CCK receptor-1 (CCKR-1) and CCKR-2, of which the 
CCKR-2 is predominantly found in the brain with the highest level in cortical area and the 
limbic system [97], a brain region that is critically involved in emotion response and 
behavior. Virtually, the CCKergic system has long been recognized as an anxiogenic factor 
for the animals [98], and this effect has been well validated in human populations as well 
[89,99,100]. Our recent study also showed that overexpression of CCKR2 in neurons of the 
forebrain of mice significantly enhanced ALBs [101]. At the same time, some candidate 
genes that are linked to ADs are also associated with HPA axis activity. For example, a 
common polymorphism at the serotonin transporter (5-HTT) gene, namely 5HTTLPR, is a 
strong candidate genetic variation for ADs and depression [102-103], and also is 
significantly implicated in HPA axis activity [104]. Similar to the CCKergic system, the HPA 
axis system has long been recognized as a stress hormone [105,106], and plays a critical role 
in the pathogenesis of ADs [107,108]. Indeed, following ELS, the activity of the HPA axis 
system is dysfunctional [109-111]. Moreover, given the overall role of both the HPA axis 
system [112-114] and the CCKergic system [115-117] in regulating neuronal, cardiovascular, 
and metabolic functions in the body, these two systems may play an integrative role in the 
pathogenesis of post-ELS disorders. 
In this study, by using our previously engineered inducible forebrain-specific CCKR-2 
transgenic (IF-CCKR-2 tg) mice [101], we demonstrated that the elevated CCKergic tone in 
the brain significantly facilitated the effect of AT on the impairment of the glucocorticoid 
negative feedback inhibition in response to a novel acute stressor during the adult stage in 
the mouse, providing direct evidence that reveals a molecular basis for this co-effect.  
2. Materials and methods 
2.1. Experimental animals  
The procedures for the generation of IF-CCKR-2 tg (simply dtg) mice were described in our 
previous publication [101]. Briefly, we used the tTA/tetO-inducible gene expression system to 
produce these dtg mice. This system requires two independent transgenic mouse strains, tTA 
transgenic and tetO/CCKR-2 transgenic mice. Accordingly, two constructs were made. The 
first was for tTA transgenic mice, in which the expression of the tTA was under the control of 
an alpha-Ca2+ calmodulin kinase II (CaMKII) promoter. The tTA transgene cassette consists of 
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metabolism or the 5-HT receptor density [42, 43] is altered following ELS. Similarly, the 
activity of the glutamatergic system [44, 45] and the cholinergic system [46, 47] are also altered 
in the brain of individuals following ELS. However, it should be emphasized that the changes 
in the hypothalamic-pituitary-adrenal (HPA) axis activity is of the most interest [48-52]. 
As the most important stress-related neuroendocrine system in the body, the HPA axis is 
anatomically and functionally composed of three major structures: the paraventricular 
nucleus of the hypothalamus (PVN), the anterior lobe of the pituitary gland, and the adrenal 
gland [53, 54]. The PVN contains magnocellular neurosecretory neurons that synthesize and 
release a corticotropin-releasing factor (CRF). CRF is a 41 amino acid peptide [55, 56], and can 
bind to three types of G-protein-coupled receptors: CRFR1, CRFR2, and CRFR3 [57-59]. In the 
mammalian brain, both CRF and CRFR1 are mainly distributed in the limbic system, while 
CRFR-2 is in the hypothalamus [60-62]. The essential role for the CRF system is to maintain the 
basal HPA axis activity as well as to trigger the HPA axis in response to stresses. After released 
from the PVN, the CRF binds to CRFR1 at the anterior pituitary and increase the release of 
adrenocorticotropic hormone (ACTH). The ACTH consequently stimulates the release of 
glucocorticoids from the adrenal gland [63]. Once released, glucocorticoids bind both high-
affinity mineralocorticoid receptors and lower-affinity glucocorticoid receptors. The 
glucocorticoids, or cortisol in humans and corticosterone in rodents, play an essential role in 
energy metabolism, growth processes, immune function, and brain functions [63, 64].  
In response to stress, CRF system plays an essential role in modifying peripheral 
physiological response to support “fight or flight” reactions, such as mobilizing energy 
stores, increasing blood sugar and heart rate, inhibiting digestive functions etc [65,66]. In 
addition, CRF itself may act on CRFR2 in the brain to directly regulate adaptive behavioral 
changes encountering stress [67-69]. Taken together, the CRF/HPA system plays a primary 
role in coordinating the endocrine, autonomic, immune, and behavioral response to stress. 
As stress, either real or imaged, is a necessary inducer for ADs, the CRF/HPA system must 
play a unique role in anxiety-related behaviors. Indeed, a huge body of evidence has 
documented this notion. For example, administration of CRF [70-72] or CRFR1 agonists 
[69,73,74] or overexpression of the CRF gene [75-77] produces Anxiety-like behaviors (ALBs) 
in the animals. On the other hand, CRFR1 antagonists exert significantly anxiolytic effects 
[78-80]. Knockout of CRF or CRFR1 in mice significantly reduces ALBs to stress and 
dramatically blunts stress-induced HPA axis activity [61,81,82]. Remarkably, previous 
chronic stress is able to enhance HPA axis activity in response to a novel acute stress, 
despite the negative feedback effects of increased glucocorticoids produced by the chronic 
stress [83-85]. For example, CCK-4-induced panic status in healthy volunteers significantly 
increases HPA axis activities [86]. Even the effects of early-life stress on HPA axis function 
are found to be associated with CCK sensitivity 130. Most interestingly, interactions between 
the CCKergic system and the CRF/HPA system exist [88-90]. For example, the CCKergic 
system was found to be involved in this chronic stress-enhanced responsiveness, since 
chronic stress can specifically facilitate the release of CCK into the PVN, which directly 
projects to the pituitary, in response to acute stress 125. All these findings have not only 
established the role of the CRF/HPA system in initiating behavioral responses to stresses, 
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but also indicate that a significant interaction may exist between the CRF/HPA system and 
CCKergic system to regulate stress-related behaviors. 
However, the vulnerability among different individuals to AT is different. This variability 
may at least partially attribute to a genetic variability [91]. A twin study of Vietnam veterans 
revealed that about 37.9% of vulnerability to PTSD was genetically related [92]. Further 
genetic evidence comes from clinical association studies, by which several candidate genes 
for ADs including PTSD have been associated, although a causative gene has not been yet 
established [91]. Among those candidate genes, cholecystokinin (CCK) receptor-2 (CCKR-2) 
has been linked to panic disorder, another major form of ADs [93,94]. 
As the most abundant neuropeptides, CCK distributes broadly in the brain and mainly in 
the limbic system [95,96]. CCK binds to CCK receptor-1 (CCKR-1) and CCKR-2, of which the 
CCKR-2 is predominantly found in the brain with the highest level in cortical area and the 
limbic system [97], a brain region that is critically involved in emotion response and 
behavior. Virtually, the CCKergic system has long been recognized as an anxiogenic factor 
for the animals [98], and this effect has been well validated in human populations as well 
[89,99,100]. Our recent study also showed that overexpression of CCKR2 in neurons of the 
forebrain of mice significantly enhanced ALBs [101]. At the same time, some candidate 
genes that are linked to ADs are also associated with HPA axis activity. For example, a 
common polymorphism at the serotonin transporter (5-HTT) gene, namely 5HTTLPR, is a 
strong candidate genetic variation for ADs and depression [102-103], and also is 
significantly implicated in HPA axis activity [104]. Similar to the CCKergic system, the HPA 
axis system has long been recognized as a stress hormone [105,106], and plays a critical role 
in the pathogenesis of ADs [107,108]. Indeed, following ELS, the activity of the HPA axis 
system is dysfunctional [109-111]. Moreover, given the overall role of both the HPA axis 
system [112-114] and the CCKergic system [115-117] in regulating neuronal, cardiovascular, 
and metabolic functions in the body, these two systems may play an integrative role in the 
pathogenesis of post-ELS disorders. 
In this study, by using our previously engineered inducible forebrain-specific CCKR-2 
transgenic (IF-CCKR-2 tg) mice [101], we demonstrated that the elevated CCKergic tone in 
the brain significantly facilitated the effect of AT on the impairment of the glucocorticoid 
negative feedback inhibition in response to a novel acute stressor during the adult stage in 
the mouse, providing direct evidence that reveals a molecular basis for this co-effect.  
2. Materials and methods 
2.1. Experimental animals  
The procedures for the generation of IF-CCKR-2 tg (simply dtg) mice were described in our 
previous publication [101]. Briefly, we used the tTA/tetO-inducible gene expression system to 
produce these dtg mice. This system requires two independent transgenic mouse strains, tTA 
transgenic and tetO/CCKR-2 transgenic mice. Accordingly, two constructs were made. The 
first was for tTA transgenic mice, in which the expression of the tTA was under the control of 
an alpha-Ca2+ calmodulin kinase II (CaMKII) promoter. The tTA transgene cassette consists of 
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0.6 kb of exon-intron splicing signal (pNN265), 1.0 kb of tTA encoding sequence (pTet-Off, 
Clontech), and 0.5 kb of SV-40 poly-A signals (pTet-Off, CLONTECH). The other construct is 
for CCKR-2 transgenic mice, in which the expression of the CCKR-2 transgene was under the 
control of the tetO promoter. The CCKR-2 transgene cassette consisted of 1.3 kb of mouse 
CCKR-2 cDNA, an upstream 0.6 kb of splicing signal (pNN265), and a downstream 1.1 kb of 
b-globin poly-A signals. All these components were subcloned into the pTRE2 vector 
(CLONTECH). CCKR-2 cDNA was cloned by RT-PCR from the total RNA extracted from the 
brain of a male B6/CBA F1 mouse (The Jackson Laboratory) with the primers of 5'-CGG GAT 
CCA TGG ATC TGC TCA AGC TG-3' and 5'-GCT CTA GAT CAG CCA GGT CCC AGC GT-
3'. A commercial RNA extraction kit (Invitrogen) and a reverse transcription kit (Stratagene) 
were used. The cloned cDNA was confirmed by sequencing. The plasmid constructs were then 
linearized with suitable enzymes and separately injected into the pronucleoli of B6/CBA F1 
zygotes, as described [118]. Transgenic founders and the transgene copy numbers were 
determined by Southern blot analyses of the tail DNA. Founder mice with suitable gene copy 
numbers were backcrossed into B6/CBA F1 mice first to produce hemizygous single transgenic 
mice and then to produce double hemizygous transgenic mice. We have totally generated nine 
CaMKII-tTA transgenic founders and seven tetO-CCKR-2 transgenic founders. Southern blot 
analyses indicated that the gene copy numbers were from 2 to 70 for tTA transgenic founders 
and 2-150 for CCKR-2 transgenic founders (data not shown). To map the tTA expression 
pattern in the brain, we crossed a tetO-Lac-Z reporter mouse line (SJL-TgN-tetoplacZ, the 
Jackson Laboratory) into different independent CaMKII-tTA mouse lines to produce different 
tTA-LacZ double transgenic mouse lines. For Lac-Z staining, a commercial X-Gal staining kit 
(Invitrogen) and the recommended staining protocol were used with sagittal brain sections (30 
µm), by which we identified a tTA transgenic line that was of the capacity to drive tetO/gene 
expression in almost all the neurons in the forebrain region (data not shown). Genotyping was 
determined by PCR analyses of both tTA (5'-AGG CTT GAG ATC TGG CCA TAC-3' and 5'-
AGG AAA AGT GAG TAT GGT G-3') and the CCKR-2 (5'-ACG GTG GGA GGC CTA TAT 
AA-3' and 5'-GAG TGT GAA GGG CATG CAA-3') transgenes. Dtg mice used here were 
around 12-16 generations since they were generated, during which duration dtg mice were 
backcrossed into B6/CBA F1 mice in every 5-6 generations, in order to avoid an inbreed effect. 
Single transgenic (tTA or tetO-CCKR-2 only) and wild-type (wt) littermates of dtg mice were 
used as controls, and are collectively and simply called wt mice hereafter.  Mice used here 
were kept in standard laboratory mouse cages under the standard condition (12 hours 
light/dark cycle, temperature at 22 ± 1 oC, humility at 75%) with food and water ad libitum. All 
experimental procedures for the use of animals were previously reviewed and approved by 
the institutional animal care and use committee at the Louisiana State University Heath 
Sciences Center at New Orleans, and all of the experiments were conducted in accordance 
with the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health. 
2.2. In situ hybridization  
The hybridization was used to detect the expression level and pattern of the CCKR-2 
transgene in the brain. Brains from both wt and dtg mice were collected by decapitation, 
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and were frozen with powered dry ice immediately. Sagittal sections (20 µm) were made 
with a Cryostat (Leica, CM 1900, Richmond, IL). An oligo probe for tTA and a cRNA probe 
for the total CCKR-2 mRNAs were labeled with 35S UTP (>1,000 Ci/mmol; NEN, Boston, 
MA) by a random labeling kit and in vitro transcription kit (Invitrogen, Carlsbad, CA), 
respectively. The hybridization was performed overnight at 55°C, and after washing, slides 
were exposed to Kodak BioMax film (NEN) for the same time.  
2.3. Adolescent trauma (AT)  
Both wt and dtg mice at the age of P25 were individually put into a small shock-box (4 X 4 X 
10 inch in high) that was modified from the shock box from a fear-conditioning system 
(Coulbourn Instruments, Whitehall, PA), in order to ensure that the mice did not have much 
space for escaping during shocking. The current of the footshock was higher (1.0 mA) than it 
was commonly used in the fear-conditioning test (0.6-0.8 mA). The footshock was conducted 
for 5 times (trials), in total, during a period of 1 minute, and each trial lasted for 2 seconds, 
with an interval of 10 seconds between trials. 
2.4. Acute stressor (AS)  
Additional acute stressor (AS; 0.8 mA for 2 seconds for one trial) with a standard fear-
conditioning paradigm as described previously [119], was used to trigger HPA axis reaction 
at the age of P60 (2 months).   
2.5. ELISA  
Commercially available kits for both the adrenocorticotropic hormone (ACTH) (MD 
Bioproducts, St. Paul, MN) and corticosteroid hormone (CORT) (R&D systems, Minneapolis, 
MN) were used to determine the serum level of these hormones. Experimental procedures 
followed the recommended steps. In order to have samples enough for triplicate 
measurements, blood was collected with a retroorbital eye bleeding method. In order to 
minimize non-specific effects, blood collection was conducted at 9:00 Am, and the procedure 
was completed within 30 seconds, by which time any possible change that might be 
produced by the sampling procedure was not yet measurable. 
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Both female and male mice were almost equally distributed in each group. Data were 
analyzed with one-way ANOVA, followed by post-hoc tests.  The p value less than 0.05 is 
considered significant.  
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3.1. Expression of the CCKR-2 transgene in the brain of dtg mice 
As shown in Fig 1, in situ hybridization revealed that the expression of the tTA was 
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expression pattern of the CCKR-2 transgene (data not shown) was the same as both the 
pattern of the tTA expression and the CCKR-2 transgene expression reported in our 
previous study [101].  
 
Figure 1. Expression pattern of the tTA mRNA detected by in situ hybridization with saggital brain 
sections in wt (A) and dtg (B) mice.  
3.2. Dtg mice with AT exhibit an increased HPA axis activity in response to AS 
Either wt (n = 60) or dtg mice (n = 60) were subjected to AT, and then were divided into 5 
groups (n = 12) for a time-course study, in which both ACTH and CORT were examined 
before the AS for the basal level, and 1, 2, 4, and 8 hours following the AS. As shown in Fig. 
2, although the difference in the basal level of ACTH (Fig.  2A) or CORT (Fig. 2C) between 
these mice was not significant, a tendency of a lower level ACTH (p = 0.0741) and CORT (p = 
0.0648) was observed in dtg groups, compared to wt groups. Following the AS, an one-way 
ANOVA revealed a significant effect of the AT and CCKR-2 transgene on ACTH [F(1,8) = 
6.781, p < 0.01] and  CORT [F(1,8) = 9.201, p < 0.01]. Detailed post-hoc tests revealed that 
both ACTH (Fig. 2B) and CORT (Fig. 2D) in either wt or dtg mice reached the peak level at 1 
hr after the AS, while a significant difference was observed at 1 and 2 hr in ACTH between 
wt and dtg groups (p > 0.05), and at 1 and 2 hr in CORT between wt and dtg groups (p > 
0.05). In both wt and dtg mice, ACTH returned to the basal level at 4 hr (Fig. 2B), while 
CORT returned to the basal level at 4 hr (Fig. 2D). All these results indicate that the 
interaction between the AT and CCKR-2 transgene does not only increase the activity of the 
HPA axis following a novel stressor, but also impairs the CORT negative feedback in 
response this stressor.  
3.3. Disassociation of the CCKR2 transgene expression and AT largely 
diminishes the effect of AT on HPA axis activity in response to AS  
In this study, both wt and dtg mice were treated with doxycycline (doxy, 2 mg/100 ml in 
drinking water) for 5 days prior to AT, so that the transgene expression in dtg mice was 
inhibited during the episode of AT, and this inhibition lasted for about 3-5 days after the 
doxy treatment. At 2 months old, these mice were subjected to AS, and 1 hr later, which is 
the peak time of HPA axis response, as described in Fig. 2, the HPA axis activity was 
measured. Surprisedly, the levels of both ACTH and CORT were indistinguishable between 
wt and dtg mice, indicating that the coupling of AT and the transgene expression is critical 
for the AT to produce impaired glucocorticoid negative feedback inhibition in the animals.  
 
CCKergic System, Hypothalamus-Pituitary-Adrenal (HPA) Axis, and Early-Life Stress (ELS) 27 
 
Figure 2. Increased HPA axis activity in dtg mice with AT/AS. A. Basal serum level of ACTH in naïve 
wt mice and naïve dtg mice. A tendency of a difference is shown, but it is not significant. Data are 
expressed as mean ± SEM. B. Time-course of ACTH response following the AS. C. Basal serum level of 
CORT in naïve wt mice and naïve dtg mice. A tendency of a difference is shown, but it is not significant. 
Data are expressed as mean ± SEM. D. Time-course of CORT response following the AS. The same 
groups of mice above were examined.  
 
Figure 3. Level of ACTH (A) and CORT (B) in the mice after AT/AS. No significant difference was 
found between wt and dtg mice when the expression of the CCKR-2 transgene was suppressed during 
AT. 
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4. Discussion  
We have for the first time demonstrated that a coupling of a higher CCKergic tone with an 
ELS event is a causative factor for the development of an impairment of glucocorticoid 
negative feedback inhibition in the animals in response to additional acute stressor at a later 
life stage.  
This demonstration is achieved based on the technical merit in our transgenic mice, in which 
the transgene expression is inducible/reversible. The time resolution for this 
inducible/reversible feature is within 1 week, which is high enough for this time-coupling 
analysis. However, it is still not clear how this real-time coupling occurs, partially due to the 
fact that the functional significance of the CCKergic system is still not fully understood. As 
G protein-coupled receptors, CCKR are associated with Ca2+ release, PKC activation, PLA2 
activity, and cAMP production [120]. In addition, there are robust interactions between the 
CCKergic system and other neurotransmitter systems including dopaminergic, serotonergic, 
and GABAergic systems at both the structural and functional levels [121,122], and therefore, 
the mechanism underlying this associative effect should be complicated, and need to be 
further studied.  
An important finding in this study is the discovery of the change in the HPA axis activity, 
and these changes include (1) a slightly lower basal level of the HPA axis activity in dtg 
mice, compared to wt mice, (2) a synergistic effect of AT and the CCKR-2 transgene on the 
peak level of the HPA axis activity in response to the AS; (3) a prolonged decay time of the 
HPA axis activity following the AS in dtg mice with AT, and (4) a requirement of real-time 
coupling of the transgene expression and TA. It should be mentioned that it has been well 
established that a previous chronic stress in the animals down-regulates the HPA axis 
activity, but enhances their response to a novel acute stress, despite the negative feedback 
effects [83,123,124]. Because chronic stress can specifically facilitate the release of CCK into 
the PVN, which directly projects to the pituitary, in response to acute stress [88], the elevated 
CCKergic tone in our dtg mice may mimic the effect of a chronic stress by working as an 
“intrinsic stressor” for the animals. Therefore, this intrinsic stressor constitutes a basis for the 
higher vulnerability of dtg mice to AT. At the same time, the impaired AS-induced CORT 
negative feedback response may, in tern, significantly alter many other physiological 
functions, and eventually lead to a pathological condition. 
As described above, following ELS, neuroanatomical changes were found in different brain 
regions. In addition, neuronal activity is altered too {125}. Consistent to the current study, 
the activity of the HPA axis system in the subject who experienced ELS was dysregulated 
[48-52]. Moreover, many other neurotransmitter systems were also affected by ELS [40, 126-
128]. Therefore, the finding from the current study has provided additional evidence 
regarding how the CCKergic system and the HPA axis system are involved in the 
pathogenesis of post-ELS disorders. 
The most important finding in this study is the demonstration of that if the transgene was 
temporally suppressed during the time of AT exposure, this impaired HPA axis inhibition 
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in response to another acute stressor was largely diminished, indicating that the temporal 
association of the elevated CCKergic tone with AT is critically pathogenic.  This finding has 
a potential translational significance. It is well know that the endogenous CCKergic activity, 
or the CCKR-2 level in the brain, plays a dominant role in the expression of anxiety. For 
example, the expression of anxiety was correlated with the increased CCKergic tone, which 
was evidenced by a higher CCK receptor-binding capacity in the brain of anxious animals, 
in comparison with non-anxious animals [129-131]. Different fear responses among different 
strains of the same animal species were attributed to different expression levels of CCKR-2 
[132-134]. On the other hand, evidence also indicates that the CCKergic tone in the brain is 
dynamically regulated by stress. Following stress, for example, both CCK peptide 
immunoreactivity and CCK receptor density in the brain were significantly increased [135-
139]. Social isolation, an anxiogenic stress, increased the CCK mRNA expression in the 
brain [140]. Especially, the effect of ELS on the HPA axis activity was associated with CCK 
activity [87]. Chronic stress could specifically facilitate the release of CCK into the PNV in 
response to acute stress [84,141]. Consistently, CCKR-2 agonists could only produce, or 
produce more pronounced, anxiogenic effect in stressed animals, but not in un-stressed 
animals [88, 142-144]. Patients with ADs were more sensitive to CCKR-2 agonists than 
normal controls [145-148]. Together with all these findings, it seems conclusive that the 
CCKergic system is dynamically involved in ELS-triggered mental disorders, and thus, an 
inhibition of the CCKergic tone timely associated with an ELS event might be useful to 
prevent the development of post-ELS disorder, especially ADs. 
In summary, our study has revealed a Novel molecular underpinning for the development 
of post-ESL disorders, especially for mental disorders, and provide insightful information 
regarding how can we develop a preventive strategy for these post-ESL disorders in the 
humans.  
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1. Introduction 
Synthetic oral steroids were initially developed in the 1940-1950’s. Although their use was 
initially limited by their high cost, as they became more affordable and began to be used for 
treatment of a wide variety of conditions, side effects associated with their use became much 
more prevalent. In fact, glucocorticoid-induced osteoporosis is now the most common 
secondary cause of osteoporosis. Until relatively recently, the mechanism of action of these 
drugs and the mechanisms involved in the development of side effects such as osteoporosis 
and the higher incidence of bone fractures was not known. Although steroids are widely 
viewed as mainly catabolic for bone a distinction needs to be made between physiologic and 
pharmacologic doses of steroids. Recent evidence demonstrates that steroids can clearly be 
anabolic for bone. In this chapter we review recent findings and mechanisms of 
glucocorticoid action on bone and some of the clinical consequences of pharmacologic doses 
of these compounds on bone. 
2. Glucocorticoids and osteoporosis 
Glucocorticoids are among the most potent anti-inflammatory and immunosuppressive 
agents and are key therapeutic agents for the management of chronic inflammatory 
diseases, including rheumatic diseases [1-4], pulmonary disease [5;6], asthma [7-11] and post 
transplantation immunotherapy [12]. However, long-term glucocorticoid therapy (>3 
months) causes bone loss resulting in osteoporosis (glucocorticoid-induced osteoporosis or 
GIOP) [3;4;13-15], a severe-side effect that occurs in 30 – 50% of patients [16-18]. The 
incidence of GIOP is indiscriminate of race, age and gender [19;20]. Children, as young as 4 
years of age, and adolescents who are on glucocorticoid therapy for various pediatric 
disorders, including asthma [20-22], juvenile rheumatoid arthritis [23;24], Crohn's disease 
[25], systemic lupus erythematosus [26;27], and inflammatory bowel disease [28;29] have 
 T e Author(s). Lic nse  InTech. This chapter is distributed under the terms of  Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
 
Glucocorticoids – New Recognition of Our Familiar Friend 40 
[145] Bradwejn J, Koszycki D, & Shriqui C (1991) Enhanced sensitivity to cholecystokinin 
tetrapeptide in panic disorder. Clinical and behavioral findings. (Translated from eng) 
Arch Gen Psychiatry 48(7):603-610 (in eng). 
[146] Brawman-Mintzer O, et al. (1997) Effects of the cholecystokinin agonist pentagastrin in 
patients with generalized anxiety disorder. (Translated from eng) Am J Psychiatry 
154(5):700-702 (in eng). 
[147] Kellner M, et al. (2000) Behavioral and endocrine response to cholecystokinin 
tetrapeptide in patients with posttraumatic stress disorder. (Translated from eng) Biol 
Psychiatry 47(2):107-111 (in eng). 
[148] van Vliet IM, Westenberg HG, Slaap BR, den Boer JA, & Ho Pian KL (1997) Anxiogenic 
effects of pentagastrin in patients with social phobia and healthy controls. (Translated 







© 2012 Shi et al., licensee InTech. This is an open access chapter distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Mechanism of Glucocorticoid-Induced 
Osteoporosis: An Update 
Xing-Ming Shi, Norman Chutkan, Mark W. Hamrick and Carlos M. Isales 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/53978 
1. Introduction 
Synthetic oral steroids were initially developed in the 1940-1950’s. Although their use was 
initially limited by their high cost, as they became more affordable and began to be used for 
treatment of a wide variety of conditions, side effects associated with their use became much 
more prevalent. In fact, glucocorticoid-induced osteoporosis is now the most common 
secondary cause of osteoporosis. Until relatively recently, the mechanism of action of these 
drugs and the mechanisms involved in the development of side effects such as osteoporosis 
and the higher incidence of bone fractures was not known. Although steroids are widely 
viewed as mainly catabolic for bone a distinction needs to be made between physiologic and 
pharmacologic doses of steroids. Recent evidence demonstrates that steroids can clearly be 
anabolic for bone. In this chapter we review recent findings and mechanisms of 
glucocorticoid action on bone and some of the clinical consequences of pharmacologic doses 
of these compounds on bone. 
2. Glucocorticoids and osteoporosis 
Glucocorticoids are among the most potent anti-inflammatory and immunosuppressive 
agents and are key therapeutic agents for the management of chronic inflammatory 
diseases, including rheumatic diseases [1-4], pulmonary disease [5;6], asthma [7-11] and post 
transplantation immunotherapy [12]. However, long-term glucocorticoid therapy (>3 
months) causes bone loss resulting in osteoporosis (glucocorticoid-induced osteoporosis or 
GIOP) [3;4;13-15], a severe-side effect that occurs in 30 – 50% of patients [16-18]. The 
incidence of GIOP is indiscriminate of race, age and gender [19;20]. Children, as young as 4 
years of age, and adolescents who are on glucocorticoid therapy for various pediatric 
disorders, including asthma [20-22], juvenile rheumatoid arthritis [23;24], Crohn's disease 
[25], systemic lupus erythematosus [26;27], and inflammatory bowel disease [28;29] have 
 T e Author(s). Lic nse  InTech. This chapter is distributed under the terms of  Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
 
Glucocorticoids – New Recognition of Our Familiar Friend 42 
been reported to endure significant bone density decrease. There is no clearly defined 
threshold for safe use of glucocorticoids. In practice, a dose equal to or greater than 5mg/day 
of prednisone is considered as low, and 10mg/day or more is high. The severity of bone loss 
in GIOP is both time- and dose-dependent. GIOP occurs in two phases: a rapid, early phase 
in which bone mineral density is reduced, within the first 5 to 7 months of therapy, possibly 
as a result of excessive bone resorption, and a slower, progressive phase in which bone 
mineral density declines because of impaired bone formation [30]. Bone loss continues as 
long as treatment is maintained. 
3. Glucocorticoid mechanism of action as anti-inflammatory and 
immunosuppressant drugs 
Glucocorticoids exert their actions via intracellular glucocorticoid receptors (GRs) [31;32]. The 
GR belongs to the ligand-regulated nuclear receptor superfamily [33]. Like other members in 
this superfamily, GR contains three major functional domains: a N-terminal activation domain 
required for transcriptional activation and association with basal transcription factors; a central 
DNA-binding domain (DBD) consisting of two highly conserved zinc finger regions that are 
critical for dimerization, DNA binding, transcriptional activation and repression; and a C-
terminal ligand-binding domain (LBD) that serves as the binding site for glucocorticoids, 
chaperone proteins, and coactivators [34;35]. In the absence of ligand, GR is predominantly 
retained in the cytoplasm as an inactive multi-protein complex consisting of heat shock protein 
(hsp90) and a number of other proteins, including the immunophilins. The binding of 
glucocorticoid triggers a conformational change in the GR and leads to dissociation of the 
multi-protein complex and exposure of a nuclear localization sequence resulting in its nuclear 
translocation. Once in the nucleus, GR, in the form of a homodimer, binds to a palindromic 
glucocorticoid-response element (GRE) in the target gene promoter and activates transcription 
(e.g., of the tyrosine amino transferase gene), or it can bind to a negative GRE (nGRE) to 
repress transcription (e.g., of the osteocalcin gene) [36].  
Glucocorticoids suppress the expression of a panel of inflammatory-relevant genes 
including cytokines [interleukins (IL) and tumor necrosis factors (TNF-,], chemokines 
(Regulated upon Activation Normal T-cell Expressed and Secreted or RANTES, 
Macrophage Inflammatory Protein-1-alpha or MIP-1, Monocyte Chemotactic Protein or 
MCP-1, -3, and -4], inflammatory enzymes (COX-2, iNOS), and adhesion molecules 
(Intercellular Adhesion Molecule 1 or ICAM-1, E-selectin) that play a key role in the 
recruitment of inflammatory cells to the inflammation sites [37-39]. However, most of these 
genes do not have negative GREs in their promoter regions, and therefore, they are not 
directly regulated by the binding of GRs to such regulatory elements. These genes do 
contain NF-B- and/or AP-1-binding sites and are activated through these sites by NF-B 
and/or AP-1 in response to stimuli (cytokines). Thus, one mechanism by which 
glucocorticoids could regulate transcription would be modulation of NF-B or AP-1 DNA-
binding activity. In 1990, three independent groups found cross-talk between GR and AP-1 
[40-42]. In these studies, it was found that activated GR can interact with c-Jun/AP-1 and 
that the formation of a GR-c-Jun complex prevents c-Jun/AP-1 DNA-binding, resulting in 
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the inhibition of gene expression. Later, it was found that the activated GR can associate 
with the p65 subunit of NF-B and inhibit gene activation mediated by NF-B [43;44]. These 
findings led to the establishment of the protein-protein interaction model. 
In 1995, it was found that glucocorticoids induce the expression of a cytoplasmic inhibitor of 
NF-B, the IB- [45;46]. These studies led to the establishment of a second model, the IB- 
upregulation model. This model proposes that glucocorticoids induce the expression of IB-
 and that the newly synthesized IB- sequesters the p65 subunit of the NF-B in the 
cytoplasm and thereby inhibits NF-B nuclear functions. However, this mechanism has been 
challenged by a number of studies. It has now been established that the effect of 
glucocorticoids on IB- expression, and subsequently NF-B nuclear translocation, is cell-
type specific. In some cell types glucocorticoid inhibition of proinflammatory stimuli-
induced p65 nuclear translocation is coupled with the induction of IB- [45-48]. In other 
cell types, however, these two events are uncoupled [49;50]. Moreover, a GR mutant that 
does not enhance IB- expression, is still able to repress NF-B activity [51].  
4. Glucocorticoid effects on bone cells 
Glucocorticoids have both anabolic and catabolic effects on bone. However, the outcome of 
glucocorticoid therapy is a net loss of bone [4;52;53]. Corticosteroid 11β-hydroxysteroid 
dehydrogenase 2 [11β-HSD2] is an enzyme that oxidizes the active form of glucocorticoid 
cortisol to the inactive metabolite cortisone, thus the levels of expression and activity of this 
enzyme is critical for glucocorticoid signaling. In vivo studies show that bone-specific 
transgenic overexpression of 11β-HSD2, under the control of type I collagen promoter, 
impairs osteoblast differentiation and bone acquisition [54-56]. These studies demonstrate 
that the endogenous glucocorticoid signaling is essential for normal skeletal development. 
However, glucocorticoid in excess such as patients with Cushing’s syndrome [22] or the 
patients on glucocorticoid therapy rapidly lose bone mass resulting in osteoporosis. The 
direct effects of glucocorticoids on bone cells are illustrated in Figure 1. 
5. Glucocorticoid effects on bone marrow Mesenchymal Stem Cells 
(MSCs) 
Bone marrow MSCs are multipotent cells that can give rise to several distinct cell lineages, 
including osteoblasts, adipocytes, and chondrocytes [57-60]. Patients on glucocorticoid 
therapy not only lose bone but also accumulate large amounts of marrow fat (fatty marrow), 
indicating that glucocorticoid has altered lineage commitment of MSC to adipocytes at the 
expense of osteoblasts because these two pathways have a reciprocal relationship [61-64]. 
Thus, one possible mechanism by which glucocorticoids alter MSC fate determination is 
through the induction of the master adipogenic regulator peroxisome proliferator-activated 
receptor gamma (PPAR) [65;66], which is transcriptionally activated by the 
CCAAT/enhancer binding protein (C/EBP) family transcription factors in response to 
glucocorticoid [67-70] (Figure 2). Indeed, Weinstein and colleagues showed that 
administration of glucocorticoids to mice reduces the numbers of osteoprogenitor cells [71]. 
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This could be achieved through induction of PPAR since under the same condition bone 
marrow adipogenesis is enhanced [72], and that a reduction in PPAR dosage 
(haploinsufficiency) in mice results in reduced adipogenesis and enhanced osteogenesis 
from bone marrow progenitors [73].  
 
Figure 1. Glucocorticoids bind to the glucocorticoid receptor (GR) and affect mesenchymal stem cell 
(MSC), osteoblast (OB), osteoclast (OC) and osteocyte (Ocyte) function. The net result is decreased bone 
formation and increased bone resorption. ↑ increase;  ↓decrease. 
  
Figure 2. Glucocorticoid reduces the number of osteoprogenitors from MSC by promoting adipogenic 
differentiation pathway. Glucocorticoid induces the expression of C/EBP family transcription factors 
that directly activate the transcription of PPAR, the master regulator of adipogenesis, and shifts the 
lineage commitment of MSCs to adipocyte pathway, thus reducing the number of osteoprogenitor cells.  
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6. Glucocorticoid effects on osteoblasts and osteocytes 
It has been known for decades that glucocorticoid inhibits bone formation [52;74], but only 
recently have we realized that glucocorticoids directly target bone cells. By administering a 
high dose of prednisolone to mice, Weinstein and colleagues found that glucocorticoid 
induces the death of mature osteoblasts and osteocytes [71;75]. In the same study, the 
authors also showed that the same is true in bone biopsy samples obtained from patients 
with glucocorticoid-induced osteoporosis. These results were further strengthened in a 
transgenic mouse model, in which the glucocorticoid signaling is disrupted by 
overexpression of 11β-HSD2 specifically in osteoblasts. The study showed that the 11β-
HSD2 transgenic mice are protected from glucocorticoid-induced osteoblasts and osteocytes 
apoptosis and suppression of bone formation [76]. These studies demonstrate that 
glucocorticoids cause bone loss by restricting the supply of bone building cells, the 
osteoblasts, and by interfering with the communication network within bone environment 
via osteocyte death. The osteocytes are the mechanosensory cells that detect and send 
signals for bone formation in response to damages caused by mechanical loading and 
unloading [77;78].  
7. Glucocorticoid effects on osteoclasts 
Osteoclasts are bone resorbing cells and play a key role in the maintenance of bone 
homeostasis through bone remodeling. In patients, glucocorticoid-induced osteoporosis 
features a rapid early phase increase in bone resorption, followed by a slow progressive 
decrease in bone formation [52]. Earlier studies showed that glucocorticoids stimulate 
osteoclast differentiation and increase their activity [72;79;80]. It is now recognized that 
glucocorticoids increase the longevity of osteoclasts but may inhibit their bone resorptive 
activity [81;82]. Moreover, a recent study suggests that glucocorticoids do not inhibit, but 
modify osteoclast resorptive behavior, making osteoclasts erode bone surfaces over long 
distances without interruption [83]. 
8. Glucocorticoid-induced Leucine Zipper (GILZ): A new glucocorticoid 
anti-inflammatory effect mediator  
The protein-protein interaction and the IB- upregulation models described earlier in this 
chapter were established prior to the discovery of a glucocorticoid-inducible protein named 
glucocorticoid-induced leucine zipper (GILZ), which was identified in 1997 [84]. GILZ is a 
member of the leucine zipper protein family [84;85] and belongs to the transforming growth 
factor-beta (TGF-)-stimulated clone-22 (TSC-22d3) family of transcription factors [86;87]. 
Members of this family of proteins contain three distinct domains; an N-terminal domain 
containing a TSC box (N-Ter), a middle leucine zipper domain (LZ), and a C-terminal poly-
proline rich domain (PRR).  
Unlike IB-, which is induced by glucocorticoids in certain cell types [49;50;88], GILZ is 
induced by glucocorticoids virtually in all cell types examined so far, including bone 
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This could be achieved through induction of PPAR since under the same condition bone 
marrow adipogenesis is enhanced [72], and that a reduction in PPAR dosage 
(haploinsufficiency) in mice results in reduced adipogenesis and enhanced osteogenesis 
from bone marrow progenitors [73].  
 
Figure 1. Glucocorticoids bind to the glucocorticoid receptor (GR) and affect mesenchymal stem cell 
(MSC), osteoblast (OB), osteoclast (OC) and osteocyte (Ocyte) function. The net result is decreased bone 
formation and increased bone resorption. ↑ increase;  ↓decrease. 
  
Figure 2. Glucocorticoid reduces the number of osteoprogenitors from MSC by promoting adipogenic 
differentiation pathway. Glucocorticoid induces the expression of C/EBP family transcription factors 
that directly activate the transcription of PPAR, the master regulator of adipogenesis, and shifts the 
lineage commitment of MSCs to adipocyte pathway, thus reducing the number of osteoprogenitor cells.  
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marrow mesenchymal stem cells, osteoblasts, adipocytes, macrophages and epithelial cells 
[89]. In vitro studies show that overexpression of GILZ protects T-cells from apoptosis 
induced by anti-CD3 monoclonal antibody, but not other apoptosis-inducing agents such as 
dexamethasone, ultraviolet irradiation, starvation, or triggered by cross-linked anti-Fas mAb 
[84]. T-cell-specific transgenic overexpression of GILZ results in thymocyte apoptosis ex vivo, 
possibly through down-regulation of Bcl-xL [90]. The in vitro actions of GILZ have been 
shown to be mediated through direct protein-protein interactions between GILZ and NF-B, 
and between GILZ and AP-1 [86;91;92]. The interaction between GILZ and NF-B blocks 
NF-B nuclear translocation and DNA-binding, and the interaction with AP-1 inhibits the 
binding of AP-1 to its DNA elements [91;92]. GILZ also interacts directly with the mitogen-
activated protein kinase (MAPK) family members, Ras and Raf-1, resulting in inhibition of 
Raf-1 phosphorylation and subsequently, inhibition of MEK/ERK-1/2 phosphorylation and 
AP-1-dependent transcription [86;93]. Moreover, GILZ can deactivate macrophages [94], 
inhibit proinflammatory cytokine-induced inflammatory enzymes such as cyclooxygenase-2 
[95], inhibit IL-2/IL-2 receptor and IL-5 expression [91;96], and stimulate the production of 
anti-inflammatory IL-10 by immature dendritic cells, thereby, preventing the production of 
inflammatory chemokines by CD40L-activated dendritic cells [97]. These studies 
demonstrate that GILZ is a glucocorticoid anti-inflammatory effect mediator and utilizes  
very similar mechanisms, to those  GR uses [98]. 
9. GILZ mediates the anabolic effect of glucocorticoids 
GILZ is a direct GR target gene with several GREs present in its promoter region [99]. In the 
absence of glucocorticoid stimulation GILZ is expressed at a very low basal level. However, 
in the presence of glucocorticoid, GILZ expression is rapidly induced (Figure 3] but GR is 
also activated, and the activated GR negatively impacts bone, both directly (i.e., inhibits 
osteocalcin gene transcription) and indirectly through other pathways as illustrated (Figure 
4]. Because of that, it is impossible to determine the role of GILZ in osteoblast differentiation 
and bone formation without the influence of GR, which plays a negative role and may 
override GILZ actions. To further study this problem, a retrovirus-mediated GILZ 
overexpression system was established in bone marrow MSCs/osteoprogenitor cells. Studies 
carried out in this system showed that GILZ has potent pro-osteogenic activity as 
demonstrated by significantly increased alkaline phosphatase activity, enhanced 
mineralized bone nodule formation, and the expression of osteoblast-associated genes such 
as Runx2, type I collagen, alkaline phosphatase, and osteocalcin [100]. Furthermore, our 
recent studies have shown that overexpression of GILZ can antagonize the inhibitory effect 
of TNF- on MSC osteogenic differentiation [101]. Possible mechanisms underlying this 
antagonism may include GILZ inhibition of TNF--induced ERK/MAP kinase activation, 
which has been shown to be responsible for TNF- down-regulation of a key osteogenic 
factor Osx [102;103], and inhibition of TNF--induced expression of E3 ubiquitin ligase 
Smurf proteins, which have been shown to accelerate the degradation of Runx2 protein [104-
106]. 
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Figure 3. GILZ enhances MSC osteogenic differentiation by shifting MSC lineage preference to 
osteogenic pathway. 
10. GR mediates the catabolic effects of glucocorticoids 
There are many glucocorticoid effectors involved in the regulation of bone development or 
metabolism through different pathways. However, it was only recently demonstrated that 
the GR was directly responsible for glucocorticoid-induced bone loss in vivo. Using a bone-
specific GR knockout mouse model, Rauch et al showed that glucocorticoids are unable to 
induce bone loss or to inhibit bone formation in these mice because the GR-deficient 
osteoblasts become refractory to glucocorticoid-induced apoptosis, inhibition of 
proliferation, and differentiation [107]. Interestingly, data from this study also demonstrated 
that GR-deficiency results in a low bone mass phenotype, confirming the previous studies 
that the endogenous glucocorticoid signaling is critical for normal bone acquisition [54-56]. 
Other evidence supporting the role of GR in glucocorticoid-induced bone loss includes: 1] 
the glucocorticoid-activated GR binds directly to the negative glucocorticoid response 
elements (nGREs) in the promoter region of the osteocalcin (Ocn) gene, an osteoblast-
specific gene that plays an important role in bone mineralization, and inhibit its 
transcription [36;108]; 2] GR transcriptionally activates the expression of MAP kinase 
phosphatase-1 (MKP-1] [109], which inactivates MAP kinase and thus inhibits osteogenic 
differentiation [64;110;111]; and 3] GR can physically interact with and inhibit the 
transcriptional functions of Smad3, an intracellular signaling mediator of transforming 
growth factor-beta (TGF-) [112] (Figure 4]. Glucocorticoids have been known to antagonize 
TGF- action in bone [113-115] and TGF- stimulates osteoprogenitor cell proliferation [116-
119] and attract osteoprogenitor cells to the remodeling sites during bone remodeling [120]. 
It is important to note that while the catabolic effects of glucocorticoids are often associated 
with long-term glucocorticoid excess [1-4;7], a short term exposure to glucocorticoid seems 
beneficial; for example, treatment of bone marrow stromal cells or osteoblasts with 
dexamethasone enhances, rather than inhibits, alkaline phosphatase (ALP) activity. The ALP 
is expressed at the early stage of osteoblast differentiation program and the increase of ALP 
expression or activity marks the entry of cells into the osteoblast lineage. 
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Figure 4. GR inhibits MSC proliferation, ERK activation and Ocn expression. Ligand-bound GR 
physically interacts with: 1] TGF- signaling mediator Smad3 and disrupts its transcriptional activity; 2] 
Activates mkp-1 transcription, by binding to GRE in the mkp-1 promoter region, resulting inhibition of 
ERK activation; and 3] Suppresses Ocn expression by binding to nGRE in the Ocn promoter region. 
11. Glucocorticoid-Induced Osteoporosis (GIOP) 
Although glucocorticoids are an essential hormone for survival and normal function, when 
present in excess (pharmacologic doses) lead to a number of serious side effects including 
bone loss and fractures. In fact, it is estimated that 30-50% of patients chronically exposed to 
high levels of glucocorticoids will develop a bone fracture [121]. Glucocorticoid excess can 
result from either endogenous (Cushing’s) or exogenous (iatrogenic) sources. 
Glucocorticoids are widely used for the treatment of a variety of inflammatory and 
autoimmune conditions. It is estimated that 0.5% of the population receives steroid therapy 
and exogenous steroids are thus the most common cause of secondary osteoporosis [122]. 
There has been a lot of discussion on the dose, duration and mode of administration of 
steroids and the impact on the development of osteoporosis. There has been a lot of debate 
on a “safe” dose for glucocorticoid replacement. Doses as low as 2.5 mg of prednisolone 
have been reported to result in osteoporosis [122]. Even patients on “physiologic” 
glucocorticoid replacement for Addison’s disease have been reported to have lower bone 
density than controls, although clearly many of these patients were overreplaced with 
steroid therapy [123]. Further, steroids even when given in an intermittent, rather than 
continuous fashion, or in an inhaled rather than oral fashion, are still associated with an 
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increased risk of fracture. In treatment guidelines by the American College of Rheumatology 
in 2010, it was recommended that for patients with low fracture risk receiving more than 7.5 
mg of prednisolone equivalents for more than 3 months receive some form of therapy for 
fracture prevention. In contrast for patients at high fracture risk it was recommended that 
they receive some form of therapy even at glucocorticoid doses lower than 5 mg and even 
for periods for less than one month [124]. 
12. Mechanism 
Glucocorticoids have multiple effects on bone and bone cells. In addition, in cases where the 
glucocorticoids are given to treat systemic inflammatory conditions (e.g. rheumatoid 
arthritis), the underlying condition also contributes to bone loss. Glucocorticoids also inhibit 
endogenous production of sex steroids (testosterone and estrogen) in addition to production 
of adrenal androgens, all of which may have protective effects against bone loss [125]. 
Further, prolonged high dose glucocorticoid use results in both muscle weakness thus 
predisposing to an increased number of falls and muscle wasting. Bone-muscle interactions 
may also contribute to maintaining bone health. Glucocorticoids also decrease intestinal 
calcium absorption thus further predisposing to osteoporosis. Recently, effects of 
glucocorticoids on decreasing bone vasculature, has also been implicated as a potential 
mechanism for glucocorticoid effects on bone [126]. There also seems to be an age-
dependence of glucocorticoid effects on bone. The likelihood of fractures with 
glucocorticoids appears to increase with increasing patient age. Glucocorticoid-induced 
bone loss appears to be biphasic with an initial rapid phase of bone loss of 5-15% /year 
followed by a more sustained bone loss rate of 2% [121].  
Glucocorticoids affect all bone cells, they result in osteocytic and osteoblastic apoptosis and 
decreased function of both osteoclasts and osteoblasts. However, they decrease osteoclastic 
apoptosis. Thus, the net effect is reduced bone formation and increased bone breakdown. 
Trabecular bone seems to be particularly sensitive to the detrimental effects of steroids 
resulting in a higher incidence of vertebral and femoral neck fractures [121]. Vertebral 
compression fractures are commonly missed since only about 30% of them are symptomatic. 
A study by Angeli et al [127] which examined the prevalence of vertebral fractures in 
patients receiving glucocorticoids for a variety of autoimmune conditions determined that 
over 37% of patients had at least one asymptomatic vertebral compression fracture and 
more than 14% had two or more asymptomatic fractures.  
Glucocorticoid effects on bone appear to be generally reversible and once therapy is stopped 
bone repair occurs over the year following drug cessation. Thus, if feasible, steroid cessation 
may be the therapy of choice for GIOP. 
13. Diagnosis 
Determining fracture risk for patients on steroids is difficult since even patients with normal 
bone densitometry on steroids have a higher fracture risk. Current use of steroids is one of 
the risk factors used in the calculation of the FRAX (Fracture Risk Assessment) score. 
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increased risk of fracture. In treatment guidelines by the American College of Rheumatology 
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fracture prevention. In contrast for patients at high fracture risk it was recommended that 
they receive some form of therapy even at glucocorticoid doses lower than 5 mg and even 
for periods for less than one month [124]. 
12. Mechanism 
Glucocorticoids have multiple effects on bone and bone cells. In addition, in cases where the 
glucocorticoids are given to treat systemic inflammatory conditions (e.g. rheumatoid 
arthritis), the underlying condition also contributes to bone loss. Glucocorticoids also inhibit 
endogenous production of sex steroids (testosterone and estrogen) in addition to production 
of adrenal androgens, all of which may have protective effects against bone loss [125]. 
Further, prolonged high dose glucocorticoid use results in both muscle weakness thus 
predisposing to an increased number of falls and muscle wasting. Bone-muscle interactions 
may also contribute to maintaining bone health. Glucocorticoids also decrease intestinal 
calcium absorption thus further predisposing to osteoporosis. Recently, effects of 
glucocorticoids on decreasing bone vasculature, has also been implicated as a potential 
mechanism for glucocorticoid effects on bone [126]. There also seems to be an age-
dependence of glucocorticoid effects on bone. The likelihood of fractures with 
glucocorticoids appears to increase with increasing patient age. Glucocorticoid-induced 
bone loss appears to be biphasic with an initial rapid phase of bone loss of 5-15% /year 
followed by a more sustained bone loss rate of 2% [121].  
Glucocorticoids affect all bone cells, they result in osteocytic and osteoblastic apoptosis and 
decreased function of both osteoclasts and osteoblasts. However, they decrease osteoclastic 
apoptosis. Thus, the net effect is reduced bone formation and increased bone breakdown. 
Trabecular bone seems to be particularly sensitive to the detrimental effects of steroids 
resulting in a higher incidence of vertebral and femoral neck fractures [121]. Vertebral 
compression fractures are commonly missed since only about 30% of them are symptomatic. 
A study by Angeli et al [127] which examined the prevalence of vertebral fractures in 
patients receiving glucocorticoids for a variety of autoimmune conditions determined that 
over 37% of patients had at least one asymptomatic vertebral compression fracture and 
more than 14% had two or more asymptomatic fractures.  
Glucocorticoid effects on bone appear to be generally reversible and once therapy is stopped 
bone repair occurs over the year following drug cessation. Thus, if feasible, steroid cessation 
may be the therapy of choice for GIOP. 
13. Diagnosis 
Determining fracture risk for patients on steroids is difficult since even patients with normal 
bone densitometry on steroids have a higher fracture risk. Current use of steroids is one of 
the risk factors used in the calculation of the FRAX (Fracture Risk Assessment) score. 
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However a recent joint position statement by the International Society for Clinical 
Densitometry and the International Osteoporosis Foundation concluded that when using 
the FRAX tool there probably was an underestimation of fracture risk with daily prednisone 
doses greater than 7.5 mg and an overestimation of fracture risk with daily prednisone 
doses of less than 2.5 mg. In addition, FRAX probably underestimated fracture risk when 
high dose inhaled steroids were used. Finally, it was concluded that for patients with 
adrenal insufficiency receiving appropriate replacement steroid doses this not be included 
in the FRAX calculation [128].  
The American College of Rheumatology recommends that some form of therapy be 
considered for all patients receiving prolonged steroid therapy and that for those who have 
a bone densitometry test (Dual energy x-ray absorptiometry or DXA), a T-score of less than -
1.0 be considered abnormal [125].  
14. Therapy 
Since glucocorticoids interfere with intestinal calcium absorption, all patients about to start 
glucocorticoid therapy should be placed on calcium and vitamin D replacement. 
Antiresorptive agents such as bisphosphonates (both oral and IV) have been used for the 
therapy of GIOP, are effective in decreasing the increased fracture risk associated with 
steroids and are approved for this indication. However, as discussed by Teitelbaum et al. 
[129], although initial use of steroids is associated with increased bone resorption (osteoclast 
mediated and related to decreased osteoclastic apoptosis and a situation in which 
antiresorptive use makes sense), more prolonged steroid use is associated with decreased 
bone formation and antiresorptive agents have the theoretical possibility of making things 
worse by further suppressing a low bone turnover state. Thus, use of an anabolic agent such 
as teriparatide (synthetic parathyroid hormone) for treatment of GIOP would appear more 
appropriate. In fact in a clinical trial, comparing alendronate vs. teriparatide for 18 months 
in 428 men/women with established osteoporosis and who had received at least 5mg of 
prednisone for at least 3 months, teriparatide was significantly more effective in both 
increasing bone mineral density at the spine [7.2 vs 3.4%) and in decreasing new vertebral 
fractures [0.6% vs 6.1%) [130]. Of note, this was a secondary instead of a primary 
osteoporosis prevention trial and there was a greater incidence of side effects associated 
with teriparatide use as compared to controls [131]. In addition, use of teriparatide by 
patients is currently limited to two years, thus alternative and better forms of therapy for 
GIOP need to be developed. 
15. Conclusion 
Although adverse side effects of glucocorticoids on bone have been long recognized, both 
from endogenous sources as described by Harvey Cushing in the 1930’s or from exogenous 
sources after development of glucocorticoids in the 1950’s the mechanisms involved in this 
process have only recently began to be understood. It is clear that although physiologic 
levels of glucocorticoids are important in normal bone development, pharmacologic doses 
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result in a high level of fractures, particularly of vertebral bone. Thus, it would seem that 
glucocorticoids have both anabolic and catabolic actions on bone. Data from our labs and 
from others suggest that GILZ may be an important mediator of GR’s anabolic actions and 
thus may be an attractive therapeutic target for drug development. 
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and Tattersfield, A.E. 2001. Adverse effects of oral corticosteroids in relation to dose in 
patients with lung disease. Thorax 56:279-284. 
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However a recent joint position statement by the International Society for Clinical 
Densitometry and the International Osteoporosis Foundation concluded that when using 
the FRAX tool there probably was an underestimation of fracture risk with daily prednisone 
doses greater than 7.5 mg and an overestimation of fracture risk with daily prednisone 
doses of less than 2.5 mg. In addition, FRAX probably underestimated fracture risk when 
high dose inhaled steroids were used. Finally, it was concluded that for patients with 
adrenal insufficiency receiving appropriate replacement steroid doses this not be included 
in the FRAX calculation [128].  
The American College of Rheumatology recommends that some form of therapy be 
considered for all patients receiving prolonged steroid therapy and that for those who have 
a bone densitometry test (Dual energy x-ray absorptiometry or DXA), a T-score of less than -
1.0 be considered abnormal [125].  
14. Therapy 
Since glucocorticoids interfere with intestinal calcium absorption, all patients about to start 
glucocorticoid therapy should be placed on calcium and vitamin D replacement. 
Antiresorptive agents such as bisphosphonates (both oral and IV) have been used for the 
therapy of GIOP, are effective in decreasing the increased fracture risk associated with 
steroids and are approved for this indication. However, as discussed by Teitelbaum et al. 
[129], although initial use of steroids is associated with increased bone resorption (osteoclast 
mediated and related to decreased osteoclastic apoptosis and a situation in which 
antiresorptive use makes sense), more prolonged steroid use is associated with decreased 
bone formation and antiresorptive agents have the theoretical possibility of making things 
worse by further suppressing a low bone turnover state. Thus, use of an anabolic agent such 
as teriparatide (synthetic parathyroid hormone) for treatment of GIOP would appear more 
appropriate. In fact in a clinical trial, comparing alendronate vs. teriparatide for 18 months 
in 428 men/women with established osteoporosis and who had received at least 5mg of 
prednisone for at least 3 months, teriparatide was significantly more effective in both 
increasing bone mineral density at the spine [7.2 vs 3.4%) and in decreasing new vertebral 
fractures [0.6% vs 6.1%) [130]. Of note, this was a secondary instead of a primary 
osteoporosis prevention trial and there was a greater incidence of side effects associated 
with teriparatide use as compared to controls [131]. In addition, use of teriparatide by 
patients is currently limited to two years, thus alternative and better forms of therapy for 
GIOP need to be developed. 
15. Conclusion 
Although adverse side effects of glucocorticoids on bone have been long recognized, both 
from endogenous sources as described by Harvey Cushing in the 1930’s or from exogenous 
sources after development of glucocorticoids in the 1950’s the mechanisms involved in this 
process have only recently began to be understood. It is clear that although physiologic 
levels of glucocorticoids are important in normal bone development, pharmacologic doses 
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result in a high level of fractures, particularly of vertebral bone. Thus, it would seem that 
glucocorticoids have both anabolic and catabolic actions on bone. Data from our labs and 
from others suggest that GILZ may be an important mediator of GR’s anabolic actions and 
thus may be an attractive therapeutic target for drug development. 
Author details 
Xing-Ming Shi 
Institute of Molecular Medicine and Genetics, Department of Pathology 
Georgia Health Sciences University, Augusta, GA, USA 
Norman Chutkan 
Department of Orthopaedic Surgery, Georgia Health Sciences University, Augusta, GA, USA 
Mark W. Hamrick 
Departments of Cellular Biology & Anatomy and Orthopaedic Surgery, Georgia Health Sciences 
University, Augusta, GA, USA 
Carlos M. Isales 
Institute of Molecular Medicine and Genetics, Departments of Orthopaedic Surgery and Medicine, 
Georgia Health Sciences University, Augusta, GA, USA 
Acknowledgement 
This work was supported by grants from the National Institutes of Health (DK76045] and 
National Institute on Aging (P01AG036675].  
16. References 
[1] Harris, E.D., Jr., Emkey, R.D., Nichols, J.E., and Newberg, A. 1983. Low dose 
prednisone therapy in rheumatoid arthritis: a double blind study. J.Rheumatol. 10:713-
721. 
[2] Conn, D.L. 2001. Resolved: Low-dose prednisone is indicated as a standard treatment in 
patients with rheumatoid arthritis. Arthritis Rheum. 45:462-467. 
[3] Locascio, V., Bonucci, E., Imbimbo, B., Ballanti, P., Adami, S., Milani, S., Tartarotti, D., 
and DellaRocca, C. 1990. Bone loss in response to long-term glucocorticoid therapy. 
Bone Miner. 8:39-51. 
[4] Nishimura, J. and Ikuyama, S. 2000. Glucocorticoid-induced osteoporosis: pathogenesis 
and management. J.Bone Miner.Metab 18:350-352. 
[5] The Lung Health Study Research Group. 2000. Effect of inhaled triamcinolone on the 
decline in pulmonary function in chronic obstructive pulmonary disease. N.Engl.J.Med. 
343:1902-1909. 
[6] Walsh, L.J., Wong, C.A., Oborne, J., Cooper, S., Lewis, S.A., Pringle, M., Hubbard, R., 
and Tattersfield, A.E. 2001. Adverse effects of oral corticosteroids in relation to dose in 
patients with lung disease. Thorax 56:279-284. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 52 
[7] Ruegsegger, P., Medici, T.C., and Anliker, M. 1983. Corticosteroid-induced bone loss. A 
longitudinal study of alternate day therapy in patients with bronchial asthma using 
quantitative computed tomography. Eur.J.Clin.Pharmacol. 25:615-620. 
[8] Bazzy-Asaad, A. 2001. Safety of inhaled corticosteroids in children with asthma. 
Curr.Opin.Pediatr. 13:523-527. 
[9] Corren, J., Nelson, H., Greos, L.S., Bensch, G., Goldstein, M., Wu, J., Wang, S., and 
Newman, K. 2001. Effective control of asthma with hydrofluoroalkane flunisolide 
delivered as an extrafine aerosol in asthma patients. Ann.Allergy Asthma Immunol. 
87:405-411. 
[10] Fernandes, A.L., Faresin, S.M., Amorim, M.M., Fritscher, C.C., Pereira, C.A., and 
Jardim, J.R. 2001. Inhaled budesonide for adults with mild-to-moderate asthma: a 
randomized placebo-controlled, double-blind clinical trial. Sao Paulo Med.J. 119:169-174. 
[11] Adinoff, A.D. and Hollister, J.R. 1983. Steroid-induced fractures and bone loss in 
patients with asthma. N.Engl.J.Med. 309:265-268. 
[12] Park, S.J., Nguyen, D.Q., Savik, K., Hertz, M.I., and Bolman, R.M., III. 2001. Pre-
transplant corticosteroid use and outcome in lung transplantation. J.Heart Lung 
Transplant. 20:304-309. 
[13] Dequeker, J. and Westhovens, R. 1995. Low dose corticosteroid associated osteoporosis 
in rheumatoid arthritis and its prophylaxis and treatment: bones of contention. 
J.Rheumatol. 22:1013-1019. 
[14] Adachi, J.D., Olszynski, W.P., Hanley, D.A., Hodsman, A.B., Kendler, D.L., Siminoski, 
K.G., Brown, J., Cowden, E.A., Goltzman, D., Ioannidis, G. et al. 2000. Management of 
corticosteroid-induced osteoporosis. Semin.Arthritis Rheum. 29:228-251. 
[15] Saag, K.G., Koehnke, R., Caldwell, J.R., Brasington, R., Burmeister, L.F., Zimmerman, B., 
Kohler, J.A., and Furst, D.E. 1994. Low dose long-term corticosteroid therapy in 
rheumatoid arthritis: an analysis of serious adverse events. Am.J.Med. 96:115-123. 
[16] Braun, J. and Sieper, J. 2001. [Glucocorticoid-induced osteoporosis]. Orthopade 30:444-450. 
[17] Clowes, J.A., Peel, N., and Eastell, R. 2001. Glucocorticoid-induced osteoporosis. 
Curr.Opin.Rheumatol. 13:326-332. 
[18] Lukert, B.P. and Raisz, L.G. 1990. Glucocorticoid-induced osteoporosis: pathogenesis 
and management. Ann.Intern.Med. 112:352-364. 
[19] Klein, G. 2004. Glucocorticoid-induced bone loss in children. Clinical Reviews in Bone and 
Mineral Metabolism 2:37-52. 
[20] VAN STAA, T.P., COOPER, C., Leufkens, H., and Bishop, N. 2003. Children and the 
Risk of Fractures Caused by Oral Corticosteroids. Journal of Bone and Mineral Research 
18:913-918. 
[21] Boot, A.M., de Jongste, J.C., Verberne, A.A.P.H., Pols, H.A.P., and de Muinck Keizer-
Schrama, S. 1997. Bone mineral density and bone metabolism of prepubertal children 
with asthma after long-term treatment with inhaled corticosteroids. Pediatr.Pulmonol. 
24:379-384. 
[22] Covar, R.A., Leung, D.Y., McCormick, D., Steelman, J., Zeitler, P., and Spahn, J.D. 2000. 
Risk factors associated with glucocorticoid-induced adverse effects in children with 
severe asthma. J Allergy Clin Immunol 106:651-659. 
 
Mechanism of Glucocorticoid-Induced Osteoporosis: An Update 53 
[23] Burnham, J.M. and Leonard, M.B. 2004. Bone disease in pediatric rheumatologic 
disorders. Curr.Rheumatol.Rep. 6:70-78. 
[24] Viswanathan, A. and Sylvester, F. 2008. Chronic pediatric inflammatory diseases: 
Effects on bone. Reviews in Endocrine & Metabolic Disorders 9:107-122. 
[25] Burnham, J.M., Shults, J., Semeao, E., Foster, B., Zemel, B.S., Stallings, V.A., and 
Leonard, M.B. 2004. Whole Body BMC in Pediatric Crohn Disease: Independent Effects 
of Altered Growth, Maturation, and Body Composition. Journal of Bone and Mineral 
Research 19:1961-1968. 
[26] Lilleby, V., Lien, G., Frey Fr_Ėslie, K., Haugen, M., Flat_Ė, B., and F_Ėrre, ś. 2005. 
Frequency of osteopenia in children and young adults with childhood-onset systemic 
lupus erythematosus. Arthritis & Rheumatism 52:2051-2059. 
[27] Compeyrot-Lacassagne, S., Tyrrell, P.N., Atenafu, E., Doria, A.S., Stephens, D., Gilday, 
D., and Silverman, E.D. 2007. Prevalence and etiology of low bone mineral density in 
juvenile systemic lupus erythematosus. Arthritis & Rheumatism 56:1966-1973. 
[28] Walther, F., Fusch, C., Radke, M., Beckert, S., and Findeisen, A. 2006. Osteoporosis in 
pediatric patients suffering from chronic inflammatory bowel disease with and without 
steroid treatment. J Pediatr.Gastroenterol.Nutr. 43:42-51. 
[29] Boot, A.M., Bouquet, J., Krenning, E.P., and Muinck Keizer-Schrama, S.M.P.F. 1998. 
Bone mineral density and nutritional status in children with chronic inflammatory 
bowel disease. Gut 42:188-194. 
[30] Mazziotti, G., Angeli, A., Bilezikian, J.P., Canalis, E., and Giustina, A. 2006. 
Glucocorticoid-induced osteoporosis: an update. Trends in Endocrinology &amp; 
Metabolism 17:144-149. 
[31] Webster, J.C. and Cidlowski, J.A. 1999. Mechanisms of Glucocorticoid-receptor-
mediated Repression of Gene Expression. Trends in Endocrinology and Metabolism 10:396-
402. 
[32] Kumar, R. and Thompson, E.B. 2005. Gene regulation by the glucocorticoid receptor: 
Structure:function relationship. The Journal of Steroid Biochemistry and Molecular Biology 
94:383-394. 
[33] Kallio, P.J., Palvimo, J., and Janne, O.A. 1994. [Nuclear hormone receptors]. Duodecim 
110:383-394. 
[34] Giguere, V., Hollenberg, S.M., Rosenfeld, M.G., and Evans, R.M. 1986. Functional 
domains of the human glucocorticoid receptor. Cell 46:645-652. 
[35] Parker, M.G. 1990. Structure and function of nuclear hormone receptors. Semin.Cancer 
Biol 1:81-87. 
[36] Morrison, N. and Eisman, J. 1993. Role of the negative glucocorticoid regulatory 
element in glucocorticoid repression of the human osteocalcin promoter. J Bone 
Miner.Res. 8:969-975. 
[37] De Bosscher, K., Vanden Berghe, W., and Haegeman, G. 2003. The Interplay between 
the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: 
Molecular Mechanisms for Gene Repression. Endocr Rev 24:488-522. 
[38] De Bosscher, K., Vanden Berghe, W., and Haegeman, G. 2000. Mechanisms of anti-
inflammatory action and of immunosuppression by glucocorticoids: negative 
 
Glucocorticoids – New Recognition of Our Familiar Friend 52 
[7] Ruegsegger, P., Medici, T.C., and Anliker, M. 1983. Corticosteroid-induced bone loss. A 
longitudinal study of alternate day therapy in patients with bronchial asthma using 
quantitative computed tomography. Eur.J.Clin.Pharmacol. 25:615-620. 
[8] Bazzy-Asaad, A. 2001. Safety of inhaled corticosteroids in children with asthma. 
Curr.Opin.Pediatr. 13:523-527. 
[9] Corren, J., Nelson, H., Greos, L.S., Bensch, G., Goldstein, M., Wu, J., Wang, S., and 
Newman, K. 2001. Effective control of asthma with hydrofluoroalkane flunisolide 
delivered as an extrafine aerosol in asthma patients. Ann.Allergy Asthma Immunol. 
87:405-411. 
[10] Fernandes, A.L., Faresin, S.M., Amorim, M.M., Fritscher, C.C., Pereira, C.A., and 
Jardim, J.R. 2001. Inhaled budesonide for adults with mild-to-moderate asthma: a 
randomized placebo-controlled, double-blind clinical trial. Sao Paulo Med.J. 119:169-174. 
[11] Adinoff, A.D. and Hollister, J.R. 1983. Steroid-induced fractures and bone loss in 
patients with asthma. N.Engl.J.Med. 309:265-268. 
[12] Park, S.J., Nguyen, D.Q., Savik, K., Hertz, M.I., and Bolman, R.M., III. 2001. Pre-
transplant corticosteroid use and outcome in lung transplantation. J.Heart Lung 
Transplant. 20:304-309. 
[13] Dequeker, J. and Westhovens, R. 1995. Low dose corticosteroid associated osteoporosis 
in rheumatoid arthritis and its prophylaxis and treatment: bones of contention. 
J.Rheumatol. 22:1013-1019. 
[14] Adachi, J.D., Olszynski, W.P., Hanley, D.A., Hodsman, A.B., Kendler, D.L., Siminoski, 
K.G., Brown, J., Cowden, E.A., Goltzman, D., Ioannidis, G. et al. 2000. Management of 
corticosteroid-induced osteoporosis. Semin.Arthritis Rheum. 29:228-251. 
[15] Saag, K.G., Koehnke, R., Caldwell, J.R., Brasington, R., Burmeister, L.F., Zimmerman, B., 
Kohler, J.A., and Furst, D.E. 1994. Low dose long-term corticosteroid therapy in 
rheumatoid arthritis: an analysis of serious adverse events. Am.J.Med. 96:115-123. 
[16] Braun, J. and Sieper, J. 2001. [Glucocorticoid-induced osteoporosis]. Orthopade 30:444-450. 
[17] Clowes, J.A., Peel, N., and Eastell, R. 2001. Glucocorticoid-induced osteoporosis. 
Curr.Opin.Rheumatol. 13:326-332. 
[18] Lukert, B.P. and Raisz, L.G. 1990. Glucocorticoid-induced osteoporosis: pathogenesis 
and management. Ann.Intern.Med. 112:352-364. 
[19] Klein, G. 2004. Glucocorticoid-induced bone loss in children. Clinical Reviews in Bone and 
Mineral Metabolism 2:37-52. 
[20] VAN STAA, T.P., COOPER, C., Leufkens, H., and Bishop, N. 2003. Children and the 
Risk of Fractures Caused by Oral Corticosteroids. Journal of Bone and Mineral Research 
18:913-918. 
[21] Boot, A.M., de Jongste, J.C., Verberne, A.A.P.H., Pols, H.A.P., and de Muinck Keizer-
Schrama, S. 1997. Bone mineral density and bone metabolism of prepubertal children 
with asthma after long-term treatment with inhaled corticosteroids. Pediatr.Pulmonol. 
24:379-384. 
[22] Covar, R.A., Leung, D.Y., McCormick, D., Steelman, J., Zeitler, P., and Spahn, J.D. 2000. 
Risk factors associated with glucocorticoid-induced adverse effects in children with 
severe asthma. J Allergy Clin Immunol 106:651-659. 
 
Mechanism of Glucocorticoid-Induced Osteoporosis: An Update 53 
[23] Burnham, J.M. and Leonard, M.B. 2004. Bone disease in pediatric rheumatologic 
disorders. Curr.Rheumatol.Rep. 6:70-78. 
[24] Viswanathan, A. and Sylvester, F. 2008. Chronic pediatric inflammatory diseases: 
Effects on bone. Reviews in Endocrine & Metabolic Disorders 9:107-122. 
[25] Burnham, J.M., Shults, J., Semeao, E., Foster, B., Zemel, B.S., Stallings, V.A., and 
Leonard, M.B. 2004. Whole Body BMC in Pediatric Crohn Disease: Independent Effects 
of Altered Growth, Maturation, and Body Composition. Journal of Bone and Mineral 
Research 19:1961-1968. 
[26] Lilleby, V., Lien, G., Frey Fr_Ėslie, K., Haugen, M., Flat_Ė, B., and F_Ėrre, ś. 2005. 
Frequency of osteopenia in children and young adults with childhood-onset systemic 
lupus erythematosus. Arthritis & Rheumatism 52:2051-2059. 
[27] Compeyrot-Lacassagne, S., Tyrrell, P.N., Atenafu, E., Doria, A.S., Stephens, D., Gilday, 
D., and Silverman, E.D. 2007. Prevalence and etiology of low bone mineral density in 
juvenile systemic lupus erythematosus. Arthritis & Rheumatism 56:1966-1973. 
[28] Walther, F., Fusch, C., Radke, M., Beckert, S., and Findeisen, A. 2006. Osteoporosis in 
pediatric patients suffering from chronic inflammatory bowel disease with and without 
steroid treatment. J Pediatr.Gastroenterol.Nutr. 43:42-51. 
[29] Boot, A.M., Bouquet, J., Krenning, E.P., and Muinck Keizer-Schrama, S.M.P.F. 1998. 
Bone mineral density and nutritional status in children with chronic inflammatory 
bowel disease. Gut 42:188-194. 
[30] Mazziotti, G., Angeli, A., Bilezikian, J.P., Canalis, E., and Giustina, A. 2006. 
Glucocorticoid-induced osteoporosis: an update. Trends in Endocrinology &amp; 
Metabolism 17:144-149. 
[31] Webster, J.C. and Cidlowski, J.A. 1999. Mechanisms of Glucocorticoid-receptor-
mediated Repression of Gene Expression. Trends in Endocrinology and Metabolism 10:396-
402. 
[32] Kumar, R. and Thompson, E.B. 2005. Gene regulation by the glucocorticoid receptor: 
Structure:function relationship. The Journal of Steroid Biochemistry and Molecular Biology 
94:383-394. 
[33] Kallio, P.J., Palvimo, J., and Janne, O.A. 1994. [Nuclear hormone receptors]. Duodecim 
110:383-394. 
[34] Giguere, V., Hollenberg, S.M., Rosenfeld, M.G., and Evans, R.M. 1986. Functional 
domains of the human glucocorticoid receptor. Cell 46:645-652. 
[35] Parker, M.G. 1990. Structure and function of nuclear hormone receptors. Semin.Cancer 
Biol 1:81-87. 
[36] Morrison, N. and Eisman, J. 1993. Role of the negative glucocorticoid regulatory 
element in glucocorticoid repression of the human osteocalcin promoter. J Bone 
Miner.Res. 8:969-975. 
[37] De Bosscher, K., Vanden Berghe, W., and Haegeman, G. 2003. The Interplay between 
the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: 
Molecular Mechanisms for Gene Repression. Endocr Rev 24:488-522. 
[38] De Bosscher, K., Vanden Berghe, W., and Haegeman, G. 2000. Mechanisms of anti-
inflammatory action and of immunosuppression by glucocorticoids: negative 
 
Glucocorticoids – New Recognition of Our Familiar Friend 54 
interference of activated glucocorticoid receptor with transcription factors. J 
Neuroimmunol. 109:16-22. 
[39] Zitnik, R.J., Whiting, N.L., and Elias, J.A. 1994. Glucocorticoid inhibition of interleukin-
1-induced interleukin-6 production by human lung fibroblasts: evidence for 
transcriptional and post-transcriptional regulatory mechanisms. Am J Respir.Cell Mol 
Biol 10:643-650. 
[40] Yang-Yen, H.F., Chambard, J.C., Sun, Y.L., Smeal, T., Schmidt, T.J., Drouin, J., and 
Karin, M. 1990. Transcriptional interference between c-Jun and the glucocorticoid 
receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. 
Cell 62:1205-1215. 
[41] Jonat, C., Rahmsdorf, H.J., Park, K.K., Cato, A.C., Gebel, S., Ponta, H., and Herrlich, P. 
1990. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) 
activity by glucocorticoid hormone. Cell 62:1189-1204. 
[42] Schule, R., Rangarajan, P., Kliewer, S., Ransone, L.J., Bolado, J., Yang, N., Verma, I.M., 
and Evans, R.M. 1990. Functional antagonism between oncoprotein c-Jun and the 
glucocorticoid receptor. Cell 62:1217-1226. 
[43] Ray, A. and Prefontaine, K.E. 1994. Physical association and functional antagonism 
between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid 
receptor. Proc.Natl.Acad.Sci.U.S.A 91:752-756. 
[44] Scheinman, R.I., Gualberto, A., Jewell, C.M., Cidlowski, J.A., and Baldwin, A.S., Jr. 1995. 
Characterization of mechanisms involved in transrepression of NF-kappa B by 
activated glucocorticoid receptors. Mol.Cell.Biol. 15:943-953. 
[45] Auphan, N., DiDonato, J.A., Rosette, C., Helmberg, A., and Karin, M. 1995. 
Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through 
induction of I kappa B synthesis. Science 270:286-290. 
[46] Scheinman, R.I., Cogswell, P.C., Lofquist, A.K., and Baldwin, A.S., Jr. 1995. Role of 
transcriptional activation of I kappa B alpha in mediation of immunosuppression by 
glucocorticoids. Science 270:283-286. 
[47] Crinelli, R., Antonelli, A., Bianchi, M., Gentilini, L., Scaramucci, S., and Magnani, M. 
2000. Selective inhibition of NF-kB activation and TNF-alpha production in 
macrophages by red blood cell-mediated delivery of dexamethasone. Blood Cells Mol Dis 
26:211-222. 
[48] Thiele, K., Bierhaus, A., Autschbach, F., Hofmann, M., Stremmel, W., Thiele, H., Ziegler, 
R., and Nawroth, P.P. 1999. Cell specific effects of glucocorticoid treatment on the NF-
kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut 45:693-704. 
[49] De Bosscher, K., Schmitz, M.L., Vanden Berghe, W., Plaisance, S.p., Fiers, W., and 
Haegeman, G. 1997. Glucocorticoid-mediated repression of nuclear factor-
__Bdependent transcription involves direct interference withĆētransactivation. PNAS 
94:13504-13509. 
[50] Brostjan, C., Anrather, J., Csizmadia, V., Stroka, D., Soares, M., Bach, F.H., and Winkler, 
H. 1996. Glucocorticoid-mediated Repression of NF__B Activity in Endothelial Cells 
Does Not Involve Induction of I__B__ Synthesis. J.Biol.Chem. 271:19612-19616. 
 
Mechanism of Glucocorticoid-Induced Osteoporosis: An Update 55 
[51] Heck, S., Bender, K., Kullmann, M., Gottlicher, M., Herrlich, P., and Cato, A.C. 1997. I 
kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid 
receptor. EMBO J 16:4698-4707. 
[52] Canalis, E., Mazziotti, G., Giustina, A., and Bilezikian, J.P. 2007. Glucocorticoid-induced 
osteoporosis: pathophysiology and therapy. Osteoporos.Int 18:1319-1328. 
[53] Lukert, B.P. and Raisz, L.G. 1994. Glucocorticoid-induced osteoporosis. Rheum. Dis. 
Clin. North Am. 20:629-650. 
[54] Sher, L.B., Woitge, H.W., Adams, D.J., Gronowicz, G.A., Krozowski, Z., Harrison, J.R., 
and Kream, B.E. 2004. Transgenic Expression of 11__-Hydroxysteroid Dehydrogenase 
Type 2 in Osteoblasts Reveals an Anabolic Role for Endogenous Glucocorticoids in 
Bone. Endocrinology 145:922-929. 
[55] Sher, L.B., Harrison, J.R., Adams, D.J., and Kream, B.E. 2006. Impaired cortical bone 
acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of 
glucocorticoid signaling. Calcif.Tissue Int 79:118-125. 
[56] Yang, M., Trettel, L.B., Adams, D.J., Harrison, J.R., Canalis, E., and Kream, B.E. 2010. 
Col3.6-HSD2 transgenic mice: A glucocorticoid loss-of-function model spanning early 
and late osteoblast differentiation. Bone 47:573-582. 
[57] Bruder, S.P., Jaiswal, N., and Haynesworth, S.E. 1997. Growth kinetics, self-renewal, 
and the osteogenic potential of purified human mesenchymal stem cells during 
extensive subcultivation and following cryopreservation. J.Cell Biochem. 64:278-294. 
[58] Engler, A.J., Sen, S., Sweeney, H.L., and Discher, D.E. 2006. Matrix Elasticity Directs 
Stem Cell Lineage Specification. Cell 126:677-689. 
[59] Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., 
Moorman, M.A., Simonetti, D.W., Craig, S., and Marshak, D.R. 1999. Multilineage 
Potential of Adult Human Mesenchymal Stem Cells. Science 284:143-147. 
[60] Prockop, D.J. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. 
Science 276:71-74. 
[61] Ahdjoudj, S., Lasmoles, F., Oyajobi, B.O., Lomri, A., Delannoy, P., and Marie, P.J. 2001. 
Reciprocal control of osteoblast/chondroblast and osteoblast/adipocyte differentiation 
of multipotential clonal human marrow stromal F/STRO-1(+) cells. J Cell Biochem. 81:23-
38. 
[62] Beresford, J.N., Bennett, J.H., Devlin, C., Leboy, P.S., and Owen, M.E. 1992. Evidence for 
an inverse relationship between the differentiation of adipocytic and osteogenic cells in 
rat marrow stromal cell cultures. J.Cell Sci. 102 ( Pt 2]:341-351. 
[63] Gori, F., Thomas, T., Hicok, K.C., Spelsberg, T.C., and Riggs, B.L. 1999. Differentiation 
of human marrow stromal precursor cells: bone morphogenetic protein-2 increases 
OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation. 
J.Bone Miner.Res. 14:1522-1535. 
[64] Jaiswal, R.K., Jaiswal, N., Bruder, S.P., Mbalaviele, G., Marshak, D.R., and Pittenger, 
M.F. 2000. Adult human mesenchymal stem cell differentiation to the osteogenic or 
adipogenic lineage is regulated by mitogen-activated protein kinase. J.Biol.Chem. 
275:9645-9652. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 54 
interference of activated glucocorticoid receptor with transcription factors. J 
Neuroimmunol. 109:16-22. 
[39] Zitnik, R.J., Whiting, N.L., and Elias, J.A. 1994. Glucocorticoid inhibition of interleukin-
1-induced interleukin-6 production by human lung fibroblasts: evidence for 
transcriptional and post-transcriptional regulatory mechanisms. Am J Respir.Cell Mol 
Biol 10:643-650. 
[40] Yang-Yen, H.F., Chambard, J.C., Sun, Y.L., Smeal, T., Schmidt, T.J., Drouin, J., and 
Karin, M. 1990. Transcriptional interference between c-Jun and the glucocorticoid 
receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. 
Cell 62:1205-1215. 
[41] Jonat, C., Rahmsdorf, H.J., Park, K.K., Cato, A.C., Gebel, S., Ponta, H., and Herrlich, P. 
1990. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) 
activity by glucocorticoid hormone. Cell 62:1189-1204. 
[42] Schule, R., Rangarajan, P., Kliewer, S., Ransone, L.J., Bolado, J., Yang, N., Verma, I.M., 
and Evans, R.M. 1990. Functional antagonism between oncoprotein c-Jun and the 
glucocorticoid receptor. Cell 62:1217-1226. 
[43] Ray, A. and Prefontaine, K.E. 1994. Physical association and functional antagonism 
between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid 
receptor. Proc.Natl.Acad.Sci.U.S.A 91:752-756. 
[44] Scheinman, R.I., Gualberto, A., Jewell, C.M., Cidlowski, J.A., and Baldwin, A.S., Jr. 1995. 
Characterization of mechanisms involved in transrepression of NF-kappa B by 
activated glucocorticoid receptors. Mol.Cell.Biol. 15:943-953. 
[45] Auphan, N., DiDonato, J.A., Rosette, C., Helmberg, A., and Karin, M. 1995. 
Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through 
induction of I kappa B synthesis. Science 270:286-290. 
[46] Scheinman, R.I., Cogswell, P.C., Lofquist, A.K., and Baldwin, A.S., Jr. 1995. Role of 
transcriptional activation of I kappa B alpha in mediation of immunosuppression by 
glucocorticoids. Science 270:283-286. 
[47] Crinelli, R., Antonelli, A., Bianchi, M., Gentilini, L., Scaramucci, S., and Magnani, M. 
2000. Selective inhibition of NF-kB activation and TNF-alpha production in 
macrophages by red blood cell-mediated delivery of dexamethasone. Blood Cells Mol Dis 
26:211-222. 
[48] Thiele, K., Bierhaus, A., Autschbach, F., Hofmann, M., Stremmel, W., Thiele, H., Ziegler, 
R., and Nawroth, P.P. 1999. Cell specific effects of glucocorticoid treatment on the NF-
kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut 45:693-704. 
[49] De Bosscher, K., Schmitz, M.L., Vanden Berghe, W., Plaisance, S.p., Fiers, W., and 
Haegeman, G. 1997. Glucocorticoid-mediated repression of nuclear factor-
__Bdependent transcription involves direct interference withĆētransactivation. PNAS 
94:13504-13509. 
[50] Brostjan, C., Anrather, J., Csizmadia, V., Stroka, D., Soares, M., Bach, F.H., and Winkler, 
H. 1996. Glucocorticoid-mediated Repression of NF__B Activity in Endothelial Cells 
Does Not Involve Induction of I__B__ Synthesis. J.Biol.Chem. 271:19612-19616. 
 
Mechanism of Glucocorticoid-Induced Osteoporosis: An Update 55 
[51] Heck, S., Bender, K., Kullmann, M., Gottlicher, M., Herrlich, P., and Cato, A.C. 1997. I 
kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid 
receptor. EMBO J 16:4698-4707. 
[52] Canalis, E., Mazziotti, G., Giustina, A., and Bilezikian, J.P. 2007. Glucocorticoid-induced 
osteoporosis: pathophysiology and therapy. Osteoporos.Int 18:1319-1328. 
[53] Lukert, B.P. and Raisz, L.G. 1994. Glucocorticoid-induced osteoporosis. Rheum. Dis. 
Clin. North Am. 20:629-650. 
[54] Sher, L.B., Woitge, H.W., Adams, D.J., Gronowicz, G.A., Krozowski, Z., Harrison, J.R., 
and Kream, B.E. 2004. Transgenic Expression of 11__-Hydroxysteroid Dehydrogenase 
Type 2 in Osteoblasts Reveals an Anabolic Role for Endogenous Glucocorticoids in 
Bone. Endocrinology 145:922-929. 
[55] Sher, L.B., Harrison, J.R., Adams, D.J., and Kream, B.E. 2006. Impaired cortical bone 
acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of 
glucocorticoid signaling. Calcif.Tissue Int 79:118-125. 
[56] Yang, M., Trettel, L.B., Adams, D.J., Harrison, J.R., Canalis, E., and Kream, B.E. 2010. 
Col3.6-HSD2 transgenic mice: A glucocorticoid loss-of-function model spanning early 
and late osteoblast differentiation. Bone 47:573-582. 
[57] Bruder, S.P., Jaiswal, N., and Haynesworth, S.E. 1997. Growth kinetics, self-renewal, 
and the osteogenic potential of purified human mesenchymal stem cells during 
extensive subcultivation and following cryopreservation. J.Cell Biochem. 64:278-294. 
[58] Engler, A.J., Sen, S., Sweeney, H.L., and Discher, D.E. 2006. Matrix Elasticity Directs 
Stem Cell Lineage Specification. Cell 126:677-689. 
[59] Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., 
Moorman, M.A., Simonetti, D.W., Craig, S., and Marshak, D.R. 1999. Multilineage 
Potential of Adult Human Mesenchymal Stem Cells. Science 284:143-147. 
[60] Prockop, D.J. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. 
Science 276:71-74. 
[61] Ahdjoudj, S., Lasmoles, F., Oyajobi, B.O., Lomri, A., Delannoy, P., and Marie, P.J. 2001. 
Reciprocal control of osteoblast/chondroblast and osteoblast/adipocyte differentiation 
of multipotential clonal human marrow stromal F/STRO-1(+) cells. J Cell Biochem. 81:23-
38. 
[62] Beresford, J.N., Bennett, J.H., Devlin, C., Leboy, P.S., and Owen, M.E. 1992. Evidence for 
an inverse relationship between the differentiation of adipocytic and osteogenic cells in 
rat marrow stromal cell cultures. J.Cell Sci. 102 ( Pt 2]:341-351. 
[63] Gori, F., Thomas, T., Hicok, K.C., Spelsberg, T.C., and Riggs, B.L. 1999. Differentiation 
of human marrow stromal precursor cells: bone morphogenetic protein-2 increases 
OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation. 
J.Bone Miner.Res. 14:1522-1535. 
[64] Jaiswal, R.K., Jaiswal, N., Bruder, S.P., Mbalaviele, G., Marshak, D.R., and Pittenger, 
M.F. 2000. Adult human mesenchymal stem cell differentiation to the osteogenic or 
adipogenic lineage is regulated by mitogen-activated protein kinase. J.Biol.Chem. 
275:9645-9652. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 56 
[65] Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., 
and Evans, R.M. 1999. PPAR gamma is required for placental, cardiac, and adipose 
tissue development. Mol.Cell 4:585-595. 
[66] Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., Spiegelman, 
B.M., and Mortensen, R.M. 1999. PPAR gamma is required for the differentiation of 
adipose tissue in vivo and in vitro. Mol.Cell 4:611-617. 
[67] Shi, X.M., Blair, H.C., Yang, X., McDonald, J.M., and Cao, X. 2000. Tandem repeat of 
C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-
induced adipocyte differentiation. J.Cell Biochem. 76:518-527. 
[68] Wu, Z., Bucher, N.L., and Farmer, S.R. 1996. Induction of peroxisome proliferator-
activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is 
mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol.Cell.Biol. 16:4128-4136. 
[69] Tang, Q.Q., Zhang, J.W., and Daniel Lane, M. 2004. Sequential gene promoter 
interactions by C/EBP[beta], C/EBP[alpha], and PPAR[gamma] during adipogenesis. 
Biochemical and Biophysical Research Communications 318:213-218. 
[70] Clarke, S.L., Robinson, C.E., and Gimble, J.M. 1997. CAAT/Enhancer Binding Proteins 
Directly Modulate Transcription from the Peroxisome Proliferator- Activated Receptor 
[gamma]2 Promoter. Biochemical and Biophysical Research Communications 240:99-103. 
[71] Weinstein, R.S., Jilka, R.L., Parfitt, A.M., and Manolagas, S.C. 1998. Inhibition of 
osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by 
glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin.Invest 
102:274-282. 
[72] Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M.C., and Lane, N.E. 2008. 
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and 
adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene 
expression in bone tissue from glucocorticoid-treated mice. Arthritis & Rheumatism 
58:1674-1686. 
[73] Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M., Chung, U.I., Kubota, N., Terauchi, 
Y., Harada, Y., Azuma, Y., Nakamura, K. et al. 2004. PPARgamma insufficiency 
enhances osteogenesis through osteoblast formation from bone marrow progenitors. 
J.Clin.Invest 113:846-855. 
[74] Canalis, E. 2005. Mechanisms of glucocorticoid action in bone. Curr.Osteoporos.Rep. 3:98-
102. 
[75] Weinstein, R.S. 2001. Glucocorticoid-induced osteoporosis. Rev.Endocr.Metab Disord. 
2:65-73. 
[76] O'Brien, C.A., Jia, D., Plotkin, L.I., Bellido, T., Powers, C.C., Stewart, S.A., Manolagas, 
S.C., and Weinstein, R.S. 2004. Glucocorticoids Act Directly on Osteoblasts and 
Osteocytes to Induce Their Apoptosis and Reduce Bone Formation and Strength. 
Endocrinology 145:1835-1841. 
[77] Robling, A.G., Niziolek, P.J., Baldridge, L.A., Condon, K.W., Allen, M.R., Alam, I., 
Mantila, S.M., Gluhak-Heinrich, J., Bellido, T.M., Harris, S.E. et al. 2008. Mechanical 
Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin. 
J.Biol.Chem. 283:5866-5875. 
 
Mechanism of Glucocorticoid-Induced Osteoporosis: An Update 57 
[78] Gluhak-Heinrich, J., Ye, L., Bonewald, L.F., Feng, J.Q., MacDougall, M., Harris, S.E., and 
Pavlin, D. 2003. Mechanical Loading Stimulates Dentin Matrix Protein 1 (DMP1] 
Expression in Osteocytes In Vivo. Journal of Bone and Mineral Research 18:807-817. 
[79] Hirayama, T., Sabokbar, A., and Athanasou, N.A. 2002. Effect of corticosteroids on 
human osteoclast formation and activity. J Endocrinol 175:155-163. 
[80] Sivagurunathan, S., Muir, M.M., Brennan, T.C., Seale, J.P., and Mason, R.S. 2005. 
Influence of Glucocorticoids on Human Osteoclast Generation and Activity. Journal of 
Bone and Mineral Research 20:390-398. 
[81] Jia, D., O'Brien, C.A., Stewart, S.A., Manolagas, S.C., and Weinstein, R.S. 2006. 
Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce 
Bone Density. Endocrinology 147:5592-5599. 
[82] Kim, H.J., Zhao, H., Kitaura, H., Bhattacharyya, S., Brewer, J.A., Muglia, L.J., Ross, F.P., 
and Teitelbaum, S.L. 2006. Glucocorticoids suppress bone formation via the osteoclast. J 
Clin Invest 116:2152-2160. 
[83] S_Ėe, K. and Delaiss_®, J.M. 2010. Glucocorticoids maintain human osteoclasts in the 
active mode of their resorption cycle. Journal of Bone and Mineral Research 25:2184-2192. 
[84] D'Adamio, F., Zollo, O., Moraca, R., Ayroldi, E., Bruscoli, S., Bartoli, A., Cannarile, L., 
Migliorati, G., and Riccardi, C. 1997. A new dexamethasone-induced gene of the leucine 
zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity. 
7:803-812. 
[85] Cannarile, L., Zollo, O., D'Adamio, F., Ayroldi, E., Marchetti, C., Tabilio, A., Bruscoli, S., 
and Riccardi, C. 2001. Cloning, chromosomal assignment and tissue distribution of 
human GILZ, a glucocorticoid hormone-induced gene. Cell Death.Differ. 8:201-203. 
[86] Ayroldi, E., Zollo, O., Macchiarulo, A., Di Marco, B., Marchetti, C., and Riccardi, C. 
2002. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-
regulated kinase pathway by binding to Raf-1. Mol.Cell Biol. 22:7929-7941. 
[87] Shibanuma, M., Kuroki, T., and Nose, K. 1992. Isolation of a gene encoding a putative 
leucine zipper structure that is induced by transforming growth factor beta 1 and other 
growth factors. J.Biol.Chem. 267:10219-10224. 
[88] Newton, R., Hart, L.A., Stevens, D.A., Bergmann, M., Donnelly, L.E., Adcock, I.M., and 
Barnes, P.J. 1998. Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced 
nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial 
cells. Eur J Biochem 254:81-89. 
[89] Eddleston, J., Herschbach, J., Wagelie-Steffen, A.L., Christiansen, S.C., and Zuraw, B.L. 
2007. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-
induced leucine zipper in epithelial cells. J Allergy Clin Immunol 119:115-122. 
[90] Delfino, D.V., Agostini, M., Spinicelli, S., Vito, P., and Riccardi, C. 2004. Decrease of Bcl-
xL and augmentation of thymocyte apoptosis in GILZ overexpressing transgenic mice. 
Blood. 
[91] Ayroldi, E., Migliorati, G., Bruscoli, S., Marchetti, C., Zollo, O., Cannarile, L., D'Adamio, 
F., and Riccardi, C. 2001. Modulation of T-cell activation by the glucocorticoid-induced 
leucine zipper factor via inhibition of nuclear factor kappaB. Blood 98:743-753. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 56 
[65] Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., 
and Evans, R.M. 1999. PPAR gamma is required for placental, cardiac, and adipose 
tissue development. Mol.Cell 4:585-595. 
[66] Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., Spiegelman, 
B.M., and Mortensen, R.M. 1999. PPAR gamma is required for the differentiation of 
adipose tissue in vivo and in vitro. Mol.Cell 4:611-617. 
[67] Shi, X.M., Blair, H.C., Yang, X., McDonald, J.M., and Cao, X. 2000. Tandem repeat of 
C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-
induced adipocyte differentiation. J.Cell Biochem. 76:518-527. 
[68] Wu, Z., Bucher, N.L., and Farmer, S.R. 1996. Induction of peroxisome proliferator-
activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is 
mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol.Cell.Biol. 16:4128-4136. 
[69] Tang, Q.Q., Zhang, J.W., and Daniel Lane, M. 2004. Sequential gene promoter 
interactions by C/EBP[beta], C/EBP[alpha], and PPAR[gamma] during adipogenesis. 
Biochemical and Biophysical Research Communications 318:213-218. 
[70] Clarke, S.L., Robinson, C.E., and Gimble, J.M. 1997. CAAT/Enhancer Binding Proteins 
Directly Modulate Transcription from the Peroxisome Proliferator- Activated Receptor 
[gamma]2 Promoter. Biochemical and Biophysical Research Communications 240:99-103. 
[71] Weinstein, R.S., Jilka, R.L., Parfitt, A.M., and Manolagas, S.C. 1998. Inhibition of 
osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by 
glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin.Invest 
102:274-282. 
[72] Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M.C., and Lane, N.E. 2008. 
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and 
adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene 
expression in bone tissue from glucocorticoid-treated mice. Arthritis & Rheumatism 
58:1674-1686. 
[73] Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M., Chung, U.I., Kubota, N., Terauchi, 
Y., Harada, Y., Azuma, Y., Nakamura, K. et al. 2004. PPARgamma insufficiency 
enhances osteogenesis through osteoblast formation from bone marrow progenitors. 
J.Clin.Invest 113:846-855. 
[74] Canalis, E. 2005. Mechanisms of glucocorticoid action in bone. Curr.Osteoporos.Rep. 3:98-
102. 
[75] Weinstein, R.S. 2001. Glucocorticoid-induced osteoporosis. Rev.Endocr.Metab Disord. 
2:65-73. 
[76] O'Brien, C.A., Jia, D., Plotkin, L.I., Bellido, T., Powers, C.C., Stewart, S.A., Manolagas, 
S.C., and Weinstein, R.S. 2004. Glucocorticoids Act Directly on Osteoblasts and 
Osteocytes to Induce Their Apoptosis and Reduce Bone Formation and Strength. 
Endocrinology 145:1835-1841. 
[77] Robling, A.G., Niziolek, P.J., Baldridge, L.A., Condon, K.W., Allen, M.R., Alam, I., 
Mantila, S.M., Gluhak-Heinrich, J., Bellido, T.M., Harris, S.E. et al. 2008. Mechanical 
Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin. 
J.Biol.Chem. 283:5866-5875. 
 
Mechanism of Glucocorticoid-Induced Osteoporosis: An Update 57 
[78] Gluhak-Heinrich, J., Ye, L., Bonewald, L.F., Feng, J.Q., MacDougall, M., Harris, S.E., and 
Pavlin, D. 2003. Mechanical Loading Stimulates Dentin Matrix Protein 1 (DMP1] 
Expression in Osteocytes In Vivo. Journal of Bone and Mineral Research 18:807-817. 
[79] Hirayama, T., Sabokbar, A., and Athanasou, N.A. 2002. Effect of corticosteroids on 
human osteoclast formation and activity. J Endocrinol 175:155-163. 
[80] Sivagurunathan, S., Muir, M.M., Brennan, T.C., Seale, J.P., and Mason, R.S. 2005. 
Influence of Glucocorticoids on Human Osteoclast Generation and Activity. Journal of 
Bone and Mineral Research 20:390-398. 
[81] Jia, D., O'Brien, C.A., Stewart, S.A., Manolagas, S.C., and Weinstein, R.S. 2006. 
Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce 
Bone Density. Endocrinology 147:5592-5599. 
[82] Kim, H.J., Zhao, H., Kitaura, H., Bhattacharyya, S., Brewer, J.A., Muglia, L.J., Ross, F.P., 
and Teitelbaum, S.L. 2006. Glucocorticoids suppress bone formation via the osteoclast. J 
Clin Invest 116:2152-2160. 
[83] S_Ėe, K. and Delaiss_®, J.M. 2010. Glucocorticoids maintain human osteoclasts in the 
active mode of their resorption cycle. Journal of Bone and Mineral Research 25:2184-2192. 
[84] D'Adamio, F., Zollo, O., Moraca, R., Ayroldi, E., Bruscoli, S., Bartoli, A., Cannarile, L., 
Migliorati, G., and Riccardi, C. 1997. A new dexamethasone-induced gene of the leucine 
zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity. 
7:803-812. 
[85] Cannarile, L., Zollo, O., D'Adamio, F., Ayroldi, E., Marchetti, C., Tabilio, A., Bruscoli, S., 
and Riccardi, C. 2001. Cloning, chromosomal assignment and tissue distribution of 
human GILZ, a glucocorticoid hormone-induced gene. Cell Death.Differ. 8:201-203. 
[86] Ayroldi, E., Zollo, O., Macchiarulo, A., Di Marco, B., Marchetti, C., and Riccardi, C. 
2002. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-
regulated kinase pathway by binding to Raf-1. Mol.Cell Biol. 22:7929-7941. 
[87] Shibanuma, M., Kuroki, T., and Nose, K. 1992. Isolation of a gene encoding a putative 
leucine zipper structure that is induced by transforming growth factor beta 1 and other 
growth factors. J.Biol.Chem. 267:10219-10224. 
[88] Newton, R., Hart, L.A., Stevens, D.A., Bergmann, M., Donnelly, L.E., Adcock, I.M., and 
Barnes, P.J. 1998. Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced 
nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial 
cells. Eur J Biochem 254:81-89. 
[89] Eddleston, J., Herschbach, J., Wagelie-Steffen, A.L., Christiansen, S.C., and Zuraw, B.L. 
2007. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-
induced leucine zipper in epithelial cells. J Allergy Clin Immunol 119:115-122. 
[90] Delfino, D.V., Agostini, M., Spinicelli, S., Vito, P., and Riccardi, C. 2004. Decrease of Bcl-
xL and augmentation of thymocyte apoptosis in GILZ overexpressing transgenic mice. 
Blood. 
[91] Ayroldi, E., Migliorati, G., Bruscoli, S., Marchetti, C., Zollo, O., Cannarile, L., D'Adamio, 
F., and Riccardi, C. 2001. Modulation of T-cell activation by the glucocorticoid-induced 
leucine zipper factor via inhibition of nuclear factor kappaB. Blood 98:743-753. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 58 
[92] Mittelstadt, P.R. and Ashwell, J.D. 2001. Inhibition of AP-1 by the glucocorticoid-
inducible protein GILZ. J.Biol.Chem. 276:29603-29610. 
[93] Ayroldi, E., Zollo, O., Bastianelli, A., Marchetti, C., Agostini, M., Di Virgilio, R., and 
Riccardi, C. 2007. GILZ mediates the antiproliferative activity of glucocorticoids by 
negative regulation of Ras signaling. J Clin Invest 117:1605-1615. 
[94] Berrebi, D., Bruscoli, S., Cohen, N., Foussat, A., Migliorati, G., Bouchet-Delbos, L., 
Maillot, M.C., Portier, A., Couderc, J., Galanaud, P. et al. 2003. Synthesis of 
glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory 
and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 
101:729-738. 
[95] Yang, N., Zhang, W., and Shi, X.M. 2007. Glucocorticoid-induced leucine zipper (GILZ) 
mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-2 
expression. J Cell Biochem 103:1760-1771. 
[96] Arthaningtyas, E., Kok, C.C., Mordvinov, V.A., and Sanderson, C.J. 2005. The conserved 
lymphokine element 0 is a powerful activator and target for corticosteroid inhibition in 
human interleukin-5 transcription. Growth Factors 23:211-221. 
[97] Cohen, N., Mouly, E., Hamdi, H., Maillot, M.C., Pallardy, M., Godot, V., Capel, F., 
Balian, A., Naveau, S., Galanaud, P. et al. 2005. GILZ expression in human dendritic 
cells redirects their maturation and prevents antigen-specific T lymphocyte response. 
Blood2005-2007. 
[98] Ayroldi, E. and Riccardi, C. 2009. Glucocorticoid-induced leucine zipper (GILZ): a new 
important mediator of glucocorticoid action. FASEB J. 23:1-10. 
[99] Asselin-Labat, M.L., Biola-Vidamment, A., Kerbrat, S., Lombes, M., Bertoglio, J., and 
Pallardy, M. 2005. FoxO3 Mediates Antagonistic Effects of Glucocorticoids and 
Interleukin-2 on Glucocorticoid-Induced Leucine Zipper Expression. Mol Endocrinol 
19:1752-1764. 
[100] Zhang, W., Yang, N., and Shi, X.M. 2008. Regulation of Mesenchymal Stem Cell 
Osteogenic Differentiation by Glucocorticoid-induced Leucine Zipper (GILZ). 
J.Biol.Chem. 283:4723-4729. 
[101] He, L., Yang, N., Isales, C.M., and Shi, X.M. 2012. Glucocorticoid-Induced Leucine 
Zipper (GILZ) Antagonizes TNF-__ Inhibition of Mesenchymal Stem Cell Osteogenic 
Differentiation. PLoS ONE 7:e31717. 
[102] Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z.P., Deng, J.M., Behringer, R.R., and de 
Crombrugghe, B. 2002. The novel zinc finger-containing transcription factor Osterix is 
required for osteoblast differentiation and bone formation. Cell 108:17-29. 
[103] Lu, X., Gilbert, L., He, X., Rubin, J., and Nanes, M.S. 2006. Transcriptional Regulation 
of the Osterix (Osx, Sp7] Promoter by Tumor Necrosis Factor Identifies Disparate 
Effects of Mitogen-activated Protein Kinase and NF+¦B Pathways. J.Biol.Chem. 281:6297-
6306. 
[104] Gilbert, L., He, X., Farmer, P., Rubin, J., Drissi, H., van Wijnen, A.J., Lian, J.B., Stein, 
G.S., and Nanes, M.S. 2002. Expression of the Osteoblast Differentiation Factor RUNX2 
(Cbfa1/AML3/Pebp2alpha A) Is Inhibited by Tumor Necrosis Factor-alpha. J.Biol.Chem. 
277:2695-2701. 
 
Mechanism of Glucocorticoid-Induced Osteoporosis: An Update 59 
[105] Kaneki, H., Guo, R., Chen, D., Yao, Z., Schwarz, E.M., Zhang, Y.E., Boyce, B.F., and 
Xing, L. 2006. Tumor Necrosis Factor Promotes Runx2 Degradation through Up-
regulation of Smurf1 and Smurf2 in Osteoblasts. J.Biol.Chem. 281:4326-4333. 
[106] Zhao, M., Qiao, M., Oyajobi, B.O., Mundy, G.R., and Chen, D. 2003. E3 ubiquitin ligase 
Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific 
role in osteoblast differentiation. J.Biol.Chem. 278:27939-27944. 
[107] Rauch, A., Seitz, S., Baschant, U., Schilling, A.F., Illing, A., Stride, B., Kirilov, M., 
Mandic, V., Takacz, A., Schmidt-Ullrich, R. et al. 2010. Glucocorticoids Suppress Bone 
Formation by Attenuating Osteoblast Differentiation via the Monomeric Glucocorticoid 
Receptor. Cell Metabolism 11:517-531. 
[108] Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M.C., and Lane, N.E. 2008. 
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and 
adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene 
expression in bone tissue from glucocorticoid-treated mice. Arthritis & Rheumatism 
58:1674-1686. 
[109] Kassel, O., Sancono, A., Kratzschmar, J., Kreft, B., Stassen, M., and Cato, A.C.B. 2001. 
Glucocorticoids inhibit MAP kinase via increased expression and decreased 
degradation of MKP-1. EMBO J 20:7108-7116. 
[110] Suzuki, A., Guicheux, J., Palmer, G., Miura, Y., Oiso, Y., Bonjour, J.P., and Caverzasio, 
J. 2002. Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase 
during osteoblastic cell differentiation. Bone 30:91-98. 
[111] Park, O.J., Kim, H.J., Woo, K.M., Baek, J.H., and Ryoo, H.M. 2010. FGF2-activated ERK 
Mitogen-activated Protein Kinase Enhances Runx2 Acetylation and Stabilization. 
J.Biol.Chem. 285:3568-3574. 
[112] Song, C.Z., Tian, X., and Gelehrter, T.D. 1999. Glucocorticoid receptor inhibits 
transforming growth factor-beta signaling by directly targeting the transcriptional 
activation function of Smad3. Proc Natl Acad Sci U.S.A 96:11776-11781. 
[113] Iu, M.F., Kaji, H., Sowa, H., Naito, J., Sugimoto, T., and Chihara, K. 2005. 
Dexamethasone suppresses Smad3 pathway in osteoblastic cells. J Endocrinol 185:131-
138. 
[114] Periyasamy, S. and Snchez, E.R. 2002. Antagonism of glucocorticoid receptor 
transactivity and cell growth inhibition by transforming growth factor-[beta] through 
AP-1-mediated transcriptional repression. The International Journal of Biochemistry & Cell 
Biology 34:1571-1585. 
[115] Song, C.Z., Tian, X., and Gelehrter, T.D. 1999. Glucocorticoid receptor inhibits 
transforming growth factor-beta signaling by directly targeting the transcriptional 
activation function of Smad3. Proc Natl Acad Sci U.S.A 96:11776-11781. 
[116] Locklin, R.M., Oreffo, R.O.C., and Triffitt, J.T. 1999. Effects of TGF[beta] and BFGF on 
the differentiation of human bone marrow stromal fibroblasts. Cell Biology International 
23:185-194. 
[117] Alliston, T., Choy, L., Ducy, P., Karsenty, G., and Derynck, R. 2001. TGF-[beta]-
induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and 
inhibits osteoblast differentiation. EMBO J 20:2254-2272. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 58 
[92] Mittelstadt, P.R. and Ashwell, J.D. 2001. Inhibition of AP-1 by the glucocorticoid-
inducible protein GILZ. J.Biol.Chem. 276:29603-29610. 
[93] Ayroldi, E., Zollo, O., Bastianelli, A., Marchetti, C., Agostini, M., Di Virgilio, R., and 
Riccardi, C. 2007. GILZ mediates the antiproliferative activity of glucocorticoids by 
negative regulation of Ras signaling. J Clin Invest 117:1605-1615. 
[94] Berrebi, D., Bruscoli, S., Cohen, N., Foussat, A., Migliorati, G., Bouchet-Delbos, L., 
Maillot, M.C., Portier, A., Couderc, J., Galanaud, P. et al. 2003. Synthesis of 
glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory 
and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 
101:729-738. 
[95] Yang, N., Zhang, W., and Shi, X.M. 2007. Glucocorticoid-induced leucine zipper (GILZ) 
mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-2 
expression. J Cell Biochem 103:1760-1771. 
[96] Arthaningtyas, E., Kok, C.C., Mordvinov, V.A., and Sanderson, C.J. 2005. The conserved 
lymphokine element 0 is a powerful activator and target for corticosteroid inhibition in 
human interleukin-5 transcription. Growth Factors 23:211-221. 
[97] Cohen, N., Mouly, E., Hamdi, H., Maillot, M.C., Pallardy, M., Godot, V., Capel, F., 
Balian, A., Naveau, S., Galanaud, P. et al. 2005. GILZ expression in human dendritic 
cells redirects their maturation and prevents antigen-specific T lymphocyte response. 
Blood2005-2007. 
[98] Ayroldi, E. and Riccardi, C. 2009. Glucocorticoid-induced leucine zipper (GILZ): a new 
important mediator of glucocorticoid action. FASEB J. 23:1-10. 
[99] Asselin-Labat, M.L., Biola-Vidamment, A., Kerbrat, S., Lombes, M., Bertoglio, J., and 
Pallardy, M. 2005. FoxO3 Mediates Antagonistic Effects of Glucocorticoids and 
Interleukin-2 on Glucocorticoid-Induced Leucine Zipper Expression. Mol Endocrinol 
19:1752-1764. 
[100] Zhang, W., Yang, N., and Shi, X.M. 2008. Regulation of Mesenchymal Stem Cell 
Osteogenic Differentiation by Glucocorticoid-induced Leucine Zipper (GILZ). 
J.Biol.Chem. 283:4723-4729. 
[101] He, L., Yang, N., Isales, C.M., and Shi, X.M. 2012. Glucocorticoid-Induced Leucine 
Zipper (GILZ) Antagonizes TNF-__ Inhibition of Mesenchymal Stem Cell Osteogenic 
Differentiation. PLoS ONE 7:e31717. 
[102] Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z.P., Deng, J.M., Behringer, R.R., and de 
Crombrugghe, B. 2002. The novel zinc finger-containing transcription factor Osterix is 
required for osteoblast differentiation and bone formation. Cell 108:17-29. 
[103] Lu, X., Gilbert, L., He, X., Rubin, J., and Nanes, M.S. 2006. Transcriptional Regulation 
of the Osterix (Osx, Sp7] Promoter by Tumor Necrosis Factor Identifies Disparate 
Effects of Mitogen-activated Protein Kinase and NF+¦B Pathways. J.Biol.Chem. 281:6297-
6306. 
[104] Gilbert, L., He, X., Farmer, P., Rubin, J., Drissi, H., van Wijnen, A.J., Lian, J.B., Stein, 
G.S., and Nanes, M.S. 2002. Expression of the Osteoblast Differentiation Factor RUNX2 
(Cbfa1/AML3/Pebp2alpha A) Is Inhibited by Tumor Necrosis Factor-alpha. J.Biol.Chem. 
277:2695-2701. 
 
Mechanism of Glucocorticoid-Induced Osteoporosis: An Update 59 
[105] Kaneki, H., Guo, R., Chen, D., Yao, Z., Schwarz, E.M., Zhang, Y.E., Boyce, B.F., and 
Xing, L. 2006. Tumor Necrosis Factor Promotes Runx2 Degradation through Up-
regulation of Smurf1 and Smurf2 in Osteoblasts. J.Biol.Chem. 281:4326-4333. 
[106] Zhao, M., Qiao, M., Oyajobi, B.O., Mundy, G.R., and Chen, D. 2003. E3 ubiquitin ligase 
Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific 
role in osteoblast differentiation. J.Biol.Chem. 278:27939-27944. 
[107] Rauch, A., Seitz, S., Baschant, U., Schilling, A.F., Illing, A., Stride, B., Kirilov, M., 
Mandic, V., Takacz, A., Schmidt-Ullrich, R. et al. 2010. Glucocorticoids Suppress Bone 
Formation by Attenuating Osteoblast Differentiation via the Monomeric Glucocorticoid 
Receptor. Cell Metabolism 11:517-531. 
[108] Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M.C., and Lane, N.E. 2008. 
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and 
adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene 
expression in bone tissue from glucocorticoid-treated mice. Arthritis & Rheumatism 
58:1674-1686. 
[109] Kassel, O., Sancono, A., Kratzschmar, J., Kreft, B., Stassen, M., and Cato, A.C.B. 2001. 
Glucocorticoids inhibit MAP kinase via increased expression and decreased 
degradation of MKP-1. EMBO J 20:7108-7116. 
[110] Suzuki, A., Guicheux, J., Palmer, G., Miura, Y., Oiso, Y., Bonjour, J.P., and Caverzasio, 
J. 2002. Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase 
during osteoblastic cell differentiation. Bone 30:91-98. 
[111] Park, O.J., Kim, H.J., Woo, K.M., Baek, J.H., and Ryoo, H.M. 2010. FGF2-activated ERK 
Mitogen-activated Protein Kinase Enhances Runx2 Acetylation and Stabilization. 
J.Biol.Chem. 285:3568-3574. 
[112] Song, C.Z., Tian, X., and Gelehrter, T.D. 1999. Glucocorticoid receptor inhibits 
transforming growth factor-beta signaling by directly targeting the transcriptional 
activation function of Smad3. Proc Natl Acad Sci U.S.A 96:11776-11781. 
[113] Iu, M.F., Kaji, H., Sowa, H., Naito, J., Sugimoto, T., and Chihara, K. 2005. 
Dexamethasone suppresses Smad3 pathway in osteoblastic cells. J Endocrinol 185:131-
138. 
[114] Periyasamy, S. and Snchez, E.R. 2002. Antagonism of glucocorticoid receptor 
transactivity and cell growth inhibition by transforming growth factor-[beta] through 
AP-1-mediated transcriptional repression. The International Journal of Biochemistry & Cell 
Biology 34:1571-1585. 
[115] Song, C.Z., Tian, X., and Gelehrter, T.D. 1999. Glucocorticoid receptor inhibits 
transforming growth factor-beta signaling by directly targeting the transcriptional 
activation function of Smad3. Proc Natl Acad Sci U.S.A 96:11776-11781. 
[116] Locklin, R.M., Oreffo, R.O.C., and Triffitt, J.T. 1999. Effects of TGF[beta] and BFGF on 
the differentiation of human bone marrow stromal fibroblasts. Cell Biology International 
23:185-194. 
[117] Alliston, T., Choy, L., Ducy, P., Karsenty, G., and Derynck, R. 2001. TGF-[beta]-
induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and 
inhibits osteoblast differentiation. EMBO J 20:2254-2272. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 60 
[118] Kassem, Kveiborg, and Eriksen. 2000. Production and action of transforming growth 
factor-__ in human osteoblast cultures: dependence on cell differentiation and 
modulation by calcitriol. European Journal of Clinical Investigation 30:429-437. 
[119] Edwards, J.R., Nyman, J.S., Lwin, S.T., Moore, M.M., Esparza, J., O'Quinn, E.C., Hart, 
A.J., Biswas, S., Patil, C.A., Lonning, S. et al. 2010. Inhibition of TGF-beta signaling by 
1D11 antibody treatment increases bone mass and quality in vivo. jbmrn-a. 
[120] Tang, Y., Wu, X., Lei, W., Pang, L., Wan, C., Shi, Z., Zhao, L., Nagy, T.R., Peng, X., Hu, 
J. et al. 2009. TGF-beta1-induced migration of bone mesenchymal stem cells couples 
bone resorption with formation. Nat.Med. 15:757-765. 
[121] Bouvard, B., Audran, M., Legrand, E., and Chappard, D. 2009. Ultrastructural 
characteristics of glucocorticoid-induced osteoporosis. Osteoporosis International 20:1089-
1092. 
[122] Berris, K.K., Repp, A.L., and Kleerekoper, M. 2007. Glucocorticoid-induced 
osteoporosis. Current Opinion in Endocrinology, Diabetes and Obesity 14. 
[123] L_Ėv_źs, K., Gjesdal, C.G., Christensen, M., Wolff, A.B., Alm_źs, B.Ė., Svartberg, J., 
Fougner, K.J., Syversen, U., Bollerslev, J., Falch, J.A. et al. 2009. Glucocorticoid 
replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J 
Endocrinol 160:993-1002. 
[124] Grossman, J.M., Gordon, R., Ranganath, V.K., Deal, C., Caplan, L., Chen, W., Curtis, 
J.R., Furst, D.E., McMahon, M., Patkar, N.M. et al. 2010. American College of 
Rheumatology 2010 recommendations for the prevention and treatment of 
glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515-1526. 
[125] van Staa, T. 2006. The Pathogenesis, Epidemiology and Management of 
Glucocorticoid-Induced Osteoporosis. Calcified Tissue International 79:129-137. 
[126] Weinstein, R.S. 2010. Glucocorticoids, osteocytes, and skeletal fragility: The role of 
bone vascularity. Bone 46:564-570. 
[127] Angeli, A., Guglielmi, G., Dovio, A., Capelli, G., de Feo, D., Giannini, S., Giorgino, R., 
Moro, L., and Giustina, A. 2006. High prevalence of asymptomatic vertebral fractures in 
post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional 
outpatient study. Bone 39:253-259. 
[128] Leib, E.S., Saag, K.G., Adachi, J.D., Geusens, P.P., Binkley, N., McCloskey, E.V., and 
Hans, D.B. 2011. Official Positions for FRAX_« Clinical Regarding Glucocorticoids: The 
Impact of the Use of Glucocorticoids on the Estimate by FRAX_« of the 10 Year Risk of 
Fracture: From Joint Official Positions Development Conference of the International 
Society for Clinical Densitometry and International Osteoporosis Foundation on 
FRAX_«. Journal of Clinical Densitometry 14:212-219. 
[129] Teitelbaum, S.L., Seton, M.P., and Saag, K.G. 2011. Should bisphosphonates be used 
for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis & Rheumatism 
63:325-328. 
[130] Saag, K.G., Shane, E., Boonen, S., Mar_Łn, F., Donley, D.W., Taylor, K.A., Dalsky, G.P., 
and Marcus, R. 2007. Teriparatide or Alendronate in Glucocorticoid-Induced 
Osteoporosis. New England Journal of Medicine 357:2028-2039. 
[131] Sambrook, P.N. 2007. Anabolic Therapy in Glucocorticoid-Induced Osteoporosis. New 






© 2012 Brunner et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Extra-Adrenal Glucocorticoid Synthesis in 
Mucosal Tissues and Its Implication in Mucosal 
Immune Homeostasis and Tumor Development 
Feodora I. Kostadinova, Nina Hostettler,  
Pamela Bianchi and Thomas Brunner 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/52788 
1. Introduction 
While glucocorticoids (GC) exert broad effects on metabolism, behavior and immunity, local 
production of even small amounts of GC, which may act in a paracrine or even autocrine 
manner, enable a specific site of the body to regulate their exposure to GC according to their 
specific needs. Mucosal tissues, for example, are at the borderline to the outside world, and 
are therefore in constant contact with either harmless foreign particles or potentially 
pathogenic microorganisms, which might provoke devastating inflammatory disorders due 
to chronic stimulation of the mucosal immune system. Increasing the local concentration of 
immunoregulatory GC by extra-adrenal de novo GC synthesis or local reactivation of 
inactive serum metabolites provides a protective mechanism to either restore homeostasis 
after clearance of infection or to regulate the critical balance between immunity and 
tolerance. 
2. Adrenal versus extra-adrenal GC synthesis 
Production of GC in the adrenal glands is regulated by hypothalamic-pituitary-adrenal 
(HPA) axis and follows under normal conditions the circadian rhythm. However, GC are 
also a major humoral response to various types of stress. [1]. Immunological stress by 
excessive activation of immune cells rapidly results in elevated plasma levels of tumor 
necrosis factor alpha (TNFα), interleukin (IL) -1 and IL-6, which then stimulate the HPA axis 
and lead to an increase of systemic GC [2]. These and similar signals stimulate also the local 
GC synthesis in mucosal tissues, as will be discussed later (Table 1). 
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manner, enable a specific site of the body to regulate their exposure to GC according to their 
specific needs. Mucosal tissues, for example, are at the borderline to the outside world, and 
are therefore in constant contact with either harmless foreign particles or potentially 
pathogenic microorganisms, which might provoke devastating inflammatory disorders due 
to chronic stimulation of the mucosal immune system. Increasing the local concentration of 
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Production of GC in the adrenal glands is regulated by hypothalamic-pituitary-adrenal 
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also a major humoral response to various types of stress. [1]. Immunological stress by 
excessive activation of immune cells rapidly results in elevated plasma levels of tumor 
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Sensitizing GABA 





Intestine Crypt cells Regulation via 
LRH-1  
Immune regulation [46-53] 
Lung unknown Reactivation by 
11β-HSD 
Immune regulation [54] 
Colon carcinoma Tumor cells Regulation via 
LRH-1 
Immunosuppression [55] 
Table 1. Extra-adrenal GC sources and their functions. 
Because most data published so far on local GC synthesis has been generated in animal 
models a brief overview of steroidogenic processes in rodents compared to humans must be 
made (Figure 1). A major difference is the implication of the enzyme 17α-hydroxylase in the 
GC synthesis in humans, but not in rodents. Pregnenolone is transformed directly into 
progesterone in most rodents, and in other mammalians and humans it is first hydroxylated 
and then metabolized into 17-OH-progesterone [56]. 11β-hydroxylase (P450C11) is an 
enzyme expressed in the zonae fasciculata et reticularis and is a product of the gene 
CYP11B1. Thus, in rodents this enzyme uses 11-deoxycorticosterone as a substrate and turns 
it into corticosterone, which is the active GC in these species. In humans 11β-hydroxylase 
metabolizes mainly 11-deoxycortisol into cortisol and to a lesser degree 11-
deoxycorticosterone into corticosterone. Hence, cortisol is the major active GC in the human. 
11-Deoxyorticosterone and corticosterone are important metabolites in both species, which 
can be hydroxylised and oxidised in the zona glomerulosa of the adrenals, subsequently 
leading to the mineralcorticosteroid aldosterone [57]. 
It is well established that the adrenal glands are the major source of systemic GC. Surgical 
removal of the adrenal glands results in a rapid drop of serum GC levels, which after a 
couple of days become undetectable, illustrating that the adrenals are primarily responsible 
for the GC levels detected in the circulation [46, 58]. However, in recent years there has been 
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accumulating evidence that several other tissues are capable of producing GC and thereby 
regulate local processes in an adrenal-independent manner [7, 59]. 
 
Legend: � enzymes; □ metabolites:  metabolic pathway; - - - absent in rodents; * inhibitory effect of metyrapone. 
Figure 1. Differences in the GC synthesis pathway in rodents and humans. 
3. Extra-adrenal sources of GC synthesis 
3.1. Thymus 
The Thymus plays a central role in the development of the immune system. Thymocyte 
development and differentiation is shaped and regulated by the interaction with the thymic 
epithelial cells and the factors secreted by them [60, 61]. 
Initial characterizations of extra-adrenal GC synthesis started in the thymus. In the mid to 
late 90ties of the last century it was described that the non-immune cells in the thymic cortex 
are capable of producing various steroid metabolites. Accordingly, the expression of various 
enzymes of the corticosteroid synthesis pathway has been demonstrated in thymic epithelial 
cells [3-5]. While the function of thymic GC has been a matter of scientific debate for some 
time [62, 63], particularly the work of Ashwell and co-workers illustrated that GC 
production in the thymus has an important role in the regulation of thymocyte development 
and selection. Interestingly, while thymocytes are exquisitely sensitive to GC and rapidly 
die by apoptosis, the in situ produced corticosterone seems to oppose the signals induced by 
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Because most data published so far on local GC synthesis has been generated in animal 
models a brief overview of steroidogenic processes in rodents compared to humans must be 
made (Figure 1). A major difference is the implication of the enzyme 17α-hydroxylase in the 
GC synthesis in humans, but not in rodents. Pregnenolone is transformed directly into 
progesterone in most rodents, and in other mammalians and humans it is first hydroxylated 
and then metabolized into 17-OH-progesterone [56]. 11β-hydroxylase (P450C11) is an 
enzyme expressed in the zonae fasciculata et reticularis and is a product of the gene 
CYP11B1. Thus, in rodents this enzyme uses 11-deoxycorticosterone as a substrate and turns 
it into corticosterone, which is the active GC in these species. In humans 11β-hydroxylase 
metabolizes mainly 11-deoxycortisol into cortisol and to a lesser degree 11-
deoxycorticosterone into corticosterone. Hence, cortisol is the major active GC in the human. 
11-Deoxyorticosterone and corticosterone are important metabolites in both species, which 
can be hydroxylised and oxidised in the zona glomerulosa of the adrenals, subsequently 
leading to the mineralcorticosteroid aldosterone [57]. 
It is well established that the adrenal glands are the major source of systemic GC. Surgical 
removal of the adrenal glands results in a rapid drop of serum GC levels, which after a 
couple of days become undetectable, illustrating that the adrenals are primarily responsible 
for the GC levels detected in the circulation [46, 58]. However, in recent years there has been 
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accumulating evidence that several other tissues are capable of producing GC and thereby 
regulate local processes in an adrenal-independent manner [7, 59]. 
 
Legend: � enzymes; □ metabolites:  metabolic pathway; - - - absent in rodents; * inhibitory effect of metyrapone. 
Figure 1. Differences in the GC synthesis pathway in rodents and humans. 
3. Extra-adrenal sources of GC synthesis 
3.1. Thymus 
The Thymus plays a central role in the development of the immune system. Thymocyte 
development and differentiation is shaped and regulated by the interaction with the thymic 
epithelial cells and the factors secreted by them [60, 61]. 
Initial characterizations of extra-adrenal GC synthesis started in the thymus. In the mid to 
late 90ties of the last century it was described that the non-immune cells in the thymic cortex 
are capable of producing various steroid metabolites. Accordingly, the expression of various 
enzymes of the corticosteroid synthesis pathway has been demonstrated in thymic epithelial 
cells [3-5]. While the function of thymic GC has been a matter of scientific debate for some 
time [62, 63], particularly the work of Ashwell and co-workers illustrated that GC 
production in the thymus has an important role in the regulation of thymocyte development 
and selection. Interestingly, while thymocytes are exquisitely sensitive to GC and rapidly 
die by apoptosis, the in situ produced corticosterone seems to oppose the signals induced by 
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the T cell receptor and thereby lower T cell receptor-induced apoptosis (negative selection). 
On the other hand T cell receptor activation also inhibits the apoptosis-inducing activity of 
GC in thymocytes [64]. Thus, the “mutual antagonism” between T cell receptor and 
glucocorticoid receptor (GR) signaling seems overall to enhance survival and thereby 
positive selection of thymocytes by increasing the threshold of T cell receptor signals 
leading to negative selection [3]. The thymus in mice produces the highest amounts of GC 
during fetal development and in the first weeks after birth. This is the time of the most 
extensive lymphocyte development and differentiation, and it occurs at a time when the 
steroidogenesis in the adrenals is not fully active. Thus, the thymus seems to depend largely 
on its own by providing the necessary GC. Whether thymic epithelial cells constitutively 
produce GC or whether this is dependent on the interaction with activated thymocytes or 
soluble factors, is presently unknown. The presence or absence of factors regulating thymic 
GC synthesis may, however, affect positive and negative selection of thymocytes, and 
thereby also affect the levels of potentially autoreactive T cells in the periphery. [6, 7]. 
3.2. Skin 
The skin is an organ with a complex structure and its purpose is to protect the inner 
organism from the environmental factors, infections, dehydration, thermal deregulations 
etc. The outer cover of the skin, the epidermis, maintains its integrity through intense self-
renewing by the proliferating keratinocytes in the basal layer and the dividing cells in the 
hair follicles. As such skin is an important component of the defense mechanisms providing 
not only a reliable mechanical barrier and producing antimicrobial enzymes and other 
substances, but also being populated with many specialized immune cells, e.g. dendritic 
cells (Langerhans cells) within the epidermis, as well as resident macrophages, dendritic 
cells and lymphocytes in the derma [65]. The skin also displays active metabolic and 
endocrine functions. Along with the synthesis of vitamin D, the skin was shown to produce 
various hormones and regulatory factors, like parathyroid-related protein, melanocyte-
stimulating hormone (MSH), β-endorphin peptides, urocortin, neurotransmitters and others 
(for review [10, 11]). With regard of this chapter’s topic of interest is the ability of the skin to 
produce all components of the HPA axis. A great contribution to the understanding of GC 
metabolism and regulation in the skin has been made by the extensive research of Slominski 
and co-workers [10]. In human keratinocytes and cells of the hair follicles expression of 
corticotropin-releasing factor (CRF) has been demonstrated at the mRNA and protein level, 
whereas in mice the local synthesis of CRF has not been proven yet. The observed local 
increased concentration of CRF in the skin could be possibly explained by its release from 
neuronal cells and its active transport into the skin along the local nerve endings [12, 15]. 
Many cell types found in the skin, e.g. keratinocytes [66], melanocytes [13], dermal 
fibroblasts [67], immune cells and endothelial cells in the derma, as well as hair follicles [16] 
and skin tissue cultures, are able to respond to CRF stimulation and to produce 
proopiomelanocortin,  which can be further processed into adrenocorticotropic hormone 
(ACTH), MSH and β -endorphin. Moreover, GC-synthesizing enzymes and active GC have 
been demonstrated in human and rodent skin.  Metabolic assays demonstrated that ex vivo 
cultured normal rat skin could transform progesterone into deoxycorticosterone and 
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corticosterone, and further to 11-dehydrocorticosterone [9]. Human skin has been 
demonstrated to respond to ACTH, to express various steroidogenic enzymes, and to be 
capable of synthesizing cortisol [8, 18]. Local steroidogenesis was demonstrated in human 
keratinocytes [19], sebaceous cells [18], fibroblasts [14], and melanocytes [13]. Hair follicles, 
also known as pilosebaceus units, appear to function as fully autonomous peripheral 
equivalents of the HPA axis. The CRF/ACTH-induced cortisol production appears to 
provide also a negative feedback on the local CRF synthesis and thereby terminate local 
steroidogenesis [15]. It has been suggested that this local HPA axis is implemented in the 
regulation of hair growth, pigmentation and modulation of local immune response [17]. 
Components of the HPA axis, mainly CRF, are proposed to affect the epithelial cell 
proliferation, apoptosis and differentiation [15]. Recent findings describe the role of local 
cortisol synthesis in a model of tissue injury. Up-regulation of CYP11B1 and subsequent 
enhanced production of cortisol was induced by the proinflammatory cytokine IL-1β and 
depressed by insulin-like growth factor 1 (IGF-1) [19]. In the same study elevation of cortisol 
synthesis was observed approximately 48 hours after acute injury and maintained the 
proper wound healing.  
In conclusion, the skin possesses an autonomous HPA axis, regulating the normal integrity 
and growth, and is able to respond to stress factors. At the same time the GC-synthesizing 
machinery of the skin can be stimulated by inflammatory mediators in order to provide an 
adequate local self-limitation of immune responses. 
3.3. Central nervous system 
The term neurosteroids was defined after the discovery that various steroid metabolites can 
be detected in the brain of simultaneously adrenalectomized and gonadectomized rats [30]. 
Among the locally synthesized and active steroids are pregnenolone and pregnenolone 
sulphate, progesterone, allopregnanolone, dehydroepiandrosterone and 
dehydroepiandrosterone sulphate. These steroids can exert their effects in neurogenesis, 
development, myelinization, memory, reactions to stress through engaging nuclear 
receptors and modulating transcription, as well as affecting neurotransmission by 
modifying the activity of gamma-aminobutiric acid (GABAA), N-methyl-D-aspartic acid 
(NMDA), and sigma receptors (for review [31, 32, 68]). Low levels of transcripts for 
CYP11A1, CYP11B1 and the other enzymes of corticosterone synthesis were detected in 
normal rat brain, in cerebral cortex and cerebellum [33], and 11β-hydroxylase protein 
expression was later demonstrated in the Purkinje cells and other cells of the hippocampus 
[35]. In vitro conversion of precursors into corticosterone has also been demonstrated in rat 
fetal hippocampal neurons [34]. The extremely low levels of CYP21 transcripts and enzyme 
(deoxycorticosterone synthetase, P450C21) detected [36] gave raise to many doubts whether 
complete GC synthesis can be sustained in the brain. Nevertheless, the activity of brain 
tissue to convert progesterone to 11-deoxycorticosterone (resp. 17α-OH-progesterone to 11-
deoxycortisol) pointed out that steroid metabolism in the brain exists. Recently, the 
expression of isoforms of CYP2D4 and CYP2D6 in rat and human brains, respectively, as 
well as demonstration of their 21-hydroxylation activity confirmed the capacity of rodent 
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the T cell receptor and thereby lower T cell receptor-induced apoptosis (negative selection). 
On the other hand T cell receptor activation also inhibits the apoptosis-inducing activity of 
GC in thymocytes [64]. Thus, the “mutual antagonism” between T cell receptor and 
glucocorticoid receptor (GR) signaling seems overall to enhance survival and thereby 
positive selection of thymocytes by increasing the threshold of T cell receptor signals 
leading to negative selection [3]. The thymus in mice produces the highest amounts of GC 
during fetal development and in the first weeks after birth. This is the time of the most 
extensive lymphocyte development and differentiation, and it occurs at a time when the 
steroidogenesis in the adrenals is not fully active. Thus, the thymus seems to depend largely 
on its own by providing the necessary GC. Whether thymic epithelial cells constitutively 
produce GC or whether this is dependent on the interaction with activated thymocytes or 
soluble factors, is presently unknown. The presence or absence of factors regulating thymic 
GC synthesis may, however, affect positive and negative selection of thymocytes, and 
thereby also affect the levels of potentially autoreactive T cells in the periphery. [6, 7]. 
3.2. Skin 
The skin is an organ with a complex structure and its purpose is to protect the inner 
organism from the environmental factors, infections, dehydration, thermal deregulations 
etc. The outer cover of the skin, the epidermis, maintains its integrity through intense self-
renewing by the proliferating keratinocytes in the basal layer and the dividing cells in the 
hair follicles. As such skin is an important component of the defense mechanisms providing 
not only a reliable mechanical barrier and producing antimicrobial enzymes and other 
substances, but also being populated with many specialized immune cells, e.g. dendritic 
cells (Langerhans cells) within the epidermis, as well as resident macrophages, dendritic 
cells and lymphocytes in the derma [65]. The skin also displays active metabolic and 
endocrine functions. Along with the synthesis of vitamin D, the skin was shown to produce 
various hormones and regulatory factors, like parathyroid-related protein, melanocyte-
stimulating hormone (MSH), β-endorphin peptides, urocortin, neurotransmitters and others 
(for review [10, 11]). With regard of this chapter’s topic of interest is the ability of the skin to 
produce all components of the HPA axis. A great contribution to the understanding of GC 
metabolism and regulation in the skin has been made by the extensive research of Slominski 
and co-workers [10]. In human keratinocytes and cells of the hair follicles expression of 
corticotropin-releasing factor (CRF) has been demonstrated at the mRNA and protein level, 
whereas in mice the local synthesis of CRF has not been proven yet. The observed local 
increased concentration of CRF in the skin could be possibly explained by its release from 
neuronal cells and its active transport into the skin along the local nerve endings [12, 15]. 
Many cell types found in the skin, e.g. keratinocytes [66], melanocytes [13], dermal 
fibroblasts [67], immune cells and endothelial cells in the derma, as well as hair follicles [16] 
and skin tissue cultures, are able to respond to CRF stimulation and to produce 
proopiomelanocortin,  which can be further processed into adrenocorticotropic hormone 
(ACTH), MSH and β -endorphin. Moreover, GC-synthesizing enzymes and active GC have 
been demonstrated in human and rodent skin.  Metabolic assays demonstrated that ex vivo 
cultured normal rat skin could transform progesterone into deoxycorticosterone and 
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corticosterone, and further to 11-dehydrocorticosterone [9]. Human skin has been 
demonstrated to respond to ACTH, to express various steroidogenic enzymes, and to be 
capable of synthesizing cortisol [8, 18]. Local steroidogenesis was demonstrated in human 
keratinocytes [19], sebaceous cells [18], fibroblasts [14], and melanocytes [13]. Hair follicles, 
also known as pilosebaceus units, appear to function as fully autonomous peripheral 
equivalents of the HPA axis. The CRF/ACTH-induced cortisol production appears to 
provide also a negative feedback on the local CRF synthesis and thereby terminate local 
steroidogenesis [15]. It has been suggested that this local HPA axis is implemented in the 
regulation of hair growth, pigmentation and modulation of local immune response [17]. 
Components of the HPA axis, mainly CRF, are proposed to affect the epithelial cell 
proliferation, apoptosis and differentiation [15]. Recent findings describe the role of local 
cortisol synthesis in a model of tissue injury. Up-regulation of CYP11B1 and subsequent 
enhanced production of cortisol was induced by the proinflammatory cytokine IL-1β and 
depressed by insulin-like growth factor 1 (IGF-1) [19]. In the same study elevation of cortisol 
synthesis was observed approximately 48 hours after acute injury and maintained the 
proper wound healing.  
In conclusion, the skin possesses an autonomous HPA axis, regulating the normal integrity 
and growth, and is able to respond to stress factors. At the same time the GC-synthesizing 
machinery of the skin can be stimulated by inflammatory mediators in order to provide an 
adequate local self-limitation of immune responses. 
3.3. Central nervous system 
The term neurosteroids was defined after the discovery that various steroid metabolites can 
be detected in the brain of simultaneously adrenalectomized and gonadectomized rats [30]. 
Among the locally synthesized and active steroids are pregnenolone and pregnenolone 
sulphate, progesterone, allopregnanolone, dehydroepiandrosterone and 
dehydroepiandrosterone sulphate. These steroids can exert their effects in neurogenesis, 
development, myelinization, memory, reactions to stress through engaging nuclear 
receptors and modulating transcription, as well as affecting neurotransmission by 
modifying the activity of gamma-aminobutiric acid (GABAA), N-methyl-D-aspartic acid 
(NMDA), and sigma receptors (for review [31, 32, 68]). Low levels of transcripts for 
CYP11A1, CYP11B1 and the other enzymes of corticosterone synthesis were detected in 
normal rat brain, in cerebral cortex and cerebellum [33], and 11β-hydroxylase protein 
expression was later demonstrated in the Purkinje cells and other cells of the hippocampus 
[35]. In vitro conversion of precursors into corticosterone has also been demonstrated in rat 
fetal hippocampal neurons [34]. The extremely low levels of CYP21 transcripts and enzyme 
(deoxycorticosterone synthetase, P450C21) detected [36] gave raise to many doubts whether 
complete GC synthesis can be sustained in the brain. Nevertheless, the activity of brain 
tissue to convert progesterone to 11-deoxycorticosterone (resp. 17α-OH-progesterone to 11-
deoxycortisol) pointed out that steroid metabolism in the brain exists. Recently, the 
expression of isoforms of CYP2D4 and CYP2D6 in rat and human brains, respectively, as 
well as demonstration of their 21-hydroxylation activity confirmed the capacity of rodent 
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and human brain to produce GC locally [37, 69], though suggesting a slightly different 
enzymatic pathway compared to that of the adrenals. Nonetheless, CRF and ACTH, likely 
released by the hypothalamus, resp. pituitary gland, seem to regulate GC synthesis in the 
brain in a similar manner as in the adrenals. Interestingly, adrenalectomy even increases the 
expression of CYP11B1 in the rat brain [70]. 
Peripheral reactivation of 11-dehydrocorticosterone to corticosterone, resp. cortisone to 
cortisol via 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity contributes 
considerably not only to the local concentrations and effects of GC, but also to the plasma 
level of GC, as shown by an almost 30% increase in corticosterone levels in the portal vein 
compared to the incoming arterial circulation [38, 39, 71]. In the brain 11β-HSD1 expression 
was found in various areas. Local levels of corticosterone in the cerebral cortex, 
hippocampus, hypothalamus and pituitary gland modulate the activity of the HPA axis. 
This effect is particularly apparent in 11β-HSD1 knockout mice. The lack of 11β-HSD1 
activity in the brain of these mice leads to considerably reduced local levels of 
corticosterone. Hence, the HPA axis is hyperactivated and higher amounts of ACTH are 
produced, which in turn causes adrenal hypertrophy. Normal or even elevated systemic 
GC fail to transmit proper feedback responses to the hypothalamus [40-42]. Other curious 
effects of the local levels of GC attributed to the activity of 11β-HSD1 in the hippocampus 
are cognitive disorders during aging. Experiments in 11β-HSD1-deficient mice showed 
that these animals are protected from the decline of the learning abilities [43, 72]. 11β-
HSD1 is expressed in the human prefrontal cortex, cerebellum and hippocampus, and its 
expression, as well as local GC levels, has also been correlated to the cognitive decline in 
elderly patients [44, 45], [42]. Furthermore, some clinical studies showed an improvement 
in verbal fluency and memory in patients treated with the specific 11β-HSD1 inhibitor 
carbenoxolone [44].  
3.4. Cardiovascular system 
The impact of mineralocorticoids and glucocorticoids on the heart and blood vessels is well 
known and described. Yet, the capacity of these structures to sustain their own supplies is 
not understood in detail. Data obtained mainly in rats indicate that vascular tissue expresses 
steroidogenic factors, such as StAR, CYP11A1, CYP11B1 and CYP11B2 [20, 21, 73]. Ex vivo 
cultured rat blood vessels were able to produce corticosterone and aldosterone [23, 73]. 
Expression of various steroidogenic enzymes has been shown also in the human heart and 
blood vessels [26, 27]. However, CYP11B1 and CYP11B2 expression was only demonstrated 
in patients with myocardial infarction and heart failure [28], but barely under steady state 
conditions or in cultured endothelial cells [29], suggesting that local GC synthesis may be 
triggered during pathological conditions. Presence of CYP11B2 (aldosterone synthetase) and 
the fact that steroidogenesis in the cardiovascular system is triggered by the angiotensin 
signaling system [24] points out that local steroidogensis in the vascular systems is 
connected to the renin-angiotensin-aldosterone regulatory mechanisms [25]. Local 
reactivation of 11-dehydrocorticosterone was also observed in the smooth muscle cells in 
arteries, where it may contribute to vascular contractility and remodeling [74], [75]. Despite 
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a clear demonstration of steroidogenesis in the vasculature detailed studies on the anti-
inflammatory role of local GC synthesis in blood vessels are still missing. 
In addition to the different tissues described above local GC synthesis was also reported in the 
placenta [76], the ovaries [77], the testis [78], the uterus [79], and the mammary gland [80].  
4. GC synthesis in mucosal tissues 
Mucosal surfaces in the gastrointestinal, respiratory and urinal tract represent important 
contact zones between the body and the outside world. They exert important functions in 
the exchange of nutrients, gases and other substances between the organism and the 
surrounding world. They comprise an enormous interactive surface and are thereby also 
constantly exposed to various antigens and microorganisms. Though, most of them are 
harmless, and thus the body has developed mechanisms to tolerate these harmless antigens. 
Yet, dangerous infections of the lung and the intestine occur, in which case the local defense 
machinery must be engaged to protect the host from invasion. The barrier between inside 
and outside is primarily formed of a simple one-layered epithelium with the respective 
specialized functions. Beneath the epithelial layer in the lamina propria of the intestine or in 
the interstitium of the lung resides a large number of immune cells. Clearly the huge 
mucosal surface must be protected from invading pathogens, and thus these epithelial 
tissues are home of the largest immune system in our body. Inappropriate activation of 
these local immune cells by environmental antigens, though, can result in uncontrolled 
inflammation and associated tissue destruction. Several lines of evidence discussed in detail 
below indicate that locally produced GC significantly contribute to the regulation of local 
immune responses and the maintenance of immune homeostasis in these epithelial tissues. 
4.1. GC synthesis in the intestinal epithelium 
In the intestinal mucosa two super-systems collide. The intestinal lumen hosts ten times 
more bacteria than cells in our body are found. At the same time, the intestinal epithelium 
and lamina propria are also home of the largest number of B and T cells, and are also 
densely populated by macrophages and dendritic cells. Accidental and uncontrolled 
activation of these cells and/or other infiltrating immune cells by harmless commensal 
bacteria or food antigens is the underlying cause of a variety of inflammatory disorders, 
such as inflammatory bowel disease and food allergies [81] 
There is accumulating evidence that local production of immunoregulatory GC significantly 
contributes to the control of intestinal immune homeostasis and prevents a clash between 
immune cells and commensal bacteria. The notion that the intestinal mucosa could be a 
steroidogenic organ has been already suggested some time ago, when it was found that 
genetic deletion of the nuclear receptor SF-1 (steroidogenic factor-1, NR5a1), largely 
responsible for the transcriptional control of the adrenal development and GC synthesis, could 
not abrogate intestinal CYP11A1 expression in the mouse embryonic gut [82]. At the same 
time remaining GC levels were observed in the circulation of prenatal mice, indicating that an 
extra-adrenal source of GC synthesis must exist [83]. Our own research started to explicitly 
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and human brain to produce GC locally [37, 69], though suggesting a slightly different 
enzymatic pathway compared to that of the adrenals. Nonetheless, CRF and ACTH, likely 
released by the hypothalamus, resp. pituitary gland, seem to regulate GC synthesis in the 
brain in a similar manner as in the adrenals. Interestingly, adrenalectomy even increases the 
expression of CYP11B1 in the rat brain [70]. 
Peripheral reactivation of 11-dehydrocorticosterone to corticosterone, resp. cortisone to 
cortisol via 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity contributes 
considerably not only to the local concentrations and effects of GC, but also to the plasma 
level of GC, as shown by an almost 30% increase in corticosterone levels in the portal vein 
compared to the incoming arterial circulation [38, 39, 71]. In the brain 11β-HSD1 expression 
was found in various areas. Local levels of corticosterone in the cerebral cortex, 
hippocampus, hypothalamus and pituitary gland modulate the activity of the HPA axis. 
This effect is particularly apparent in 11β-HSD1 knockout mice. The lack of 11β-HSD1 
activity in the brain of these mice leads to considerably reduced local levels of 
corticosterone. Hence, the HPA axis is hyperactivated and higher amounts of ACTH are 
produced, which in turn causes adrenal hypertrophy. Normal or even elevated systemic 
GC fail to transmit proper feedback responses to the hypothalamus [40-42]. Other curious 
effects of the local levels of GC attributed to the activity of 11β-HSD1 in the hippocampus 
are cognitive disorders during aging. Experiments in 11β-HSD1-deficient mice showed 
that these animals are protected from the decline of the learning abilities [43, 72]. 11β-
HSD1 is expressed in the human prefrontal cortex, cerebellum and hippocampus, and its 
expression, as well as local GC levels, has also been correlated to the cognitive decline in 
elderly patients [44, 45], [42]. Furthermore, some clinical studies showed an improvement 
in verbal fluency and memory in patients treated with the specific 11β-HSD1 inhibitor 
carbenoxolone [44].  
3.4. Cardiovascular system 
The impact of mineralocorticoids and glucocorticoids on the heart and blood vessels is well 
known and described. Yet, the capacity of these structures to sustain their own supplies is 
not understood in detail. Data obtained mainly in rats indicate that vascular tissue expresses 
steroidogenic factors, such as StAR, CYP11A1, CYP11B1 and CYP11B2 [20, 21, 73]. Ex vivo 
cultured rat blood vessels were able to produce corticosterone and aldosterone [23, 73]. 
Expression of various steroidogenic enzymes has been shown also in the human heart and 
blood vessels [26, 27]. However, CYP11B1 and CYP11B2 expression was only demonstrated 
in patients with myocardial infarction and heart failure [28], but barely under steady state 
conditions or in cultured endothelial cells [29], suggesting that local GC synthesis may be 
triggered during pathological conditions. Presence of CYP11B2 (aldosterone synthetase) and 
the fact that steroidogenesis in the cardiovascular system is triggered by the angiotensin 
signaling system [24] points out that local steroidogensis in the vascular systems is 
connected to the renin-angiotensin-aldosterone regulatory mechanisms [25]. Local 
reactivation of 11-dehydrocorticosterone was also observed in the smooth muscle cells in 
arteries, where it may contribute to vascular contractility and remodeling [74], [75]. Despite 
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a clear demonstration of steroidogenesis in the vasculature detailed studies on the anti-
inflammatory role of local GC synthesis in blood vessels are still missing. 
In addition to the different tissues described above local GC synthesis was also reported in the 
placenta [76], the ovaries [77], the testis [78], the uterus [79], and the mammary gland [80].  
4. GC synthesis in mucosal tissues 
Mucosal surfaces in the gastrointestinal, respiratory and urinal tract represent important 
contact zones between the body and the outside world. They exert important functions in 
the exchange of nutrients, gases and other substances between the organism and the 
surrounding world. They comprise an enormous interactive surface and are thereby also 
constantly exposed to various antigens and microorganisms. Though, most of them are 
harmless, and thus the body has developed mechanisms to tolerate these harmless antigens. 
Yet, dangerous infections of the lung and the intestine occur, in which case the local defense 
machinery must be engaged to protect the host from invasion. The barrier between inside 
and outside is primarily formed of a simple one-layered epithelium with the respective 
specialized functions. Beneath the epithelial layer in the lamina propria of the intestine or in 
the interstitium of the lung resides a large number of immune cells. Clearly the huge 
mucosal surface must be protected from invading pathogens, and thus these epithelial 
tissues are home of the largest immune system in our body. Inappropriate activation of 
these local immune cells by environmental antigens, though, can result in uncontrolled 
inflammation and associated tissue destruction. Several lines of evidence discussed in detail 
below indicate that locally produced GC significantly contribute to the regulation of local 
immune responses and the maintenance of immune homeostasis in these epithelial tissues. 
4.1. GC synthesis in the intestinal epithelium 
In the intestinal mucosa two super-systems collide. The intestinal lumen hosts ten times 
more bacteria than cells in our body are found. At the same time, the intestinal epithelium 
and lamina propria are also home of the largest number of B and T cells, and are also 
densely populated by macrophages and dendritic cells. Accidental and uncontrolled 
activation of these cells and/or other infiltrating immune cells by harmless commensal 
bacteria or food antigens is the underlying cause of a variety of inflammatory disorders, 
such as inflammatory bowel disease and food allergies [81] 
There is accumulating evidence that local production of immunoregulatory GC significantly 
contributes to the control of intestinal immune homeostasis and prevents a clash between 
immune cells and commensal bacteria. The notion that the intestinal mucosa could be a 
steroidogenic organ has been already suggested some time ago, when it was found that 
genetic deletion of the nuclear receptor SF-1 (steroidogenic factor-1, NR5a1), largely 
responsible for the transcriptional control of the adrenal development and GC synthesis, could 
not abrogate intestinal CYP11A1 expression in the mouse embryonic gut [82]. At the same 
time remaining GC levels were observed in the circulation of prenatal mice, indicating that an 
extra-adrenal source of GC synthesis must exist [83]. Our own research started to explicitly 
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investigate the possibility that the intestinal mucosa is an important source of 
immunoregulatory GC some ten years ago. Investigating the function of so-called intraepithelial 
lymphocytes, T cells that reside within the intestinal epithelial layer, it was found that these cells 
rapidly died upon isolation and ex vivo culture, but could be partially rescued when the GR 
was blocked by the receptor antagonist RU-486 [84]. This observation suggested that these 
intestinal T cells were constantly exposed to GC, and that removal of survival signals, e.g. by 
detachment from the epithelial layer, would promote GR-dependent apoptosis. 
Subsequent studies revealed that the intestinal mucosa is home of a complex steroidogenic 
system, likely adapted to cope with the specialized environment of the gut. Many of the 
steroidogenic enzymes required for the synthesis of corticosterone from cholesterol or the 
reactivation of corticosterone from dehydrocorticosterone are constitutively expressed in the 
intestinal epithelium, whereas other enzymes become strongly induced upon 
immunological stress [46, 52, 53]. The ability of the intestinal tissue to synthesize 
corticosterone in mice [46] and humans [55] indicates that the intestinal mucosa expresses 
the complete and functional enzymatic machinery. This steroidogenic capacity is further 
confirmed by the use of metyrapone, a potent 11β-hydroxylase inhibitor with some 
inhibitory effects also on P450scc and 11β-HSD1, which efficiently blocks ex vivo GC 
synthesis in intestinal organ cultures [46, 55], confirming that GC measured were produced 
locally in the tissue. 
While in most experiments and ex vivo organ cultures basal GC levels are detected, a 
significant induction is usually observed, when mice are stressed by immune cell-activating 
agents. Administration of T cell-activating anti-CD3ε antibody, macrophage-activating 
lipopolysaccharides, or TNFα, infection of mice with viruses or chemically induced 
intestinal inflammation promotes the expression of certain steroidogenic enzymes, e.g. 
CYP11A1 and CYP11B1, and strongly stimulates the synthesis of intestinal GC. In some of 
these in vivo experiments a role of intestinal GC synthesis in the control of intestinal 
immune cells could also be confirmed. Most pronounced are the effects reported on viral 
infection and experimental colitis. Infection of mice with the lymphocytic choriomeningitis 
virus (LCMV) leads to a rapid expansion of the virus, which infects various target organs, 
including the intestine [46, 85, 86]. The virus promotes a massive expansion of virus-specific 
cytotoxic T cells, which in turn control the viral expansion by killing virus-infected cells. 
Employing this experimental system it has been shown that intestinal T cells from mice with 
deregulated intestinal GC synthesis (using the pharmacological inhibitor of GC synthesis 
metyrapone) became more profoundly activated by the virus, and expressed activation 
markers and inflammatory cytokines at much higher levels [46]. Similarly, in experimental 
models of colitis defective intestinal GC synthesis resulted in a more rapid and more 
pronounced induction of intestinal inflammation, as monitored by immune cell infiltration, 
epithelial layer damage, weight loss, etc. [49, 53].  
4.2. Regulation of intestinal GC synthesis 
The regulation of adrenal GC synthesis has been well documented over many decades of 
research (reviewed in [87]). The connection between physical, emotional and immunological 
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stress, and the activation of the HPA axis has been well established. Similarly, the role of the 
hormone ACTH in stimulating adrenal GC synthesis, and the nuclear receptor SF-1 in the 
transcriptional control of adrenal steroidogenesis is widely accepted [88]. In agreement with 
this critical role of SF-1 in the induction of steroidogenic enzymes in the adrenal glands is 
the observation that mice deficient for SF-1 have no detectable corticosterone in the serum. 
In fact, SF-1-deficient mice even lack adrenal glands, as SF-1 is also required for the 
embryonic development of the adrenal glands. As discussed above, mice lacking SF-1 
expression still express the steroidogenic enzyme gene CYP11A1 in the primitive gut of 
embryonic mice, supporting the notion that in the intestine steroidogensis is differentially 
controlled. Along these lines, it was found that SF-1 expression is basically absent in the 
intestine, but functionally replaced by its close homolog LRH-1 (liver receptor homolog-1, 
NR5a2). LRH-1 has strong sequence homology with SF-1, and regulates gene expression by 
binding to identical transcription factor response elements in the promoter of their target 
genes [47]. In general, SF-1 and LRH-1 have a mutually exclusive expression pattern, with 
very low LRH-1 expression in the adrenals, but very high expression in epithelial cells from 
the liver, pancreas, intestine and ovaries [89]. 
The role of LRH-1 in the regulation of extra-adrenal GC synthesis in the intestine has been 
investigated in intestinal epithelial cell lines in vitro as well as in vivo models [47, 49]. 
Overexpression of LRH-1 in intestinal epithelial cells induces the expression of the 
steroidogenic enzymes CYP11A1 and CYP11B1, and mutation of corresponding response 
elements in their promoter abrogates their LRH-1- and SF-1-induced activation [47]. 
Similarly, inhibition of LRH-1 expression or function leads to reduced expression of these 
steroidogenic enzymes in intestinal epithelial cells. Overexpression of LRH-1 in turn directly 
promotes detectable levels of corticosterone in the supernatant of intestinal epithelial cell 
cultures. In vivo the role of LRH-1 has been investigated by the use of LRH-1 haplodeficient 
as well as conditional LRH-1 knockout mice [48, 49]. LRH-1 haplodeficient mice showed a 
largely reduced induction of steroidogenic enzymes after anti-CD3ε injection and a complete 
block in intestinal GC synthesis induction, confirming an important role of LRH-1 in the 
regulation of intestinal GC synthesis. While induction of DSS (dextran sodium sulfate)- or 
TNBS (trinitrobenzen sulfonic acid)-mediated colitis stimulates the expression of steroidogenic 
enzmymes and a transient intestinal GC synthesis [51], deletion of LRH-1 in intestinal 
epithelial cells largely abrogates intestinal steroidogenesis [49]. More importantly, absence of 
LRH-1 and associated intestinal GC synthesis also leads to a more pronounced and accelerated 
colitis, confirming an important role of LRH-1 and intestinal GC synthesis in the regulation of 
local immune responses. LRH-1 likely regulates intestinal GC synthesis not only via the 
induction of certain steroidogenic enzymes. Steroid acute regulator (StAR) has an important 
role in transporting cholesterol within the cell, and thus supplying the steroid synthesizing 
machinery with the substrate for GC synthesis. As LRH-1 also transcriptionally regulates StAR 
expression [90], LRH-1 seems to control intestinal GC synthesis at many levels. 
Interestingly, LRH-1 appears to have various modes of activation. Though initially 
defined as orphan nuclear receptor due the lack of known ligands, the crystallization of 
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investigate the possibility that the intestinal mucosa is an important source of 
immunoregulatory GC some ten years ago. Investigating the function of so-called intraepithelial 
lymphocytes, T cells that reside within the intestinal epithelial layer, it was found that these cells 
rapidly died upon isolation and ex vivo culture, but could be partially rescued when the GR 
was blocked by the receptor antagonist RU-486 [84]. This observation suggested that these 
intestinal T cells were constantly exposed to GC, and that removal of survival signals, e.g. by 
detachment from the epithelial layer, would promote GR-dependent apoptosis. 
Subsequent studies revealed that the intestinal mucosa is home of a complex steroidogenic 
system, likely adapted to cope with the specialized environment of the gut. Many of the 
steroidogenic enzymes required for the synthesis of corticosterone from cholesterol or the 
reactivation of corticosterone from dehydrocorticosterone are constitutively expressed in the 
intestinal epithelium, whereas other enzymes become strongly induced upon 
immunological stress [46, 52, 53]. The ability of the intestinal tissue to synthesize 
corticosterone in mice [46] and humans [55] indicates that the intestinal mucosa expresses 
the complete and functional enzymatic machinery. This steroidogenic capacity is further 
confirmed by the use of metyrapone, a potent 11β-hydroxylase inhibitor with some 
inhibitory effects also on P450scc and 11β-HSD1, which efficiently blocks ex vivo GC 
synthesis in intestinal organ cultures [46, 55], confirming that GC measured were produced 
locally in the tissue. 
While in most experiments and ex vivo organ cultures basal GC levels are detected, a 
significant induction is usually observed, when mice are stressed by immune cell-activating 
agents. Administration of T cell-activating anti-CD3ε antibody, macrophage-activating 
lipopolysaccharides, or TNFα, infection of mice with viruses or chemically induced 
intestinal inflammation promotes the expression of certain steroidogenic enzymes, e.g. 
CYP11A1 and CYP11B1, and strongly stimulates the synthesis of intestinal GC. In some of 
these in vivo experiments a role of intestinal GC synthesis in the control of intestinal 
immune cells could also be confirmed. Most pronounced are the effects reported on viral 
infection and experimental colitis. Infection of mice with the lymphocytic choriomeningitis 
virus (LCMV) leads to a rapid expansion of the virus, which infects various target organs, 
including the intestine [46, 85, 86]. The virus promotes a massive expansion of virus-specific 
cytotoxic T cells, which in turn control the viral expansion by killing virus-infected cells. 
Employing this experimental system it has been shown that intestinal T cells from mice with 
deregulated intestinal GC synthesis (using the pharmacological inhibitor of GC synthesis 
metyrapone) became more profoundly activated by the virus, and expressed activation 
markers and inflammatory cytokines at much higher levels [46]. Similarly, in experimental 
models of colitis defective intestinal GC synthesis resulted in a more rapid and more 
pronounced induction of intestinal inflammation, as monitored by immune cell infiltration, 
epithelial layer damage, weight loss, etc. [49, 53].  
4.2. Regulation of intestinal GC synthesis 
The regulation of adrenal GC synthesis has been well documented over many decades of 
research (reviewed in [87]). The connection between physical, emotional and immunological 
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stress, and the activation of the HPA axis has been well established. Similarly, the role of the 
hormone ACTH in stimulating adrenal GC synthesis, and the nuclear receptor SF-1 in the 
transcriptional control of adrenal steroidogenesis is widely accepted [88]. In agreement with 
this critical role of SF-1 in the induction of steroidogenic enzymes in the adrenal glands is 
the observation that mice deficient for SF-1 have no detectable corticosterone in the serum. 
In fact, SF-1-deficient mice even lack adrenal glands, as SF-1 is also required for the 
embryonic development of the adrenal glands. As discussed above, mice lacking SF-1 
expression still express the steroidogenic enzyme gene CYP11A1 in the primitive gut of 
embryonic mice, supporting the notion that in the intestine steroidogensis is differentially 
controlled. Along these lines, it was found that SF-1 expression is basically absent in the 
intestine, but functionally replaced by its close homolog LRH-1 (liver receptor homolog-1, 
NR5a2). LRH-1 has strong sequence homology with SF-1, and regulates gene expression by 
binding to identical transcription factor response elements in the promoter of their target 
genes [47]. In general, SF-1 and LRH-1 have a mutually exclusive expression pattern, with 
very low LRH-1 expression in the adrenals, but very high expression in epithelial cells from 
the liver, pancreas, intestine and ovaries [89]. 
The role of LRH-1 in the regulation of extra-adrenal GC synthesis in the intestine has been 
investigated in intestinal epithelial cell lines in vitro as well as in vivo models [47, 49]. 
Overexpression of LRH-1 in intestinal epithelial cells induces the expression of the 
steroidogenic enzymes CYP11A1 and CYP11B1, and mutation of corresponding response 
elements in their promoter abrogates their LRH-1- and SF-1-induced activation [47]. 
Similarly, inhibition of LRH-1 expression or function leads to reduced expression of these 
steroidogenic enzymes in intestinal epithelial cells. Overexpression of LRH-1 in turn directly 
promotes detectable levels of corticosterone in the supernatant of intestinal epithelial cell 
cultures. In vivo the role of LRH-1 has been investigated by the use of LRH-1 haplodeficient 
as well as conditional LRH-1 knockout mice [48, 49]. LRH-1 haplodeficient mice showed a 
largely reduced induction of steroidogenic enzymes after anti-CD3ε injection and a complete 
block in intestinal GC synthesis induction, confirming an important role of LRH-1 in the 
regulation of intestinal GC synthesis. While induction of DSS (dextran sodium sulfate)- or 
TNBS (trinitrobenzen sulfonic acid)-mediated colitis stimulates the expression of steroidogenic 
enzmymes and a transient intestinal GC synthesis [51], deletion of LRH-1 in intestinal 
epithelial cells largely abrogates intestinal steroidogenesis [49]. More importantly, absence of 
LRH-1 and associated intestinal GC synthesis also leads to a more pronounced and accelerated 
colitis, confirming an important role of LRH-1 and intestinal GC synthesis in the regulation of 
local immune responses. LRH-1 likely regulates intestinal GC synthesis not only via the 
induction of certain steroidogenic enzymes. Steroid acute regulator (StAR) has an important 
role in transporting cholesterol within the cell, and thus supplying the steroid synthesizing 
machinery with the substrate for GC synthesis. As LRH-1 also transcriptionally regulates StAR 
expression [90], LRH-1 seems to control intestinal GC synthesis at many levels. 
Interestingly, LRH-1 appears to have various modes of activation. Though initially 
defined as orphan nuclear receptor due the lack of known ligands, the crystallization of 
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LRH-1 and subsequent structural analysis revealed a ligand binding to the ligand-binding 
domain of LRH-1. This ligand was identified as phosphatidylinositol, however, it is very 
likely that a larger variety of natural and synthetic ligands may bind to this ligand-
binding domain and transactivate LRH-1. Of interest are recent reports demonstrating 
LRH-1 activation by testosterone [91], the herbizide atrazin [92] as well as several 
synthetic ligands with selective activities for LRH-1 over SF-1 [93]. However, ligand 
binding may not be an absolute requirement for LRH-1 activation. In particular, mouse 
LRH-1 can be activated in a ligand-independent manner, as mutation of the ligand-
binding domain does not affect its activity [94]. 
In marked contrast, phosphorylation by upstream kinases may selectively activate both, 
human and mouse LRH-1. Two serine residues in the hinge region of LRH-1 have been 
identified as phosphorylation targets of the MAP kinase ERK1/2, and mutation of these two 
serine residues strongly affects LRH-1 activity [95]. In line with this idea of LRH-1 activation 
via the MAP kinase pathway is the observation that the MEK1 inhibitor U0126 also blocks 
LRH-1 activity ([95]; Bianchi, Brunner, unpublished). Next to ERK1/2 also other yet to be 
identified kinases may be involved in LRH-1 phosphorylation and activation. 
As many other nuclear receptors LRH-1 is also efficiently regulated by cofactors and 
repressors. For example, SRC-1 (steroid receptor coactivator-1) binds to LRH-1 and 
enhances its transcriptional activity. On the other hand, various inhibitors of LRH-1, such as 
DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, 
gene 1), SHP (small heterodimer partner) and Prox-1 (Prospero homeobox protein 1) have 
been shown to interact with LRH-1 and inhibit its activity [89, 96, 97]. Of interest is the fact 
that SHP is a major transcriptional target of LRH-1, and SHP induction likely represents a 
negative feedback loop terminating the transcriptional activity of LRH-1. 
Thus far intestinal GC synthesis has been always described in the context of immunological 
stress and inflammation. Clearly, factors released by activated immune cells must be able to 
trigger steroidogenesis in intestinal epithelial cells, likely via the activation of LRH-1. Of 
major interest in this regard are factors that also promote adrenal GC synthesis. 
Surprisingly, ACTH or ACTH receptor signaling pathways, such as an increase in cellular 
cyclic AMP, fail to promote intestinal GC synthesis and rather inhibit it [47] indicating that 
next to the preferential use of SF-1 and LRH-1 there are other elements in the regulation of 
adrenal versus intestinal GC synthesis that are different. The pro-inflammatory cytokines 
IL-6 and TNFα are known as potent triggers of adrenal GC synthesis. While no evidence 
could be found for a role of IL-6 in the immune cell-mediated induction of intestinal steroid 
synthesis, TNFα appears to represent a critical mediator of intestinal GC synthesis. TNFα 
alone promotes the expression of steroidogenic enzymes in intestinal epithelial cells in vitro 
and in vivo, and stimulates the synthesis of corticosterone. More importantly, induction of 
intestinal GC synthesis by injection of anti-CD3ε, LPS as well as experimental colitis largely 
depends on the signaling via TNF receptors [53]. Surprisingly, deletion of either one of the 
two TNF receptors abrogates immune cell-induced intestinal GC synthesis [52], indicating 
that simultaneous signaling via both receptors is required.  
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The important role of TNFα in the induction of intestinal GC synthesis is particularly 
evident when analyzing different models of experimentally induced colitis. While DSS and 
the hapten TNBS promote intestinal steroidogenesis, the hapten oxazolone fails to do so, 
despite very comparable induction of inflammation [53]. Clearly, inflammation alone is 
insufficient to initiate intestinal steroidogensis, but the type of inflammation may be critical. 
DSS and TNBS stimulate an immune response with Th1 cytokine predominance, abundant 
TNFα and IFNγ, whereas oxazolone promotes a Th2 type cytokine response with no TNFα, 
but IL-4 and IL-5. Supporting the important role of TNFα in these processes, it was found 
that oxazolone does not trigger intestinal GC synthesis, however injection of recombinant 
TNFα can restore the expression of steroidogenic enzymes and GC synthesis, and thereby 
ameliorate intestinal inflammation induced by oxazolone. Thus, TNFα seems to be an 
important sensor of immunological stress in the intestine and responsible for initiating 
negative feedback mechanisms via the induction of intestinal GC synthesis. This is 
inasmuch surprising as TNFα is an important therapeutic target in the pathogenesis of 
inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis [98-100]. 
TNFα is an important disease promoting and initiating factor during IBD, and its 
neutralization inhibits inflammatory processes right from the start. Its role in the regulation 
of intestinal GC synthesis, however, point also out a thus far unrecognized anti-
inflammatory role of TNFα (reviewed in [51]).  
4.3. GC synthesis in the lung  
The intestinal and the lung epithelium have much in common. Their main function is the 
absorption of nutrients and gases, respectively, and due to their enormous surface to cope 
with this task they are also constantly exposed to a plethora of antigens, microbes and 
potential pathogens. Thus, much alike the intestinal mucosa the lung harbors a large 
number of resident immune cells, mostly macrophages and dendritic cells, and is rapidly 
populated by infiltrating immune cells upon infection or stimulation with antigens. 
Similarly, uncontrolled immune responses in the lung may lead to chronic disorders, such 
as allergen-induced asthma and chronic obstructive pulmonary disorder (COPD). This 
illustrates on one hand the need for an efficient immune response in the lung in order to 
defend this vast epithelial surface from infection and invasion by pathogens, but also points 
out that local immune responses must be tightly regulated to avoid chronic inflammation, 
tissue damage and resulting loss of function of the absorptive epithelium. 
All these thoughts suggest that similar regulatory mechanisms exist in the lung as in the 
intestinal mucosa, and local GC synthesis may represent such a homeostatic control 
mechanism. Indeed, it has been described that genes involved in the GC synthesis pathway 
are transiently expressed in the developing mouse lung [101]. More recently, our own 
research has investigated the capacity of the adult lung to express steroidogenic enzymes 
and to synthesize GC in response to immunological stress [54]. Unlike the intestinal 
epithelium, the entire enzymatic machinery appears to be constitutively expressed in the 
adult lung tissue, and only CYP11A1, encoding P450scc, is induced upon immunological 
stress initiated by injection of T cell-activating anti-CD3ε antibody or macrophage-activating 
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LRH-1 and subsequent structural analysis revealed a ligand binding to the ligand-binding 
domain of LRH-1. This ligand was identified as phosphatidylinositol, however, it is very 
likely that a larger variety of natural and synthetic ligands may bind to this ligand-
binding domain and transactivate LRH-1. Of interest are recent reports demonstrating 
LRH-1 activation by testosterone [91], the herbizide atrazin [92] as well as several 
synthetic ligands with selective activities for LRH-1 over SF-1 [93]. However, ligand 
binding may not be an absolute requirement for LRH-1 activation. In particular, mouse 
LRH-1 can be activated in a ligand-independent manner, as mutation of the ligand-
binding domain does not affect its activity [94]. 
In marked contrast, phosphorylation by upstream kinases may selectively activate both, 
human and mouse LRH-1. Two serine residues in the hinge region of LRH-1 have been 
identified as phosphorylation targets of the MAP kinase ERK1/2, and mutation of these two 
serine residues strongly affects LRH-1 activity [95]. In line with this idea of LRH-1 activation 
via the MAP kinase pathway is the observation that the MEK1 inhibitor U0126 also blocks 
LRH-1 activity ([95]; Bianchi, Brunner, unpublished). Next to ERK1/2 also other yet to be 
identified kinases may be involved in LRH-1 phosphorylation and activation. 
As many other nuclear receptors LRH-1 is also efficiently regulated by cofactors and 
repressors. For example, SRC-1 (steroid receptor coactivator-1) binds to LRH-1 and 
enhances its transcriptional activity. On the other hand, various inhibitors of LRH-1, such as 
DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, 
gene 1), SHP (small heterodimer partner) and Prox-1 (Prospero homeobox protein 1) have 
been shown to interact with LRH-1 and inhibit its activity [89, 96, 97]. Of interest is the fact 
that SHP is a major transcriptional target of LRH-1, and SHP induction likely represents a 
negative feedback loop terminating the transcriptional activity of LRH-1. 
Thus far intestinal GC synthesis has been always described in the context of immunological 
stress and inflammation. Clearly, factors released by activated immune cells must be able to 
trigger steroidogenesis in intestinal epithelial cells, likely via the activation of LRH-1. Of 
major interest in this regard are factors that also promote adrenal GC synthesis. 
Surprisingly, ACTH or ACTH receptor signaling pathways, such as an increase in cellular 
cyclic AMP, fail to promote intestinal GC synthesis and rather inhibit it [47] indicating that 
next to the preferential use of SF-1 and LRH-1 there are other elements in the regulation of 
adrenal versus intestinal GC synthesis that are different. The pro-inflammatory cytokines 
IL-6 and TNFα are known as potent triggers of adrenal GC synthesis. While no evidence 
could be found for a role of IL-6 in the immune cell-mediated induction of intestinal steroid 
synthesis, TNFα appears to represent a critical mediator of intestinal GC synthesis. TNFα 
alone promotes the expression of steroidogenic enzymes in intestinal epithelial cells in vitro 
and in vivo, and stimulates the synthesis of corticosterone. More importantly, induction of 
intestinal GC synthesis by injection of anti-CD3ε, LPS as well as experimental colitis largely 
depends on the signaling via TNF receptors [53]. Surprisingly, deletion of either one of the 
two TNF receptors abrogates immune cell-induced intestinal GC synthesis [52], indicating 
that simultaneous signaling via both receptors is required.  
Extra-Adrenal Glucocorticoid Synthesis in Mucosal Tissues and  
Its Implication in Mucosal Immune Homeostasis and Tumor Development 71 
The important role of TNFα in the induction of intestinal GC synthesis is particularly 
evident when analyzing different models of experimentally induced colitis. While DSS and 
the hapten TNBS promote intestinal steroidogenesis, the hapten oxazolone fails to do so, 
despite very comparable induction of inflammation [53]. Clearly, inflammation alone is 
insufficient to initiate intestinal steroidogensis, but the type of inflammation may be critical. 
DSS and TNBS stimulate an immune response with Th1 cytokine predominance, abundant 
TNFα and IFNγ, whereas oxazolone promotes a Th2 type cytokine response with no TNFα, 
but IL-4 and IL-5. Supporting the important role of TNFα in these processes, it was found 
that oxazolone does not trigger intestinal GC synthesis, however injection of recombinant 
TNFα can restore the expression of steroidogenic enzymes and GC synthesis, and thereby 
ameliorate intestinal inflammation induced by oxazolone. Thus, TNFα seems to be an 
important sensor of immunological stress in the intestine and responsible for initiating 
negative feedback mechanisms via the induction of intestinal GC synthesis. This is 
inasmuch surprising as TNFα is an important therapeutic target in the pathogenesis of 
inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis [98-100]. 
TNFα is an important disease promoting and initiating factor during IBD, and its 
neutralization inhibits inflammatory processes right from the start. Its role in the regulation 
of intestinal GC synthesis, however, point also out a thus far unrecognized anti-
inflammatory role of TNFα (reviewed in [51]).  
4.3. GC synthesis in the lung  
The intestinal and the lung epithelium have much in common. Their main function is the 
absorption of nutrients and gases, respectively, and due to their enormous surface to cope 
with this task they are also constantly exposed to a plethora of antigens, microbes and 
potential pathogens. Thus, much alike the intestinal mucosa the lung harbors a large 
number of resident immune cells, mostly macrophages and dendritic cells, and is rapidly 
populated by infiltrating immune cells upon infection or stimulation with antigens. 
Similarly, uncontrolled immune responses in the lung may lead to chronic disorders, such 
as allergen-induced asthma and chronic obstructive pulmonary disorder (COPD). This 
illustrates on one hand the need for an efficient immune response in the lung in order to 
defend this vast epithelial surface from infection and invasion by pathogens, but also points 
out that local immune responses must be tightly regulated to avoid chronic inflammation, 
tissue damage and resulting loss of function of the absorptive epithelium. 
All these thoughts suggest that similar regulatory mechanisms exist in the lung as in the 
intestinal mucosa, and local GC synthesis may represent such a homeostatic control 
mechanism. Indeed, it has been described that genes involved in the GC synthesis pathway 
are transiently expressed in the developing mouse lung [101]. More recently, our own 
research has investigated the capacity of the adult lung to express steroidogenic enzymes 
and to synthesize GC in response to immunological stress [54]. Unlike the intestinal 
epithelium, the entire enzymatic machinery appears to be constitutively expressed in the 
adult lung tissue, and only CYP11A1, encoding P450scc, is induced upon immunological 
stress initiated by injection of T cell-activating anti-CD3ε antibody or macrophage-activating 
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LPS. Furthermore, particularly CYP11B1, although detectable by quantitative PCR, seems to 
be expressed at very low levels and not to be induced as in the intestine. When analyzing 
corticosterone synthesis in ex vivo lung cultures two observations are compelling. The lung 
tissue constitutively synthesizes considerable amounts of corticosterone in unchallenged 
mice, and the induced GC levels upon immunological stress are much higher when 
compared to equal amounts of tissue in the intestine [54]. Importantly, also in the lung ex 
vivo GC synthesis is efficiently blocked by the pharmacological inhibitor metyrapone, 
supporting the idea that GC measured are de novo synthesized in the lung tissue, though 
here its effect may not be via the inhibition of 11β-hydroxylase. This indicates that the lung 
tissue may be an even more potent extra-adrenal source of immunoregulatory GC than the 
intestinal epithelium.  
Thus far, the cellular source of lung GC synthesis has not been identified yet. Very likely, 
though, lung epithelial cells, either type I or type II epithelial cells, may be the relevant 
source of lung GC. In support of this hypothesis is the observation that lung epithelial cell 
lines express steroidogenic enzymes and are capable of metabolizing steroid precursors to 
corticosterone (Hostettler, Brunner, unpublished observations). Despite the many 
similarities between the intestinal and the lung epithelium in terms of response to 
inflammatory triggers and the synthesis of GC, there are also many differences in the 
induction of intestinal versus lung GC synthesis. While systemic activation of immune cells 
by anti-CD3 or LPS injection triggers both, intestinal and lung GC synthesis [52, 54], the 
response to local inflammation seems to be regulated somewhat differently. A typical model 
of allergic airway inflammation is the sensitization of mice with the model antigen 
ovalbumin in the context of alum as adjuvant, and the challenge with the antigen via 
aerosol. This leads to a T helper 2 type inflammatory response with a major eosinophilic and 
neutrophilic granulocyte infiltration of the lung tissue and lung lumen within 24 hours. 
Despite the massive inflammation and infiltration with immune cells only a minimal and 
not significant transient increase in local GC synthesis is observed, not comparable to the 
high concentrations measured after stimulation with anti-CD3 or LPS [54]. Given the fact 
that ovalbumin airway hypersensitivity and oxazolone-induced colitis are both T helper 2-
driven immune responses, the idea that lack of TNFα secretion could be the missing 
stimulator of lung GC synthesis appears very attractive. Indeed, only minimal TNFα levels 
are measured in the serum and the bronchoalveolar lavage (BAL) after ovalbumin challenge 
[54]. Similarly, when TNFα is injected into mice local GC synthesis in the lung can be 
efficiently induced. However, experiments in TNF receptor-deficient mice using anti-CD3 as 
a trigger clearly showed that TNFα signaling is not required for immune cell-stimulated 
local GC synthesis in the lung tissue. Thus, very likely other cytokines and/or factors, yet to 
be identified, may be substituting TNFα as a sensor of immune cell activation and trigger of 
local GC synthesis. It is feasible to believe that such a sensor of immunological stress is not 
induced during allergic inflammation of the lung, e.g. asthma, but present during contact 
with pathogens, such as influenza infection, thereby helping to reestablish local immune 
homeostasis via the secretion of GC. The identification of this or these critical inducers of 
local GC synthesis may lead to interesting targets for therapeutic intervention of chronic 
inflammation of the lung via the induction of local GC synthesis.  
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4.4. Regulation of lung GC synthesis 
Presently, not much is know regarding the molecular mechanisms of lung GC synthesis, and 
more detailed analysis of the regulatory pathways leading to the induction and activation of 
steroidogenic enzymes in the lung tissue will be needed. While the presence of all 
steroidogenic enzymes required for the synthesis of corticosterone from cholesterol suggests 
identical synthesis pathways in the lung, adrenals and intestine, metabolic assays indicate 
major differences between the tissues. Interestingly, ex vivo cultured lung tissue failed to 
convert radioactively labeled deoxycorticosterone into corticosterone, suggesting that the 
expression levels of CYP11B1/11β-hydroxylase are insufficient to promote this pathway of 
GC synthesis. In contrast, dehydrocorticosterone is efficiently metabolized by the lung tissue 
into corticosterone, supporting the idea that reactivation of inactive serum 
dehydrocorticosterone via an 11β-HDS1-dependent pathway is the primary corticosterone 
synthesis pathway in the lung. Along these lines is the observation that the lung expresses 
very low levels of CYP11B1 but very high levels of HSD11B1, and that adrenalectomy 
completely abolishes lung GC synthesis [54]. Though metyrapone has been reported to be 
selective for 11β-hydroxylase, inhibition of 11β-HSD1 has also been noted [102], explaining 
why ex vivo GC synthesis in lung tissue is efficiently blocked by metyrapone. A dominant 
role for an 11β-HSD1-dependent corticosterone synthesis pathway is also supported by the 
lack of evidence for a role of LRH-1 in the regulation of lung GC synthesis. While anti-CD3-
induced intestinal GC synthesis was significantly reduced in LRH-1 haplodeficient mice 
[48], lung GC synthesis was found to be normal [54], indicating that other nuclear receptors 
or transcription factors are involved in the regulation of steroidogenesis in the lung tissue. 
5. GC synthesis in colorectal tumors 
The role of tumor immunology in the surveillance of transformed cells and the control of 
tumor development is a highly controversial issue. While tumor-specific immune responses 
and even tumor-specific T cells can be demonstrated in certain types of tumors, stimulation 
of tumor-specific T cells by immunization has thus far not been too successful in the 
prevention or treatment of tumors. A major exception is the vaccination against human 
papilloma virus, which strongly reduces the incidence of cervical cancer [103, 104]. Despite 
relatively disappointing results of such immunization protocols, clinical and histological 
studies support the notion that tumor-infiltrating leukocytes (TIL) are indeed capable of 
limiting the growth and development of certain types of cancer. An extensive study in 
patients with colorectal cancer revealed that those patients that had a pronounced 
infiltration of the tumor with lymphocytes, and in particular with memory T cells, showed a 
significantly prolonged survival compared to patients with little or no immune cell infiltrate 
[105]. Though an indirect proof, these studies demonstrate a strong correlation between 
anti-tumor immune responses, tumor development and patient survival. These findings, 
however, also suggest that tumors capable of escaping or suppressing immune responses by 
any means may have a major advantage and kill the patient more rapidly.  
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LPS. Furthermore, particularly CYP11B1, although detectable by quantitative PCR, seems to 
be expressed at very low levels and not to be induced as in the intestine. When analyzing 
corticosterone synthesis in ex vivo lung cultures two observations are compelling. The lung 
tissue constitutively synthesizes considerable amounts of corticosterone in unchallenged 
mice, and the induced GC levels upon immunological stress are much higher when 
compared to equal amounts of tissue in the intestine [54]. Importantly, also in the lung ex 
vivo GC synthesis is efficiently blocked by the pharmacological inhibitor metyrapone, 
supporting the idea that GC measured are de novo synthesized in the lung tissue, though 
here its effect may not be via the inhibition of 11β-hydroxylase. This indicates that the lung 
tissue may be an even more potent extra-adrenal source of immunoregulatory GC than the 
intestinal epithelium.  
Thus far, the cellular source of lung GC synthesis has not been identified yet. Very likely, 
though, lung epithelial cells, either type I or type II epithelial cells, may be the relevant 
source of lung GC. In support of this hypothesis is the observation that lung epithelial cell 
lines express steroidogenic enzymes and are capable of metabolizing steroid precursors to 
corticosterone (Hostettler, Brunner, unpublished observations). Despite the many 
similarities between the intestinal and the lung epithelium in terms of response to 
inflammatory triggers and the synthesis of GC, there are also many differences in the 
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4.4. Regulation of lung GC synthesis 
Presently, not much is know regarding the molecular mechanisms of lung GC synthesis, and 
more detailed analysis of the regulatory pathways leading to the induction and activation of 
steroidogenic enzymes in the lung tissue will be needed. While the presence of all 
steroidogenic enzymes required for the synthesis of corticosterone from cholesterol suggests 
identical synthesis pathways in the lung, adrenals and intestine, metabolic assays indicate 
major differences between the tissues. Interestingly, ex vivo cultured lung tissue failed to 
convert radioactively labeled deoxycorticosterone into corticosterone, suggesting that the 
expression levels of CYP11B1/11β-hydroxylase are insufficient to promote this pathway of 
GC synthesis. In contrast, dehydrocorticosterone is efficiently metabolized by the lung tissue 
into corticosterone, supporting the idea that reactivation of inactive serum 
dehydrocorticosterone via an 11β-HDS1-dependent pathway is the primary corticosterone 
synthesis pathway in the lung. Along these lines is the observation that the lung expresses 
very low levels of CYP11B1 but very high levels of HSD11B1, and that adrenalectomy 
completely abolishes lung GC synthesis [54]. Though metyrapone has been reported to be 
selective for 11β-hydroxylase, inhibition of 11β-HSD1 has also been noted [102], explaining 
why ex vivo GC synthesis in lung tissue is efficiently blocked by metyrapone. A dominant 
role for an 11β-HSD1-dependent corticosterone synthesis pathway is also supported by the 
lack of evidence for a role of LRH-1 in the regulation of lung GC synthesis. While anti-CD3-
induced intestinal GC synthesis was significantly reduced in LRH-1 haplodeficient mice 
[48], lung GC synthesis was found to be normal [54], indicating that other nuclear receptors 
or transcription factors are involved in the regulation of steroidogenesis in the lung tissue. 
5. GC synthesis in colorectal tumors 
The role of tumor immunology in the surveillance of transformed cells and the control of 
tumor development is a highly controversial issue. While tumor-specific immune responses 
and even tumor-specific T cells can be demonstrated in certain types of tumors, stimulation 
of tumor-specific T cells by immunization has thus far not been too successful in the 
prevention or treatment of tumors. A major exception is the vaccination against human 
papilloma virus, which strongly reduces the incidence of cervical cancer [103, 104]. Despite 
relatively disappointing results of such immunization protocols, clinical and histological 
studies support the notion that tumor-infiltrating leukocytes (TIL) are indeed capable of 
limiting the growth and development of certain types of cancer. An extensive study in 
patients with colorectal cancer revealed that those patients that had a pronounced 
infiltration of the tumor with lymphocytes, and in particular with memory T cells, showed a 
significantly prolonged survival compared to patients with little or no immune cell infiltrate 
[105]. Though an indirect proof, these studies demonstrate a strong correlation between 
anti-tumor immune responses, tumor development and patient survival. These findings, 
however, also suggest that tumors capable of escaping or suppressing immune responses by 
any means may have a major advantage and kill the patient more rapidly.  
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Various immune escape mechanisms have been described in different tumors. Tumor cells 
secrete suppressive cytokines, such as TGFβ and IL-10, express pro-apoptotic ligands (Fas 
ligand and TRAIL), which kill TIL, or simply reduce their immunogenicity by 
downregulating MHC molecules and associated antigen presentation on their surface. In this 
paragraph we will also discuss the proposed role of extra-adrenal GC synthesis in colorectal 
tumors as a mechanism of immune escape. Though various types of tumors have been shown 
to be active sources of steroid hormones, most of these tumors derive from steroidogenic 
tissues, such as the adrenal glands, ovaries or testis. For example, adrenal hyperplasia and 
tumors often lead to a massive release of GC, resulting in Cushing syndrome [106]. In 
addition, small cell bronchogenic carcinoma, carcinoids of thymus, pancreas, ovary, as well as 
medullary carcinoma of thyroid gland etc. have been shown to release ACTH or in rare cases 
CRH, and thereby to stimulate indirectly the release of systemic GC from the adrenals with 
subsequent suppression of the immune system [107, 108]. Yet, thus far no direct GC synthesis 
in tumors from non-steroidogenic tissues has been described. 
As discussed in detail above, LRH-1 has a prominent role in the regulation of intestinal GC 
synthesis [48, 52]. Interestingly, however, LRH-1 has also been implicated in other aspects of 
intestinal epithelial cell biology. LRH-1 is primarily expressed in the pluripotent and 
proliferating cells of the intestinal crypts where it regulates the expression of cyclin D1. 
Furthermore, in collaboration with the Wnt signaling pathway and β-catenin it also controls 
the expression of cyclin E1 and c-Myc, and thereby the proliferation of crypt cells and the 
renewal of the intestinal epithelial layer (reviewed in [109, 110]). Not surprisingly, this 
mitogenic role of LRH-1 appears to be also involved in the development of intestinal 
tumors. Mice with a mutation in the APC gene (APCmin/+ mice) spontaneously develop 
adenomas in both small and large bowel. Interestingly tumor development is significantly 
reduced in mice with LRH-1 deficiency [111]. Thus, LRH-1 appears to be a proto-oncogene 
in the development of intestinal tumors. In line with this idea is the observation that 
different tumors derived from endoderm tissue show LRH-1 overexpression. For example, 
LRH-1 is overexpressed in colorectal [55] and in pancreatic tumors [112], where it also 
regulates cell cycle progression. 
Given the important role of LRH-1 in cell cycle regulation as well as intestinal GC synthesis 
LRH-1-mediated synthesis of immunoregulatory GC in colorectal tumors as a mechanism to 
control anti-tumor immune responses appears to be an attractive idea. Indeed, considerable 
synthesis of cortisol can be measured in colorectal cancer cell lines as well as primary 
colorectal tumors using radioimmuno assay, bioassay as well as metabolic assays [55]. In 
line with this steroidogenic potential of colorectal tumor cells is the widely distributed 
expression of LRH-1 and steroidogenic enzymes. Furthermore, overexpression of LRH-1 
further boost the expression of steroidogenic enyzmes and the synthesis of cortisol, whereas 
inhibition of LRH-1 expression downregulates these processes. Interestingly, GC synthesis 
in colorectal tumor cell lines as well as ex vivo cultured primary tumors seems to be 
constitutive, whereas in normal colonic tissue it is inducible by phorbol ester, likely via the 
ERK1/2-mediated activation of LRH-1. This suggests that in colorectal tumors LRH-1 may be 
constitutively active, and suggests that signal transduction pathways leading to tumor 
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development and proliferation also govern the activation of LRH-1 and associated GC 
synthesis. Of interest in this regard is that LRH-1 not only controls cell cycle progression, 
but that its activity is also controlled by the cell cycle [50]. Various mitogenic signals 
controlling tumor cell proliferation may therefore also promote the activation of LRH-1. In 
line with this idea is the observation that many colorectal tumors have activating mutations 
of the epidermal growth factor receptor pathway [113] and that epidermal growth factor can 
stimulate LRH-1 activation in an ERK1/2-dependent manner in Hela cells [95]. However, 
more detailed analysis of the signaling pathways leading to LRH-1 activation and GC 
synthesis in colorectal tumors will be required to confirm whether mitogenic stimuli are 
indeed important triggers of extra-adrenal GC synthesis in tumor cells. 
 
Abbreviations: B – B-Lymphocytes; DC – dendritic cells; LPS – lipopolysaccharides; Mϕ – macrophages; NK – natural 
killer cells; T – T-Lymphocytes; Tu – tumor cells. 
Figure 2. Proposed role of intestinal GC synthesis in maintaining immune homeostasis in normal gut 
mucosa and promoting immune escape in colon cancer. 
While the immunoregulatory role of GC synthesis in normal intestinal tissue is quite well 
established [46, 49, 52, 53], the evidence in colorectal tumors is yet relatively indirect. The 
supernatant of colorectal tumor cell lines and primary tumors has been found to contain a 
suppressive activity, which inhibits the activation of primary T cells, as measured by the 
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induction of activation marker CD69 [55]. Similarly, tumor-derived supernatant was able to 
promote apoptosis in GC sensitive immune cells. Importantly, these suppressive or pro-
apoptotic activities were blocked by either interfering with the GC synthesis pathway in 
tumor cells by metyrapone, or by blocking the GR in immune cells [55]. While colorectal 
tumor cells may also secrete other immunoregulatory factors, such as TGFβ, these finding 
demonstrate that GC are present in the supernatant of tumor cells and that their 
concentration is high enough to promote biological responses and immunosuppression. The 
secretion of immunoregulatory GC by colorectal tumors may thus represent a novel 
mechanism how tumor cells escape from destruction by the immune system. Similar 
mechanisms may also exist in tumors from tissues capable of secreting bioactive GC, e.g. 
lung cancer. 
6. Conclusion 
In summary, the extremely potent GC synthesizing activity of the adrenal glands has 
obscured for a long time the fact that various other extra-adrenal tissues are important 
sources of immunoregulatory GC. This chapter has highlighted in particular the role of the 
pulmonary and intestinal mucosa, and its associated tumors, as potent sources of extra-
adrenal GC synthesis. Their more recent identification has lead to new interpretations of 
how locally produced GC may be involved in the maintenance of tissue homeostasis, 
regulation of inflammatory processes and tumor development. Finally, the detailed analysis 
of the differential signal transduction pathways controlling GC synthesis in the adrenals 
versus extra-adrenal tissues may offer novel opportunities for the development of 
therapeutic interventions. 
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1. Introduction 
Glucocorticoids (GC) are commonly used as anti-inflammatory and immunosuppressive 
therapy by approximately 1% of the total adult population. Glucocorticoid therapy has also 
been used in non-autoimmune and non-inflammatory conditions such as acute myocardial 
infarction, angina, endocarditis as well as in invasive cardiology, coronary interventions and 
cardiopulmonary- bypass surgery. Despite ample evidence for GC’s role as a natural, 
physiologic regulator of the immune system, little is known about the molecular events 
induced by GCs during a stress response.  Autophagy is a survival mechanism which is 
upregulated in response to stress in the cell. It has been described as the cell’s major 
adaptive strategy in response to a multitude of extracellular stresses, such as nutrient 
deprivation, mitochondrial damage, endoplasmic reticulum stress or infection. Conserved in 
all eukaryotes, it is mediated by a unique organelle, the autophagosome, which, under 
inclusion of cytoplasmic cargo, fuses with lysosomes in order to yield recyclable nutrient 
metabolites. Basal autophagic activity plays a vital role in maintaining homeostasis during 
cellular stress. Its malfunction has been implicated with human pathologies such as heart 
disease, neurological storage disease and cancer.  
It is known that GC-triggered autophagy plays a role in cell death during development. 
However, recent landmark studies also indicate that autophagy operates as a hub, 
integrating cellular stress, metabolism and glucocorticoid mediated anti-inflammatory 
action. Importantly, recent lines of evidence suggest that glucocorticoids impact on key 
signalling components, which control the activity of the autophagic machinery.    
In this review we will focus on the connections between these key signaling components 
and autophagy, describing their central roles as modulators of GC-induced protection 
during a cellular stress response.  
 The Author(s). Licensee InTech. This chapter is distributed under the ms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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2. Glucocorticoid generation and metabolism 
The understanding of the physiological regulation of glucocorticoid activity has 
considerably improved over the last few decades. The generation of glucocorticoids from 
cholesterol, which occurs in the zonae fasiculata and reticularis of the adrenal cortex, is 
tightly regulated by the hypothalamic-pituitary-adrenal (HPA) axis where glucocorticoids 
regulate its own generation through negative feedback inhibition.  Glucocorticoids are 
produced de novo under this control and are released into the blood as required, with a 
definite circadian rhythm producing peak concentrations in the early morning [1]. When 
secreted into the blood, most (90-95%) of glucocorticoids are sequestered to corticosteroid-
binding globulin and albumin with the unbound fraction available to interact with their 
receptors [2]. Metabolic inactivation of glucocorticoids occurs predominantly in the liver, 
but also in the kidney with inactive metabolites excreted in the urine.  
3. Molecular actions of glucocorticoids: Genomic and non-genomic 
pathways 
The classical mode of glucocorticoid-induced gene expression, i.e. the genomic effect 
involves ligand-dependent activation and release from chaperone proteins (heat shock 
protein-90 and others), translocation of the receptor-complex to the nucleus where binding 
of the glucocorticoid receptor to glucocorticoid response element (GRE) in the promoter of 
the target genes will lead to transcriptional activation of the genes within hours [3, 4]. 
Activation of glucocorticoid-responsive genes occurs via interaction between the DNA-
bound GR and transcriptional co-activator molecules such as CREB-binding protein, which 
have intrinsic histone acetyltransferase activity and cause acetylation of core histones. This 
tags histones to recruit chromatin remodeling engines and subsequent association of RNA 
polymerase II resulting in gene activation [5]. Increasing evidence suggests that 
glucocorticoids can also cause rapid activation of signaling molecules prior to altering gene 
expression. These so called non-genomic effects occur within minutes of glucocorticoid 
exposure and are not affected by inhibiting RNA transcription [5, 6].  
Metabolic effects of glucocorticoids represent most of the adverse effects of glucocorticoid 
therapy and are mainly ascribed to the transcriptional activity of the glucocorticoid receptor, 
whereas the therapeutically beneficial anti-inflammatory actions are thought to be 
predominantly caused by the mechanism of transrepression where the activated GR can 
selectively repress the transcription of specific inflammatory genes without binding to DNA 
itself but by a number of pleiotropic actions at the promoters of inflammatory genes. 
Inflammatory genes are regulated by the actions of proinflammatory transcription factors 
such as nuclear factor-B (NF-B), activator protein -1 (AP-1), and signal transducer and 
transcription proteins. Activated GR binds to these transcription factors, either directly or 
indirectly, and recruits co-repressor proteins that blunt the ability of these transcription 
factors to switch on inflammatory genes [7]. Furthermore, many pro-inflammatory genes are 
repressed by GC at post-transcriptional level via mRNA destabilization or inhibition of 
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translation, however, this phenomenon cannot be accounted for by transrepression, 
therefore suggest the existence of an additional anti-inflammatory mechanism of GCs [8].  
4. Ischemia/reperfusion-induced stress in the heart 
Glucocorticoids play a key role in the response to stress in the heart where it can influence 
the regulation of blood pressure, inflammation, immune function and cellular energy 
metabolism [9-10]. These acute effects contribute to an adaptive response in the short term. 
Although the cardioprotective effects of glucocorticoids in the acute setting of 
ischemia/reperfusion have been experimentally demonstrated in animals [11-13] and 
humans [14], the molecular mechanisms still need to be fully elucidated.  
Ischemia can be defined as an imbalance between the amount of oxygen, glucose and other 
substrates needed by the heart [15,16]. This leads to anaerobic metabolism and reduced 
contractile function. A biochemical imbalance occurs as the maintenance of the metabolism 
cannot be kept at a steady state due to inadequate coronary flow. A reduction in metabolite 
clearance also occurs during ischemia and intracellular pH levels drop as the acid by-
products of glycolysis accumulate. The severity of ischemic injury depends on the duration 
of ischemia and subsequent reperfusion [15,16]. If, ischemia is maintained, reversible injury 
gradually transitions to irreversible injury and a myocardial infarct develops. Reperfusion 
with its reinforced oxygen and substrate availability is thus a prerequisite for myocardial 
salvage [16]. However, reperfusion after an ischemic period causes generation of free 
radicals and is associated with detrimental changes such as enzyme release, arrhythmias and 
intramyocardial haemorrhage which are known as reperfusion injuries [17]. Cardiomyocytes 
are highly dependent on a continuous supply of oxygen. During ischemia, cardiomyocyte 
capacity to generate sufficient ATP and creatine phosphate becomes depleted and multiple 
adaptive processes occur in response to these hypoxic environments created during ischemia. 
To reduce oxygen consumption, oxidative phosphorylation is limited and glycolysis is 
stimulated. This aids in ATP production, even under low oxygen supply [18]. Prolonged 
ischemia leads to cardiac failure which is characterized by the progressive death of myocytes 
[19]. Three major morphologies of cell death have been described, viz. apoptosis (type I), cell 
death associated with autophagy (type II) and necrosis (type III).  
5. The basic mechanisms of Autophagy 
Autophagy, from greek self eating, is a conserved degradation and recycling system for long-
lived proteins and other sub-cellular constituents. This degradation system is inherent to all 
eukaryotes and is mediated by a unique organelle, the autophagosome, which, under 
inclusion of cytoplasmic cargo, fuses with lysosomes in order to yield recyclable nutrient 
metabolites. Although already described in 1966 by de Duve and Wattiaux [20], Autophagy 
has received significant renewed attention in the last years. This new interest is primarily 
based on the recently gained understanding of the molecular components of the autophagic 
machinery. Genetic analyses in yeast identified more than 30 autophagy-related genes 
(ATG), and their corresponding proteins (Atg) participating in the autophagic pathway [21].  
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translation, however, this phenomenon cannot be accounted for by transrepression, 
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with its reinforced oxygen and substrate availability is thus a prerequisite for myocardial 
salvage [16]. However, reperfusion after an ischemic period causes generation of free 
radicals and is associated with detrimental changes such as enzyme release, arrhythmias and 
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Multiple mechanisms exist for the mode of delivery of cytoplasmic material to the lysosome, 
giving rise to different types of autophagy. While microphagy is characterized by cytoplasm 
engulfment directly at the lysosomal surface by invagination of its membrane, 
macroautophagy involves the synthesis of double-membrane vesicles, which sequester 
portions of the cytoplasm [22]. Chaperone mediated autophagy (CMA) on the other hand 
involves selective motif tagged protein translocation directly through the lysosomal 
membrane [23]. However, shared by all three mechanisms is the final step of lysosomal 
cargo degradation by hydrolases, allowing the recycling of degraded material. Here we will 
focus on macroautophagy (herein referred to as autophagy), as it is the primary mechanism 
for cytoplasm-to-lysosome delivery.  
The autophagic process can be divided into distinct steps, which include the induction, 
cargo packaging, vesicle nucleation, vesicle expansion and protein retrieval, docking and 
fusion and finally vesicle degradation [21]. In brief, the first event is the formation of the 
isolation membrane of the autophagosome. The Atg1 kinase complex governs these early 
steps in autophagosome formation. Central to this regulation is the nutrient sensor kinase 
mTOR (TORC). When mTOR is suppressed due to nutrient starvation, Atg1 kinase activity 
is triggered and affinity for Atg13 increases [24], which leads to the recruiting of other Atg 
proteins to initiate autophagosome formation. Cellular sources for this autophagosome 
formation step have been shown to be Golgi, ER, mitochondria and the plasma membrane 
[25]. During this process, two strongly interdependent conjugation systems are coordinating 
the events leading to the formation, elongation and sealing of the isolation membrane [26]. 
In the first conjugation system, Atg proteins 5, 7, 10 and 12 undergo a multimerization step 
with Atg16, leading to the formation of an Atg16 homotetramer, which assembles with four 
Atg12-Atg5 conjugates [27]. In the second conjugation system, the protein Atg8 is Atg4 
dependently conjugated with phosphatidylethanolamine (PE) [28]. Reactive oxygen species 
play a role in controlling this step, as Atg4 oxidization enables autophagosome formation to 
proceed [29]. Next, two kinase complexes, PI3 kinase and Atg1, participate in the late stages 
of autophagosome formation. Atg6 (the mammalian orthologue, beclin-1) belongs to the PI3 
kinase (PI3-K) class III complex. When Atg1 interacts with Atg13, progression towards a 
complete autophagosome takes place [27]. Cytoplasmic cargo is now confined. Docking and 
fusion with a lysosome will allow acidification of the autophagosome lumen, leading to the 
complete and rapid degradation of cargo into constituent components that are released into 
cytoplasmic space via permeases (Figure 1). 
6. Autophagy as a protective response during stress in the heart 
The terminally differentiated nature of cardiomyocytes demands a strong molecular reliance 
upon a functional autophagic degradation system. In cardiomyocytes autophagy has been 
described already in the late 1970’s where it was emphasized as an important repair 
mechanism of sublethal injury [30]. Sybers and coworkers demonstrated the occurrence of 
myocyte autophagy in a fetal mouse heart that was kept for 1 h in organ culture. In addition 
they observed that Autophagy was accelerated by oxygen and glucose deprivation, but the 
hearts function could be restored following resupply of glucose and oxygen. However, 
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when the period of injury lasted for longer than four hours, necrotic cell death was induced 
[30]. To date, many models have produced clear evidence that upregulation of autophagy 
promotes cell survival under conditions of metabolic perturbations and energy deprivation 
[31-33]. In the ischaemic myocardium, autophagy is upregulated rapidly following 20 
minutes of coronary artery occlusion, leading to an increased number in autophagosomes 
[34]. In isolated cardiomyocytes exposed to anoxia-reoxygenation it was shown that 
inhibition of autophagy leads to an increase in necrotic cell death, which was further 
increased by additional inhibition of apoptosis [35]. However, enhancing autophagic flux, as 
indicated by an increased rate of autophagosomal clearance, protects cardiac myocytes 
against ischaemic injury by reducing apoptosis [31]. Moreover, the homeostatic role of 
functional basal autophagic activity in the myocardium has been demonstrated by cardiac 
specific disruption of Atg5, manifesting in impaired contractility, hypertrophy, dilation and 





Figure 1. Schematic representation of the autophagic process, indicating the signalling network from 
induction to permease efflux with amino acid release, providing substrates for the TCA cycle. 
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7. Detrimental effects of Autophagy in the heart  
Literature suggests that autophagy is uniquely controlled during ischemia and reperfusion. 
A large body of evidence indicates that upregulation of autophagy particularly during the 
reperfusion phase is detrimental and exacerbates myocyte death. Energy sensing mediated 
by the 5’-AMP-activated protein kinase (AMPK) appears to be central to this control 
mechanism. In glucose-deprived cardiac myocytes, autophagy resulting from ischemia has 
been shown to be accompanied by AMPK activation, and was inhibited by dominant 
negative AMPK, suggesting an AMPK dependent mechanism [34]. AMPK is rapidly 
activated during myocardial ischemia, and leads to an increase in glucose uptake and 
oxidation as well as fatty acid oxidation [38]. Autophagy is enhanced after reperfusion, 
which is accompanied by an inactivation of AMPK and an increase in beclin-1 [34]. As 
AMPK switches off ATP-dependent processes, [39] its inactivation at reperfusion may 
contribute to an unfavorable metabolic environment. Moreover, data indicate that energy 
sensing mediated by AMPK is also differentially controlled depending on the severity of 
the ischaemic insult [40]. These reports are strengthened by recent data derived from 
cultured myoblasts, where a differential induction of cell death was observed, which was 
dependent on the severity and duration of the ischaemic insult [33]. Only mild ischaemic 
injury induced autophagy and apoptosis, while severe injury led to primarily necrotic cell 
death.  
8. Autophagy and myocardial metabolism 
The total cellular ATP amount in the cardiac myocyte is consumed in less than one minute 
[41] indicating the very high metabolic demand of the myocardium, and at the same time 
highlighting the existence of an extremely efficient system of energy conversion. In 
ischaemic conditions, energy metabolism is disrupted to a level where energy production 
cannot meet the myocardial energy demand. However, there is a clear role for autophagy in 
ischemia to influence the cell’s energy profile, indicative to maintain metabolic supply-
demand homeostasis [33]. ATP levels decrease rapidly with ischemia and recover rapidly 
after reperfusion [42]. These dynamics of ATP depletion become highly relevant when 
considering the molecular overlap between autophagy, apoptosis and necrosis [32; 43-44, 
Figure 2]. It has been demonstrated that an ATP depletion of >50% is needed in order to 
change the mode of cell death from apoptotic to necrotic [45]. Vice versa, a progressive 
replacement of necrosis with apoptosis has been described, when intracellular ATP becomes 
available again [46]. Recent evidence strongly indicates the previously underestimated 
metabolic role of autophagy in generating metabolite substrates by shifting the cellular 
energetic balance [33; 47-49], suggesting that intracellular ATP availability may be 
controlled to a significant degree by the autophagic flux (Figure 2). These data strongly 
suggest that not only the magnitude of autophagic activity but also the cell’s metabolic 
profile and microenvironment are crucial in controlling a favorable cellular response other 
than necrosis, and delaying apoptosis [32] (Figure 3). 
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Figure 2. Recent evidence strongly indicates the previously underestimated metabolic role of 
autophagy in generating metabolite substrates and ATP by shifting the cellular energetic balance, with a 
direct and indirect effect on apoptosis and necrosis.  
 
Figure 3. Whether autophagy may manifest in cytoprotection or type II programmed cell death is 
dependent on the severity and duration of the ischaemic insult, as well as autophagic flux- and 
metabolic parameters.  
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The above results also stress the significance of the severity and duration of the ischaemic 
event, to allow a sufficient induction of the autophagic machinery to take place. In fact, a 
direct relationship between autophagic flux and myocardial function has recently been 
proposed [50], indicating the strong need to measure autophagic activity accurately.  
Further characterization of the autophagic flux in clear context with myocardial injury will 
help to answer questions when autophagy functions as a primarily destructive pathway, 
manifesting in type II programmed cell death or when autophagy functions in a 
cytoprotective manner.  
9. Autophagy and glucocorticoids-relationship and metabolic response  
The multifaceted relationship between autophagy and glucocorticoids is already indicated 
in embryogenesis. Recent reports not only demonstrate an important metabolic role for 
autophagy during embryogenesis and postnatal development [51,52], but also indicate a 
likely molecular link between autophagic programmed cell death and steroids during 
development [53]. Embryos from the atg5-/- knockout mouse model die perinatally due to 
energy depletion, leading to a reduced plasma- and tissue amino acid concentration [54]. 
Moreover, increased apoptosis is displayed in various embryonic tissues derived from such 
embryos, supporting a role for autophagy in the removal of apoptotic bodies or in delaying 
the onset of apoptotic cell death [54]. Targeted disruption of beclin 1 in mice also leads to 
early death in embryogenesis [55]. Many examples of autophagy as a mode of programmed 
cell death during embryogenesis exist, suggesting that an important role for autophagic cell 
death in development. It has been shown that autophagic cell death requires the genes 
ATG7 as well as beclin 1 and can be induced by caspase-8 inhibition [56]. In addition, 
embryonic fibroblasts from Bax/Bak double knockout mice undergo autophagic cell death, 
which can be suppressed by inhibitors of autophagy and which is dependent on ATG5. 
These data suggest a role for Bcl-2 family proteins controlling also non-apoptotic cell death 
in addition to regulating apoptosis [57]. Especially in lower eukaryotes, the rise in steroid 
titers can elicit a transcription regulatory hierarchy that results in synchronous autophagic 
cell death [53]. Such steroid triggered programmed autophagic cell death has been 
observed in larval salivary gland cells [53] as well as motorneurons [58]. These findings 
suggest that steroids can play a governing role in very specific scenarios, controlling 
autophagic activity and the duration of increased flux, which in turn can control the 
synchronous induction of cell death. It is however not known, whether a robust increase 
in cortisol release in humans following psychological stress, trauma, sepsis or starvation 
can elicit similar effects on autophagic activity during embryogenesis. Such studies 
deserve a great deal of attention.  
Although limited data are available, similarities exist between the role of the autophagic 
pathway as a response mechanism to metabolic perturbations and glucocorticoids in the 
regulation of metabolic responses.  Chronic excessive activation of glucocorticoid receptors 
leads to major cellular metabolic rearrangements such as insulin resistance, glucose 
intolerance and dyslipidaemia. Obesity and metabolic syndrome, which are characterized 
by a nutrient overload, have been associated with a hyperactivation of tissue mTOR, 
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indicating a blunted autophagic response [59]. The systemic glucocorticoid excess is 
associated with an increase in cardiovascular risk factors [60]. One of the major causes of 
impact on these risk factors is thought to be the glucocorticoid mediated intravascular 
volume overload [60]. As the access of glucocorticoids to their receptors is controlled by the 
isozymes of 11-β-hydroxysteroid dehydrogenase in a tissue specific manner, makes 
manipulation of this pathway an attractive therapeutic target. By selective isozyme 
inhibitors, the glucocorticoid activity can be modulated locally, keeping systemic 
glucocorticoid concentrations within homeostatic range.  
Also in the acute setting a relationship exists between glucocorticoid availability and 
autophagy induction. In the treatment of acute lymphoblastic leukemia, glucocorticoids are 
used as crucial therapeutic agent, due to their effect on inducing G1 phase cell cycle arrest 
and apoptosis. Recently it was shown that dexamethasone treatment induces cell death and 
involves the induction of autophagy before the onset of apoptosis [61]. Moreover, another 
level of interaction has been demonstrated as the role of autophagy in innate immunity has 
recently become clear. Both the ATG16L1 risk allele as well as ATG5 are selectively 
important for the function of the Paneth cell, a specialized epithelial cell in the small 
intestine [62]. Through genome-wide association screenings it was shown that the 
autophagic pathway plays a fundamental role in the predisposition to the inflammatory 
bowel condition Chron’s disease [63]. Taken together, these data indicate the dynamic 
relationship between glucocorticoid-induced metabolic perturbations, autophagy induction, 
inflammation and cell death susceptibility. Further investigations are likely to provide new 
insights into this complex relationship to treat cardiovascular disease more effectively by 
exploiting the modulation of the autophagic machinery in context with controlling local 
glucocorticoid activity.   
10. The role of the mitogen-activated protein kinases (MAPKs) during 
ischemia/reperfusion-induced stress in the heart 
Great efforts have been made to disentangle the intricate relationship between signalling 
pathways and the stress response of the heart during ischemia/reperfusion-induced injury. 
Analysis is complicated due to the fact that several pathways can be activated 
simultaneously with differential effects. It has become however evident that the MAPKs are 
major mediators of I/R-induced injury. Recent data pin point the MAPK’s as one of the 
crossroads between autophagy and glucocorticoid signalling events.  
Three major classes of MAPKs (Figure 4), which include the extracellular signal regulated 
protein kinase (ERK)/p42/44, c-Jun NH2-terminal protein kinase (JNK)/stress activated 
protein kinase (SAPK) and p38 MAPK families have been identified [64,65]. The ERK 
pathway has been depicted as a pro-survival pathway and is activated by a variety of 
mitogens and phorbol esters [66,67]. The JNK and p38 MAPK pathways are regarded as pro-
apoptotic pathways and are mainly activated by environmental stress and inflammatory 
cytokines [67,68].  
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protein kinase (ERK)/p42/44, c-Jun NH2-terminal protein kinase (JNK)/stress activated 
protein kinase (SAPK) and p38 MAPK families have been identified [64,65]. The ERK 
pathway has been depicted as a pro-survival pathway and is activated by a variety of 
mitogens and phorbol esters [66,67]. The JNK and p38 MAPK pathways are regarded as pro-
apoptotic pathways and are mainly activated by environmental stress and inflammatory 
cytokines [67,68].  
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Figure 4. MAPK activation in stress-induced signalling in the heart. A variety of stress signals can 
activate the MAPKs directly or indirectly. MAPKs comprise a family of tyrosine/threonine kinases. 
Receptor activation initiates a cascade of phosphorylation events involving sequential activation of G 
proteins, MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) and finally MAPK. Activated 
MAPK, in turn, is responsible for the phosphorylation and activation of various other regulatory 
proteins and transcription factors, which induce the expression of genes involved in the regulation of 
cell proliferation and apoptosis. ERK kinases mediate cell survival and proliferation, whereas JNK and 
p38 induce growth arrest and apoptosis (modified from Wernig and Xu, 2002).  
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Studies using chemical inhibitors have led to the conclusion that activation of the p38-
MAPK promotes cardiac myocyte death during extended periods of ischemia [69-71].  In a 
cultured neonatal rat cardiac myocyte model, inhibition of p38-MAPK protects against 
ischaemic injury by decreasing LDH release [69,70]. In addition, Barancik and co-workers 
(2000) reported that a specific inhibitor of p38-MAPK, SB203580, protected pig myocardium 
against ischaemic injury in an in vivo model by reducing infarct size [71]. Several studies 
indicated that p38-MAPK plays a pivotal role in promoting myocardial apoptosis [69,72-73]. 
Ma and co-workers (1999) demonstrated that in isolated perfused rabbit hearts, ischemia 
alone caused a moderate but transient increase in p38-MAPK activity [72]. Ten minutes’ 
reperfusion further activated p38-MAPK, which remained elevated throughout reperfusion 
(20 minutes). Administration of SB203580 before ischemia and during reperfusion 
completely inhibited p38 MAPK activation and exerted significant cardioprotective effects, 
characterized by decreased myocardial apoptosis and improved post-ischaemic function, as 
well as attenuated myocardial necrotic injury. In contrast, administering SB203580 10 
minutes after reperfusion (a time point when maximal MAPK activation had already been 
achieved), failed to convey significant cardioprotection. Mackay and Mochly-Rosen (1999) 
indicated that in neonatal rat cardiac myocytes, two distinct phases of p38 activation were 
observed during ischemia: the first phase began within 10 minutes and lasted less than 1 
hour, and the second began after 2 hours and lasted throughout the ischaemic period [69]. 
They demonstrated that SB203580 also protected cardiac myocytes against ischemia by 
reducing activation of caspase-3, a key event in apoptosis. However, the protective effect 
was seen even when the inhibitor was present during only the second, sustained phase of 
p38 MAPK activation. Subsequent studies by Yue and co-workers (2000), exposing rat 
neonatal cardiomyocytes to ischemia showed a rapid and transient activation of p38-MAPK 
and JNK [73]. On reoxygenation, further activation of SAPKs was noted. With pretreatment 
of the cells with SB203580 apoptotic cells were reduced, suggesting p38 MAPK activation 
mediates apoptosis in rat cardiac myocytes subjected to ischemia/reoxygenation. In 
addition, Yue and co-workers (2000) also showed that SB203580 improved cardiac 
contractile function in rat isolated ischaemic hearts. Inhibition of p38 MAPK activation, 
therefore, correlated with cardioprotection against ischemia/reperfusion injury in cardiac 
myocytes as well as in isolated hearts [73]. 
Zechner and co-workers (1998) also reported that overexpression of MKK6 (Figure 4), an 
upstream activator of p38 MAPK, resulted in protection of cardiac myocytes from apoptosis 
induced either by anisomycin or MEKK1, an upstream activator of the JNK pathway [74]. In 
addition, expression of MKK6 elicited a hyperthrophic response, which was enhanced by 
co-infection of p38 [75]. Therefore, a distinct isoform of p38 MAPK, p38, may participate 
in mediating cell survival. In contrast, over expression of MKK3 in mouse cardiomyocytes 
led to apoptosis, which was increased by co-infection of p38 [75]. Therefore differential 
activation of p38-MAPK isoforms may exert opposing effects: p38 is implicated in cell 
death, while p38 may mediate myocardial survival. 
To determine whether p38 MAPK activation was isoform selective, rat neonatal 
cardiomyocytes were infected with adenovirus encoding wild-type p38 or p38 [70]. They 
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Figure 4. MAPK activation in stress-induced signalling in the heart. A variety of stress signals can 
activate the MAPKs directly or indirectly. MAPKs comprise a family of tyrosine/threonine kinases. 
Receptor activation initiates a cascade of phosphorylation events involving sequential activation of G 
proteins, MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) and finally MAPK. Activated 
MAPK, in turn, is responsible for the phosphorylation and activation of various other regulatory 
proteins and transcription factors, which induce the expression of genes involved in the regulation of 
cell proliferation and apoptosis. ERK kinases mediate cell survival and proliferation, whereas JNK and 
p38 induce growth arrest and apoptosis (modified from Wernig and Xu, 2002).  
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upstream activator of p38 MAPK, resulted in protection of cardiac myocytes from apoptosis 
induced either by anisomycin or MEKK1, an upstream activator of the JNK pathway [74]. In 
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co-infection of p38 [75]. Therefore, a distinct isoform of p38 MAPK, p38, may participate 
in mediating cell survival. In contrast, over expression of MKK3 in mouse cardiomyocytes 
led to apoptosis, which was increased by co-infection of p38 [75]. Therefore differential 
activation of p38-MAPK isoforms may exert opposing effects: p38 is implicated in cell 
death, while p38 may mediate myocardial survival. 
To determine whether p38 MAPK activation was isoform selective, rat neonatal 
cardiomyocytes were infected with adenovirus encoding wild-type p38 or p38 [70]. They 
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showed that transfected p38 and p38 were differentially activated during sustained 
ischemia, with p38 remaining activated but p38 deactivated. Furthermore, cells 
expressing a dominant negative p38, which prevented ischemia-induced p38 MAPK 
activation, were resistant to sustained ischaemic injury. Therefore, activation of p38 MAPK 
isoform is detrimental during ischemia. 
11. MAPK inactivation by phosphatases 
Dephosphorylation of either the threonine or tyrosine residue within the MAPK activation 
loop TxY motif alone can result in their enzymatic inactivation. In intact cells, 
dephosphorylation and inactivation of MAPK occur, within minutes to several hours 
depending on the cell type and activating stimulus. In endothelial cells, exposure to serum 
leads to ERK activation that is sustained at high levels for over 2 h. In contrast, different 
patterns can be observed in the a PC12 cell line where EGF-stimulated ERK activation is 
transient, with inactivation initiated within 5 min and nearly complete within 15-30 min, 
whereas this MAPK displays prolonged activation for several hours on stimulation with NGF 
[76]. It is believed that different patterns of ERK activation elicited by EGF and NGF underlie 
their differential effects to drive either cellular proliferation of differentiation, respectively [77]. 
Using PC12 cells as a model system to identify key phosphatases suppressing ERK activation, 
biochemical studies revealed that early rapid inactivation of these MAPKs reflects, in part, 
threonine dephosphorylation by the serine/threonine protein phosphatase PP2A [76].  
In addition to threonine dephosphorylation, these studies also indicated that tyrosine-
specific protein phosphatases (PTPs) also contribute to ERK inactivation [76]. Currently, 50 
or more PTPs have been characterized [78-80], and although the PC12 cell PTPs were not 
identified molecularly [76], recent studies in other cell types have identified a possible role 
for three related PTP gene family members [81-84]. Notwithstanding the importance of these 
early reports on PP2A and tyrosine-specific PTPs inactivating ERKs, little is known about 
their general importance in terminating MAPK signaling, of the molecular mechanisms that 
may control phosphatase catalytic activity, or of their specificity for inactivating different 
MAPK isoforms.  
In contrast to these protein phosphatase classes, there has been significant and rapid 
progress in our understanding of the role played by a subclass of PTP that possess activity 
for dephosphorylating both phosphotyrosine and phosphothreonine residues, known as the 
dual specificity phosphatases (DSPs).  
The first mammalian DSP was identified as the mouse immediate early gene 3CH134 or its 
human orthologue CL100, which is induced rapidly after exposure to growth factors, heat 
shock, or oxidative stress [85-87]. Recombinant CL100/3CH134 was shown to 
dephosphorylate threonine and tyrosine residues of ERK, which was paralleled by its 
inactivation. These studies showed that CL100/3CH134 was specific for dephosphorylation 
of ERK when compared to a number of other unrelated phosphoproteins [76]. A correlation 
between 3CH134 levels and ERK inactivation was also found in mammalian cells, leading to 
its renaming as MAPK phosphatase-1 (MKP-1) [88]. Despite this important early work, the 
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relevance of MKP-1 in ERK inactivation remains to be elucidated. Firstly, ERK activity is 
apparently normal after deletion of the MKP-1 gene in mice [89]. Secondly, it has also 
become evident that MKP-1 is at least as effective in inactivating JNK and p38 when 
compared to the ERKs [90-91].  Thirdly, newly identified members of the DSP gene family 
appear highly selective for ERK and may represent the true physiological regulators of this 
MAPK isoform.  Since the initial cloning of MKP-1, eight additional mammalian DSP gene 
family members have been identified and characterized, which include MKP-2, MKP-3, 
MKP-4, MKP-5, MKP-X, PAC1, M3/6 and B59. These DSPs all appear to be effective in 
mediating inactivation of MAPKs. 
The following model for MAPK inactivation by DSP is suggested (Figure 5). Stimulation by 
growth factors, cytokines, cellular stresses or some active oncogenes leads to rapid 
transcription of one or a subset of DSP genes. Increased DSP transcription may reflect 
activation of specific MAPK, although alternative pathways are not excluded. After 
translation of the DSP mRNA into protein, the catalytically inactive DSP translocates to a 
specific subcellular compartment within either the nucleus or the cytosol. Upon 
encountering its target MAPK, the DSP binds tightly through its amino terminus, which in 
turn triggers activation of the phosphatase catalytic domain. If the bound MAPK is already 
activated, then this will result in its rapid inactivation. Conversely, if the MAPK is not 
 
Figure 5. Cell exposure to growth factors, cytokines and cell stresses leads to induction of a subset of 
DSP genes. Increased expression is likely to reflect activation of transcription factors (black circles) via 
both MAPK-dependent and independent pathways. Newly synthesized DSPs translocate to specific 
subcellular compartments as dictated by anchorage and/or localization motifs not yet identified. 
Specific binding to target MAPKs through regions within the DSP amino terminus then triggers 
activation of the phosphatase catalytic domain. Bound MAPKs are in turn inactivated by 
dephosphorylation on threonine and tyrosine residues localized within the “activation loop” motif of 
TxY. Inactive MAPKs then dissociate, leaving the DSP free to bind and inactivate another MAPK 
molecule. In the absence of continued DSP gene transcription and protein synthesis, rapid degradation 





































Glucocorticoids – New Recognition of Our Familiar Friend 96 
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apparently normal after deletion of the MKP-1 gene in mice [89]. Secondly, it has also 
become evident that MKP-1 is at least as effective in inactivating JNK and p38 when 
compared to the ERKs [90-91].  Thirdly, newly identified members of the DSP gene family 
appear highly selective for ERK and may represent the true physiological regulators of this 
MAPK isoform.  Since the initial cloning of MKP-1, eight additional mammalian DSP gene 
family members have been identified and characterized, which include MKP-2, MKP-3, 
MKP-4, MKP-5, MKP-X, PAC1, M3/6 and B59. These DSPs all appear to be effective in 
mediating inactivation of MAPKs. 
The following model for MAPK inactivation by DSP is suggested (Figure 5). Stimulation by 
growth factors, cytokines, cellular stresses or some active oncogenes leads to rapid 
transcription of one or a subset of DSP genes. Increased DSP transcription may reflect 
activation of specific MAPK, although alternative pathways are not excluded. After 
translation of the DSP mRNA into protein, the catalytically inactive DSP translocates to a 
specific subcellular compartment within either the nucleus or the cytosol. Upon 
encountering its target MAPK, the DSP binds tightly through its amino terminus, which in 
turn triggers activation of the phosphatase catalytic domain. If the bound MAPK is already 
activated, then this will result in its rapid inactivation. Conversely, if the MAPK is not 
 
Figure 5. Cell exposure to growth factors, cytokines and cell stresses leads to induction of a subset of 
DSP genes. Increased expression is likely to reflect activation of transcription factors (black circles) via 
both MAPK-dependent and independent pathways. Newly synthesized DSPs translocate to specific 
subcellular compartments as dictated by anchorage and/or localization motifs not yet identified. 
Specific binding to target MAPKs through regions within the DSP amino terminus then triggers 
activation of the phosphatase catalytic domain. Bound MAPKs are in turn inactivated by 
dephosphorylation on threonine and tyrosine residues localized within the “activation loop” motif of 
TxY. Inactive MAPKs then dissociate, leaving the DSP free to bind and inactivate another MAPK 
molecule. In the absence of continued DSP gene transcription and protein synthesis, rapid degradation 





































Glucocorticoids – New Recognition of Our Familiar Friend 98 
active, then its tight interaction with an active DSP is expected to block any possibility of 
kinase activation by a subsequent stimulus. MAPKs that fail to bind the DSP within its 
amino terminus remain active or susceptible to activation after extracellular stimulation. 
Depending on their cellular localization, these regulatory effects allow for selected inhibition 
of MAPK activities in specific subcellular compartments. Some DSPs have been shown to 
possess short half-lives [76], suggesting that in the absence of continued gene transcription 
and protein synthesis, their rapid turnover limits their duration of action in cells. Overall, 
tight control of DSP gene induction, combined with their differential binding and catalytic 
activation by a specific repertoire of MAPKs, provides a sophisticated mechanism for rapid 
targeted inactivation of selected MAPK activities.  
12. MAP kinase phosphatase-1 (MKP-1): A mediator of the beneficial 
effects of glucocorticoids during ischemia/reperfusion-induced stress in 
the heart 
It is noteworthy that many genes that are positively regulated at post-transcriptional level 
by p38-MAPK, are negatively regulated at the same level by glucocorticoids. Lasa and co-
workers investigated the effects of GCs on the p38-MAPK pathway and have shown that 
dexamethasone destabilized cyclooxygenase-2 (COX-2) mRNA by inhibiting the function, 
but not the expression of p38-MAPK [92]. The inhibition of p38-MAPK was then shown to 
be mediated by MKP-1. We and others have also demonstrated that dexamethasone induces 
the expression of MKP-1 which potently inactivated p38-MAPK [93-94].  
Wu and Bennet (2005) demonstrated that MKP-1 promotes cell survival in fibroblasts 
through the attenuation of stress responsive MAPK-mediated apoptosis [95]. Upregulation 
of MKP-1 has also been shown to be associated with cardioprotection by long-chain 
polyunsaturated fatty acids [93]. It has also been reported that transgenic mice 
overexpressing MKP-1 were protected, whereas knock-out mice show greater injury after 
ischemia/reperfusion [96]. The exact mechanism of the beneficial effects of glucocorticoids 
on the heart during ischemia/reperfusion-induced stress still remain to be established. In 
view of the significant contribution of apoptosis, necrosis and autophagy during 
ischemia/reperfusion-induced stress, it is expected that GC-induced cardioprotection to be 
associated with reduced apoptosis and necrosis. Indeed, Fan and co-workers have 
demonstrated that dexamethasone, administered intraperitoneally or added directly to the 
perfusate, significantly improved post-ischemic functional recovery and reduced infarct size 
compared to untreated controls [94]. These were associated with associated with 
upregulation of MKP-1 protein expression [94]. Furthermore, it was also shown by us that 
upregulation of MKP-1 during simulated ischemia/reperfusion is associated with an 
attenuation of apoptosis in neonatal cardiomyocytes [93].  
13. Conclusions  
It has been suggested that upregulation of MKP-1 during ischemia/reperfusion-induced 
stress attenuates myocardial injury [93,94]. MKP-1, found predominantly in the nucleus, is a 
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dual specific phosphatase which dephosphorylates phosphotyrosine and 
phosphothreonine-containing protein kinases such as the MAPKs. MAPKs are known to be 
involved in intracellular signalling pathways that regulate gene expression in response to a 
variety of extracellular signals. MAPKs are activated during ischemia/reperfusion-induced 
stress in the heart. It was also demonstrated that glucocorticoids act via MKP-1 induction 
and subsequent p38-MAPK inhibition to induce cardioprotection during 
ischemia/reperfusion-induced stress [94].  
MAPKs have been found to be involved in autophagic, apoptotic and necrotic cell death 
during stress responses of the heart [97-102]. Autophagy is foremost a survival mechanism 
which is activated in cells subjected to nutrient or growth factor deprivation. However, 
when the cellular stress continues, cell death may occur via autophagy, or becomes 
associated with features of apoptotic or necrotic cell death [103]. Apoptosis is essential for 
removal of specifically targeted cells, through the process of apoptotic body formation and 
phagocytosis [104]. Necrosis is a pathological cellular response requiring no ATP.  Necrotic 
cells are morphologically characterized by disrupted membranes, cytoplasm and 
mitochondrial swelling, disintegration of organelles and complete cell lysis [105]. Cell death 
following ischemia/reperfusion-induced stress is thought to manifest in morphological 
features indicative for all three, apoptotic, necrotic and autophagic cell death [106].  
MKP-1 has been shown to be involved in the regulation of apoptosis [107] and it was also 
very recently demonstrated that MKP-1 may lead to autophagy induction in cancer cells 
[108]. We have recently demonstrated that inhibition of MKP-1 and subsequent increased 
p38-MAPK phosphorylation during ischemia/reperfusion-induced stress is associated with 
attenuated autophagy and increased apoptosis and necrosis in the heart (unpublished data). 
We thus propose the following mechanism of GC-induced protection in the heart: During 
ischemia/reperfusion-induced stress in the heart, p38 MAPK is activated, GCs 
sustain/upregulate autophagy via an increase in MKP-1 and subsequent  dephosphorylation 
of  p38 MAPK which ultimately protects the heart from apoptosis and necrosis, driven by 
the effects of autophagy on the metabolic balance sheet of the heart.  
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1. Introduction 
For thousands, perhaps millions of years, human have marveled to understand how the 
body is formed and function, how it maintains its wholeness and healthy state, and how 
disordered states occur. In frame of holistic philosophy of ancient eastern cultures, a person 
had been accepted as physical, emotional, mental, and spiritual ones. In this concept, the 
balance of the body, mind and spirit were accepted as the healthy state of an individual 
[1,2]. The ancient Greeks defended the concept of the four humors doctrine; blood, black 
bile, yellow bile, and phlegm. Ad modum this doctrine these four humors in a healthy person 
were believed to be balanced, and the reason why a person fell ill was due to the fact that 
these fluids were disturbed [3,4]. With the separation of medicine from superstition, magic 
and religion by famous Greek physician Hippocrates in around 5th century B.C., more 
realistic and relevant approaches could be developed to better understanding the life, 
structures of living creatures and their healthy and diseased conditions. These and the time-
dependent innovative developments in technology and science throughout the following 
centuries led to more concrete observations, mainly on animals. Gathered evidences and 
additive knowledge base from these observations mankind led mankind to make realistic 
definitions on the subjects “the structure, integrity and functions” of the animal and human 
body. In 19th century Louis Pasteur, a French chemist and microbiologist, stated the germ 
theory of diseases. He believed that micro-organisms (bacteria) infect animals and humans, 
thus they cause diseases [5]. At the same times, a French Physiologist Claude Bernard tried 
to understand how living creatures maintain their integrity, and how it is regulated, and 
defeated. He discriminated the internal environment from the external environment and 
was in opinion that living creatures maintain their internal milieu relatively constant under 
continuously changing environmental conditions. Claude Bernard [6] attributed also an 
important role to nervous system in the maintenance of internal environment in 
physiological ranges in human and animal organisms and remarked the substantial 
differences between animals and plants in this respect. Since that time, the interest of the 
researchers in different fields worldwide is mainly focused on possible regulation 
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mechanisms of various living species. Thus, it can be said that the philosophical roots of the 
concept “stress” and “stress physiology” is going back to the early observations that living 
creatures are exposed continuously to the effects of various environmental challenges 
against which they have to defend their integrity, and following statement from Claude 
Bernard that living creatures strive to maintain their internal environments relatively 
constant via various homeokinetic mechanisms even if their environmental conditions are 
changing, thereby keep their normal physiological functioning and prerequisite for a free, 
independent live or shortly ‘la fixité du miliéu interieur est la condition d'une vie libre et 
indépendante’ as defined by him “Il y a pour l'animal deux milieux: un milieu extérieur dans 
lequel est placé l'organisme, et un milieu intérieur dans lequel vivent les éléments des tissus”. 
However, Hans Selye, one of the Pioneers and founders of stress from 1930’s, was the first 
who introduced the term “stress” as the real or perceived physical or psychological events 
which are threaten the homeokinesis in medical terminology. Ad modum Selye the stress is 
somewhat like living, not so easy to define, although there is no doubt about its presence [7]. 
The environmental challenges affecting a living creature, thus causing stress, can vary from 
physical, to chemical and bio-psycho-social factors, while all the reactants, their contra- 
and/or co-players within the living systems are of chemical nature at the last instance; 
intracellular or intra-bodily signaling elements as either hormones including glucocorticoids 
and catecholamines or neurotransmitters, cytokines and chemokines, etc., or a group or all 
of them functioning simultaneously within the body for the same purposes.  
Stress and the glucocorticoids are associated or interweaving concepts with each other. 
Indeed, to physiologists the term “stress” has come to mean any event that elicits increased 
cortisol secretion [8]. However, as it is well known, glucocorticoids are not only mediators of 
the stress responses; they take a part in peripheral components of stress responses. The 
stress response is mediated by the stress system which is composed of two components; 
central nervous system and the peripheral part. The central, greatly interconnected effectors 
of this system include the hypothalamic hormones arginine vasopressin, corticotropin-
releasing hormone/factor (CRH/CRF) and pro-opiomelanocortin-derived peptides, and the 
locus ceruleus and autonomic norepinephrine centers in the brainstem. The peripheral 
components of the stress system include (a) the peripheral limbs of the hypothalamic-
pituitary-adrenal (HPA) axis; (b) the efferent sympathetic-adrenomedullary system, and (c) 
components of the parasympathetic system [9-11]. There are also bidirectional positive 
feedback regulation between the CRF secreted paraventricular nucleus of hypothalamus 
and central noradrenergic system [9,11,12].  
Stressors activate different physiological processes. The first classical response is the 
secretion of adrenalin and noradrenalin hormones from the adrenal medulla via activation 
of sympathetic nervous system. This response is called “fight or flight syndrome”, because 
adrenaline and noradrenalin increase the respiratory rate, the heartbeat, the concentration of 
glucose in circulating blood and the blood flow to the skeletal muscles. This fast response is 
primarily related to survival. Stressors also activate the HPA axis. The activation of this axis 
begins with the stimulation of parvocelular neurons of hypothalamus and secretion of CRH. 
CRH stimulates the secretion of adrenocorticotrophic hormone (ACTH) from the 
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adenohypophsis and the ACTH acts on cortex of adrenal glands and stimulates the release 
of glucocorticoid hormones. GC hormones (corticosterone in rodents and cortisol in 
humans), which are the ultimate product of HPA axis activation, act on multiple bodily 
systems to maintain homeokinesis. They stimulate protein catabolism, gluconeogenesis and 
release of glycerol and fatty acids into the blood, maintain the vasoconstructive effect of 
norepinephrine, inhibit glucose uptake and oxidation by many body cells except the brain 
(insulin antagonism) and also inhibit inflammation and specific immune response [8-11].  
The secretion of ACTH, and therefore of cortisol or corticosterone, is stimulated by several 
hormones and molecules in addition to hypothalamic CRH. Depending on the stressor, 
substances such as vasopressin, epinephrine, angiotensin II, various cytokines (tumor 
necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6), and lipid mediators of inflammation 
affect the hypothalamic, pituitary, and/or adrenal components of the HPA axis and 
potentiate its activity. Glucocorticoids play an important role in the regulation of basal 
activity of the HPA axis, as well as in the termination of the stress response by acting at 
extra-hypothalamic centers, the hypothalamus, and the pituitary gland. The negative 
feedback of glucocorticoids on the secretion of CRH and ACTH serves to limit the duration 
of the total tissue exposure of the organism to glucocorticoids, thus minimizing the 
catabolic, lipogenic, anti-reproductive, and immunosuppressive effects of these hormones 
[8,10,11].  
The activation of the HPA is a longer-term adjustment by the humans or animals to the 
changes in their micro- or surrounding environments. Selye [7] called it as the ‘general 
adaptation syndrome’ (GAS). The process of adaptation, also known as “allostasis” (literally 
“maintaining stability, through change”), supports the homeokinesis [13]. In acute stress, the 
activation of both sympathetic system and HPA axis are essential for survival of individual 
and they help to re-establish or maintain homeokinesis through adaptation. However, in 
chronic periods, prolonged or repeated activation of stress systems can result in cumulative 
biological changes (known as allostatic load) and can alter adaptive mechanism. If the 
ability of the organisms to maintain their integrity is poor or not strong enough to 
compensate the effects of environmental challenges, they can also harm the living creatures 
via various mechanisms. Excessive or inappropriate, inadequate adaptive responses to stress 
may play a causal role in development of certain diseases [10,11,14,15]. Indeed, depending 
on the stressors and their severity as well as the capability of living creatures to respond 
them, the reactions of living creatures to the stressors can be systematic, also reflecting itself 
throughout the whole body, or mainly local or regional, reflecting self at the 
organel/celluler/organ or system levels [11,14]. Similarly, the application of glucocorticoids 
for a long time can also cause events with serious consequences [16]. 
The gastrointestinal tract and the immune system are particularly responsive to different 
stressors. This system has many cellular targets for the stress mediators such as 
catecholamines, glucocorticoids and CRF [17-19]. The association between stress and various 
gastrointestinal diseases, including functional bowel disorders, inflammatory bowel disease 
(IBD), peptic ulcer disease and gastroeosophageal reflux disease, is being actively 
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Bernard that living creatures strive to maintain their internal environments relatively 
constant via various homeokinetic mechanisms even if their environmental conditions are 
changing, thereby keep their normal physiological functioning and prerequisite for a free, 
independent live or shortly ‘la fixité du miliéu interieur est la condition d'une vie libre et 
indépendante’ as defined by him “Il y a pour l'animal deux milieux: un milieu extérieur dans 
lequel est placé l'organisme, et un milieu intérieur dans lequel vivent les éléments des tissus”. 
However, Hans Selye, one of the Pioneers and founders of stress from 1930’s, was the first 
who introduced the term “stress” as the real or perceived physical or psychological events 
which are threaten the homeokinesis in medical terminology. Ad modum Selye the stress is 
somewhat like living, not so easy to define, although there is no doubt about its presence [7]. 
The environmental challenges affecting a living creature, thus causing stress, can vary from 
physical, to chemical and bio-psycho-social factors, while all the reactants, their contra- 
and/or co-players within the living systems are of chemical nature at the last instance; 
intracellular or intra-bodily signaling elements as either hormones including glucocorticoids 
and catecholamines or neurotransmitters, cytokines and chemokines, etc., or a group or all 
of them functioning simultaneously within the body for the same purposes.  
Stress and the glucocorticoids are associated or interweaving concepts with each other. 
Indeed, to physiologists the term “stress” has come to mean any event that elicits increased 
cortisol secretion [8]. However, as it is well known, glucocorticoids are not only mediators of 
the stress responses; they take a part in peripheral components of stress responses. The 
stress response is mediated by the stress system which is composed of two components; 
central nervous system and the peripheral part. The central, greatly interconnected effectors 
of this system include the hypothalamic hormones arginine vasopressin, corticotropin-
releasing hormone/factor (CRH/CRF) and pro-opiomelanocortin-derived peptides, and the 
locus ceruleus and autonomic norepinephrine centers in the brainstem. The peripheral 
components of the stress system include (a) the peripheral limbs of the hypothalamic-
pituitary-adrenal (HPA) axis; (b) the efferent sympathetic-adrenomedullary system, and (c) 
components of the parasympathetic system [9-11]. There are also bidirectional positive 
feedback regulation between the CRF secreted paraventricular nucleus of hypothalamus 
and central noradrenergic system [9,11,12].  
Stressors activate different physiological processes. The first classical response is the 
secretion of adrenalin and noradrenalin hormones from the adrenal medulla via activation 
of sympathetic nervous system. This response is called “fight or flight syndrome”, because 
adrenaline and noradrenalin increase the respiratory rate, the heartbeat, the concentration of 
glucose in circulating blood and the blood flow to the skeletal muscles. This fast response is 
primarily related to survival. Stressors also activate the HPA axis. The activation of this axis 
begins with the stimulation of parvocelular neurons of hypothalamus and secretion of CRH. 
CRH stimulates the secretion of adrenocorticotrophic hormone (ACTH) from the 
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adenohypophsis and the ACTH acts on cortex of adrenal glands and stimulates the release 
of glucocorticoid hormones. GC hormones (corticosterone in rodents and cortisol in 
humans), which are the ultimate product of HPA axis activation, act on multiple bodily 
systems to maintain homeokinesis. They stimulate protein catabolism, gluconeogenesis and 
release of glycerol and fatty acids into the blood, maintain the vasoconstructive effect of 
norepinephrine, inhibit glucose uptake and oxidation by many body cells except the brain 
(insulin antagonism) and also inhibit inflammation and specific immune response [8-11].  
The secretion of ACTH, and therefore of cortisol or corticosterone, is stimulated by several 
hormones and molecules in addition to hypothalamic CRH. Depending on the stressor, 
substances such as vasopressin, epinephrine, angiotensin II, various cytokines (tumor 
necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6), and lipid mediators of inflammation 
affect the hypothalamic, pituitary, and/or adrenal components of the HPA axis and 
potentiate its activity. Glucocorticoids play an important role in the regulation of basal 
activity of the HPA axis, as well as in the termination of the stress response by acting at 
extra-hypothalamic centers, the hypothalamus, and the pituitary gland. The negative 
feedback of glucocorticoids on the secretion of CRH and ACTH serves to limit the duration 
of the total tissue exposure of the organism to glucocorticoids, thus minimizing the 
catabolic, lipogenic, anti-reproductive, and immunosuppressive effects of these hormones 
[8,10,11].  
The activation of the HPA is a longer-term adjustment by the humans or animals to the 
changes in their micro- or surrounding environments. Selye [7] called it as the ‘general 
adaptation syndrome’ (GAS). The process of adaptation, also known as “allostasis” (literally 
“maintaining stability, through change”), supports the homeokinesis [13]. In acute stress, the 
activation of both sympathetic system and HPA axis are essential for survival of individual 
and they help to re-establish or maintain homeokinesis through adaptation. However, in 
chronic periods, prolonged or repeated activation of stress systems can result in cumulative 
biological changes (known as allostatic load) and can alter adaptive mechanism. If the 
ability of the organisms to maintain their integrity is poor or not strong enough to 
compensate the effects of environmental challenges, they can also harm the living creatures 
via various mechanisms. Excessive or inappropriate, inadequate adaptive responses to stress 
may play a causal role in development of certain diseases [10,11,14,15]. Indeed, depending 
on the stressors and their severity as well as the capability of living creatures to respond 
them, the reactions of living creatures to the stressors can be systematic, also reflecting itself 
throughout the whole body, or mainly local or regional, reflecting self at the 
organel/celluler/organ or system levels [11,14]. Similarly, the application of glucocorticoids 
for a long time can also cause events with serious consequences [16]. 
The gastrointestinal tract and the immune system are particularly responsive to different 
stressors. This system has many cellular targets for the stress mediators such as 
catecholamines, glucocorticoids and CRF [17-19]. The association between stress and various 
gastrointestinal diseases, including functional bowel disorders, inflammatory bowel disease 
(IBD), peptic ulcer disease and gastroeosophageal reflux disease, is being actively 
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investigated [15,17]. However, there is a parodox that the chronic stress plays a role in 
inflammatory bowel disease while the glucocorticoid therapy is widely used to cure the same 
disease. 
Gastrointestinal system (GIS) is the biggest surface area (~200 m2) of the body that is binding 
the organism to the external environment. This system is continuously exposed to various 
antigens from consumed foods and resident bacteria and also from potentially harmful 
pathogens, such as viruses, bacteria, fungi or parasites. Besides digestion and absorption 
processes, it forms a barrier between the internal and external environments [20]. Intestinal 
barrier is composed of various components such as tight junction conformation between the 
intestinal epithelial cells, mucosal immune system, mucin secretion, and intestinal 
microbiota. The barrier function is quite critical process because of the barrier should 
confirm the hyporesponsiveness or tolerance towards commensal bacteria while 
maintaining the ability to fight pathogenic microorganisms. The breakdown of this critical 
balance usually results in inflammation-associated damages. Gastrointestinal system is 
rather complex system, which has own nervous and endocrine system. The enteric nervous 
system is connected bidirectionally to the brain by parasympathetic and sympathetic 
pathways forming the brain–gut axis. The description of stress-induced alterations in this 
axis is thought to be important for the solving problems of many stress-related 
gastrointestinal disorders [17,20]. A number of paracine acting endocrine cells have 
important functions for the regulation of digestion processes. These hormones exist in both 
central nervous system and gastrointestinal plexus neurons where they function as 
neurotransmitters or neuromodulators [8]. Recent findings suggest that glucocorticoid 
hormones may also be synthesized from extra-adrenal tissues such as brain, skin, vascular 
endothelium and intestine. These tissues express steroidogenic enzymes and were claimed 
to be potential extra-adrenal sources of glucocorticoids [21]. It is emphasized that intestinal 
glucocorticoid synthesis might be of potential importance in regulation of mucosal immune 
responses and information of inflammatory bowel disease [22]. 
Gastrointestinal system hosts also a large number of microorganisms. They all together are 
called as gastrointestinal microbiota, and form the great part of the system. The microbiota–
host interactions play an active role in many physiologic and pathophysiologic processes of 
the host [19,23,24]. While gastrointestinal microbiota could affect the stress response [25] 
and intestinal structure and functions of the host [23,24], stress hormones of the host 
organism such as the catecholamines can also alter directly growth, motility, biofilm 
formation and/or virulence of pathogens and commensal bacteria [19,26,27] or they may 
affect their microbiota indirectly by changing the intestinal environment [20]. 
The effects of stress on important physiological functions of the gut include; motility, 
secretion and absorption, visceral sensitivity, mucosal integrity, permeability, immune 
system, blood flow, microbiota and microbiota-host interactions [17,20]. Some stress-related 
alterations in gut physiology also can be induced by exogenous glucocorticoids [28-30]. 
However; recent findings using central and peripheral CRF administration showed that CRF 
and their receptor subtypes (CRF1 and CRF2) are playing important roles in many stress-
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related alterations of the gut. The stress-related alterations including intestinal permeability, 
mast cell activity [20], goblet cell and mucin formation [31], and motility alterations [32] can 
be mimicked by the CRF agonists and inhibited by CRF receptor antagonists. Therefore; 
CRF have been suggested as a target to treat stress-induced functional gastrointestinal 
disorders. 
In this chapter, the effects of stress and stress-related hormones, especially glucocorticoids 
on the components of intestinal environment suc as intestinal epithelium, mucin formation, 
mucosal immune system, intestinal microbiota and microbiota-host interactions, and also 
the role of corticosteroids and stress in bacterial colonization and intestinal diseases were 
reviewed.  
2. Stress models for gastrointestinal studies  
A great number of animal models of stress (acute/chronic, early life/adult, physical/ 
psychological or both physical and psychological) have been described for studying the 
effects of stress on gastrointestinal functions. For this purpose, rather naturally (Wistar-
Kyoto rats) or genetically modified stress susceptible animals were also used. As denoted by 
Soderholm and Perdue [20], stress models that psychological effects are more powerful than 
the physical effects are preferred for mimicking the effects of the life and environmental 
stress on several pathologies. However, the kind and duration of stressors and other factors 
including genetic or perinatal environment, etc. might be a key factor in the evaluation of 
the stress effects on specific gastrointestinal functions such as stress-induced visceral 
hyperalgesia. Depending on the characteristics of the stressors and the time-course of their 
effects, alterations caused by stress can be immediate, delayed, transient or sustained or 
never be seen [33,34]. For example, the small intestinal transit was significantly inhibited by 
restraint stress, but not by footshock stress although plasma corticosterone levels were 
significantly elevated to the same extent by restraint stress and foot-shock stress [33].  
Williams et al [35] reported that acute mild restraint (wrap restraint) elevated plasma levels 
of adrenocorticotropic hormone and beta-endorphin, and caused analgesia. Gastric ulcer did 
not form, gastric emptying was not affected, however, small intestinal transit was inhibited, 
and large intestinal transit was stimulated by wrap restraint stress, and there was an 
associated increase in fecal excretion. Because of neither adrenalectomy nor hypophysectomy 
have prevented the response of the intestine to stress, they suggested that adrenal or 
pituitary-derived factors are not responsible for mediating the effects of stress on the gut. 
Restraint stress is most widely used as an acute stress model. Restraining can be supplied 
with restraint devices or by wrap restraint for times varying from 30 min to 4 hours. This 
model could be modified with a cold environment (cold restraint stress) or water immersion 
(water immersion restraint stress) for creating both physical and psychological stress [20]. 
Cold enhanced the changes in rat intestine caused by restraining. However, plasma 
corticosterone levels increased in both restraint and cold restraint stressed rats in same 
extent compared with fasted unstressed rats. Fasting corticosterone levels also increased 
compared with the fed rats [36].    
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investigated [15,17]. However, there is a parodox that the chronic stress plays a role in 
inflammatory bowel disease while the glucocorticoid therapy is widely used to cure the same 
disease. 
Gastrointestinal system (GIS) is the biggest surface area (~200 m2) of the body that is binding 
the organism to the external environment. This system is continuously exposed to various 
antigens from consumed foods and resident bacteria and also from potentially harmful 
pathogens, such as viruses, bacteria, fungi or parasites. Besides digestion and absorption 
processes, it forms a barrier between the internal and external environments [20]. Intestinal 
barrier is composed of various components such as tight junction conformation between the 
intestinal epithelial cells, mucosal immune system, mucin secretion, and intestinal 
microbiota. The barrier function is quite critical process because of the barrier should 
confirm the hyporesponsiveness or tolerance towards commensal bacteria while 
maintaining the ability to fight pathogenic microorganisms. The breakdown of this critical 
balance usually results in inflammation-associated damages. Gastrointestinal system is 
rather complex system, which has own nervous and endocrine system. The enteric nervous 
system is connected bidirectionally to the brain by parasympathetic and sympathetic 
pathways forming the brain–gut axis. The description of stress-induced alterations in this 
axis is thought to be important for the solving problems of many stress-related 
gastrointestinal disorders [17,20]. A number of paracine acting endocrine cells have 
important functions for the regulation of digestion processes. These hormones exist in both 
central nervous system and gastrointestinal plexus neurons where they function as 
neurotransmitters or neuromodulators [8]. Recent findings suggest that glucocorticoid 
hormones may also be synthesized from extra-adrenal tissues such as brain, skin, vascular 
endothelium and intestine. These tissues express steroidogenic enzymes and were claimed 
to be potential extra-adrenal sources of glucocorticoids [21]. It is emphasized that intestinal 
glucocorticoid synthesis might be of potential importance in regulation of mucosal immune 
responses and information of inflammatory bowel disease [22]. 
Gastrointestinal system hosts also a large number of microorganisms. They all together are 
called as gastrointestinal microbiota, and form the great part of the system. The microbiota–
host interactions play an active role in many physiologic and pathophysiologic processes of 
the host [19,23,24]. While gastrointestinal microbiota could affect the stress response [25] 
and intestinal structure and functions of the host [23,24], stress hormones of the host 
organism such as the catecholamines can also alter directly growth, motility, biofilm 
formation and/or virulence of pathogens and commensal bacteria [19,26,27] or they may 
affect their microbiota indirectly by changing the intestinal environment [20]. 
The effects of stress on important physiological functions of the gut include; motility, 
secretion and absorption, visceral sensitivity, mucosal integrity, permeability, immune 
system, blood flow, microbiota and microbiota-host interactions [17,20]. Some stress-related 
alterations in gut physiology also can be induced by exogenous glucocorticoids [28-30]. 
However; recent findings using central and peripheral CRF administration showed that CRF 
and their receptor subtypes (CRF1 and CRF2) are playing important roles in many stress-
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related alterations of the gut. The stress-related alterations including intestinal permeability, 
mast cell activity [20], goblet cell and mucin formation [31], and motility alterations [32] can 
be mimicked by the CRF agonists and inhibited by CRF receptor antagonists. Therefore; 
CRF have been suggested as a target to treat stress-induced functional gastrointestinal 
disorders. 
In this chapter, the effects of stress and stress-related hormones, especially glucocorticoids 
on the components of intestinal environment suc as intestinal epithelium, mucin formation, 
mucosal immune system, intestinal microbiota and microbiota-host interactions, and also 
the role of corticosteroids and stress in bacterial colonization and intestinal diseases were 
reviewed.  
2. Stress models for gastrointestinal studies  
A great number of animal models of stress (acute/chronic, early life/adult, physical/ 
psychological or both physical and psychological) have been described for studying the 
effects of stress on gastrointestinal functions. For this purpose, rather naturally (Wistar-
Kyoto rats) or genetically modified stress susceptible animals were also used. As denoted by 
Soderholm and Perdue [20], stress models that psychological effects are more powerful than 
the physical effects are preferred for mimicking the effects of the life and environmental 
stress on several pathologies. However, the kind and duration of stressors and other factors 
including genetic or perinatal environment, etc. might be a key factor in the evaluation of 
the stress effects on specific gastrointestinal functions such as stress-induced visceral 
hyperalgesia. Depending on the characteristics of the stressors and the time-course of their 
effects, alterations caused by stress can be immediate, delayed, transient or sustained or 
never be seen [33,34]. For example, the small intestinal transit was significantly inhibited by 
restraint stress, but not by footshock stress although plasma corticosterone levels were 
significantly elevated to the same extent by restraint stress and foot-shock stress [33].  
Williams et al [35] reported that acute mild restraint (wrap restraint) elevated plasma levels 
of adrenocorticotropic hormone and beta-endorphin, and caused analgesia. Gastric ulcer did 
not form, gastric emptying was not affected, however, small intestinal transit was inhibited, 
and large intestinal transit was stimulated by wrap restraint stress, and there was an 
associated increase in fecal excretion. Because of neither adrenalectomy nor hypophysectomy 
have prevented the response of the intestine to stress, they suggested that adrenal or 
pituitary-derived factors are not responsible for mediating the effects of stress on the gut. 
Restraint stress is most widely used as an acute stress model. Restraining can be supplied 
with restraint devices or by wrap restraint for times varying from 30 min to 4 hours. This 
model could be modified with a cold environment (cold restraint stress) or water immersion 
(water immersion restraint stress) for creating both physical and psychological stress [20]. 
Cold enhanced the changes in rat intestine caused by restraining. However, plasma 
corticosterone levels increased in both restraint and cold restraint stressed rats in same 
extent compared with fasted unstressed rats. Fasting corticosterone levels also increased 
compared with the fed rats [36].    
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The acute (one time) and chronic (1 hour/day for 10 consecutive days) models of water 
avoidance stress are also preferred potent psychological models in determination of stress-
induced gastrointestinal functions. These models result in elevations of ACTH and 
corticosterone within 30 min [37], and induce enlargement of the adrenal glands [38]. 
Recently, Vicario et al [39,40] reported that crowding stress (8 rats/cage) or sham-crowding 
(2 rats/cage) for up to 15 consecutive days triggers reversible inflammation, mast cell-
mediated barrier dysfunctions, persistent epithelial dysfunction, and colonic hyperalgesia. 
Crowding-stressed rats showed higher plasma corticosterone levels than sham-stressed 
animals from day 1 and up to day 15. After 15 days of crowding stress, corticosterone levels 
decreased %38 (slightly adaptation), but HPA reactivity to incoming stressors was preserved. 
Crowding stress, differently from the stress models induced in laboratory, is actualized in 
natural environment of animals and may reflect life stress well for humans. Thus, this model 
has been also suggested as a suitable animal model to unravel the complex pathophysiology 
underlying to common human intestinal stress-related disorders, such as IBS.  
Early life stress models such as maternal deprivation of pups from the dams have also been 
widely used [31,41,43,44], because stressful events in the early period of life (in the form of 
abuse, neglect or loss of the primary caregiver) have been shown to modify adult immune 
and gastrointestinal tract functions [12]. 
3. Intestine and its microenvironment 
The gastrointestinal system is a tubular organ and the part ‘intestine’ extends downwards 
from the pyloric sphincter. With its many loops and coils, small and large intestines fill 
much of the abdominal cavity. Microscopically, both the small and large intestine are 
composed of four distinct layers; the mucosa covering the internal site of the tube, the 
submucosa, the muscularis externa and the serosa. The mucosa consists of layer of epithelia, 
loose connective tissue layer (lamina propia) containing blood vessels, lymphatics, and some 
lymphoid tissue, and muscularis mucosa. They both have different types of cells as building 
blocks; however, some of them are especially important in relation to luminal challenges via 
different agents including undigested or partly digested dietary proteins, gut microbiota 
and its metabolites. Located among the enterocytes are goblet cells secreting mucin which 
per se build a barrier; scattered enteroendocrine cells with paracrine and endocrine actions; 
Paneth cells characterized by their granules containing lysozyme, tumor necrosis factor-α 
and defensins have antibacterial roles; M cells with their well-known roles in antigen 
sampling and transportation; and the intestinal subepithelial myofibroblasts located in 
proximity to the mucosal epithelium and produce growth factors including hepatocyte 
growth factor promoting the proliferation of the intestinal epithelial stem cells, thus 
responsible for regeneration and maintaining of the integrity of the intestinal mucosa; and 
dendritic cells (DCs) highly specialized for antigen presentation which can capture non-self 
proteins and recognize microbial products [45-55]. 
Intestinal epithelial cells continuously contact with two different environments; first, 
luminal environment, which include intestinal secretions, food antigens, commensal 
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bacteria, and also noxious or pathogenic materials, and second, the interstitial fluid 
surrounding the cells at the basolateral side. The single layer intestinal epithelium along the 
small and large intestine has a number of physiologic functions; it forms a barrier between 
the external (luminal) and internal environments besides its digestive and absorptive 
functions, and this epithelial barrier limits the space for bacterial growth. The ability of the 
epithelium to control uptake of molecules into the body is denoted as the intestinal barrier 
function [20,56,57]. The characteristics of intestinal epithelium for participation to the barrier 
function include; tight junction adherence between the epithelial cells, fluid and mucin 
secretions, secretions of numerous antimicrobial peptides, transepithelial transport of 
secretory IgA and the antigen presenting cell activity. However, intestinal epithelium is not 
only component of the intestinal barrier. Mucosal immune system, microbiota and 
microbiota-host interactions exist in major components of intestinal barrier [23,24]. All these 
components of intestinal barrier are controlled by the mediators of neuro-endocrine-
immune network, and stress and stress mediators have significant impact on these 
components and regulatory network [20,24]. 
4. The effects of stress and glucocorticoids on intestinal barrier function 
Intestinal mucosal epithelium is very sensitive against different types of stress because of 
the half-time of mucosal epithelia which may be as short as one and half day in certain parts. 
In other words, compared to many other tissues in the human and animal body, it is not 
well differentiated and very fragile [8,57]. The effects of acute or chronic stress on intestinal 
barrier function or intestinal permeability does not appear very different from each other in 
animal models of stress. However, the duration and repetition of stressors may influence 
severity, and the alterations may be temporary or permanent [34,58]. Generally, intestinal 
ion secretion [40,59], macromolecular permeability [60,61], inflammation [40,59], visceral 
hypersensivity and colonic motility increased [40], while gastric motility decreased in 
various animal models of stress [62-64]. These stress responses have been also described in 
IBD patients and involve dysregulation of HPA axis [12,15,17]. They are mediated by stress-
related neuropeptides such as CRF, neural mechanisms and mast cells [18,20,65]. Various 
stress factors including heat, nutritional alterations, overcrowding, physical restraints and 
transporting also destroy the microbial balance and their microenvironment in the gut 
[66,67]. When the stressful events cause a decrease in beneficial bacteria, they generally 
increase the pathogenic species within the gut microenvironment [67-69]. In following 
sections, the effects of stress mediators on each component of barrier were discussed in 
details.  
5. The physical barrier of epithelium 
Cell-cell and cell–basement membrane interactions of intestinal epithelial cells control the 
transcellular and paracellular transports of luminal macromolecules and prevent bacteria 
from translocating into the subepithelial layer. Tight junctions (TJ) are primary physical 
components of intestinal barrier, located at the most apical part of lateral membranes of 
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The acute (one time) and chronic (1 hour/day for 10 consecutive days) models of water 
avoidance stress are also preferred potent psychological models in determination of stress-
induced gastrointestinal functions. These models result in elevations of ACTH and 
corticosterone within 30 min [37], and induce enlargement of the adrenal glands [38]. 
Recently, Vicario et al [39,40] reported that crowding stress (8 rats/cage) or sham-crowding 
(2 rats/cage) for up to 15 consecutive days triggers reversible inflammation, mast cell-
mediated barrier dysfunctions, persistent epithelial dysfunction, and colonic hyperalgesia. 
Crowding-stressed rats showed higher plasma corticosterone levels than sham-stressed 
animals from day 1 and up to day 15. After 15 days of crowding stress, corticosterone levels 
decreased %38 (slightly adaptation), but HPA reactivity to incoming stressors was preserved. 
Crowding stress, differently from the stress models induced in laboratory, is actualized in 
natural environment of animals and may reflect life stress well for humans. Thus, this model 
has been also suggested as a suitable animal model to unravel the complex pathophysiology 
underlying to common human intestinal stress-related disorders, such as IBS.  
Early life stress models such as maternal deprivation of pups from the dams have also been 
widely used [31,41,43,44], because stressful events in the early period of life (in the form of 
abuse, neglect or loss of the primary caregiver) have been shown to modify adult immune 
and gastrointestinal tract functions [12]. 
3. Intestine and its microenvironment 
The gastrointestinal system is a tubular organ and the part ‘intestine’ extends downwards 
from the pyloric sphincter. With its many loops and coils, small and large intestines fill 
much of the abdominal cavity. Microscopically, both the small and large intestine are 
composed of four distinct layers; the mucosa covering the internal site of the tube, the 
submucosa, the muscularis externa and the serosa. The mucosa consists of layer of epithelia, 
loose connective tissue layer (lamina propia) containing blood vessels, lymphatics, and some 
lymphoid tissue, and muscularis mucosa. They both have different types of cells as building 
blocks; however, some of them are especially important in relation to luminal challenges via 
different agents including undigested or partly digested dietary proteins, gut microbiota 
and its metabolites. Located among the enterocytes are goblet cells secreting mucin which 
per se build a barrier; scattered enteroendocrine cells with paracrine and endocrine actions; 
Paneth cells characterized by their granules containing lysozyme, tumor necrosis factor-α 
and defensins have antibacterial roles; M cells with their well-known roles in antigen 
sampling and transportation; and the intestinal subepithelial myofibroblasts located in 
proximity to the mucosal epithelium and produce growth factors including hepatocyte 
growth factor promoting the proliferation of the intestinal epithelial stem cells, thus 
responsible for regeneration and maintaining of the integrity of the intestinal mucosa; and 
dendritic cells (DCs) highly specialized for antigen presentation which can capture non-self 
proteins and recognize microbial products [45-55]. 
Intestinal epithelial cells continuously contact with two different environments; first, 
luminal environment, which include intestinal secretions, food antigens, commensal 
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bacteria, and also noxious or pathogenic materials, and second, the interstitial fluid 
surrounding the cells at the basolateral side. The single layer intestinal epithelium along the 
small and large intestine has a number of physiologic functions; it forms a barrier between 
the external (luminal) and internal environments besides its digestive and absorptive 
functions, and this epithelial barrier limits the space for bacterial growth. The ability of the 
epithelium to control uptake of molecules into the body is denoted as the intestinal barrier 
function [20,56,57]. The characteristics of intestinal epithelium for participation to the barrier 
function include; tight junction adherence between the epithelial cells, fluid and mucin 
secretions, secretions of numerous antimicrobial peptides, transepithelial transport of 
secretory IgA and the antigen presenting cell activity. However, intestinal epithelium is not 
only component of the intestinal barrier. Mucosal immune system, microbiota and 
microbiota-host interactions exist in major components of intestinal barrier [23,24]. All these 
components of intestinal barrier are controlled by the mediators of neuro-endocrine-
immune network, and stress and stress mediators have significant impact on these 
components and regulatory network [20,24]. 
4. The effects of stress and glucocorticoids on intestinal barrier function 
Intestinal mucosal epithelium is very sensitive against different types of stress because of 
the half-time of mucosal epithelia which may be as short as one and half day in certain parts. 
In other words, compared to many other tissues in the human and animal body, it is not 
well differentiated and very fragile [8,57]. The effects of acute or chronic stress on intestinal 
barrier function or intestinal permeability does not appear very different from each other in 
animal models of stress. However, the duration and repetition of stressors may influence 
severity, and the alterations may be temporary or permanent [34,58]. Generally, intestinal 
ion secretion [40,59], macromolecular permeability [60,61], inflammation [40,59], visceral 
hypersensivity and colonic motility increased [40], while gastric motility decreased in 
various animal models of stress [62-64]. These stress responses have been also described in 
IBD patients and involve dysregulation of HPA axis [12,15,17]. They are mediated by stress-
related neuropeptides such as CRF, neural mechanisms and mast cells [18,20,65]. Various 
stress factors including heat, nutritional alterations, overcrowding, physical restraints and 
transporting also destroy the microbial balance and their microenvironment in the gut 
[66,67]. When the stressful events cause a decrease in beneficial bacteria, they generally 
increase the pathogenic species within the gut microenvironment [67-69]. In following 
sections, the effects of stress mediators on each component of barrier were discussed in 
details.  
5. The physical barrier of epithelium 
Cell-cell and cell–basement membrane interactions of intestinal epithelial cells control the 
transcellular and paracellular transports of luminal macromolecules and prevent bacteria 
from translocating into the subepithelial layer. Tight junctions (TJ) are primary physical 
components of intestinal barrier, located at the most apical part of lateral membranes of 
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epithelial cells and restrict paracellular passage. The breakdown of tight junctions during 
bacterial infections results in gut barrier failure, often termed “leaky gut” [20,23]. Proteins 
that constitute the TJ complex include transmembrane proteins such as occludin, claudin, 
junction adhesion molecules and intracytoplasmic proteins zonula occludens 1 and 2 
(ZO1-ZO2) and members of the membrane-associated guanylate kinase (MAGUK) protein 
family [70]. Tight junctions are highly dynamic structures, and their permeability is 
regulated by several physiological and pathophysiological conditions. Signals from 
intestinal microbiota may promote integrity of the epithelial barrier and have been shown 
to regulate tight junctions and protect intestinal epithelial cells (IECs) from injury by 
controlling the rate of IEC proliferation and inducing cytoprotective proteins [23]. 
Inflammatory cytokines can disrupt tight junctions and impair gut barrier integrity. 
Treating epithelial monolayers with TNF-α or IL-1b increased the permeability of tight 
junctions by stimulating transcription and activation of myosin light chain kinase (MLCK) 
[71-73]. The acute partial wrap restraint stress increased colonic permeability and rectal 
hypersensitivity via epithelial cell cytoskeleton contraction through myosin light chain 
kinase activation [74]. Acute immobilization stress also induced an increase in TJ 
permeability in the rat terminal ileum. These changes were mainly due to irregularly 
distribution of TJ transmembrane protein occludin and of the plaque protein ZO-1 which 
were seen after 2 hours from the stress induction and returned to a normal pattern within 
24 hours [70]. Mazzon and Cuzzocrea [75] also suggested that TNF-α has active roles in 
the increase of tight junction permeability during acute restraint stress. They 
demonstrated in vivo in a TNF-α R1 knock-out mouse (TNF-α R1KO) model of restraint 
stress that the inhibition of TNF-α attenuates the development of TJ alteration in the 
ileum. Restraint stress caused the increase of heat shock protein-70 expression and 
associated decrease in the expression of type 1 (ZO-1) protein in the colonic epithelium of 
mice. These stress-induced changes can be inhibited by the glucocorticoid receptor 
antagonist mifepristone [76]. However, Boivin et al. [77] reported that glucocorticoids 
enhanced epithelial barrier function by suppressing transcription of myosin light chain 
kinase. Bacterial pathogens target tight junctions and breach epithelial integrity to 
promote colonization, obtain nutrients and access the underlying tissues [23]. So, 
alterations in gastrointestinal microbiota induced by several stressors or exogenous 
glucocorticoids might be an important threat for the barrier disruption. 
6. Fluid and ion secretion 
Due to their diluting and flushing effects, fluid and ion secretion of epithelial cells is another 
protective mechanism contributing to the barrier function [20]. In humans, the jejunal net 
water and sodium chloride absorption decreased during both psychological (induced by 
dichotomous listening) [78] and physical stress (induced by cold pain) [79], and also ion 
absorption is changed toward secretion in psychological form [78]. Both acute and chronic 
stress inductions increased short circuit current (an in vitro technique used for measuring the 
secretory response of intestines) in several parts of rodent intestines [36,41,59,80]. In 
addition, the peripheral non-selective CRF antagonists astressin or α-helical CRF9-41 
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abolished stress- induced alterations [41,80,81]. Intraperitoneal injection of a newly 
developed selective CRF(1) peptide agonist cortagine also induced an increase in defecation 
and watery diarrhea in mice and rats [82]. The effects of mineralocorticoids and 
glucocorticoids on intestinal water and ion movements are well known. Methylprednisolone 
for 3 days increased Na+K+adenosinetriphosphatase activity and Na+ absorption [83]; it also 
increased guanylate cyclase activity and Cl- secretion in the jejunum and ileum 6 h after 
administration [84,85]. However, there is no direct information about the increase of water 
and ion secretion related with increased glucocorticoid secretions in different stressful 
conditions. 
7. Intestinal permeability and mast cell functions 
An increase in intestinal permeability was reported in animals [61,86] and humans [87] 
submitted to acute or chronic stress, and in IBD and IBS patients [88,89]. Increase of 
intestinal permeability or macromolecular permeability also involves mucosal 
inflammation, mucosal damage, and mast cell hyperactivity. The barrier properties of the 
intestinal epithelium are usually studied by assessing the permeability to various 
probe/marker molecules (such as horseradishperoxidase, 51Cr-EDTA, mannitol) in vivo or in 
vitro with intestinal segments mounted in Ussing-type chambers [20]. Bagchi et al [90] 
investigated the effects of acute (90 minute by water immersion) and chronic (15 min/day for 
15 consecutive days by water immersion) stress on the production of reactive oxygen species 
(ROS) and oxidative tissue damage in gastric and intestinal mucosa. Both acute and chronic 
stress increased ROS production, lipid peroxidation and DNA fragmentation in both gastric 
and intestinal mucosa, but acute stress produced greater injury when compared to chronic 
stress. Colonic myeloperoxidase, mucosal mast cell activity and colonic permeability 
increased (as assessed with macroscopic damage and bacterial translocation to mesenteric 
lymph nodes, liver and spleen) at 12 weeks-period in maternally deprived rat pups induced 
by separation from their mothers on 2-14 days period for 3 hours a day [91]. Besides, the 
responses of maternally deprived rats to the TNBS-induced colitis were more prominent 
compared with the control rats. Both acute and chronic cold stress could cause oxidative 
stress of duodenum and a change in iNOS, which was related to the intestinal damage 
process in broiler chicks [92]. There are also evidences about the bacterial production of 
iNOS [93]. Boudry et al [58] suggested that both apoptosis in the crypts and an immature 
epithelium covering the villus surface can be responsible for a barrier defect in rats 
submitted to WAS (1 h/day) for 5 or 10 days. Morphologic [39,94] and enzymatic alterations 
[40] in mitochondria of the intestinal epithelium can also participate to promotion of 
intestinal dysfunctions in stress-induced animals. 
Mast cell activity of gastrointestinal mucosa has altered in both acute and chronic stress 
models. They contain inflammatory and immunmodulating mediators such as 
prostaglandins, histamine and serotonin that directly alter epithelial transport properties 
[80] and nerve and muscle functions [95]. So it has a pivotal role in visceral hypersensivity 
[34], intestinal inflammation, intestinal mucin secretion [96] and epithelial barrier 
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epithelial cells and restrict paracellular passage. The breakdown of tight junctions during 
bacterial infections results in gut barrier failure, often termed “leaky gut” [20,23]. Proteins 
that constitute the TJ complex include transmembrane proteins such as occludin, claudin, 
junction adhesion molecules and intracytoplasmic proteins zonula occludens 1 and 2 
(ZO1-ZO2) and members of the membrane-associated guanylate kinase (MAGUK) protein 
family [70]. Tight junctions are highly dynamic structures, and their permeability is 
regulated by several physiological and pathophysiological conditions. Signals from 
intestinal microbiota may promote integrity of the epithelial barrier and have been shown 
to regulate tight junctions and protect intestinal epithelial cells (IECs) from injury by 
controlling the rate of IEC proliferation and inducing cytoprotective proteins [23]. 
Inflammatory cytokines can disrupt tight junctions and impair gut barrier integrity. 
Treating epithelial monolayers with TNF-α or IL-1b increased the permeability of tight 
junctions by stimulating transcription and activation of myosin light chain kinase (MLCK) 
[71-73]. The acute partial wrap restraint stress increased colonic permeability and rectal 
hypersensitivity via epithelial cell cytoskeleton contraction through myosin light chain 
kinase activation [74]. Acute immobilization stress also induced an increase in TJ 
permeability in the rat terminal ileum. These changes were mainly due to irregularly 
distribution of TJ transmembrane protein occludin and of the plaque protein ZO-1 which 
were seen after 2 hours from the stress induction and returned to a normal pattern within 
24 hours [70]. Mazzon and Cuzzocrea [75] also suggested that TNF-α has active roles in 
the increase of tight junction permeability during acute restraint stress. They 
demonstrated in vivo in a TNF-α R1 knock-out mouse (TNF-α R1KO) model of restraint 
stress that the inhibition of TNF-α attenuates the development of TJ alteration in the 
ileum. Restraint stress caused the increase of heat shock protein-70 expression and 
associated decrease in the expression of type 1 (ZO-1) protein in the colonic epithelium of 
mice. These stress-induced changes can be inhibited by the glucocorticoid receptor 
antagonist mifepristone [76]. However, Boivin et al. [77] reported that glucocorticoids 
enhanced epithelial barrier function by suppressing transcription of myosin light chain 
kinase. Bacterial pathogens target tight junctions and breach epithelial integrity to 
promote colonization, obtain nutrients and access the underlying tissues [23]. So, 
alterations in gastrointestinal microbiota induced by several stressors or exogenous 
glucocorticoids might be an important threat for the barrier disruption. 
6. Fluid and ion secretion 
Due to their diluting and flushing effects, fluid and ion secretion of epithelial cells is another 
protective mechanism contributing to the barrier function [20]. In humans, the jejunal net 
water and sodium chloride absorption decreased during both psychological (induced by 
dichotomous listening) [78] and physical stress (induced by cold pain) [79], and also ion 
absorption is changed toward secretion in psychological form [78]. Both acute and chronic 
stress inductions increased short circuit current (an in vitro technique used for measuring the 
secretory response of intestines) in several parts of rodent intestines [36,41,59,80]. In 
addition, the peripheral non-selective CRF antagonists astressin or α-helical CRF9-41 
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abolished stress- induced alterations [41,80,81]. Intraperitoneal injection of a newly 
developed selective CRF(1) peptide agonist cortagine also induced an increase in defecation 
and watery diarrhea in mice and rats [82]. The effects of mineralocorticoids and 
glucocorticoids on intestinal water and ion movements are well known. Methylprednisolone 
for 3 days increased Na+K+adenosinetriphosphatase activity and Na+ absorption [83]; it also 
increased guanylate cyclase activity and Cl- secretion in the jejunum and ileum 6 h after 
administration [84,85]. However, there is no direct information about the increase of water 
and ion secretion related with increased glucocorticoid secretions in different stressful 
conditions. 
7. Intestinal permeability and mast cell functions 
An increase in intestinal permeability was reported in animals [61,86] and humans [87] 
submitted to acute or chronic stress, and in IBD and IBS patients [88,89]. Increase of 
intestinal permeability or macromolecular permeability also involves mucosal 
inflammation, mucosal damage, and mast cell hyperactivity. The barrier properties of the 
intestinal epithelium are usually studied by assessing the permeability to various 
probe/marker molecules (such as horseradishperoxidase, 51Cr-EDTA, mannitol) in vivo or in 
vitro with intestinal segments mounted in Ussing-type chambers [20]. Bagchi et al [90] 
investigated the effects of acute (90 minute by water immersion) and chronic (15 min/day for 
15 consecutive days by water immersion) stress on the production of reactive oxygen species 
(ROS) and oxidative tissue damage in gastric and intestinal mucosa. Both acute and chronic 
stress increased ROS production, lipid peroxidation and DNA fragmentation in both gastric 
and intestinal mucosa, but acute stress produced greater injury when compared to chronic 
stress. Colonic myeloperoxidase, mucosal mast cell activity and colonic permeability 
increased (as assessed with macroscopic damage and bacterial translocation to mesenteric 
lymph nodes, liver and spleen) at 12 weeks-period in maternally deprived rat pups induced 
by separation from their mothers on 2-14 days period for 3 hours a day [91]. Besides, the 
responses of maternally deprived rats to the TNBS-induced colitis were more prominent 
compared with the control rats. Both acute and chronic cold stress could cause oxidative 
stress of duodenum and a change in iNOS, which was related to the intestinal damage 
process in broiler chicks [92]. There are also evidences about the bacterial production of 
iNOS [93]. Boudry et al [58] suggested that both apoptosis in the crypts and an immature 
epithelium covering the villus surface can be responsible for a barrier defect in rats 
submitted to WAS (1 h/day) for 5 or 10 days. Morphologic [39,94] and enzymatic alterations 
[40] in mitochondria of the intestinal epithelium can also participate to promotion of 
intestinal dysfunctions in stress-induced animals. 
Mast cell activity of gastrointestinal mucosa has altered in both acute and chronic stress 
models. They contain inflammatory and immunmodulating mediators such as 
prostaglandins, histamine and serotonin that directly alter epithelial transport properties 
[80] and nerve and muscle functions [95]. So it has a pivotal role in visceral hypersensivity 
[34], intestinal inflammation, intestinal mucin secretion [96] and epithelial barrier 
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disruption [20,61]. Castagliuolo et al. [96] found that mast cells are essential for the colonic 
mucin and prostaglandin secretions in immobilization stressed mice, because of these 
secretions were absent in mast-cell deficient animals. Even, reconstitution of bone marrow 
with mast cells reversed that response to normal stress values [96]. Mast cell-deficient rats 
(Ws/Ws) and their normal mast cell-containing littermates (1/1) were submitted to water 
avoidance (1 h/day) or sham stress for 5 consecutive days. Stress increased baseline jejunal 
epithelial ion secretion, ionic permeability, macromolecular permeability [61,94], and the 
number and proportion of mucosal mast cells [94] in 1/1 rats but not in Ws/Ws rats, 
compared with non-stressed controls. Morphological, inflammatory and permeability 
changes were not seen in ileum and colon of mast cell-deficient rats in a chronic stress 
model [42]. Kim et al [97] reported that acute stress increased mast cell number and 
mucosal proteinase-activated receptor-2 (PAR2) expression (G-protein coupled receptor 
which can be activated by mast cell tryptase and modulate gastrointestinal functions) in the 
rat colon. Because of CRF-antagonist astressin inhibited these alterations, they suggested 
that CRF can be mediator of these events. Dexamethasone treatment improves PAR-2 
agonist-induced visceral hypersensitivity, but does not prevent PAR-2 agonist-induced 
increase in colonic permeability in rats. This effect is coupled with a reduction of colonic 
mast cell numbers and RMCP-II contents [98]. Chronic stressful stimulus also caused 
greatest numbers of degranulated mast cells [99] and mast cell hyperplasia in the intestine 
of rats [100]. In our unpublished study, we found that while acute cold swimming stress 
(swimming in 18 0C water, for 15 min) increased the mucosal mast cell numbers in ileum, 
dexamethasone decreased their numbers significantly. It has been reported that mast cell 
numbers and their protease II activity were decreased in different dexamethasone 
treatments [98,101,102]. Wrap restraining stress in rats for 2 hours increased histamine 
content in colonic mast cells without degranulation, and this was found to be mediated by 
interleukin I and CRF [103]. Santos et al [80] reported that CRH, when injected 
intraperitoneally, mimicked the effects of acute restraint stress on colon epithelium such as 
increased colonic ion secretion, macromolecular permeability via cholinergic and 
adrenergic nerves and mast cells. Because CRH-induced alterations in colon epithelium 
inhibited by CRH-antagonist, adrenergic, nicotinic and muscarinic receptor antagonists 
and mast cell stabilizing agent doxantrazole, but not by aminoglutethimide 
(mineralcorticoid and glucocorticoid synthesis blocker, they suggested that steroids have 
no role in CRH-induced colonic pathology. They also denoted that stimulatory effects of 
CRH on mast cells can be mediated by direct or indirect neural pathways. Also in humans, 
CRH mediates transcellular uptake of HRP in colonic mucosal biopsy samples via CRH 
receptor subtypes R1 and R2 on subepithelial mast cells [104].  
8. Mucin – Physicochemical barrier 
Mucin secretion is also a major component of intestinal barrier which protects the mucosa by 
forming a coating layer over the epithelium against bacterial penetration. In addition to 
providing a biophysical barrier, mucus forms a matrix that allows the retention of high 
concentrations of specific and nonspecific antimicrobial molecules, such as secretory IgA and 
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defensins in close proximity to the epithelial surface [23,105,106]. The secreted mucus forms 
two layers, a thinner inner layer that is accepted to be sterile and difficult to dislodge and an 
outer layer that is not sterile and is more easily removed. Mainly MUC2 type mucin is 
synthesized from goblet cells in small and large intestines. Epithelial cells and Paneth cells 
secrete antimicrobial peptides that help preventing of bacteria to penetrate the inner mucus 
layer. Both the physicochemical structure and thickness of mucin coating show differences 
through the gastrointestinal canal. It was suggested that mucus thickness is increased and the 
increase was correlated with luminal bacterial concentrations of related parts of 
gastrointestinal canal. The inner layer is ~15–30 μm and the outer layer is 100–400 μm in 
small intestine and it is thickest in ileum because there are approximately 105–107 bacteria per 
gram of faeces in the lumen. Otherwise, the inner layer of ~100 μm and a thick outer layer of 
~700 μm in large intestine where 1010–1012 bacteria per gram of luminal content resides [106]. 
Mucin is not only a barrier against the bacteria but also nutritional source for bacteria. In 
addition, bacteria capable of colonizing mucus can avoid rapid expulsion via peristalsis of the 
intestine and take an advantage for transmitting their signaling pathway to the host [107]. 
Microbiota can stimulate mucin secretion via bacterial products and increase MUC2 
expression via activation of TLRs and NOD-like receptors or other signaling pathways at 
transcriptional level. Mucin secretion is also influenced by hormones, inflammatory 
mediators, several signaling peptides, growth factors and infectious bacteria [106,107]. 
Castagliuolo et al. [108] reported that acute stress caused a depletion of goblet cells and an 
increase of mucin secretion related with decrease of mucin containing goblet cell numbers via 
an increase of CRF secretion [20]. They proposed that although rapid mucin release during 
acute stress would increase the barrier properties and provide a degree of protection against 
invasion of a leaky epithelium, goblet cell depletion would be deleterious in a longer time 
period because of the reduced capacity to respond to ongoing or new threats. A 10-day 
chronic stress model was resulted in barrier dysfunction in the ileum and colon (increased 
macromolecular permeability and depletion of mucus) and ultrastructural changes in 
epithelial cells (enlarged mitochondria and presence of autophagosomes) associated with 
bacterial adhesion and their penetration into enterocytes [42]. Studies revealed that CRF 
signaling can activate mucin secretion because goblet cells have CRF1 receptors and stress 
and peripheral injection of CRF induces mucus depletion in rat distal colon [18]. On the other 
hand, maternal separation stress increased mucus secretion and thus caused an elevation in 
the number of mucosal goblet cells in rats [109]. In our unpublished study, both acute cold 
swimming stress and dexamethasone injection increased the goblet cell counts in the ileum 
within six hours, but the effects of dexamethasone were more prominent than the swimming 
stress. Further, while the effect of the dexamethasone on goblet cells maintained in 24 hours 
period that of swimming stress was disappeared [Ünsal et al., unpublished data]. Finnie et al. 
[110] reported that exogenous prednisolone and hydrocortisone also increased the mucin 
secretion significantly in left slightly and in right uninvolved colonic biopsies of patients with 
ulcerative colitis. They suggested that therapeutic effects of corticosteroids in ulcerative colitis 
may be related partly with their stimulatory effects on mucin synthesis. 
As partly mentioned above, most stress-induced gastrointestinal (GI) dysfunctions can be 
induced by peripheral CRF agonists and prevented by CRF receptor antagonists [18]. In a 
 
Glucocorticoids – New Recognition of Our Familiar Friend 116 
disruption [20,61]. Castagliuolo et al. [96] found that mast cells are essential for the colonic 
mucin and prostaglandin secretions in immobilization stressed mice, because of these 
secretions were absent in mast-cell deficient animals. Even, reconstitution of bone marrow 
with mast cells reversed that response to normal stress values [96]. Mast cell-deficient rats 
(Ws/Ws) and their normal mast cell-containing littermates (1/1) were submitted to water 
avoidance (1 h/day) or sham stress for 5 consecutive days. Stress increased baseline jejunal 
epithelial ion secretion, ionic permeability, macromolecular permeability [61,94], and the 
number and proportion of mucosal mast cells [94] in 1/1 rats but not in Ws/Ws rats, 
compared with non-stressed controls. Morphological, inflammatory and permeability 
changes were not seen in ileum and colon of mast cell-deficient rats in a chronic stress 
model [42]. Kim et al [97] reported that acute stress increased mast cell number and 
mucosal proteinase-activated receptor-2 (PAR2) expression (G-protein coupled receptor 
which can be activated by mast cell tryptase and modulate gastrointestinal functions) in the 
rat colon. Because of CRF-antagonist astressin inhibited these alterations, they suggested 
that CRF can be mediator of these events. Dexamethasone treatment improves PAR-2 
agonist-induced visceral hypersensitivity, but does not prevent PAR-2 agonist-induced 
increase in colonic permeability in rats. This effect is coupled with a reduction of colonic 
mast cell numbers and RMCP-II contents [98]. Chronic stressful stimulus also caused 
greatest numbers of degranulated mast cells [99] and mast cell hyperplasia in the intestine 
of rats [100]. In our unpublished study, we found that while acute cold swimming stress 
(swimming in 18 0C water, for 15 min) increased the mucosal mast cell numbers in ileum, 
dexamethasone decreased their numbers significantly. It has been reported that mast cell 
numbers and their protease II activity were decreased in different dexamethasone 
treatments [98,101,102]. Wrap restraining stress in rats for 2 hours increased histamine 
content in colonic mast cells without degranulation, and this was found to be mediated by 
interleukin I and CRF [103]. Santos et al [80] reported that CRH, when injected 
intraperitoneally, mimicked the effects of acute restraint stress on colon epithelium such as 
increased colonic ion secretion, macromolecular permeability via cholinergic and 
adrenergic nerves and mast cells. Because CRH-induced alterations in colon epithelium 
inhibited by CRH-antagonist, adrenergic, nicotinic and muscarinic receptor antagonists 
and mast cell stabilizing agent doxantrazole, but not by aminoglutethimide 
(mineralcorticoid and glucocorticoid synthesis blocker, they suggested that steroids have 
no role in CRH-induced colonic pathology. They also denoted that stimulatory effects of 
CRH on mast cells can be mediated by direct or indirect neural pathways. Also in humans, 
CRH mediates transcellular uptake of HRP in colonic mucosal biopsy samples via CRH 
receptor subtypes R1 and R2 on subepithelial mast cells [104].  
8. Mucin – Physicochemical barrier 
Mucin secretion is also a major component of intestinal barrier which protects the mucosa by 
forming a coating layer over the epithelium against bacterial penetration. In addition to 
providing a biophysical barrier, mucus forms a matrix that allows the retention of high 
concentrations of specific and nonspecific antimicrobial molecules, such as secretory IgA and 
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defensins in close proximity to the epithelial surface [23,105,106]. The secreted mucus forms 
two layers, a thinner inner layer that is accepted to be sterile and difficult to dislodge and an 
outer layer that is not sterile and is more easily removed. Mainly MUC2 type mucin is 
synthesized from goblet cells in small and large intestines. Epithelial cells and Paneth cells 
secrete antimicrobial peptides that help preventing of bacteria to penetrate the inner mucus 
layer. Both the physicochemical structure and thickness of mucin coating show differences 
through the gastrointestinal canal. It was suggested that mucus thickness is increased and the 
increase was correlated with luminal bacterial concentrations of related parts of 
gastrointestinal canal. The inner layer is ~15–30 μm and the outer layer is 100–400 μm in 
small intestine and it is thickest in ileum because there are approximately 105–107 bacteria per 
gram of faeces in the lumen. Otherwise, the inner layer of ~100 μm and a thick outer layer of 
~700 μm in large intestine where 1010–1012 bacteria per gram of luminal content resides [106]. 
Mucin is not only a barrier against the bacteria but also nutritional source for bacteria. In 
addition, bacteria capable of colonizing mucus can avoid rapid expulsion via peristalsis of the 
intestine and take an advantage for transmitting their signaling pathway to the host [107]. 
Microbiota can stimulate mucin secretion via bacterial products and increase MUC2 
expression via activation of TLRs and NOD-like receptors or other signaling pathways at 
transcriptional level. Mucin secretion is also influenced by hormones, inflammatory 
mediators, several signaling peptides, growth factors and infectious bacteria [106,107]. 
Castagliuolo et al. [108] reported that acute stress caused a depletion of goblet cells and an 
increase of mucin secretion related with decrease of mucin containing goblet cell numbers via 
an increase of CRF secretion [20]. They proposed that although rapid mucin release during 
acute stress would increase the barrier properties and provide a degree of protection against 
invasion of a leaky epithelium, goblet cell depletion would be deleterious in a longer time 
period because of the reduced capacity to respond to ongoing or new threats. A 10-day 
chronic stress model was resulted in barrier dysfunction in the ileum and colon (increased 
macromolecular permeability and depletion of mucus) and ultrastructural changes in 
epithelial cells (enlarged mitochondria and presence of autophagosomes) associated with 
bacterial adhesion and their penetration into enterocytes [42]. Studies revealed that CRF 
signaling can activate mucin secretion because goblet cells have CRF1 receptors and stress 
and peripheral injection of CRF induces mucus depletion in rat distal colon [18]. On the other 
hand, maternal separation stress increased mucus secretion and thus caused an elevation in 
the number of mucosal goblet cells in rats [109]. In our unpublished study, both acute cold 
swimming stress and dexamethasone injection increased the goblet cell counts in the ileum 
within six hours, but the effects of dexamethasone were more prominent than the swimming 
stress. Further, while the effect of the dexamethasone on goblet cells maintained in 24 hours 
period that of swimming stress was disappeared [Ünsal et al., unpublished data]. Finnie et al. 
[110] reported that exogenous prednisolone and hydrocortisone also increased the mucin 
secretion significantly in left slightly and in right uninvolved colonic biopsies of patients with 
ulcerative colitis. They suggested that therapeutic effects of corticosteroids in ulcerative colitis 
may be related partly with their stimulatory effects on mucin synthesis. 
As partly mentioned above, most stress-induced gastrointestinal (GI) dysfunctions can be 
induced by peripheral CRF agonists and prevented by CRF receptor antagonists [18]. In a 
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review article Larauche et al [18] reported about “CRF signaling” and emphasized that 
peripheral injection of CRF or urocortin stimulates colonic transit, motility, Fos expression in 
myenteric neurons, and defecation through activation of CRF1 receptors, whereas it decreases 
ileal contractility via CRF2 receptors. Additionally, intraperitoneal administration of CRF 
induces colonic mast cells degranulation via both CRF1 and CRF2 receptors and increases ion 
secretion and mucosal permeability to macromolecules, which can in turn promote intestinal 
inflammation and alters visceral sensitivity. Furthermore, CRF peptides can reproduce 
secretomotor and mucosal alterations in vitro. Although there are a lot of events that CRF is 
primary mediator in stress-induced alterations of GIS in animals and humans [17,18,32,80-
82,111], similar reports for the glucocorticoids are limited [28-30]. Meddings and Swain [28] 
reported that stress-induced increases in gastrointestinal epithelial permeability seemed to be 
mediated by adrenal corticosteroids and disappeared after adrenalectomy or pharmacologic 
blockade of glucocorticoid receptors. Besides, dexamethasone treatment of control animals 
increased gastrointestinal permeability and mimicked the effects of stress. Spitz et al. [29,30] 
evaluated the effects of dexamethasone on intestinal barrier functions in various conditions 
such as starvation and after bacterial contamination. They found that starvation significantly 
impairs secretory IgA, promotes bacterial adherence to the mucosa and increases intestinal 
permeability to f-MLP in rats given 0.8 mg/kg dexamethasone intraperitoneally. These effects 
are significantly attenuated by the feeding of rat chow [30]. In other study, they also found out 
that dexamethasone administration increased intestinal permeability and bacterial adherence 
to the mucosa [29]. However, antibiotic decontamination of the intestine completely abrogated 
the intestinal permeability defects observed in this model. Basing these findings they 
concluded that bacterial-mucosal cell interactions may be responsible for alterations in 
intestinal permeability after dexamethasone administration. 
9. Intestinal immune system 
Intestinal homeokinesis depends on complex interactions between the microbiota, the 
intestinal epithelium and the host immune system. Innate and acquired immune cells of the 
intestine have critical roles in barrier function because of they should tolerate the antigens 
belonging to the food and commensal microbiota as well as they should protect the body 
against pathogen microorganisms [20,57]. Systemic nonresponsiveness to antigens that are 
introduced orally is a phenomenon known as “oral tolerance”. Oral tolerance is typically 
characterized by the suppression of the systemic T helper 1 (Thl) response to antigens and 
elevated levels of IL-I0, TGF-β and antigen-specific sIgA at the mucosal surface. The T 
helper 2 (Th2) response also promotes the induction of tolerance in the gut. Production of 
IL-4 and IL- 5 during Th2 response acts synergistically to enhance IgA production. These 
cytokines also act further to inhibit the Thl response [57]. The cells of the innate immunity 
discriminate potentially pathogenic microbes from harmless antigens through pattern 
recognition receptors (PRR). Toll-like receptors (TLRs) are a family of pathogen-recognition 
receptors of the innate immune system. TLRs are present on a variety of cell types such as 
intestinal epithelium, monocytes, and dendritic cells. They recognize conserved molecular 
motifs on microorganisms called pathogen associated molecular patterns (PAMPS). TLRs 
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are activated by various components of microorganisms, e.g. TLR4 binds lipopolysaccharide 
(LPS) in gram-negative bacteria. Besides, TLR5 binds to flagellin, TLR2/6 binds to fungal 
zymosan and TLR7 binds single stranded RNA (ssRNA) from viruses. Activation of the 
TLRs by either pathogenic ligands or host factors results in downstream activation or 
inhibition of pathways involved in inflammation. Toll-like receptor activation by 
commensal bacteria plays an essential role in maintaining colonic homeostasis and 
controlling tolerance in the gut [57,112,113,114]. However, inappropriate activation of their 
signaling pathways may lead to deleterious inflammation and tissue injury. TLRs have been 
implicated in the pathogenesis of many GI disorders [57,114]. Although intestinal immune 
system is thought to have a critical role in stress-induced alterations of GIS functions, the 
studies about this situation are limited as this also the case for other functions of GIS such as 
motility, secretion and permeability [18,115,116]. McKernan et al. [116] investigated for the 
first time the regulation of TLR expression in the colonic mucosa in two distinct chronic 
stress models; Wistar-Kyoto (WKY) rats and maternally separated rats where Sprague 
Dawley rats were used as controls. Significant increases are seen in the mRNA levels of 
TLR3, 4 and 5 in both the distal and proximal colonic mucosa of MS rats compared with 
controls. No significant differences were noted for TLR 2, 7, 9 and 10 while TLR 6 could not 
be detected in any samples in both rat strains. The WKY strain showed increased levels of 
mRNA expression of TLR3, 4, 5, 7, 8, 9 and 10 both in the distal and proximal colonic mucosa 
compared to the control animals of Sprague-Dawley strain. No significant differences in 
expression were found for TLR2 in all samples of both strains. These authors suggested that 
the up-regulation of TLR 4 and 5 may indicate increases in cytokine production in response to 
the increases in sensitivity to gut bacteria. In addition, they suggested that the observed 
differences in TLR expression activity between MS and WKY rats might be related with their 
different neuroendocrine responses or microbiota. In spleens isolated from mice subjected to 
chronic 12-hour daily physical restraint for two days, TLR-4 expression significantly 
increased, T helper 1 (Th1) cytokine IFN-γ and IL-2 levels were found to be decreased, but 
Th2 cytokine and IL-4 increased. They suggested that stress modulates the immune system 
through a TLR4-dependent mechanism, because TLR4-deficient mice are resistant to stress-
induced lymphocyte reduction and the restraint stress significantly inhibits changes of Th1 
and Th2 cytokines in TLR4-deficient mice compared with the wild type mice [117]. Repeated 
social defeat stress (SDR) has been shown to increase the expression of TLR2 and TLR4 [118] 
and can activate dendritic cells for enhanced cytokine secretion in response to TLR specific 
stimuli. Besides, glucocorticoid resistance was determined in CD11+ dendritic cells isolated 
from spleens of SDR mice, whereas under baseline conditions DCs are highly sensitive to 
glucocorticoids [119]. Glucocorticoids and catecholamines appear to be able to regulate the 
expression of certain TLRs [116]. Toll-like receptor agonist-induced cytokine (IL1b, IL6, IL8 
and TNF-α) release was markedly enhanced in stimulated whole blood samples from IBS 
patients compared with healthy controls. Plasma levels of cortisol, IL-6 and IL-8 were also 
significantly increased in IBS patients [120]. 
Chronic stress (induced by water avoidance stress for 1 hour/day for 10 consecutive days) 
induced the infiltration of neutrophils and mononuclear cells, and increased 
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review article Larauche et al [18] reported about “CRF signaling” and emphasized that 
peripheral injection of CRF or urocortin stimulates colonic transit, motility, Fos expression in 
myenteric neurons, and defecation through activation of CRF1 receptors, whereas it decreases 
ileal contractility via CRF2 receptors. Additionally, intraperitoneal administration of CRF 
induces colonic mast cells degranulation via both CRF1 and CRF2 receptors and increases ion 
secretion and mucosal permeability to macromolecules, which can in turn promote intestinal 
inflammation and alters visceral sensitivity. Furthermore, CRF peptides can reproduce 
secretomotor and mucosal alterations in vitro. Although there are a lot of events that CRF is 
primary mediator in stress-induced alterations of GIS in animals and humans [17,18,32,80-
82,111], similar reports for the glucocorticoids are limited [28-30]. Meddings and Swain [28] 
reported that stress-induced increases in gastrointestinal epithelial permeability seemed to be 
mediated by adrenal corticosteroids and disappeared after adrenalectomy or pharmacologic 
blockade of glucocorticoid receptors. Besides, dexamethasone treatment of control animals 
increased gastrointestinal permeability and mimicked the effects of stress. Spitz et al. [29,30] 
evaluated the effects of dexamethasone on intestinal barrier functions in various conditions 
such as starvation and after bacterial contamination. They found that starvation significantly 
impairs secretory IgA, promotes bacterial adherence to the mucosa and increases intestinal 
permeability to f-MLP in rats given 0.8 mg/kg dexamethasone intraperitoneally. These effects 
are significantly attenuated by the feeding of rat chow [30]. In other study, they also found out 
that dexamethasone administration increased intestinal permeability and bacterial adherence 
to the mucosa [29]. However, antibiotic decontamination of the intestine completely abrogated 
the intestinal permeability defects observed in this model. Basing these findings they 
concluded that bacterial-mucosal cell interactions may be responsible for alterations in 
intestinal permeability after dexamethasone administration. 
9. Intestinal immune system 
Intestinal homeokinesis depends on complex interactions between the microbiota, the 
intestinal epithelium and the host immune system. Innate and acquired immune cells of the 
intestine have critical roles in barrier function because of they should tolerate the antigens 
belonging to the food and commensal microbiota as well as they should protect the body 
against pathogen microorganisms [20,57]. Systemic nonresponsiveness to antigens that are 
introduced orally is a phenomenon known as “oral tolerance”. Oral tolerance is typically 
characterized by the suppression of the systemic T helper 1 (Thl) response to antigens and 
elevated levels of IL-I0, TGF-β and antigen-specific sIgA at the mucosal surface. The T 
helper 2 (Th2) response also promotes the induction of tolerance in the gut. Production of 
IL-4 and IL- 5 during Th2 response acts synergistically to enhance IgA production. These 
cytokines also act further to inhibit the Thl response [57]. The cells of the innate immunity 
discriminate potentially pathogenic microbes from harmless antigens through pattern 
recognition receptors (PRR). Toll-like receptors (TLRs) are a family of pathogen-recognition 
receptors of the innate immune system. TLRs are present on a variety of cell types such as 
intestinal epithelium, monocytes, and dendritic cells. They recognize conserved molecular 
motifs on microorganisms called pathogen associated molecular patterns (PAMPS). TLRs 
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are activated by various components of microorganisms, e.g. TLR4 binds lipopolysaccharide 
(LPS) in gram-negative bacteria. Besides, TLR5 binds to flagellin, TLR2/6 binds to fungal 
zymosan and TLR7 binds single stranded RNA (ssRNA) from viruses. Activation of the 
TLRs by either pathogenic ligands or host factors results in downstream activation or 
inhibition of pathways involved in inflammation. Toll-like receptor activation by 
commensal bacteria plays an essential role in maintaining colonic homeostasis and 
controlling tolerance in the gut [57,112,113,114]. However, inappropriate activation of their 
signaling pathways may lead to deleterious inflammation and tissue injury. TLRs have been 
implicated in the pathogenesis of many GI disorders [57,114]. Although intestinal immune 
system is thought to have a critical role in stress-induced alterations of GIS functions, the 
studies about this situation are limited as this also the case for other functions of GIS such as 
motility, secretion and permeability [18,115,116]. McKernan et al. [116] investigated for the 
first time the regulation of TLR expression in the colonic mucosa in two distinct chronic 
stress models; Wistar-Kyoto (WKY) rats and maternally separated rats where Sprague 
Dawley rats were used as controls. Significant increases are seen in the mRNA levels of 
TLR3, 4 and 5 in both the distal and proximal colonic mucosa of MS rats compared with 
controls. No significant differences were noted for TLR 2, 7, 9 and 10 while TLR 6 could not 
be detected in any samples in both rat strains. The WKY strain showed increased levels of 
mRNA expression of TLR3, 4, 5, 7, 8, 9 and 10 both in the distal and proximal colonic mucosa 
compared to the control animals of Sprague-Dawley strain. No significant differences in 
expression were found for TLR2 in all samples of both strains. These authors suggested that 
the up-regulation of TLR 4 and 5 may indicate increases in cytokine production in response to 
the increases in sensitivity to gut bacteria. In addition, they suggested that the observed 
differences in TLR expression activity between MS and WKY rats might be related with their 
different neuroendocrine responses or microbiota. In spleens isolated from mice subjected to 
chronic 12-hour daily physical restraint for two days, TLR-4 expression significantly 
increased, T helper 1 (Th1) cytokine IFN-γ and IL-2 levels were found to be decreased, but 
Th2 cytokine and IL-4 increased. They suggested that stress modulates the immune system 
through a TLR4-dependent mechanism, because TLR4-deficient mice are resistant to stress-
induced lymphocyte reduction and the restraint stress significantly inhibits changes of Th1 
and Th2 cytokines in TLR4-deficient mice compared with the wild type mice [117]. Repeated 
social defeat stress (SDR) has been shown to increase the expression of TLR2 and TLR4 [118] 
and can activate dendritic cells for enhanced cytokine secretion in response to TLR specific 
stimuli. Besides, glucocorticoid resistance was determined in CD11+ dendritic cells isolated 
from spleens of SDR mice, whereas under baseline conditions DCs are highly sensitive to 
glucocorticoids [119]. Glucocorticoids and catecholamines appear to be able to regulate the 
expression of certain TLRs [116]. Toll-like receptor agonist-induced cytokine (IL1b, IL6, IL8 
and TNF-α) release was markedly enhanced in stimulated whole blood samples from IBS 
patients compared with healthy controls. Plasma levels of cortisol, IL-6 and IL-8 were also 
significantly increased in IBS patients [120]. 
Chronic stress (induced by water avoidance stress for 1 hour/day for 10 consecutive days) 
induced the infiltration of neutrophils and mononuclear cells, and increased 
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myeloperoxidase (MPO) activity in ileum and colon mucosa, but these changes were not 
shown in mast cell deficient rats [42]. Similary, jejunal inflammatory cells such as 
neutrophils, eosinophils and mononuclear cells and expression of IL-4 (TH2 type cytokine) 
increased, while interferon–γ (IFN- γ) (TH1 type cytokine) decreased in same chronic stress 
model of rats. Treatment of stressed rats with an antagonist to CRH eliminated the 
manifestations of intestinal hypersensitivity [121].  
Velin et al [122] evaluated the M cell-containing follicle associated epithelium (specialized in 
antigen uptake) in acute and chronic stress conditions. Acute stress increased horseradish 
peroxidase (HRP) flux in villus as well as in follicle-associated epithelium (FAE), and 
chronic stress increased E. coli passage in follicle-associated epithelium whereas there was 
no significant increase in villus epithelium. In patients with Crohn’s disease (CD), 
transmucosal uptake of non-pathogenic E. coli across the FAE increased in ileum, despite 
unchanged macromolecular permeability, but these changes were not observed in patients 
with ulcerative colitis [123]. Recently, Keita [124] showed that application of CRF agonist 
increased HRP and E. coli passage, stress-induced increases in uptake across FAE of HRP, 
and E. coli were reduced by CRF antagonist, mast cell stabilizer and atropine. Chronic 
restraint stress increases eosinophils expressing CRF in the jejunum, which participate to the 
recruitment of mast cells and epithelial barrier dysfunction [125]. The influence of CRF 
signaling on intestinal mast cell activity is detailed above. However, the information about 
their effects on other immune components of intestine (such as intestinal epithelial cells, 
TLR expression or intraepithelial lymphocytes) is limited. Larauche et al [82] reported that 
treatment of mice with CRF-1 agonist cortagine exhibits a dose-related interferon-γ (IFNγ) 
response indicating T cell and/or natural killer (NK) cell activation, which is followed by 
tight junction deregulation and dose dependent apoptotic loss of different cell populations 
in ileum. 
IECs participate in initiating adaptive immune responses in the gut by transporting luminal 
antigens to underlying immune cells for presentation by professional antigen presenting 
cells or can present antigen themselves [57]. intraepithelial lymphocyte (IEL) and paneth 
cells (specialized IEC located at the base of intestinal crypts in small intestine) do also 
synthesis the antimicrobial peptides such as lysozymes, alpha defensins, cathelicidins, 
lipocalins, and C-type lectins such as RegIIIγ [126]. Production of RegIIIg [127] and alpha-
defensins [128] as well as that of secretory IgA [129] are induced by commensal bacteria. 
Nutritional and infection stress affected the secretory activity of Paneth cells in human [130]. 
In women, acute cold stress induced the release of α-defensin in the jejunum [131]. 
Evidences suggested that dysfunction of Paneth cells and impaired defensin secretion may 
contribute to IBD susceptibility [57,105]. 
Corticosteroids and catecholamines are well recognized and accepted powerful regulators 
and players of the body in its response to environmental challenges including biological 
factors of stress. Stress or corticosteroid applications are known to have also profound 
effects on intestinal wall structure and functioning. Intestinal submucosa is the place where 
lymphocytes, eosinophils and mast cells reside in men and animals under normal 
conditions. Jarillo-Luna et al. [115] investigated the effects of chronic restraint stress in mice 
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submitted to different procedures (adrenalectomy, chemical sympathectomy, and treatment 
with a glucocorticoid antagonist (RU486), dexamethasone, and epinephrine) on 
intraepithelial lymphocyte (IEL) numbers. They found that chronic restraint-stress reduced 
the IEL population in the small intestine and adrenal catecholamines and glucocorticoids are 
essential in preserving IEL population because adrenalectomy, treatment with RU-486 and 
chemical sympathectomy decreased the number of γδ, CD4+ and CD8+ T cells in non-
stressed groups. They also found that adrenalectomy did not buffered the stress-induced 
reduction in CD8 lympocytes, but glucocorticoid receptor antagonist RU-486 buffered 
stress-induced decrease in γδ and CD8+, but not in CD4+ T cells. Besides, low and high 
doses of dexamethasone (5 and 50 mg/kg BW) significantly reduced the number of γδ and 
CD8+ T cells, and epinefrin (0.1-0.5 mg/kg) reduced the number of γδ, CD4+ and CD8+ T 
cells in intact mice. Also many other studies reported that both stress-related endogen rises 
of glucocorticoids [115,132-134] and exogenous glucocorticoid administrations [135,136] 
induce decreases in intraepithelial lymphocytes and/or those in ileal Peyer patches. 
Pretreatment with glucocorticoid receptor antagonist mifepristone significantly reduced 
apoptosis in both T- and B-cell populations in intraepithelial lymphocytes after the burn 
injury [133]. Experimental studies also suggested that single or repeated parenteral 
applications of cortisone cause a decrease in eosinophil concentration in all parts of 
examined gastrointestinal wall from stomach up to colon [137,138]. Immunosuppressive 
effects of glucocorticoids are explained mainly by an increase of apoptosis and a decrease of 
cytokine production. Corticosterone impaired the maturation of DCs and cytokine 
production and reduced the ability of DCs to prime naive CD8+ T cells in vivo; there was no 
reduction in surface TLR4 expression in CORT-treated DCs [139]. However, McEwen et al. 
[140] proposed that although glucocorticoids are mainly known with and used widely for 
their immunsuppressive aspects, adrenal steroids play also different roles as important 
modulators of the immune system. Pharmacological as well as physiological changes in 
glucocorticoids result in a decrease in lymphocyte, monocyte and eosinophil numbers and 
an increase in neutrophil numbers in the blood of men and rodents. These changes are not 
related with the glucocorticoid-induced leukocyte deaths. The nonspecific stress and 
glucocorticoid administration cause redistribution of leukocytes from peripheral blood into 
various tissues and organs, such as bone marrow, spleen and lymph nodes [140-142]. 
10. Intestinal microbiota 
One of the important groups of the environmental biological stressors belongs to the 
microbiota, and it is associated with every multicellular organism on earth. It is estimated 
that in humans and many animals reside at least 1014 microorganisms, making 
approximately 1.5 kg biomass, in various parts of the body, most abundant of them residing 
the distal part of the gut in humans and animals with exception of ruminants [143-146]. 
These parts of the body lined by the skin or mucous membranes and all are in direct contact 
with the environment. Although the microorganisms are preferable grouped as pathogenic, 
while they harm the multicellular organisms, and saprophytic, while they seemingly do not 
harm their hosts instead they build symbiotic relationships, but possibly this depends only 
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myeloperoxidase (MPO) activity in ileum and colon mucosa, but these changes were not 
shown in mast cell deficient rats [42]. Similary, jejunal inflammatory cells such as 
neutrophils, eosinophils and mononuclear cells and expression of IL-4 (TH2 type cytokine) 
increased, while interferon–γ (IFN- γ) (TH1 type cytokine) decreased in same chronic stress 
model of rats. Treatment of stressed rats with an antagonist to CRH eliminated the 
manifestations of intestinal hypersensitivity [121].  
Velin et al [122] evaluated the M cell-containing follicle associated epithelium (specialized in 
antigen uptake) in acute and chronic stress conditions. Acute stress increased horseradish 
peroxidase (HRP) flux in villus as well as in follicle-associated epithelium (FAE), and 
chronic stress increased E. coli passage in follicle-associated epithelium whereas there was 
no significant increase in villus epithelium. In patients with Crohn’s disease (CD), 
transmucosal uptake of non-pathogenic E. coli across the FAE increased in ileum, despite 
unchanged macromolecular permeability, but these changes were not observed in patients 
with ulcerative colitis [123]. Recently, Keita [124] showed that application of CRF agonist 
increased HRP and E. coli passage, stress-induced increases in uptake across FAE of HRP, 
and E. coli were reduced by CRF antagonist, mast cell stabilizer and atropine. Chronic 
restraint stress increases eosinophils expressing CRF in the jejunum, which participate to the 
recruitment of mast cells and epithelial barrier dysfunction [125]. The influence of CRF 
signaling on intestinal mast cell activity is detailed above. However, the information about 
their effects on other immune components of intestine (such as intestinal epithelial cells, 
TLR expression or intraepithelial lymphocytes) is limited. Larauche et al [82] reported that 
treatment of mice with CRF-1 agonist cortagine exhibits a dose-related interferon-γ (IFNγ) 
response indicating T cell and/or natural killer (NK) cell activation, which is followed by 
tight junction deregulation and dose dependent apoptotic loss of different cell populations 
in ileum. 
IECs participate in initiating adaptive immune responses in the gut by transporting luminal 
antigens to underlying immune cells for presentation by professional antigen presenting 
cells or can present antigen themselves [57]. intraepithelial lymphocyte (IEL) and paneth 
cells (specialized IEC located at the base of intestinal crypts in small intestine) do also 
synthesis the antimicrobial peptides such as lysozymes, alpha defensins, cathelicidins, 
lipocalins, and C-type lectins such as RegIIIγ [126]. Production of RegIIIg [127] and alpha-
defensins [128] as well as that of secretory IgA [129] are induced by commensal bacteria. 
Nutritional and infection stress affected the secretory activity of Paneth cells in human [130]. 
In women, acute cold stress induced the release of α-defensin in the jejunum [131]. 
Evidences suggested that dysfunction of Paneth cells and impaired defensin secretion may 
contribute to IBD susceptibility [57,105]. 
Corticosteroids and catecholamines are well recognized and accepted powerful regulators 
and players of the body in its response to environmental challenges including biological 
factors of stress. Stress or corticosteroid applications are known to have also profound 
effects on intestinal wall structure and functioning. Intestinal submucosa is the place where 
lymphocytes, eosinophils and mast cells reside in men and animals under normal 
conditions. Jarillo-Luna et al. [115] investigated the effects of chronic restraint stress in mice 
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submitted to different procedures (adrenalectomy, chemical sympathectomy, and treatment 
with a glucocorticoid antagonist (RU486), dexamethasone, and epinephrine) on 
intraepithelial lymphocyte (IEL) numbers. They found that chronic restraint-stress reduced 
the IEL population in the small intestine and adrenal catecholamines and glucocorticoids are 
essential in preserving IEL population because adrenalectomy, treatment with RU-486 and 
chemical sympathectomy decreased the number of γδ, CD4+ and CD8+ T cells in non-
stressed groups. They also found that adrenalectomy did not buffered the stress-induced 
reduction in CD8 lympocytes, but glucocorticoid receptor antagonist RU-486 buffered 
stress-induced decrease in γδ and CD8+, but not in CD4+ T cells. Besides, low and high 
doses of dexamethasone (5 and 50 mg/kg BW) significantly reduced the number of γδ and 
CD8+ T cells, and epinefrin (0.1-0.5 mg/kg) reduced the number of γδ, CD4+ and CD8+ T 
cells in intact mice. Also many other studies reported that both stress-related endogen rises 
of glucocorticoids [115,132-134] and exogenous glucocorticoid administrations [135,136] 
induce decreases in intraepithelial lymphocytes and/or those in ileal Peyer patches. 
Pretreatment with glucocorticoid receptor antagonist mifepristone significantly reduced 
apoptosis in both T- and B-cell populations in intraepithelial lymphocytes after the burn 
injury [133]. Experimental studies also suggested that single or repeated parenteral 
applications of cortisone cause a decrease in eosinophil concentration in all parts of 
examined gastrointestinal wall from stomach up to colon [137,138]. Immunosuppressive 
effects of glucocorticoids are explained mainly by an increase of apoptosis and a decrease of 
cytokine production. Corticosterone impaired the maturation of DCs and cytokine 
production and reduced the ability of DCs to prime naive CD8+ T cells in vivo; there was no 
reduction in surface TLR4 expression in CORT-treated DCs [139]. However, McEwen et al. 
[140] proposed that although glucocorticoids are mainly known with and used widely for 
their immunsuppressive aspects, adrenal steroids play also different roles as important 
modulators of the immune system. Pharmacological as well as physiological changes in 
glucocorticoids result in a decrease in lymphocyte, monocyte and eosinophil numbers and 
an increase in neutrophil numbers in the blood of men and rodents. These changes are not 
related with the glucocorticoid-induced leukocyte deaths. The nonspecific stress and 
glucocorticoid administration cause redistribution of leukocytes from peripheral blood into 
various tissues and organs, such as bone marrow, spleen and lymph nodes [140-142]. 
10. Intestinal microbiota 
One of the important groups of the environmental biological stressors belongs to the 
microbiota, and it is associated with every multicellular organism on earth. It is estimated 
that in humans and many animals reside at least 1014 microorganisms, making 
approximately 1.5 kg biomass, in various parts of the body, most abundant of them residing 
the distal part of the gut in humans and animals with exception of ruminants [143-146]. 
These parts of the body lined by the skin or mucous membranes and all are in direct contact 
with the environment. Although the microorganisms are preferable grouped as pathogenic, 
while they harm the multicellular organisms, and saprophytic, while they seemingly do not 
harm their hosts instead they build symbiotic relationships, but possibly this depends only 
 
Glucocorticoids – New Recognition of Our Familiar Friend 122 
on the balance or imbalance among numerous groups of microorganisms constituting the 
microbiota in a definite part of the body and between the microbiota and its host, in general. 
The first days, weeks, months or years, the time spent in mothers’ womb or in egg-shall of 
the metazoan life is the only time which they are free of microbes. The delivery into the 
outside exposes them to an enormous range of microbes from diverse environments. This is 
the first encounters with life forms with different morphology and functions. The studies 
have shown that within a short time following delivery, the microrganisms are present on 
the skin and mucosal surfaces of the body. With time, a dense, complex gastrointestinal 
microbiota develops [147,148]. Due to the unique properties of microorganisms including 
their small size, metabolic versatility and genetic plasticity, microorganisms can tolerate and 
easily adapt to unfavorable and immense variety of continuously changing environmental 
conditions [149]. However, although a wide variety of microorganisms were exposed to 
representative individuals from start up throughout the life periods, only a limited numbers 
of species are able to colonize permanently in available body surfaces of man and animals. 
The microorganisms display a tissue tropism; e.g., they colonize predominantly only certain 
body sites. Consequently, each side is inhabited by only certain species of microorganisms. 
The microorganisms found at a particular body site constitute what is known as the 
indigenous or normal microbiota of this site, wherein the term ‘indigenous’ include all of 
viruses, protozoa, archae, and fungi [150,151]. The GIT is inhabited with 1013–1014 
microorganisms, approximately 500 to over 1000 different species and more than 7000 
strains. Their counts exceed ten times the numbers of somatic cells of their hosts [144,151-
154].  
The very complex and diverse gastro-intestinal microbiota differs from species to species, in 
dependence of nutritional habits with some geographic motives. Besides, it varies from one 
segment to another and varies over time in the same individual, because the environment of 
the GIT varies considerable along its length and with the lifetime of an individual [144]. 
Thus, the composition and intensity of the microbiota of a newborn is quite different from 
those of an adult which are in turn quite different from that of an elderly individual 
[155,156]. Colonization begins at birth with facultative bacteria and the colonization of 
anaerobic bacteria which are composed of more than %90 of GIS microbiota develops later. 
In humans, the microbiota has a stable adult-like signature by 1 year of age [113,154]. 
Similarly, the composition and intensity of the microbiota varies along the gastrointestinal 
tract where they are attached to the mucosa or are present in the contents. In stomach and 
duodenum of humans, microorganism numbers is 103CFU/ml and include more lactobacilli, 
streptococci and yeasts species. In jejunum (104CFU/ml) and ileum (107-8 CFU/ml) 
Lactobacillus, Bacteroides, Enterobacteriaceae, Streptococci, Bifidobacterium and Fusobacteria 
species are more existent. The highest numbers of bacteria (1011-12 CFU/ml) displaying 
enormous diversity are found in colon, predominant species being Bacteroides, Fusobacterium, 
Eubacterium,Peptococcus, Peptostreptococcus, Veillonella, Bifidobacterium, Escherichia, Clostridium, 
Lactobacillus and others [147,154]. Although only 40-45% part of GI microbiota could be 
growth with classical microbial culture tecniques, recently developed moleculer techniques 
allow the definition of non-culturable members of microbiota. The vast majority of 
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microorganisms belong to the phyla of Firmicutes, Bacteroidetes, Actinobacteria, and 
Proteobacteria while Fusobacteria, Verrucomicrobia and TM7 are represent in relatively lower 
numbers [144,145,157,158]. There are also some fungi and Archaea present in the 
gastrointestinal tract [144,159,160], but they comprise less than 1% of total inhabitants. The 
majority of the intestinal bacteria are composed of gram-negative anaerobes [143]. 
With the acquisition and establishment in the intestinal lumina with various microbial 
populations bidirectional interactions between microbiota and host organism starts 
[161,162]. There are symbiotic relationships between the host and its GI microbiota in 
steady-state conditions. The gastrointestinal tract serves a natural habitat for a dynamic 
microbial community of different origins while the microbiota is very essential for both 
gastrointestinal integrity [163] and general health of host organisms [113]. Comparison 
between the conventional and germ-free animals has allowed obtaining information about 
the effects of microbiota on morphologic, functional and metabolic characteristics of host 
organisms [23,113,154,160]. Germ free animals have enlarged cecum [164], they have thinner 
gut wall, smaller total surface area and more cubic epithelium than the columnar, increased 
enterochromaffin cell area and smaller Peyer’s patches, and intestinal epithelium has slower 
turnover rate compared with the conventional animals [160,165]. The materiality of the gut 
microbiota also for many gut functions such as motility, immune and barrier functions are 
reviewed by several authors [23,113]. 
Complex association between the host and its microbiota collectively extends the processing 
indigestible parts of food to the benefits of the host organisms via metabolic capacities which 
are not coded in host genomes like mammalian and avian species [166-168]. They digest the 
unusable parts of the diets; metabolites reach to the intestinal lumina within various 
secretions and desquamated cells of their hosts for growth and proliferation. At the same 
time, they also supply the host organisms with a considerable amount of nutrients, which 
makes this ecosystem an invaluable, essential metabolic organ, which contributes 
significantly to the homeokinesis of the host organisms [23,113,152,169]. They produce 
substances including vitamins, volatile or short-chain fatty acids (SCFAs) and polyamines 
which are absorbed throughout the intestinal wall and used directly by intestinal epithelial 
cells or other cells of the body [170,171]. SCFA profoundly influence gut barrier functions, 
host immunity, epithelial proliferation and bacterial pathogenesis [172]. Zheng et al. [171] 
showed extensive gut microbiota modulation of host systemic metabolism involving short-
chain fatty acids, tryptophan and tyrosine metabolism, and possibly a compensatory 
mechanism of indole-melatonin production. All these metabolites have also many 
regulatory functions in host organisms. Tryptophan and tyrosine are precursors of 
neurotransmitters acting directly at the central nervous system level [113]. Thus, the gut 
microbiota enhances the host’s metabolic capacity for processing nutrients and modulates 
the activities of multiple pathways in a variety of organ systems, including the brain. 
Microbiota acts as a luminal barrier against incoming pathogens; this phenomenon has been 
described as colonization resistance [23,154]. Beneficial and pathogen microorganism 
compete with each other for the attachment sites and for nutrients, so microbiota and their 
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on the balance or imbalance among numerous groups of microorganisms constituting the 
microbiota in a definite part of the body and between the microbiota and its host, in general. 
The first days, weeks, months or years, the time spent in mothers’ womb or in egg-shall of 
the metazoan life is the only time which they are free of microbes. The delivery into the 
outside exposes them to an enormous range of microbes from diverse environments. This is 
the first encounters with life forms with different morphology and functions. The studies 
have shown that within a short time following delivery, the microrganisms are present on 
the skin and mucosal surfaces of the body. With time, a dense, complex gastrointestinal 
microbiota develops [147,148]. Due to the unique properties of microorganisms including 
their small size, metabolic versatility and genetic plasticity, microorganisms can tolerate and 
easily adapt to unfavorable and immense variety of continuously changing environmental 
conditions [149]. However, although a wide variety of microorganisms were exposed to 
representative individuals from start up throughout the life periods, only a limited numbers 
of species are able to colonize permanently in available body surfaces of man and animals. 
The microorganisms display a tissue tropism; e.g., they colonize predominantly only certain 
body sites. Consequently, each side is inhabited by only certain species of microorganisms. 
The microorganisms found at a particular body site constitute what is known as the 
indigenous or normal microbiota of this site, wherein the term ‘indigenous’ include all of 
viruses, protozoa, archae, and fungi [150,151]. The GIT is inhabited with 1013–1014 
microorganisms, approximately 500 to over 1000 different species and more than 7000 
strains. Their counts exceed ten times the numbers of somatic cells of their hosts [144,151-
154].  
The very complex and diverse gastro-intestinal microbiota differs from species to species, in 
dependence of nutritional habits with some geographic motives. Besides, it varies from one 
segment to another and varies over time in the same individual, because the environment of 
the GIT varies considerable along its length and with the lifetime of an individual [144]. 
Thus, the composition and intensity of the microbiota of a newborn is quite different from 
those of an adult which are in turn quite different from that of an elderly individual 
[155,156]. Colonization begins at birth with facultative bacteria and the colonization of 
anaerobic bacteria which are composed of more than %90 of GIS microbiota develops later. 
In humans, the microbiota has a stable adult-like signature by 1 year of age [113,154]. 
Similarly, the composition and intensity of the microbiota varies along the gastrointestinal 
tract where they are attached to the mucosa or are present in the contents. In stomach and 
duodenum of humans, microorganism numbers is 103CFU/ml and include more lactobacilli, 
streptococci and yeasts species. In jejunum (104CFU/ml) and ileum (107-8 CFU/ml) 
Lactobacillus, Bacteroides, Enterobacteriaceae, Streptococci, Bifidobacterium and Fusobacteria 
species are more existent. The highest numbers of bacteria (1011-12 CFU/ml) displaying 
enormous diversity are found in colon, predominant species being Bacteroides, Fusobacterium, 
Eubacterium,Peptococcus, Peptostreptococcus, Veillonella, Bifidobacterium, Escherichia, Clostridium, 
Lactobacillus and others [147,154]. Although only 40-45% part of GI microbiota could be 
growth with classical microbial culture tecniques, recently developed moleculer techniques 
allow the definition of non-culturable members of microbiota. The vast majority of 
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microorganisms belong to the phyla of Firmicutes, Bacteroidetes, Actinobacteria, and 
Proteobacteria while Fusobacteria, Verrucomicrobia and TM7 are represent in relatively lower 
numbers [144,145,157,158]. There are also some fungi and Archaea present in the 
gastrointestinal tract [144,159,160], but they comprise less than 1% of total inhabitants. The 
majority of the intestinal bacteria are composed of gram-negative anaerobes [143]. 
With the acquisition and establishment in the intestinal lumina with various microbial 
populations bidirectional interactions between microbiota and host organism starts 
[161,162]. There are symbiotic relationships between the host and its GI microbiota in 
steady-state conditions. The gastrointestinal tract serves a natural habitat for a dynamic 
microbial community of different origins while the microbiota is very essential for both 
gastrointestinal integrity [163] and general health of host organisms [113]. Comparison 
between the conventional and germ-free animals has allowed obtaining information about 
the effects of microbiota on morphologic, functional and metabolic characteristics of host 
organisms [23,113,154,160]. Germ free animals have enlarged cecum [164], they have thinner 
gut wall, smaller total surface area and more cubic epithelium than the columnar, increased 
enterochromaffin cell area and smaller Peyer’s patches, and intestinal epithelium has slower 
turnover rate compared with the conventional animals [160,165]. The materiality of the gut 
microbiota also for many gut functions such as motility, immune and barrier functions are 
reviewed by several authors [23,113]. 
Complex association between the host and its microbiota collectively extends the processing 
indigestible parts of food to the benefits of the host organisms via metabolic capacities which 
are not coded in host genomes like mammalian and avian species [166-168]. They digest the 
unusable parts of the diets; metabolites reach to the intestinal lumina within various 
secretions and desquamated cells of their hosts for growth and proliferation. At the same 
time, they also supply the host organisms with a considerable amount of nutrients, which 
makes this ecosystem an invaluable, essential metabolic organ, which contributes 
significantly to the homeokinesis of the host organisms [23,113,152,169]. They produce 
substances including vitamins, volatile or short-chain fatty acids (SCFAs) and polyamines 
which are absorbed throughout the intestinal wall and used directly by intestinal epithelial 
cells or other cells of the body [170,171]. SCFA profoundly influence gut barrier functions, 
host immunity, epithelial proliferation and bacterial pathogenesis [172]. Zheng et al. [171] 
showed extensive gut microbiota modulation of host systemic metabolism involving short-
chain fatty acids, tryptophan and tyrosine metabolism, and possibly a compensatory 
mechanism of indole-melatonin production. All these metabolites have also many 
regulatory functions in host organisms. Tryptophan and tyrosine are precursors of 
neurotransmitters acting directly at the central nervous system level [113]. Thus, the gut 
microbiota enhances the host’s metabolic capacity for processing nutrients and modulates 
the activities of multiple pathways in a variety of organ systems, including the brain. 
Microbiota acts as a luminal barrier against incoming pathogens; this phenomenon has been 
described as colonization resistance [23,154]. Beneficial and pathogen microorganism 
compete with each other for the attachment sites and for nutrients, so microbiota and their 
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products can prevent pathogen colonization directly. On the other hand, microbiota acts on 
barrier functions also indirectly by stimulating mucosal immune system [172]. The abundant 
antigenic stimulus supplied by microbiota and their products are essential for the 
stimulation of immune system cells locally and systemically [173-175]. In germ-free animals, 
besides the poor developed Peyer’s patches, altered compositions of CD4+ T cells and IgA-
producing B cells in the lamina propria [165], TH 17 cells, which is a subset of the T cells and 
contribute to resistance against colonization by pathogens were virtually absent in germ free 
animals [176,177]. Chow and Mazmanian [177] denoted that although Th17 cells are 
essential for immunity, they have also been implicated in the pathogenesis of many 
autoimmune diseases, including IBD, arthritis, psoriasis, and experimental autoimmune 
encephalomyelitis (EAE). 
The gut microbiota has recently been identified as the main source of highest biological 
variability confined in an individual [178]. Because the metazoan life-forms and the 
inhabitation of their gastrointestinal tract with microorganisms evolved together, there are 
close links between any host or its epi-genome and its very complex diverse gastrointestinal 
microbiota with their multitude genomes. It is estimated that this microbial community has 
70–140 times more total genes than the human host. These functional inter-relationships 
between host and microbiota or two different genomes determine the health or disease state 
of the metazoan hosts and the balance among different microorganism populations 
[113,172,179]. It is well accepted that the intestinal microbiota involves in metabolome of the 
host, thus promotes actively fat accumulation and weight gain and sustains indirectly a low-
grade systemic inflammation especially when imbalanced, and consequently, enhances the 
risk for complex, multifactorial diseases such as insulin resistance, diabetes, obesity and 
cardiovascular diseases. The search of global obesity epidemic led to the growing evidences 
about the possible roles of intestinal microbiota in these respects [180,181,182]. Claus et al. 
[170] has noted that the colonization of the gut microbiota was associated with a rapid 
increase in body weights of animals up to 4% within 5 days of colonization. Findings of 
various studies also revealed that gut microbiota profile of obese and diabetic individuals 
differ by phylum level both in its quantity and quality from that of lean and nonobese 
individuals [182,183]. Recent evidences exhibit that the composition of the gut microbiome 
may influence body weight of the host by various mechanisms including enhancing the 
ability of intestines to extract energy from food [184], regulating fat storage in tissues [185] 
and affecting satiety by modulating the levels of local hormones that regulate satiety and by 
direct effects in central nervous system [186]. 
There is a growing appreciation of the critical roles played by the commensal microbiota, 
both in general well-being of the hosts and in the specific functioning of the brain–gut axis 
[113]. Bidirectional communications of brain–gut–enteric microbiota axis simply actualized 
by through signals from the brain can influence the motor, sensory, and secretory modalities 
of the gastrointestinal tract and conversely, visceral messages from the gastrointestinal tract 
can influence brain functions [187]. Sudo and colleagues [25] showed that gut microbiota 
effect the stress responses of host organisms. They compared the response of the HPA axis 
to stress in GF, specific pathogen free (SPF) and gnotobiotic mice that were mono-associated 
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with a single bacterium. Restraint stress caused an exaggerated ACTH and corticosterone 
elevation in GF rather than SPF mice. This hyper-response of the HPA axis was reversed by 
mono-association with Bifidobacterium infantis. They also showed in following experiments 
that the levels of brain-derived nerve factor (BDNF), norepinephrine and 5- 5-
hydroxytryptamine (5-HT) in the cortex and hippocampus were significantly lower in GF 
mice than in SPF mice [188]. Improvements of stress-related symptoms by probiotic 
administration also support the possible regulatory effects of microbiota on HPA axis and 
brain functions [44,189]. Gareau et al [44] reported that probiotic treatments improved colonic 
dysfunction and corrected the higher corticosterone levels in stressed rats induced by 
maternal seperation. L. rhamnosus (JB-1) reduced stress-induced corticosterone and anxiety- 
and depression-related behavior in mice. In different region of brain, this therapy also altered 
GABA receptor expression implicated in the pathogenesis of anxiety and depression, which 
are highly comorbid with functional bowel disorders. Due to the neurochemical and 
behavioral effects were not found in vagotomized mice, they suggested that vagus could be 
a major modulatory constitutive communication pathway between the bacteria exposed to 
the gut and the brain [189]. The roles of probiotics and gut microbiota in modulation of 
visceral and even somatic pain perception and their possible roles in alterations of mood 
and behavior were reviewed by Forsythe et al. [190] and Grenham et al. [113]. 
As mentioned above, intestinal dysbiosis can adversely influence gut physiology both by 
direct effects to the surrounding gut wall and by leading to inappropriate brain–gut axis 
signaling and associated consequences for CNS functions and disease states. Stress at the 
level of the CNS can also impact on gut functions and lead to perturbations of the 
microbiota [113]. 
11. Stress and intestinal microbiota 
Intestinal microbiota have once been seen as potential treat for the host organisms, but 
recently accepted as an integral part of metazoan life and even as an organ with a huge 
variety of building blocks which mainly cooperate with each other and with the host for 
maintaining the health and survival [113,144]. However, various stress factors such as heat, 
cold, nutritional alterations, overcrowding, physical restraints and transporting or fouled or 
contaminated foods can destroy the microbial balance in the gastrointestinal system 
[66,67,191-195] and alter their relationships with each other and with their hosts. Stressful 
stimuli can affect gastrointestinal microbiota directly, for example via limited availability of 
food ingredients or direct actions of stress mediators such as adrenaline or noradrenaline on 
microbiota [27,196], and indirectly via altering the intestinal environment of bacteria such as 
intestinal secretion, motility, permeability and immune functions as reviewed above. 
The effects of several stressors and stress mediators on intestinal microbiota were given in 
Table 1. Bailey et al [197] induced social disruption stress (SDR) in mice to determine 
whether the microbiome contributes to stressor-induced immune enhancements. They 
analyzed bacterial populations in the cecum with using bacterial tag-encoded FLX amplicon 
pyrosequencing (bTEFAP) and found that microbiota significantly changed immediately 
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products can prevent pathogen colonization directly. On the other hand, microbiota acts on 
barrier functions also indirectly by stimulating mucosal immune system [172]. The abundant 
antigenic stimulus supplied by microbiota and their products are essential for the 
stimulation of immune system cells locally and systemically [173-175]. In germ-free animals, 
besides the poor developed Peyer’s patches, altered compositions of CD4+ T cells and IgA-
producing B cells in the lamina propria [165], TH 17 cells, which is a subset of the T cells and 
contribute to resistance against colonization by pathogens were virtually absent in germ free 
animals [176,177]. Chow and Mazmanian [177] denoted that although Th17 cells are 
essential for immunity, they have also been implicated in the pathogenesis of many 
autoimmune diseases, including IBD, arthritis, psoriasis, and experimental autoimmune 
encephalomyelitis (EAE). 
The gut microbiota has recently been identified as the main source of highest biological 
variability confined in an individual [178]. Because the metazoan life-forms and the 
inhabitation of their gastrointestinal tract with microorganisms evolved together, there are 
close links between any host or its epi-genome and its very complex diverse gastrointestinal 
microbiota with their multitude genomes. It is estimated that this microbial community has 
70–140 times more total genes than the human host. These functional inter-relationships 
between host and microbiota or two different genomes determine the health or disease state 
of the metazoan hosts and the balance among different microorganism populations 
[113,172,179]. It is well accepted that the intestinal microbiota involves in metabolome of the 
host, thus promotes actively fat accumulation and weight gain and sustains indirectly a low-
grade systemic inflammation especially when imbalanced, and consequently, enhances the 
risk for complex, multifactorial diseases such as insulin resistance, diabetes, obesity and 
cardiovascular diseases. The search of global obesity epidemic led to the growing evidences 
about the possible roles of intestinal microbiota in these respects [180,181,182]. Claus et al. 
[170] has noted that the colonization of the gut microbiota was associated with a rapid 
increase in body weights of animals up to 4% within 5 days of colonization. Findings of 
various studies also revealed that gut microbiota profile of obese and diabetic individuals 
differ by phylum level both in its quantity and quality from that of lean and nonobese 
individuals [182,183]. Recent evidences exhibit that the composition of the gut microbiome 
may influence body weight of the host by various mechanisms including enhancing the 
ability of intestines to extract energy from food [184], regulating fat storage in tissues [185] 
and affecting satiety by modulating the levels of local hormones that regulate satiety and by 
direct effects in central nervous system [186]. 
There is a growing appreciation of the critical roles played by the commensal microbiota, 
both in general well-being of the hosts and in the specific functioning of the brain–gut axis 
[113]. Bidirectional communications of brain–gut–enteric microbiota axis simply actualized 
by through signals from the brain can influence the motor, sensory, and secretory modalities 
of the gastrointestinal tract and conversely, visceral messages from the gastrointestinal tract 
can influence brain functions [187]. Sudo and colleagues [25] showed that gut microbiota 
effect the stress responses of host organisms. They compared the response of the HPA axis 
to stress in GF, specific pathogen free (SPF) and gnotobiotic mice that were mono-associated 
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with a single bacterium. Restraint stress caused an exaggerated ACTH and corticosterone 
elevation in GF rather than SPF mice. This hyper-response of the HPA axis was reversed by 
mono-association with Bifidobacterium infantis. They also showed in following experiments 
that the levels of brain-derived nerve factor (BDNF), norepinephrine and 5- 5-
hydroxytryptamine (5-HT) in the cortex and hippocampus were significantly lower in GF 
mice than in SPF mice [188]. Improvements of stress-related symptoms by probiotic 
administration also support the possible regulatory effects of microbiota on HPA axis and 
brain functions [44,189]. Gareau et al [44] reported that probiotic treatments improved colonic 
dysfunction and corrected the higher corticosterone levels in stressed rats induced by 
maternal seperation. L. rhamnosus (JB-1) reduced stress-induced corticosterone and anxiety- 
and depression-related behavior in mice. In different region of brain, this therapy also altered 
GABA receptor expression implicated in the pathogenesis of anxiety and depression, which 
are highly comorbid with functional bowel disorders. Due to the neurochemical and 
behavioral effects were not found in vagotomized mice, they suggested that vagus could be 
a major modulatory constitutive communication pathway between the bacteria exposed to 
the gut and the brain [189]. The roles of probiotics and gut microbiota in modulation of 
visceral and even somatic pain perception and their possible roles in alterations of mood 
and behavior were reviewed by Forsythe et al. [190] and Grenham et al. [113]. 
As mentioned above, intestinal dysbiosis can adversely influence gut physiology both by 
direct effects to the surrounding gut wall and by leading to inappropriate brain–gut axis 
signaling and associated consequences for CNS functions and disease states. Stress at the 
level of the CNS can also impact on gut functions and lead to perturbations of the 
microbiota [113]. 
11. Stress and intestinal microbiota 
Intestinal microbiota have once been seen as potential treat for the host organisms, but 
recently accepted as an integral part of metazoan life and even as an organ with a huge 
variety of building blocks which mainly cooperate with each other and with the host for 
maintaining the health and survival [113,144]. However, various stress factors such as heat, 
cold, nutritional alterations, overcrowding, physical restraints and transporting or fouled or 
contaminated foods can destroy the microbial balance in the gastrointestinal system 
[66,67,191-195] and alter their relationships with each other and with their hosts. Stressful 
stimuli can affect gastrointestinal microbiota directly, for example via limited availability of 
food ingredients or direct actions of stress mediators such as adrenaline or noradrenaline on 
microbiota [27,196], and indirectly via altering the intestinal environment of bacteria such as 
intestinal secretion, motility, permeability and immune functions as reviewed above. 
The effects of several stressors and stress mediators on intestinal microbiota were given in 
Table 1. Bailey et al [197] induced social disruption stress (SDR) in mice to determine 
whether the microbiome contributes to stressor-induced immune enhancements. They 
analyzed bacterial populations in the cecum with using bacterial tag-encoded FLX amplicon 
pyrosequencing (bTEFAP) and found that microbiota significantly changed immediately 
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after stressor exposure as summarized in Table 1, and stress also increased circulating levels 
of IL-6 and MCP-1, which were significantly correlated with stressor-induced changes to 
three bacterial genera (i.e., Coprococcus, Pseudobutyrivibrio, and Dorea spp). However in 
antibiotic treated mice, exposure to SDR failed to increase IL-6 and MCP-1. Bailey et al [191] 
reported that restraint stress also significantly change the composition of the intestinal 
microbiota in mice and disruption of the microbiota increased susceptibility to murine 
enteric pathogen Citrobacter rodentium which can be associated with reduced competitive 
exclusion of commensal bacteria and increased tumor necrosis factor alpha (TNF-α) gene 
expression in colonic tissue. Reduction in bifidobacteria and lactobacilli numbers in fecal 
samples of infant monkeys whose mother had been exposed to stress in either early or late 
pregnancy period showed that maternal pregnancy conditions affect infant health and can 
enhance susceptibility to infection [68]. Similarly, early life stress induced by maternal 
separation altered fecal microbiota with concomitant increases in corticosterone and also 
visceral hypersensitivity and systemic immune response to in vitro lipopolysaccharide 
challenges in rats [198]. Knowles et al [199] reported that non-extreme ‘every day’ stress 
events such as exam stress can affect the integrity of the indigenous gastrointestinal 
microflora of humans but these changes are not supported by cortisol responses. Maternal 
separation of rhesus macaques also caused to decrease of lactobacilli at 3th days post-
separation but significant differences in the cortisol responses did not predict the magnitude 
of the reduction of lactobacilli numbers. These authors suggested that more than one neuro-
hormone can modulate microbiota changes.  
Because of their immune-suppressive or stress-mediating effects, some studies have been 
focused on the effects of glucocorticoids on intestinal microbiota. These studies showed that 
exogenous glucocorticoid applications to the host organisms are also able to cause changes in 
gastrointestinal microbiota. We [200,Ünsal et al., unpublished study] and others [29,30,201] 
demonstrated that exogenous glucocorticoid administrations can also affect gut microbiota 
by enhancing total aerobe and gram negative enteric bacteria and their translocation to 
extraintestinal tissues [201]. We compared the effects of different doses of dexamethasone on 
ileal microbiota and found, in contrast to well-known stress effects, that 5mg/kg 
dexamethasone injection also increased the numbers of total anaerobe and lactobacilli in ileal 
content of rats [200]. However, their number did not change in lower doses of 
dexamethasone. Also in our unpublished study acute cold swimming stress decreased the 
numbers of lactobacilli, while dexamethasone in dose of 5 mg/kg increased total aerobe, 
gram-negative enteric bacteria and lactobacilli. Thus, the evidences available suggest that 
several stressors reduce the number of lactobacilli, while on the contrary, they increases 
growth, epithelial adherence and mucosal uptake of Gram-negative pathogens. Lactobacilli 
may possible be defined as stress indicator bacteria of the gut microbiota which is sensible to 
the effects of various stressors, in general. Although it is known that exogenous 
glucocorticoids increase the counts of gram negative enteric bacteria [29,30,201], no other 
information about their effects on the lactobacilli in the gut could be found.  
The roles of stress and stress-related hormones in the pathogenesis of infectious diseases are 
beyond any argument. Microbial endocrinology is a new research area which appeared 
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from the demand how stress influence the bacterial infections, how neuro-endocrine-
immune secretions of host organisms influence their harboring microbiota and how 
infectious microbes can actively use the neurohormonal products of the stress to their own 
advantages [202,203]. Recently, several in vitro studies have focused on direct effects of 
stress hormones on bacterial growth and their virulence in an effort to explore and 
understand the interactions of so-called stress hormones and infections. These studies 
gathered the evidence that catecholamines stimulate the growth of a wide variety of gram-
negative bacterial species, including those of medical importance [27,196,204-209]. 
Furthermore, catecholamines were also found to be able to induce E.coli to produce a heat-
stable autoinducer of growth [19,27,204,210] as well as for adhesion required K99 pilus and 
shigella-like toxins I and II, which may have important roles in its pathogenic activity [210].  
The effects of norepinephrine and its receptor antagonists on mucosal bacterial adherence 
were also determined in sheets obtained from different parts of the gut, mounted in Ussing 
chamber. Norepinephrine increased the adherence of enterohemorrhagic Escherichia coli 
O157:H7 (EHEC) to colonic epithelium through interactions with α-2 adrenergic receptors 
[211-213] and it increased the internalization of enterohemorrhagic E. coli O157:H7 (EHEC) 
and S. enterica serovar Choleraesuis in jejunal mucosa containing Peyer’s patch follicles 
[214,215]. Parallel studies related to the direct actions of other stress mediators such as 
cortisol or CRF on bacterial growth could not be found. However, Kakuno et al. [216] 
suggested that hydrocortisone enhance intracellular colonizations of E. coli and Schreiber 
and Brown [217] reported that ACTH increased EHEC adherence to the porcine colonic 
mucosa.  
Many factors participate in the pathology of inflammatory bowel disease (IBD) such as genetic 
and immune status of host organism, the gut microbiota, and environmental triggers [218]. 
Some scientific events support that the enteric microbiota is involved in abnormal 
inflammatory responses observed in diverse animal models for inflammatory bowel disease 
[219,220]. These events reviewed by the authors [219,220] are arranged as the reduction or 
absence of intestinal inflammation in animal models of colitis in antibiotic-treated or germ-free 
animals; colitis formation with some bacterial inoculations to germ free rats or not to formation 
with other bacterial species; and beneficial effects of probiotics and prebiotics in IBD patients 
or animal models of IBD. However, although microbiota has been thought to play an active 
role in etiopathogenesis of inflammatory bowel disease, it is not clear whether they are cause 
or outcome. In other words, whether alterations in intestinal microenvironment of microbiota 
such as mucin secretion, immune modifications and epithelial dysfunctions cause to changes 
in commensal microbiota or microbial alterations cause to inflammatory responses of intestinal 
mucosa in stressful conditions is not clear yet [221]. 
Although the reports in microbiome composition of IBD-patients or models show 
differences, changes in microbiota composition are characterized more likely by decreases in 
lactobacilli and bifidobacteria, and increases or unchange in aerobe and facultative 
anaerobic bacteria [222]. Molecular analysis of the microbiota of IBD patients have shown 
that temporal stability and diversity of the gut microbiota composition in IBD patients 
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after stressor exposure as summarized in Table 1, and stress also increased circulating levels 
of IL-6 and MCP-1, which were significantly correlated with stressor-induced changes to 
three bacterial genera (i.e., Coprococcus, Pseudobutyrivibrio, and Dorea spp). However in 
antibiotic treated mice, exposure to SDR failed to increase IL-6 and MCP-1. Bailey et al [191] 
reported that restraint stress also significantly change the composition of the intestinal 
microbiota in mice and disruption of the microbiota increased susceptibility to murine 
enteric pathogen Citrobacter rodentium which can be associated with reduced competitive 
exclusion of commensal bacteria and increased tumor necrosis factor alpha (TNF-α) gene 
expression in colonic tissue. Reduction in bifidobacteria and lactobacilli numbers in fecal 
samples of infant monkeys whose mother had been exposed to stress in either early or late 
pregnancy period showed that maternal pregnancy conditions affect infant health and can 
enhance susceptibility to infection [68]. Similarly, early life stress induced by maternal 
separation altered fecal microbiota with concomitant increases in corticosterone and also 
visceral hypersensitivity and systemic immune response to in vitro lipopolysaccharide 
challenges in rats [198]. Knowles et al [199] reported that non-extreme ‘every day’ stress 
events such as exam stress can affect the integrity of the indigenous gastrointestinal 
microflora of humans but these changes are not supported by cortisol responses. Maternal 
separation of rhesus macaques also caused to decrease of lactobacilli at 3th days post-
separation but significant differences in the cortisol responses did not predict the magnitude 
of the reduction of lactobacilli numbers. These authors suggested that more than one neuro-
hormone can modulate microbiota changes.  
Because of their immune-suppressive or stress-mediating effects, some studies have been 
focused on the effects of glucocorticoids on intestinal microbiota. These studies showed that 
exogenous glucocorticoid applications to the host organisms are also able to cause changes in 
gastrointestinal microbiota. We [200,Ünsal et al., unpublished study] and others [29,30,201] 
demonstrated that exogenous glucocorticoid administrations can also affect gut microbiota 
by enhancing total aerobe and gram negative enteric bacteria and their translocation to 
extraintestinal tissues [201]. We compared the effects of different doses of dexamethasone on 
ileal microbiota and found, in contrast to well-known stress effects, that 5mg/kg 
dexamethasone injection also increased the numbers of total anaerobe and lactobacilli in ileal 
content of rats [200]. However, their number did not change in lower doses of 
dexamethasone. Also in our unpublished study acute cold swimming stress decreased the 
numbers of lactobacilli, while dexamethasone in dose of 5 mg/kg increased total aerobe, 
gram-negative enteric bacteria and lactobacilli. Thus, the evidences available suggest that 
several stressors reduce the number of lactobacilli, while on the contrary, they increases 
growth, epithelial adherence and mucosal uptake of Gram-negative pathogens. Lactobacilli 
may possible be defined as stress indicator bacteria of the gut microbiota which is sensible to 
the effects of various stressors, in general. Although it is known that exogenous 
glucocorticoids increase the counts of gram negative enteric bacteria [29,30,201], no other 
information about their effects on the lactobacilli in the gut could be found.  
The roles of stress and stress-related hormones in the pathogenesis of infectious diseases are 
beyond any argument. Microbial endocrinology is a new research area which appeared 
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from the demand how stress influence the bacterial infections, how neuro-endocrine-
immune secretions of host organisms influence their harboring microbiota and how 
infectious microbes can actively use the neurohormonal products of the stress to their own 
advantages [202,203]. Recently, several in vitro studies have focused on direct effects of 
stress hormones on bacterial growth and their virulence in an effort to explore and 
understand the interactions of so-called stress hormones and infections. These studies 
gathered the evidence that catecholamines stimulate the growth of a wide variety of gram-
negative bacterial species, including those of medical importance [27,196,204-209]. 
Furthermore, catecholamines were also found to be able to induce E.coli to produce a heat-
stable autoinducer of growth [19,27,204,210] as well as for adhesion required K99 pilus and 
shigella-like toxins I and II, which may have important roles in its pathogenic activity [210].  
The effects of norepinephrine and its receptor antagonists on mucosal bacterial adherence 
were also determined in sheets obtained from different parts of the gut, mounted in Ussing 
chamber. Norepinephrine increased the adherence of enterohemorrhagic Escherichia coli 
O157:H7 (EHEC) to colonic epithelium through interactions with α-2 adrenergic receptors 
[211-213] and it increased the internalization of enterohemorrhagic E. coli O157:H7 (EHEC) 
and S. enterica serovar Choleraesuis in jejunal mucosa containing Peyer’s patch follicles 
[214,215]. Parallel studies related to the direct actions of other stress mediators such as 
cortisol or CRF on bacterial growth could not be found. However, Kakuno et al. [216] 
suggested that hydrocortisone enhance intracellular colonizations of E. coli and Schreiber 
and Brown [217] reported that ACTH increased EHEC adherence to the porcine colonic 
mucosa.  
Many factors participate in the pathology of inflammatory bowel disease (IBD) such as genetic 
and immune status of host organism, the gut microbiota, and environmental triggers [218]. 
Some scientific events support that the enteric microbiota is involved in abnormal 
inflammatory responses observed in diverse animal models for inflammatory bowel disease 
[219,220]. These events reviewed by the authors [219,220] are arranged as the reduction or 
absence of intestinal inflammation in animal models of colitis in antibiotic-treated or germ-free 
animals; colitis formation with some bacterial inoculations to germ free rats or not to formation 
with other bacterial species; and beneficial effects of probiotics and prebiotics in IBD patients 
or animal models of IBD. However, although microbiota has been thought to play an active 
role in etiopathogenesis of inflammatory bowel disease, it is not clear whether they are cause 
or outcome. In other words, whether alterations in intestinal microenvironment of microbiota 
such as mucin secretion, immune modifications and epithelial dysfunctions cause to changes 
in commensal microbiota or microbial alterations cause to inflammatory responses of intestinal 
mucosa in stressful conditions is not clear yet [221]. 
Although the reports in microbiome composition of IBD-patients or models show 
differences, changes in microbiota composition are characterized more likely by decreases in 
lactobacilli and bifidobacteria, and increases or unchange in aerobe and facultative 
anaerobic bacteria [222]. Molecular analysis of the microbiota of IBD patients have shown 
that temporal stability and diversity of the gut microbiota composition in IBD patients 
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decreased compared to non-IBD controls [223], and commensal bacteria, particularly members 
of the phyla Firmicutes and Bacteroidetes decreased and Proteobacteria and Actinobacteria 
increased [224]. These changes look alike to those that seen following effects of stress on 
intestinal microbiota. 
 
Stress and/or Stress Mediators Microbiota Method References 
Social disruption stress (SDR) in 
mice (total of 6, two-hour cycles of 
SDR) 
Decrease in Bacteroides spp., 
tended to decrease in 
Lactobacillus spp., tended to 
increase in Clostridium spp. 
and changes in Coprococcus, 
Pseudobutyrivibrio, and Dorea 
spp. in cecal content 
(bTEFAP) 197 
Restraint stress for 7 days in mice 
(between 18.00- 08.00 h) 
Overgrowth of facultatively 
anaerobic microbiota, 
reduction in family 
Porphyromonadaceae,and genus 
Tanneralla,reducing 
microbial richness and 







Prenatal stress induced by 
acoustical startle paradigm 
for 6 weeks in early or late 
pregnancy in Rhesus Monkey 
prenatal stress reduced the 
overall numbers of 
bifidobacteria and lactobacilli 




Maternal separation in rhesus 
macaques (Macaca mulatta) 
Decrease of lactobacilli in 
fecal samples at 3th days 
postseparation, not correlated 




Academic stress in undergraduate 
students 
Reduction in fecal lactic acid 
bacteria, unsignificantly 




Food, water and bedding 
deprivation in mice  
Decrease in lactobacilli in 
stomach, increase of coliforms 
in jejunum, ileum and cecum, 
reduction in fusiform-shaped 
bacteria associated with 
mucosal epithelium of cecum 




Dexemethasone (0.8 mg/kg) 
Dexamethosone (0.8 mg/kg)+ 
starvation for 48 h in Fischer rat 
impairs secretory IgA, 
promotes bacterial adherence 
to the mucosa, increase of 
intestinal permeability  
 29,30,225 
 
Glucocorticoids and the Intestinal Environment 129 
Stress and/or Stress Mediators Microbiota Method References 
Dexamethasone 5 mg/kg in rats Increase of total aerobe 








Methylprednisolone (3 mg/kg) in 
rats subjected to temporary liver 
inflow occlusion 
Increase of intestinal 
Klebsiella spp and Proteus spp 





Pregnant rats were treated with 
either cortisone acetate or normal 
saline on days 18-21 of gestation 
Total bacteria and gram-
negatives found in 
association with the mucosa 
were significantly lower in 





Norepinephrine action on porcine 
or murine cecum/ colon/jejunum 
explants  
Increases cecal-colonic 
adherence of E. coli O157:H7; 
changes Salmonella and E. 
coli uptake into Peyer’s 
patches 
 211-215 
ACTH action on explants of 
porcine distal colonic mucosa  
Increases adherence of E. coli 
O157:H7 to colonic mucosa 
 217 
Table 1. The effects of some different type stressors and/or stress mediators on intestinal microbiota 
12. Nutritional stress 
Nutrition and nutrients of metazoans play very important multifunctional key roles both for 
metazoan host and for its gastrointestinal microbiota. They are essential not only in 
colonization, growth and survival of the microbiota in intestinal system but also in 
maintaining the balance among different species and their localization within its lumina 
[67,192,227,228]. Nutrition plays an important role as stressor for host organisms and their 
gastrointestinal tract via three mechanisms. Firstly, foods supply nutrients for intestinal 
microbiota and also serve as carriers of various microorganisms into gastrointestinal tract 
which may under circumstances lead to imbalances among different species; secondly, 
nutritional deficiencies or imbalances are perceived from the organisms as stressors setting 
them to the state of well-known alarm reaction of stress; and thirdly, certain food 
ingredients in their undigested forms as foreign substances accepted as non-self from 
organisms and stimulate a stress situation. In cases of carrying the microorganisms into 
gastrointestinal tract or acting as antigens, the foreign treats come into direct contact with 
the wall of gastrointestinal tract. A great part of microorganisms stay in gastrointestinal 
canal for a short time period, while others colonize its lumina permanently and their genera 
can be life-long present there, mostly in a symbiotic relationship with the host organisms. 
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decreased compared to non-IBD controls [223], and commensal bacteria, particularly members 
of the phyla Firmicutes and Bacteroidetes decreased and Proteobacteria and Actinobacteria 
increased [224]. These changes look alike to those that seen following effects of stress on 
intestinal microbiota. 
 
Stress and/or Stress Mediators Microbiota Method References 
Social disruption stress (SDR) in 
mice (total of 6, two-hour cycles of 
SDR) 
Decrease in Bacteroides spp., 
tended to decrease in 
Lactobacillus spp., tended to 
increase in Clostridium spp. 
and changes in Coprococcus, 
Pseudobutyrivibrio, and Dorea 
spp. in cecal content 
(bTEFAP) 197 
Restraint stress for 7 days in mice 
(between 18.00- 08.00 h) 
Overgrowth of facultatively 
anaerobic microbiota, 
reduction in family 
Porphyromonadaceae,and genus 
Tanneralla,reducing 
microbial richness and 







Prenatal stress induced by 
acoustical startle paradigm 
for 6 weeks in early or late 
pregnancy in Rhesus Monkey 
prenatal stress reduced the 
overall numbers of 
bifidobacteria and lactobacilli 




Maternal separation in rhesus 
macaques (Macaca mulatta) 
Decrease of lactobacilli in 
fecal samples at 3th days 
postseparation, not correlated 




Academic stress in undergraduate 
students 
Reduction in fecal lactic acid 
bacteria, unsignificantly 




Food, water and bedding 
deprivation in mice  
Decrease in lactobacilli in 
stomach, increase of coliforms 
in jejunum, ileum and cecum, 
reduction in fusiform-shaped 
bacteria associated with 
mucosal epithelium of cecum 




Dexemethasone (0.8 mg/kg) 
Dexamethosone (0.8 mg/kg)+ 
starvation for 48 h in Fischer rat 
impairs secretory IgA, 
promotes bacterial adherence 
to the mucosa, increase of 
intestinal permeability  
 29,30,225 
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Stress and/or Stress Mediators Microbiota Method References 
Dexamethasone 5 mg/kg in rats Increase of total aerobe 








Methylprednisolone (3 mg/kg) in 
rats subjected to temporary liver 
inflow occlusion 
Increase of intestinal 
Klebsiella spp and Proteus spp 





Pregnant rats were treated with 
either cortisone acetate or normal 
saline on days 18-21 of gestation 
Total bacteria and gram-
negatives found in 
association with the mucosa 
were significantly lower in 





Norepinephrine action on porcine 
or murine cecum/ colon/jejunum 
explants  
Increases cecal-colonic 
adherence of E. coli O157:H7; 
changes Salmonella and E. 
coli uptake into Peyer’s 
patches 
 211-215 
ACTH action on explants of 
porcine distal colonic mucosa  
Increases adherence of E. coli 
O157:H7 to colonic mucosa 
 217 
Table 1. The effects of some different type stressors and/or stress mediators on intestinal microbiota 
12. Nutritional stress 
Nutrition and nutrients of metazoans play very important multifunctional key roles both for 
metazoan host and for its gastrointestinal microbiota. They are essential not only in 
colonization, growth and survival of the microbiota in intestinal system but also in 
maintaining the balance among different species and their localization within its lumina 
[67,192,227,228]. Nutrition plays an important role as stressor for host organisms and their 
gastrointestinal tract via three mechanisms. Firstly, foods supply nutrients for intestinal 
microbiota and also serve as carriers of various microorganisms into gastrointestinal tract 
which may under circumstances lead to imbalances among different species; secondly, 
nutritional deficiencies or imbalances are perceived from the organisms as stressors setting 
them to the state of well-known alarm reaction of stress; and thirdly, certain food 
ingredients in their undigested forms as foreign substances accepted as non-self from 
organisms and stimulate a stress situation. In cases of carrying the microorganisms into 
gastrointestinal tract or acting as antigens, the foreign treats come into direct contact with 
the wall of gastrointestinal tract. A great part of microorganisms stay in gastrointestinal 
canal for a short time period, while others colonize its lumina permanently and their genera 
can be life-long present there, mostly in a symbiotic relationship with the host organisms. 
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Dietary ingredients, which are not digestible for the host organisms or which are digestible 
but escape from the intestinal digestion can be utilized as substrate for growth from 
microbiota colonized in the following sections of the gut [229,230]. All microorganisms 
residing in gastrointestinal tract needs the nutrients that necessary for their growth and 
proliferation are continuously supplied via foods of their hosts and from host organisms in 
secretions of digestive organs including saliva, gastric juice, pancreatic, hepatic (bile) and 
intestinal wall secretions and desquamated epithelial structures. The composition and 
amount of the food, even the compositions of these secrets may undergo substantial 
changes. This is why the hosts’ balanced nutrition and physiological state exerts a strong 
controlling effect on its microbiota [160,181,192,231-237]. Thus, any nutritional deficiency or 
imbalance of their hosts serve the most important challenge for the growth, survival and 
balance of different microbial species within the intestinal lumina. 
Malnutritions in different nature or nutritional imbalances had always been and are still 
very widespread health problems of men and animals worldwide and frequently seen in 
infants and elderly, and those subjects having malignancies, getting chemotherapy and/or 
radiotherapy or infected with human immunodeficiency virus. Very common forms of 
malnutrition are protein, calorie and protein calorie deficiencies which almost always are 
complicated with deficiencies of other nutrients, especially that of minerals and vitamins 
[238]. As mentioned above, deficiencies of calories, proteins, minerals or vitamins in hosts’ 
food can influence the indigenous microbiota both directly via the restricted availability of 
the metabolites and their indigestible parts for hosts and indirectly by inducing a stress 
response within the host organism and affecting the compositions of gastrointestinal 
morphology and secretions as well as by impairing the general and local immune responses 
and neuro-endocrine-immune network leading to an imbalance between the host organism 
and its microbiota, in general. These changed milieus offer possibilities to certain new 
species of the microbiota for adaptation in gastrointestinal tract or cause their dispersion 
from their localization areas to others. In protein calorie malnutrition, colonic type 
microbiota known to spread to and proliferate in the upper small intestine which may cause 
a variety of metabolic disturbances including steatorrhea, vitamin deficiencies, nutrient 
malabsorbtions, and consequently water leakage into lumina and diarrhea [160,239-241]. 
Generally, pathogenic microorganisms including Enterobacteriaceae, Pseudomonas, 
Klebsiella and Candida were increased [240,241]. In such clinical cases of complicated 
protein and/or calorie malnutrition, pathogenic microorganisms often cause endotoxemia 
and infection in addition to intestinal disruptions including diarrhea and metabolic diseases 
[242,243]. Thus, they all affect the composition of the intestinal digesta and its passage time, 
which in turn may influence the composition of the indigenous intestinal microbiota and 
their relationships with the intestinal wall [244-246]. 
Generally, experimental studies use deficiencies or excesses of a definite dietary component 
or several components, and animals are held under more hygienic, defined conditions 
throughout the rearing and experimental periods than their counterparts, whereas clinical 
cases develop spontaneously in man and animals. Thus, they give the possibility to detect 
the possible effects of a certain dietary component on the behavior of the gastrointestinal 
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microbiota. However, such experimental evidences from studies using deficiencies or 
imbalances of definite nutrients in this respect are very sparse. So, an almost protein-free 
diet disrupted the cecal microbiota, and made mice more susceptible to bacterial 
translocation than those mice nourished adequately [227,236,247]. The counts of cecal total 
aerobic bacteria and Gram-negative enteric bacilli were found to be increased time-
dependently when CD-1 mice were fed an almost N-free diet for 21 days [236]. The results 
of another study on adult female Crl:CD-1[CR]BR mice also showed that both the feeding an 
almost protein-free and 20% fat containing diet for 14 days and starvation for 3 days 
resulted in an increase in counts of Gram-negative enteric bacilli and a decrease in counts of 
lactobacilli and strict anaerobes [227]. In certain studies the effects of dietary manipulations 
combined and/or compared with those of endotoxemia were investigated. So, Deitch et al. 
[227] studied the effects of starvation and malnutrition alone or in combination with 
endotoxemia and found that the spread of bacteria from the gut could not be controlled nor 
translocated bacteria be cleared in protein malnourished mice as effectively as in the 
controls. However, no association between protein malnutrition and bacterial translocation 
could be found by Katayama et al. [247]. Instead, these authors determined that the total 
numbers of Gram-negative enteric bacilli adherent to the mucosa of ileum and cecum were 
less in protein malnourished rats than in their adequately nourished controls. Further, there 
was also a significant negative correlation between the duration of protein malnutrition and 
bacterial adherence to the intestinal mucosa. Only, E. coli binding to insoluble ileal mucus 
was increased in the rats receiving endotoxin. Tannock and Savage [192] reported that the 
deprivation of food and water and bedding for 48 hours increased the counts of coliform 
bacteria while they decreased the counts of cecal lactobacilli of CD-1 and C57BL mice 
strainsIn a preliminary study, we found that feeding an almost protein-free diet to male 
Wistar rats for 35 days affected especially the total aerobe microorganisms and lactobacilli 
while total anaerobe and Enterobacteriaceae remained relatively unaffected. Compared to 
controls with balanced nutrition, both dietary qualitative and quantitative protein 
malnutrition decreased mean lactobacilli counts. Also, the quality and quantity of the 
dietary protein made a difference in their effects on intestinal microbiota; compared to 
gelatin-fed animals, lower aerobe and higher lactobacilli counts could be observed in cecal 
samples of rats given an almost protein-free diet. Furthermore, it could also be shown that 
the actual immune status (e.g. suppression of neutrophils) of the host can modify the effects 
of the qualitative and quantitative protein malnutrition on the intestinal microbiota [193].  
Human cultural characteristics may also have implications on the compositions of the 
gastrointestinal microbiota. Living on a high carbohydrate diet caused also the presence of 
fewer bacteriodes and more enterococci in feces of the people than those living on a Western 
diet with more fat and animal proteins [231]. 
After all, the mechanisms via which different type of diets or dietary manipulations affect the 
host and its guest organ ‘gut microbiota’ are still not exactly cleared. The effects of dietary 
qualitative and/or quantitative protein malnutrition on regulatory systems in men and 
animals are well characterized and are the topic of numerous texts. Earlier studies with 
definite protein malnutrition were summarized by Aschkenasy [248] and suggest that protein 
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Dietary ingredients, which are not digestible for the host organisms or which are digestible 
but escape from the intestinal digestion can be utilized as substrate for growth from 
microbiota colonized in the following sections of the gut [229,230]. All microorganisms 
residing in gastrointestinal tract needs the nutrients that necessary for their growth and 
proliferation are continuously supplied via foods of their hosts and from host organisms in 
secretions of digestive organs including saliva, gastric juice, pancreatic, hepatic (bile) and 
intestinal wall secretions and desquamated epithelial structures. The composition and 
amount of the food, even the compositions of these secrets may undergo substantial 
changes. This is why the hosts’ balanced nutrition and physiological state exerts a strong 
controlling effect on its microbiota [160,181,192,231-237]. Thus, any nutritional deficiency or 
imbalance of their hosts serve the most important challenge for the growth, survival and 
balance of different microbial species within the intestinal lumina. 
Malnutritions in different nature or nutritional imbalances had always been and are still 
very widespread health problems of men and animals worldwide and frequently seen in 
infants and elderly, and those subjects having malignancies, getting chemotherapy and/or 
radiotherapy or infected with human immunodeficiency virus. Very common forms of 
malnutrition are protein, calorie and protein calorie deficiencies which almost always are 
complicated with deficiencies of other nutrients, especially that of minerals and vitamins 
[238]. As mentioned above, deficiencies of calories, proteins, minerals or vitamins in hosts’ 
food can influence the indigenous microbiota both directly via the restricted availability of 
the metabolites and their indigestible parts for hosts and indirectly by inducing a stress 
response within the host organism and affecting the compositions of gastrointestinal 
morphology and secretions as well as by impairing the general and local immune responses 
and neuro-endocrine-immune network leading to an imbalance between the host organism 
and its microbiota, in general. These changed milieus offer possibilities to certain new 
species of the microbiota for adaptation in gastrointestinal tract or cause their dispersion 
from their localization areas to others. In protein calorie malnutrition, colonic type 
microbiota known to spread to and proliferate in the upper small intestine which may cause 
a variety of metabolic disturbances including steatorrhea, vitamin deficiencies, nutrient 
malabsorbtions, and consequently water leakage into lumina and diarrhea [160,239-241]. 
Generally, pathogenic microorganisms including Enterobacteriaceae, Pseudomonas, 
Klebsiella and Candida were increased [240,241]. In such clinical cases of complicated 
protein and/or calorie malnutrition, pathogenic microorganisms often cause endotoxemia 
and infection in addition to intestinal disruptions including diarrhea and metabolic diseases 
[242,243]. Thus, they all affect the composition of the intestinal digesta and its passage time, 
which in turn may influence the composition of the indigenous intestinal microbiota and 
their relationships with the intestinal wall [244-246]. 
Generally, experimental studies use deficiencies or excesses of a definite dietary component 
or several components, and animals are held under more hygienic, defined conditions 
throughout the rearing and experimental periods than their counterparts, whereas clinical 
cases develop spontaneously in man and animals. Thus, they give the possibility to detect 
the possible effects of a certain dietary component on the behavior of the gastrointestinal 
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microbiota. However, such experimental evidences from studies using deficiencies or 
imbalances of definite nutrients in this respect are very sparse. So, an almost protein-free 
diet disrupted the cecal microbiota, and made mice more susceptible to bacterial 
translocation than those mice nourished adequately [227,236,247]. The counts of cecal total 
aerobic bacteria and Gram-negative enteric bacilli were found to be increased time-
dependently when CD-1 mice were fed an almost N-free diet for 21 days [236]. The results 
of another study on adult female Crl:CD-1[CR]BR mice also showed that both the feeding an 
almost protein-free and 20% fat containing diet for 14 days and starvation for 3 days 
resulted in an increase in counts of Gram-negative enteric bacilli and a decrease in counts of 
lactobacilli and strict anaerobes [227]. In certain studies the effects of dietary manipulations 
combined and/or compared with those of endotoxemia were investigated. So, Deitch et al. 
[227] studied the effects of starvation and malnutrition alone or in combination with 
endotoxemia and found that the spread of bacteria from the gut could not be controlled nor 
translocated bacteria be cleared in protein malnourished mice as effectively as in the 
controls. However, no association between protein malnutrition and bacterial translocation 
could be found by Katayama et al. [247]. Instead, these authors determined that the total 
numbers of Gram-negative enteric bacilli adherent to the mucosa of ileum and cecum were 
less in protein malnourished rats than in their adequately nourished controls. Further, there 
was also a significant negative correlation between the duration of protein malnutrition and 
bacterial adherence to the intestinal mucosa. Only, E. coli binding to insoluble ileal mucus 
was increased in the rats receiving endotoxin. Tannock and Savage [192] reported that the 
deprivation of food and water and bedding for 48 hours increased the counts of coliform 
bacteria while they decreased the counts of cecal lactobacilli of CD-1 and C57BL mice 
strainsIn a preliminary study, we found that feeding an almost protein-free diet to male 
Wistar rats for 35 days affected especially the total aerobe microorganisms and lactobacilli 
while total anaerobe and Enterobacteriaceae remained relatively unaffected. Compared to 
controls with balanced nutrition, both dietary qualitative and quantitative protein 
malnutrition decreased mean lactobacilli counts. Also, the quality and quantity of the 
dietary protein made a difference in their effects on intestinal microbiota; compared to 
gelatin-fed animals, lower aerobe and higher lactobacilli counts could be observed in cecal 
samples of rats given an almost protein-free diet. Furthermore, it could also be shown that 
the actual immune status (e.g. suppression of neutrophils) of the host can modify the effects 
of the qualitative and quantitative protein malnutrition on the intestinal microbiota [193].  
Human cultural characteristics may also have implications on the compositions of the 
gastrointestinal microbiota. Living on a high carbohydrate diet caused also the presence of 
fewer bacteriodes and more enterococci in feces of the people than those living on a Western 
diet with more fat and animal proteins [231]. 
After all, the mechanisms via which different type of diets or dietary manipulations affect the 
host and its guest organ ‘gut microbiota’ are still not exactly cleared. The effects of dietary 
qualitative and/or quantitative protein malnutrition on regulatory systems in men and 
animals are well characterized and are the topic of numerous texts. Earlier studies with 
definite protein malnutrition were summarized by Aschkenasy [248] and suggest that protein 
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malnutrition of different types or amino acid imbalances generally result in increases of 
adrenalin and glucocorticoid concentrations in man and animals. Torún and Viteri [249] also 
noted that in protein and/or protein-calorie malnutrition, the concentrations of adrenalin and 
glucocorticoids are either increased or showed no important change while many other 
hormones with exceptions of aldosterone and growth hormone decreased significantly. 
However, such studies have very important drawbacks as they look only one aspect of the 
regulators such as their concentrations in blood. Generally, the concomitant expression status 
of the enzymes which interconvert active and inactive forms of a given hormone and their 
receptors in target tissues or cells are ignored or not evaluated concurrently. A study 
conducted by Marroqui et al. [250] on mice demonstrated that during a protein malnutrition 
plasma glucagon concentration increased, but the ability of exogenous glucagon to raise 
plasma glucose levels were lower in mice given a low protein diet. 
13. Conclusion 
Since their introduction in the terminology of scientific medicine, the terms environment, 
stress and microorganisms were probably never been so important in mind of mankind for 
the development, health and welfare of men and animals. Although the roles of stress and 
stress-dependent disruptions of the intestinal microbiota both in developments and in 
promotion of the symptoms of various diseases and disorders including those of 
gastrointestinal system in men and animals are well accepted, there is still a lack of 
information about many aspects including which strains play really a role in the 
etiopathogenesis of a given condition, and which mechanisms are effective in such cases 
[24,113]. The stress-dependent dysfunctions of HPA axis can manifest itself in different 
ways. In many cases it may be related to high or low cortisol concentrations in blood 
whereas in other situations no detectable change of cortisol occurs. Further, the response 
given by hypothalamus and pituitary gland to the cortisol can be increased or decreased 
depending on the receptor numbers [10,11,14,15]. While in classic stress response 
sympathetic nervous system and glucocorticoids thought to be responsible for stress-
dependent processes, studies within last two decades suggest that many disordered 
situations of the gastrointestinal system mediated by CRF. Both CRF-related peptides and 
CRF receptors are also expressed within the intestine, where they may activate directly the 
enteric, endocrine, and immune cells and may be involved in intestinal manifestations such 
as mucosal permeability, secretion, mast cell function, motility, mucin formation, immune 
function and many disorders of the gut. In other words, the peripheral changes produced by 
stress can be mimicked by CRF-injection and prevented by CRF-receptor antagonists 
[18,20,31,32,82]. Therefore, CRF have been suggested as a new target in treating stress 
induced functional gastrointestinal disorders.  
Recently, intestinal microbiota imbalances gain growing interests both as the subject and 
cause of stress and stress-related diseases which are connected with not only the 
gastrointestinal system but also all other systems or organs of the metazoan hosts including 
the adipose tissue [24,113, 179, 184,185]. Basing on experimental and clinical studies, certain 
 
Glucocorticoids and the Intestinal Environment 133 
phyla and species are currently related with a given specific condition [180,181]. However, 
all these studies are looking mainly on one side of the iceberg, like for example changes in a 
specific member of the microbiota in respect to stress stimuli and a specific neurotransmitter 
in brain, as it also the case in search of the mediating regulatory pathways. Understanding 
the roles of stress and stress-related microbiotal changes and their mechanisms in the role of 
various physiopathological conditions would be helpful in improvements of the 
relationships of the metazoan hosts with their microenvironments including its microbiota 
and thus, would contribute greatly to the health state of men and animals. 
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hormones with exceptions of aldosterone and growth hormone decreased significantly. 
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receptors in target tissues or cells are ignored or not evaluated concurrently. A study 
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plasma glucagon concentration increased, but the ability of exogenous glucagon to raise 
plasma glucose levels were lower in mice given a low protein diet. 
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promotion of the symptoms of various diseases and disorders including those of 
gastrointestinal system in men and animals are well accepted, there is still a lack of 
information about many aspects including which strains play really a role in the 
etiopathogenesis of a given condition, and which mechanisms are effective in such cases 
[24,113]. The stress-dependent dysfunctions of HPA axis can manifest itself in different 
ways. In many cases it may be related to high or low cortisol concentrations in blood 
whereas in other situations no detectable change of cortisol occurs. Further, the response 
given by hypothalamus and pituitary gland to the cortisol can be increased or decreased 
depending on the receptor numbers [10,11,14,15]. While in classic stress response 
sympathetic nervous system and glucocorticoids thought to be responsible for stress-
dependent processes, studies within last two decades suggest that many disordered 
situations of the gastrointestinal system mediated by CRF. Both CRF-related peptides and 
CRF receptors are also expressed within the intestine, where they may activate directly the 
enteric, endocrine, and immune cells and may be involved in intestinal manifestations such 
as mucosal permeability, secretion, mast cell function, motility, mucin formation, immune 
function and many disorders of the gut. In other words, the peripheral changes produced by 
stress can be mimicked by CRF-injection and prevented by CRF-receptor antagonists 
[18,20,31,32,82]. Therefore, CRF have been suggested as a new target in treating stress 
induced functional gastrointestinal disorders.  
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all these studies are looking mainly on one side of the iceberg, like for example changes in a 
specific member of the microbiota in respect to stress stimuli and a specific neurotransmitter 
in brain, as it also the case in search of the mediating regulatory pathways. Understanding 
the roles of stress and stress-related microbiotal changes and their mechanisms in the role of 
various physiopathological conditions would be helpful in improvements of the 
relationships of the metazoan hosts with their microenvironments including its microbiota 
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1. Introduction 
1.1. Glucocorticoids therapeutic effects  
Synthetic glucocorticoids (GCs) as effective anti-inflammatory therapeutics are the most 
widely prescribed drugs in the clinic for the treatment of various conditions including 
asthma, ulcerative colitis, rheumatoid arthritis and hay fever [1-4]. Glucocorticoids in some 
cases exert effective anti-neoplastic effects in cancers of blood origin such as acute 
lymphocytic leukaemia (ALL) as a result of the ability of these hormones to induce cell 
death in blood cells [1-3]. Resistance to glucocorticoid mediated cell death remains one of 
the main reasons for inefficient therapy [1] and usually occurs upon prolonged 
glucocorticoid treatment [2] compromising significantly the success of therapy [3]. The 
molecular mechanisms mediating glucocorticoid dependent initiation of programmed cell 
death have been extensively investigated but there are several aspects of these pathways 
that have not yet been clearly defined. Since understanding of these mechanisms would be 
beneficial towards improving the glucocorticoids therapeutic efficacy further research 
exemplifying resistance to glucocrticoid treatment is necessary. 
Glucocorticoids (GCs) exert their anti-inflammatory and immunosuppressive effects 
through either genomic or non-genomic mechanisms. Non-genomic early effects of 
glucocorticoids are induced in tissues bearing high concentrations of this hormone by 
interfering with the physicochemical properties of plasma and mitochondrial membranes 
[4]. In particular, glucocorticoids intercalate into these membranes altering lipid 
peroxidation and membrane permeability [5]. In addition, non-genomic effects of 
glucocorticoids include early suppression of the mitogen-activated protein kinase (MAPK) 
and hence inflammatory signal transduction cascades such as calcium influx, phagocytosis, 
 The A thor(s). Licens e InTech. This chapter is distributed under the terms of the Creative C mmons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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neutrophil degranulation and cellular adhesion [6, 7, 8, 9, 10, 11]. The non genomic effects of 
GCs are very important in delivering short-term therapeutic benefits to asthma and 
rheumatoid arthritis which are diseases characterized by high inflammatory state [12].  
2. Mechanisms of GC-mediated cell death  
At the molecular level GCs exert their function by interacting with their intracellular GC 
receptor (GR), which is a hormone responsive transcription factor that modulates gene 
expression of its target genes [13]. Glucocorticoids activate the cellular death machinery 
through transcriptional and non-transcriptional pathways by means of either the extrinsic or 
intrinsic pathway of apoptosis [3, 14, 15, 16].  
The extrinsic pathway is induced upon activation of the membrane death receptors such as 
the tumour necrosis factor (TNF) receptor superfamily, member 6, Fas-Ligand (Fas-L) [17]. 
The binding of Fas-L leads to the activation of effector caspases (caspases 3, 6 and 7) via the 
activation of inducer caspases, particularly caspase 8 [18]. Evidence that glucocorticoids are 
involved in the regulation of the extrinsic pathway of apoptosis has been provided by 
observations suggesting that glucocorticoids inhibit the induction of Fas-L (but not Fas) 
signalling in T-cell hybridomas [19, 20]. On the contrary inhibition of the extrinsic pathway 
using the caspase 8 inhibitor cytokine response modifier A (crmA) in pre-B leukemic cells 
treated with glucocorticoids indicated that GR does not initiate apoptosis in these cells 
through the extrinsic pathway [21, 22]. The involvement of the intrinsic pathway, on the 
other hand, in the glucocorticoid mediated cell death and in particular the regulation of the 
balance between pro- and anti-apoptotic members of the bcl-2 family has been shown in 
hepatocytes, small cell lung cancer, primary ALL lymphoblasts and animal systems [23, 24].  
The intrinsic pathway of cell death is stimulated in response to intracellular signals, and 
involves mitochondria releasing pro-apoptotic molecules, formation of the apoptosome and 
activation of the effector caspases via the initiator caspase 9 [25]. The balance between pro- 
and anti-apoptotic members of the B cell leukaemia/ lymphoma 2-like (Bcl-2) family plays a 
crucial role in the execution of apoptosis by glucocorticoids through the intrinsic pathway 
[18]. In particular, glucocorticoids regulate the expression of various genes involved in the 
initiation of apoptosis, including the pro-apoptotic Bcl-2 family member BCL2-like 11 (Bim) 
[22, 26, 27, 28]. Transactivation of Bim results in the activation of the Bcl-2–associated X 
protein (Bax) and the Bcl2-antagonist/killer 1 (Bak), which mediate the disruption of 
mitochondrial membrane potential and the release of cytochrome c into the cytosol [29]. 
Cytochrome c then binds to its adaptor apoptotic protease activating factor (Apaf-1), thereby 
activating caspase 9 and several effector caspases [30]. Furthermore, mitochondria mediate 
the generation of reactive oxygen species (ROS), which may potentially have an add-on 
effect on glucocorticoid-induced apoptosis [31]. 
In some cases glucocorticoids induce apoptosis by using both the intrinsic and the extrinsic 
pathways. This is mediated by the cleaved caspase-8 which subsequently leads to activation 
of the pro-apoptotic member of the Bcl-2 family, Bcl-2 homology 3 (BH3) interacting domain 
death agonist (Bid) [32]. The C-terminal truncated Bid (t-Bid) activates caspase 9 and the 
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effector caspases 3, 6 and 7 [33]. The intrinsic and extrinsic pathways through which 
glucocorticoids induce apoptosis in cells responsive to these hormones are illustrated in 
Figure 1. 
 
Figure 1. Schematic diagram indicating the extrinsic and intrinsic pathways through which 
glucocorticoids regulate apoptosis. 
Several mechanisms have been proposed to explain the evasion of glucocorticoid mediated 
apoptosis in resistant cells [34]. These include alterations in the activity of the glucocorticoid 
receptor [35, 36] either due to changes in GR protein levels, presence of multiple GR 
variants, or post-translational modifications. GR induces apoptosis by directly modulating 
the expression of genes involved in cell survival/apoptosis [18, 37], or affecting gene 
networks involved in stress signalling resulting in an apoptotic stimulus [36, 38]. 
3. GR transcriptional activity is necessary for its pro-apoptotic function  
Glucocorticoid induced apoptosis depends on the presence of adequate amounts of 
transcriptionally active GR [34, 39, 40, 41, 42]. It has also been shown that the presence of 
specific GR splicing variants is necessary for the stimulation of GCs dependent apoptosis 
[3]. Alternative hGR splicing produces two receptor variants called GRα and GRβ, which 
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are highly homologous differing by 50 additional amino acids present in the carboxy 
terminal region of GRα [43]. GRα is mainly cytoplasmic, and exhibits the typical 
glucocorticoid receptor function in terms of ligand-dependent transcriptional regulation and 
as such it is the major functional GR isoform therefore its expression is crucial for cellular 
sensitivity to GCs [3]. GRβ on the other hand, does not bind ligands, and exerts a dominant 
negative effect on GRα transcriptional activity [43, 44, 45]. In clinical studies reduced GRα 
protein levels correlate with resistance to GCs induced apoptosis and disadvantageous 
prognosis in ALL [3]. Additional indication that GR transcriptional activity is necessary for 
the initiation of the GCs mediated apoptosis has been provided by the observation that 
various mutations affecting GR transcriptional activity have been detected in patients 
exhibiting resistance to glucocorticoids treatment [2, 46]. Furthermore, prolonged 
glucocorticoid treatment significantly reduces GRα expression [47], whereas GRβ expression 
is not affected [48]. 
4. GR dependent regulation of the balance between pro- and anti-
apoptotic Bcl-2 family members 
B cell leukaemia/ lymphoma 2-like (Bcl-2) family members are categorised into pro- and 
anti-apoptotic and the balance between the levels of these two types of proteins 
determines the cellular fate (survival or death) [23]. The involvement of the Bcl-2 family 
members in the glucocorticoid-induced apoptosis has been shown in cellular and animal 
studies [49]. For example, the expression of the anti-apoptotic Bcl-2 family member in 
glucocorticoid-sensitive thymocytes is lower compared to that in glucocorticoid-resistant 
ones [2], and overexpression of the anti-apoptotic Bcl-2 and B-cell lymphoma-extra large 
(Bcl-xL) in human ALL prevents glucocorticoids induced apoptosis [50, 51, 52, 53] 
whereas knock down of the pro-apoptotic member Bim confers resistance to 
dexamethasone mediated apoptosis [54]. Furthermore, over-expression of the pro-
apoptotic Bax [55] and knock down of the myeloid cell leukemia sequence 1 (Mcl-1) 
sensitises ALL cells to glucocorticoid treatment [56]. We have shown recently that the 
balance between Mcl-1 and phorbol-12-myristate-13-acetate-induced protein 1 (Noxa) is a 
determinant of resistance / sensitivity of ALL cells to glucocorticoid-induced apoptosis 
[57, 58]. Several studies have shown that the pro-apoptotic Bcl-2 family member Bim plays 
crucial role in the glucocorticoid-induced apoptosis but further investigation is required 
to define the detailed molecular mechanisms of this process. Up-regulated Bim has been 
observed in various cell lines upon glucocorticoid treatment including ALL cells [59], 
primary chronic lymphocytic leukaemia (CLL) cells [27], and some patients with ALL [60]. 
Moreover knockout of Bim, p53 up-regulated modulator of apoptosis (Puma) or Noxa, or 
double knockouts of Bax and Bak confer resistance to glucocorticoid-mediated apoptosis 
in thymocytes [61, 62, 63]. Overall the balance of the levels between pro- and anti-
apoptotic Bcl-2 family members has been recognised as a crucial factor in the 
determination of lymphocytes survival or death and induction of the glucocorticoid 
dependent programmed cell death.  
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Gene Protein Function Role in glucocorticoid-induced apoptosis 
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[41, 64] 
BCL-xL  B-cell lymphoma-
extra large (Bcl-xL) 
Anti-
apoptotic 
Over-expression of Bcl-xL in human ALL cells 
prevents glucocorticoids induced apoptosis 
[23] 
BCL2L11 BCL2 Like 11 (Bim) Pro-apoptotic 
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cells to glucocorticoid-induced apoptosis [65]. 
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Pro-apoptotic 
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Noxa/Mcl-1 balance determines cell survival 









Puma facilitates glucocorticoid-induced 
apoptosis of lymphocytes [62, 65]. 
Bax Bcl-2–associated X 
(Bax) 
Pro-apoptotic 
Bax protein regulates glucocorticoid induced 
apoptosis in thymocytes [67]. Double 
knockouts of Bax and Bak confer resistance to 







Double knockouts of Bax and Bak confer 
resistance to glucocorticoid-mediated 
apoptosis in thymocytes [68]. 
Table 1. Pro- and anti-apoptotic Bcl-2 family members implicated in the glucocorticoids induced 
apoptosis 
5. Autophagy 
Autophagy is a several steps process leading to cellular degradation of unfolded or 
aggregated proteins and organelles in response to diverse types of stress such as starvation 
or metabolic stress and is an essential mechanism contributing to survival, differentiation, 
development, and homeostasis. Autophagy protects against chronic inflammatory 
conditions occurring in a variety of pathological situations such as infections, cardiovascular 
disease, neurodegenaration, inflammatory bowel diseases, aging and cancer [69]. 
Autophagy has been shown to be involved in prosurvival processes facilitating resistance of 
cancer cells to chemotherapy as well as under certain conditions in apoptosis [70]. Taking 
into account the fact that autophagy is prosurvival in addition to reports indicating that 
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into account the fact that autophagy is prosurvival in addition to reports indicating that 
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inhibitors of autophagy re-sensitise cancer cells to anticancer therapeutics [70, 71] as well as 
that autophagy is associated with inflammation and resistance to cancer therapy 
investigators were prompted to study the role of autophagy in the resistance to 
glucocorticoid induced apoptosis in ALL [72, 73]. These studies have indicated that 
dexamethasone induces autophagy before the initiation of apoptosis in ALL cells and in 
actual fact autophagy is a prerequisite for the efficient execution of apoptosis mediated by 
dexamethasone [72, 73]. More recently the molecular mechanism by which activation of 
autophagy overturns glucocorticoid resistance has been elucidated [74] signifying the 
important role of the autophagy inducer beclin-1 and the anti-apoptotic Bcl-2 family 
member Mcl-1 [74, 75]. Furthermore the inhibition of caspase by selective degradation of 
catalase and consequent generation of high concentrations of reactive oxygen species might 
be an alternative mechanism explaining the role of autophagy in dexamethasone induced 
apoptosis [76]. 
6. Post-translational modifications 
Post-translational modifications of GR are important in regulating its transcriptional 
activity, protein stability, binding of GR with other transcription factors or co-modulators 
and subcellular localisation, and for these reasons post-translational modifications are 
highly relevant to glucocorticoids therapeutic efficacy [77, 78, 79, 80, 81]. GR acetylation is 
cell type dependent and it is suggested to suppress the receptor’s transcriptional activity by 
reducing its ability to bind to the Glucocorticoid Responsive Elements (GREs) present in its 
target genes [82], or inhibit the ability of GR to translocate into the nucleus [83]. Regulation 
of GR transcriptional activity also takes place through ubiquitination and proteasomal 
degradation of the receptor upon ligand binding [84, 85]. Ubiquitination promotes 
interaction of GR with E2 conjugating and E3 ligase proteins causing turnover of the 
receptor and thus down-regulation of its transcriptional activity [85]. In support of these 
conclusions the proteasome inhibitor MG-132 enhances the transcriptional activity of GR 
[84]. Ligand-independent sumoylation has been shown to both inhibit [86, 87] as well as to 
stabilise and potentiate GR transcriptional activity [88]. Three sumoylation sites have been 
identified within the GR protein conferring GR transcriptional target selectivity [87]. We 
have recently reported that GR sumoylation is assisted by its phosphorylation at particular 
sites under certain conditions [89]. 
GR phosphorylation has been extensively investigated and several different kinases have 
been identified to induce phosphorylation of the receptor at distinct serine and threonine 
residues located within the N-terminal AF-1 transactivation domain of the receptor, either in 
the presence or in the absence of glucocorticoid hormone [90, 91, 92, 93, 94, 95]. S203 residue 
in human GR is targeted by cyclin/cyclin dependent kinase (CDK) complexes and is located 
mostly in the cytoplasm thus it is thought to be transcriptionally inactive [89, 95]. GR 
phosphorylated at S211 is transcriptionally active due to conformational changes which 
facilitate increased recruitment of the receptor to GRE-containing promoters and is a target 
for phosphorylation by both cyclin/CDK kinases and MAPK families depending on the cell 
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type [91, 96]. GR phosphorylation at S226 results in inhibition of the GR function, possibly 
due to increased GR nuclear export and is a result of JNK activation [80, 89, 97, 98]. Finally, 
phosphorylation of GR at S404 attenuates GR signalling and is due to GSK3 kinase 
activation [99]. We have recently reported that differential GR phosphorylation in the 
resistant CEM-C1-15 versus sensitive CEM-C7-14 ALL cells modulates GR transcriptional 
activity and target selectivity resulting in diverse pro- or anti-apoptotic Bcl-2 family 
members’ gene expression in the two cell lines [58]. In particular we have shown that GR 
phosphorylation at S211 is predominant in the glucocorticoid-sensitive CEM-C7-14 whereas 
GR phosphorylation at S226 by c-Jun N-terminal Kinase (JNK) occurs more frequently in the 
glucocorticoid-resistant CEM-C1-15 cells [58]. These observations lend support to the 
suggestion that different kinase pathways are responsible for GR phosphorylation in 
resistant versus sensitive cells to glucocorticoid induced apoptosis, thereby causing GR 
transcriptional inactivity in the resistant cell lines [58] concomitant Mcl-1 overexpression 
and hence resistance to GC treatment [56]. 
Apart from the differential expression of pro- and anti-apoptotic Bcl-2 family members [58] 
we have recently reported that GR isoforms localised in mitochondria are predominantly 
phosphorylated at serine 232 compared to serine 246 of the rat GR (corresponding to human 
GR Ser211 and Ser226 respectively) [96] possibly due to differential conformation of the two 
phosphoisoforms or diverse interaction patterns with components of the mitochondrial 
import machinery of the GR phosphorylated at serine 211 versus the GR phosphorylated at 
serine 226. These observations provide an additional potential explanation for the resistance 
of the CEM-C1-15 to glucocorticoids induced apoptosis in accord with recent reports 
indicating differential GR mitochondrial localisation in resistant compared to sensitive ALL 
cells to glucocorticoid induced apoptosis [93, 94, 95, 97]. 
7. Mitochondrial GR, glucocorticoids and cellular energy metabolism  
Glucocorticoid hormones directly affect mitochondrial membranes inducing loss of 
mitochondrial transmembrane potential, thereby affecting vital cellular processes mediated 
by the function of this organelle such as ATP generation via oxidative phosphorylation, 
regulation of calcium flux and apoptosis [98]. In addition, glucocorticoids exert their effects 
on mitochondrial biogenesis through the mitochondrial GR [97, 99, 100, 101]. The 
intracellular trafficking of the glucocorticoid receptor has been shown to play important role 
in glucocorticoid-induced apoptosis [97, 102]. The glucocorticoid receptor translocates to 
mitochondria [97, 100, 101, 102], in various cells including rat brain and various other 
tissues’ mitochondria [99], as well as lymphoma cells [97]. GR translocation to the nucleus 
occurs in both glucocorticoid-sensitive and glucocorticoid-resistant cells, whereas in 
contrast, GR translocation into mitochondria occurs only in the glucocorticoid-sensitive and 
not the resistant cells [97, 103]. The mechanisms by which GR translocates to mitochondria 
and its effects on the regulation of the expression of mitochondrially encoded genes have 
been partially elucidated [97, 100, 101, 102] and require further investigation. However, it is 
noteworthy that glucocorticoids modulate mitochondrial biogenesis and mitochondrial 
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inhibitors of autophagy re-sensitise cancer cells to anticancer therapeutics [70, 71] as well as 
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Glucocorticoid hormones directly affect mitochondrial membranes inducing loss of 
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by the function of this organelle such as ATP generation via oxidative phosphorylation, 
regulation of calcium flux and apoptosis [98]. In addition, glucocorticoids exert their effects 
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intracellular trafficking of the glucocorticoid receptor has been shown to play important role 
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mitochondria [97, 100, 101, 102], in various cells including rat brain and various other 
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been partially elucidated [97, 100, 101, 102] and require further investigation. However, it is 
noteworthy that glucocorticoids modulate mitochondrial biogenesis and mitochondrial 
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energy production pathways by regulating the transcription of the mitochondrial genome 
[99, 100]. 
The process of programmed cell death is energy dependent requiring the precise 
coordination of several biochemical processes including the transcriptional regulation of 
the expression of genes encoding enzymatic components of the energy production 
pathways (oxidative phosphorylation (OXPHOS) and glycolysis) [29] and mutations 
affecting cellular energy production lead to defects in apoptosis and tumourigenesis [104, 
105, 106, 107, 108, 109]. In humans the OXPHOS pathway consists of five multi-subunit 
complexes whose components are encoded by genes located in both the nuclear and the 
mitochondrial genomes [110] supporting the notion that a transcription factor operating 
in both subcellular compartments could coordinate the expression of nuclear and 
mitochondrial genes ensuring appropriate stoichiometry and timely gene expression of 
the components of the respiratory chain [111]. In addition to the availability of the 
components encoded in the nuclear and the mitochondrial compartments an appropriate 
assembly mechanism of these subunits is essential for the functionality of the oxidative 
phosphorylation system [110]. One possible candidate transcription factor able to 
orchestrate nuclear and mitochondrial gene expression is the glucocorticoid receptor 
which mediates gene expression of both nuclear and mitochondrial encoded genes [98, 99, 
100, 102, 112, 113, 114, 115, 116].  
In fact, dexamethasone has been shown to affect energy metabolism and the balance 
between OXPHOS and glycolysis [117, 118]. Also, evidence has been recently presented 
indicating that changes in metabolic patterns and cellular proliferation are key aspects of 
resistance to GC mediated apoptosis in ALL [39]. Elevated glycolytic rate due to increased 
expression of genes involved in glucose metabolism are associated with resistance to 
glucocorticoid induced apoptosis and this resistance can be reversed by inhibitors of 
glycolysis in ALL [119, 120]. Moreover, glucocorticoid induced apoptosis is regulated by 
genes involved in cellular energy metabolism [121, 122, 123, 124] suggesting that 
dexamethasone contributes to the apoptosis / survival decisions in ALL cells indirectly by 
modulating the balance between OXPHOS and glycolysis [15, 120]. Indeed coordination of 
oxidative phosphorylation and glycolysis by mechanisms involving glucocorticoid receptor 
mediated transcriptional regulation of genes encoding enzymes implicated in both 
pathways has been extensively reported in the literature [99, 125, 126]. Enzymes 
participating in the tricarboxylic acid cycle encoded by the nuclear genome such as malate 
dehydrogenase 1 (Mdh1) and succinyl coenzyme A synthetase (Suclg1) are GR 
transcriptional target genes [127]. In addition, several mitochondrial genes encoding 
subunits of the OXPHOS pathway possess one or more functional glucocorticoid responsive 
elements [99, 100, 102, 112, 113] implying that glucocorticoids exert direct effects on 
mitochondrial biogenesis and respiration. Key enzymes involved in glycolysis including 6-
phosphofructo-2-kinase/fructose-2, 6-bisphosphatase [126] lactate dehydrogenase B (LdhB) 
and aldolase A (AldoA) [128] are under GR transcriptional control [120]. 
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To shed light on the molecular mechanisms involved in GR mediated regulation of the 
OXPHOS pathway bioinformatic analysis using the TRED or CCTFSP software [129, 130, 
131] was performed to identify potential glucocorticoid responsive elements (GREs) in the 
promoters of genes encoding Surf-1, and SCO2 enzymes which are essential for the 
assembly of the Cytochrome c Oxidase (COX) wholoenzyme [132, 133, 134]. Similar 
approaches were used to detect possible existence of potential GREs in the regulatory region 
of the promoter of the nuclear gene encoding COX-Va. Putative GREs were identified in the 
regulatory regions of the promoters of Surf-1, SCO2, and COX-Va using this approach. To 
test whether these GREs conferred glucocorticoid responsiveness to the expression of these 
genes, qRT-PCR experiments were performed to quantify their mRNA levels in untreated or 
dexamethasone treated CEM-C1-15 (resistant to glucocorticoid induced apoptosis) and 
CEM-C7-14 (sensitive to glucocorticoid induced apoptosis) ALL cells [135] (Figure 2).  
 
Figure 2. Relative mRNA levels of the COX assembly enzymes Surf-1 (A), SCO-2 (B), and the nuclear 
COX-Va (C) OXPHOS subunit were followed in the resistant CEM-C1-15 and the sensitive CEM-C7-14 
to glucocorticoid induced apoptosis ALL cells treated with dexamethasone for the indicated time points 
by quantitative real-time PCR. Solid lines represent mRNA levels in CEM-C1-15 and dotted lines 
correspond to mRNA levels determined in CEM-C7-14 cells. Error bars represent standard error of the 
mean of five independent experiments and asterisks indicate statistical significance of p<0.05 compared 
to the untreated sample. 
A marked reduction of Surf-1 mRNA levels in the resistant CEM-C1-15 cells was observed 
after 6 and 12 hours of dexamethasone treatment compared to the non-treated cells (Figure 
2A, solid line). In contrast, in the sensitive to glucocorticoid-induced apoptosis CEM-C7-14 
cells, Surf-1 mRNA levels remained constant during the first 6 hours of dexamethasone 
treatment and a moderate increase of Surf-1 mRNA levels was observed only 12h after the 
addition of the hormone (Figure 2A, dotted line). SCO-2 mRNA levels initially increased 
after 3h and 6h of dexamethasone treatment in CEM-C1-15 cells and later after 12h of 
dexamethasone treatment decreased to the level of that exhibited in the untreated cells 
(Figure 2B, solid line). 
The fact that COX-Va expression is altered in various tumours and its association with 
Surf-1 in the formation of sub-complexes consisting of variable COX subunits such as 
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energy production pathways by regulating the transcription of the mitochondrial genome 
[99, 100]. 
The process of programmed cell death is energy dependent requiring the precise 
coordination of several biochemical processes including the transcriptional regulation of 
the expression of genes encoding enzymatic components of the energy production 
pathways (oxidative phosphorylation (OXPHOS) and glycolysis) [29] and mutations 
affecting cellular energy production lead to defects in apoptosis and tumourigenesis [104, 
105, 106, 107, 108, 109]. In humans the OXPHOS pathway consists of five multi-subunit 
complexes whose components are encoded by genes located in both the nuclear and the 
mitochondrial genomes [110] supporting the notion that a transcription factor operating 
in both subcellular compartments could coordinate the expression of nuclear and 
mitochondrial genes ensuring appropriate stoichiometry and timely gene expression of 
the components of the respiratory chain [111]. In addition to the availability of the 
components encoded in the nuclear and the mitochondrial compartments an appropriate 
assembly mechanism of these subunits is essential for the functionality of the oxidative 
phosphorylation system [110]. One possible candidate transcription factor able to 
orchestrate nuclear and mitochondrial gene expression is the glucocorticoid receptor 
which mediates gene expression of both nuclear and mitochondrial encoded genes [98, 99, 
100, 102, 112, 113, 114, 115, 116].  
In fact, dexamethasone has been shown to affect energy metabolism and the balance 
between OXPHOS and glycolysis [117, 118]. Also, evidence has been recently presented 
indicating that changes in metabolic patterns and cellular proliferation are key aspects of 
resistance to GC mediated apoptosis in ALL [39]. Elevated glycolytic rate due to increased 
expression of genes involved in glucose metabolism are associated with resistance to 
glucocorticoid induced apoptosis and this resistance can be reversed by inhibitors of 
glycolysis in ALL [119, 120]. Moreover, glucocorticoid induced apoptosis is regulated by 
genes involved in cellular energy metabolism [121, 122, 123, 124] suggesting that 
dexamethasone contributes to the apoptosis / survival decisions in ALL cells indirectly by 
modulating the balance between OXPHOS and glycolysis [15, 120]. Indeed coordination of 
oxidative phosphorylation and glycolysis by mechanisms involving glucocorticoid receptor 
mediated transcriptional regulation of genes encoding enzymes implicated in both 
pathways has been extensively reported in the literature [99, 125, 126]. Enzymes 
participating in the tricarboxylic acid cycle encoded by the nuclear genome such as malate 
dehydrogenase 1 (Mdh1) and succinyl coenzyme A synthetase (Suclg1) are GR 
transcriptional target genes [127]. In addition, several mitochondrial genes encoding 
subunits of the OXPHOS pathway possess one or more functional glucocorticoid responsive 
elements [99, 100, 102, 112, 113] implying that glucocorticoids exert direct effects on 
mitochondrial biogenesis and respiration. Key enzymes involved in glycolysis including 6-
phosphofructo-2-kinase/fructose-2, 6-bisphosphatase [126] lactate dehydrogenase B (LdhB) 
and aldolase A (AldoA) [128] are under GR transcriptional control [120]. 
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correspond to mRNA levels determined in CEM-C7-14 cells. Error bars represent standard error of the 
mean of five independent experiments and asterisks indicate statistical significance of p<0.05 compared 
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A marked reduction of Surf-1 mRNA levels in the resistant CEM-C1-15 cells was observed 
after 6 and 12 hours of dexamethasone treatment compared to the non-treated cells (Figure 
2A, solid line). In contrast, in the sensitive to glucocorticoid-induced apoptosis CEM-C7-14 
cells, Surf-1 mRNA levels remained constant during the first 6 hours of dexamethasone 
treatment and a moderate increase of Surf-1 mRNA levels was observed only 12h after the 
addition of the hormone (Figure 2A, dotted line). SCO-2 mRNA levels initially increased 
after 3h and 6h of dexamethasone treatment in CEM-C1-15 cells and later after 12h of 
dexamethasone treatment decreased to the level of that exhibited in the untreated cells 
(Figure 2B, solid line). 
The fact that COX-Va expression is altered in various tumours and its association with 
Surf-1 in the formation of sub-complexes consisting of variable COX subunits such as 
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COX-I, COX-II, COX-III, and COX-IV [136] triggered our interest to investigate the 
regulation of the expression of the COX-Va gene. This investigation aimed to test whether 
differential COX-Va cellular levels in the resistant versus the sensitive CEM cells in 
response to glucocorticoid treatment was taking place in a similar way as that observed 
for Surf-1. COX-Va mRNA levels were higher in CEM-C7-14 compared to those detected 
in the CEM-C1-15 cells in all time points of dexamethasone treatment investigated in this 
study and the longer the incubation with the hormone the higher the COX-Va mRNA 
levels in the CEM-C7-14 cells (Figure 2C, compare dotted to solid line). Results shown in 
Figure 2A, 2B, and 2C support the notion that the Surf-1 and COX-Va genes encoded by 
the nuclear genome are under GR transcriptional control and their expression is higher in 




Figure 3. Western blot analysis of Surf-1, SCO-2, and COX-Va in CEM-C1-15 (A) and CEM-C7-14 (B) 
cells treated with dexamethasone for the indicated times. Actin was used as a loading control. 
Densitometric analysis of the western blots presented in A and B was carried out using Image J 
software. The intensity of the bands of Surf-1 (C), SCO2 (D) and COX-Va (E) at each time point was 
normalised to the intensity of the actin band at the respective time point and the obtained values were 
plotted. The intensity of the bands in the untreated cells normalised to the intensity of the actin band in 
the untreated cells was arbitrarily set to 100. The values representing the intensities of the bands in the 
treated cells were calculated as follows: Intensity of band in treated cells/intensity of actin band in 
treated cells x 100 / intensity of band in untreated cells/intensity of actin in untreated cells. Black bars 
represent the CEM-C1-15 cells and the grey bars the CEM-C7-14 cells.  
The protein levels of Surf-1, SCO2 and COX-Va were also followed in CEM-C7-14 and CEM-
C1-15 cells under the same conditions (Figure 3). Higher Surf-1 protein levels were observed 
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in dexamethasone treated CEM-C7-14 cells compared to the non-treated cells for all time 
points tested (Figure 3A, B and C compare grey bars 2, 3 and 4 to grey bar 1). In contrast 
lower Surf-1 protein levels were observed in the dexamethasone treated CEM-C1-15 cells 
irrespectively of the length of the dexamethasone treatment compared to the untreated cells 
(Figure 3A, B and C compare black bars 2, 3 and 4 to black bar 1). In a similar manner to that 
observed for Surf-1, increasing SCO2 protein levels were observed in CEM-C7-14 cells 
treated with dexamethasone for 12h and 24h compared to the untreated cells (Figure 3A, B 
and D compare grey bars 2 and 3 to bar 1). On the contrary lower SCO2 protein levels were 
observed in CEM-C7-14 cells 36h after the addition of dexamethasone compared to the 
untreated cells (Figure 3A, B and D compare grey bar 4 to grey bar 1). On the other side the 
SCO2 protein levels in CEM-C1-15 cells were lower than those measured in the untreated 
cells for all the time points of dexamethasone treatment examined in this study (Figure 3A, 
B and D compare black bars 2, 3 and 4 to black bar 1). Finally the COX-Va protein levels 
were higher in both CEM-C1-15 and CEM-C7-14 cells treated with dexamethasone 
compared to the non-treated cells (Figure 3A, B and E compare black and grey bars 2, 3, and 
4 to grey and black bars 1).  
The expression of COX subunits and oxidative phosphorylation are affected by 
glucocorticoid treatment [137] possibly through the GR transcriptional activity. Given that 
some OXPHOS subunits are encoded by the nuclear genome, and others by the 
mitochondrial DNA, it was thought that glucocorticoids exert indirect effects on the 
regulation of transcription of mitochondrial encoded OXPHOS subunits by modulating the 
activity of nuclear factors involved in the gene expression of mitochondrial genes [101]. 
However, the identification of mitochondrial GR, and the existence of GRE-like domains in 
the mitochondrial genome [100, 101, 138] suggest that glucocorticoids exert direct effects on 
mitochondrial transcription. Taking into consideration the fact that glucocorticoid receptor 
potentially regulates the expression of several COX assembly factors and nuclear COX 
subunits (Figure 2A, 2B and 2C) it was interesting to investigate whether GR fine tunes the 
expression of OXPHOS genes in both nuclear and mitochondrial genomes. In order to assess 
this hypothesis, and in parallel, to strengthen the perception that energy metabolism is a 
possible pathway by which CEM cells determine resistance / sensitivity to glucocorticoid 
induced apoptosis we followed the mRNA levels of the mitochondrial OXPHOS subunits 
COX-I, COX-II and COX-III in CEM C1-15 and CEM C7-14 cells treated with dexamethasone 
(Figures 4A, 4B and 4C). 
A similar picture to that observed for the nuclear OXPHOS components was observed for 
the mitochondrial OXPHOS subunits. Specifically higher cellular levels of the 
mitochondrial COX-I, COX-II and COX-III OXPHOS subunits were observed in CEM-C7-
14 compared to CEM-C1-15 cells (Figure 4A-4C). Increased levels of COX-I mRNA in both 
cell lines after 12 hours of dexamethasone treatment were observed in both CEM-C1-15 
and CEM-C7-14 cells (Figure 4A, compare solid with dotted line). COX-II mRNA 
expression initially decreased in both cell lines 3h after the addition of dexamethasone 
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in dexamethasone treated CEM-C7-14 cells compared to the non-treated cells for all time 
points tested (Figure 3A, B and C compare grey bars 2, 3 and 4 to grey bar 1). In contrast 
lower Surf-1 protein levels were observed in the dexamethasone treated CEM-C1-15 cells 
irrespectively of the length of the dexamethasone treatment compared to the untreated cells 
(Figure 3A, B and C compare black bars 2, 3 and 4 to black bar 1). In a similar manner to that 
observed for Surf-1, increasing SCO2 protein levels were observed in CEM-C7-14 cells 
treated with dexamethasone for 12h and 24h compared to the untreated cells (Figure 3A, B 
and D compare grey bars 2 and 3 to bar 1). On the contrary lower SCO2 protein levels were 
observed in CEM-C7-14 cells 36h after the addition of dexamethasone compared to the 
untreated cells (Figure 3A, B and D compare grey bar 4 to grey bar 1). On the other side the 
SCO2 protein levels in CEM-C1-15 cells were lower than those measured in the untreated 
cells for all the time points of dexamethasone treatment examined in this study (Figure 3A, 
B and D compare black bars 2, 3 and 4 to black bar 1). Finally the COX-Va protein levels 
were higher in both CEM-C1-15 and CEM-C7-14 cells treated with dexamethasone 
compared to the non-treated cells (Figure 3A, B and E compare black and grey bars 2, 3, and 
4 to grey and black bars 1).  
The expression of COX subunits and oxidative phosphorylation are affected by 
glucocorticoid treatment [137] possibly through the GR transcriptional activity. Given that 
some OXPHOS subunits are encoded by the nuclear genome, and others by the 
mitochondrial DNA, it was thought that glucocorticoids exert indirect effects on the 
regulation of transcription of mitochondrial encoded OXPHOS subunits by modulating the 
activity of nuclear factors involved in the gene expression of mitochondrial genes [101]. 
However, the identification of mitochondrial GR, and the existence of GRE-like domains in 
the mitochondrial genome [100, 101, 138] suggest that glucocorticoids exert direct effects on 
mitochondrial transcription. Taking into consideration the fact that glucocorticoid receptor 
potentially regulates the expression of several COX assembly factors and nuclear COX 
subunits (Figure 2A, 2B and 2C) it was interesting to investigate whether GR fine tunes the 
expression of OXPHOS genes in both nuclear and mitochondrial genomes. In order to assess 
this hypothesis, and in parallel, to strengthen the perception that energy metabolism is a 
possible pathway by which CEM cells determine resistance / sensitivity to glucocorticoid 
induced apoptosis we followed the mRNA levels of the mitochondrial OXPHOS subunits 
COX-I, COX-II and COX-III in CEM C1-15 and CEM C7-14 cells treated with dexamethasone 
(Figures 4A, 4B and 4C). 
A similar picture to that observed for the nuclear OXPHOS components was observed for 
the mitochondrial OXPHOS subunits. Specifically higher cellular levels of the 
mitochondrial COX-I, COX-II and COX-III OXPHOS subunits were observed in CEM-C7-
14 compared to CEM-C1-15 cells (Figure 4A-4C). Increased levels of COX-I mRNA in both 
cell lines after 12 hours of dexamethasone treatment were observed in both CEM-C1-15 
and CEM-C7-14 cells (Figure 4A, compare solid with dotted line). COX-II mRNA 
expression initially decreased in both cell lines 3h after the addition of dexamethasone 
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(Figure 4B, compare solid and dotted lines 3h point) and then started to increase steadily 
at 6 and 12h after the treatment with the hormone but it reached higher levels in the CEM-
C7-14 cells (Figure 4B, compare solid line with dotted line). COX-III gene expression 
remains unaffected by glucocorticoid treatment during the first 3 hours, in CEM-C1-15 
cells, followed by two fold increase 6h and 12h after hormone addition (Figure 4C, solid 
line compare 0 time point with 6 and 12h time points). A similar pattern was evident in 
CEM-C7-14 cells where the induction of COX-III mRNA after 6h and 12h of 
dexamethasone treatment was four and five fold higher respectively compared to those 
detected in the untreated cells (Figure 4C, dotted line compare 0 time point with 6 and 
12h time points). 
 
Figure 4. Relative mRNA levels of the mitochondrial OXPHOS subunits COX-I (A), COX-II (B), and 
COX-III (C) were followed in the resistant CEM-C1-15 and the sensitive CEM-C7-14 to glucocorticoid 
induced apoptosis ALL cells treated with dexamethasone for the indicated time points by quantitative 
real-time PCR. Solid lines represent mRNA levels in CEM-C1-15 and dotted lines correspond to mRNA 
levels determined in CEM-C7-14 cells. Error bars represent standard error of the mean of five 
independent experiments and asterisks indicate statistical significance of p<0.05 compared to the 
untreated sample. 
Taken together, results presented in this manuscript endorse the hypothesis that the 
glucocorticoid resistance / sensitivity in CEM cells is determined by differences in the 
efficacy of the OXPHOS system to produce energy in the two cell lines. Support to this 
conclusion is lent by observations shown in Figure 2A, 2B and 2C indicating that the mRNA 
levels of nuclear encoded components of the OXPHOS system were higher in the sensitive 
CEM-C7-14 than in the resistant CEM-C1-15 cells. Higher levels of COX assembly factors in 
CEM-C7-14 cells imply a more efficient energy metabolism in these cells. This could be a 
result of distinct signalling pathways operating in the two cell lines giving rise to increased 
transactivation function of GR in CEM-C7-14 cells, where the receptor could be 
phosphorylated at S211 [58] and stimulate the expression of its potential transcription 
targets Surf-1 and COX-Va, whereas on the contrary, it is phosphorylated at S226 in CEM-
C1-15 cells, thereby targeted to different subset of its transcriptional targets in these cells 
[58]. The link between altered metabolism in cancer cells and varying expression of COX 
subunits has been well established [139, 140, 141]. The presence of mitochondrial GR and of 
GRE-like domains in the mitochondrial genome [100, 102, 138, 142, 143, 144] and regulation 
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of the mitochondrial COX subunits (COX-I, COX-II and COX-III) provide a probable 
mechanism explaining the dexamethasone dependent regulation of the mitochondrial COX 
subunits gene expression (Figure 4). In addition, differences in post translational 
modifications of the receptor, which in the case of CEM-C7-14 cells, allow activation [58] 
and possibly translocation of GR into mitochondria [96] while in CEM-C1-15 cells these 
events are not permissible could be an additional justification for these observations.  
8. Conclusions and future perspectives  
Resistance to glucocorticoid induced apoptosis in ALL has been attributed to several 
different processes and pathways including predominance of certain GR isoforms with 
reduced transcriptional activity [34, 145, 146], either due to altered binding capacity of the 
receptor to other transcription factors [147, 148, 149, 150] or co-regulators [81, 151], disparate 
expression and consequent dissimilar balance between pro- versus anti-apoptotic members 
of the Bcl-2 family [18], GR mitochondrial localisation [97], autophagy [72, 73, 74, 75], and 
post-translational modifications which affect GR transcription target selectivity and protein 
stability [22, 38, 89, 152, 153].  
We have recently presented evidence to suggest that differential GR phosphorylation in 
resistant versus sensitive to glucocorticoid induced apoptosis ALL cells results in selective 
induction of anti-apoptotic and inhibition of pro-apoptotic Bcl-2 family members gene 
expression in the resistant cells [58]. Several reports have indicated the potential role of 
differential kinase activity in glucocorticoid resistant and sensitive cells in determining the 
GR subcellular localisation [96, 98, 154] and diverse effects on the induction of autophagy 
[72, 73, 74]. 
In this study we provide new evidence signifying the differential expression of OXPHOS 
components in glucocorticoid resistant versus sensitive ALL cells and we propose that 
resistant and sensitive CEM cells use different pathways to produce energy. These results are 
in accord with reports showing that resistance to GC in ALL is associated with increased 
glucose consumption [155] with concomitant induction of Mcl-1 expression and resistance to 
apoptosis [39]. In our anticipated model (Figure 5) in resistant lymphocytes the predominantly 
phosphorylated at S226 GR is possibly transcriptionally inactive and thus incapable to 
significantly induce OXPHOS assembly enzymes and COX subunits gene expression or 
translocate into mitochondria thereby exhibiting reduced oxidative phosphorylation consistent 
with a proliferative phenotype, and this is probably one of the mechanisms employed by the 
glucocorticoid-resistant CEM-C1-15 cells to survive GC treatment.  
The results presented in this study endorse the hypothesis that differential GR 
phosphorylation affects components of cellular energy production pathways in distinct 
ways in resistant versus sensitive cells altering energy production and possibly ROS 
generation in unique ways in the two cell lines, suggesting that combination of kinase 
inhibitors, and glycolytic modulators together with dexamethasone could be a possible 
mean by which resistance to glucocorticoid induced apoptosis could be circumvented in 
ALL. 
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phosphorylated at S211 [58] and stimulate the expression of its potential transcription 
targets Surf-1 and COX-Va, whereas on the contrary, it is phosphorylated at S226 in CEM-
C1-15 cells, thereby targeted to different subset of its transcriptional targets in these cells 
[58]. The link between altered metabolism in cancer cells and varying expression of COX 
subunits has been well established [139, 140, 141]. The presence of mitochondrial GR and of 
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of the mitochondrial COX subunits (COX-I, COX-II and COX-III) provide a probable 
mechanism explaining the dexamethasone dependent regulation of the mitochondrial COX 
subunits gene expression (Figure 4). In addition, differences in post translational 
modifications of the receptor, which in the case of CEM-C7-14 cells, allow activation [58] 
and possibly translocation of GR into mitochondria [96] while in CEM-C1-15 cells these 
events are not permissible could be an additional justification for these observations.  
8. Conclusions and future perspectives  
Resistance to glucocorticoid induced apoptosis in ALL has been attributed to several 
different processes and pathways including predominance of certain GR isoforms with 
reduced transcriptional activity [34, 145, 146], either due to altered binding capacity of the 
receptor to other transcription factors [147, 148, 149, 150] or co-regulators [81, 151], disparate 
expression and consequent dissimilar balance between pro- versus anti-apoptotic members 
of the Bcl-2 family [18], GR mitochondrial localisation [97], autophagy [72, 73, 74, 75], and 
post-translational modifications which affect GR transcription target selectivity and protein 
stability [22, 38, 89, 152, 153].  
We have recently presented evidence to suggest that differential GR phosphorylation in 
resistant versus sensitive to glucocorticoid induced apoptosis ALL cells results in selective 
induction of anti-apoptotic and inhibition of pro-apoptotic Bcl-2 family members gene 
expression in the resistant cells [58]. Several reports have indicated the potential role of 
differential kinase activity in glucocorticoid resistant and sensitive cells in determining the 
GR subcellular localisation [96, 98, 154] and diverse effects on the induction of autophagy 
[72, 73, 74]. 
In this study we provide new evidence signifying the differential expression of OXPHOS 
components in glucocorticoid resistant versus sensitive ALL cells and we propose that 
resistant and sensitive CEM cells use different pathways to produce energy. These results are 
in accord with reports showing that resistance to GC in ALL is associated with increased 
glucose consumption [155] with concomitant induction of Mcl-1 expression and resistance to 
apoptosis [39]. In our anticipated model (Figure 5) in resistant lymphocytes the predominantly 
phosphorylated at S226 GR is possibly transcriptionally inactive and thus incapable to 
significantly induce OXPHOS assembly enzymes and COX subunits gene expression or 
translocate into mitochondria thereby exhibiting reduced oxidative phosphorylation consistent 
with a proliferative phenotype, and this is probably one of the mechanisms employed by the 
glucocorticoid-resistant CEM-C1-15 cells to survive GC treatment.  
The results presented in this study endorse the hypothesis that differential GR 
phosphorylation affects components of cellular energy production pathways in distinct 
ways in resistant versus sensitive cells altering energy production and possibly ROS 
generation in unique ways in the two cell lines, suggesting that combination of kinase 
inhibitors, and glycolytic modulators together with dexamethasone could be a possible 
mean by which resistance to glucocorticoid induced apoptosis could be circumvented in 
ALL. 
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Figure 5. Model summarising the proposed mechanism determining resistance / sensitivity of CEM 
cells to glucocorticoid-induced apoptosis. Differential phosphorylation of GR in glucocorticoid resistant 
versus sensitive cells leads to the reduction of gene expression of OXPHOS subunits and pro-apoptotic 
Bcl-2 family members in the resistant cells (left panel) whereas the opposite is the case for the sensitive 
cells (right panel). 
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1. Introduction 
Chronic inflammatory diseases place a social and financial burden on society. 
Glucocorticoids, a class of steroid hormones existing in almost every vertebrate, have been 
exploited for more than 60 years as a therapeutic option for the inflammatory diseases. For 
example, the therapeutic effects of synthetic glucocorticoids, first observed in rheumatoid 
arthritis (RA), led to the awarding of a Nobel prize in 1950 (Slocumb et al., 1950). Based on 
their rapid, profound and wide-ranging effects, glucocorticoids are a mainstay of treatment 
for virtually all inflammatory diseases besides RA, and now are among the most frequently 
prescribed of all medications (Hillier, 2007). Indeed, a community practice survey in 2000 
indicated that up to 1% of the entire adult population is taking systemic glucocorticoids at 
any given time (van Staa et al., 2000). Glucocorticoids have widespread systemic effects, 
particularly on the inflammation and immune response (Barnes, 2006; Chrousos, 1995). 
However, glucocorticoids are associated with dose dependent side effects, including 
diabetes mellitus, osteoporosis, weight gain, and hypertension (Huscher et al., 2009), as well 
as increased risk of cardiovascular events (Davis et al., 2007). Much effort has been expended 
identifying glucocorticoid anti-inflammatory mechanisms of action (Barnes, 2006;  Scha¨cke 
et al., 2002). Understanding of the mechanism of action of glucocorticoids is essential in 
order to devise better ways to treat inflammatory disease, ideally retaining the beneficial 
effects of glucocorticoids but not their adverse effects. 
The discovery of a glucocorticoid-induced protein that could emulate the beneficial, but not 
harmful, effects of glucocorticoids, would represent a landmark in inflammation 
translational research on a glucocorticoid alternative therapy. Glucocorticoid induced 
leucine zipper (GILZ) may be such a candidate molecule. GILZ was first identified in 1997 in 
a gene extraction library, where it was found to be dramatically induced by dexamethasone 
(D'Adamio et al., 1997). Subsequent studies, mostly utilizing forced over expression of GILZ 
have ascertained that GILZ has anti-inflammatory functions that include interactions with 
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as increased risk of cardiovascular events (Davis et al., 2007). Much effort has been expended 
identifying glucocorticoid anti-inflammatory mechanisms of action (Barnes, 2006;  Scha¨cke 
et al., 2002). Understanding of the mechanism of action of glucocorticoids is essential in 
order to devise better ways to treat inflammatory disease, ideally retaining the beneficial 
effects of glucocorticoids but not their adverse effects. 
The discovery of a glucocorticoid-induced protein that could emulate the beneficial, but not 
harmful, effects of glucocorticoids, would represent a landmark in inflammation 
translational research on a glucocorticoid alternative therapy. Glucocorticoid induced 
leucine zipper (GILZ) may be such a candidate molecule. GILZ was first identified in 1997 in 
a gene extraction library, where it was found to be dramatically induced by dexamethasone 
(D'Adamio et al., 1997). Subsequent studies, mostly utilizing forced over expression of GILZ 
have ascertained that GILZ has anti-inflammatory functions that include interactions with 
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the NF-κB and AP-1 pathways (Di Marco et al., 2007;  Mittelstadt & Ashwell, 2001), which 
closely mimics the anti-inflammatory effects of glucocorticoids. Moreover, it has recently 
been shown that GILZ is also expressed in rheumatoid arthritis (RA) synovial tissues, where 
it exerts inhibitory effects on cytokine expression, and inhibiting the expression of GILZ 
results in exacerbation of disease in a mouse model of RA. As we will summarise in this 
Chapter, GILZ is a pivotal endogenous regulator of inflammation and immune responses, 
which could represent a potential new therapeutic alternate to glucocorticoids. 
2. GILZ structure and expression  
2.1. Molecular structure of GILZ 
As shown in Fig 1, GILZ, also named TSC22 domain family protein 3 (TSC22D3),  is a 137-
amino acid protein, consisting of three major domains: the N-terminal (1-75 aa), leucine 
zipper (76-97 aa), and C-terminal domains (98-137 aa) (Beaulieu & Morand, 2011). To date, 
four isoforms of GILZ have been characterized as splice variants from the Tsc22d gene and 
named GILZ1-4 (Soundararajan et al., 2007). The leucine zipper motif of GILZ is located in 
the central part of the protein and mainly mediates the homodimerization of GILZ required 
for many of its functions (Di Marco et al., 2007), while the other two domains are responsible 
for protein-protein interactions between GILZ and transcription factors and signaling 
molecules. For example, the C-terminal of GILZ is a proline-rich region necessary for direct 
binding of GILZ to the p65 subunit of NF-κB (Di Marco et al., 2007;  Riccardi et al., 2001). In 
2001, Aryoldi and colleagues showed that the over expression of GILZ in T cells inhibits the 
activation of NF-κB by binding the p65 subunit of NF-κB and preventing its nuclear 
translocation (Ayroldi et al., 2001). GILZ was co-precipitated with the p65 subunit of NF-κB in 
macrophages stimulated with glucocorticoids, and expression of GILZ with an NF-κB reporter 
inhibits reporter activity (Berrebi et al., 2003). The N-terminal domain of GILZ directly binds 
with the upstream MAP kinase pathway activating molecule Raf-1, to inhibit its function. The 
interaction between GILZ and c-Fos and c-Jun (two constituents of AP-1) also occurs via the 
N-terminal domain of GILZ. Moreover, GILZ also binds to Ras via its tuberous sclerosis 
complex (TSC) box (61-75 aa), or even interacts with Ras and Raf together to form a trimer. 
 
Figure 1. Functional domains of GILZ 
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2.2. Expression of GILZ 
GILZ gene expression is exquisitely sensitive to induction by glucocorticoids. For example, 
in human RA synovial fibroblasts, dexamethasone (Dex), a synthetic drug derived from  
glucocorticoid class of steroid, induced a more than 10-fold increase in GILZ transcripts at a 
concentration of only 1 nM, while 100 nM dexamethasone increased GILZ mRNA by over 
100-fold (Beaulieu et al., 2010a). In vivo, exogenous glucocorticoids induce GILZ expression, 
while blockade of endogenous glucocorticoids inhibits GILZ expression in mouse, and GILZ 
expression is reduced in response to reductions in circulating cortisol in humans (Beaulieu et 
al., 2010a;  Lekva et al., 2009). The dramatic effect of glucocorticoids on GILZ is mediated via 
the direct binding of the glucocorticoid/glucocorticoid receptor (GR) complex to six 
glucocorticoid-responsive elements (GREs) located in the promoter region of the GILZ gene. 
The GILZ promoter also contains two functional forkhead-responsive elements (FHREs), 
which when bound to the transcription factor forkhead box O 3 (FoxO3) facilitate maximal 
GILZ expression induced by glucocorticoid receptor binding (Asselin-Labat et al., 2005b).  
Although GILZ expression is mainly controlled by glucocorticoids (Beaulieu et al., 2010b;  
Berrebi et al., 2003;  Eddleston et al., 2007a), it is also modulated by a variety of cytokines 
(Eddleston et al., 2007a). For example, GILZ is up-regulated by IL-10 (Berrebi et al., 2003), IL-
15 and TGF- (Ayroldi & Riccardi, 2009;  Cohen et al., 2006a), whereas GILZ is down-
regulated by IL-2 in some cell types. IL-2 can inhibit FoxO3 transcriptional activity, thus 
inhibiting glucocorticoid induced GILZ expression (Asselin-Labat et al., 2005a). Some 
inflammatory stimuli, such as tumor necrosis factor (TNF) and lipopolysaccharide (LPS), 
were also found to reduce GILZ mRNA expression in fibroblast like synoviocytes (Beaulieu 
et al., 2010b). GILZ expression can also be regulated by other anti-inflammatory molecule 
such as Annexin A1. Yang et al have reported that in Annexin A1 deficient cells, 
dexamethasone failed to significantly induce GILZ, in contrast to wild type cells (Yang et al., 
2009), which indicates a regulatory role of Annexin A1 on GILZ expression.  
Interestingly, GILZ expression is also modulated by the oxygen environment. Wang and 
colleagues recently found that hypoxia not only remarkably upregulated the expression of 
GILZ, but also significantly enhanced Dex-induced expression of GILZ in macrophages and 
the spleen of rats (Wang et al., 2011). They also reported ERK MAP kinase activity is 
involved in the upregulation of GILZ induced by hypoxia. 
To date, GILZ has been discovered to be expressed in a variety of tissues (Table 1). This 
information indicates a widespread distribution of GILZ in the human body and suggests it 
is well placed for a role as a pivotal regulator of inflammation. Moreover, growing evidence 
showed that GILZ is present in a wide range of cell types that are sensitive to 
glucocorticoids in vitro. In 1997, GILZ was first identified in T cells, in which GILZ inhibited 
T cell receptor (TCR)-mediated T cell activation (D'Adamio et al., 1997). Since then, GILZ has 
been shown to be expressed in other immune cells, including monocytes/macrophages, mast 
cells, and dendritic cells (Berrebi et al., 2003; Cohen et al., 2006b; Godot et al., 2006; Hamdi et 
al., 2007a), and to have numerous anti-inflammatory functions in these cells. These functions 
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the NF-κB and AP-1 pathways (Di Marco et al., 2007;  Mittelstadt & Ashwell, 2001), which 
closely mimics the anti-inflammatory effects of glucocorticoids. Moreover, it has recently 
been shown that GILZ is also expressed in rheumatoid arthritis (RA) synovial tissues, where 
it exerts inhibitory effects on cytokine expression, and inhibiting the expression of GILZ 
results in exacerbation of disease in a mouse model of RA. As we will summarise in this 
Chapter, GILZ is a pivotal endogenous regulator of inflammation and immune responses, 
which could represent a potential new therapeutic alternate to glucocorticoids. 
2. GILZ structure and expression  
2.1. Molecular structure of GILZ 
As shown in Fig 1, GILZ, also named TSC22 domain family protein 3 (TSC22D3),  is a 137-
amino acid protein, consisting of three major domains: the N-terminal (1-75 aa), leucine 
zipper (76-97 aa), and C-terminal domains (98-137 aa) (Beaulieu & Morand, 2011). To date, 
four isoforms of GILZ have been characterized as splice variants from the Tsc22d gene and 
named GILZ1-4 (Soundararajan et al., 2007). The leucine zipper motif of GILZ is located in 
the central part of the protein and mainly mediates the homodimerization of GILZ required 
for many of its functions (Di Marco et al., 2007), while the other two domains are responsible 
for protein-protein interactions between GILZ and transcription factors and signaling 
molecules. For example, the C-terminal of GILZ is a proline-rich region necessary for direct 
binding of GILZ to the p65 subunit of NF-κB (Di Marco et al., 2007;  Riccardi et al., 2001). In 
2001, Aryoldi and colleagues showed that the over expression of GILZ in T cells inhibits the 
activation of NF-κB by binding the p65 subunit of NF-κB and preventing its nuclear 
translocation (Ayroldi et al., 2001). GILZ was co-precipitated with the p65 subunit of NF-κB in 
macrophages stimulated with glucocorticoids, and expression of GILZ with an NF-κB reporter 
inhibits reporter activity (Berrebi et al., 2003). The N-terminal domain of GILZ directly binds 
with the upstream MAP kinase pathway activating molecule Raf-1, to inhibit its function. The 
interaction between GILZ and c-Fos and c-Jun (two constituents of AP-1) also occurs via the 
N-terminal domain of GILZ. Moreover, GILZ also binds to Ras via its tuberous sclerosis 
complex (TSC) box (61-75 aa), or even interacts with Ras and Raf together to form a trimer. 
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2.2. Expression of GILZ 
GILZ gene expression is exquisitely sensitive to induction by glucocorticoids. For example, 
in human RA synovial fibroblasts, dexamethasone (Dex), a synthetic drug derived from  
glucocorticoid class of steroid, induced a more than 10-fold increase in GILZ transcripts at a 
concentration of only 1 nM, while 100 nM dexamethasone increased GILZ mRNA by over 
100-fold (Beaulieu et al., 2010a). In vivo, exogenous glucocorticoids induce GILZ expression, 
while blockade of endogenous glucocorticoids inhibits GILZ expression in mouse, and GILZ 
expression is reduced in response to reductions in circulating cortisol in humans (Beaulieu et 
al., 2010a;  Lekva et al., 2009). The dramatic effect of glucocorticoids on GILZ is mediated via 
the direct binding of the glucocorticoid/glucocorticoid receptor (GR) complex to six 
glucocorticoid-responsive elements (GREs) located in the promoter region of the GILZ gene. 
The GILZ promoter also contains two functional forkhead-responsive elements (FHREs), 
which when bound to the transcription factor forkhead box O 3 (FoxO3) facilitate maximal 
GILZ expression induced by glucocorticoid receptor binding (Asselin-Labat et al., 2005b).  
Although GILZ expression is mainly controlled by glucocorticoids (Beaulieu et al., 2010b;  
Berrebi et al., 2003;  Eddleston et al., 2007a), it is also modulated by a variety of cytokines 
(Eddleston et al., 2007a). For example, GILZ is up-regulated by IL-10 (Berrebi et al., 2003), IL-
15 and TGF- (Ayroldi & Riccardi, 2009;  Cohen et al., 2006a), whereas GILZ is down-
regulated by IL-2 in some cell types. IL-2 can inhibit FoxO3 transcriptional activity, thus 
inhibiting glucocorticoid induced GILZ expression (Asselin-Labat et al., 2005a). Some 
inflammatory stimuli, such as tumor necrosis factor (TNF) and lipopolysaccharide (LPS), 
were also found to reduce GILZ mRNA expression in fibroblast like synoviocytes (Beaulieu 
et al., 2010b). GILZ expression can also be regulated by other anti-inflammatory molecule 
such as Annexin A1. Yang et al have reported that in Annexin A1 deficient cells, 
dexamethasone failed to significantly induce GILZ, in contrast to wild type cells (Yang et al., 
2009), which indicates a regulatory role of Annexin A1 on GILZ expression.  
Interestingly, GILZ expression is also modulated by the oxygen environment. Wang and 
colleagues recently found that hypoxia not only remarkably upregulated the expression of 
GILZ, but also significantly enhanced Dex-induced expression of GILZ in macrophages and 
the spleen of rats (Wang et al., 2011). They also reported ERK MAP kinase activity is 
involved in the upregulation of GILZ induced by hypoxia. 
To date, GILZ has been discovered to be expressed in a variety of tissues (Table 1). This 
information indicates a widespread distribution of GILZ in the human body and suggests it 
is well placed for a role as a pivotal regulator of inflammation. Moreover, growing evidence 
showed that GILZ is present in a wide range of cell types that are sensitive to 
glucocorticoids in vitro. In 1997, GILZ was first identified in T cells, in which GILZ inhibited 
T cell receptor (TCR)-mediated T cell activation (D'Adamio et al., 1997). Since then, GILZ has 
been shown to be expressed in other immune cells, including monocytes/macrophages, mast 
cells, and dendritic cells (Berrebi et al., 2003; Cohen et al., 2006b; Godot et al., 2006; Hamdi et 
al., 2007a), and to have numerous anti-inflammatory functions in these cells. These functions 
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are outlined in the following sections. Besides immune cells, GILZ has also been shown to 
express in other cell types such as epithelial cells and bone-marrow-derived mesenchymal 
stem cells (MSCs). For example, GILZ was reported to inhibit NF-κB activation in epithelial 
cells and MSCs (Eddleston et al., 2007b;  Yang et al., 2008). The studies also reported the 
expression of GILZ is necessary for dexamethasone-mediated inhibition of IL-8 production 
in respiratory epithelial cells and similarly for the dexamethasone-dependent inhibition of 
cyclo-oxygenase 2 expression in MSCs. 
 
Tissue types Expression of GILZ Reference(s)
   
Lymphoid tissue  Lymphocytes mainly from 
thymus, spleen, and lymph nodes
(Asselin-Labat et al., 2004;  D'Adamio 
et al., 1997;  Riccardi et al., 2001) 
Brain  Ubiquitously expressed in rat 
brain  
(van der Laan, 2008) 
Renal epithelium mammalian kidney epithelial 
cells 
(Soundararajan et al., 2009) 
Collecting duct  the cortical collecting duct of the 
mouse kidney 
(Robert-Nicoud et al., 2001) 
Ovaries normal ovary and epithelial 
ovary cancer  
(Redjimi et al., 2009) 
Bone tissue fetal osteoblasts, mesenchymal 
stem cells, and osteoclasts 
(Lekva et al., 2010) 
Skeletal muscle 
and cardiac tissue 
skeletal muscle tissue and 
myoblasts 
(Bruscoli et al., 2010) 
Table 1. Expression of GILZ in different tissues 
3. Effects of GILZ on the immune response 
3.1. Innate immunity 
A variety of studies suggest that GILZ has critical inhibitory effects on the activity of the 
innate immune system. In a monocytic cell line (THP-1), RANTES (also known as CCL5) 
and MIP-1 (also known as CCL3), antigen presenting MHC class II molecules, B7 co-
stimulatory molecules CD80 and CD86, and the the pathogen-associated molecular pattern 
(PAMP) receptor TLR2, are all modulated by GILZ, with an expected effect on reducing 
recruitment and activation of inflammatory cells (Berrebi et al., 2003;  Cohen et al., 2006b). 
Furthermore, in liver disease, GILZ expression in Kupffer macrophages due to 
glucocorticoids treatment reduces the production of pro-inflammatory mediators in 
response to LPS (Hamdi et al., 2007a). Besides macrophages and monocytes, GILZ is also 
expressed in human airway epithelial cells and inhibited by IL-1, TNF and interferon 
(IFN)-, and overexpression of GILZ inhibited the activation of NF-κB by IL-1 and TLR 
ligands (Eddleston et al., 2007b). Currently, it is known that GILZ expression is inhibited by 
different pro-inflammatory mediators. For example, GILZ was not produced in granulomas 
in Crohn disease and tuberculosis since the macrophages in the granulomas were activated 
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with the strong expression of the RANTES gene (Berrebi et al., 2003). By contrast, GILZ 
expression is retained in macrophages in Burkitt lymphomas, potentially contributing to the 
failure of the immune system to reject the tumor (Berrebi et al., 2003). Taken together, these 
results above indicate a wide range of inhibitory effects of GILZ in a variety of innate immune 
responses. Clearly, immune responses, such as the expression of cytokines, chemokines and 
TLRs, are highly pertinent to the known pathology of inflammatory diseases such as RA. Of 
note, no in vivo studies of the role of GILZ in regulating classic innate immune responses, such 
as responses to endotoxin or other TLR ligands, have been reported.  
3.2. Adaptive immunity 
Parallel to innate immune responses, multiple critical functions of GILZ have been found 
which regulate the activity of antigen-presenting and effector cells of the adaptive immune 
response. For example, GILZ can mediate the effects of glucocorticoids on dendritic cells 
(DCs), whose maturation and antigen presentation are impaired in the presence of increased 
GILZ. Cohen et al demonstrated that GILZ over expression altered MHC and co-stimulatory 
molecule expression, resulting in reduced antigen presentation (Cohen et al., 2006a), and 
subsequent decreased T lymphocyte activation. Moreover, the expression of GILZ is 
induced by glucocorticoids and transforming growth factor  (TGF-β) in immature DCs, and 
oral administration of glucocorticoids to patients increased the expression of GILZ in 
antigen-presenting cells (Cohen et al., 2006b). The overexpression of GILZ is also able to 
drive the development of regulatory DCs, which secrete IL-10, and prevent the production 
of pro-inflammatory cytokines induced by CD40L. Furthermore, these GILZ-expressing 
regulatory DCs were found to induced CD25hiFoxP3+CTLA-4+, IL-10 secreting T-regulatory 
cells from CD4+ T-lymphocytes (Hamdi et al., 2007b), resulting in inhibition of subsequent 
immune responses to specific antigens (Suffia et al., 2006). Regulatory T cells (Tregs) that 
inhibit activation of other T lymphocytes are generated in response to GILZ over expressing 
dendritic cells (Hamdi et al., 2007b), providing a further immunomodulatory effect of GILZ. 
This immunosuppressive effect of GILZ on DCs is extremely relevant in the context of 
inflammatory pathology since DCs determine whether antigen presentation will lead to an 
immune response or a tolerogenic response. 
Additional knowledge of the effects of GILZ in adaptive immunity arises from studies of 
modified GILZ expression in T lymphocyte cells. For example, Cannarile and colleagues 
have demonstrated increased secretion of cytokines associated with a TH2 response, such as 
IL-4, IL-10, IL-5, and IL-13, and reduced expression of cytokines associated with a TH1 
response such as IFN-γ in GILZ overexpressing cells compared with wild type T cells 
(Cannarile et al., 2006a). In their study on GILZ transgenic T lymphocytes, they found there 
was decreased expression of T-box protein 21 (T-bet) (Cannarile et al., 2006a), a transcription 
factor specifically associated with a TH1 response, and increased expression of the 
transcription factors GATA-3 and STAT6. As STAT6 modulates GATA3 which is important 
for polarization towards a TH2 phenotype (Wurster et al., 2000;  Zheng & Flavell, 1997), these 
studies indicate that the expression of GILZ promotes T lymphocyte development towards a 
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are outlined in the following sections. Besides immune cells, GILZ has also been shown to 
express in other cell types such as epithelial cells and bone-marrow-derived mesenchymal 
stem cells (MSCs). For example, GILZ was reported to inhibit NF-κB activation in epithelial 
cells and MSCs (Eddleston et al., 2007b;  Yang et al., 2008). The studies also reported the 
expression of GILZ is necessary for dexamethasone-mediated inhibition of IL-8 production 
in respiratory epithelial cells and similarly for the dexamethasone-dependent inhibition of 
cyclo-oxygenase 2 expression in MSCs. 
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thymus, spleen, and lymph nodes
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(van der Laan, 2008) 
Renal epithelium mammalian kidney epithelial 
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3. Effects of GILZ on the immune response 
3.1. Innate immunity 
A variety of studies suggest that GILZ has critical inhibitory effects on the activity of the 
innate immune system. In a monocytic cell line (THP-1), RANTES (also known as CCL5) 
and MIP-1 (also known as CCL3), antigen presenting MHC class II molecules, B7 co-
stimulatory molecules CD80 and CD86, and the the pathogen-associated molecular pattern 
(PAMP) receptor TLR2, are all modulated by GILZ, with an expected effect on reducing 
recruitment and activation of inflammatory cells (Berrebi et al., 2003;  Cohen et al., 2006b). 
Furthermore, in liver disease, GILZ expression in Kupffer macrophages due to 
glucocorticoids treatment reduces the production of pro-inflammatory mediators in 
response to LPS (Hamdi et al., 2007a). Besides macrophages and monocytes, GILZ is also 
expressed in human airway epithelial cells and inhibited by IL-1, TNF and interferon 
(IFN)-, and overexpression of GILZ inhibited the activation of NF-κB by IL-1 and TLR 
ligands (Eddleston et al., 2007b). Currently, it is known that GILZ expression is inhibited by 
different pro-inflammatory mediators. For example, GILZ was not produced in granulomas 
in Crohn disease and tuberculosis since the macrophages in the granulomas were activated 
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with the strong expression of the RANTES gene (Berrebi et al., 2003). By contrast, GILZ 
expression is retained in macrophages in Burkitt lymphomas, potentially contributing to the 
failure of the immune system to reject the tumor (Berrebi et al., 2003). Taken together, these 
results above indicate a wide range of inhibitory effects of GILZ in a variety of innate immune 
responses. Clearly, immune responses, such as the expression of cytokines, chemokines and 
TLRs, are highly pertinent to the known pathology of inflammatory diseases such as RA. Of 
note, no in vivo studies of the role of GILZ in regulating classic innate immune responses, such 
as responses to endotoxin or other TLR ligands, have been reported.  
3.2. Adaptive immunity 
Parallel to innate immune responses, multiple critical functions of GILZ have been found 
which regulate the activity of antigen-presenting and effector cells of the adaptive immune 
response. For example, GILZ can mediate the effects of glucocorticoids on dendritic cells 
(DCs), whose maturation and antigen presentation are impaired in the presence of increased 
GILZ. Cohen et al demonstrated that GILZ over expression altered MHC and co-stimulatory 
molecule expression, resulting in reduced antigen presentation (Cohen et al., 2006a), and 
subsequent decreased T lymphocyte activation. Moreover, the expression of GILZ is 
induced by glucocorticoids and transforming growth factor  (TGF-β) in immature DCs, and 
oral administration of glucocorticoids to patients increased the expression of GILZ in 
antigen-presenting cells (Cohen et al., 2006b). The overexpression of GILZ is also able to 
drive the development of regulatory DCs, which secrete IL-10, and prevent the production 
of pro-inflammatory cytokines induced by CD40L. Furthermore, these GILZ-expressing 
regulatory DCs were found to induced CD25hiFoxP3+CTLA-4+, IL-10 secreting T-regulatory 
cells from CD4+ T-lymphocytes (Hamdi et al., 2007b), resulting in inhibition of subsequent 
immune responses to specific antigens (Suffia et al., 2006). Regulatory T cells (Tregs) that 
inhibit activation of other T lymphocytes are generated in response to GILZ over expressing 
dendritic cells (Hamdi et al., 2007b), providing a further immunomodulatory effect of GILZ. 
This immunosuppressive effect of GILZ on DCs is extremely relevant in the context of 
inflammatory pathology since DCs determine whether antigen presentation will lead to an 
immune response or a tolerogenic response. 
Additional knowledge of the effects of GILZ in adaptive immunity arises from studies of 
modified GILZ expression in T lymphocyte cells. For example, Cannarile and colleagues 
have demonstrated increased secretion of cytokines associated with a TH2 response, such as 
IL-4, IL-10, IL-5, and IL-13, and reduced expression of cytokines associated with a TH1 
response such as IFN-γ in GILZ overexpressing cells compared with wild type T cells 
(Cannarile et al., 2006a). In their study on GILZ transgenic T lymphocytes, they found there 
was decreased expression of T-box protein 21 (T-bet) (Cannarile et al., 2006a), a transcription 
factor specifically associated with a TH1 response, and increased expression of the 
transcription factors GATA-3 and STAT6. As STAT6 modulates GATA3 which is important 
for polarization towards a TH2 phenotype (Wurster et al., 2000;  Zheng & Flavell, 1997), these 
studies indicate that the expression of GILZ promotes T lymphocyte development towards a 
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TH2 instead of TH1 phenotype. Moreover, mice transgenic for GILZ under the control of the 
CD2 promoter, that overexpresse GILZ in T cells, display a TH2-skewed phenotype, and are 
protected from the TH1-dependent model of dinitrobenzene sulfonic acid (DNBS)-induced 
colitis but exhibit an increase in the ‘allergenic’ TH2 Oxazolone-induced colitis (Cannarile et 
al., 2009). Another study investigated the levels of inflammatory mediators in wild type and 
GILZ transgenic mice induced with DNBS, and were able to demonstrate a decrease in pro-
inflammatory cytokines and NF-κB activation in GILZ transgenic mice compared to wild 
type. Furthermore, in T-cell specific GILZ transgenic mice, young animals do not exhibit a 
significant difference in thymic weight. However, there was a significant decrease in 
CD4+CD8+ double positive thymocytes. There was also a parallel increase in CD4-CD8- 
double negative and CD8+ T-cells, but no change in the CD4+ population (Delfino et al., 
2004). In the aged mice, the CD4+ population also increased in a significant manner, 
although not as dramatically as the CD8+ or the CD4-CD8- populations, signifying a 
disturbance in thymic maturation. The observation above is interesting since GILZ might 
mediate some of the glucocorticoid-triggered apoptotic effects during thymic development. 
Microarray studies also show that GILZ is expressed in resting B cells, and it is presumed 
that GILZ down-regulation facilitates B-cell activation (Glynne et al., 2000). 
4. Effect of GILZ on signalling pathways 
4.1. NF-κB pathway 
To date, much research has focused on the function of the NF-κB pathway in the anti-
inflammatory effects of glucocorticoids (Auphan et al., 1995;  DeBosscher & Haegeman, 
2009;  Gossye et al., 2009). Glucocorticoids are known as effective inhibitors of the NF-κB 
pathway, and considerable research directed at understanding the antagonistic effects of 
glucocorticoids on this pathway has been undertaken (De Bosscher et al., 2003). As shown in 
Fig 2, GILZ, significantly up regulated in the presence of glucocorticoids, participates in the 
inhibition of NF-κB by glucocorticoids through a physical interaction with the NF-κB p65 
subunit (Ayroldi et al., 2001), preventing its nuclear translocation. The inhibition of GILZ is 
independent from other IB- or Rel-related proteins, since GILZ was found to co-
immunoprecipitate with NF-κB p65 subunit in the presence or absence of IB (Ayroldi et al., 
2001). Subsequently, Yang et al demonstrated the role of GILZ in the inhibition of the 
inflammatory mediator COX-2 in MCSs in response to IL-1 and TNF-, by preventing NF-κB 
p65 subunit nuclear transport (Yang et al., 2008). Similarly, the mechanism of GILZ-NF-κB 
mediated inhibition of COX-2 transcription has been shown in epithelial cells (Eddleston et 
al., 2007b). The inhibition of NF-κB by GILZ has also been demonstrated in vivo, in a transgenic 
mouse model in which GILZ expression is driven by the CD2 promoter, resulting in the 
overexpression of GILZ in thymocytes (Delfino et al., 2006). When subjected to T-cell receptor-
triggered apoptosis, the nuclear translocation and DNA binding of NF-κB were impaired in T 
cells from GILZ transgenic mice, whereas the translocation of transcription factors belonging 
to the NFAT family was not affected. All the findings above arouse interest in GILZ and its 
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function in the pathogenesis of NF-B–related inflammatory diseases. For example, GILZ 
transgenic mice demonstrated reduced NF-κB activation in spinal cord injury in comparison to 
wild type mice, and overexpression of GILZ protects TH1 inflammatory responses in colitis 
associated with inhibition of nuclear and phosphorylated p65 (Cannarile et al., 2009; Esposito et 
al. 2011). Moreover, Srinivasan and colleagues have described a novel NF-κB p65-binding 
GILZ-derived peptide which exhibited therapeutic potential as a small molecule NF-κB 
inhibitor in experimental autoimmune encephalomyelitis (EAE), a model of human multiple 
sclerosis (Srinivasan & Janardhanam, 2011a).  
4.2. AP-1 pathway 
The transcription factor AP-1 is another major participant in inflammatory and immune 
responses (Adcock & Caramori, 2001). AP-1, as a heterodimer of the c-Fos and c-Jun 
proteins, can be phosphorylated to significantly increase its transcriptional activity. The 
direct inhibitory effects of the glucocorticoid-glucocorticoid receptor complex on AP-1 
signaling are well documented (De Bosscher et al., 2003). It is also known that 
glucocorticoids lead to the repression of mitogen-activated protein kinase (MAPK) activity 
and hence AP-1 activation through the expression of phosphatases that exert inhibitory 
interactions with various MAPK members (Aeberli et al., 2006). Of interest, Mittelstadt and 
colleagues showed direct binding of GILZ to the AP-1 components c-Jun and c-Fos (Fig 2) in 
Jurkat cells (an immortalized line of T cells) (Mittelstadt & Ashwell, 2001). The paper also 
showed GILZ is critical for the regulation of FasL expression in response to glucocorticoids. 
FasL is a promoter containing NFAT binding elements and under regulation of the 
NFAT/AP-1 complex signalling. FasL promoter and its enhancer elements, early growth 
response factor (Erg) -2 and Erg-3 were inhibited by transient transfection of GILZ in 
Jurkat cells. The authors demonstrated that c-Fos and c-Jun do in fact interact with N-
terminal, but not the LZ or PER domains, of GILZ. Furthermore, Ayroldi et al. confirmed 
the interaction of GILZ with c-Fos and c-Jun, and further showed that GILZ expression 
interferes with c-Fos transcription in response to anti-CD3 stimulation of IL-2, but not c-
Jun, and also by negatively interfering with upstream signalling of Raf-1-ERK pathway 
(Ayroldi et al., 2002).  
4.3. MAP kinase pathways 
The MAP kinase family consists of extracellular signal-regulated kinase (ERK), p38 kinase, 
and JNK, all of which can be activated by upstream molecules such as Ras and Raf-1 
(Rincon, 2001) and all of which phosphorylate downstream proteins in the respective 
cascades to regulate expression of a variety of genes related to inflammation, cell 
proliferation, differentiation and apoptosis. GILZ has also been shown to bind to both Raf-1 
(Ayroldi et al., 2002) and Ras (Ayroldi et al., 2007) and thereby to modulate downstream 
signalling (Fig 2). Ayroldi and colleagues reported that GILZ overexpression in anti-CD3-
stimulated T cells can bind to Raf-1, which inhibits phosphorylation of Raf-1 and results in 
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TH2 instead of TH1 phenotype. Moreover, mice transgenic for GILZ under the control of the 
CD2 promoter, that overexpresse GILZ in T cells, display a TH2-skewed phenotype, and are 
protected from the TH1-dependent model of dinitrobenzene sulfonic acid (DNBS)-induced 
colitis but exhibit an increase in the ‘allergenic’ TH2 Oxazolone-induced colitis (Cannarile et 
al., 2009). Another study investigated the levels of inflammatory mediators in wild type and 
GILZ transgenic mice induced with DNBS, and were able to demonstrate a decrease in pro-
inflammatory cytokines and NF-κB activation in GILZ transgenic mice compared to wild 
type. Furthermore, in T-cell specific GILZ transgenic mice, young animals do not exhibit a 
significant difference in thymic weight. However, there was a significant decrease in 
CD4+CD8+ double positive thymocytes. There was also a parallel increase in CD4-CD8- 
double negative and CD8+ T-cells, but no change in the CD4+ population (Delfino et al., 
2004). In the aged mice, the CD4+ population also increased in a significant manner, 
although not as dramatically as the CD8+ or the CD4-CD8- populations, signifying a 
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mediate some of the glucocorticoid-triggered apoptotic effects during thymic development. 
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4. Effect of GILZ on signalling pathways 
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function in the pathogenesis of NF-B–related inflammatory diseases. For example, GILZ 
transgenic mice demonstrated reduced NF-κB activation in spinal cord injury in comparison to 
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GILZ-derived peptide which exhibited therapeutic potential as a small molecule NF-κB 
inhibitor in experimental autoimmune encephalomyelitis (EAE), a model of human multiple 
sclerosis (Srinivasan & Janardhanam, 2011a).  
4.2. AP-1 pathway 
The transcription factor AP-1 is another major participant in inflammatory and immune 
responses (Adcock & Caramori, 2001). AP-1, as a heterodimer of the c-Fos and c-Jun 
proteins, can be phosphorylated to significantly increase its transcriptional activity. The 
direct inhibitory effects of the glucocorticoid-glucocorticoid receptor complex on AP-1 
signaling are well documented (De Bosscher et al., 2003). It is also known that 
glucocorticoids lead to the repression of mitogen-activated protein kinase (MAPK) activity 
and hence AP-1 activation through the expression of phosphatases that exert inhibitory 
interactions with various MAPK members (Aeberli et al., 2006). Of interest, Mittelstadt and 
colleagues showed direct binding of GILZ to the AP-1 components c-Jun and c-Fos (Fig 2) in 
Jurkat cells (an immortalized line of T cells) (Mittelstadt & Ashwell, 2001). The paper also 
showed GILZ is critical for the regulation of FasL expression in response to glucocorticoids. 
FasL is a promoter containing NFAT binding elements and under regulation of the 
NFAT/AP-1 complex signalling. FasL promoter and its enhancer elements, early growth 
response factor (Erg) -2 and Erg-3 were inhibited by transient transfection of GILZ in 
Jurkat cells. The authors demonstrated that c-Fos and c-Jun do in fact interact with N-
terminal, but not the LZ or PER domains, of GILZ. Furthermore, Ayroldi et al. confirmed 
the interaction of GILZ with c-Fos and c-Jun, and further showed that GILZ expression 
interferes with c-Fos transcription in response to anti-CD3 stimulation of IL-2, but not c-
Jun, and also by negatively interfering with upstream signalling of Raf-1-ERK pathway 
(Ayroldi et al., 2002).  
4.3. MAP kinase pathways 
The MAP kinase family consists of extracellular signal-regulated kinase (ERK), p38 kinase, 
and JNK, all of which can be activated by upstream molecules such as Ras and Raf-1 
(Rincon, 2001) and all of which phosphorylate downstream proteins in the respective 
cascades to regulate expression of a variety of genes related to inflammation, cell 
proliferation, differentiation and apoptosis. GILZ has also been shown to bind to both Raf-1 
(Ayroldi et al., 2002) and Ras (Ayroldi et al., 2007) and thereby to modulate downstream 
signalling (Fig 2). Ayroldi and colleagues reported that GILZ overexpression in anti-CD3-
stimulated T cells can bind to Raf-1, which inhibits phosphorylation of Raf-1 and results in 
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suppression of MEK and ERK1/2 phosphorylation (Ayroldi et al., 2002). They also found that 
GILZ can bind to Raf-1 via the NH2-terminal region of GILZ and Ras via the TSC box of 
GILZ. The interaction of GILZ with Ras or Raf-1 has been shown to be dependent on the 
activation of Ras, where GILZ will bind predominately to Raf-1 in the absence of active Ras. 
However, as Ras is activated, Raf-1 will bind to Ras to a stronger degree than it will bind to 
GILZ. Furthermore, the affinity of GILZ to Ras will also increase, leading to predominately 
GILZ-Ras complexes (Ayroldi, 2007). GILZ may also form a trimer with both Ras and Raf-1, 
and this is also dependent on Ras activation. All the results above suggest that GILZ inhibits 
cell activation and inflammation via regulation of MAPK signaling molecules.  
4.4. PI3K/Akt and apoptotic signalling pathways  
The inhibition by GILZ of Ras and Raf-1 also decreases the activation of another 
downstream signalling pathway, the PI3 kinase (PI3K)/Akt pathway, which is involved in 
cell survival as well as activation. Recent studies have uncovered a crucial role for FoxO3 in 
mediation of PI3K/Akt pathway. In the cell, non-phosphorylated FoxO3 migrates into the 
nucleus and up-regulates several mediators of cell cycle progression, such as G1/S-specific 
cyclin-D1, p27KIP1 (also known as cyclin-dependent kinase inhibitor 1B), Fas ligand (also 
known as tumor necrosis factor ligand superfamily member 6) and Bim (also known as Bcl-
2-like protein 11), to inhibit cell proliferation (Schmidt et al., 2002). Activation of Akt leads to 
the phosphorylation of FoxO3, which results in the nuclear exclusion of FoxO3 and thus 
leads to the inhibition of their cognate transcriptional targets. Interestingly, the gene 
encoding GILZ has been identified as a transcriptional target of FoxO3 (Asselin-Labat et al., 
2005b). Other studies have demonstrated that GILZ can inhibit its own expression through a 
negative feedback effect to promote nuclear exclusion of FoxO3 shown in Fig 2 (Latre de 
Late et al., 2010). However, until now, the net effect of the PI3K/Akt-FoxO3–GILZ regulatory 
loop on cell proliferation has not yet been clearly defined. 
GILZ has also been shown to modulate the expression of a variety of apoptosis pathway 
proteins in accordance with the observations that GILZ can prevent anti-CD3 mediated 
apoptosis (D'Adamio et al., 1997). Asselin-Labat and colleagues showed that an increase in 
GILZ expression down-regulates the expression of Bim, a pro-apoptotic member of the Bcl-2 
family, but has no effect on Bcl-xL protein, an anti-apoptotic Bcl-2 family protein, to prevent 
apoptosis. In the same study, they demonstrated that knockdown of GILZ accelerates IL-2-
deprivation-mediated apoptosis in the IL-2-dependent, CTLL-2 cell line, through increased 
levels of Bim (Asselin-Labat et al., 2004). Furthermore, they showed that GILZ acts on Bim 
through the transcriptional factor FoxO3. Using a Bim-promoter-luciferase construct, GILZ 
expression was shown to repress Bim transcription, and these effects were abrogated with 
the co-expression of FoxO3 (Asselin-Labat et al., 2004). However, it had been previously 
shown in CD4+CD8+ double positive T cells that overexpression of GILZ leads to an increase 
in the spontaneous apoptosis, and an interaction with, and reduction of, Bcl-xL. 
Furthermore, GILZ expression was associated with an increase in the activation of extrinsic 
apoptotic caspases -3 and -8, but not caspase-9, involved in the mitochondrial/cytochrome C 
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pathway (Delfino et al., 2004). The authors suggested that NF-κB inhibition is the 
mechanism by which TCR mediated apoptosis is inhibited by GILZ in over expression 
models, and that NF-κB may be involved in control of Bcl-xL (Delfino et al., 2006). Whilst the 
mechanism of GILZ in regulation of cell apoptosis has yet to be well understood, it follows 
the general trend of GILZ to display a dual activity in regards to apoptosis and cell survival. 
4.5. Other non-inflammatory signalling pathways 
In addition to mediating glucocorticoid effects in inflammation and immunity, GILZ may 
also play a critical role in non-immune function such as adipogenesis and osteogenesis. For 
example, Shi et al reported that GILZ directly binds to CCAAT/enhancer-binding protein 
(C/EBP) DNA binding sites in the PPAR-2 promoter, with consequent inhibition of 
mesenchymal cell adipogenesis (Shi et al., 2003). Previously, glucocorticoids had been shown 
to activate C/EBP directly, and therefore promote PPAR-2 expression and adipocyte 
differentiation (Shi et al., 2003). This observation thus suggests a potential role of GILZ as a 
direct transcriptional repressor of gene expression in a direction opposite to the effects of 
Glucocorticoids. Of note, this is in contrast to the effects of GILZ binding to pro-inflammatory 
transcription factors where it mimics the effects of glucocorticoids. Moreover, as PPAR-2 is a 
key regulator of adipogenesis, GILZ’s prevention of C/EBP action inhibits adipogenesis, and 
thereby promotes osteogenesis (Zhang et al., 2008b), again an effect opposite to those of 
glucocorticoids which promote osteoporosis. The findings offer the suggestion of a possible 
GILZ-based therapy wherein GILZ exhibits beneficial glucocorticoid anti-inflammatory 
actions without the negative side effects of adiposity and osteoporosis.  
 
Figure 2. Roles of GILZ as a mediator in immune signaling pathways 
 
Glucocorticoids – New Recognition of Our Familiar Friend 182 
suppression of MEK and ERK1/2 phosphorylation (Ayroldi et al., 2002). They also found that 
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GILZ. Furthermore, the affinity of GILZ to Ras will also increase, leading to predominately 
GILZ-Ras complexes (Ayroldi, 2007). GILZ may also form a trimer with both Ras and Raf-1, 
and this is also dependent on Ras activation. All the results above suggest that GILZ inhibits 
cell activation and inflammation via regulation of MAPK signaling molecules.  
4.4. PI3K/Akt and apoptotic signalling pathways  
The inhibition by GILZ of Ras and Raf-1 also decreases the activation of another 
downstream signalling pathway, the PI3 kinase (PI3K)/Akt pathway, which is involved in 
cell survival as well as activation. Recent studies have uncovered a crucial role for FoxO3 in 
mediation of PI3K/Akt pathway. In the cell, non-phosphorylated FoxO3 migrates into the 
nucleus and up-regulates several mediators of cell cycle progression, such as G1/S-specific 
cyclin-D1, p27KIP1 (also known as cyclin-dependent kinase inhibitor 1B), Fas ligand (also 
known as tumor necrosis factor ligand superfamily member 6) and Bim (also known as Bcl-
2-like protein 11), to inhibit cell proliferation (Schmidt et al., 2002). Activation of Akt leads to 
the phosphorylation of FoxO3, which results in the nuclear exclusion of FoxO3 and thus 
leads to the inhibition of their cognate transcriptional targets. Interestingly, the gene 
encoding GILZ has been identified as a transcriptional target of FoxO3 (Asselin-Labat et al., 
2005b). Other studies have demonstrated that GILZ can inhibit its own expression through a 
negative feedback effect to promote nuclear exclusion of FoxO3 shown in Fig 2 (Latre de 
Late et al., 2010). However, until now, the net effect of the PI3K/Akt-FoxO3–GILZ regulatory 
loop on cell proliferation has not yet been clearly defined. 
GILZ has also been shown to modulate the expression of a variety of apoptosis pathway 
proteins in accordance with the observations that GILZ can prevent anti-CD3 mediated 
apoptosis (D'Adamio et al., 1997). Asselin-Labat and colleagues showed that an increase in 
GILZ expression down-regulates the expression of Bim, a pro-apoptotic member of the Bcl-2 
family, but has no effect on Bcl-xL protein, an anti-apoptotic Bcl-2 family protein, to prevent 
apoptosis. In the same study, they demonstrated that knockdown of GILZ accelerates IL-2-
deprivation-mediated apoptosis in the IL-2-dependent, CTLL-2 cell line, through increased 
levels of Bim (Asselin-Labat et al., 2004). Furthermore, they showed that GILZ acts on Bim 
through the transcriptional factor FoxO3. Using a Bim-promoter-luciferase construct, GILZ 
expression was shown to repress Bim transcription, and these effects were abrogated with 
the co-expression of FoxO3 (Asselin-Labat et al., 2004). However, it had been previously 
shown in CD4+CD8+ double positive T cells that overexpression of GILZ leads to an increase 
in the spontaneous apoptosis, and an interaction with, and reduction of, Bcl-xL. 
Furthermore, GILZ expression was associated with an increase in the activation of extrinsic 
apoptotic caspases -3 and -8, but not caspase-9, involved in the mitochondrial/cytochrome C 
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pathway (Delfino et al., 2004). The authors suggested that NF-κB inhibition is the 
mechanism by which TCR mediated apoptosis is inhibited by GILZ in over expression 
models, and that NF-κB may be involved in control of Bcl-xL (Delfino et al., 2006). Whilst the 
mechanism of GILZ in regulation of cell apoptosis has yet to be well understood, it follows 
the general trend of GILZ to display a dual activity in regards to apoptosis and cell survival. 
4.5. Other non-inflammatory signalling pathways 
In addition to mediating glucocorticoid effects in inflammation and immunity, GILZ may 
also play a critical role in non-immune function such as adipogenesis and osteogenesis. For 
example, Shi et al reported that GILZ directly binds to CCAAT/enhancer-binding protein 
(C/EBP) DNA binding sites in the PPAR-2 promoter, with consequent inhibition of 
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NF-κB, activated by a variety of inflammatory stimulation, translocates into the nucleus and 
binds to target genes encoding pro-inflammatory factors. Glucocorticoid bound to the 
receptor GR can directly interact with NF-κB to prevent its nuclear translocation. In 
addition, the GC/GR complex can translocate into the nucleus and bind to glucocorticoid 
response elements on the GILZ gene to induce GILZ expression. GILZ in turn binds to NF-
κB and prevents its nuclear translocation. GILZ can also directly bind to c-Jun and c-Fos, 
two constituents of AP-1, to inhibit their transcriptional activity and gene expression of pro-
inflammatory molecules. The location, in the cytoplasm or nucleus, where GILZ binds to 
AP-1 subunits is still unknown. In the cytoplasm, GILZ also modulates cell survival by 
blocking Ras activation and the downstream PI3K/Akt signaling pathway. GILZ binds and 
inhibits Ras and Raf phosphorylation and thus inhibits downstream MEK-1/2 and ERK-1/2 
activation. As part of a negative feedback loop, GILZ prevents nuclear translocation of 
FoxO3, which is in turn a key transcriptional factor to upregulate GILZ gene expression. 
5. Effect of GILZ on inflammatory and autoimmune diseases 
The reported actions of GILZ suggest GILZ may exert anti-inflammatory effects in immune 
and inflammatory diseases. Studies in animal disease models, or in human pathology, 
remain limited, but favour a role for GILZ as a modulator of immune-inflammatory 
responses. For example, Cannarile and colleagues reported GILZ effects on delayed-type 
hypersensitivity (DTH) responses in the GILZ transgenic mouse (Cannarile et al., 2006b). In 
response to ovalbumin (OVA) immunization, GILZ overexpression mice exhibited 
significantly less swelling than wild type control, which indicates the essential role of GILZ 
in T cells in inhibiting TH1 dependent DTH responses. The authors also investigated a 
murine model of colitis, in which it was shown that significant inhibition was observed in 
mice overexpressing GILZ in T cells (Cannarile et al., 2009). In addition, studies of these T 
cells showed reduction of the TH1 cytokine IFN-. Moreover, colon lysates from GILZ 
overexpressing mice have lower total and phosphorylated Ser536 NF-κB p65, which 
indicates that GILZ overexpression in T cells protects mice from TH1-mediated colitis disease 
by inhibition of NF-κB activity.  
Recently, Beaulieu and colleagues investigated the role of endogenous GILZ in RA (Beaulieu 
et al., 2010a). GILZ was potently induced by glucocorticoids in cultured human RA synovial 
cells in vitro, and in murine arthritis in vivo. GILZ silencing by in vivo siRNA administration 
resulted in increased severity of the collagen-induced model of RA in mice, and in parallel 
GILZ overexpression inhibited chemokine and cytokine expression in human synovial cells. 
These results suggest GILZ as a key endogenous regulatory molecule in RA. Another study 
showed that GILZ was noticeably absent in granulomas in Crohn disease and tuberculosis 
(Berrebi et al., 2003), which suggests inhibitor regulation of GILZ in the presence of chronic 
inflammatory disease, while human asthma patients demonstrated increased GILZ 
expression in response to glucocorticoid therapy (Kelly et al., 2011).  
GILZ is also reported to attenuate experimental autoimmune encephalomyelitis (EAE), a 
disease model of human multiple sclerosis. Srinivasan and colleagues demonstrated that 
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delivery of a GILZ-derived peptide is protective against EAE in mice (Srinivasan & 
Janardhanam, 2011b). The GILZ fragment they isolated, containing a proline rich domain, can 
directly interact with p65 NF-B, thereby inhibiting p65 translocation from activated human 
CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs) (Srinivasan & 
Janardhanam, 2011a). As T cells are a major target of glucocorticoids in EAE (Wust et al., 2008), 
these data provide further evidence that exogenous GILZ could exert therapeutically useful 
anti-inflammatory properties.  
6. Perspective and expectations: GILZ as a glucocorticoid sparing target 
GILZ, a molecule mainly modulated by glucocorticoids, play a pivotal role in the regulation 
of inflammation and immune responses. Expressed in multiple cells and tissues, GILZ 
inhibits the expression of a variety of inflammatory mediators and modulates the immune 
response. In this chapter, we have summarised GILZ structure and function, the effects of 
GILZ in immune responses, and its interaction with a number of key transduction pathways 
pivotal to the pathogenesis of inflammatory diseases. The more recent observations that 
GILZ exerts immunomodulatory and anti-inflammatory effects in vivo that mimic the 
inhibitory actions of glucocorticoids strongly suggests GILZ is a potential substitute for 
glucocorticoids in the therapy of inflammatory diseases. 
As we have noted, currently a number of important anti-inflammatory molecules, such as 
Annexin A1 and MKP-1, are induced by glucocorticoids, and evidence that synthetic 
glucocorticoids lose their effectiveness in the absence of these molecules has been adduced 
(Furst et al., 2007;  Ralph & Morand, 2008;  Yang et al., 2009;  Yang et al., 2004;  Yang et al., 
2006). Attention to the molecules that glucocorticoids amplify the expression of will permit 
discovery of the means to develop a surrogate for glucocorticoids’ beneficial impact on 
immune activation without their toxicity. Importantly, the presence of GILZ exerts immune 
and inflammation modulatory effects in the absence of glucocorticoids. A GILZ-based 
therapeutic approach, therefore, could potentially offer profound glucocorticoid-like 
regulatory effects in autoimmune disease. Investigation of the metabolic effects of any GILZ-
based therapy is required in order to ensure that the undesirable effects of glucocorticoids 
are not recapitulated. Early results are encouraging in this regard. In mesenchymal stem 
cells, differentiation towards osteogenic precursors is enhanced by GILZ, whereas silencing 
of GILZ reduced osteogenic differentiation (Zhang et al., 2008a), suggesting that a GILZ 
therapy might have protective rather than harmful effects on bone. GILZ expression was 
also associated with osteoblast development, and GILZ silencing increased osteoblast 
expression of OPG and RANKL in favour of osteoclastogenesis (Lekva et al., 2010), further 
suggesting that GILZ-based therapy might have a bone-protective effect. Studies of the role 
of GILZ in glucocorticoid-induced osteoporosis in vivo are eagerly awaited.  
GILZ-based therapies could be based around the administration of recombinant protein or 
NF-κB binding peptides. As we have introduced above, Srinivasan and colleagues have 
described a novel NF-κB p65 binding GILZ peptide which exhibited therapeutic potential as 
a NF-κB inhibitor in EAE (Srinivasan & Janardhanam, 2011b). Alternatively, a gene therapy 
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NF-κB, activated by a variety of inflammatory stimulation, translocates into the nucleus and 
binds to target genes encoding pro-inflammatory factors. Glucocorticoid bound to the 
receptor GR can directly interact with NF-κB to prevent its nuclear translocation. In 
addition, the GC/GR complex can translocate into the nucleus and bind to glucocorticoid 
response elements on the GILZ gene to induce GILZ expression. GILZ in turn binds to NF-
κB and prevents its nuclear translocation. GILZ can also directly bind to c-Jun and c-Fos, 
two constituents of AP-1, to inhibit their transcriptional activity and gene expression of pro-
inflammatory molecules. The location, in the cytoplasm or nucleus, where GILZ binds to 
AP-1 subunits is still unknown. In the cytoplasm, GILZ also modulates cell survival by 
blocking Ras activation and the downstream PI3K/Akt signaling pathway. GILZ binds and 
inhibits Ras and Raf phosphorylation and thus inhibits downstream MEK-1/2 and ERK-1/2 
activation. As part of a negative feedback loop, GILZ prevents nuclear translocation of 
FoxO3, which is in turn a key transcriptional factor to upregulate GILZ gene expression. 
5. Effect of GILZ on inflammatory and autoimmune diseases 
The reported actions of GILZ suggest GILZ may exert anti-inflammatory effects in immune 
and inflammatory diseases. Studies in animal disease models, or in human pathology, 
remain limited, but favour a role for GILZ as a modulator of immune-inflammatory 
responses. For example, Cannarile and colleagues reported GILZ effects on delayed-type 
hypersensitivity (DTH) responses in the GILZ transgenic mouse (Cannarile et al., 2006b). In 
response to ovalbumin (OVA) immunization, GILZ overexpression mice exhibited 
significantly less swelling than wild type control, which indicates the essential role of GILZ 
in T cells in inhibiting TH1 dependent DTH responses. The authors also investigated a 
murine model of colitis, in which it was shown that significant inhibition was observed in 
mice overexpressing GILZ in T cells (Cannarile et al., 2009). In addition, studies of these T 
cells showed reduction of the TH1 cytokine IFN-. Moreover, colon lysates from GILZ 
overexpressing mice have lower total and phosphorylated Ser536 NF-κB p65, which 
indicates that GILZ overexpression in T cells protects mice from TH1-mediated colitis disease 
by inhibition of NF-κB activity.  
Recently, Beaulieu and colleagues investigated the role of endogenous GILZ in RA (Beaulieu 
et al., 2010a). GILZ was potently induced by glucocorticoids in cultured human RA synovial 
cells in vitro, and in murine arthritis in vivo. GILZ silencing by in vivo siRNA administration 
resulted in increased severity of the collagen-induced model of RA in mice, and in parallel 
GILZ overexpression inhibited chemokine and cytokine expression in human synovial cells. 
These results suggest GILZ as a key endogenous regulatory molecule in RA. Another study 
showed that GILZ was noticeably absent in granulomas in Crohn disease and tuberculosis 
(Berrebi et al., 2003), which suggests inhibitor regulation of GILZ in the presence of chronic 
inflammatory disease, while human asthma patients demonstrated increased GILZ 
expression in response to glucocorticoid therapy (Kelly et al., 2011).  
GILZ is also reported to attenuate experimental autoimmune encephalomyelitis (EAE), a 
disease model of human multiple sclerosis. Srinivasan and colleagues demonstrated that 
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delivery of a GILZ-derived peptide is protective against EAE in mice (Srinivasan & 
Janardhanam, 2011b). The GILZ fragment they isolated, containing a proline rich domain, can 
directly interact with p65 NF-B, thereby inhibiting p65 translocation from activated human 
CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs) (Srinivasan & 
Janardhanam, 2011a). As T cells are a major target of glucocorticoids in EAE (Wust et al., 2008), 
these data provide further evidence that exogenous GILZ could exert therapeutically useful 
anti-inflammatory properties.  
6. Perspective and expectations: GILZ as a glucocorticoid sparing target 
GILZ, a molecule mainly modulated by glucocorticoids, play a pivotal role in the regulation 
of inflammation and immune responses. Expressed in multiple cells and tissues, GILZ 
inhibits the expression of a variety of inflammatory mediators and modulates the immune 
response. In this chapter, we have summarised GILZ structure and function, the effects of 
GILZ in immune responses, and its interaction with a number of key transduction pathways 
pivotal to the pathogenesis of inflammatory diseases. The more recent observations that 
GILZ exerts immunomodulatory and anti-inflammatory effects in vivo that mimic the 
inhibitory actions of glucocorticoids strongly suggests GILZ is a potential substitute for 
glucocorticoids in the therapy of inflammatory diseases. 
As we have noted, currently a number of important anti-inflammatory molecules, such as 
Annexin A1 and MKP-1, are induced by glucocorticoids, and evidence that synthetic 
glucocorticoids lose their effectiveness in the absence of these molecules has been adduced 
(Furst et al., 2007;  Ralph & Morand, 2008;  Yang et al., 2009;  Yang et al., 2004;  Yang et al., 
2006). Attention to the molecules that glucocorticoids amplify the expression of will permit 
discovery of the means to develop a surrogate for glucocorticoids’ beneficial impact on 
immune activation without their toxicity. Importantly, the presence of GILZ exerts immune 
and inflammation modulatory effects in the absence of glucocorticoids. A GILZ-based 
therapeutic approach, therefore, could potentially offer profound glucocorticoid-like 
regulatory effects in autoimmune disease. Investigation of the metabolic effects of any GILZ-
based therapy is required in order to ensure that the undesirable effects of glucocorticoids 
are not recapitulated. Early results are encouraging in this regard. In mesenchymal stem 
cells, differentiation towards osteogenic precursors is enhanced by GILZ, whereas silencing 
of GILZ reduced osteogenic differentiation (Zhang et al., 2008a), suggesting that a GILZ 
therapy might have protective rather than harmful effects on bone. GILZ expression was 
also associated with osteoblast development, and GILZ silencing increased osteoblast 
expression of OPG and RANKL in favour of osteoclastogenesis (Lekva et al., 2010), further 
suggesting that GILZ-based therapy might have a bone-protective effect. Studies of the role 
of GILZ in glucocorticoid-induced osteoporosis in vivo are eagerly awaited.  
GILZ-based therapies could be based around the administration of recombinant protein or 
NF-κB binding peptides. As we have introduced above, Srinivasan and colleagues have 
described a novel NF-κB p65 binding GILZ peptide which exhibited therapeutic potential as 
a NF-κB inhibitor in EAE (Srinivasan & Janardhanam, 2011b). Alternatively, a gene therapy 
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approach, which has already been successfully used in vivo to suppress arthritis via delivery 
of the anti-inflammatory cytokine IL-10 (Apparailly et al., 2002), could be applied to GILZ. 
Inducing GILZ expression other than through the use of glucocorticoids, for example by 
modifying activity of the transcription factor FoxO3, could represent a further means to 
increase available GILZ protein, as could inhibition of the as-yet unidentified mechanisms of 
GILZ protein turnover. Finally, structure-function analysis of the molecules with which 
GILZ interacts in order to achieve its immune modifying effects could reveal targets for 
synthetic GILZ mimetics. Although considerable work remains, the first proof of concept 
studies of an in vivo GILZ-based therapeutic approach is under development in the authors’ 
laboratory (unpublished observations).  
In conclusion, glucocorticoids remain among the most widely used drugs in human 
diseases, and in particular in autoimmune disease. Their effectiveness is increasingly well 
understood, based on their effects on inflammatory signal transduction, but their use is 
constrained by toxicity, which also relates to their specific physiological actions. GILZ is a 
key molecule in glucocorticoid biology, which now represents a candidate mediator of 
glucocorticoid regulation of immune and inflammatory responses, and deserves further 
investigation. 
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1. Introduction 
Choosing the right mate is fundamental to reproductive success. Selecting the right genes 
with which to combine one’s own increases the chances of offspring survival and 
reproduction. Choosing wisely, then, can increase the number of copies of genetic material 
being passed on to future generations. This means that it serves an individual well to signal 
their own strengths and qualities in order to attract mates, and it serves the opposite sex 
well to express preferences for honest signals of mate quality. As opposed to natural 
selection (the process by which traits which confer a survival advantage are selected for [1]), 
sexual selection is selection for those traits that confer benefits in terms of attracting, and 
mating with, members of the opposite sex [2]. Such sexually selected traits often serve to 
reduce the chances of survival and their adaptive function is solely to increase an 
individual’s mating success. Classic examples are the peacock’s extravagant tail plumage 
that dramatically increases chances of predation [3], and the display of the bowerbird, which 
bears a heavy energetic cost to construct [4]. These traits have evolved as the benefits of 
attracting members of the opposite sex outweigh the associated costs to survival. In order 
for these social signalling systems to work, however, the signal must provide an honest 
indication of quality [5, 6]. If it is possible to cheat, the system could not function: elaborate 
displays would no longer signal a genetic benefit for offspring.  
Honest signals of mate-choice relevant qualities fall into two broad categories, both of which 
are impossible to fake. These are qualities that infer “indirect” benefits, which include 
heritable traits such as a strong immune system [7, 8], and those that infer “direct” benefits, 
such as the ability and willingness to provide resources and parental care. Over the last 
decade evidence has accumulated to suggest that the physiological stress response may be 
linked to both sets of characteristics. For one, the glucocorticoid hormones modulate the 
immune system, meaning that stress may influence health and condition which, in turn, 
influence the ability of an individual to mate successfully or to provision and care for 
offspring [9, 10]. Alternatively, between-individual variation in dimensions of the stress 
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response such as the peak levels of glucocorticoids secreted in response to a stressor and the 
time taken for levels to return to baseline are heritable, meaning that individuals are likely 
to differ in their ability to cope effectively and efficiently with stress [11, 12]. There is a 
growing body of evidence that demonstrates that females assess the glucocorticoid status of 
potential opposite sex partners, and express preferences for cues to low stress.  
Given the role of hormones in directing the allocation of energy to different physiological 
and behavioural functions, it is not surprising that they have received attention in the 
context of mate choice and sexual signalling. Testosterone has received by far the most 
attention in this domain due to evidence for its role in the development of those male traits 
used to attract females. Among many other traits testosterone is, for example, consistently 
found to relate to the vitality of sexually selected plumage colouration in birds (see for 
example [13, 14]), the size and strength of antlers in red deer stags (Cervus elaphus; see for 
example [15, 16]) and the intensity and complexity of bird song (see for example [17, 18]). In 
essence, high testosterone results in a strong signal that, in turn, translates into mating 
success. In the Immunocompetence Handicap Hypothesis of sexual selection [7], 
testosterone-dependent traits are proposed to provide an honest signal of the strength of a 
male’s immune system due to the hormone’s immunosuppressive actions. In other words, 
only those males who have inherited a robust immune system can afford the costs of the 
elevated testosterone required for development of extravagant sexual signals. A large 
antlered red deer stag, then, is signalling his superior immune system. This, in turn, should 
attract female mates who seek to acquire such “good genes” for their offspring. In the years 
since its inception, this model has generated a huge body of research, with a Google Scholar 
search for “Immunocompetence Handicap” returning ~2, 500 publications.  
Despite providing an elegant explanation for the maintenance of variation in the expression 
of sexual signals as honest indicators of quality, and good evidence that such traits are 
linked to parasite resistance, however, one of the Immunocompetence Handicap model’s 
fundamental assumptions fails to receive adequate support. Reviews show inconsistency in 
evidence for immunosuppression by testosterone [19]. As a consequence, biologists have 
attempted to address this weakness by identifying additional or alternative endocrinological 
factors that may contribute to the system. And this is where the glucocorticoids have 
attracted attention. These stress hormones are correlated with testosterone across species 
(albeit the direction of the relationship is variable; see for example [11, 20 – 23]) and 
modulate immune function [24] and body condition [9, 10]. In [11], for example, the authors 
demonstrated that an immunosuppressive effect of testosterone in the house sparrow (Passer 
domesticus) disappeared when the effects of the primary avian glucocorticoid corticosterone 
were controlled for statistically. They concluded that the effects of testosterone on the 
immune system may be mediated or moderated by co-occurring levels of glucocorticoids. 
More recently, it has been suggested that low levels of glucocorticoids may be preferable 
due to detrimental effects of high levels on body condition and health [10]. The following 
discussion addresses the evidence to date to suggest functions of glucocorticoids in mate 
choice and sexual selection. 
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2. How do glucocorticoids influence mate choice? 
Human research offers excellent opportunities to test roles of stress in mate choice. There is 
evidence that cortisol (the primary human glucocorticoid) and testosterone are positively 
correlated [25], although this finding is not consistent (see for example [26, 27]) and may 
depend upon, for example, the intensity of recent exercise [28]. Sexually dimorphic facial 
characteristics derive from sex differences in the ratio of the male and female sex hormones 
that emerge at puberty (see for example [29]). A surge of testosterone in males during 
adolescence promotes cranio-facial bone growth resulting in heavier jaws and eyebrow 
ridges. These changes are inhibited in females by the action of oestrogen. In adulthood there 
are positive relationships between both circulating testosterone [30] and testosterone 
response to a challenge [31] and masculinity of the male face, as well as between oestrogen 
and femininity in female faces [32]. This means that there are cues to testosterone in the 
male face that we can parametrically manipulate using sophisticated digital face morphing 
techniques. Circulating levels of cortisol and testosterone can be measured using non-
invasive methods that reduce activation of the stress response to provide an accurate 
estimate of baseline levels of the hormones. Furthermore, it is possible to obtain ratings by 
women of perceptions of facial stimuli that differ in cues to the hormones. These are 
luxuries not so easily afforded by work with other species and mean that we are able to 
identify any mediating or moderating role of cortisol on relationships between testosterone 
and attractiveness in a uniquely controlled way.  
The relationship between sexual dimorphism and attractiveness is fairly consistent for 
female faces, with both men and women agreeing that the more feminine a face, the more 
attractive it is (see for example [33, 34]). For male faces, however, the story is more 
complicated, with variation in women’s preferences suggestive of a trade-off in the relative 
importance of a committed, reliable partner versus a partner who signals “good genes”. 
Given the relationship between testosterone and masculinity of the male face, masculine 
faced males may signal a robust immune system. While this is likely to be attractive to 
women seeking to secure a strong immune system for offspring, it must be balanced up 
against the negative personality characteristics that are attributed to the owners of 
masculine male faces, including dishonesty, low likelihood to commit to a relationship and 
aggression (see for example [35, 36]). This perhaps explains why women tend to prefer 
feminine-faced men who are attributed with honesty, commitment and good parenting in 
general, but to switch to preferences for more masculine faces at times when the chances of 
conception are high including the fertile phase of the menstrual cycle (see for example [37]), 
when commitment is less important to mate choice decisions, such as when faces are judged 
for a short term rather than a long term relationship (see for example [38]) and in societies in 
which there is greater competition for resources [39] or in which the costs of ill health are 
high [40].  
In a sample of 69 Scottish male students, my colleagues and I measured testosterone and 
cortisol from saliva samples collected by passive drool at two time-points (one in the 
morning and one in the afternoon), to control for circadian fluctuations in both hormones, 
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2. How do glucocorticoids influence mate choice? 
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which there is greater competition for resources [39] or in which the costs of ill health are 
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In a sample of 69 Scottish male students, my colleagues and I measured testosterone and 
cortisol from saliva samples collected by passive drool at two time-points (one in the 
morning and one in the afternoon), to control for circadian fluctuations in both hormones, 
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using enzyme-linked immunosorbant assays. Mean testosterone leves ranged from 0.07 – 
0.63 ng/mL, and mean cortisol from 3.7 – 24.04 nmol/L. We also took facial photographs of 
participants under standardized conditions (e.g. with diffuse flash lighting, at the same 
distance from the camera and with glasses removed and neutral expression). We  
assessed the effects of testosterone and cortisol on facial attractiveness in two ways. First, we 
asked a sample of female participants to rate the faces for attractiveness, masculinity and 
health on 1 – 7 scales (1 = not at all attractive/masculine/healthy, 7 = extremely 
attractive/masculine/healthy). The faces of males with low cortisol were rated as 
significantly more attractive than those with high cortisol (r2 = -0.36, p = 0.027). There were 
no relationships between cortisol, health and masculinity and, unlike previous studies ([37] 
for example), testosterone was not related to women’s perceptions of the faces (all p > 0.3). 
Next, we used the face morphing software Psychomorph to create “composite” facial images 
which contained cues to combinations of high and low levels of testosterone and cortisol 
[41]. For this, we identified groups of 5 – 6 males with the following combinations of 
hormones, based on median splits: high testosterone and high cortisol, high testosterone and 
low cortisol, low testosterone and high cortisol, low testosterone and low cortisol. We then 
“averaged” together the faces of the participants in each of these groups to give composite 




Figure 1. Composite male faces constructed to differ in combinations of testosterone and cortisol. From 
left to right: high testosterone with high cortisol, high testosterone with low cortisol, low testosterone 
with high cortisol, low testosterone with low cortisol. Taken from Moore et al. 2011. Proceedings of the 
Royal Society of London Series B, doi:10.1098/rspb.2010.1678. 
The stimuli were then rated by a novel sample of female participants during the fertile and 
non-fertile phases of their menstrual cycles. Using mixed model Anova, we found that 
women consistently preferred the low cortisol composites (F(1, 42) = 5.11, p = 0.029). Post hoc 
analyses revealed that this effect was significant in the fertile (F(1, 42)= 6.44, p = 0.015), but not 
the non-fertile (p > 0.1) cycle phase (see Figure 2). We concluded that women can detect cues 
to cortisol in the male face, and that low cortisol is desirable in a male partner. We also 
suggested that low cortisol may be associated with beneficial heritable characteristics as 
women expressed the strongest preferences for facial cues to low cortisol at times when they 
were most likely to conceive [26].   
 




Figure 2. Mean attractiveness ratings of composite male faces constructed to differ in cues to cortisol by 
women during the non-fertile (empty bars) and fertile (filled bars) phases of their menstrual cycles with 
error bars showing +- 1 SE. In a mixed model anova there was a significant effect of cortisol on 
attractiveness (F(1, 42) = 5.11, p = 0.029). Post hoc tests revealed that this effect was significant only during 
the fertile phase of the cycle (F(1, 42)= 6.44, p = 0.015) [26]. 
We replicated this pattern of results in a different sample of faces with a novel sample of 
female raters, again recruited from UK student populations. Once again, women preferred 
the faces of males with low cortisol, and didn’t express preferences for testosterone. In this 
second study, we also tested the effects of the hormones on perceived dominance and 
health, finding that low cortisol faces were also rated as more dominant and healthy than 
high cortisol faces [26, 27]. The findings of both studies are consistent with work in other 
species that shows that females prefer males with low levels of glucocorticoids. In [12], for 
example, the authors found that female zebra finch (Tynopygea guttatta) preferred males 
with low corticosterone, and expressed no preference for cues to testosterone.  
Spectrophotometric measures of plumage suggested that dimensions of plumage colour and 
brightness provided cues to the stress status of the male. Similarly, in [42] Leary and 
colleagues found that female great plains toads (Bufo cognatus) preferred the calls of males 
with low glucocorticoids. There is growing evidence, then, that glucocorticoids play a role in 
mate choice. Why this may be, however, is unclear.  
Glucocorticoids and testosterone 
One possibility is that the hormonal underpinnings in expression of sexual traits that have 
previously been attributed to testosterone are, in fact, due to the effects of the 
glucocorticoids (see for example [11]). If this were the case, however, we would expect to 
find effects of testosterone that disappear once glucocorticoids are controlled for statistically. 
Although this pattern of results was reported for a study of effects of the hormones on the 
immune function of the house sparrow, this has not been replicated in other species. It 
seems unlikely, then, that the role of stress is so straightforward. Rather than simple 
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above we found an interaction between testosterone and cortisol, such that the detrimental 
effects of cortisol were stronger in those males with low testosterone compared to those with 
high testosterone (See Figure 3). We proposed that high testosterone males (i.e. those 
signalling the strength of their immune system) are better able to cope with the detrimental 
effects of stress [26, 27]. In order to test this explanation, however, it is necessary to 
experimentally manipulate stress in males who differ in their level of testosterone and test 
for any divergent effects on immune system and/or sexual signals. 
 
Figure 3. Mean attractiveness ratings of composite faces that differ in combinations of testosterone and 
cortisol (+1 s.e.) by women during the non-fertile (empty) and fertile (filled) phases of their menstrual 
cycles. The figure shows an interaction between the hormones, such that cortisol reduces attractiveness 
in males with low testosterone, but enhances it in males with high testosterone. Taken from Moore et al. 
2011. Proceedings of the Royal Society of London Series B, doi:10.1098/rspb.2010.1678. 
While we have replicated the interaction between testosterone and cortisol in two UK 
samples, in a recent attempt to determine whether our results extend across human 
populations, we found evidence to suggest that the effects of combinations of sex and stress 
hormones on facial appearance are population-dependent. In a third study, we tested 
relationships between testosterone, cortisol and facial attractiveness in a sample of 74 male 
students. This time we tested relationships across the faces of individual males, rather than 
in digitally manipulated composite faces and measured testosterone and cortisol from 
intravenous blood samples rather than from saliva as this allowed us to take simultaneous 
measurements of immune function. Contrary to previous studies, we found a positive 
relationship between testosterone and men’s facial attractiveness, but no relationship 
between cortisol and attractiveness. While we found an interaction between testosterone 
and cortisol in effects on facial attractiveness, it’s nature differed to that reported in our 
previous studies such that this time the positive relationship between testosterone and 

























Figure 4. Relationships between testosterone and (a) facial attractiveness in a sample of Latvian male 
students rated by female participants drawn from the same population, showing an interaction with 
cortisol such that the relationship was strongest in those males with low cortisol (solid line) and 
weakest in those with high cortisol (broken line) and (b) antibody response to a hepatitis B vaccine, 
showing an interaction with cortisol such that the relationship was strongest in those males with low 
cortisol (solid line) and weakest in those with high cortisol (broken line). From [43]. 
Why should we find differences in the nature of the interaction between testosterone and 
cortisol on facial attractiveness between our samples? It seems unlikely that we can attribute 
this to differences in our methods. In all 3 studies we tested for relationships between the 
hormones and face perceptions across individual faces and failed to find interactions 
between testosterone and cortisol in either of the first two studies. Does the construction of 
composites result in spurious results? Only further testing will adequately test this, but an 
alternative possibility is that societal-level factors cause systematic variation in the effects of 
sex- and stress- hormones (and combinations of the two) on attractiveness. While the 
samples in our first two studies were taken from populations of UK students, the sample for 
our third study – the one in which we found a different interaction between the hormones – 
was drawn from a sample of male students and female raters from the University of 
Daugavpils in Latvia.  Could societal-level differences in the strategies employed by women 
to assess the attractiveness of male faces underpin the differences we report in the effects of 
sex- and stress-hormones on facial attractiveness? There is evidence to suggest that this 
could be the case. In [40], for example, Debruine and colleagues reported that societal level 
health measures were related to women’s preferences for cues to testosterone in the male 
face.  That is, women in societies in which the costs of ill health are high express stronger 
preferences for cues to high testosterone. Perhaps, then, cultural differences in the provision 
of healthcare, or in other social and economic factors, cause the female raters in our samples 
to express divergent preferences for cues to testosterone and/or cortisol, which in turn will 
(a) (b)
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influence the nature of the interaction between the two. This is insightful as identification of 
the socioecological factors that underpin variation in preferences for cues to the hormones 
can contribute to our understanding of the traits and characteristics that they signal. My 
collaborators and I are currently conducting further cross-cultural research to achieve this. 
That population-level differences in socioecology could influence the nature of the role of 
stress in mate choice is further supported by cross-species differences in interactions 
between testosterone and glucocorticoids on sexual traits. Such interactions have been 
reported in several avian species. In the red grouse, for example, a positive relationship 
between testosterone and comb area was stronger in males with low levels of co-occurring 
glucocorticoids than in those with physiological markers of high stress [44]. Conversely, in 
the red bishop (Euplectes orix), the relationship between testosterone and plumage colour 
was inverse under high stress, but positive or non-significant under low stress [45]. Despite 
evidence, then, that testosterone-dependent signalling is contingent upon concurrent stress, 
the nature of interactions between sex and stress hormones is inconsistent.  
In order to begin to interpret the meaning of this inconsistency, it is necessary to understand 
a little more about how the two hormones interact at a physiological level. One way is 
through competition for binding sites on the two types of glucocorticoid receptor. The first of 
these has a high affinity for the stress hormones, so glucocorticoids tend to bind to these first, 
meaning that the receptors are typically saturated at peak points in the circadian cycle and 
therefore serve primarily to regulate circadian rhythms. The second type, although more 
abundant, have a lower binding affinity, so tend to bind once all the first type are engaged.  
These, then, are the receptors that are bound during response to a stressor and regulate the 
stress response  [46]. This means that baseline and peak response glucocorticoids can be 
conceptualized as different hormonal systems as their binding to different types of receptors 
results in divergent effects on physiology and behaviour [46]. As the proteins which bind 
glucocorticoids (corticosteroid binding globulins) can also bind testosterone, there may be 
competition between the hormones for binding sites – particularly in avian species who lack 
independent sex steroid binding globulins [47, 48]. It is possible, for example, that elevated 
glucocorticoids reduce the numbers of receptors available for testosterone, reducing bound 
levels and increasing free levels which may influence effects of testosterone on behaviour and 
signalling. Perhaps, then, relationships between testosterone and glucocorticoids, and their 
combined effects on sexual signals, depend upon the species and the dimension of the stress 
response that is measured (e.g. peak versus baseline).  
Immunocompetence 
The “stress-linked” model of hormonally-mediated sexual selection as originally proposed 
over a decade ago [11, 49], in acknowledgement of increasing awareness that extant 
endocrinological models did not sufficiently explain variation in the cross-species data, 
proposed that effects of glucocorticoids on sexual traits were likely to occur through their 
effects on the immune system. Despite evidence for an immunomodulatory role of stress, 
meaning that this seems to be a viable possibility, it poses a difficult problem to address, 
and an even more difficult system to model, as it is not simply the case that stress 
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suppresses the immune system. Depending upon the nature, duration and predictability of 
a stressor, for example, stress can enhance, suppress or redistribute immune activity [24]. 
How, then, can we model and test roles of stress in sexual selection that are mediated by 
effects on the immune system? To date, a handful of studies of avian species have tested 
inter-relationships between stress, immune function and sexual signalling demonstrating 
complex relationships between immune function, stress and sexual signals. A study of red 
grouse, for example, reported a positive relationship between glucocorticoids and parasite 
load and an inverse relationship between parasite load, and testosterone-dependent 
ornament (i.e. supraorbital comb) area [44]. Similarly, a study of blue tits (Cyanistes 
caeruleus) demonstrated parasite load to be positively related to a physiological marker of 
stress (heat shock proteins) and inversely to sexually selected colouration [50]. Conversely, a 
study of song sparrows (Melospiza melodia) reported no relationship between stress and 
immune function [51], meaning that detrimental effects of stress on song repertoire were not 
mediated by immunocompetence. In our work with human faces, my colleagues and I 
found that the pattern of the interaction between testosterone and cortisol on attractiveness 
was mirrored by the same pattern in effects on antibody response to a vaccine [43]. See 
Figure 4b. While there is some evidence, then, to suggest that the combined effects of 
testosterone and cortisol on sexual signalling are concurrent with those on immune 
function, it seems likely that such results are dependent upon the arm of the immune system 
that is assessed as well as the measurement of stress.  
Stress and body condition 
Husak and Moore [10] suggested that glucocorticoids could influence the intensity of 
sexual signals via their detrimental effects on body condition. If stress reduces body 
condition (e.g. body mass and/or fat stores), an individual who is experiencing stress is less 
likely to be able to afford to allocate energy and metabolic resources to sexual signalling. 
Effects of stress on body condition, however, are inconsistent, with studies from some 
species showing that stress reduces body condition (song sparrow (Melospiza melodia) [51]; 
upland geese (Chloephaga picta) [52]; zebra finches [53]), others showing stress to increase 
body condition (Beldings ground squirrels (Spermophilus beldingi) [54]) and still others 
showing no effect (e.g. mallard ducks (Anas platyrhynchos) [55]). Furthermore, few studies 
have shown effects of stress on sexual signals that were consistent with those on condition.  
An exception is the red grouse, in which parasite load was shown to reduce body 
condition, increase physiological markers of stress and reduce the expression of plumage 
colouration [56].  The evidence, then, suggests that any effects of stress on sexual signals do 
not occur via its action on body condition. In fact, in some cases, stress may cause a 
reallocation of resources away from body condition and into sexual signalling. Positive 
relationships between stress and the expression of carotenoid – based colouration at the 
cost of condition have been reported in the zebra finch [53] and the common lizard [57]. 
This suggests that, in some cases, stress causes a redistribution of energy and resources 
away from long term goals and instead to short term priorities (e.g. mating). This would 
seem to be a sensible strategy when, for example, survival was threatened, which may be 
signalled by elevated stress hormones.  
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not occur via its action on body condition. In fact, in some cases, stress may cause a 
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In addition to sexual signals such as ornaments, colouration or song, stress also impacts 
upon behaviours relevant to reproduction. There may, then, be behavioural cues to 
glucocorticoid status which females make use of in their mate choice decisions, or stress-
dependent sexual signals may provide insight into an individual’s likely behaviour. 
Activation of the hypothalamic-pituitary-adrenal axis in response to stress suppresses the 
hypothalamic-pituitary-gonadal axis which is responsible for mediating sexual behaviour 
[58], resulting in reduced expression of sexual behaviours. One mechanism, for example, by 
which stress suppresses reproductive behaviour is via inhibition of the gonadotropin 
protein hormones which regulate reproductive function by glucocorticoids [59, 60]. It is well 
known that chronically elevated stress suppresses reproduction by, for example, reducing 
sex drive, courtship behaviour and fertility(see for example  [61 - 63]). There is also evidence 
that acutely elevated glucocorticoids have a similar outcome with, for example, 
glucocorticoids elevated by fasting reducing courtship behaviour such as singing in the 
male zebra finch [64] and the locomotor activity that contributes to foraging and 
reproduction in male Allegheny dusky salamanders (Desmognathus ochrophaeus;[65]). 
Elevated glucocorticoids are also associated with reduced provisioning of offspring (see for 
example [66]).It is possible, then, that females attend to behavioural indications of high 
stress, or that stress-dependent sexual signals provide an indication of reproductive function 
and/or ability to provision offspring. Avoiding individuals who are currently experiencing 
stress will reduce the chances of attempting to mate with a member of the opposite sex with 
reduced reproductive function and/or ability to provision offspring, thereby allowing the 
female to maximise her reproductive success.  
There are also relationships between stress and dominance, although these are typically 
complex and dependent upon, among many others, both the status of an individual in a 
hierarchy and the stability of the social structure. Attention to cues to stress, then, may 
enable an individual to select an opposite sex partner who occupies a high status position in 
a dominance hierarchy, with associated high status and access to premium resources, 
ensuring high status, well-provisioned offspring. It is not simply the case, however, that 
high stress is a cue to low rank in a hierarchy. Creel [67], for example, demonstrates that, 
although agonistic social interactions can provoke a large glucocorticoid response, in 
established social groups, where individuals know the hierarchy, such responses are not 
necessarily the case and in some cooperative breeding species (i.e. a social system in which 
individuals contribute to the care of others’ offspring) such as the meerkat (Suricata 
suricatta), for example, dominant individuals may have higher glucocorticoids that 
subordinates. It seems likely that divergent levels of stress hormones in accordance with 
strata of the social structure are dependent upon both the nature of the hierarchy which is, 
in turn, dependent upon species socioecology but also upon stability of the hierarchy. In 
unstable structures, if dominant individuals are involved in the most agonistic encounters, 
then it is the dominant individuals who experience the highest levels of stress. In mallards 
and pintails (Anas acuta; [55]), bison (Bison bison; [68]) and ring necked pheasants (Phasianus 
colchicus; [56]), for example, dominant males have higher levels of glucocorticoids than 
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subordinate males. It seems likely, then, that if cues to stress are used to infer information 
about a potential partner’s dominance status or, vice versa, if dominance status influences 
stress levels, the direction of such relationships will be species dependent. 
Future research 
Despite evidence to suggest that glucocorticoids play a role in sexual selection and mate 
choice, the nature and function of that role remains unclear. The effects of stress, while 
typically serving to reduce male attractiveness and the expression of sexual signals, are not 
consistent with some studies showing positive effects. Furthermore, despite proposals that 
the effects of stress occur through its action on immune function and/or body condition, 
there is little evidence to support this. Therefore, while we know that females prefer males 
with cues to low levels of stress hormones, we do not yet know what cues they attend to or 
what is signalled by “low stress”. Despite a growing body of research, then, we are still 
confronted by a number of unknowns. Is it the case, for example, that males signal their 
current stress status? Or do they rather signal their ability to respond optimally to a stressor 
(i.e. an adaptive response which promotes survival but reduces the detrimental costs to 
health)? Are all sexual traits and signals similarly influenced by stress? That is, does stress 
affect those traits which show great plasticity during adulthood (e.g. plumage colouration in 
birds, or skin health in humans) differently to those which emerge at set developmental 
stages (e.g. bird song or human facial sexual dimorphism). Is the link with immune function 
so complex that we have to look at redistribution of resources across the arms of the 
immune system in response to chronic versus acute, and predictable versus unpredictable 
stressors? To begin to answer these questions, and to model roles of stress in mate choice, it 
is now necessary to test the effects of baseline stress, and of dimensions of the stress 
response (e.g. total amount of glucocorticoids produced in response to a standardised 
stressor and time to return to baseline) on different types of sexual signals (e.g. those that 
are typically dependent upon current condition versus those that develop at set life history 
stages) and to interpret findings in the context of species and population ecology [69]. Cross-
cultural and cross-species comparisons can likewise contribute to our understanding of the 
traits signalled by low glucocorticoids. 
3. Conclusion 
To summarise, then, there is a growing body of evidence to show that the glucocorticoid 
hormones are implicated in mate choice and sexual selection. Women prefer the faces of 
males with low levels of cortisol, for example, and female zebra finch prefer males with low 
levels of corticosterone. We do not know, however, why females express these preferences 
as it is not yet clear what characteristics are signalled by cues to low glucocorticoids. 
Suggestions in the literature are that stress reduces body condition or suppresses the 
immune system which, in turn, reduce the extent to which individuals seek to attract 
members of the opposite sex. The extant evidence, however, does not consistently support 
these theories. It has also been proposed that stress mediates the effect of testosterone on 
sexual signals. Again, there is little support for this with results instead suggesting an 
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interaction between testosterone and glucocorticoids – the nature of which is dependent 
upon the species, population and, in all likelihood, current socioecological conditions. What 
is clear is that there is increasing evidence for stress in sexual selection. It is now necessary 
to seek to better understand and model its precise roles and functions by conducting 
research which clearly operationalises the dimension of the stress response and the type of 
trait under investigation. 
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1. Introduction 
Given the demands of modern life, it is no wonder that the concept of stress has become a 
household topic for discussion. Also in the academic realm the phenomenon which is stress, 
is topping the charts in terms of research interest. The short term costs as well as the long 
term maladaptive effects of stress have been a popular topic of research in especially 
physiology and psychology for the past few decades, ever since Hans Selye defined the term 
“stress” in 1956 (Selye, 1956). Stress-related chronic disease, such as cardiovascular disease, 
diabetes and depression, places an ever-increasing burden on society – medically, socially 
and financially. Therefore, if we are to limit the spread and impact of this “pandemic”, it is 
imperative to properly manage the effects of stress on our bodies. This of course, is only 
possible if we have a complete understanding of the body’s response to stress. 
The response to stress is almost never localised and contained. Rather, a stress response is 
initiated in response to a local physical (e.g. contusion to skeletal muscle) or mental (e.g. the 
loss of a loved one) stressor, but always culminates in a wide-spread, systemic response 
process that affects many organs and systems. Consider for a moment a less complex 
research model in a different discipline. Metabolic pathways (e.g. the Krebs cycle or 
glycolysis) can easily be manipulated in cell culture assays using one single cell type at a 
time, since these pathways (including substrate supply and waste removal systems) are 
contained in its entirety within each cell. In contrast, with the stress response pathways this 
is clearly not the case.  
The stress response is a complex network of events, which is directed via two interlinked 
pathways, one endocrine (the hypothalamic pituitary adrenal (HPA)-axis) and one neural 
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“stress” in 1956 (Selye, 1956). Stress-related chronic disease, such as cardiovascular disease, 
diabetes and depression, places an ever-increasing burden on society – medically, socially 
and financially. Therefore, if we are to limit the spread and impact of this “pandemic”, it is 
imperative to properly manage the effects of stress on our bodies. This of course, is only 
possible if we have a complete understanding of the body’s response to stress. 
The response to stress is almost never localised and contained. Rather, a stress response is 
initiated in response to a local physical (e.g. contusion to skeletal muscle) or mental (e.g. the 
loss of a loved one) stressor, but always culminates in a wide-spread, systemic response 
process that affects many organs and systems. Consider for a moment a less complex 
research model in a different discipline. Metabolic pathways (e.g. the Krebs cycle or 
glycolysis) can easily be manipulated in cell culture assays using one single cell type at a 
time, since these pathways (including substrate supply and waste removal systems) are 
contained in its entirety within each cell. In contrast, with the stress response pathways this 
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(the locus coeruleus norepinephrine (LC-NE) or sympatho-adrenal medullary (SAM)-
system). While the neural pathway is mainly activated neurally in response to stress 
perception, leading to the well-known “fight-or-flight” response, the endocrine pathway has 
many more triggers. Apart from neural activation, the HPA-axis is also activated by a large 
number of hormones and even chemical messengers, such as interleukin-6, a cytokine and 
mediator of inflammation, which is known to increase cortisol secretion. A contributing 
factor to the complexity of the HPA-axis is the fact that cortisol, the main end product of this 
stress response, has both endocrine and metabolic functions. Although cortisol is commonly 
known as the “stress hormone” in the context of psychological stress, its main function is 
actually metabolic – to maintain glucose supply to the brain. Therefore, the HPA-axis is 
structured not only for activation in response to perceived stress, but also to react to 
metabolic stimuli. Furthermore, while the stress response should be powerful and fast in an 
acute stress situation, the response should be controlled and relatively more limited in a 
situation of chronic stress, to prevent detrimental effects to the organism in the long term. 
One can appreciate therefore the need for relatively complex signalling networks in this 
regard, which serves to activate, limit or inhibit the stress response. To achieve this, 
numerous molecular mechanisms are in place, and react and interact in response to various 
stress signals. To give just one example, the glucocorticoid receptor, which is present on 
most cells to enable cortisol’s effect on these cells, is up-regulated in response to acute stress, 
but down-regulated after a period of chronic stress.  
Such complexities make the choice of a suitable stress research model both a difficult, and 
vital one. While some mechanisms, e.g. activation agents of specific adrenal or pituitary cell 
types, may be elucidated in cell culture, a whole-system model is required in order to assess 
the net effect of any stressor to these systems. This does not imply that there is no place for 
ex vivo or in vitro studies in the discipline of stress research, far from it! A large number of 
cell-based – and more recently organotypic culture-based – studies have contributed 
substantially to our understanding of specific mechanisms and/or partial pathways relevant 
to stress. The important point here is that ideally, in vitro work should at some point be 
followed up by in vivo investigations, in order to test the applicability of results obtained in 
vitro, to a whole system.  
The importance of in vivo assessments, and the need for conducting them in a model 
specifically suitable to answer the question at hand, is clear when one considers the huge 
number of described animal models in the scientific literature. Apart from more 
conventional models using genetically “intact” rodents, recent advances in biotechnology 
have made possible research using non-physiological models such as gene-knock out 
animals. These animals may be genetically modified to erase the gene coding for a particular 
protein, so that the researcher may elect to produce animals completely lacking a particular 
protein of interest (e.g. IL-6 knockout mice), or in some cases lacking it in only one organ or 
system (e.g. STAT-3 knocked out or “switched off” in skeletal muscle only). These models 
may be used to shed light on various in vivo mechanisms which could previously not be 
properly elucidated using the conventional methods. However, these models have their 
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limitations. For example, when doing research on inflammation, an animal in which a pro-
inflammatory cytokine was knocked out, may display increased or decreased basal levels of 
other pro-inflammatory cytokines, or an altered anti-inflammatory cytokine profile, or even 
up- or down-regulated cytokine responses on activation, as a spontaneous compensatory 
mechanism. The resultant net effect of the genetic manipulation therefore may result in a 
model that is not physiologically accurate, and responses measured may not accurately 
reflect normal in vivo responses. Furthermore, these compensatory mechanisms and/or the 
mere absence of an important protein may also result in other – sometimes unanticipated – 
side-effects (such as severe constipation in IL-6 knockout mice). Apart from being a 
confounding factor in the intended study, in some cases these undesired outcomes may 
result in poor health or even shortened life expectancy of the experimental animal, so that it 
limits the application of such a model even further. Of course, chain-reaction compensatory 
responses will also limit the extent to which results obtained in such models, may be 
extrapolated to a (at least genetically) normal situation. 
Relatively “old-fashioned”, or more conventional methods, when applied optimally, 
therefore still have an important place in research, both in applied areas such as 
pharmacology and in areas of basic research. Only when a situation that is physiologically 
relevant is recreated or simulated, can one realistically assess either the response to a 
challenge, or the outcome of a remedial intervention. 
Therefore, in this chapter, I would like to reflect on methods used to simulate a variety of 
stressors to the body, starting with a variety of models used to simulate psychological stress, 
ranging in severity from non-extreme (mild) psychological stress to extreme mental trauma. 
I will also discuss general considerations in picking the appropriate animal model to use, 
which may determine the difference between success and failure in your research. Details 
on the various models will be provided, including issues such as repeatability and 
standardisation. Models will also be discussed in terms of their suitability for different 
research approaches or objectives, as well as in terms of their limitations. Arguments for and 
against the use of any particular model will also be illustrated using actual research data.  
2. General considerations when choosing a rodent stress model 
Small rodents are an obvious choice for research models in need of a whole body system, 
since they are relatively small and prolifically reproducing mammals, making them 
relatively economical to breed and house. Although rats and mice are physiologically very 
similar to humans in terms of organs and systems implicated in their response to stress, 
there are some fundamental differences between rodents and humans that may greatly 
influence results obtained using such models. It is necessary to understand these differences 
and the impact that it may have on any particular study employing rodents, and to adapt 
protocols to accommodate these differences in order to maximise the validity of results 
obtained. Let us consider just a few general factors that have huge impact on study outcome, 
but which may often be ignored or overlooked.  
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actually metabolic – to maintain glucose supply to the brain. Therefore, the HPA-axis is 
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acute stress situation, the response should be controlled and relatively more limited in a 
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stress signals. To give just one example, the glucocorticoid receptor, which is present on 
most cells to enable cortisol’s effect on these cells, is up-regulated in response to acute stress, 
but down-regulated after a period of chronic stress.  
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types, may be elucidated in cell culture, a whole-system model is required in order to assess 
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followed up by in vivo investigations, in order to test the applicability of results obtained in 
vitro, to a whole system.  
The importance of in vivo assessments, and the need for conducting them in a model 
specifically suitable to answer the question at hand, is clear when one considers the huge 
number of described animal models in the scientific literature. Apart from more 
conventional models using genetically “intact” rodents, recent advances in biotechnology 
have made possible research using non-physiological models such as gene-knock out 
animals. These animals may be genetically modified to erase the gene coding for a particular 
protein, so that the researcher may elect to produce animals completely lacking a particular 
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limitations. For example, when doing research on inflammation, an animal in which a pro-
inflammatory cytokine was knocked out, may display increased or decreased basal levels of 
other pro-inflammatory cytokines, or an altered anti-inflammatory cytokine profile, or even 
up- or down-regulated cytokine responses on activation, as a spontaneous compensatory 
mechanism. The resultant net effect of the genetic manipulation therefore may result in a 
model that is not physiologically accurate, and responses measured may not accurately 
reflect normal in vivo responses. Furthermore, these compensatory mechanisms and/or the 
mere absence of an important protein may also result in other – sometimes unanticipated – 
side-effects (such as severe constipation in IL-6 knockout mice). Apart from being a 
confounding factor in the intended study, in some cases these undesired outcomes may 
result in poor health or even shortened life expectancy of the experimental animal, so that it 
limits the application of such a model even further. Of course, chain-reaction compensatory 
responses will also limit the extent to which results obtained in such models, may be 
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relevant is recreated or simulated, can one realistically assess either the response to a 
challenge, or the outcome of a remedial intervention. 
Therefore, in this chapter, I would like to reflect on methods used to simulate a variety of 
stressors to the body, starting with a variety of models used to simulate psychological stress, 
ranging in severity from non-extreme (mild) psychological stress to extreme mental trauma. 
I will also discuss general considerations in picking the appropriate animal model to use, 
which may determine the difference between success and failure in your research. Details 
on the various models will be provided, including issues such as repeatability and 
standardisation. Models will also be discussed in terms of their suitability for different 
research approaches or objectives, as well as in terms of their limitations. Arguments for and 
against the use of any particular model will also be illustrated using actual research data.  
2. General considerations when choosing a rodent stress model 
Small rodents are an obvious choice for research models in need of a whole body system, 
since they are relatively small and prolifically reproducing mammals, making them 
relatively economical to breed and house. Although rats and mice are physiologically very 
similar to humans in terms of organs and systems implicated in their response to stress, 
there are some fundamental differences between rodents and humans that may greatly 
influence results obtained using such models. It is necessary to understand these differences 
and the impact that it may have on any particular study employing rodents, and to adapt 
protocols to accommodate these differences in order to maximise the validity of results 
obtained. Let us consider just a few general factors that have huge impact on study outcome, 
but which may often be ignored or overlooked.  
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2.1. When to stress: lights on or off? 
The timing of stress exposure, interventions to relieve stress and sampling of blood or tissue 
for analysis is a vital consideration, with many confounders complicating the issue. Firstly, 
the rat is nocturnally active, while humans obviously are not naturally nocturnal. Therefore, 
the question arises of whether to stress the rats during their active time, at night, or during 
the day, when they are asleep – which would most accurately mimic the physiological 
responses of humans? One could argue that it would be more applicable to expose an 
animal to a psychological stressor while it is awake, i.e. in the darkness – after all, how can 
one stress a rat when it is half asleep during the day anyway? However, this seemingly 
logical argument is not correct, for a very simple reason. Whether the rodent is asleep or 
wide awake when exposed to an experimental stressor is not the determining factor – rather, 
the normal rhythmic changes of hormones over the course of a day hugely affects the ability 
to respond to stress.  
A typical circadian rhythm graph for corticosterone is presented in Figure 1. The circadian 
rhythm illustrated is expected in experiments employing a normal light-dark cycle – 
convention would be a 12 hour light-dark cycle, with lights switched on at 7am, and off at 
7pm. Reversal of the light cycle has significant effects on the circadian rhythms, the 
“pattern” of which follows the delay in timing from the conventional one. This effect of light 
and darkness may be partially explained by the fact that sympathetic input to the adrenal 
gland is photo-sensitive: in periods of darkness, a dramatic increase in basal norepinephrine 
secretions from sympathetic nerves occurs (Hashimoto et al., 1999), so that basal 
corticosterone secretion is up-regulated in periods of darkness. However, one can also see 
from the curve that corticosterone secretion starts to increase after the nadir at a time of day 
when there is still much light – this further illustrates the complexity of this regulation, 
pointing to the existence of additional important causative factors. 
 
Figure 1. Expected circadian rhythm graph for corticosterone in rats. Dark bars at the bottom indicate 
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It is of importance to note that adaptation to changes in lighting conditions is not 
synchronised, and so does not occur within similar time frames, for all hormones. For 
example, while the corticosterone rhythm was shown to adapt to a 12-hour delay (phase 
reversal) and become constant after about 6 days, the rhythm for adrenaline only adapted 
after 10 days, indicating that the pituitary adrenocortical system adapts more readily to 
light-dark cycle shifts, while the sympatho-adrenal medullary system requires relatively 
more time (Miki and Sudo, 1996). 
Researchers working on models using juvenile animals should also take note that the 
circadian rhythms for these hormone fluctuations are not fully developed at birth. The 
diurnal rhythm for corticosterone for example is only regular from about day 30-32 in rats 
(Allen and Kendall, 1967). Also, circadian rhythms are affected by many stress-related 
disorders – in this context, a chronic mild stress model of depression has been shown to 
cause fluctuations in corticosterone rhythm which only normalised after 8 weeks of chronic 
mild stress, and which was dependent on resilience of animals exposed to stress 
(Christiansen et al., 2012).  
Therefore, in planning an experiment, it is most important to decide whether the stress 
exposure and sample collection should take place during the rising or falling phase of a 
hormone pulse. In the context of stress for example, one would time stress exposure and 
sample collection to coincide with the natural decrease of hormones expected to increase in 
response to stress, such as corticosterone and the catecholamines. Otherwise, if done at a 
time when hormone levels were increasing naturally, the circadian rhythm may effectively 
mask the acute response to stress. Even though these experiments should always include 
control samples taken from unstressed animals at the same time of day, unsynchronised 
sampling may still increase the variability of data, and thus decrease statistical power. This 
consideration is especially important in models employing physiologically relevant levels of 
stress, since the response seen is usually not enormous, and any potential confounders 
should be excluded as far as possible. Therefore, a suggestion is that all stress exposure 
interventions should be performed in the early morning hours, so that subsequent sample 
collection may to completed before noon, when the nadir for corticosterone occurs. 
2.2. Metabolic rate 
Another very important way in which rodents differ from humans is their much faster basal 
metabolic rate. Rats have a metabolic rate roughly 10 times and mice 30 times that of 
humans. This would obviously have huge implications for any study design with a 
pharmacological component. For example, when testing the potential of a stress relief 
medication, one would have to either increase the dose recommended by the manufacturer 
for human consumption, or decrease the dosage interval in rodents to ensure the 
maintenance of a therapeutic concentration of the drug at the level of the target tissue. Both 
these approaches have their drawbacks though. On the one hand, administration of a mega 
dose may result in intolerance reactions to the drug, most often including side effects such 
as gastroenteritis, with obvious confounding results given the interaction between 
 
Glucocorticoids – New Recognition of Our Familiar Friend 214 
2.1. When to stress: lights on or off? 
The timing of stress exposure, interventions to relieve stress and sampling of blood or tissue 
for analysis is a vital consideration, with many confounders complicating the issue. Firstly, 
the rat is nocturnally active, while humans obviously are not naturally nocturnal. Therefore, 
the question arises of whether to stress the rats during their active time, at night, or during 
the day, when they are asleep – which would most accurately mimic the physiological 
responses of humans? One could argue that it would be more applicable to expose an 
animal to a psychological stressor while it is awake, i.e. in the darkness – after all, how can 
one stress a rat when it is half asleep during the day anyway? However, this seemingly 
logical argument is not correct, for a very simple reason. Whether the rodent is asleep or 
wide awake when exposed to an experimental stressor is not the determining factor – rather, 
the normal rhythmic changes of hormones over the course of a day hugely affects the ability 
to respond to stress.  
A typical circadian rhythm graph for corticosterone is presented in Figure 1. The circadian 
rhythm illustrated is expected in experiments employing a normal light-dark cycle – 
convention would be a 12 hour light-dark cycle, with lights switched on at 7am, and off at 
7pm. Reversal of the light cycle has significant effects on the circadian rhythms, the 
“pattern” of which follows the delay in timing from the conventional one. This effect of light 
and darkness may be partially explained by the fact that sympathetic input to the adrenal 
gland is photo-sensitive: in periods of darkness, a dramatic increase in basal norepinephrine 
secretions from sympathetic nerves occurs (Hashimoto et al., 1999), so that basal 
corticosterone secretion is up-regulated in periods of darkness. However, one can also see 
from the curve that corticosterone secretion starts to increase after the nadir at a time of day 
when there is still much light – this further illustrates the complexity of this regulation, 
pointing to the existence of additional important causative factors. 
 
Figure 1. Expected circadian rhythm graph for corticosterone in rats. Dark bars at the bottom indicate 



















Using Rodent Models to Simulate Stress of Physiologically Relevant Severity: When, Why and How 215 
It is of importance to note that adaptation to changes in lighting conditions is not 
synchronised, and so does not occur within similar time frames, for all hormones. For 
example, while the corticosterone rhythm was shown to adapt to a 12-hour delay (phase 
reversal) and become constant after about 6 days, the rhythm for adrenaline only adapted 
after 10 days, indicating that the pituitary adrenocortical system adapts more readily to 
light-dark cycle shifts, while the sympatho-adrenal medullary system requires relatively 
more time (Miki and Sudo, 1996). 
Researchers working on models using juvenile animals should also take note that the 
circadian rhythms for these hormone fluctuations are not fully developed at birth. The 
diurnal rhythm for corticosterone for example is only regular from about day 30-32 in rats 
(Allen and Kendall, 1967). Also, circadian rhythms are affected by many stress-related 
disorders – in this context, a chronic mild stress model of depression has been shown to 
cause fluctuations in corticosterone rhythm which only normalised after 8 weeks of chronic 
mild stress, and which was dependent on resilience of animals exposed to stress 
(Christiansen et al., 2012).  
Therefore, in planning an experiment, it is most important to decide whether the stress 
exposure and sample collection should take place during the rising or falling phase of a 
hormone pulse. In the context of stress for example, one would time stress exposure and 
sample collection to coincide with the natural decrease of hormones expected to increase in 
response to stress, such as corticosterone and the catecholamines. Otherwise, if done at a 
time when hormone levels were increasing naturally, the circadian rhythm may effectively 
mask the acute response to stress. Even though these experiments should always include 
control samples taken from unstressed animals at the same time of day, unsynchronised 
sampling may still increase the variability of data, and thus decrease statistical power. This 
consideration is especially important in models employing physiologically relevant levels of 
stress, since the response seen is usually not enormous, and any potential confounders 
should be excluded as far as possible. Therefore, a suggestion is that all stress exposure 
interventions should be performed in the early morning hours, so that subsequent sample 
collection may to completed before noon, when the nadir for corticosterone occurs. 
2.2. Metabolic rate 
Another very important way in which rodents differ from humans is their much faster basal 
metabolic rate. Rats have a metabolic rate roughly 10 times and mice 30 times that of 
humans. This would obviously have huge implications for any study design with a 
pharmacological component. For example, when testing the potential of a stress relief 
medication, one would have to either increase the dose recommended by the manufacturer 
for human consumption, or decrease the dosage interval in rodents to ensure the 
maintenance of a therapeutic concentration of the drug at the level of the target tissue. Both 
these approaches have their drawbacks though. On the one hand, administration of a mega 
dose may result in intolerance reactions to the drug, most often including side effects such 
as gastroenteritis, with obvious confounding results given the interaction between 
 
Glucocorticoids – New Recognition of Our Familiar Friend 216 
inflammation and the glucocorticoid response. When choosing this method, parameters to 
monitor gut integrity, such as prostaglandin E2 levels or serum lipopolysaccharide levels, 
should ideally be included in the testing profile. On the other hand, decreasing the dosage 
interval requires more frequent handling of the experimental animals, which increases the 
possibility of an undesired stress response to the constant handling. This last obstacle can be 
partially overcome with the use of osmotic mini-pumps – these tiny pumps are implanted 
subcutaneously behind the neck of the rodent where it cannot reach, and releases the drug 
constantly at a pre-selected rate and over a pre-selected number of days. It is debatable 
however whether or not this method accurately reflects in vivo conditions for and effects of a 
drug that is, for example, intended to be administered orally once or twice a day, rather than 
continuously. A further limitation of this method is that labile substances can’t be tested in 
this way, since the drug can only be maintained at body temperature (i.e. not cooled) for the 
duration of the infusion.  
2.3. Social issues 
A factor that should be of particular interest to researchers investigating effects of 
psychological stress, is the social hierarchy that exists within experimental rodent colonies. 
Rats in particular are a very social species, and individual housing of rats actually causes a 
degree of psychological stress. Therefore, standard practise is to house rats in groups of four 
to five, when using standard sized cages. This in itself is a limiting factor, since it is 
logistically not really possible to monitor appetite or food and water consumption of 
individual rats (which are usually done using metabolic cages in which rats are individually 
housed) without causing a stress response to housing conditions. Logistic factors aside, it is 
interesting to see that within these small groups, a social hierarchy quickly emerges, with 
some rats being submissive, while others are clearly dominant. Dominant rats have been 
shown to grow faster and to be relatively more resistant to stress interventions that 
submissive rats. This is both good and bad for the researcher. On the one hand, having this 
social hierarchy in a way simulates human situations, making the model more 
representative of the human population as a whole. On the other hand, the variation in the 
response to stress resulting from social hierarchy results in great variations in data obtained 
within the same experimental group, which could hide differences between experimental 
groups. This lowers the statistical power of any experiment, necessitating the use of larger 
experimental groups, which of course is more time and resource consuming. In our 
experience, experimental groups for the purpose of research into the psychological stress 
response should consist of at least 10-15 rats, on condition that all rats have been properly 
accustomed to the environment, handlers and protocols. 
2.4. Practical tips 
Apart from the factors discussed above, there are a few more general considerations to keep 
in mind when setting up an animal model of stress. I will touch on these just briefly. 
Research has shown that the mood (emotional state) of the animal handler(s) also affect the 
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basal anxiety level of animals. Therefore some personality types may be more suited to work 
using animal models than others. For example, in our group we had two students 
conducting stress studies on sibling rats from the same litters. One student was completely 
at ease with the rats and handled them with natural ease, while the other student was very 
nervous around the rats and anxious about handling them. When assessing corticosterone 
levels in the control rats from the first student’s study, serum concentrations were all lower 
than 10ng/ml. However, those from the more nervous student all had values in excess of 
40ng/ml. (All samples were collected at the same time of day, so that diurnal variation did 
not play a role.) Of course, the fact that even unstressed animals had clearly elevated 
corticosterone levels, severely limits the conclusions that may be drawn from this specific 
experiment.  
Different strains of animals have also been shown to vary substantially in their natural 
sensitivity to stress. This has been comprehensively reviewed elsewhere, in the context of 
neurobiology (Ellenbroek et al., 2005). Perhaps of specific interest for the stress researcher 
is the fact that these differences in stress sensitivity seems to be the effect of differences at 
adrenocortical level, rather than a central effect, since restraint were reported to elicit 
similar hippocampal and hypothalamic responses across five rat strains, although 
differences were quite clearly present at adrenal level (Gomez et al., 1996). An interesting 
fact is that some of these supposedly strain-dependent differences are more the result of 
nurture than nature: for example, if a spontaneously hypertensive rat (SHR) is reared by a 
Wistar-Kyoto rat (WKY), its hypertension is significantly less pronounced. One should 
therefore exercise caution in the selection of a strain to breed for the purpose of stress 
research. Furthermore, even within an established strain, differences occur. For example, 
first-time rat mothers have been shown to yield pups with relatively less resistance to 
stress, so that litters from first-time mothers should be avoided by the stress researcher. 
Also, a vital point to remember is that the experimental animal does not speak human! 
When conducting research in humans, it is possible – and ethically required – to explain 
to any volunteer the intervention that he or she will be subjected to, including expected 
risks. Therefore, when a human is stressed experimentally (e.g. by participating in a 
maths test or public speaking), although they will mount a psychological stress response, 
they also know that the test, or stressor, won’t be permanently detrimental. A rodent on 
the other hand, has no way of knowing whether an acutely applied stressor will be lethal 
or not, so that even mild stressors are perceived as quite severe the first time. Therefore, if 
the requirement for research purposes is to simulate stress of a physiologically relevant 
severity in rodents, the stress intervention may actually seem relatively mild in 
comparison to what one might expect to be necessary. 
From just these few considerations it is clear that the ideal in vivo model for psychological 
stress may simply not exist. However, if one is aware of potential confounders, the protocol 
may be optimised, and interpretation of results approached with the necessary caution, 
making in vivo models very valuable and realistic tools. So, how does one go about setting 
up the optimum model?  
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3. Design and setup of an animal model 
Moving on to the actual setting up of a model, there are several precautions to include in the 
protocol, that are unique to studies on stress, especially psychological stress. For this section, 
I will limit myself to a discussion of rat models for stress, since this is the species of choice 
for this discipline, and also the species that I have most experience working with.  
Putting first things first, one has to decide what situation of stress should be simulated. 
This is directly dependent on the research question. For example, if the question is related 
to the effect of a calming tablet administered to someone who has been exposed to a 
sudden trauma (e.g. car hi-jacking), a model where rats are subjected to a severe acute 
stressor is obviously the best choice. When a daily supplement is tested for stress relieving 
properties, or the effect of long-term occupational/stress on a specific organ is 
investigated, a model with multiple exposures to a relatively milder stressor would be 
more ideal. Sometimes, it may even be useful to combine protocols to achieve a mix of 
acute and chronic stress, in order to most accurately simulate actual human situations. 
Rats have been reported to be able to adjust to any mild stressor within a period of about 
3 days (Garcia et al., 2000). Therefore, a study requiring mild stress to continue for a 
relatively long time, may require combination of a number of stressors in order to 
maintain a stressful environment. 
3.1. What does a rat find stressful? 
The decision of the type of stressor again depends on the situation being simulated. 
Stressors in real life vary from “mild irritation” to traumatic. Similar variety is therefore 
required in models for stress. Arguably the most popular simulation of prolonged trauma is 
a model known as maternal separation. Normally, pups remain with their mother 
throughout the first few weeks of their life until they are weaned at the age of 21-30 days, 
dependent on laboratory standard operating procedure. In the maternal separation model, 
rat pups are removed from their mother during a critical time in their development, usually 
during the first two or three weeks after birth, for a period of three hours per day. This 
traumatic separation is characterised by changes in both behavioural responses (such as 
anxious-like behaviour and hyperactivity in the open field test) and HPA-axis responses 
(such as decreased expression of glucocorticoid receptor in the hippocampus and ≈15% 
higher basal blood corticosterone concentrations) to stress, that persists into adulthood. 
These changes suggest an increased natural anxiety in response to chronic severe stress 
during early development. This technique is uniquely suited for and commonly used for 
investigating the development of psychiatric disorders such as anxiety and depression. Note 
that the endocrine responses seen in this model is relatively small in comparison to for 
example restraint stress models, even though it represents trauma, i.e. the most severe type 
of stress. One has to keep in mind though that these changes are assessed in the “rested” 
state, and reflects chronic changes, which are always smaller in magnitude than acute 
responses assessed directly after application of an acute stressor. 
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A somewhat milder form of stress may be simulated using restraint (sometimes called 
immobilisation). This technique is highly variable due to research group-specific differences 
in the execution of this technique. On the extreme end, animals are literally taped down on a 
flat board, immobilising them completely, for a period between one and two hours. Rats are 
fairly vocal in response to this particular protocol, so that it is advisable to conduct this 
particular protocol in soundproof facilities, to prevent negative effects on the rest of the 
animals housed in the same unit. A much milder form of restraint is to place rats in small 
cages that limit their movement. An example of a Perspex restraint cage (restraining up to 6 
rats simultaneously) as used by our group is presented in Figure 2.  
This particular cage has compartments 6cm wide x 7cm high x 18 cm long, and works best 
for restraint of mature Wistar rats, weighing around 300-350 g (this type of restraint is only 
successful when rats fit tightly into restraint compartments). Note the use of Perspex as 
material for the cages: this prevents the rats from having a stress response to being isolated 
from their group because they can still see their “neighbours”. Also, body heat from peers 
warms the sides of the cages, creating a similar effect to when rats sleep clumped together, 
as they habitually do. When rats are put into these compartments, they typically turn 
around once or twice (invariably getting stuck halfway through the turn), and then stop 
trying to move. Grooming behaviour – a known self-pacifying behaviour in rats – indicates 
that rats are feeling claustrophobic, i.e. a psychological stress response can be expected. Rats 
are usually restrained for a period of 30 minutes to 2 hours once per day. During this time, 
they do not have access to food or water, but sufficient ventilation holes at both ends allow 
for normal ventilation. Keep in mind that when restraining nocturnal animals during light 
hours, they won’t have a huge requirement to feed or drink, so that the absence of food and 
water is not perceived as stressful and does not impact significantly on their normal 
metabolism. 
 
Figure 2. Restraint stress by confinement in purpose-designed Perspex cages elicits a mild form of 
psychological stress in rats. Adult male Wistar rats weighing more than 300g were used in this 
particular instance. Note the two rats on each side that were able to turn around in the cage once, but 
prefer not to attempt it again. 
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A somewhat milder form of stress may be simulated using restraint (sometimes called 
immobilisation). This technique is highly variable due to research group-specific differences 
in the execution of this technique. On the extreme end, animals are literally taped down on a 
flat board, immobilising them completely, for a period between one and two hours. Rats are 
fairly vocal in response to this particular protocol, so that it is advisable to conduct this 
particular protocol in soundproof facilities, to prevent negative effects on the rest of the 
animals housed in the same unit. A much milder form of restraint is to place rats in small 
cages that limit their movement. An example of a Perspex restraint cage (restraining up to 6 
rats simultaneously) as used by our group is presented in Figure 2.  
This particular cage has compartments 6cm wide x 7cm high x 18 cm long, and works best 
for restraint of mature Wistar rats, weighing around 300-350 g (this type of restraint is only 
successful when rats fit tightly into restraint compartments). Note the use of Perspex as 
material for the cages: this prevents the rats from having a stress response to being isolated 
from their group because they can still see their “neighbours”. Also, body heat from peers 
warms the sides of the cages, creating a similar effect to when rats sleep clumped together, 
as they habitually do. When rats are put into these compartments, they typically turn 
around once or twice (invariably getting stuck halfway through the turn), and then stop 
trying to move. Grooming behaviour – a known self-pacifying behaviour in rats – indicates 
that rats are feeling claustrophobic, i.e. a psychological stress response can be expected. Rats 
are usually restrained for a period of 30 minutes to 2 hours once per day. During this time, 
they do not have access to food or water, but sufficient ventilation holes at both ends allow 
for normal ventilation. Keep in mind that when restraining nocturnal animals during light 
hours, they won’t have a huge requirement to feed or drink, so that the absence of food and 
water is not perceived as stressful and does not impact significantly on their normal 
metabolism. 
 
Figure 2. Restraint stress by confinement in purpose-designed Perspex cages elicits a mild form of 
psychological stress in rats. Adult male Wistar rats weighing more than 300g were used in this 
particular instance. Note the two rats on each side that were able to turn around in the cage once, but 
prefer not to attempt it again. 
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The response obtained using this model is of mild severity, and is ideal for studying normal 
adaptation to both acute and chronic stress. Given the wide relevance of this severity of 
stress to the human population, it is also a valuable model to use in the pharmacological, 
psychological and physiological testing of therapies, drugs and daily supplements intended 
to decrease stress levels or counter the side-effects of stress. This particular model is 
relatively easy to standardise in terms of diet, stress duration, light-dark cycle, etc. and is 
highly repeatable within a research group, as long as particular care is taken in selection of 
animal handlers and other factors already discussed. However, inter-research group 
differences do exist, so that care should be taken to consider changes in stress intervention 
protocols when comparing results reported by different laboratories. Commonly expected 
values with the restraint model used as an acute stress intervention lasting one hour, in our 
hands, are presented below (Figure 3) for changes in body mass, corticosterone, testosterone 
and the pro-inflammatory cytokine interleukin (IL)-1β.  
 
Figure 3. Effects of acute short-term restraint stress (1 hour) and recovery from stress on mean a) body 
mass, b) serum corticosterone, c) serum interleukin-1β and d) serum testosterone concentrations. Bars 
on graphs illustrate mean values, while error bars indicate standard deviations. 
Body mass decreases significantly, but only transiently, in response to acute stress as 
applied by our group. This is mainly the result of increased defecation and urination. In 
terms of corticosterone, an acute increase of between 8-12-fold is seen. This response 
plateaus after one hour, and rats are able to recover from one exposure to restraint within 
one day. Testosterone concentrations are not acutely affected by acute stress, but it may 
increase during the recovery period. This effect is similar to that seen in athletes after a 
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stressful bout of exercise, and may suggest an ability to cope and resist the stressful effects 
of the particular stressor. 
In the chronic model, since the rat is not able to fully recover between stress exposure 
sessions when done daily for an extended time, testosterone levels do decrease with this 
model, resulting in a more catabolic state, and even up-regulation of the proteolytic 
pathways. In other words, although only mild in severity, this model is severe enough to 
result in undesirable side-effects in the longer term, making it an excellent simulation for 
chronic stress such as occupation-related stress in humans. From the cytokine data, restraint 
stress clearly has a pro-inflammatory effect as well, which makes this a particularly suitable 
model for investigations into the efficacy of e.g. anti-inflammatory interventions. Note that 
the IL-1β levels are still significantly elevated even after the recovery period – this is most 
likely due to the relatively long half-life of the cytokine. Again, in the long term, a shift 
toward a pro-inflammatory status is achieved.  
Some groups have used involuntary swimming (forced swimming in a 1m3 swimming pool 
warmed to 24°C) as stressor. Although acute forced swimming is a recognised test to assess 
depressive-like behaviour (although this is being disputed), rats are natural swimmers, so it 
is doubtful whether this method – when applied chronically - is really a significant stressor. 
In fact, in the discipline of exercise science, researchers train rats to swim in order to study 
hypertrophy and metabolic adaptation to exercise training. These anabolic responses are the 
direct opposite of the catabolic response that is the stress response, further placing doubt on 
the use of this technique to realistically simulate chronic stress. Furthermore, in our 
experience, females are more willing swimmers than males. Males were found to simply 
climb onto the most submissive animal, which would then literally be drowned without 
investigator intervention. Alternatively, they might hold their breath and sit at the bottom of 
the pool for as long as they can before jumping/swimming up for a breath of air, rather than 
exercising the whole time. Although females tend to actually swim a lot better without the 
constant prodding required with males, their voluntary exercise capacity/willingness to 
exercise also varies dramatically. Therefore, as with voluntary running models (using 
purpose-designed running wheels), the “natural athletes” have to be selected from a larger 
cohort prior to the study. This then has the disadvantage of possible genetic pre-selection, 
which may yield data that is not widely applicable across the whole population. It is clear 
therefore, that this model has many limitations and should not be a first choice for 
simulation of psychological stress.  
A number of other stressors may be employed, and some of these are not very labour-
intensive, so that they are commonly used in combination with the stressors discussed 
above, to prevent adaptation, as mentioned earlier. These include soiled bedding, tail flick, 
and inversion or cage tilt. Bedding is soiled with water by simply pouring 300ml of water 
onto cage bedding and leaving rats to endure this discomfort for an hour before changing 
the bedding again. For the tail flick protocol, a rat is manually restrained and its tail placed 
in a water bath kept at 49 °C until the rat voluntarily flicks it out. For the cage tilt, the 
restraint cage is turned upside down for the duration of a restraint session which usually 
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lasts from 30 minutes to an hour when used in combination with cage tilt. These are all 
examples of mild severity stressors. Extreme heat or cold are also referred to as stress 
models, but these stressors are more metabolic than psychological in nature. 
3.2. Keeping experimental animal stress free 
Although left for last in this section, the following point is perhaps the most important. 
When conducting any experiment investigating the response to stress, it is of major 
importance to keep all animals “otherwise” stress free. In other words, one has to ensure 
that rats are only exposed to the standardised stressors used as interventions in the study. 
Several precautions may be needed to prevent other stressors from confounding data. For 
example, vibration has recently been identified as a stressor in terms of the immune system. 
Animals exposed to constant low grade vibration may deplete their lymphocytes in as little 
as two to three weeks. Considering that lymphocytes make up the bulk of rat white blood 
cells (about 75%), it is clear that the end result is an immune-compromised animal with very 
abnormal cytokine profile. Therefore, while it may seem like a good idea to have a generator 
handy, the constant vibration it causes, may in fact be detrimental to your study. 
Furthermore, new male rats should never be introduced to existing housing groups (e.g. if 
one rat dies, it should not be replaced with another adult rat), and adult male rats should 
not redistributed between cages after they have established their hierarchy. They have a 
social hierarchy and such changes will result in social stress, the result of which is difficult 
to determine before it is too late. Lastly, rodents in particular have to be handled to 
accustom them to their handlers. During this time, they also become used to the sounds and 
smells associated with their housing environment. Introduction of a new sound or smell 
may result in an uncontrolled, unstandardized stress response. In our laboratory, the simple 
guideline during acclimation of rats after arrival from the breeding unit, is to expose them to 
all sounds, smells (e.g. disinfectants used both during every day maintenance and during 
sample collection procedures), actions (e.g. weighing, sham injections, oral gavage with tap 
water only) and people required for the intervention study, with the exception of the 
intervention itself. During sacrifice, a meticulous procedure has to be followed: Firstly, all 
surfaces should be disinfected with a disinfectant the animal has been habituated to, in 
order to disguise any body odour from the previously sacrificed animal. Then, the rat is 
taken from its cage and euthanasia applied as soon as possible. Rats still in line for sacrifice 
have to be protected from any sound or smell that could alert them to what is happening; 
otherwise they will have a severe acute stress response. Sprague-Dawley rats for example 
has been shown to have increased heart rate and mean arterial blood pressure when present 
in the same room where other rats were being exposed to a variety of interventions, which 
included routine actions such as cage changes, but also experimental interventions such as 
decapitation (Sharp et al., 2002).  
Interestingly in this study, witness rats that were individually housed, showed a greater 
stress response than rats group housed, further illustrating the additive effect of different 
stressors. The magnitude of this acute stress response can indeed be enormous. In a study 
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by our group, corticosterone responses were determined in rats that could smell and hear 
experimental procedures for sacrifice. When sorted according to the order of sacrifice, it is 
clear that the rats waiting their turn were experiencing acute stress that accumulated with 
time (Figure 4). 
 
Figure 4. Cumulative corticosterone levels in an acute stress response that was elicited by witnessing 
the experimental killing of littermates in male Wistar rats killed approximately 15-20 minutes apart.  
4. Quantifying stress responses 
In terms of psychological stress, an obvious and very popular assessment technique in 
humans are the use of validated, standardised questionnaires designed to assess levels of 
perceived stress, anxiety, depression, hardiness, job satisfaction, etc. Quite clearly this 
method is not of use in animal models. Instead, tests to analyse and quantify stressed 
behaviour have been developed. The most common techniques in this context are the open 
field and elevated plus maze tests, as well as the forced swimming test mentioned earlier. To 
increase the accuracy of interpretations made from behavioural tests, it is advised to 
combine at least two behavioural tests, rather than to rely on the results from only one 
technique. 
For the open field test, the researcher relies on the fact that rats naturally fear large open 
spaces, since this would expose them to predators. For this test, an “open field” of 1m2 with 
gridlines, with high walls around all sides, are used (Figure 5). The rat to be assessed is 
simply placed in the centre of the open field, and its exploratory behaviour assessed by 
quantification of movement frequency and distance. A variation of this test is to have a 
second open field test on a separate day, which involves placing a novel object in the centre 
of the open field – the number of approaches made to this object is recorded. The 
interpretation of the results is not without complexity though. While a greater degree of 
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locomotor activity and more time spent in the inner zone is usually seen as indicative of a 
relaxed emotional state, this same result is obtained in young rats after the traumatic 
experience of maternal separation. The latter condition is seen as an anxious, hyperreactivity 
or hyperarousal state. The “novel object” open field test can distinguish between these two 
explanations for the same behavioural test result: while an emotionally relaxed rat would 
approach the novel object often to investigate, the hyperaroused rat would be much less 
keen to explore the novelty.  
 
Figure 5. The open field test platform 
The elevated plus maze test uses this same basic principle. The maze consist of a platform in 
the shape of a plus sign (+), with two opposite arms open (i.e. looking a bit like a diving 
platform) and the other arms closed along the sides. This platform is placed at a height of 0.5 
m off the floor (Figure 6). Similar to the open field test, the rat is placed in the centre of the 
plus, and its courage to enter the open arms, versus the relatively safer closed arms (at least 
as perceived by a rodent), is assessed in terms of not only the number of times an open or 
closed arm is entered, but also the time spent in the respective arms, either moving about or 
sitting in one position, as well as the rat’s aggressive (rearing) or self-soothing (grooming) 
behaviour while in the arms. In this way, a lot of data on behavioural changes may be 
generated, to use on its own, or to correlate with physiological data such as hormone levels. 
However, as with the open field test, the data is not easy to interpret. Therefore, again, no 
one measure should be considered as a stand-alone result.  
It is of importance to note that the intervention protocol, or stress model used, may also 
dictate or limit the assessment techniques that are possible. Firstly, the behavioural tests are 
performed over the space of a few minutes. Therefore, if the investigation was related to the 
upstream stress responses to acute stress on the level of the brain, the physiological aspects 
 
Using Rodent Models to Simulate Stress of Physiologically Relevant Severity: When, Why and How 225 
of these responses need to be assessed immediately after exposure to the stressor. Doing a 
behavioural test first will result in central effects being missed, because the tissue sample 
will be collected too late. A suggestion to get around this is to perform the behavioural tests 
one day prior to the collection of tissue and blood samples for physiological and/or 
biochemical analyses. The use of appropriate control animals will prevent the behavioural 







Figure 6. The elevated plus maze, with a technical drawing below to indicate dimensions.  
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Secondly, the type of stress intervention chosen may influence behaviour quite 
dramatically. For example, when considering the elevated plus maze, an anxious or 
stressed rat does not move about freely and would prefer the closed arms of the elevated 
plus maze, while an emotionally relaxed animal will exhibit more exploratory behaviour, 
and be more willing to enter and explore the open arms. However, when testing stressed 
or anxious behaviour in a rat that has just been restrained for an hour, the opposite effect 
is seen: an example of behavioural data illustrating this phenomenon in an elevated plus 
maze test is provided in Table 1. Data show that stressed rats chose to enter open arms 
more frequently than controls, which in this case may be interpreted as a counter 
reaction to having been confined to a small space during restraint. The latter explanation 
is very feasible, since the restraint stressed rats entered the closed arms less frequently 
than the controls. Although this decision would normally indicate a relaxed state, one 
has to keep in mind that the normally comforting closed arms would now resemble the 
restraint cage unit the rat had just “escaped” from, so that the rat, even though stressed, 
decided that the open arms are the safer option. The third parameter illustrated in Table 
1, grooming, which is a self-soothing behaviour as stated earlier, clearly shows that 
despite the atypical result just described, the restrained rats were indeed stressed, since 
they spent more than four times as long trying to calm themselves than the control 
animals. 
 
 Number of entriesinto open arms 
Number of entries 
into closed arms 
Time spent grooming 
(in seconds) 
Control 4.3 ± 0.5 8.3 ± 0.7 11.3 ± 2.3 
Stressed 5.9 ± 0.6* 6.1± 0.5* 49.8 ± 8.5** 
Table 1. Selected parameters indicating behavioural responses to repeated restraint stress in male 
Wistar rats. Asterisks indicate values significantly different from controls (ANOVA with Bonferroni post 
hoc tests: *P<0.05; **P<0.001). 
In terms of physiological assessment, stress can be assessed in terms of neuronal and 
endocrine pathways, as well as signalling proteins such as cytokines. Factors which may 
impact significantly on the quality of data is the method and timing of sacrifice and of 
sample collection. Recent studies on rodents commonly use intraperitoneal injection of a 
sodium pentabarbitone overdose. This is relatively painless and the animal loses 
consciousness fairly quickly. This method is also useful in the context of stress, with the 
exception of studies with the aim of investigating central changes. The reason for this is 
that the rodent will perceive the “loss of control” when losing consciousness, resulting in 
a central stress effect. While this effect may not reach downstream tissues in time to 
affect the outcome of analyses significantly, definite changes will be seen in the brain 
itself. Therefore, when conducting in vivo studies in the field of neurophysiology, it may 
be advisable to rather use cervical dislocation or decapitation techniques. The timing of 
sample a sample is of course vital. Sample collection for hormones should take into 
account diurnal variation in glucocorticoid levels, as discussed earlier. (For rodents, 
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corticosterone is the glucocorticoid produced in highest quantities, whereas in humans it 
is cortisol.) For example, samples for determination of corticosterone levels should all be 
taken at the same time of day AND at the same period of recovery after the last stress 
exposure, so that the experiment may require quite a bit of logistical synchronisation. 
Also, the biological half-life of parameters of interest should be considered. For example, 
while corticosterone is a down-stream output of the stress pathways and has a relatively 
long half-life, ACTH is secreted fairly early in the stress response and has a half-life of 
less than 15 minutes, so that samples obtained at the end of a two-hour restraint protocol 
will probably not have detectable levels of ACTH, but sufficient corticosterone to be able 
to quantify the stress response. The design of stress protocols will therefore have 
different endpoints, depending on the aim of the investigation, for example a short 
restrain period may be more ideal for detection of upstream events in the stress 
pathways, while a longer one may be required for down-stream parameters to become 
available in circulation. Therefore, in order to time the sacrifice of an animal and 
collection of samples optimally, it is necessary to understand the basic biochemistry 
and/or pharmacology of parameters of interest. 
In some instances it may be even more useful to determine down-stream effects related to 
earlier events, rather than trying to “catch” upstream parameters in circulation at an optimal 
time. This is also true when the parameter of interest can have its origin from more than one 
source. For example, when considering the inflammatory component of the response to 
stress – which has been linked to many chronic diseases recently – it is difficult to pinpoint 
the origin of cytokines when only assessed in blood, since most of them are released from a 
wide variety of cells. Also, since some cytokines, such as IL-6, have an autocrine-type action, 
its level in circulation is often not indicative of events at cellular level. In these instances, 
immunostaining of tissue levels of these parameters are very useful. Indirect measurements 
of e.g. inflammatory responses can also inform on the response to stress. For example, 
instead of measuring TNF-α levels in blood, activity of the proteolytic pathways in tissue 
may be employed as indirect indicator of TNF-α activity, which known to play an important 
role in muscle wasting, or cachexia. In this way, the timing of sampling become less critical, 
and the effect at the level of the target tissue, may be directly elucidated.  
5. Characterisation and standardisation of stress models 
The severity of the stressor will determine the extent of acute activation of the HPA-axis 
and/or SAM pathway, as well as the adaptability of the animal to the stressor, i.e. the 
chronic response to any particular stressor. This necessitates the standardisation and 
characterisation of any particular model by researchers prior to its application for research 
purposes. Our group have characterised our model of restraint stress in terms of a variety of 
parameters. One of these is the corticosterone response, which is presented for protocols of 
different durations in Figure 7.  
This figure illustrates the significant difference in the response to a specific stressor acutely, 
and after chronic intermittent exposure, after which one may expect habituation to the 
 
Glucocorticoids – New Recognition of Our Familiar Friend 226 
Secondly, the type of stress intervention chosen may influence behaviour quite 
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despite the atypical result just described, the restrained rats were indeed stressed, since 
they spent more than four times as long trying to calm themselves than the control 
animals. 
 
 Number of entriesinto open arms 
Number of entries 
into closed arms 
Time spent grooming 
(in seconds) 
Control 4.3 ± 0.5 8.3 ± 0.7 11.3 ± 2.3 
Stressed 5.9 ± 0.6* 6.1± 0.5* 49.8 ± 8.5** 
Table 1. Selected parameters indicating behavioural responses to repeated restraint stress in male 
Wistar rats. Asterisks indicate values significantly different from controls (ANOVA with Bonferroni post 
hoc tests: *P<0.05; **P<0.001). 
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The severity of the stressor will determine the extent of acute activation of the HPA-axis 
and/or SAM pathway, as well as the adaptability of the animal to the stressor, i.e. the 
chronic response to any particular stressor. This necessitates the standardisation and 
characterisation of any particular model by researchers prior to its application for research 
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parameters. One of these is the corticosterone response, which is presented for protocols of 
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stressor. One can see from these data that the stressor employed was indeed mild; although 
there was a substantial increase in corticosterone concentration in serum immediately after 
the restraint (at the “acute” time point), the rat was able to completely recover its 
corticosterone levels to control levels one day after the single restraint session. The data 
further indicates the effectiveness of this model to induce chronic stress: the value labelled 
“4 days” indicates that 3 restraint stress sessions over 3 days resulted in a corticosterone 
response that the rats could not completely recover from overnight, resulting in a 
significantly elevated corticosterone level even after a period of recovery, albeit not as 










Figure 7. Corticosterone responses to one hour of restraint stress daily, for protocols of different 
durations. Values are means for at least n=10 rats per experimental group.  
However, as discussed earlier, these results in its entirety will probably only be valid for the 
model as executed in our hands. Although the same trend should be seen – e.g. the 
increased corticosterone levels in stressed rats – the magnitude of this response as well as 
the animal’s ability to habituate to it, is largely dependent on the execution of the model by 
various research groups, who each adapts the protocol to be best suited for their own 
particular research interests. Therefore, it is vital to include sufficient control groups for all 
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6. Conclusion 
Conducting research using experimental animal models is a complex endeavour, with many 
considerations, adaptations to make and precautions to take. However, when applied by 
researchers with the ability to adapt a protocol to make the most of it, results achieved are 
very satisfactory in terms of quality, repeatability and direct applicability to actual 
physiological situations. Therefore, in conclusion, cell-based scientists and systems 
biologists should combine efforts to successfully counter the effects of stress. 
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1. Introduction 
Glucocorticoids can readily diffuse into the cells due to their lipophilic nature and bind to 
glucocorticoid (GR) and mineralocorticoid (MR) receptors, which, in the inactive form, are 
associated with other proteins in the cytosol. MR was shown to bind most of the 
glucocorticoids under basal conditions. However, after an increase in the circulating levels 
of glucocorticoids (i.e. caused by exposure to stress or during the circadian and ultradian 
peaks of glucocorticoid secretion) GRs are predominantly activated (de Kloet et al., 2005). 
The activated receptor undergoes conformational changes followed by the translocation of 
the ligand-bound complex to the nucleus. Within this subcellular compartment, this 
complex can form homo or heterodimers and bind to responsive elements (GREs) in the 
promoter region of target genes, a mechanism known as transactivation, or interact with 
transcription factors as monomers to modulate the transcription of responsive genes, a 
mechanism known as transrepression. The main transcriptional factors involved in these 
responses are the nuclear factor kappa B (NFB) and the AP-1 protein family. 
More recently, it has been suggested that nontranscriptional actions may account for the 
very rapid effects observed with acute glucocorticoid treatment (Limbourg & Liao, 2003). 
These actions differ from the classic genomic responses by the targets, type of interaction 
and period of action, being detected within few minutes after hormone secretion (Mikics et 
al., 2004; Sandi et al., 1996). The administration of high doses of dexamethasone was shown 
to protect the myocardial tissue from infarction and stroke through the prompt activation of 
endothelial nitric oxide (NO) system (Hafezi-Moghadam et al., 2002). During the 1990’s, NO 
has been identified as a potent vasodilatatory gas. Its properties in decreasing blood 
pressure are still clinically explored by the use of NO donors as anti-hypertensive drugs. 
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More recently, NO has also been implicated in neuromodulation, exerting its actions in an 
autocrine or paracrine manner in the central nervous system (CNS). 
In general, these rapid effects mediated by glucocorticoids seem to modulate signaling 
(through actions on ion channels, neuromodulators, neurotransmitters and other receptors 
systems), being very distinctive depending on the brain areas involved. It is generally 
accepted that glucocorticoids increase the excitability in some areas, like hippocampus and 
amygdala, and potentially decrease neuronal activity in others, such as the hypothalamus. 
Since the expression of glucocorticoid receptors vary considerably in the CNS, 
glucocorticoids are likely to modulate not only the activity of the hypothalamic-pituitary-
adrenal (HPA) axis, but also indirectly modify the inputs to hypothalamic neurons, 
projecting from the limbic system and cerebral cortex. 
The classic glucocorticoid receptors GR and MR have already been identified in neuronal 
and non-neuronal cellular membranes, although their involvement in these nongenomic 
responses is still controversial (Gametchu et al., 1993; Lipositis & Bohn, 1993). In pituitary-
derived cells, the use of a GR antagonist prevented the dexamethasone-induced 
translocation of annexin-1, which was implicated in the rapid inhibition of 
adrenocorticotrophic hormone (ACTH) release (Buckingham et al., 2003; Solito et al., 2003; 
Tierney et al., 2003). Nevertheless, a GR-independent pathway has been also reported in the 
fast feedback mechanism at the pituitary level in vivo (Hinz & Hirschelmann, 2000). 
Another line of evidence suggests that most of nongenomic responses are mediated by the 
glucocorticoid binding to G-coupled protein receptors (Liu & Chen, 1995; Orchinik et al., 
1991). In tumor-derived cells, a receptor coupled to an inhibitory G-protein (Gi) has been 
implicated in the glucocorticoid-induced inhibition of ACTH release (Iwasaki et al., 1997). In 
the hypothalamus, however, the production and release of neuromodulators 
(endocannabinoids and NO) seem to be driven by the activation of a membrane receptor 
associated with a stimulatory G-protein (Gs) (Di et al., 2009). Endocannabinoids were shown 
to mediate most of the nongenomic actions of the glucocorticoids, including the rapid 
negative feedback on the HPA axis (Evanson et al., 2010). Accordingly, several signaling 
pathways have been implicated in the responses induced by glucocorticoids downstream 
from the putative membrane receptors, mainly including protein kinase A (PKA)- and 
protein kinase C (PKC)-derived mechanisms (Han et al., 2002, 2005; Lou & Chen, 1998; Qiu 
et al, 1998, 2003). 
2. Glucocorticoids and energy balance 
2.1. The control of food intake by glucocorticoids: novel aspects 
The motivated behaviour of eating comprises one of the most primordial responses in all 
species. It is regulated by several factors, including adiposity (leptin and insulin) and satiety 
signals (such as mechanical and chemical stimulation of stomach and small intestine), as 
well as hormones [such as cholecystokinin (CCK)] (Schwartz et al., 2000). The adiposity 
factors are involved in the long-term control of energy balance and act primarily in 
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hypothalamic neurons expressing orexigenic or anorexigenic neuropeptides (Schwartz et al., 
2000). Neuropeptide Y (NPY) and agouti related protein (AgRP) in the arcuate nucleus of 
the hypothalamus (ARC), and orexins and melanin-concentrating hormone (MCH) in the 
lateral hypothalamic area (LHA), represent the main hypothalamic orexigenic 
neuropeptides (Gehlert, 1999; Smith & Ferguson, 2008; Valassi et al., 2008). In contrast, 
proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript (CART) 
in the ARC, and corticotrophin-releasing factor (CRF) and oxytocin (OT) in the 
paraventricular nucleus of the hypothalamus (PVN) are the main mediators involved in the 
inhibition of food intake (Schwartz et al., 2000; Valassi et al., 2008). The localization of the 
above mentioned neuropeptides in hypothalamic nuclei is summarized in Table 1. The 
satiety signals, in turn, are implicated in the short-term control of food intake and have their 
actions mediated by brainstem areas, primarily by the nucleus of the solitary tract (NTS), 
which is implicated in the control of meal size (Havel, 2001). It is well established that the 
hypothalamic nuclei involved in the control of food intake have reciprocal connections with 
the brainstem (Sawchenko & Swanson, 1982; Swanson & Kuypers, 1980). This evidence 
provides the neuroanatomical basis for the hypothesis that adiposity signals may modulate 
satiety (Matson & Ritter, 1999; Wang et al., 2000).   
 
Neuropeptides Localization in the hypothalamus 
NPY ARC 
AgRP ARC 
Orexins LHA and PFA 
MCH LHA 
POMC ARC 
CART ARC, PVN and SON 
CRF PVN 
OT PVN and SON 
Table 1. Hypothalamic localization of the neuropeptides involved in the control of food intake. NPY, 
neuropeptide Y; ARC, arcuate nucleus of the hypothalamus; AgRP, agouti related protein; LHA, lateral 
hypothalamic area; PFA, perifornical area; MCH, melanin-concentrating hormone; POMC, 
proopiomelanocortin; CART,  cocaine and amphetamine-regulated transcript; PVN, paraventricular 
nucleus of the hypothalamus; SON, supraoptic nucleus of the hypothalamus; CRF, corticotrophin-
releasing factor; OT, oxytocin. 
Glucocorticoids play an important role in the control of energy balance (La Fleur, 2006). It is 
well established that a peak in the concentration of glucocorticoids occurs immediately 
before or at the onset of the activity period, with a progressive decrease in the HPA axis 
activity being detected over the remaining period within 24 hours, resulting in the classic 
circadian rhythm (Moreira & Leal, 1997). In addition, this rhythm occurs due to 
glucocorticoids release from the adrenal gland in discrete pulses, which results in an 
ultradian rhythm. Changes in the amplitude of these pulses, and to a lesser extent in their 
frequency, determine the pattern of the circadian rhythm (Lightman et al., 2008). In fact, it 
has been also demonstrated that feeding is a major synchronizer of the HPA axis 
rhythmicity (Leal & Moreira, 1997), being the size of the meal directly related to 
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More recently, NO has also been implicated in neuromodulation, exerting its actions in an 
autocrine or paracrine manner in the central nervous system (CNS). 
In general, these rapid effects mediated by glucocorticoids seem to modulate signaling 
(through actions on ion channels, neuromodulators, neurotransmitters and other receptors 
systems), being very distinctive depending on the brain areas involved. It is generally 
accepted that glucocorticoids increase the excitability in some areas, like hippocampus and 
amygdala, and potentially decrease neuronal activity in others, such as the hypothalamus. 
Since the expression of glucocorticoid receptors vary considerably in the CNS, 
glucocorticoids are likely to modulate not only the activity of the hypothalamic-pituitary-
adrenal (HPA) axis, but also indirectly modify the inputs to hypothalamic neurons, 
projecting from the limbic system and cerebral cortex. 
The classic glucocorticoid receptors GR and MR have already been identified in neuronal 
and non-neuronal cellular membranes, although their involvement in these nongenomic 
responses is still controversial (Gametchu et al., 1993; Lipositis & Bohn, 1993). In pituitary-
derived cells, the use of a GR antagonist prevented the dexamethasone-induced 
translocation of annexin-1, which was implicated in the rapid inhibition of 
adrenocorticotrophic hormone (ACTH) release (Buckingham et al., 2003; Solito et al., 2003; 
Tierney et al., 2003). Nevertheless, a GR-independent pathway has been also reported in the 
fast feedback mechanism at the pituitary level in vivo (Hinz & Hirschelmann, 2000). 
Another line of evidence suggests that most of nongenomic responses are mediated by the 
glucocorticoid binding to G-coupled protein receptors (Liu & Chen, 1995; Orchinik et al., 
1991). In tumor-derived cells, a receptor coupled to an inhibitory G-protein (Gi) has been 
implicated in the glucocorticoid-induced inhibition of ACTH release (Iwasaki et al., 1997). In 
the hypothalamus, however, the production and release of neuromodulators 
(endocannabinoids and NO) seem to be driven by the activation of a membrane receptor 
associated with a stimulatory G-protein (Gs) (Di et al., 2009). Endocannabinoids were shown 
to mediate most of the nongenomic actions of the glucocorticoids, including the rapid 
negative feedback on the HPA axis (Evanson et al., 2010). Accordingly, several signaling 
pathways have been implicated in the responses induced by glucocorticoids downstream 
from the putative membrane receptors, mainly including protein kinase A (PKA)- and 
protein kinase C (PKC)-derived mechanisms (Han et al., 2002, 2005; Lou & Chen, 1998; Qiu 
et al, 1998, 2003). 
2. Glucocorticoids and energy balance 
2.1. The control of food intake by glucocorticoids: novel aspects 
The motivated behaviour of eating comprises one of the most primordial responses in all 
species. It is regulated by several factors, including adiposity (leptin and insulin) and satiety 
signals (such as mechanical and chemical stimulation of stomach and small intestine), as 
well as hormones [such as cholecystokinin (CCK)] (Schwartz et al., 2000). The adiposity 
factors are involved in the long-term control of energy balance and act primarily in 
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hypothalamic neurons expressing orexigenic or anorexigenic neuropeptides (Schwartz et al., 
2000). Neuropeptide Y (NPY) and agouti related protein (AgRP) in the arcuate nucleus of 
the hypothalamus (ARC), and orexins and melanin-concentrating hormone (MCH) in the 
lateral hypothalamic area (LHA), represent the main hypothalamic orexigenic 
neuropeptides (Gehlert, 1999; Smith & Ferguson, 2008; Valassi et al., 2008). In contrast, 
proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript (CART) 
in the ARC, and corticotrophin-releasing factor (CRF) and oxytocin (OT) in the 
paraventricular nucleus of the hypothalamus (PVN) are the main mediators involved in the 
inhibition of food intake (Schwartz et al., 2000; Valassi et al., 2008). The localization of the 
above mentioned neuropeptides in hypothalamic nuclei is summarized in Table 1. The 
satiety signals, in turn, are implicated in the short-term control of food intake and have their 
actions mediated by brainstem areas, primarily by the nucleus of the solitary tract (NTS), 
which is implicated in the control of meal size (Havel, 2001). It is well established that the 
hypothalamic nuclei involved in the control of food intake have reciprocal connections with 
the brainstem (Sawchenko & Swanson, 1982; Swanson & Kuypers, 1980). This evidence 
provides the neuroanatomical basis for the hypothesis that adiposity signals may modulate 
satiety (Matson & Ritter, 1999; Wang et al., 2000).   
 
Neuropeptides Localization in the hypothalamus 
NPY ARC 
AgRP ARC 
Orexins LHA and PFA 
MCH LHA 
POMC ARC 
CART ARC, PVN and SON 
CRF PVN 
OT PVN and SON 
Table 1. Hypothalamic localization of the neuropeptides involved in the control of food intake. NPY, 
neuropeptide Y; ARC, arcuate nucleus of the hypothalamus; AgRP, agouti related protein; LHA, lateral 
hypothalamic area; PFA, perifornical area; MCH, melanin-concentrating hormone; POMC, 
proopiomelanocortin; CART,  cocaine and amphetamine-regulated transcript; PVN, paraventricular 
nucleus of the hypothalamus; SON, supraoptic nucleus of the hypothalamus; CRF, corticotrophin-
releasing factor; OT, oxytocin. 
Glucocorticoids play an important role in the control of energy balance (La Fleur, 2006). It is 
well established that a peak in the concentration of glucocorticoids occurs immediately 
before or at the onset of the activity period, with a progressive decrease in the HPA axis 
activity being detected over the remaining period within 24 hours, resulting in the classic 
circadian rhythm (Moreira & Leal, 1997). In addition, this rhythm occurs due to 
glucocorticoids release from the adrenal gland in discrete pulses, which results in an 
ultradian rhythm. Changes in the amplitude of these pulses, and to a lesser extent in their 
frequency, determine the pattern of the circadian rhythm (Lightman et al., 2008). In fact, it 
has been also demonstrated that feeding is a major synchronizer of the HPA axis 
rhythmicity (Leal & Moreira, 1997), being the size of the meal directly related to 
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glucocorticoid secretion (Honma et al., 1983). At the same time, increased food intake and 
body weight gain have been observed in humans following glucocorticoid treatment 
(Tataranni et al., 1996). Stress conditions, characterized by elevated circulating 
glucocorticoids levels, are also associated with increased food intake, body weight gain and 
obesity (Dallman et al., 2003; La Fleur, 2006; Spencer & Tilbrook, 2011).  
Consistent with the importance of glucocorticoids on energy homeostasis are two very 
prevalent clinical conditions: 1) Cushing’s syndrome, which is characterized by clinical 
findings that include abnormalities in the HPA axis rhythmicity, insulin resistance and 
hyperglycaemia secondary to hypercortisolism. The most common cause of Cushing’s 
syndrome is the administration of pharmacological doses of oral, parenteral and, rarely, by 
topical glucocorticoids. Endogenous glucocorticoid excess may arise from ACTH–secreting 
pituitary tumors, ectopic (nonpituitary) ACTH production, or adrenal tumors. 
Hypercortisolaemia is associated with increased glucose production, decreased glucose 
transport and utilization, decreased protein synthesis, increased protein degradation in 
muscle and body weight gain (Nieuwenhuizen & Rutters, 2008; Shibli-Rahhal et al., 2006); 
(2) Addison’s disease or primary adrenal insufficiency, first described by Addison in 1855, is 
characterized by an inability of the adrenal cortex to synthesize and secrete glucocorticoids 
and mineralocorticoids. Chronically, the main clinical findings observed in patients with 
Addison’s disease include malaise, fatigue, anorexia, weight loss, darkening of the skin, 
hyponatraemia, hypoglycaemia and hyperkalaemia (Nieman and Chanco Turner, 2006). 
It has been shown that the effects of glucocorticoids on food intake can vary according to 
their concentration in the circulation (Devenport et al., 1989).  Low doses of corticosterone 
administered to adrenalectomized (ADX) rats activate MR and induce a stimulatory effect 
on fat intake, body weight gain and fat depot, being these effects prevalent at the late phase 
of the feeding period, the same period in which HPA axis activity is reduced during the 
circadian variation  (Tempel & Leibowitz, 1994, 1989; Tempel et al., 1991). In contrast, GRs 
are activated by higher doses of circulating corticosterone, being this effect observed just 
before or at the first hours after the beginning of the feeding period, mimicking the peak of 
glucocorticoids secretion within the 24 hours of circadian rhythm. Such high levels of 
circulating glucocorticoids produce an increase in carbohydrate ingestion and metabolism 
(Goldstein et al., 1993; Kumar & Leibowitz, 1988; Kumar et al., 1988; Tempel & Leibowitz, 
1994, 1989; Tempel et al., 1993). In addition, extremely high corticosterone plasma 
concentrations, such as those observed in response to stress or food restriction, stimulate fat 
and protein catabolism (mainly from muscular source) and, consequently, body weight loss, 
which increases the availability of gluconeogenesis substrates and enhances glucose plasma 
concentrations (Tempel & Leibowitz, 1994; Tomas et al., 1979).  
Historically, the brain has been considered the main regulator of hunger and satiety. 
However, the existence of a unique hypothalamic satiety or hunger center, as proposed a 
few decades ago, is no longer acceptable. It has been demonstrated that dexamethasone 
injection into the lateral ventricle not only stimulates food intake but also enhances body 
weight gain in rats, being these effects accompanied by hyperleptinaemia and 
hyperinsulinaemia (Cusin et al., 2001; Zakrzewska et al., 1999).  These central effects of 
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glucocorticoids seem to be mediated by their interaction with neurons co-expressing 
glucocorticoid receptors and neuropeptides involved in the control of energy homeostasis 
(Aronsson et al., 1988; Hisano et al., 1988). This hypothesis has been evaluated by Zakrzewska 
and co-workers (1999), who demonstrated that the hypothalamic levels of NPY and CRF were, 
respectively, increased and decreased in response to the intracerebroventricular 
administration of dexamethasone. In addition, circulating glucocorticoids were shown to be 
required for the feeding-induced decrease in the expression of orexigenic neuropeptides in the 
ARC, as well as for the increased expression of the anorexigenic neuropeptide POMC in the 
same nucleus (Uchoa et al., 2012). It has been hypothesized by these authors that these effects 
would occur either by a direct effect of glucocorticoids on ARC neurons or indirectly by the 
feeding-induced secretion of leptin and insulin.  
The removal of endogenous glucocorticoids induced by bilateral ADX surgery is one of the 
most used experimental models for replicating the human Addison’s disease. The food 
intake and body weight gain are reduced in ADX animals, being these effects reversed by 
glucocorticoid replacement (Freedman et al., 1985; Uchoa et al., 2009a, 2009b, 2010). 
Furthermore, ADX is effective in diminishing hyperphagia and obesity under diverse 
experimental conditions (Bruce et al., 1982; Dubuc and Wilden, 1986; Yukimura et al., 1978). 
The ADX-induced hypophagia has been associated with a decrease of hypothalamic NPY 
and AgRP mRNA expression (Strack et al., 1995; Uchoa et al., 2012). Conversely, ADX 
induces an increase in the expression of CRF and OT in PVN (Uchoa et al., 2009b and 2010). 
The actions on these two peptides in the control of food intake were confirmed by the 
central administration of OT and CRF-2 receptor antagonists, which were able to reverse the 
ADX-induced hypophagic effect (Uchoa et al., 2009b and 2010). 
It has been hypothesized that the stimulatory action of glucocorticoids on food intake may 
involve an increased drive for eating. Accordingly, it is believed that the ADX-induced 
hypophagia is caused, at least in part, by a reduction of this motivated behaviour. However, 
there are few evidences concerning the role of glucocorticoids on the satiety-related 
responses. Recent studies have demonstrated that the hypophagic response induced by 
ADX is associated with increased activation of satiety-related responses mediated by 
brainstem and hypothalamic circuits (Uchoa et al., 2009a, 2009b). Accordingly, the activation 
of NTS neurons, assessed by the increased number of cells expressing the nuclear c-Fos 
protein, is increased in ADX animals after feeding, indicating that this nucleus may be 
involved in the increased satiety responses following glucocorticoid deficiency (Uchoa et al., 
2009a). Interestingly, the activation of CRF and OT neurons was also enhanced in the PVN 
of fed ADX rats, indicating that, besides the brainstem, the hypothalamus may be also 
involved in these satiety-related responses. Furthermore, this increased activation of satiety-
related responses in the NTS following ADX is reversed by CRF2 receptor antagonist, 
indicating that CRF also plays an important functional neuromodulatory role in the 
brainstem (Uchoa et al., 2010). 
In addition to the reduced drive to eat and the increased satiety observed in ADX animals, a 
change in both the concentration as well as in the sensitivity to peripheral factors seems to 
underlie the hypophagic effect of glucocorticoid deficiency. Accordingly, ADX reduces 
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glucocorticoid secretion (Honma et al., 1983). At the same time, increased food intake and 
body weight gain have been observed in humans following glucocorticoid treatment 
(Tataranni et al., 1996). Stress conditions, characterized by elevated circulating 
glucocorticoids levels, are also associated with increased food intake, body weight gain and 
obesity (Dallman et al., 2003; La Fleur, 2006; Spencer & Tilbrook, 2011).  
Consistent with the importance of glucocorticoids on energy homeostasis are two very 
prevalent clinical conditions: 1) Cushing’s syndrome, which is characterized by clinical 
findings that include abnormalities in the HPA axis rhythmicity, insulin resistance and 
hyperglycaemia secondary to hypercortisolism. The most common cause of Cushing’s 
syndrome is the administration of pharmacological doses of oral, parenteral and, rarely, by 
topical glucocorticoids. Endogenous glucocorticoid excess may arise from ACTH–secreting 
pituitary tumors, ectopic (nonpituitary) ACTH production, or adrenal tumors. 
Hypercortisolaemia is associated with increased glucose production, decreased glucose 
transport and utilization, decreased protein synthesis, increased protein degradation in 
muscle and body weight gain (Nieuwenhuizen & Rutters, 2008; Shibli-Rahhal et al., 2006); 
(2) Addison’s disease or primary adrenal insufficiency, first described by Addison in 1855, is 
characterized by an inability of the adrenal cortex to synthesize and secrete glucocorticoids 
and mineralocorticoids. Chronically, the main clinical findings observed in patients with 
Addison’s disease include malaise, fatigue, anorexia, weight loss, darkening of the skin, 
hyponatraemia, hypoglycaemia and hyperkalaemia (Nieman and Chanco Turner, 2006). 
It has been shown that the effects of glucocorticoids on food intake can vary according to 
their concentration in the circulation (Devenport et al., 1989).  Low doses of corticosterone 
administered to adrenalectomized (ADX) rats activate MR and induce a stimulatory effect 
on fat intake, body weight gain and fat depot, being these effects prevalent at the late phase 
of the feeding period, the same period in which HPA axis activity is reduced during the 
circadian variation  (Tempel & Leibowitz, 1994, 1989; Tempel et al., 1991). In contrast, GRs 
are activated by higher doses of circulating corticosterone, being this effect observed just 
before or at the first hours after the beginning of the feeding period, mimicking the peak of 
glucocorticoids secretion within the 24 hours of circadian rhythm. Such high levels of 
circulating glucocorticoids produce an increase in carbohydrate ingestion and metabolism 
(Goldstein et al., 1993; Kumar & Leibowitz, 1988; Kumar et al., 1988; Tempel & Leibowitz, 
1994, 1989; Tempel et al., 1993). In addition, extremely high corticosterone plasma 
concentrations, such as those observed in response to stress or food restriction, stimulate fat 
and protein catabolism (mainly from muscular source) and, consequently, body weight loss, 
which increases the availability of gluconeogenesis substrates and enhances glucose plasma 
concentrations (Tempel & Leibowitz, 1994; Tomas et al., 1979).  
Historically, the brain has been considered the main regulator of hunger and satiety. 
However, the existence of a unique hypothalamic satiety or hunger center, as proposed a 
few decades ago, is no longer acceptable. It has been demonstrated that dexamethasone 
injection into the lateral ventricle not only stimulates food intake but also enhances body 
weight gain in rats, being these effects accompanied by hyperleptinaemia and 
hyperinsulinaemia (Cusin et al., 2001; Zakrzewska et al., 1999).  These central effects of 
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glucocorticoids seem to be mediated by their interaction with neurons co-expressing 
glucocorticoid receptors and neuropeptides involved in the control of energy homeostasis 
(Aronsson et al., 1988; Hisano et al., 1988). This hypothesis has been evaluated by Zakrzewska 
and co-workers (1999), who demonstrated that the hypothalamic levels of NPY and CRF were, 
respectively, increased and decreased in response to the intracerebroventricular 
administration of dexamethasone. In addition, circulating glucocorticoids were shown to be 
required for the feeding-induced decrease in the expression of orexigenic neuropeptides in the 
ARC, as well as for the increased expression of the anorexigenic neuropeptide POMC in the 
same nucleus (Uchoa et al., 2012). It has been hypothesized by these authors that these effects 
would occur either by a direct effect of glucocorticoids on ARC neurons or indirectly by the 
feeding-induced secretion of leptin and insulin.  
The removal of endogenous glucocorticoids induced by bilateral ADX surgery is one of the 
most used experimental models for replicating the human Addison’s disease. The food 
intake and body weight gain are reduced in ADX animals, being these effects reversed by 
glucocorticoid replacement (Freedman et al., 1985; Uchoa et al., 2009a, 2009b, 2010). 
Furthermore, ADX is effective in diminishing hyperphagia and obesity under diverse 
experimental conditions (Bruce et al., 1982; Dubuc and Wilden, 1986; Yukimura et al., 1978). 
The ADX-induced hypophagia has been associated with a decrease of hypothalamic NPY 
and AgRP mRNA expression (Strack et al., 1995; Uchoa et al., 2012). Conversely, ADX 
induces an increase in the expression of CRF and OT in PVN (Uchoa et al., 2009b and 2010). 
The actions on these two peptides in the control of food intake were confirmed by the 
central administration of OT and CRF-2 receptor antagonists, which were able to reverse the 
ADX-induced hypophagic effect (Uchoa et al., 2009b and 2010). 
It has been hypothesized that the stimulatory action of glucocorticoids on food intake may 
involve an increased drive for eating. Accordingly, it is believed that the ADX-induced 
hypophagia is caused, at least in part, by a reduction of this motivated behaviour. However, 
there are few evidences concerning the role of glucocorticoids on the satiety-related 
responses. Recent studies have demonstrated that the hypophagic response induced by 
ADX is associated with increased activation of satiety-related responses mediated by 
brainstem and hypothalamic circuits (Uchoa et al., 2009a, 2009b). Accordingly, the activation 
of NTS neurons, assessed by the increased number of cells expressing the nuclear c-Fos 
protein, is increased in ADX animals after feeding, indicating that this nucleus may be 
involved in the increased satiety responses following glucocorticoid deficiency (Uchoa et al., 
2009a). Interestingly, the activation of CRF and OT neurons was also enhanced in the PVN 
of fed ADX rats, indicating that, besides the brainstem, the hypothalamus may be also 
involved in these satiety-related responses. Furthermore, this increased activation of satiety-
related responses in the NTS following ADX is reversed by CRF2 receptor antagonist, 
indicating that CRF also plays an important functional neuromodulatory role in the 
brainstem (Uchoa et al., 2010). 
In addition to the reduced drive to eat and the increased satiety observed in ADX animals, a 
change in both the concentration as well as in the sensitivity to peripheral factors seems to 
underlie the hypophagic effect of glucocorticoid deficiency. Accordingly, ADX reduces 
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plasma leptin levels in ad libitum rats (Germano et al., 2007; Savontaus et al., 2002), as well as 
the meal-induced insulin secretion (Germano et al., 2008; Uchoa et al., 2012), whereas 
glucocorticoid treatment increases leptin secretion and leptin expression in adipocytes 
(Jahng et al., 2008; Slieker et al., 1996; Zakrzewska et al., 1999). Furthermore, the sensitivity 
to insulin and leptin seems to be enhanced after ADX (Chavez et al., 1997; Zakrzewska et al., 
1997), although CCK administration did not significantly alter food intake in ADX rats 
(Uchoa et al, 2009a). Another hormone that arises as a candidate for the modulation by 
glucocorticoids is ghrelin, although the effects of this hormone on food intake may also be 
produced independently of glucocorticoid action.  
The physiological instinct of obtaining energy through food intake is parallel to the equally 
important development of satiation signals, which may terminate the ingestive behaviour as 
soon as the organism is replenished. Glucocorticoids have a well established role in both 
processes, contributing to the enhanced drive to eat as well as to the reduction of satiety-
related responses. However, it is believed that, particularly in humans, the initiation of a 
meal often starts in the absence of any depletion signal, which means that it is possible for 
other brain areas such as the cortex and the limbic system to overcome the inputs coming 
from the hypothalamus and the brainstem, turning the organism into an ingestive mode, 
which actually exceeds its needs. Accordingly, both real and potential challenges that 
activate the HPA axis and, consequently, alter the secretion of glucocorticoids, may also 
disrupt this balance. 
2.2. Glucocorticoids in the interface of immune challenges and food intake 
Under acute immune challenges, the body produces a strong inflammatory response to the 
pathogens. This generalized reaction, triggered by the organism in order to safeguard the 
host homeostasis, comprises physiological and behavioural changes (Langhans, 2000). 
However, in a severe condition in which the overwhelming infection leads to life-
threatening low blood pressure and decreased tissue perfusion, a medical emergency 
known as septic shock may contribute to organ damage and death. Microbial products such 
as lipopolisaccharides (LPS) from the outer lipid bilayer of gram-negative bacteria cell walls 
are commonly used to model acute illness, leading to the development of sepsis or 
endotoxaemia, depending on the dose of the endotoxin (Borges et al., 2007; 2011; Giusti-
Paiva et al., 2002).  
Hypophagia is part of the acute-phase response to illness. During endotoxaemia, food 
intake is limited and there is an impairment of energy expenditure. Experimental models 
have demonstrated that LPS dramatically reduces food consumption (Gautron et al., 2005; 
Sachot et al., 2004), being this hypophagic effect mainly elicited by the production of 
proinflammatory cytokines (Johnson, 1998; Wise et al., 2006). Consistent with the 
contribution of proinflammatory cytokines to this illness-induced hypophagia are the 
studies showing that their peripheral or central administration restrains eating, and that the 
acute antagonism of their actions attenuates this anorexic response (Asarian & Langhans, 
2010). 
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The systemic administration of LPS triggers the synthesis and release of interleukin (IL)-1β, 
IL-6 and tumor necrosis factor (TNF)-α by monocytes and macrophages. In turn, these 
cytokines can exert local actions as signaling molecules to activate the immune system and 
the HPA axis (Turnbull and Rivier, 1999; Turnbull et al., 1998). Accordingly, it has been 
demonstrated that cytokines induce intense nuclear c-Fos immunoreactivity in CRF 
parvocellular neurons of the PVN (Matsunaga et al., 2000). Endotoxin also increases CRF 
synthesis and secretion, stimulating ACTH release from the pituitary corticotrophs and, 
consequently, the secretion of glucocorticoids from the adrenal cortex (Borges et al., 2007; 
Turnbull & Rivier, 1999). In turn, glucocorticoids inhibit the induction of proinflammatory 
cytokines, mostly by interacting with the intracellular GR, which culminates with the 
activation of NFκB and AP-1 (Jonat et al., 1990; Munoz et al., 1996). After glucocorticoid 
binding to the cytosolic GR, the activated complex is translocated to the cell nucleus, where 
it interacts with the specific transcription factors AP-1 and NF-κB and prevents the 
transcription of targeted genes, in a process called transrepression. Glucocorticoids are able 
to prevent the transcription of many inflammation-associated genes, such as those ones 
encoding cytokines, including interleukins IL-1B, IL-4, IL-5 and IL-8, chemokines, 
arachidonic acid metabolites and adhesion molecules. The immunosuppressant action 
exerted by glucocorticoids may be also evidenced by the increased hypothalamic messenger 
RNA (mRNA) expression of cytokines and IL-1β plasma levels observed in response to LPS 
administration to ADX rats (Goujon et al., 1996).  
Within this context, glucocorticoids appear as crucial hormones involved in the mobilization 
of stored peripheral energy, directing the metabolism to the production of key substrates 
utilized by the liver to sustain gluconeogenesis. Studies performed in rats show that the 
search and consumption of palatable foods are stimulated by corticosterone in a dose-
related fashion (Dallman et al., 2007). Accordingly, these authors have also demonstrated 
that ADX rats exhibit poor weight gain, low fat content and increased sympathetic and HPA 
axis outflow, effects that are, in general, reversed by replacement with corticosterone. The 
removal of the negative feedback exerted by glucocorticoids in ADX animals has been also 
implicated in the increased expression of CRF mRNA in the PVN (Herman & Morrison, 
1996; Rorato et al., 2008). In addition to its essential function in the control of HPA axis 
activity, CRF also has a physiological role in the control of food intake, as evidenced by the 
anorexigenic response induced by central administration of CRF and CRF-related peptides 
to experimental animals (Kalra et al., 1999; Richard et al., 2002), as previously discussed in 
this chapter. Furthermore, the use of a CRF receptor antagonist partially reverses the 
reduction in food intake induced by different stress paradigms (Hotta et al., 1999; Krahn et 
al., 1986). Accordingly, Borges and coworkers (2007) observed that increased CRF mRNA 
expression in the PVN precedes LPS-induced anorexia. Hence, an interchange between 
feeding control and HPA axis activity is conceivable to operate in basal conditions as well as 
following an immune challenge. 
Recently, Saito and Watanabe (2008) have described that dexamethasone treatment 
attenuates the production of multiple proinflammatory cytokines by the brain and liver, 
suggesting a potential preventive effect of glucocorticoids on the LPS-induced hypophagia. 
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plasma leptin levels in ad libitum rats (Germano et al., 2007; Savontaus et al., 2002), as well as 
the meal-induced insulin secretion (Germano et al., 2008; Uchoa et al., 2012), whereas 
glucocorticoid treatment increases leptin secretion and leptin expression in adipocytes 
(Jahng et al., 2008; Slieker et al., 1996; Zakrzewska et al., 1999). Furthermore, the sensitivity 
to insulin and leptin seems to be enhanced after ADX (Chavez et al., 1997; Zakrzewska et al., 
1997), although CCK administration did not significantly alter food intake in ADX rats 
(Uchoa et al, 2009a). Another hormone that arises as a candidate for the modulation by 
glucocorticoids is ghrelin, although the effects of this hormone on food intake may also be 
produced independently of glucocorticoid action.  
The physiological instinct of obtaining energy through food intake is parallel to the equally 
important development of satiation signals, which may terminate the ingestive behaviour as 
soon as the organism is replenished. Glucocorticoids have a well established role in both 
processes, contributing to the enhanced drive to eat as well as to the reduction of satiety-
related responses. However, it is believed that, particularly in humans, the initiation of a 
meal often starts in the absence of any depletion signal, which means that it is possible for 
other brain areas such as the cortex and the limbic system to overcome the inputs coming 
from the hypothalamus and the brainstem, turning the organism into an ingestive mode, 
which actually exceeds its needs. Accordingly, both real and potential challenges that 
activate the HPA axis and, consequently, alter the secretion of glucocorticoids, may also 
disrupt this balance. 
2.2. Glucocorticoids in the interface of immune challenges and food intake 
Under acute immune challenges, the body produces a strong inflammatory response to the 
pathogens. This generalized reaction, triggered by the organism in order to safeguard the 
host homeostasis, comprises physiological and behavioural changes (Langhans, 2000). 
However, in a severe condition in which the overwhelming infection leads to life-
threatening low blood pressure and decreased tissue perfusion, a medical emergency 
known as septic shock may contribute to organ damage and death. Microbial products such 
as lipopolisaccharides (LPS) from the outer lipid bilayer of gram-negative bacteria cell walls 
are commonly used to model acute illness, leading to the development of sepsis or 
endotoxaemia, depending on the dose of the endotoxin (Borges et al., 2007; 2011; Giusti-
Paiva et al., 2002).  
Hypophagia is part of the acute-phase response to illness. During endotoxaemia, food 
intake is limited and there is an impairment of energy expenditure. Experimental models 
have demonstrated that LPS dramatically reduces food consumption (Gautron et al., 2005; 
Sachot et al., 2004), being this hypophagic effect mainly elicited by the production of 
proinflammatory cytokines (Johnson, 1998; Wise et al., 2006). Consistent with the 
contribution of proinflammatory cytokines to this illness-induced hypophagia are the 
studies showing that their peripheral or central administration restrains eating, and that the 
acute antagonism of their actions attenuates this anorexic response (Asarian & Langhans, 
2010). 
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The systemic administration of LPS triggers the synthesis and release of interleukin (IL)-1β, 
IL-6 and tumor necrosis factor (TNF)-α by monocytes and macrophages. In turn, these 
cytokines can exert local actions as signaling molecules to activate the immune system and 
the HPA axis (Turnbull and Rivier, 1999; Turnbull et al., 1998). Accordingly, it has been 
demonstrated that cytokines induce intense nuclear c-Fos immunoreactivity in CRF 
parvocellular neurons of the PVN (Matsunaga et al., 2000). Endotoxin also increases CRF 
synthesis and secretion, stimulating ACTH release from the pituitary corticotrophs and, 
consequently, the secretion of glucocorticoids from the adrenal cortex (Borges et al., 2007; 
Turnbull & Rivier, 1999). In turn, glucocorticoids inhibit the induction of proinflammatory 
cytokines, mostly by interacting with the intracellular GR, which culminates with the 
activation of NFκB and AP-1 (Jonat et al., 1990; Munoz et al., 1996). After glucocorticoid 
binding to the cytosolic GR, the activated complex is translocated to the cell nucleus, where 
it interacts with the specific transcription factors AP-1 and NF-κB and prevents the 
transcription of targeted genes, in a process called transrepression. Glucocorticoids are able 
to prevent the transcription of many inflammation-associated genes, such as those ones 
encoding cytokines, including interleukins IL-1B, IL-4, IL-5 and IL-8, chemokines, 
arachidonic acid metabolites and adhesion molecules. The immunosuppressant action 
exerted by glucocorticoids may be also evidenced by the increased hypothalamic messenger 
RNA (mRNA) expression of cytokines and IL-1β plasma levels observed in response to LPS 
administration to ADX rats (Goujon et al., 1996).  
Within this context, glucocorticoids appear as crucial hormones involved in the mobilization 
of stored peripheral energy, directing the metabolism to the production of key substrates 
utilized by the liver to sustain gluconeogenesis. Studies performed in rats show that the 
search and consumption of palatable foods are stimulated by corticosterone in a dose-
related fashion (Dallman et al., 2007). Accordingly, these authors have also demonstrated 
that ADX rats exhibit poor weight gain, low fat content and increased sympathetic and HPA 
axis outflow, effects that are, in general, reversed by replacement with corticosterone. The 
removal of the negative feedback exerted by glucocorticoids in ADX animals has been also 
implicated in the increased expression of CRF mRNA in the PVN (Herman & Morrison, 
1996; Rorato et al., 2008). In addition to its essential function in the control of HPA axis 
activity, CRF also has a physiological role in the control of food intake, as evidenced by the 
anorexigenic response induced by central administration of CRF and CRF-related peptides 
to experimental animals (Kalra et al., 1999; Richard et al., 2002), as previously discussed in 
this chapter. Furthermore, the use of a CRF receptor antagonist partially reverses the 
reduction in food intake induced by different stress paradigms (Hotta et al., 1999; Krahn et 
al., 1986). Accordingly, Borges and coworkers (2007) observed that increased CRF mRNA 
expression in the PVN precedes LPS-induced anorexia. Hence, an interchange between 
feeding control and HPA axis activity is conceivable to operate in basal conditions as well as 
following an immune challenge. 
Recently, Saito and Watanabe (2008) have described that dexamethasone treatment 
attenuates the production of multiple proinflammatory cytokines by the brain and liver, 
suggesting a potential preventive effect of glucocorticoids on the LPS-induced hypophagia. 
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Furthermore, Rorato and coworkers (2008) reported that the anorexigenic effect induced by 
LPS is amplified in ADX rats and that the ADX-induced glucocorticoid deficiency promotes 
an increased activation of hypothalamic CRF and POMC neurons. It has been already 
demonstrated that the activation of POMC neurons promotes the release of α-melanocyte 
stimulating hormone (α-MSH), which, in turn, activates melanocortin 4 receptor (MC4R) 
(Cone, 2005). Melanocortin has been also implicated in the LPS-induced hypophagia, since 
the administration of exogenous α-MSH intensified, whereas the antagonism of MC4R 
attenuated the inhibitory effect of LPS on food intake (Fan et al., 1997; Huang et al., 1999). 
Within this context, glucocorticoids appear as negative regulators of melanocortin signaling, 
since ADX was shown not only to reduce AgRP expression in the hypothalamus of wild 
type mice, but also to reverse obese phenotype and restore hypothalamic melanocortin tone 
to control levels in leptin-deficient ob/ob mice (Makimura et al., 2000). 
A growing body of evidence has recently linked obesity to a chronic low-grade 
inflammatory state (Paternain et al., 2011; Trayhurn & Wood, 2005). In fact, inflammation 
may contribute to a range of metabolic disturbances related to obesity, such as diabetes 
mellitus and cardiovascular diseases (Oren et al., 2007). Rats fed with high-fat diet express 
high levels of TNF-α, IL-6 and IL-1β in the hypothalamus, which is consistent with the 
development of an inflammatory process (Milanski et al., 2009). Cani and coworkers (2007) 
have demonstrated that endotoxaemia dysregulates the inflammatory tone and induces 
body weight gain and diabetes in mice, showing that a 4-week high-fat diet induced a two 
to three-fold increase in plasma LPS concentrations. The bacterial endotoxin is normally 
present in the human intestinal tract (Kelly et al., 2012). Accordingly, LPS is detectable in the 
circulation of both healthy and obese individuals, but it may transiently raises following 
energy-rich meals. It has also been shown that the intake of fat-rich diet acts as an inducer of 
chronic stress, elevating basal glucocorticoid levels and enhancing HPA axis responses to 
stress (Tannenbaum et al., 1997), suggesting that glucocorticoids are likely to participate in 
the pathogenesis of metabolic syndrome and obesity (Milagro et al., 2007; Paternain et al., 
2011), even though obese individuals and patients with metabolic syndrome do not 
necessarily show elevated systemic glucocorticoid concentrations (Pereira et al., 2012). 
In face of these findings, efforts are now being turned to clarify the significance of 
glucocorticoids in counteracting the pathophysiology of illness-induced hypophagia. The 
better understanding of these processes may place glucocorticoids as important 
pharmacological targets to deal with obesity and metabolic syndrome, in which 
inflammatory modulators seem to play a key role.  
3. Endocannabinoids as potential intermediates of glucocorticoids actions 
3.1. Endocannabinoids: general aspects 
The pharmacological properties of the plant Cannabis sativa are knwon since ancient times. 
The first cannabinoid receptor (CB1R) was characterized in 1988 and its predominant 
distribution through the CNS initially suggested a relationship with the control of cognitive 
function. However, over the past few years, the number of studies investigating the 
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participation of CB1R in several areas has increased dramatically. Pioneer studies revealed 
that the exogenous administration of “cannabis-like” compounds inhibits the activity of 
diverse neuroendocrine functions (Lomax, 1970; Rettori et al., 1990; Tyrey, 1978). 
Accordingly, it has been demonstrated that the mRNA for the CB1R is expressed in the 
hypothalamus and in the external layer of the median eminence of rodents (Herkenham et 
al., 1991; Wittmann et al., 2007), as well as in both the anterior and intermediate lobes of the 
human pituitary gland (Pagotto et al., 2001). The evidence of the local production of 
endocannabinoids provided by this later group further suggested a role for these substances 
on the direct control of pituitary function.  
In this context, the CB1R has been implicated in most, if not all, the actions of endogenously 
produced cannabinoids in neurotransmission. It has been also demonstrated that 
hippocampal astrocytes functionally express the CB1R and respond with elevations in 
intracellular calcium concentrations to the stimulation by neurotransmitters released locally 
from neuronal sources (Navarrete & Araque, 2008). This evidence suggests that non-
neuronal populations can also contribute to the complexity of the responses elicited by 
endocannabinoids within the CNS. Differently from CB1R, the second cannabinoid receptor 
(CB2R) was identified in immune cells, being predominantly distributed in the peripheral 
organs, but not restricted to them. Most of the actions of the endocannabinoid system are 
mediated by the interaction of endogenous ligands with CB1R or CB2R, although the precise 
actions of orphan receptors, such as GPR55, still remain to be elucidated. 
The identification of this receptor system, as well as the description of well-known effects 
induced by the consumption or administration of “cannabis-like” substances in humans, 
suggested the existence of endogenous ligands to be discovered. Anandamide (AEA) was 
the first one, followed by 2-araquidonoilglicerol (2-AG), the main endocannabinoids studied 
so far. AEA binds to CB1R with high affinity and regulates the signaling cascade as a partial 
agonist (Bouaboula et al., 1995). On the other hand, 2-AG, besides being the most abundant 
endocannabinoid produced by the CNS, has a lower affinity for CB1R when compared to 
AEA but stimulates the intracellular signaling pathway as a full agonist (Mechoulam et al., 
1995). Both AEA and 2-AG are synthesized on demand from membrane phospholipids after 
the activation of membrane-associated glucocorticoid receptors. AEA and 2-AG are also 
metabolized by independent enzymatic pathways (Freund et al., 2003). Indeed, AEA acts as 
a very promiscuous ligand, since it can also bind to type 1 vanilloid (TRPV1) receptors with 
high affinity (Tóth et al., 2005). Accordingly, some of the effects induced by AEA cannot be 
mimicked by the administration of the synthetic cannabinoid agonist WIN55,212-2 (Al-
Hayani et al., 2001) and the well-known AEA-induced antinociception is still preserved in 
experimental animals lacking the CB1R gene (Di Marzo et al., 2000). 
3.2. Endocannabinoids and the ingestive behaviour 
3.2.1. Food intake 
It has been demonstrated that glucocorticoids increase endocannabinoid levels in 
hypothalamic PVN slices, supporting the hypothesis that at least part of the effects induced 
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Furthermore, Rorato and coworkers (2008) reported that the anorexigenic effect induced by 
LPS is amplified in ADX rats and that the ADX-induced glucocorticoid deficiency promotes 
an increased activation of hypothalamic CRF and POMC neurons. It has been already 
demonstrated that the activation of POMC neurons promotes the release of α-melanocyte 
stimulating hormone (α-MSH), which, in turn, activates melanocortin 4 receptor (MC4R) 
(Cone, 2005). Melanocortin has been also implicated in the LPS-induced hypophagia, since 
the administration of exogenous α-MSH intensified, whereas the antagonism of MC4R 
attenuated the inhibitory effect of LPS on food intake (Fan et al., 1997; Huang et al., 1999). 
Within this context, glucocorticoids appear as negative regulators of melanocortin signaling, 
since ADX was shown not only to reduce AgRP expression in the hypothalamus of wild 
type mice, but also to reverse obese phenotype and restore hypothalamic melanocortin tone 
to control levels in leptin-deficient ob/ob mice (Makimura et al., 2000). 
A growing body of evidence has recently linked obesity to a chronic low-grade 
inflammatory state (Paternain et al., 2011; Trayhurn & Wood, 2005). In fact, inflammation 
may contribute to a range of metabolic disturbances related to obesity, such as diabetes 
mellitus and cardiovascular diseases (Oren et al., 2007). Rats fed with high-fat diet express 
high levels of TNF-α, IL-6 and IL-1β in the hypothalamus, which is consistent with the 
development of an inflammatory process (Milanski et al., 2009). Cani and coworkers (2007) 
have demonstrated that endotoxaemia dysregulates the inflammatory tone and induces 
body weight gain and diabetes in mice, showing that a 4-week high-fat diet induced a two 
to three-fold increase in plasma LPS concentrations. The bacterial endotoxin is normally 
present in the human intestinal tract (Kelly et al., 2012). Accordingly, LPS is detectable in the 
circulation of both healthy and obese individuals, but it may transiently raises following 
energy-rich meals. It has also been shown that the intake of fat-rich diet acts as an inducer of 
chronic stress, elevating basal glucocorticoid levels and enhancing HPA axis responses to 
stress (Tannenbaum et al., 1997), suggesting that glucocorticoids are likely to participate in 
the pathogenesis of metabolic syndrome and obesity (Milagro et al., 2007; Paternain et al., 
2011), even though obese individuals and patients with metabolic syndrome do not 
necessarily show elevated systemic glucocorticoid concentrations (Pereira et al., 2012). 
In face of these findings, efforts are now being turned to clarify the significance of 
glucocorticoids in counteracting the pathophysiology of illness-induced hypophagia. The 
better understanding of these processes may place glucocorticoids as important 
pharmacological targets to deal with obesity and metabolic syndrome, in which 
inflammatory modulators seem to play a key role.  
3. Endocannabinoids as potential intermediates of glucocorticoids actions 
3.1. Endocannabinoids: general aspects 
The pharmacological properties of the plant Cannabis sativa are knwon since ancient times. 
The first cannabinoid receptor (CB1R) was characterized in 1988 and its predominant 
distribution through the CNS initially suggested a relationship with the control of cognitive 
function. However, over the past few years, the number of studies investigating the 
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participation of CB1R in several areas has increased dramatically. Pioneer studies revealed 
that the exogenous administration of “cannabis-like” compounds inhibits the activity of 
diverse neuroendocrine functions (Lomax, 1970; Rettori et al., 1990; Tyrey, 1978). 
Accordingly, it has been demonstrated that the mRNA for the CB1R is expressed in the 
hypothalamus and in the external layer of the median eminence of rodents (Herkenham et 
al., 1991; Wittmann et al., 2007), as well as in both the anterior and intermediate lobes of the 
human pituitary gland (Pagotto et al., 2001). The evidence of the local production of 
endocannabinoids provided by this later group further suggested a role for these substances 
on the direct control of pituitary function.  
In this context, the CB1R has been implicated in most, if not all, the actions of endogenously 
produced cannabinoids in neurotransmission. It has been also demonstrated that 
hippocampal astrocytes functionally express the CB1R and respond with elevations in 
intracellular calcium concentrations to the stimulation by neurotransmitters released locally 
from neuronal sources (Navarrete & Araque, 2008). This evidence suggests that non-
neuronal populations can also contribute to the complexity of the responses elicited by 
endocannabinoids within the CNS. Differently from CB1R, the second cannabinoid receptor 
(CB2R) was identified in immune cells, being predominantly distributed in the peripheral 
organs, but not restricted to them. Most of the actions of the endocannabinoid system are 
mediated by the interaction of endogenous ligands with CB1R or CB2R, although the precise 
actions of orphan receptors, such as GPR55, still remain to be elucidated. 
The identification of this receptor system, as well as the description of well-known effects 
induced by the consumption or administration of “cannabis-like” substances in humans, 
suggested the existence of endogenous ligands to be discovered. Anandamide (AEA) was 
the first one, followed by 2-araquidonoilglicerol (2-AG), the main endocannabinoids studied 
so far. AEA binds to CB1R with high affinity and regulates the signaling cascade as a partial 
agonist (Bouaboula et al., 1995). On the other hand, 2-AG, besides being the most abundant 
endocannabinoid produced by the CNS, has a lower affinity for CB1R when compared to 
AEA but stimulates the intracellular signaling pathway as a full agonist (Mechoulam et al., 
1995). Both AEA and 2-AG are synthesized on demand from membrane phospholipids after 
the activation of membrane-associated glucocorticoid receptors. AEA and 2-AG are also 
metabolized by independent enzymatic pathways (Freund et al., 2003). Indeed, AEA acts as 
a very promiscuous ligand, since it can also bind to type 1 vanilloid (TRPV1) receptors with 
high affinity (Tóth et al., 2005). Accordingly, some of the effects induced by AEA cannot be 
mimicked by the administration of the synthetic cannabinoid agonist WIN55,212-2 (Al-
Hayani et al., 2001) and the well-known AEA-induced antinociception is still preserved in 
experimental animals lacking the CB1R gene (Di Marzo et al., 2000). 
3.2. Endocannabinoids and the ingestive behaviour 
3.2.1. Food intake 
It has been demonstrated that glucocorticoids increase endocannabinoid levels in 
hypothalamic PVN slices, supporting the hypothesis that at least part of the effects induced 
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by glucocorticoids on food intake are mediated by these lipid-derived mediators (Malcher-
Lopes et al., 2006). In this study, Malcher-Lopes and colleagues also demonstrated that the 
glucocorticoid-mediated activation of a membrane receptor coupled to a Gαs–cAMP–PKA 
signaling cascade leads to an increase in endocannabinoid synthesis. Accordingly, increased 
hypothalamic levels of endocannabinoids have been also observed in vivo following 
glucocorticoid treatment (Hill et al., 2010).  
Both endocannabinoids and glucocorticoids injected into hypothalamic areas induce similar 
effects on eating behaviour, increasing food consumption (Jamshidi & Taylor, 2001; Tempel 
et al., 1992). The synthesis of endocannabinoids in the hypothalamus and the expression of 
both endocannabinoids and glucocorticoid receptors in synapses and in hypothalamic 
neurons that synthesize peptides with a key role in food consumption reinforce this 
assumption (Castelli et al., 2007; Cota et al., 2003; Deli et al. 2009; Di Marzo et al., 2001; 
Malcher-Lopes et al., 2006). In fact, the neuropeptides CRF, OT and TRH, which have well 
described anorexigenic properties (Arletti et al., 1989, 1990; Morley et al., 1983; Steward et 
al., 2003), appear as potential targets for endocannabinoid-mediated actions induced by 
glucocorticoids. Therefore, the glucocorticoid-mediated blockade of excitatory glutamatergic 
synapses induced by endocannabinoids via CB1R has been already described in CRF, OT 
and TRH hypothalamic neurons (Di et al., 2003). 
Although feeding is one of the main synchronizers of the HPA axis activity and both the 
endocannabinoid system and glucocorticoids seem to drive the organism into an increased 
ingestive behaviour under physiological conditions, several studies reported both 
stimulatory and inhibitory roles for endocannabinoids in the control of stress responses. In 
the experiments conducted by Patel and co-workers (2004), mice pretreated with a CB1R 
antagonist exhibited a robust increase in the restraint-induced glucocorticoid release and c-
Fos immunolabeling in the PVN. In addition, the administration of a CB1R agonist, an 
inhibitor of endocannabinoid transport or a FAAH inhibitor attenuated the restraint-
induced increase in glucocorticoid secretion. Although these authors hypothesized that the 
activation of endogenous CB1R may negatively modulate the HPA axis activity, they also 
demonstrated that the hypothalamic contents of 2-AG were, respectively, decreased and 
enhanced after acute and sustained stress. This finding is not consistent with an 
endocannabinoid-mediated inhibition of the HPA axis activity, but rather indicates that 
glucocorticoids may centrally inhibit the production of endocannabinoids. Similar results 
were obtained by Borges and colleagues (2011), who reported decreased hypothalamic 2-AG 
contents after acute LPS administration. Additionally, increased CRF mRNA expression, 
glucocorticoid plasma concentrations and hypophagia were found by this group in 
experimental animals submitted to a single LPS injection, being all these responses 
completely restored to basal levels following repeated LPS administration. 
Conversely, an increase in hypothalamic 2-AG levels after acute restraint stress has also 
been recently reported (Evanson et al., 2010). According to these findings, these authors 
proposed that the CB1R-mediated signaling is required for glucocorticoid negative 
feedback, but not for the initial HPA axis response to restraint. In addition, a down-
regulation of CB1R and an impaired glucocorticoid-mediated inhibition of excitatory inputs 
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to parvocellular PVN neurons were observed in hypothalamic slices from rats submitted to 
repeated immobilization stress (Wamsteeker et al., 2010). Interestingly, application of a 
CB1R agonist to the bath did not suppress the excitatory inputs onto PVN neurons, 
suggesting that the CB1R-mediated signaling may be disrupted after prolonged exposure to 
stress. It has been recently reported by our group that the pharmacological blockade of the 
CB1R-mediated signaling during LPS-induced endotoxaemia produces a remarkable 
increase in the activation of CRF neurons in the parvocellular subdivision of the PVN, which 
is associated with a pronounced hypophagia (Rorato et al., 2011). Although further studies 
are needed to clarify the precise actions of endocannabinoids on stress responses, the 
majority of studies suggest that the endocannabinoid system may mediate the fast negative 
feedback exerted by glucocorticoids at both hypothalamic and pituitary levels, avoiding the 
overloading of this system and making it continuously responsive to other potential 
challenges.  
It has been also observed that the peripheral nutrition-related hormone leptin reverses the 
increases in PVN endocannabinoid levels induced by glucocorticoids, indicating a central 
crosstalk between glucocorticoids and this satiety signal (Malcher-Lopes et al., 2006). In fact, 
Obese Zucker rats, which do not express leptin receptors, are hyperphagic and exhibit 
elevated glucocorticoid plasma levels (Ahima, 2000; Freedman et al., 1985) and increased 
hypothalamic levels of endocannabinoids (Di Marzo et al., 2001; Kirkham et al., 2002). 
Within this context, the study of the CB1R-mediated signaling has a great clinical relevance 
and expectation, since obesity is emerging as a very concerning heath problem worldwide, 
either considered alone or in association with other chronic degenerative diseases. 
Accordingly, an increasing number of recent studies have focused on the glucocorticoid-
related effects mediated by CB1R, such as the central control of food consumption (Di 
Marzo et al., 2001) and satiety (Matias & Di Marzo, 2007), as well as the peripheral control of 
adiposity, a predictor of several chronic metabolic disorders (Westerink & Visseren, 2011). 
Although the endocannabinoid system has been implicated in several physiological and 
pathological functions related to the control of food intake and body weight by 
glucocorticoids (Ameri, 1999; Bisogno et al., 2005; Di Marzo & Matias, 2005; Marco et al., 
2011), it has been also demonstrated that these lipid-derived mediators can act 
independently of the glucocorticoid-mediated signalling (Jamshidi & Taylor, 2001; Kirkham 
& Williams, 2001; Williams & Kirkham, 1999; Williams et al. 1998). Most of these effects are 
also mediated by the activation of the CB1R, since the administration of the CB1R antagonist 
rimonabant reverses the cannabinoid-induced increase in food intake (Jamshidi & Taylor, 
2001; Williams & Kirkham, 2002). Consistent with the CB1R-mediated orexigenic effects of 
endocannabinoids, transgenic mice that lack this receptor subtype or experimental animals 
treated with the CB1R antagonist exhibit decreased food consumption (Colombo et al. 1998; 
Di Marzo et al. 2001; Pertwee, 2005). 
This rimonabant-induced decrease in food intake is, at least in part, mediated by changes in 
endocannabinoid signalling within the hypothalamus (Cota et al., 2003; Mailleux & 
Vanderhaeghen, 1992; Marsicano & Lutz, 1999). It has been already reported that the CB1R 
is co-expressed with several anorexigenic peptides such as CART and CRF (Asakawa et al., 
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by glucocorticoids on food intake are mediated by these lipid-derived mediators (Malcher-
Lopes et al., 2006). In this study, Malcher-Lopes and colleagues also demonstrated that the 
glucocorticoid-mediated activation of a membrane receptor coupled to a Gαs–cAMP–PKA 
signaling cascade leads to an increase in endocannabinoid synthesis. Accordingly, increased 
hypothalamic levels of endocannabinoids have been also observed in vivo following 
glucocorticoid treatment (Hill et al., 2010).  
Both endocannabinoids and glucocorticoids injected into hypothalamic areas induce similar 
effects on eating behaviour, increasing food consumption (Jamshidi & Taylor, 2001; Tempel 
et al., 1992). The synthesis of endocannabinoids in the hypothalamus and the expression of 
both endocannabinoids and glucocorticoid receptors in synapses and in hypothalamic 
neurons that synthesize peptides with a key role in food consumption reinforce this 
assumption (Castelli et al., 2007; Cota et al., 2003; Deli et al. 2009; Di Marzo et al., 2001; 
Malcher-Lopes et al., 2006). In fact, the neuropeptides CRF, OT and TRH, which have well 
described anorexigenic properties (Arletti et al., 1989, 1990; Morley et al., 1983; Steward et 
al., 2003), appear as potential targets for endocannabinoid-mediated actions induced by 
glucocorticoids. Therefore, the glucocorticoid-mediated blockade of excitatory glutamatergic 
synapses induced by endocannabinoids via CB1R has been already described in CRF, OT 
and TRH hypothalamic neurons (Di et al., 2003). 
Although feeding is one of the main synchronizers of the HPA axis activity and both the 
endocannabinoid system and glucocorticoids seem to drive the organism into an increased 
ingestive behaviour under physiological conditions, several studies reported both 
stimulatory and inhibitory roles for endocannabinoids in the control of stress responses. In 
the experiments conducted by Patel and co-workers (2004), mice pretreated with a CB1R 
antagonist exhibited a robust increase in the restraint-induced glucocorticoid release and c-
Fos immunolabeling in the PVN. In addition, the administration of a CB1R agonist, an 
inhibitor of endocannabinoid transport or a FAAH inhibitor attenuated the restraint-
induced increase in glucocorticoid secretion. Although these authors hypothesized that the 
activation of endogenous CB1R may negatively modulate the HPA axis activity, they also 
demonstrated that the hypothalamic contents of 2-AG were, respectively, decreased and 
enhanced after acute and sustained stress. This finding is not consistent with an 
endocannabinoid-mediated inhibition of the HPA axis activity, but rather indicates that 
glucocorticoids may centrally inhibit the production of endocannabinoids. Similar results 
were obtained by Borges and colleagues (2011), who reported decreased hypothalamic 2-AG 
contents after acute LPS administration. Additionally, increased CRF mRNA expression, 
glucocorticoid plasma concentrations and hypophagia were found by this group in 
experimental animals submitted to a single LPS injection, being all these responses 
completely restored to basal levels following repeated LPS administration. 
Conversely, an increase in hypothalamic 2-AG levels after acute restraint stress has also 
been recently reported (Evanson et al., 2010). According to these findings, these authors 
proposed that the CB1R-mediated signaling is required for glucocorticoid negative 
feedback, but not for the initial HPA axis response to restraint. In addition, a down-
regulation of CB1R and an impaired glucocorticoid-mediated inhibition of excitatory inputs 
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to parvocellular PVN neurons were observed in hypothalamic slices from rats submitted to 
repeated immobilization stress (Wamsteeker et al., 2010). Interestingly, application of a 
CB1R agonist to the bath did not suppress the excitatory inputs onto PVN neurons, 
suggesting that the CB1R-mediated signaling may be disrupted after prolonged exposure to 
stress. It has been recently reported by our group that the pharmacological blockade of the 
CB1R-mediated signaling during LPS-induced endotoxaemia produces a remarkable 
increase in the activation of CRF neurons in the parvocellular subdivision of the PVN, which 
is associated with a pronounced hypophagia (Rorato et al., 2011). Although further studies 
are needed to clarify the precise actions of endocannabinoids on stress responses, the 
majority of studies suggest that the endocannabinoid system may mediate the fast negative 
feedback exerted by glucocorticoids at both hypothalamic and pituitary levels, avoiding the 
overloading of this system and making it continuously responsive to other potential 
challenges.  
It has been also observed that the peripheral nutrition-related hormone leptin reverses the 
increases in PVN endocannabinoid levels induced by glucocorticoids, indicating a central 
crosstalk between glucocorticoids and this satiety signal (Malcher-Lopes et al., 2006). In fact, 
Obese Zucker rats, which do not express leptin receptors, are hyperphagic and exhibit 
elevated glucocorticoid plasma levels (Ahima, 2000; Freedman et al., 1985) and increased 
hypothalamic levels of endocannabinoids (Di Marzo et al., 2001; Kirkham et al., 2002). 
Within this context, the study of the CB1R-mediated signaling has a great clinical relevance 
and expectation, since obesity is emerging as a very concerning heath problem worldwide, 
either considered alone or in association with other chronic degenerative diseases. 
Accordingly, an increasing number of recent studies have focused on the glucocorticoid-
related effects mediated by CB1R, such as the central control of food consumption (Di 
Marzo et al., 2001) and satiety (Matias & Di Marzo, 2007), as well as the peripheral control of 
adiposity, a predictor of several chronic metabolic disorders (Westerink & Visseren, 2011). 
Although the endocannabinoid system has been implicated in several physiological and 
pathological functions related to the control of food intake and body weight by 
glucocorticoids (Ameri, 1999; Bisogno et al., 2005; Di Marzo & Matias, 2005; Marco et al., 
2011), it has been also demonstrated that these lipid-derived mediators can act 
independently of the glucocorticoid-mediated signalling (Jamshidi & Taylor, 2001; Kirkham 
& Williams, 2001; Williams & Kirkham, 1999; Williams et al. 1998). Most of these effects are 
also mediated by the activation of the CB1R, since the administration of the CB1R antagonist 
rimonabant reverses the cannabinoid-induced increase in food intake (Jamshidi & Taylor, 
2001; Williams & Kirkham, 2002). Consistent with the CB1R-mediated orexigenic effects of 
endocannabinoids, transgenic mice that lack this receptor subtype or experimental animals 
treated with the CB1R antagonist exhibit decreased food consumption (Colombo et al. 1998; 
Di Marzo et al. 2001; Pertwee, 2005). 
This rimonabant-induced decrease in food intake is, at least in part, mediated by changes in 
endocannabinoid signalling within the hypothalamus (Cota et al., 2003; Mailleux & 
Vanderhaeghen, 1992; Marsicano & Lutz, 1999). It has been already reported that the CB1R 
is co-expressed with several anorexigenic peptides such as CART and CRF (Asakawa et al., 
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2001; Cota et al., 2003; Füzesi et al., 2008; Morley et al., 1983; Vrang et al., 2000). Accordingly, 
CB1R knockout mice exhibit increased CRF mRNA expression in the PVN (Cota et al., 2003). 
It has been also demonstrated that acute rimonabant treatment induces an increase in the co-
localization of c-Fos with CART in the PVN and ARC and with POMC in the ARC, as well 
as promotes a decrease in both the protein and the mRNA for NPY in the ARC (Verty et al., 
2009a). Conversely, no changes in NPY or POMC mRNA expression were found in the ARC 
of lean rats treated with rimonabant (Doyon et al., 2006), although the administration of 
AM251, a selective CB1R antagonist, blocked NPY release from hypothalamic explants 
(Gamber et al., 2005) and the POMC-expressing neurons were shown to release 
endocannabinoids under basal conditions (Hentges et al. 2005).  
In the brainstem, the CB1R and the enzyme that metabolizes AEA, fatty acid amide 
hydrolase (FAAH), are expressed in the dorsal vagal complex, which includes the NTS (Van 
Sickle et al., 2001). In addition, peripheral vagal afferents expressing CB1R and the local 
production of AEA by the gastrointestinal tract are important food-stimulated signals 
involved with the control of food intake and meal size (Burdyga et al., 2004, 2010; Gómez et 
al., 2002; Jelsing et al., 2009a,b). Accordingly, our group has recently demonstrated that the 
previous CB1R blockade potentiates LPS-induced increase in the number of TH-expressing 
neurons of the NTS co-localizing c-Fos, suggesting that endocannabinoids may modulate 
satiety during an immune challenge. 
Endocannabinoids can also modulate the hedonistic component of food intake. It has been 
demonstrated that the cannabinoid agonist THC increases the motivation to eat palatable 
food (Gallate et al., 1999), whereas the CB1R antagonism reduces this response (Simiand et 
al., 1998). Changes in content of endocannabinoids in the limbic forebrain regions were 
shown to be correlated with the nutritional status in experimental animals (Kirkham et al., 
2002). Furthermore, the expression of the CB1R in the accumbens shell nucleus (NAcS), a 
key structure involved with motivation and reward, reinforce this hypothesis (Di Marzo et 
al., 2009). It is already known that dopamine release within NAcS is associated with 
rewarding associated with the addictive properties of abuse drugs (Volkow et al., 2007). 
Interestingly, it was observed that the administration of a CB1R antagonist attenuates the 
increases in dopamine release within this nucleus induced by a novel high palatable food 
(Melis et al., 2007), indicating that endocannabinoids may account for the integrated control 
of feeding-associated motivated behaviour. 
In addition to their central effects on the control of hunger and satiety, the endocannabinoid 
signalling has been also implicated in the peripheral control of body weight through 
changes in energy storage and expenditure (Silvestri et al., 2011). Interestingly, SV40 
immortalised murine white and brown adipocytes treated with rimonabant show increased 
uncoupling protein 1 (UCP1) expression (Perwitz et al., 2010), which is associated with the 
preferential production of heat. Furthermore, Quarta and colleagues (2010) have 
demonstrated that mice lacking CB1R exhibit a lean phenotype due to an increased lipid 
oxidation and thermogenesis. Accordingly, prolonged rimonabant administration was 
shown to increase lipolysis and decrease fat storage in white adipose tissue of mice with 
diet-induced obesity (Jbilo et al., 2005). A recent report from Verty and co-workers (2009b) 
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has proposed that this response may be mediated by the autonomic nervous system, since 
the denervation of the sympathetic afferents blocked the effect of rimonabant on body 
weight.  
3.2.2. Fluid intake 
Although the endocannabinoid system has a great impact on the regulation of energy 
homeostasis, its participation in the control of fluid intake remains elusive. A pioneer study 
has demonstrated that the exogenous administration of compounds derived from the plant 
Cannabis sativa inhibits water intake (Sofia & Knobloch, 1976). On the other hand, the CB1R 
blockade significantly reduced water intake in the experiments conducted by Gardner & 
Mallet (2006). Recent studies have also reported that endocannabinoids increase the 
preference for palatable solutions such as sucrose (Higgs et al., 2003; Jarrett et al., 2005), 
without altering the drinking of salty solutions or distilled water induced by fluid 
deprivation (Yoshida et al., 2010). However, these conflicting results could be explained, at 
least in part, by the parallel effects of the endocannabinoid system in the control of 
locomotor activity, which could directly interfere with the search for eating and drinking. 
The specific appetite for sodium and water is a very important adaptative response 
recruited to restore body fluid homeostasis. However, the excessive intake of sodium in 
industrialized food has a great impact in modern society, since it may be directly associated 
with the impairment of cardiovascular and renal functions. The neuropeptide OT appears as 
an important negative modulator of salt appetite in rats, being particularly relevant in 
osmolality- but not in the sodium-dependent inhibition of this ingestive behaviour 
(Blackburn et al., 1993). Furthermore, OT has been implicated in the central inhibition of 
water intake induced by water deprivation, hypertonic saline administration and 
angiotensin II injection (Arletti et al., 1990). More recently, studies developed by Verty and 
co-workers (2004) revealed that these effects of OT on water intake may be partially 
mediated by CB1R. 
An empirical and very interesting observation is that animals that undergo periods of 
restricted or no access to water also reduce their food consumption, being this anorexic state 
as long as the water restriction persists. It is believed that this reduction in food intake is a 
compensatory mechanism, since a slight change in the osmolality of the gastrointestinal tract 
circulation may be detected after the beginning of the digestive process. This would 
contribute to a further increase in the already enhanced plasma osmolality, constituting a 
very life-threatening situation. Although some studies suggest the participation of central 
increases in CRF in this anorexic response induced by chronic exposure to osmotic stress 
(Koob et al., 1993; Krahn et al., 1986; Morley, 1987), it is clear that this decreased food intake 
occurs earlier than the activation of the HPA axis. Accordingly, no changes in c-Fos/CRF 
immunoreactivity or CRF mRNA expression were found in the hypothalamus of animals 
submitted to 24 hours (h) water restriction, despite the fact that the anorexigenic response, 
as well as the decrease in body weight, had already been observed after this short period 
(Ruginsk et al., 2011).  
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2001; Cota et al., 2003; Füzesi et al., 2008; Morley et al., 1983; Vrang et al., 2000). Accordingly, 
CB1R knockout mice exhibit increased CRF mRNA expression in the PVN (Cota et al., 2003). 
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localization of c-Fos with CART in the PVN and ARC and with POMC in the ARC, as well 
as promotes a decrease in both the protein and the mRNA for NPY in the ARC (Verty et al., 
2009a). Conversely, no changes in NPY or POMC mRNA expression were found in the ARC 
of lean rats treated with rimonabant (Doyon et al., 2006), although the administration of 
AM251, a selective CB1R antagonist, blocked NPY release from hypothalamic explants 
(Gamber et al., 2005) and the POMC-expressing neurons were shown to release 
endocannabinoids under basal conditions (Hentges et al. 2005).  
In the brainstem, the CB1R and the enzyme that metabolizes AEA, fatty acid amide 
hydrolase (FAAH), are expressed in the dorsal vagal complex, which includes the NTS (Van 
Sickle et al., 2001). In addition, peripheral vagal afferents expressing CB1R and the local 
production of AEA by the gastrointestinal tract are important food-stimulated signals 
involved with the control of food intake and meal size (Burdyga et al., 2004, 2010; Gómez et 
al., 2002; Jelsing et al., 2009a,b). Accordingly, our group has recently demonstrated that the 
previous CB1R blockade potentiates LPS-induced increase in the number of TH-expressing 
neurons of the NTS co-localizing c-Fos, suggesting that endocannabinoids may modulate 
satiety during an immune challenge. 
Endocannabinoids can also modulate the hedonistic component of food intake. It has been 
demonstrated that the cannabinoid agonist THC increases the motivation to eat palatable 
food (Gallate et al., 1999), whereas the CB1R antagonism reduces this response (Simiand et 
al., 1998). Changes in content of endocannabinoids in the limbic forebrain regions were 
shown to be correlated with the nutritional status in experimental animals (Kirkham et al., 
2002). Furthermore, the expression of the CB1R in the accumbens shell nucleus (NAcS), a 
key structure involved with motivation and reward, reinforce this hypothesis (Di Marzo et 
al., 2009). It is already known that dopamine release within NAcS is associated with 
rewarding associated with the addictive properties of abuse drugs (Volkow et al., 2007). 
Interestingly, it was observed that the administration of a CB1R antagonist attenuates the 
increases in dopamine release within this nucleus induced by a novel high palatable food 
(Melis et al., 2007), indicating that endocannabinoids may account for the integrated control 
of feeding-associated motivated behaviour. 
In addition to their central effects on the control of hunger and satiety, the endocannabinoid 
signalling has been also implicated in the peripheral control of body weight through 
changes in energy storage and expenditure (Silvestri et al., 2011). Interestingly, SV40 
immortalised murine white and brown adipocytes treated with rimonabant show increased 
uncoupling protein 1 (UCP1) expression (Perwitz et al., 2010), which is associated with the 
preferential production of heat. Furthermore, Quarta and colleagues (2010) have 
demonstrated that mice lacking CB1R exhibit a lean phenotype due to an increased lipid 
oxidation and thermogenesis. Accordingly, prolonged rimonabant administration was 
shown to increase lipolysis and decrease fat storage in white adipose tissue of mice with 
diet-induced obesity (Jbilo et al., 2005). A recent report from Verty and co-workers (2009b) 
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has proposed that this response may be mediated by the autonomic nervous system, since 
the denervation of the sympathetic afferents blocked the effect of rimonabant on body 
weight.  
3.2.2. Fluid intake 
Although the endocannabinoid system has a great impact on the regulation of energy 
homeostasis, its participation in the control of fluid intake remains elusive. A pioneer study 
has demonstrated that the exogenous administration of compounds derived from the plant 
Cannabis sativa inhibits water intake (Sofia & Knobloch, 1976). On the other hand, the CB1R 
blockade significantly reduced water intake in the experiments conducted by Gardner & 
Mallet (2006). Recent studies have also reported that endocannabinoids increase the 
preference for palatable solutions such as sucrose (Higgs et al., 2003; Jarrett et al., 2005), 
without altering the drinking of salty solutions or distilled water induced by fluid 
deprivation (Yoshida et al., 2010). However, these conflicting results could be explained, at 
least in part, by the parallel effects of the endocannabinoid system in the control of 
locomotor activity, which could directly interfere with the search for eating and drinking. 
The specific appetite for sodium and water is a very important adaptative response 
recruited to restore body fluid homeostasis. However, the excessive intake of sodium in 
industrialized food has a great impact in modern society, since it may be directly associated 
with the impairment of cardiovascular and renal functions. The neuropeptide OT appears as 
an important negative modulator of salt appetite in rats, being particularly relevant in 
osmolality- but not in the sodium-dependent inhibition of this ingestive behaviour 
(Blackburn et al., 1993). Furthermore, OT has been implicated in the central inhibition of 
water intake induced by water deprivation, hypertonic saline administration and 
angiotensin II injection (Arletti et al., 1990). More recently, studies developed by Verty and 
co-workers (2004) revealed that these effects of OT on water intake may be partially 
mediated by CB1R. 
An empirical and very interesting observation is that animals that undergo periods of 
restricted or no access to water also reduce their food consumption, being this anorexic state 
as long as the water restriction persists. It is believed that this reduction in food intake is a 
compensatory mechanism, since a slight change in the osmolality of the gastrointestinal tract 
circulation may be detected after the beginning of the digestive process. This would 
contribute to a further increase in the already enhanced plasma osmolality, constituting a 
very life-threatening situation. Although some studies suggest the participation of central 
increases in CRF in this anorexic response induced by chronic exposure to osmotic stress 
(Koob et al., 1993; Krahn et al., 1986; Morley, 1987), it is clear that this decreased food intake 
occurs earlier than the activation of the HPA axis. Accordingly, no changes in c-Fos/CRF 
immunoreactivity or CRF mRNA expression were found in the hypothalamus of animals 
submitted to 24 hours (h) water restriction, despite the fact that the anorexigenic response, 
as well as the decrease in body weight, had already been observed after this short period 
(Ruginsk et al., 2011).  
 
Glucocorticoids – New Recognition of Our Familiar Friend 246 
Furthermore, it has been also demonstrated by Ruginsk and coworkers (2011) that the 
number of CART neurons activated to produce c-Fos is increased in the hypothalamus of 
24h water-deprived rats. Since CART is a well-known anorexigenic peptide, these results 
suggest a possible intersection between pathways controlling food and fluid intake. These 
results further propose the existence of an osmolality-related mechanism in this interface, 
since the immunoreactivity for c-Fos/CART and the CART mRNA expression in the PVN 
and supraoptic (SON) nuclei of the hypothalamus were increased after hypertonic but not 
isotonic extracellular volume expansion (Ruginsk et al., 2011). 
4. Endocannabinoids and the control of hydromineral homeostasis 
The magnocellular neurosecretory system consists of a group of neurons whose cell bodies 
are located at the PVN and SON in the hypothalamus and whose terminals, located at the 
neurohypophysis, release vasopressin (AVP) and OT in response to depolarization. Both 
neuropeptides act in the kidneys to control the excretion of water and electrolytes. AVP is 
mostly known for its antidiuretic and vasoconstrictor effects, while OT, together with atrial 
natriuretic peptide (ANP) produced by the heart, are the two major circulating hormones 
stimulating natriuresis and diuresis.  
Immunohistochemical studies have revealed that GR and MR are co-localized in the 
parvocellular subdivision of the PVN, but not in magnocellular neurons, which 
predominantly express MR (Han et al., 2005). Accordingly, it has been demonstrated that 
high doses of dexamethasone can inhibit OT but not AVP secretion in response to 
hypertonic extracellular volume expansion (Durlo et al., 2004; Ruginsk et al., 2007) and 
central cholinergic, angiotensinergic and osmotic stimulation (Lauand et al., 2007). These 
effects were also correlated with immunohistochemical data, showing that the 
magnocellular neurons of the PVN and SON are inhibited by dexamethasone administration 
(Ruginsk et al., 2007).  
More recently, the activation of membrane-associated glucocorticoid receptors has been 
proposed using hypothalamic slice preparations. It has been demonstrated that 
glucocorticoids could activate at least two divergent intracellular pathways mediated by Gαs 
and Gβγ subunits. The local production of endocannabinoids and NO would then result in 
two synapse-specific mechanisms, respectively: 1) suppression of excitatory (glutamatergic) 
synaptic inputs and 2) facilitation of inhibitory (GABAergic) synaptic inputs to the 
hypothalamic magnocellular neurosecretory system (Di et al., 2003, 2005, 2009), 
consequently decreasing AVP and OT release from neurohypophyseal terminals. These 
actions on glutamatergic neurotransmission would be dependent on the activation of the 
CB1R, located mainly at presynaptic terminals. Accordingly, it has been recently 
demonstrated that the administration of rimonabant potentiates AVP and OT release as well 
as the number of c-Fos/AVP and c-Fos/OT double immunoreactive neurons in the PVN and 
SON of experimental animals submitted to hypertonic extracellular volume expansion 
(Ruginsk et al., 2010). Furthermore, the participation of the CB1R in the glucocorticoid-
induced inhibition of the magnocellular neurosecretory system was clearly demonstrated by 
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the same group, since the previous administration of rimonabant reversed the inhibitory 
effects of dexamethasone on hormone release (Ruginsk et al., 2012). 
Although many brain regions seem to share similar cellular mechanisms triggered by 
endocannabinoids, their central actions can vary widely within the CNS. Several studies 
suggest that the endocannabinoid system can mediate not only the central effects of 
glucocorticoids but also independently modulate the excitability of postsynaptic terminals 
after the dendritic-mediated release of neuropeptides like OT (Hirasawa et al., 2004; 
McDonald et al., 2008; Oliet et al., 2007). This mechanism is likely to be implicated in the 
intra-hypothalamic feedback on hormone release and neuroplasticity (de Kock et al., 2003). 
The CB1R is also expressed in the NTS (Tsou et al., 1998), a key structure involved in the 
control of cardiovascular function that projects to the hypothalamus. Accordingly, the 
central administration of CB1R agonists was shown to reduce blood pressure and heart rate 
(Lake et al., 1997), while the microinjection of a CB1R antagonist into the NTS resulted in 
prolonged hypotension after activation of the baroreflex in experimental animals 
(Rademacher et al., 2003).  
Besides participating in the central control of cardiovascular function, recent reports also 
suggest a role for peripherally-synthesized cannabinoids in the control of blood pressure. 
This hypothesis is supported by the evidence that the CB1R is expressed by human, rat and 
guinea-pig atria (Bonz et al., 2003; Kurz et al., 2008; Sterin-Borda et al., 2005). Within the 
heart, the activation of the CB1R induces a negative inotropic response on muscular fibers, 
thus reducing blood pressure. This is of particular interest for the study of the integrated 
cardiovascular and neuroendocrine responses to an increase in the circulating volume, since 
the distension of cardiac chambers (especially the right atria) in response to such 
experimental condition is the main stimulus for ANP secretion. Indeed, a role for the CB1R 
in ANP release has been recently proposed (Ruginsk et al., 2012), although further studies 
are needed to support this hypothesis. 
5. Conclusions and perspectives 
Besides the well-known effects on energy homeostasis and metabolism, the ability of 
glucocorticoids to suppress inflammatory responses has been extensively explored in 
therapeutics during the last fifty years. However, the clinical potential of glucocorticoids has 
not been fully achieved because of the severe dose-limiting side effects as well as the 
development of glucocorticoid resistance. More recently, a lot of expectation was put on 
characterization of non-steroidal dissociated GR agonists and modulators, which try to 
uncouple the desired and adverse effects of glucocorticoid administration based on the type 
of GR interaction with the DNA (transactivation and trasnrepression). However, the 
difficulty to transpose the effects to in vivo set-ups and their still unproved long-term safety 
have limited the use of these drugs in clinical practice so far.  
In this context, different approaches to improve the benefit/risk ratio of glucocorticoids also 
include the development of drugs that selectively target the activation of membrane-
associated GRs and its downstream nongenomic events, without evoking adverse effects, 
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Furthermore, it has been also demonstrated by Ruginsk and coworkers (2011) that the 
number of CART neurons activated to produce c-Fos is increased in the hypothalamus of 
24h water-deprived rats. Since CART is a well-known anorexigenic peptide, these results 
suggest a possible intersection between pathways controlling food and fluid intake. These 
results further propose the existence of an osmolality-related mechanism in this interface, 
since the immunoreactivity for c-Fos/CART and the CART mRNA expression in the PVN 
and supraoptic (SON) nuclei of the hypothalamus were increased after hypertonic but not 
isotonic extracellular volume expansion (Ruginsk et al., 2011). 
4. Endocannabinoids and the control of hydromineral homeostasis 
The magnocellular neurosecretory system consists of a group of neurons whose cell bodies 
are located at the PVN and SON in the hypothalamus and whose terminals, located at the 
neurohypophysis, release vasopressin (AVP) and OT in response to depolarization. Both 
neuropeptides act in the kidneys to control the excretion of water and electrolytes. AVP is 
mostly known for its antidiuretic and vasoconstrictor effects, while OT, together with atrial 
natriuretic peptide (ANP) produced by the heart, are the two major circulating hormones 
stimulating natriuresis and diuresis.  
Immunohistochemical studies have revealed that GR and MR are co-localized in the 
parvocellular subdivision of the PVN, but not in magnocellular neurons, which 
predominantly express MR (Han et al., 2005). Accordingly, it has been demonstrated that 
high doses of dexamethasone can inhibit OT but not AVP secretion in response to 
hypertonic extracellular volume expansion (Durlo et al., 2004; Ruginsk et al., 2007) and 
central cholinergic, angiotensinergic and osmotic stimulation (Lauand et al., 2007). These 
effects were also correlated with immunohistochemical data, showing that the 
magnocellular neurons of the PVN and SON are inhibited by dexamethasone administration 
(Ruginsk et al., 2007).  
More recently, the activation of membrane-associated glucocorticoid receptors has been 
proposed using hypothalamic slice preparations. It has been demonstrated that 
glucocorticoids could activate at least two divergent intracellular pathways mediated by Gαs 
and Gβγ subunits. The local production of endocannabinoids and NO would then result in 
two synapse-specific mechanisms, respectively: 1) suppression of excitatory (glutamatergic) 
synaptic inputs and 2) facilitation of inhibitory (GABAergic) synaptic inputs to the 
hypothalamic magnocellular neurosecretory system (Di et al., 2003, 2005, 2009), 
consequently decreasing AVP and OT release from neurohypophyseal terminals. These 
actions on glutamatergic neurotransmission would be dependent on the activation of the 
CB1R, located mainly at presynaptic terminals. Accordingly, it has been recently 
demonstrated that the administration of rimonabant potentiates AVP and OT release as well 
as the number of c-Fos/AVP and c-Fos/OT double immunoreactive neurons in the PVN and 
SON of experimental animals submitted to hypertonic extracellular volume expansion 
(Ruginsk et al., 2010). Furthermore, the participation of the CB1R in the glucocorticoid-
induced inhibition of the magnocellular neurosecretory system was clearly demonstrated by 
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the same group, since the previous administration of rimonabant reversed the inhibitory 
effects of dexamethasone on hormone release (Ruginsk et al., 2012). 
Although many brain regions seem to share similar cellular mechanisms triggered by 
endocannabinoids, their central actions can vary widely within the CNS. Several studies 
suggest that the endocannabinoid system can mediate not only the central effects of 
glucocorticoids but also independently modulate the excitability of postsynaptic terminals 
after the dendritic-mediated release of neuropeptides like OT (Hirasawa et al., 2004; 
McDonald et al., 2008; Oliet et al., 2007). This mechanism is likely to be implicated in the 
intra-hypothalamic feedback on hormone release and neuroplasticity (de Kock et al., 2003). 
The CB1R is also expressed in the NTS (Tsou et al., 1998), a key structure involved in the 
control of cardiovascular function that projects to the hypothalamus. Accordingly, the 
central administration of CB1R agonists was shown to reduce blood pressure and heart rate 
(Lake et al., 1997), while the microinjection of a CB1R antagonist into the NTS resulted in 
prolonged hypotension after activation of the baroreflex in experimental animals 
(Rademacher et al., 2003).  
Besides participating in the central control of cardiovascular function, recent reports also 
suggest a role for peripherally-synthesized cannabinoids in the control of blood pressure. 
This hypothesis is supported by the evidence that the CB1R is expressed by human, rat and 
guinea-pig atria (Bonz et al., 2003; Kurz et al., 2008; Sterin-Borda et al., 2005). Within the 
heart, the activation of the CB1R induces a negative inotropic response on muscular fibers, 
thus reducing blood pressure. This is of particular interest for the study of the integrated 
cardiovascular and neuroendocrine responses to an increase in the circulating volume, since 
the distension of cardiac chambers (especially the right atria) in response to such 
experimental condition is the main stimulus for ANP secretion. Indeed, a role for the CB1R 
in ANP release has been recently proposed (Ruginsk et al., 2012), although further studies 
are needed to support this hypothesis. 
5. Conclusions and perspectives 
Besides the well-known effects on energy homeostasis and metabolism, the ability of 
glucocorticoids to suppress inflammatory responses has been extensively explored in 
therapeutics during the last fifty years. However, the clinical potential of glucocorticoids has 
not been fully achieved because of the severe dose-limiting side effects as well as the 
development of glucocorticoid resistance. More recently, a lot of expectation was put on 
characterization of non-steroidal dissociated GR agonists and modulators, which try to 
uncouple the desired and adverse effects of glucocorticoid administration based on the type 
of GR interaction with the DNA (transactivation and trasnrepression). However, the 
difficulty to transpose the effects to in vivo set-ups and their still unproved long-term safety 
have limited the use of these drugs in clinical practice so far.  
In this context, different approaches to improve the benefit/risk ratio of glucocorticoids also 
include the development of drugs that selectively target the activation of membrane-
associated GRs and its downstream nongenomic events, without evoking adverse effects, 
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primarily attributed to the activation of genomic pathways. Therefore, the study of the 
nongenomic actions of glucocorticoids has introduced a novel player in the complexity of 
the circuitries regulated by the HPA axis and the integrated control of homeostasis. The 
endocannabinoid system appears as an important mediator of both central and peripheral 
effects of glucocorticoids, constituting a possible target by which several aspects of stress-
mediated responses and energy acquisition/expenditure could be manipulated under 
diverse physiological and pathological conditions.  
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primarily attributed to the activation of genomic pathways. Therefore, the study of the 
nongenomic actions of glucocorticoids has introduced a novel player in the complexity of 
the circuitries regulated by the HPA axis and the integrated control of homeostasis. The 
endocannabinoid system appears as an important mediator of both central and peripheral 
effects of glucocorticoids, constituting a possible target by which several aspects of stress-
mediated responses and energy acquisition/expenditure could be manipulated under 
diverse physiological and pathological conditions.  
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1. Introduction 
A close relationship between the key bodily regulatory systems, hypophysis-adrenal and 
hypophysis-thyroid systems, is fairly well-known.  
However, the mechanisms of their interaction at different levels have not been conclusively 
established. This is of considerable interest due to glucocorticoids and thyroid hormones 
playing a key role in regulation of the most important systems of vital activity and 
adaptation. The role of glucocorticoids in regulation of thyroid cell function is interesting 
due to marked growth of thyroid pathology in different world’s regions, along with 
considerably improved iodine prevention [1], as well as an increased level of environmental 
stressogenicity. One should also note an increased tension in life of the individual and the 
society on the whole (psychological, social and other types of stress). The development of 
the society has actually created a new human environment with a raised level of 
stressogenic factors. The chronic stress –induced development of hypercorticism can play a 
significant pathogenetic role in the changed thyroid function which does not only depend 
on bodily iodine allowances.  
Thyroid-stimulating hormone (TSH) [2, 3, 4], iodine [4, 5], thyroglobulin (ThG) [6], estrogens 
[7], cytokines [8] and other biologically active molecules play an important role in regulation 
of thyroid cell functions. It is interesting that deficiency of iodine, the key substrate for 
synthesis of thyroid hormones, decreases the activity of the HPA-axis. It was found [9] that 
rats with chronic iodine deficiency showed the absence of a normal circadian rhythm of 
corticosterone secretion and a weakened secretory rise of a corticosterone level under stress 
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that remains to be diminished in amplitude during a month following restoration of the 
iodine status. 
Thyroid cell function can be regulated by glucocorticoids via changes in the 
concentrations of the pivotal bioregulators: thyroid-stimulating hormone, TSH, iodine 
and thyroglobulin. The mechanisms and effects of these interactions call for further 
studies. Thyrocytes express glucocorticoid receptors, alpha (GR-alpha) and beta (GR-
beta), which seem to play an important role in differentiation of thyroid cells since cells 
of thyroid adenoma demonstrated a decrease of mRA GR-alpha and an increase in GR-
beta [10]. 
1.1. Relationships between regulatory effects of hypothalamic and hypophyseal 
hormones of hypothalamo-hypophyseal-adrenal and hypothalamo-
hypophyseal-thyroid axes  
Relationships between the hypothalamo-hypophyseal-adrenal (HHA) and hypothalamo-
hypophyseal-thyroid (HHT) systems were established at different regulatory levels.  
Administration of a thyrotropin-releasing hormone (TRH) was accompanied by a decreased 
adrenocorticotropic hormone (ACTH) level in blood serum of stressed rats [11]. 
Corticotropin-releasing hormone (CRH) increased plasma TSH and T4 [12]. Banos C. et al. 
[13] demonstrated that administration of 2 mg ACTH to healthy volunteers decreased the 
TSH response to TRH. These results characterize certain antagonism between TSH and 
ACTH.  
1.2. Effects of glucocorticoids on TRH and TSH levels 
TSH synthesis is determined by balance of positive regulation and negative regulation by 
TRH and  triiodothyronine (T3), respectively; in addition, somatostatin and dopamine also 
exert inhibitory control (Diagram 1). Glucocorticoids decreased serum TSH in animals and 
humans. Administration of a high dose of dexamethasone not only suppressed TSH but also 
decreased the TSH response to TRH administration [14]; the suppressive effect of 
dexamethasone on TSH decreased in elderly people [15].  
Administration of a single dose of hydrocortisone (500 mg) increased both TSH production 
and stimulation by TRH [16]; only long-term hypocorticism (Cushing’s disease) may be a 
cause for decreased TSH level. The earlier recovery (up to control values) of the diurnal 
rhythm of TSH than that of cortisol suggests that the TSH rhythm is not under the direct 
control of circulating cortisol [17]. In adrenalectomized rats the TSH level decreased in 
serum but not in the pituitary gland [18]. Glucocorticoids decrease blood serum TSH 
concentrations in humans and animals. Dexamethasone administration to hypothyroid rats 
decreased serum TSH; dexamethasone augmented a T3-induced decrease of TSH. 
However, changes in pituitary TSH - and β-subunit mRNA concentrations were not 
found [19]. 
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Scheme 1. Effect of glucocorticoids on TSH. +, stimulatory effect; -, inhibitory effect; ↓ – weakening of 
stimulatory effect; ↑ – enhancement of inhibitory effect 
Kakucska I. et al. obtained clearer results on the effects of glucocorticoids on the 
hypothalamo-pituitary-thyroid axis [20]. In the paraventricular hypothalamic nuclei of 
adrenalectomized rats, an increase in corticotropin releasing hormone (CRH) mRNA 
occurred in parallel to the increase (68.3%) in pro-TRH mRNA. On the contrary, 
administration of corticosterone or dexamethasone caused a marked decrease in CRH 
mRNA and pro-TRH mRNA by 43.2 and 73.3%, respectively. Insignificant changes in pro-
TRH mRNA were found in the lateral hypothalamus.  
Mechanisms of the stress-induced decrease in TRH/TSH secretion possibly involve 
glucocorticoids, cytokines, and opioids. Recently, a new regulatory mechanism, involving 
pituitary neuromedin B, gastrin-releasing peptide, and pituitary leptin, acting as local 
inhibitors of TSH release, has been proposed [21]. In vitro studies have shown that the 
lipocortin-1 (LC1) protein is a mediator of the glucocorticoid-induced suppression of TSH 
secretion by the anterior pituitary [53]. Treatment of anterior pituitary cells with 0.1 μM 
dexamethasone significantly increased the amount of LC1, associated with the outer surface 
of the pituitary cells and decreased the intracellular content of LC1. Addition of an N-
terminal LC1 fragment (residues 1-188) decreased TSH release mediated by vasoactive 
intestinal peptide and forskolin, but failed to influence those initiated by 10 μM BAYK 8644, 
the calcium channel stimulator. The inhibitory action of dexamethasone was substantially 
reversed by a specific monoclonal anti-LC1 antibody [22]. The inhibitory effect of 
dexamethasone was used for monitoring of subclinical hypothyroidism in obese patients. 
Administration of TRH after dexamethasone increased the TSH level only in hypothyroid 
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1.3. Effect of glucocorticoids on iodine uptake by the thyroid gland 
Iodine uptake is the most important function of thyroid cells; it is controlled by TSH, which 
stimulates 131I uptake in vivo and in vitro and also expression of sodium-iodide symporter 
(NIS) in the culture of human thyrocytes [24]. Sodium-iodide symporter (NIS) is located on 
the apical membrane of thyrocytes; its activity is coupled to Na+,K+-ATPase. TSH influences 
transcription of NIS gene through Pax-8 and factors activated by intercellular interaction 
during folliculogenesis [25]. High iodine doses directly inhibit iodide uptake by influencing 
regulation of NIS protein and mRNA expression [26, 27].  
Immobilization stress and also ACTH administration to rats with pituitary damages 
increased 131I uptake by the thyroid gland in vitro [28]. Cultivation of FRTL-5 thyrocytes 
under hypoxic conditions was accompanied by increase iodide uptake [29]; heat stress (15 
min at 45°C) eliminated this effect. Using culture of ewe thyroid gland follicles it was found 
that combination of TSH and 10 nM cortisol was optimal for stimulation of iodide uptake 
without additive and synergistic effects; this effect was also reproduced by combination of 
TSH with dexamethasone [30]. In addition, the stimulating effect of TSH was potentiated by 
physiological concentrations of insulin and insulin-like growth factors (IGF I and IGF II). 
Subsequent studies demonstrated a direct biphasic effect of hydrocortisone on metabolism 
of thyroid gland cells. Physiological concentrations of hydrocortisone (1—1000 nM) in a 
dose-dependent manner stimulated TSH- and 8-bromo-cAMP-induced iodide uptake, 
realized via increased production of cAMP and activation of cAMP-dependent metabolic 
pathways in the primary cultures of porcine thyrocytes [31]. The stimulating effect of 
hydrocortisone in combination with TSH was inhibited by the glucocorticoid antagonist 
RU486; the specific hydrocortisone effect appears to be mediated by a thyrocyte 
glucocorticoid receptor.  
It is suggested that the stimulating effect of glucocorticoids on 131I uptake may be used for 
treatment for breast cancer [32] and prostate cancer [33]. Incubation of NP-1 cells with 
dexamethasone (10–8–10–6 M) caused a 1.5-fold increase in iodide uptake, and a 1.7-fold 
increase in expression of Na+/I–- simporter (NIS) mRNA and protein concentration; NP-1 cell 
death increased from 55 to 95%, thus suggesting increased cytotoxicity of 131I. These studies 
(employing clonogenic assay and nonradioactive proliferation assay) also revealed that 
treatment of NP-1 cells decreased proliferation of prostate cancer cells. Thus, stress (at least 
acute stress) may be considered as a factor activating iodide content in the thyroid gland; 
however, univocal solution of this problem requires further investigations because of 
multilevel effects of glucocorticoids on thyroid homeostasis  
1.4. Effects of glucocorticoids on iodine oxidation and organification in 
thyrocytes 
Single reports on the effect of stress or glucocorticoids on iodide oxidation by 
thyroperoxidase (TPO), thyroglobulin iodination and subsequent thyroid hormone secretion 
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are available in the literature. Corticosterone administration for 10 days in three different 
doses (25, 50, 100 mg per 100 g of body weight) inhibited thyroid gland TPO of juvenile 
female turtles [34], but the mechanism of the inhibitory effect was not studied. Studies in 
this direction are especially important due to the key role of TPO in thyroid hormone 
biosynthesis.  
The electron microscopy study of thyrocytes revealed accumulation of colloidal droplets in 
follicle cytoplasm; this suggests that prednisone may decrease basal secretion of thyroid 
hormones by inhibiting lysosomal hydrolysis of colloid in the follicular cells [35].  
1.5. Role of glucocorticoids in the regulation of thyroid hormone receptors 
It is known that most of T3 effects are realized via nuclear receptors of thyroid hormones. T3 
and glucocorticoid hormones synergistically interact in biosynthesis of growth hormone in 
the rat pituitary and in the T3-induced metamorphoses in amphibians. Glucocorticoid 
hormones potentiated metabolic effect of T3 [36]. Dexamethasone increased rat liver specific 
receptor binding of thyroid hormones. Dexamethasone administration to adrenalectomized 
rats increased the concentration of protein and mRNA of beta 1 receptor [36]. Molecular 
studies employing transfection of COS-7 cells revealed that dexamethasone increased 
transcription activity of thyroid hormone receptor beta 1 promoter [36].  
1.6. Effect of stress on peripheral metabolism of thyroid hormones (deiodinase 
activity in target tissues) 
Brain, liver, kidney, heart, muscles, and immune system are the most important targets for 
thyroid hormones. It is possible that glucocorticoids control tissue levels of T3. Acute stress 
(footshock) increased the brain T3 content in male and female rats by 12—19% [37]. Two 
days of total water and food deprivation as stress increased the thymus lymphocyte T3 
content in weanling and adult female rats [38], which was normalized after 48 h [39]. It is 
known that thyroxine (T4) is the main hormone produced by the thyroid gland, however, 
since it does not exhibit biological activity and therefore thyroxin may be considered as a 
prohormone or a plasma storage form of thyroid hormones, which plays an important 
physiological role. A family of selenocysteine oxidoreductases known as iodothyronine 
deiodinases (D) plays the major role in T4 activation. Three types of these enzymes (mainly 
determining realization of the hormonal effect of thyroid hormones) have been identified. 
Their localization and activity are tissue-specific (Scheme 2, 3).  
Glucocorticoids exhibit differentiated tissue- and age-specific effects on various tissue 
deiodinases [40, 41]; they also regulate deiodinases during embryogenesis. Dexamethasone 
administration to pregnant ewes increased activity of DI in the fetal liver and decreased DIII 
activity in fetal kidneys [42]. In 20-day-old fetuses, glucocorticoids had no effects on 
circulating thyroid hormone levels despite their clear decrease in the activity of hepatic and 
renal deiodinases and an increased activity in the brain, thereby indicating that in this age  
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transcription of NIS gene through Pax-8 and factors activated by intercellular interaction 
during folliculogenesis [25]. High iodine doses directly inhibit iodide uptake by influencing 
regulation of NIS protein and mRNA expression [26, 27].  
Immobilization stress and also ACTH administration to rats with pituitary damages 
increased 131I uptake by the thyroid gland in vitro [28]. Cultivation of FRTL-5 thyrocytes 
under hypoxic conditions was accompanied by increase iodide uptake [29]; heat stress (15 
min at 45°C) eliminated this effect. Using culture of ewe thyroid gland follicles it was found 
that combination of TSH and 10 nM cortisol was optimal for stimulation of iodide uptake 
without additive and synergistic effects; this effect was also reproduced by combination of 
TSH with dexamethasone [30]. In addition, the stimulating effect of TSH was potentiated by 
physiological concentrations of insulin and insulin-like growth factors (IGF I and IGF II). 
Subsequent studies demonstrated a direct biphasic effect of hydrocortisone on metabolism 
of thyroid gland cells. Physiological concentrations of hydrocortisone (1—1000 nM) in a 
dose-dependent manner stimulated TSH- and 8-bromo-cAMP-induced iodide uptake, 
realized via increased production of cAMP and activation of cAMP-dependent metabolic 
pathways in the primary cultures of porcine thyrocytes [31]. The stimulating effect of 
hydrocortisone in combination with TSH was inhibited by the glucocorticoid antagonist 
RU486; the specific hydrocortisone effect appears to be mediated by a thyrocyte 
glucocorticoid receptor.  
It is suggested that the stimulating effect of glucocorticoids on 131I uptake may be used for 
treatment for breast cancer [32] and prostate cancer [33]. Incubation of NP-1 cells with 
dexamethasone (10–8–10–6 M) caused a 1.5-fold increase in iodide uptake, and a 1.7-fold 
increase in expression of Na+/I–- simporter (NIS) mRNA and protein concentration; NP-1 cell 
death increased from 55 to 95%, thus suggesting increased cytotoxicity of 131I. These studies 
(employing clonogenic assay and nonradioactive proliferation assay) also revealed that 
treatment of NP-1 cells decreased proliferation of prostate cancer cells. Thus, stress (at least 
acute stress) may be considered as a factor activating iodide content in the thyroid gland; 
however, univocal solution of this problem requires further investigations because of 
multilevel effects of glucocorticoids on thyroid homeostasis  
1.4. Effects of glucocorticoids on iodine oxidation and organification in 
thyrocytes 
Single reports on the effect of stress or glucocorticoids on iodide oxidation by 
thyroperoxidase (TPO), thyroglobulin iodination and subsequent thyroid hormone secretion 
Role of Glucocorticoids in Regulation of Iodine Metabolism in Thyroid Gland:  
Effects of Hyper-And Hypocorticism 269 
are available in the literature. Corticosterone administration for 10 days in three different 
doses (25, 50, 100 mg per 100 g of body weight) inhibited thyroid gland TPO of juvenile 
female turtles [34], but the mechanism of the inhibitory effect was not studied. Studies in 
this direction are especially important due to the key role of TPO in thyroid hormone 
biosynthesis.  
The electron microscopy study of thyrocytes revealed accumulation of colloidal droplets in 
follicle cytoplasm; this suggests that prednisone may decrease basal secretion of thyroid 
hormones by inhibiting lysosomal hydrolysis of colloid in the follicular cells [35].  
1.5. Role of glucocorticoids in the regulation of thyroid hormone receptors 
It is known that most of T3 effects are realized via nuclear receptors of thyroid hormones. T3 
and glucocorticoid hormones synergistically interact in biosynthesis of growth hormone in 
the rat pituitary and in the T3-induced metamorphoses in amphibians. Glucocorticoid 
hormones potentiated metabolic effect of T3 [36]. Dexamethasone increased rat liver specific 
receptor binding of thyroid hormones. Dexamethasone administration to adrenalectomized 
rats increased the concentration of protein and mRNA of beta 1 receptor [36]. Molecular 
studies employing transfection of COS-7 cells revealed that dexamethasone increased 
transcription activity of thyroid hormone receptor beta 1 promoter [36].  
1.6. Effect of stress on peripheral metabolism of thyroid hormones (deiodinase 
activity in target tissues) 
Brain, liver, kidney, heart, muscles, and immune system are the most important targets for 
thyroid hormones. It is possible that glucocorticoids control tissue levels of T3. Acute stress 
(footshock) increased the brain T3 content in male and female rats by 12—19% [37]. Two 
days of total water and food deprivation as stress increased the thymus lymphocyte T3 
content in weanling and adult female rats [38], which was normalized after 48 h [39]. It is 
known that thyroxine (T4) is the main hormone produced by the thyroid gland, however, 
since it does not exhibit biological activity and therefore thyroxin may be considered as a 
prohormone or a plasma storage form of thyroid hormones, which plays an important 
physiological role. A family of selenocysteine oxidoreductases known as iodothyronine 
deiodinases (D) plays the major role in T4 activation. Three types of these enzymes (mainly 
determining realization of the hormonal effect of thyroid hormones) have been identified. 
Their localization and activity are tissue-specific (Scheme 2, 3).  
Glucocorticoids exhibit differentiated tissue- and age-specific effects on various tissue 
deiodinases [40, 41]; they also regulate deiodinases during embryogenesis. Dexamethasone 
administration to pregnant ewes increased activity of DI in the fetal liver and decreased DIII 
activity in fetal kidneys [42]. In 20-day-old fetuses, glucocorticoids had no effects on 
circulating thyroid hormone levels despite their clear decrease in the activity of hepatic and 
renal deiodinases and an increased activity in the brain, thereby indicating that in this age  
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Types of 
deiodinases 
Target tissues Effect Reference 
DI fetal liver, ewes ↑ [42] 
DIII fetal kidneys, ewes ↓ [42] 
DIII 5-day-pups liver, rat ↑ [43] 
DIII 5-day-pups kidneys, rat ↑ [43] 
DIII 5-day-pups brain, rat – [43] 
DIII brown adipose tissue, rat ↓ [58] 
DII brain, rat ↑ [44] 
DI liver, rat ↓ [51] 
DI kidneys, rat ↓ [52] 
DI hepatocytes in vitro ↑ [54] 
Table 1. Effect of GC and stress on activities of various types of deiodinases in rat tissues (↑ – 
stimulatory effect; ↓– inhibitory effect; – no effect) 
thyroid circulating thyroid hormone levels are more dependent on thyroidal secretion than 
on peripheral deiodination. In 5-day-pups, dexamethasone increased blood T3 and T4 and 
DII activity in the liver, kidney but not in the brain; however, in 12-day-old pups, the 
dexamethasone effects were maintained only on liver and kidney DIII activity [43]. 
Effects of stress on deiodinase activity in various tissues still require better elucidation. The 
most significant effect of glucocorticoids was found on brain DII activity. Even mild, short-
term stress (intraperitoneal injection of saline, intragastric intubation, and two different 
forms of handling (being grasped as for intraperitoneal injection and being moved from one 
cage to another, and a 2-h period spent in a slowly rotating drum) caused a significant 
increase in brain DII activity [44], this was accompanied by a 300%-increase in T3 
concentration. These effects were not found in the liver and no changes of DI activity were 
found in the brain and liver. Dexamethasone caused up-regulation of DII activity [45]. 
Administration of steroidogenesis inhibitors (aminoglutethimide and metyrapone) to rats 
decreased adrenal DII activity both in physiological rest and under stress [46]; this suggests 
normal corticosterone levels required for a deiodinase response to the stress treatment. It 
appears that the glucocorticoid regulation of DII is the most differentiated. Recent in vitro 
data obtained using mouse and rat pituitary cells demonstrated that addition of 
glucocorticoids increased the activity of this enzyme and its mRNA [47], whereas the 
opposite effect was obtained in mouse mammary gland epithelial cells [48]. In the AtT-20 
mouse pituitary tumor cells, glucocorticoids and CRH stimulated expression of mRNA and 
activity of DII [49]. Effects of glucocorticoids, found in experiments on cultivated 
hypophyseal cells, confirm their important stimulatory role in the metabolism of thyroid 
hormones in the CNS. 
A decrease in blood thyroid hormones and TRH mRNA seen in fasting and food 
deprivation was accompanied by the increase DII activity and DII mRNA. Studies of 
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cage to another, and a 2-h period spent in a slowly rotating drum) caused a significant 
increase in brain DII activity [44], this was accompanied by a 300%-increase in T3 
concentration. These effects were not found in the liver and no changes of DI activity were 
found in the brain and liver. Dexamethasone caused up-regulation of DII activity [45]. 
Administration of steroidogenesis inhibitors (aminoglutethimide and metyrapone) to rats 
decreased adrenal DII activity both in physiological rest and under stress [46]; this suggests 
normal corticosterone levels required for a deiodinase response to the stress treatment. It 
appears that the glucocorticoid regulation of DII is the most differentiated. Recent in vitro 
data obtained using mouse and rat pituitary cells demonstrated that addition of 
glucocorticoids increased the activity of this enzyme and its mRNA [47], whereas the 
opposite effect was obtained in mouse mammary gland epithelial cells [48]. In the AtT-20 
mouse pituitary tumor cells, glucocorticoids and CRH stimulated expression of mRNA and 
activity of DII [49]. Effects of glucocorticoids, found in experiments on cultivated 
hypophyseal cells, confirm their important stimulatory role in the metabolism of thyroid 
hormones in the CNS. 
A decrease in blood thyroid hormones and TRH mRNA seen in fasting and food 
deprivation was accompanied by the increase DII activity and DII mRNA. Studies of 
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mechanisms of DII activation during fasting revealed that the decrease in leptin levels plays 
a permissive role during glucocorticoid-induced regulation of the DII enzyme [50].  
There are contradictory data on the effects of glucocorticoids on DI activity in various 
tissues. Cold stress of rats either for 24 h or 28 days (as well as that combined with 
immobilization) significantly reduced DI activity in the liver [51]. Immobilization of rats for 
6 - 8 h was accompanied by the decrease in DI activity in the liver and kidneys; this was 
attributed to the decrease in the enzyme activity rather than to decreased substrate 
availability because serum T4 concentration remained unchanged [52]. In adult rats, 
glucocorticoids decreased DI activity in the liver [53]. In vitro studies on the cultured rat 
hepatocytes revealed the opposite effects: glucocorticoids increased DI activity and 
expression of DI mRNA [54]. In kidney NRK 52E cells, dexamethasone increased DI activity 
and expression of DI mRNA, while in cultured pituitary tumor cells, glucocorticoids did not 
influence DI mRNA [55]. In the fish Nile tilapia, dexamethasone decreased activity of DI and 
DII in the liver; long-term administration of this hormone increased availability of 
circulating T3 [56].   
The decrease in plasma T3 and the increase in rT3 concentrations observed in stress may be 
associated with glucocorticoid stimulation of DIII [57]. Regulatory mechanisms of effects of 
thyroid hormones in various tissue cells have not been conclusively established. 
Glucocorticoids decreased DIII expression in rat brown adipose tissue [58]. The study of 
deiodinase activities in human cell lines revealed that estradiol increased DIII activity in 
ECC-1 cells, dexamethasone inhibited DIII in WRL-68 cells only in the presence of fetal calf 
serum in the medium [59]. Dexamethasone in a dose-dependent manner decreased the 
stimulatory effect of T3 on ICAM-1 protein in human ECV 304 cells [74].  
All these results indicate that glucocorticoids modulate effects of thyroid hormones by 
influencing deiodinase activity in various target tissues. They cause significant increase of 
DII activity in the brain (and thus increase brain T3 level); stress exhibited inhibitory effect 
on DI activity in the liver and kidneys. Nevertheless, mechanisms underlying 
glucocorticoid regulation of T4 deiodination in various tissues require further 
investigation.  
1.7. Thyroid gland function under impaired adrenal functions 
Taking into consideration the multilevel effects of glucocorticoids on the thyroid status and 
peripheral metabolism of thyroid hormones, a study of functional activity of the thyroid 
gland under conditions of adrenal impairments appears to quite reasonable.  
Adrenalectomy in rats increased thyroid gland stimulation by TSH and its secretory 
activity [60]. In patients with adrenal insufficiency cessation of replacement 
glucocorticoid therapy resulted in an increase of T3 and a decrease of (reversive 
triiodothyronine) rT3 concentrations, whereas the level of T4 and TSH remained 
basically unchanged [61]. 
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There are clinical case reports on impairments of thyroid function in patients with 
hypercorticism before and after adrenalectomy and with adrenal insufficiency. The state of 
the pituitary-adrenal axis mainly determines the thyroid status in humans. Under 
hypercorticism  in patients with Cushing’s syndrome there were decreased serum 
concentrations of thyroid hormones and TSH; in addition, in 56.2--66.6% there was a 
prevalence of thyroid nodular disease; this was significantly higher than in the control 
group [63]. Long-term hypercorticism in patients with Cushing’s syndrome was 
accompanied by inhibition of basal and TRH-stimulated TSH secretion [62]. These patients 
had an attenuated pituitary response to TRH administration and there was a negative 
correlation between plasma levels of TSH and cortisol (but not T3); after convalescence the 
reaction to TRH normalized [64]. There was a single case report on the development of 
Graves’s disease characterized by pronounced hyperthyroidism after a successful surgical 
operation in a patient with Cushing’s syndrome [65]. Authors suggest that suppression of 
hypercorticism activated latent autoimmune processes in the thyroid gland. Graves’s 
disease with hyperthyroidism manifestations was diagnosed 9 months after unitaleral 
adrenalectomy in a woman with Cushing’s syndrome [66]. In some patients subjected to 
surgical adrenalectomy for hypercorticism transitory dysfunction of the thyroid gland with 
symptoms of hypo- or hyperthyroidism developed [67]. Silent thyroiditis developed in a 
female patient after unilateral adrenalectomy for treatment of Cushing’s syndrome followed 
by a gradual tapering of replacement dose of prednisolone to 5 mg/day; thus thyroiditis was 
characterized by low TSH, increased thyroid hormone levels, extremely low iodine uptake 
and increased titers of antimicrosomal and antithyroglobulin antibodies [68]. Recent 
observations have demonstrated that secondary hypothyroidism and hypercalciemia are 
consequences of the glucocorticoid deficiency developed after adrenalectomy for Cushing’s 
syndrome [69].  
In 103 patients with ACTH deficiency Murakami T. et al. [70] found signs of 
hypothyroidism (a decrease in free T3 and T4 concentrations, high TSH) and characteristic 
symptoms of clinical manifestations of thyroid insufficiency (cold intolerance, muscle 
rigidity, loss of interest in life). After hydrocortisone therapy all signs of impairments of the 
pituitary-thyroid axis disappeared in more than 70% cases; this suggests that glucocorticoid 
insufficiency is one of reasons underlying thyroid dysfunction. A high TSH level was found 
in patients with Addison’s disease; administration of glucocorticoids caused dose-
dependent inhibition of TRH-induced stimulation of TSH secretion; it is possible that 
glucocorticoids regulate pituitary sensitivity to TRH [71].  
Moderate hypothyroidism is a consequence of exogenous or endogenous hypercorticism. In 
prepubertal children with nonclassical congenital adrenal hyperplasia (NCCAH) TSH and 
cortisol were secreted in a pulsatile and circadian fashion with a clear nocturnal TSH surge; 
daytime TSH levels were lower in the NCCAH group than in control children. The cross-
correlation analysis of the 24-h raw data demonstrated that TSH and cortisol were 
negatively correlated, with a 2.5-h lag time [72].  
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Adrenalectomy not only reduced plasma corticosterone levels to almost zero, but also 
decreased plasma T3 and T4 levels, but diurnal rhythms of the HPT axis did not depend on 
rhythms of the HPA axis [73]. In pregnant female rats adrenalectomized on gestation day 8 
there was a decrease in TRH mRNA, increase in serum TSH, and a decrease of T3 only in 
females [74]; it appears that maternal glucocorticoids determine the development of the 
hypothalamic-pituitary-thyroid axis in progeny.  
Conclusion. The analysis of the literature data shows that the role of glucocotricoids in 
regulation of iodine metabolism in thyroid cells as well as their effects on the HHT system 
have not been conclusively established. Very few data are available on early changes in 
thyrocyte iodine metabolism induced by psychoemotional stress which characterize 
triggering of adaptation in metabolic systems. The idea is very important of the mechanisms 
of iodine oxidation and organification and the function of the key enzyme in thyroid 
hormone biosynthesis, TPO, with the activity governing synthesis of thyroid hormones. This 
seems to be especially topical in relation to increased levels of stressogenic factors in human 
environment and functions of all the systems under the stress of hypocoticism. 
The goal of the above research is to assess the effects of glucocorticoids on the activities of 
the main steps of thyroid iodine metabolism and to study the features of iodine metabolism 
under exposure to short-term and chronic psychoemotional stresses.  
2. Materials and methods 
Experimental animal models. All the experiments were carried out on Wistar female rats (160-
180g body weight) which were fed on a standard laboratory diet. Control and experimental 
groups contained 10-12 animals. 
Acute unavoidable psychoemotional stress. This model was aimed at simulation of negative 
emotions in rats (fear, alarm, anger and aggression). To this end, we used the modified 
techniques of Desiderato O. [75] and Tolmachev D.A. [76]. The rats were exposed to a 
combined stress (each animal was placed in an individual box) in a special chamber whose 
metallic floor was penetrated with 5-mA electric current. The mild painless irritation of the low 
extremities was accompanied by interrupted noise (electric bell) and light (100-Wt electric 
bulb) during 20 min or 5-60 min singly. Stress was always given at the same time from 9.00 to 
10.00 o’clock in the morning. No manipulations were carried out before placing the animals to 
penal cells and taking them out. The number of animals in the groups was 8 to 10.  
Short-term repeated psychoemotional stress was simulated using the modified techniques of 
Desiderato O. [75] and Tolmachev D.A. [76] but the exposure was repeated: 20 min daily 
during 28 days. Animals with normal thyroid status were subjected to multiple exposures to 
psychoemotional stress. 
Simulation of hypocorticism in rats. To simulate glucocorticoid deficiency, the animals were 
subjected to bilateral adrenalectomy (AE) (n=10). The surgery was performed by a 
conventional method [30] under ester anaesthesia. After the surgery, the animals were fed 
on the standard laboratory diet and received a 0.9 sodium chloride solution as a drinking 
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fluid. The animals were selected for experimental groups after a 3-day recovery period 
following the surgery. 
Administration of high doses of potassium iodide to animals with normal and reduced 
glucocorticoid status. 
Single administration. A KI solution was administered by a gastric tube at doses of 0.7; 7.0 
and 70.0 mg/kg B.W. (which corresponds to 10, 100 and 1000 daily KI doses [77] or 0.54; 5.35; 
53.51 mg iodide/kg B.W.) in the volume of 0.4-0.6 ml. The control rats received distilled 
water (0.5 ml). The animals were decapitated after 24 h following the administration. 
Multiple administration. Potassium iodide was administered by a gastric tube at doses of 0.07, 
0.21, 0.70 and 7.0 and 35 mg/kg body weight (which corresponds to 1, 3, 10, 100 and 500 
daily doses of potassium iodide or 0.05, 0.16, 0.64, 5.35 and 27.76 mg iodine / kg body 
weight) in a volume of 0.4-0.6 ml at 9 o’clock daily over 14 days.  The control rats received 
distilled water in a volume of 0.5 ml. After 24 h following the last (14th) administration of KI, 
the animals were decapitated. 
Studies on thyroid iodine metabolism. Determination of total (It), protein-bound (Ib) and free 
iodine (If) in rat thyroid tissue. The method for determination of total iodine and its protein-
bound and free fractions in thyroid tissue was developed directly for this research applying 
a commonly used catalytic cerium-arsenite method for measurement of iodine in the urine 
[78]. To determine the total iodine content, 0.125 ml of thyroid homogenate (1:2000) was 
placed to a test-tube and 0.3 ml of concentrated HClO3 and HClO4 (5:1) was added. The 
samples were incubated at 110°C for 60 min. They were cooled to a room temperature and 1 
ml of a 0.5% sodium arsenite solution was added. The samples were shaken, and after 20 
min, 0.5 ml of 1.2% cerium ammonium sulfate was added. Optical density was measured 
after 20 min at a wavelength of 400 nm. Iodine concentration was calculated by a calibration 
curve. To construct the calibration curve, we used KIO4 at concentrations of 0, 20, 50, 100, 
150 and 200 μg/l.  
To measure the contents of protein-bound and free iodine in the thyroid homogenate, the 
proteins were sedimented with 5.2% perchloric acid and 0.125 ml of the supernatant was 
used to determine free iodine concentration, the sediment was used to measure protein-
bound iodine concentration. After the separation of the iodine fractions, the procedure of 
measurement corresponded to that described above (I total). 
Determination of urinary total iodine concentration in rats. To determine urinary iodine 
concentration, 0.125 ml of urine from the morning portion (collected between 7 and 9 a.m.) 
was used. At high iodine concentrations, the samples were diluted 5-, 10-fold and over. 
Then the urine was burned in a mixture of concentrated HClO3 and HClO4 and the sample 
was assayed for iodine content as was described above. 
Determination of TPO activity. To determine TPO activity, we used the method based on 
reactions of iodine enzymatic oxidation [79]. 2.8 ml of 0.05 M of sodium phosphate buffer, 
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subjected to bilateral adrenalectomy (AE) (n=10). The surgery was performed by a 
conventional method [30] under ester anaesthesia. After the surgery, the animals were fed 
on the standard laboratory diet and received a 0.9 sodium chloride solution as a drinking 
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fluid. The animals were selected for experimental groups after a 3-day recovery period 
following the surgery. 
Administration of high doses of potassium iodide to animals with normal and reduced 
glucocorticoid status. 
Single administration. A KI solution was administered by a gastric tube at doses of 0.7; 7.0 
and 70.0 mg/kg B.W. (which corresponds to 10, 100 and 1000 daily KI doses [77] or 0.54; 5.35; 
53.51 mg iodide/kg B.W.) in the volume of 0.4-0.6 ml. The control rats received distilled 
water (0.5 ml). The animals were decapitated after 24 h following the administration. 
Multiple administration. Potassium iodide was administered by a gastric tube at doses of 0.07, 
0.21, 0.70 and 7.0 and 35 mg/kg body weight (which corresponds to 1, 3, 10, 100 and 500 
daily doses of potassium iodide or 0.05, 0.16, 0.64, 5.35 and 27.76 mg iodine / kg body 
weight) in a volume of 0.4-0.6 ml at 9 o’clock daily over 14 days.  The control rats received 
distilled water in a volume of 0.5 ml. After 24 h following the last (14th) administration of KI, 
the animals were decapitated. 
Studies on thyroid iodine metabolism. Determination of total (It), protein-bound (Ib) and free 
iodine (If) in rat thyroid tissue. The method for determination of total iodine and its protein-
bound and free fractions in thyroid tissue was developed directly for this research applying 
a commonly used catalytic cerium-arsenite method for measurement of iodine in the urine 
[78]. To determine the total iodine content, 0.125 ml of thyroid homogenate (1:2000) was 
placed to a test-tube and 0.3 ml of concentrated HClO3 and HClO4 (5:1) was added. The 
samples were incubated at 110°C for 60 min. They were cooled to a room temperature and 1 
ml of a 0.5% sodium arsenite solution was added. The samples were shaken, and after 20 
min, 0.5 ml of 1.2% cerium ammonium sulfate was added. Optical density was measured 
after 20 min at a wavelength of 400 nm. Iodine concentration was calculated by a calibration 
curve. To construct the calibration curve, we used KIO4 at concentrations of 0, 20, 50, 100, 
150 and 200 μg/l.  
To measure the contents of protein-bound and free iodine in the thyroid homogenate, the 
proteins were sedimented with 5.2% perchloric acid and 0.125 ml of the supernatant was 
used to determine free iodine concentration, the sediment was used to measure protein-
bound iodine concentration. After the separation of the iodine fractions, the procedure of 
measurement corresponded to that described above (I total). 
Determination of urinary total iodine concentration in rats. To determine urinary iodine 
concentration, 0.125 ml of urine from the morning portion (collected between 7 and 9 a.m.) 
was used. At high iodine concentrations, the samples were diluted 5-, 10-fold and over. 
Then the urine was burned in a mixture of concentrated HClO3 and HClO4 and the sample 
was assayed for iodine content as was described above. 
Determination of TPO activity. To determine TPO activity, we used the method based on 
reactions of iodine enzymatic oxidation [79]. 2.8 ml of 0.05 M of sodium phosphate buffer, 
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0.05 ml of 0.6 M KI and 0.1 ml of thyroid homogenate (1:80) or its microsomal fraction were 
placed in a 1-cm thermostatically controlled cell. The reaction mixture was stirred and 
incubated for 15 min at temperature of 28°C. The reaction was started by addition of 0.05 ml 
of 12 μM H2O2. The reaction rate was recorded for 1 min at a wavelength of 353 nm using a 
Cary-100 spectrophotometer. The TPO activity was calculated using the molar extinction 
coefficient of ε =22900 M-1 x cm -1 for the product formed [77]. Enzyme activity was 
expressed as μmol/min x g protein. 
Determination of thyroid hormone concentration in blood serum. The concentrations of total T4 
and total and free blood serum T3 were measured radioimmunologically using RIA-T4 –CT 
and RIA-T3-CT kits (Institute of Bioorganic Chemistry, National Academy of Sciences of 
Belarus, Republic of Belarus).  
Determination of total corticosterone concentration in rat blood serum. Blood serum total 
corticosterone concentration was measured by high performance liquid chromatography 
(HPLC). The assay was carried out using 0.2 ml of blood serum which was placed to a test-
tube with a ground stopper, 1.0 ml of chloroform and 10 μМ dexamethasone solution were 
added (as an internal standard) followed by addition of 40 μl of fresh 1.0 M solution of 
sodium hydroxide. Corticosteroids were extracted for 1 min. The test-tubes were 
centrifuged for 3 min at 600 g and then the lower (chloroform) fraction was carefully 
collected. The chloroform fraction was evaporated to dryness in a nitrogen flow. The 
samples were dissolved in 20 μl of the mobile phase and applied on a column. The steroids 
were separated on KAX-1-64-3 columns (2x64 mm) filled with a Silasorb -600 (LC) normal-
phase sorbent with the particle diameter of 5 μm (Lachema, Czech Republic). The mixture of 
hexan-chloroform-methanol in the volume ratio of 7:1:1 was used as the mobile phase [80]. 
A Milikhrom liquid microcolumn chromatograph (Russia) was used for detection in a UV-
detector at a wavelength of 246 nm. The rate of the eluent supply was 200 μl/min. Steroids 
were identified from the retention time. Corticosterone concentration was calculated from 
the calibration curve and expressed as nM. A corticosterone (Sigma) solution was used to 
construct the calibration curve and a dexamethasone (Sigma) solution was used as an 
internal standard.  
Statistical analysis. The data were processed statistically using Mann-Whitney’s U-test. The 
results are presented as means (M) ± standard deviation of the mean.  * Р<0,05; ** P<0,01; *** 
P<0,001. The critical value for the significance level was taken to be 5%.  
3. Results 
3.1. Studies on iodine metabolism under hypercorticism (stress and post-stress 
periods) 
Under psychoemotional stress, the corticosterone content was most elevated (405.8-447.7%) 
for 15-60 min. It was decreased following 2 hours after stress cessation (2.9-fold) and 
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increased after 6 hours (2.1-fold) at the post-stress period (Fig. 1). Analysing the wave-like 
dynamics of changes in corticosterone concentration at the post-stress period, we should 
note that the rats were stressed in the morning (9.00 to 10.00 a.m.) and the rise in 
corticosterone concentration at the post-stress period was not related to its circadian rhythm 
(since the circadian rhythm of corticosterone is characterized by maxima per 20.00 hour). 
The corticosterone concentration was observed to increase in the afternoon (16.00 p.m.) after 
6 hours following the post-stress period, and this elevation of serum corticosterone is a 
characteristic manifestation of a regulatory feedback mechanism. As a response to a marked 
reduction of corticosterone concentration after 2 hours following stress, the ACTH 
concentration elevated, which  induced a new wave in increasing blood and adrenal 
corticosterone concentration that is a manifestation of the adaptation syndrome.  
 
 
Figure 1. Blood serum (A) and adrenal (B) corticosterone concentrations in rats at acute stress and post-
stress periods, after exposure to psychoemotional stress (n=8). 
A, B, C, D, E, F, G are groups of animals, respectively. The letters under each column indicate statistically 
significant changes in the parameter (p<0.05) compared to the corresponding group (e.g., in Fig.1A, the parameter 
for Groups 15B, 30C, 45D, 60E is statistically significant compared to Group A). The same designations are in 
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The dynamics of changes in the parameters characterizing thyroid iodine metabolism was of 
a wave-like pattern, which indicates a pronounced response of the rat thyroid to stress. This 
was most pronounced for changes  
in the index If, which is quite explicable. During 15-30 min of stress the thyroid total iodine 
concentrations remained unchanged (176.9-234.9 μg/g tissue). However, after 60 min, its 
content was 39.3% decreased in comparison with 15-and 30-min stress (Fig. 2А). During the 
acute stress phase (15-30 min), intensification of iodide organification was noticed: the 
concentration of its protein-bound fraction was 37.6% elevated, and the ratio of protein-
bound I to total I was 1.2-fold increased (Fig. 2B).  The 70.5% elevation of free iodide 
concentration in the thyroid gland (Fig. 2C) was probably due to activation of proteolytic 
processes in thyroglobulin and thyroid hormone formation. We cannot also exclude 
activation of iodine uptake with consideration for the absence of iodine supply to the body 
during stress, which can be due to increased activities of tissue deiodinases. Along with this, 
in spite of the evidence for Na+/I–- simporter expression in some cells (salivary and 
mammary glands) the literature lacks information about other iodine depots in addition to 
the TG. After 60-min stress, the thyroid showed diminished concentrations of free and 
protein-bound iodine, which seemed to be a consequence of highly active secretory 
processes and inhibition of iodine organification, TPO activity (Fig. 3) remained at a level of 
control values during 30-min exposure to stress, decreasing by 34.8% after 45 min, which 
was accompanied by a 16.8% reduction of protein-bound I concentration. The stress- 
induced drop in TPO activity can be due to changed kinetic parameters of the enzyme. TPO 
was found to be sensitive to elevation of ROS concentrations and aldehyde products of lipid 
peroxidation in thyroid cells [81]. Moreover, an important role in this case can be played by 
a decreased TSH level that regulates key processes in the TG. Taking into consideration the 
antagonistic relations between ACTH and TSH, one can suggest the metabolic changes in 
the TG to be caused by a stress-induced increase of the ACTH level which can induce a 
decrease of TSH production.  
The correlation analysis of the results did not show a correlation between thyroid TPO 
activities and glucocorticoid levels in the blood serum and adrenal glands. After 60-min 
stress, a negative correlation was found between the total thyroid iodide and adrenal 
corticosterone (r= –0.952, p=0.003). In the control group, the content of adrenal 
corticosterone positively correlated with the protein-bound I to total I ratio (r=0.955, 
p=0.01), which indicates involvement of glucocorticoids in regulation of iodine homeostasis 
in the TG. 
The decrease in corticosterone concentration after 2 h following the stress exposure was 
followed by activation of TPO (3.6-fold) as opposed to 60-min stress and control (3.4-fold). 
The TPO activation at the post-stress period suggests the presence of regulatory 
mechanisms for its activity which are related to a corticosterone level since it is at that 
period that its blood and adrenal concentrations were diminished most appreciably. The 
subsequent elevation of corticosterone concentrations in 4 and 6 h within the recovery 
period was followed by a dramatic decrease of thyroid TPO activity.  
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Figure 2. Rat thyroid total (A), protein-bound (B), and free (C) concentration of iodine during acute 
stress and post-stress periods.  
A, B, C, D, E, F, G represent respective designations for groups of animals. 
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Figure 3. Rat thyroid TPO activity at acute stress and post-stress periods. 
A, B, C, D, E, F, G represent corresponding designations for animal groups. 
A, B, C, D, E represent statistically significant changes in parameter (p<0.05) compared to the 
corresponding group. 
 
Figure 4. Rat blood iodine concentration at acute stress and post-stress periods. 
A, B, C, D, E, F, G represent corresponding designations for animal groups. 
A, B, C, D, E, F represent statistically significant changes in the parameter (p<0.05) compared to the 
corresponding group. 
The iodine status restoration after the 2- h post-stress period is characterized by elevated 
concentrations of total I, protein-bound I and free I (55.5, 38.3 and 40.8%, respectively). A 
marked restoration to the control values of all the thyroid parameters studied was noticed 
after 4-6 h following the cessation of stress exposure. Under physiological conditions, the 
blood serum iodine content was not high (approx. 20 μg/l). However, acute stress 
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diminished its level (52.3%) at the post-stress recovery period (after 6 h following stress), 
which can be a consequence of restoration of the iodine status in the thyroid (Fig. 4).   
 
 Control Stress, 15 min Stress, 30 min Stress, 45 min 
Groups А B C D 
Т4 total, nM 59.4±4.1 60.6±3.6 60.5±2.4 59.09±4.4 
Т3 free, nM 2.9±0.22 2.9±0.21 2.3±0.12 2.3±0.20А,B 
     
 Stress, 60 min 
Stress, 60 
min + 2-hour post-
stress periods 
Stress, 60 min +
4-hour post-
stress periods 




Groups E F G H 
Т4 total, nM 58.7±3.5 59.1±2.2 64.8±6.0 51.6±4.5 
Т3 free, nM 2.1±0.21 А,B 2.7±0.29 2.1±0.13А,B,F 2.0±0.26 А,B,F 
А,B,F P<0.05 compared to control. 
Table 2. Rat blood T4 and T3 concentrations at acute stress and post-stress periods  
The stress exposure did not produce significant changes in the concentration of blood serum 
total T4. However, the free T3 content lowered at the 30th minute of stress and remained to 
be 18.6 to 28.5% lowered throughout the experiment. It was not until 2 hours later that it 
increased up to the control values (Table 1). 
Our findings show involvement of the TG in adaptation of the body to acute stress. We 
should note the thyroid ability to a rapid recovery of the iodine status at the post-stress 
period. Throughout a short period of time (15-30 min), the acute stress induced activation 
and uptake of iodide and thyroid hormone secretion.  
However, oxidation of iodide was inhibited and the contents of total I, protein-bound I and 
free I were decreased after 45 and, significantly, after 60 min.  
The 60-min exposure to psychoemotional stress revealed a negative correlation between the 
concentration of total I in the thyroid and the corticosterone concentration in the adrenals (r= 
–0.952, p=0.003). This shows that overproduction of glucocorticoids under stress induces a 
decrease of thyroid iodine content, resulting in a negative iodine balance at the post-stress 
period. The 2-hour recovery period is characterized by a pronounced activation of thyroid 
iodine metabolism (TPO activity rose over 3-fold), and the partial restoration of the thyroid 
iodine status (after 4-6 hours) was accompanied by a decreased blood serum iodine content.  
The following correlations were established at the post-stress recovery period: 
 after 4 hours, the blood serum iodide concentration negatively correlated with the 
corticosterone concentration (r= –0.831, p=0.040); 
 after 6 hours, there was a highly significant correlation (r=0.937, p=0.006) between the 
blood corticosterone level and the ratio of protein-bound I to total I; 
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The data for the recovery period demonstrate that the blood corticosterone level can be 
viewed as a factor inducing a decrease of blood iodine concentration in rats. 
Thus, the short-term stress (5-30 min) induced activation of biosynthesis and secretion of 
thyroid hormones. The most important regularity of the post-stress period is restoration of 
the thyroid iodine status due to activation of iodine uptake and organification as well as the 
presence of a close negative correlation between the thyroid concentration of I total and the 
adrenal corticosterone concentration (r= –0.956, p=0.003). After 6 h of the recovery period, 
the concentration of blood corticosterone was positively correlated to the ratio of protein-
bound I/total I in the TG (r=0.937, p=0.006). A close correlation found between the levels of 
corticosterone and iodine in the thyroid gland may primarily show possible regulatory 
effects of glucocorticoids on iodine uptake. But no effects of glucocorticoids on TPO were 
found, which definitely indicates the absence of direct interactions. However, elevation of 
thyroid iodine concentration, induced by glucocorticoids, can activate TPO.  
The above findings show that the exposure to stress induced a marked imbalance in the 
thyroid iodine status which was rapidly recovered at the post-stress period due to the 
decreased blood serum iodine concentration and that the restoration of the thyroid iodine 
status is most closely related to the glucocorticoid status. 
3.2. Studies on the effect of acute exposure to stress on the kinetics of iodine 
metabolism in rats after administration of physiological potassium iodide doses  
We studied the effects of 30-min psychoemotional stress on the iodine metabolism after 
administration of three daily doses of potassium iodide (KI was administered directly before 
the exposure to stress). The administration of three daily doses of KI increased 4.3-fold the 
blood iodine level within 6 hours. This concentration was decreased to the control values 
after 24 h (Fig. 5). In the group of rats subjected to stress, the iodine content also increased 
(296.7%) after 30 min following the administration of 3 daily doses of KI. In contrast to the 
control rats, the stressed rats showed a pronounced maximum of blood iodine concentration 
after 6 h (839.4% elevation, 170.7μg/l). After 24 h, the level of blood iodine in the stressed 
rats did not differ from that in the controls. The stress-induced changes in the kinetics of 
blood iodine concentration are a consequence of a disturbed regulation of iodine 
homeostasis. The dramatic, over 800%, elevation of blood iodine concentration can be due to 
an imbalance in the activity of its uptake: lowering of uptake in the TG and activation of 
uptake in the gastrointestinal tract at the post-stress period. It should be noted that it is at 
that period that the rat blood showed an increase in the corticosterone concentration (Table 
2). A comparative examination of the curves characterizing changes in thyroid iodine 
concentrations in two animal groups (Fig. 5 B) shows that after 24 h, the thyroid iodine 
concentration elevated 1.7-fold in the control rats and remained essentially unchanged in the 
stressed rats (1.2-fold increase).  
The 30-min psychoemotional stress leveled off the increase in the thyroid iodine status after 
administration of 3 daily KI doses. The changed concentrations of thyroid protein-bound I 
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and free I (Fig. 5, B and C) reflect changes in TPO activity in the thyroid gland (Fig. 5D). The 
administration of 3 daily KI doses was accompanied by activation of its organification in the 
group of control rats within 1 h (the level of protein-bound I was increased by 54.1%) and 
elevation of its concentration by 74.3% after 24 h. 
 
Figure 5. Effect of 30-min exposure to psychoemotional stress on iodine content in rat blood serum (A), 
total iodine (B), protein-bound iodine (C), activity of TPO (D) in rat thyroids after administration of 3 
daily doses of KI within 24 h of the post-stress period (^ P<0.05 compared to the initial level (0 h); * P<0.05 
when comparing the indices in control and stressed rats; $ P<0.05; 0 – 0.1p0.05 compared to group of 0 h; 
24 – 0.1p<0.05 when comparing the indices in stressed rats to controls (24 h). 
The dynamics of changes in TPO activity in the stressed animals treated with 3 daily doses 
of KI had an essentially opposite character in comparison with the controls (Figure 5D). The 
post-stress increase in TPO activity after 1 h was accompanied by 41.5% decrease of its 
activity by 6 h as opposed to the initial level. As compared to the control animals, the 
activity of TPO in the thyroid of the stressed rats diminished over 2-fold , whereas the 
concentration of protein-bound I decreased 1.4-fold after 24 h following the administration 
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The data obtained indicate that the 30-min exposure to stress after the administration of 3 
daily KI doses changed the kinetics of iodine metabolism in rats within 24 h of the post-
stress period. These data reflect complex relationships between the regulatory effects of the 
pituitary-thyroid and pituitary-adrenal systems as well as the whole complex of metabolic 
stress changes in the organism in respect to the key steps in thyroid iodine metabolism. 
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Table 3. Effect of 30-min stress exposure on corticosterone concentration in rat blood after 
administration of 3 daily doses of KI within 24 h of post-stress period 
The most pronounced stress-induced changes in iodine metabolism after administration of 
physiological KI doses (3 daily doses) are characterized by: 
 abnormal kinetics of changes in blood iodine concentration within 24 h after 
administration of KI, which was manifested by accumulation of blood iodine (839.4% 
elevation) after 6 h at the post-stress period;  
 changes in the kinetics of iodine uptake and oxidation in the TG, which results in a 
decreased content of total I and protein-bound I in thyroids of stressed rats after 
administration of 3 daily doses of KI as opposed to the control group which showed an 
increase of these parameters.  
3.3. Effect of unavoidable repeated short-term psychoemotional stress on the 
functional activity of the rat thyroid 
A research was carried out into a short-term stress effect (daily, over a long period of time) 
on the activities of the key steps in iodine metabolism in the rat thyroid. The data obtained 
indicate that daily 20-min exposure to stress (4 weeks) induced pronounced changes in 
thyroid iodine metabolism. 
Figure 6 shows that the total thyroid iodine content in stressed animals was elevated 1.97- 
fold as opposed to controls and amounted to 491.8±15.5 μg/g tissue. The contents of its 
protein-bound and free fractions corresponded to 329.9±8.3 μg/g tissue and 161.8±18.4 μg/g 
tissue, which was 1.6-and 3.1-fold higher compared to the controls. The increased thyroid 
iodine concentration was accompanied by a changed ratio of its various fractions (Table 3). 
The 2-fold elevated free I/protein-bound I ratio and the lowered protein-bound I/total I ratio 
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(1.18-fold) are indicative of a lowered efficiency of thyroid iodine organification under 
stress. 
 
*statistically significant changes vs control group (p<0.05) 
Figure 6. Effect of 4-week psychoemotional stress (20 min, daily) on contents of total I, protein-bound I 
and free I in the rat thyroid 
Indices Control Stress 
Free I/protein-bound I 0.260.034 0.500.066* 
Protein-bound I/total I 0.790.021 0.670.028* 
Urinary I, μg/l 17.92.29 22.21.94 
* P<0.05 compared to control.  
Table 4. Effect of short-term daily psychoemotional stress on the ratio of different rat thyroid iodine 
fractions and urinary iodine excretion 
Indices Control Stress 
T4 total, nM 49.22.82 51.73.34 
T3 total, nM 1.20.06 1.30.07 
TPO, μmol/min x g tissue 23.42.70 20.92.91 
Thyroid weight, mg 15.70.63 13.30.47* 
Thyroid cytosolic protein, mg/g tissue 158.53.6 137.95.3* 
* P<0.05 compared to control.  
Table 5. Effect of short-term daily psychoemotional stress on the concentration of blood thyroid 
hormones, TPO activity, thyroid weight and thyroid protein concentration  
No changes were found in the activity of TPO, the key enzyme of thyroid hormone 
biosynthesis (Table 5). The thyroid weight in stressed rats was lowered by 18%, whereas the 
protein concentration in the thyroid cytosolic fraction – by 13%. The blood thyroid hormone 
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Table 5. Effect of short-term daily psychoemotional stress on the concentration of blood thyroid 
hormones, TPO activity, thyroid weight and thyroid protein concentration  
No changes were found in the activity of TPO, the key enzyme of thyroid hormone 
biosynthesis (Table 5). The thyroid weight in stressed rats was lowered by 18%, whereas the 
protein concentration in the thyroid cytosolic fraction – by 13%. The blood thyroid hormone 
 
Glucocorticoids – New Recognition of Our Familiar Friend 286 
content at the post-stress period was maintained at the level of control values (Table 5), the 
level of corticosterone was increased by 32.8% (Table 6) and the weight of the adrenal 
glands rose by 13%. 
 
Indices Control Stress 
Blood serum corticosterone, nM 383.265.9 509.290.0# 
Adrenal corticosterone, nmol/g tissue 152.817.9 176.230.8 
Adrenal weight, mg 46.61.9 52.72.5* 
* P<0.05; # P<0.1 compared to control. 
Table 6. Effects of short-term daily psychoemotional stress on adrenal weight, blood corticosterone 
concentration and corticosterone concentration in rat adrenals. 
As our data show, stress caused multidirectional changes in the activities of the key steps 
of thyroid iodine metabolism. The elevated content of the total and free iodine is a 
consequence of stimulation of its absorption at the post-stress period [28]. The decreased 
efficiency of iodine organification may be due to TPO inhibition and lowering of 
thyroglobulin concentration. The stress-induced lowering of thyroid TPO activity was 
shown earlier. As Table 7 demonstrates, the repeated exposure to short-term stress 
during 7 days and over was accompanied by a decrease of thyroid TPO activity both 
















81.4±21.43* 60.2±4.9* 66.6±9.4* 62.6±18.22* 
Group A animals were decapitated directly after the last exposure to stress; Group B animals were decapitated 24 h 
after the last exposure to stress. * P<0.05 compared to control. 
Table 7. Effect of short-term (20 min) psychoemotional stress (daily, 7, 14 days) on thyroid TPO activity 
Effects of stress on iodine oxidation and organification in thyroid cells have not been 
virtually investigated. We found only one study on female tortoises. Thyroid TPO activity in 
young female tortoises was lowered after ten-fold administration of corticosterone (25, 50, 
100 μg/100 g body weight) [34]. Nothing has been known of the effect of stress on 
thyroglobulin biosynthesis. However, the diminished level of thyroid protein-bound I can 
be stipulated by its impaired biosynthesis. Moreover, a consequence of stress was a 13%- 
decreased total protein concentration in the thyroid cytosolic fraction. This certainly applies 
to thyroglobulin, taking into consideration that it amounts to 75-80% and up of the total 
thyroid protein. 
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The main regulator of TPO and thyroglobulin synthesis is TSH whose secretion is inhibited 
by glucocorticoids [20], which can induce depression of thyroid hormone synthesis. Stress is 
suggested to cause a decrease of TSH production via pituitary neuromedin B, gastrin-
releasing peptide and pituitary leptin acting as local inhibitors of TSH release under stress 
[21]. It was found that lipocortin -1 is a mediator of glucocorticoid-induced suppression of 
TSH secretion by the anterior lobe of the pituitary gland [21]. 
The inhibitory effect of stress seems to be followed by activation of thyroid metabolism at 
the post-stress period and the restoration of thyrocyte function is related to activation of 
thyroid hormone secretion, which is confirmed by resorption of colloid and depletion of 
thyroid follicules. These conditions disturb the thyroglobulin synthesis/secretion balance. As 
a result, the thyrocytes and follicular lumen accumulate a considerable amount of non-
organified iodine, which is confirmed by our findings. Stress decreases thyroid weight, 
which can be both a consequence of its hypersecretion and destructive processes; the 
mechanism of this change is certainly interesting.  
The experimental findings show that a consequence of the repeated exposures to 
psychoemotional stress are pronounced structural and metabolic changes in the TG that are 
characterized by an elevated iodine content, a decreased extent of its organification, 
development of oxidative stress and lymphocyte infiltration along with the impaired 
thyroid follicular structure. The mechanisms of the regularities found call for detailed 
research and are of great interest to disclose the pathogenesis of autoimmune thyroiditis, 
thyroid carcinoma as well as the contribution of the thyroid component to development of 
endemic and nodular goiters. 
There are presently no unambiguous data on the role of stress in induction of thyroid 
pathology in humans. Individual cases have been described of autoimmune thyroiditis 
developed after surgical treatment of hypercorticism (Cushing’s syndrome) [65]. A 
pronounced stress effect can be an onset of Graves’ disease [82]. There were reports about 
relationships between stress and Hashimoto’s thyroiditis [83]. According to Polish 
researchers [84] secondary adrenal deficiency can be a cause of autoimmune thyroid 
diseases in humans: stress affects the immune system, and immunologic modulations are 
considered to be a factor inducing autoimmune thyroiditis in genetically prone individuals 
[85]. Stress hormones, affecting antigen-presenting immune cells, can influence the 
differentiation of bipolar T-helpers from Th1 to Th2 phenotype, which causes suppression of 
cellular immunity and enhancement of humoral immunity. Stress is likely to contribute to 
the development of Graves’ disease by shifting the Th1/Th2 ratio from Th1 to Th2. Recovery 
after stress or immunosuppressive effect of pregnancy can induce a “reverse shift” in Th2  
Th1, causing autoimmune (sporadic) thyroiditis [85]. 
Stress-induced impairment of thyroid function characterized by development of oxidative 
and iodine stress is likely to be viewed as a main mechanism of thyroid ageing in humans 
and, consequently, to be a cause of diseases of age related to thyroid deficiency [86, 87]. 
Further studies are needed to disclose the mechanisms of stress-induced impairment of 
thyroid functions.  
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3.4. Studies on rat thyroid iodine metabolism under hypocorticism (after 
adrenalectomy) 
The above findings confirm that stress considerably changes thyroid iodine metabolism, 
affecting its uptake and organification. Since all the experimental studies were carried out 
using models characterizing hyperfunction of the adrenal glands (stress), a comparative 
investigation of iodine metabolism in rats with adrenal deficiency should be done in order 
to establish the biochemical mechanisms. 
The glucocorticoid status in rats was assessed by the level of corticosterone which was 
lowered 4.4 to 6.4-fold in adrenalectomized (AE) rats compared to controls. Adrenal 
deficiency was a cause of 44.2 % - decreased thyroid TPO activity (Fig. 7B). The 
administration of 1000 daily doses of KI (a dose=70 mg/kg) decreased thyroid TPO activity 
in the TG of the control rats and elevated it in the glucocorticoid-deficient animals with to 
the control values. The administration of 1000 daily doses of KI was accompanied by 
increases in thyroid total I (42.2%), protein-bound I (19.1%) and free I (90.6%) in AE rats (Fig. 
8). This indicates that under hypocorticism the regulatory mechanisms for thyrocyte 
functions can be disturbed by high iodine doses. 
 
Figure 7. Effect of single administration of 1000 daily doses of KI on concentration of blood serum 
corticosterone (nM) (A) and TPO activity (μmol/min x g protein) in thyroids of intact and AE rats (B) 
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Figure 8. Effect of single administration of 1000 daily KI doses on contents of total I, protein-bound I 
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Figure 8. Effect of single administration of 1000 daily KI doses on contents of total I, protein-bound I 





Glucocorticoids – New Recognition of Our Familiar Friend 290 
The blood thyroid hormone levels in AE rats were above the control values (27% for T4 and 
35% for T3), but administration of KI lowered the concentrations of T4 by 41.1% and T3 by 
34% compared to the AE animals. T4 was 29% decreased even in comparison with the 
controls (Fig. 9). 












































Figure 9. Effect of single administration of high KI dose on concentrations of total blood serum T4 and 
T3 in rats with normal and decreased glucocorticoid statuses 
Index Control 
1000 daily 





 А B C D 
TBARS, nmol/g tissue 131.28.9 212.522.9А 150.415.0 115.59.6B,C 
Cаtalasa, μmol/ming protein 36.81.3 40.01.6 32.20.8А,B 33.71.7B 
SOD, activity u./ming protein 43.24.2 56.81.4А 51.12.0А,B 48.92.9B 
GR, μmol/ming protein 24.01.2 22.71.0 26.71.0B 25.51.5 
Table 8. Effect of single administration of 1000 daily doses of KI on TBARS levels and antioxidant 
enzyme activities in thyroids of rats with normal and decreased glucocorticoid statuses 
In contrast to the rats with the normal glucocorticoid status, in which the administration of 
KI inhibited the thyroid function and induced activation of oxidative processes (62.0% 
elevation of TBARS concentration, 54.3% activation of SOD), the adrenalectomized rats did 
not show activation of lipid peroxidation (the level of TBARS was decreased by 23.2%, 
Table 8). 
The AE animals demonstrated elevated concentrations of T3 and T4 in the blood serum (Fig. 
9). These changes seemed to be caused by alterations in thyroid iodine metabolism since the 
contents of its different fractions did not change under decreased glucocorticoid status (Fig. 
8). It was found earlier that AE caused enhancement of liver thyroxin-binding globulin 
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synthesis and its binding capacity in the blood [88] as well as inhibition of the peripheral 
metabolism of thyroid hormones. Enhancement of deposition of blood thyroid hormones 
and, consequently, inhibition of their metabolism may cause elevation of thyroid hormone 
concentrations.  
Most interesting changes were found after administration of high iodine doses to rats. In 
contrast to control animals with the characteristic acute Wolff – Chaikoff’s effect, we did 
not observe inhibition of iodide organification in this group. Moreover, a pronounced 
lowering of T4 and T3 concentrations in the blood serum of AE rats after the administration 
of high iodine doses suggests that the cause of the absence of the Wolff-Chaikoff’s effect 
under hypocorticism can be impaired maturing of the prohormone, thyroglobulin, and 
abnormal secretion of thyroid hormones to the blood, which provides for elevated 
concentration of protein-bound I in this group. Elevated TSH concentrations and enhanced 
NIS expression and, consequently, increased uptake of iodide absorption by the TG are 
also possible. 
Our findings show that the effects of the single administration of the high KI dose on the 
activity of hormonogenesis in thyroids from normal and AE animals are multidirectional. 
Thyroids from the intact rats show inhibition of iodide organification accompanied by 
induction of oxidative stress, whereas the hypocorticoid rats demonstrate a reverse effect: 
activation of iodide uptake and organification as well as a decrease in the intensity of lipid 
peroxidation. These results are of a considerable interest in relation to some clinical studies 
which prove that impairments in the glucocorticoid status can be linked to development of 
autoimmune thyroid diseases. Lowering of the functional activity in the hypophyseal link 
(ACTH) and/or the adrenal (cortisol) link was noted in patients with autoimmune tyroiditis 
[89, 90]. It was shown that autoimmune tyroiditis and diabetes mellitus are developed on 
the average 7 years after autoimmune damage of the adrenal glands [91]. In patients 
suffering from hypercorticism of different genesis, AE contributes to development of 
autoaggression in their thyroids [68, 66, 92]. It is suggested that puerperal thyroiditis, as a 
consequence of a temporary decrease of the glucocorticoid status in females at the 
puerperal period [93], is due to ACTН-releasing hormone inhibition of the synthesis and 
secretion of maternal hypothalamic ACTH-releasing hormone and that this inhibition is of 
a placental origin. It should be mentioned that impaired functional activities of the 
pituitary-adrenal axis are also noted in other autoimmune diseases [94]. The mechanisms 
of the regularities found certainly require further studies since the literature lacks 
information on this problem. 
3.5. Excess administration of iodine induces development of hyperthyroiditis in 
rats with glucocorticoid deficiency 
Glucocorticoid deficiency is a cause for impairments of the adequate regulation of the 
thyroid status and thyroid iodine metabolism. It was interesting to study the properties of 
the iodine metabolism after its repeated administration to rats with adrenal deficiency. 
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After 2 weeks following AE, the blood serum thyroid hormone concentrations in operated 
animals were partially restored and amounted to 23.7-42.3% of the control values (Fig. 10) 
 
*** statistically significant changes vs control group (p<0.001) 
Figure 10. Effect of 14-day administration of 1-500 daily doses of KI on blood serum corticosterone 
concentration in AE rats.  
Studies on the thyroid iodine metabolism showed that repeated administration of high KI 
doses resulted in 46.9-115.7% increased concentrations of total I and caused 120.4 to 223.9% 
elevations of free I in all the experimental groups (Fig. 11). Glucocorticoid hormones are 
likely to inhibit iodide uptake by erythrocytes since the levels of nonorganified iodine were 
1.2-fold increased after AE in rats which did not receive supplementary KI. One more 
confirmation is a more considerable growth of free I concentrations in thyroids of rats with 
hypocorticism (120.4-223.9%, Fig. 11) compared to controls (94.8-128.0%) after 
administration of KI at the same doses. Iodine organification in AE rats was enhanced by 32-
86% in rats treated with 3 to 500 daily doses of KI (Fig. 11). TPO activity in AE rats was 
29.4% elevated and 2.4, 3.9 and 3.7-fold increased (Table 9) after administration of 3, 100 and 




Daily doses of KI administered to AE animals 
No 
administration




173.9±22.5 193.8±10.3 275.4±77.4 387.9±78.4* 616.5±178.1* 579.7±120.6* 
Table 9. Effect of 2-week administration of 1 to 500 daily doses of potassium iodide on TPO activity 
(μm/ming tissue) in thyroids of AE rats 
Control
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*statistically significant changes vs control group (p<0.05), **p<0.01; ***p<0.001 
Figure 11. Effect of 14-day administration of 1-500 daily doses of KI on the concentrations of total I, 
protein-bound I and free I in thyroids of AE rats 
 
* statistically significant changes vs control group (p<0.05) 
Figure 12. Effect of 14-day administration of 1 to 500 daily doses of potassium iodide on the 
concentrations of total T4 and T3 in the blood serum of rats with normal and lowered glucocorticoid 
statuses 
The repeated and single administrations of excess potassium iodide to rats with 
hypocorticism were characterized by activation of iodide metabolism in the TG, which was 
followed by development of pronounced hyperthyroidism in AE animals. The blood serum 
total T4 concentration (Fig. 12) was increased by 52-100% in rats with adrenal deficiency 
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treated with KI for 14 days compared to control animals. The T3 concentration (Fig. 12) 
reached 145.5-177.5% of the control level. 
In this situation, a pronounced disturbance in the regulatory mechanisms of the pituitary-
thyroid axis may be observed, which is accompanied by development of hypothyroidism 
and indicates a permissive (coordinating) role of glucocorticoids in regulation of thyroid 
homeostasis.  
Our findings indicate that regulation of iodide uptake is very closely related to the state of 
the pituitary-adrenal system. Excess iodine intake under hypocorticism causes development 
of hyperthyroiditis.  
4. Conclusion 
1. Short-term stress (5-30 min) induced activation of biosynthesis and secretion of thyroid 
hormones. The most important established regularity of the post-stress period is 
restoration of the iodine thyroid status due to activation of uptake and organification of 
iodine as well as  a negative correlation between the total thyroid concentration and 
adrenal corticosterone concentration (r= –0.952, p=0.003), which indicates participation 
of glucocorticoids in regulation of iodine thyroid homeostasis. 
2. The most pronounced stress-induced changes in iodine metabolism after the treatment 
by physiological KI doses (3 daily doses) are characterized by: 
- disturbed kinetics of blood iodine content within 24 h following the KI treatment, 
which was characterized by accumulation of blood iodine (826%) after 6 hours 
following the post-stress period;   
- changed dynamics of thyroid uptake and oxidation of iodine, which caused a 
decrease in the concentrations of total I and protein-bound I in thyroids of stressed 
rats after the treatment with 3 daily doses of KI in contrast to the control group 
which showed elevation of these indices. 
3. It was shown that repeated exposure to short-term psychoemotional stress (for 4 weeks) 
induced pronounced structural and metabolic changes in the thyroid gland that were 
characterized by elevated iodine content, as well as a decrease of the extent of its 
organification and development of oxidative stress.  
4. The lowered glucocorticoid status in rats is characterized by increased blood thyroid 
hormone concentrations and decreased TPO activity (44.2%). In contrast to the 
animals with normal glucocorticoid status, the AE rats did not show any inhibitory 
effect of high iodine doses (Wolff-Chaikoff’s effect) after the single administration of 
1000 daily doses of KI, and activation of thyroid iodide uptake and organification was 
observed. 
5. The 2-week administration of KI (1-500 daily doses) to rats with glucocorticoid 
deficiency increased the levels of free iodine (120-224%) and protein-bound iodine (32-
86%) as well as thyroid TPO activity. In contrast to controls, this was followed by 
development of pronounced hyperthyroiditis (T4 amounts to 152-200% and T3 – 145 to 
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177% of the control values), which is a consequence of impairments in the key 
mechanisms of thyrocyte regulation and shows a permissive (coordinating) role of 
glucocorticoids in respect to the given effects. 
The state of chronic stress may be a cause of impaired iodine metabolism in thyroid cells, 
which can induce development of hypothyroiditis and autoimmune thyroid pathology. 
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1. Introduction 
Glucocorticoids (GCs), steroid hormones produced predominantly by the adrenal gland, are 
key mediators of stress responses. Whilst the acute and chronic effects of pharmacological 
glucocorticoid excess are well-recognized (including induction of hyperglycemia, insulin 
resistance, hyperlipidemia, hypertension and dysphoria, with suppression of immune, 
inflammatory and cognitive processes), their role in the biology of the response to stress is 
more nuanced, with balanced homeostatic effects to facilitate short-term survival and 
recovery from challenge [1, 2]. In addition, glucocorticoids play an essential role in normal 
fetal development and are important for the development and maturation of various fetal 
tissues including the liver, lungs, gut, skeletal muscle and adipose tissue in preparation for 
extrauterine life. Glucocorticoids most notably act during late gestation to stimulate 
surfactant production by the lung. This action is critical to prepare the fetus for extrauterine 
life, and it is for this reason that synthetic glucocorticoid treatment is so widely used in 
preterm pregnancies where lung immaturity threatens neonatal viability. Although these 
treatments greatly improve survival [3], they are not without adverse effects.  
Glucocorticoids regulate many of the processes required for successful embryo 
implantation, as well as for the subsequent growth and development of the fetus and 
placenta. In utero, the endometrium, placenta and embryo/fetus are each exposed to 
physiological glucocorticoids arising from either maternal or fetal adrenal glands. It has 
been shown that glucocorticoids have several roles in improving the intrauterine 
environment. For example, in uterus, glucocorticoids regulate the synthesis of 
prostaglandins that have been implicated to play critical roles during implantation by 
increasing stromal vascular permeability [4] and in the initiation of parturition [5]. The peri-
implantation secretion of human chorionic gonadotrophin (hCG) from human term 
trophoblasts can be stimulated by up to 10-fold by treatment for 24 to 72 h with synthetic 
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glucocorticoids dexamethasone and triamcinolone [6, 7]. Glucocorticoids have several anti-
inflammatory actions required for implantation. In first trimester human cytotrophoblasts, 
cortisol can suppress the synthesis of the pro-inflammatory interleukin (IL)-1b [8]. Similarly, 
in term human placental cytotrophoblasts, physiological concentrations of cortisol and 
numerous synthetic glucocorticoids can inhibit secretion of pro-inflammatory cytokines 
tumor necrosis factor (TNF)-α, IL-6 and IL-8 without affecting the expression of anti-
inflammatory cytokine IL-10 [9-11]. Glucocorticoids contribute to preventing immunological 
rejection of the fetal semiallograft in the pregnant uterus by inhibiting eosinophil infiltration 
[12]. Moreover, glucocorticoids profoundly and specifically suppress expression of 
fibronectin and laminin, two extracellular matrix proteins that are important mediators of 
uterine–placental adherence [6]. 
Furthermore, glucocorticoids activate many of the biochemical processes in these tissues 
such as altering expression of numerous receptors, enzymes, ion channels, transporters, 
growth factors, cytoskeleton proteins, binding proteins, clotting factors, gap and tight 
junction proteins and intracellular signaling pathways’ components involved in growth. 
Taken together, these glucocorticoid-induced changes in cell physiology combine to 
produce functional alterations at the systemic level [13]. 
In pregnancy, glucocorticoid administration is used mainly in the management of women 
at risk of preterm labor and in the antenatal treatment of fetuses at risk of congenital 
adrenal hyperplasia. It is recommended that, for pregnant women who are at risk of 
preterm delivery within 7 days between 24 weeks and 34 weeks of gestation, a single 
course of corticosteroid administration should be performed. And a single course of  
antenatal corticoids should be administered to women with premature rupture of 
membranes before 32 weeks gestation to reduce the risks of respiratory distress syndrome, 
perinatal mortality and other morbidities [14]. Numerous evidence indicates that increased 
exposure of the fetus to glucocorticoids in mid- to late pregnancy may result in adverse 
outcomes including intrauterine growth restriction (IUGR) [15-18], postnatal hypertension 
[15, 19], postnatal cardiovascular disease [20], postnatal glucose intolerance [20], increased 
postnatal activity in the hypothalamo–pituitary–adrenal axis [21-24], effects on fetal brain 
development [21, 25, 26].  
Glucocorticoid actions within the cell are regulated by Glucocorticoid Receptor (GR) [27]. 
On hormone binding, activated GR translocates from the cytoplasm to the nucleus as a 
dimer to associate with specific DNA sequences termed glucocorticoid response elements 
(GREs) and acts as a ligand-dependent transcription factor [28]. GR-mediated 
transcriptional activation is modulated by phosphorylation [29]. GRs are highly expressed in 
decidua, chorion, amnion, stromal fibroblasts, vascular smooth muscle cells and endothelial 
cells of human term placentas, with moderate expression in cytotrophoblasts and negligible 
expression in syncytiotrophoblast [30-34]. Because the significance of glucocorticoids to the 
early mammalian embryo is clear and glucocorticoid action within the cell is regulated by 
GR, we investigated GR expression during the course of rat embryogenesis until day 12 of 
gestation. The demonstrated ontogenetic pattern of GR expression indicates the potential 
 
The Effects of Glucocorticoids on Fetal and Placental Development 307 
sites of biological action of the glucocorticoids, providing supportive evidence for its critical 
importance during the course of embryogenesis in rats [35].  
The intracellular enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD) catalyzes the 
interconversion of bioactive glucocorticoids (cortisol and corticosterone) and their inactive 
metabolites (cortisone and 11-dehydrocorticosterone). Thus, it is an important modulator of 
glucocorticoid  bioavailability  in  both  glucocorticoid  and  mineralocorticoid  target organs  
[36]. To date, two 11β-HSD isoenzymes (known as 11β-HSD1 and 11β-HSD2) have been 
identified, characterized and cloned [37]. The conversion of cortisone to active cortisol is 
catalyzed by 11β-HSD1, whereas the metabolism of cortisol to cortisone is mediated via both 
11β-HSD1 and 11β-HSD2 [38]. In placenta, 11β-HSD1 protein is expressed specifically in the 
placental villous endothelial cells, amnion, chorionic and extravillous trophoblasts (EVTs). 
11β-HSD1 expression increases throughout pregnancy in response to progesterone [39]. As 
the placenta differentiates, there is an up-regulation in the expression of 11β-HSD2 enzyme 
that becomes the major placental isoenzyme [40]. 11β-HSD2 protein is localized exclusively 
in the syncytiotrophoblast and invasive extravillous trophoblasts with no expression in the 
chorion or amnion [41-43]. The distinct pattern of 11β-HSD1 and -2 localizations may 
indicate having different physiological functions. In normal pregnancy, maternal 
glucocorticoid levels are markedly higher than those in the fetal circulation. It has been 
stated that the role of placental 11β-HSD is to protect the fetus from adverse effects of 
maternal glucocorticoids. 11β-HSD2 is better suitable for this role because of its location (the 
site of maternal–fetal exchange) and its enzymatic properties (higher affinity for cortisol). 
This enzyme acts as a ‘barrier’ to prevent premature or inappropriate action at 
glucocorticoid-responsive tissues during fetal development [44]. It has been suggested that a 
reduction in the expression or activity of placental 11β-HSD2, by leading to increased 
transplacental passage of active glucocorticoids, reduces fetal growth. 11β-HSD2 knockout 
(11β-HSD2−/−) mice exhibit reduced birth weight and heightened anxiety in adulthood [45]. 
Numerous studies have shown that inhibition of 11β-HSD2 during pregnancy leads to a 
reduction in birth weight and the development of later hypertension and glucose 
intolerance [46-48], as well as programming increased HPA axis activity and anxiety-related 
behaviors [49]. Moreover, placentas from 11β-HSD2 knockout mice fetuses have impaired 
labyrinth zone capillary development accompanied by a decline in vascular endothelial 
growth factor (VEGF)-A mRNA expression and altered transport of nutrients by system A 
amino acid transporter (SNAT) [50]. Furthermore, a correlation between decreased activity 
of 11β-HSD2 in the human placenta and IUGR has been reported [15, 51, 52]. In addition, 
mutations in the HSD11B2 gene in humans, although rare, markedly reduce birth weight 
[53]. It was found that while maternal administration of glucocorticoids caused IUGR, 
glucocorticoid administration directly into the fetal circulation did not restrict fetal growth, 
which suggests that the growth limiting effects of glucocorticoids are mediated via actions 
in the utero-placental unit rather than effects on fetal tissues [54] 
Placental development is a critical determinant of fetal growth and glucocorticoids affect 
growth and development of the fetus indirectly by affecting placental development and 
function. The actions of glucocorticoids on fetal growth are mediated, in part, by changes in 
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the placenta. In sheep, rats, mice and non-human primates, administration of synthetic 
glucocorticoids during late gestation reduces placental weight. In most of these species, the 
effect of glucocorticoids on the placenta is greater than that on the fetus [13]. Glucocorticoids 
have been implicated in the fusion of cytotrophoblast cells to form the syncytiotrophoblast 
and associated with morphological (accelerated apical microvilli formation, nuclear 
maturation, and increase in cell organelle number) and functional (elevated hCG secretion 
and increased 11β-HSD2 mRNA expression) markers of syncytiotrophoblast differentiation. 
These findings suggest that glucocorticoids stimulate syncytiotrophoblast differentiation 
and maturation [55-57].  
Microarray analysis showed that maternal glucocorticoid administration leads to marked 
changes in the gene expression profile in the placenta. Dexamethasone (Dex) caused a 
decrease in expression of genes involved in cell division such as cyclins A2, B1, D2, CDK 2, 
CDK 4 and M-phase protein kinase along with growth-promoting genes such as epidermal 
growth factor receptor, bone morphogenetic protein 4 and insulin-like growth factor-
binding protein 3. In addition, Dex treatment led to down-regulation of genes involved in 
protein biosynthesis, skeletal development, and collagen metabolism. There was also 
decreased expression of genes involved in cell division, DNA replication, chromosome 
segregation, DNA alkylation, nucleotide and nucleoside biosynthesis, microtubule-based 
processes, B-cell activation and differentiation processes, innate immune response, antigen 
processing and presentation, and complement system [58]. Treatment of rats with 
glucocorticoids restricts placental vascular development via inhibition of the VEGF-A and 
peroxisome proliferator-activated receptor γ (PPARγ) which is regulated by VEGF-A 
expression [59, 60]. In addition, in response to glucocorticoid treatment of either the mother 
or fetus, there are changes in the placental handling of certain amino acids such as 
alanine, glutamine and glutamate. However, there have been few studies on the effects of 
glucocorticoids on amino acid transporters in the placenta of any species to date [61, 62]. 
Additionally, glucocorticoids change the production and metabolism of hormones by the 
placenta such as prostaglandins, placental lactogen, leptin, corticotrophin-releasing 
hormone (CRH), estrogens, progesterone and other progestagens [63, 64]. Glucocorticoids 
also alter the placental activity of various enzymes involved in the synthesis and 
inactivation of steroids and thyroid hormones such as 17,20-lyase, 17α-hydroxylase, 
aromatase, renin and endothelial nitric oxide synthase [63].  
2. The effects of glucocorticoids on placental cell cycle 
Glucocorticoids play a fundamental role in pregnancy with effects on decidualization, 
implantation, placental development, fetal brain development, lung maturation and 
parturition but fetal-placental exposure to maternally administered glucocorticoids may 
lead to abnormalities of fetal and placental growth [15, 19, 65]. The mode of action of 
glucocorticoids in placental growth inhibition has not been determined.  
Human placental development is established by trophoblast invasion into the uterine 
endometrium and its vasculature. The resulting changes will facilitate an increase in 
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intervillous blood flow and, hence, the exchange of nutrients and molecules between 
maternal and fetal blood. The transports as well as metabolic and endocrine functions of 
the placenta reside primarily in the floating villi covered by the syncytiotrophoblast, a 
tissue that results from terminal differentiation of underlying villous cytotrophoblasts 
and their subsequent fusion. Anchoring villi establish physical connection of the placenta 
with the decidua predominantly by a subpopulation of cytotrophoblasts known as EVT. 
They accumulate at the tips of the anchoring villi and form cell columns. Both villous 
and extravillous cytotrophoblast subpopulations arise by proliferation and 
differentiation from stem cells located within the cytotrophoblast layer of the chorionic 
villi [66]. 
On the basis of the immunostaining of the Ki67 antigen, a cell cycle regulator with yet 
unknown role, EVTs have been categorized as the proliferative phenotype, which is 
primarily located in the proximal part, and the invasive phenotype that is located mainly in 
the distal part of cell columns [66]. Current understanding assumes that EVT can 
differentiate, thereby acquiring an invasive phenotype, which eventually enables them to 
invade the maternal decidua and spiral arteries. Thus placental development involves 
proliferation and differentiation of the cytotrophoblasts in a manner that is tightly regulated 
in time and space. 
Eukaryotic cell cycle consists of four phases, G1, S, G2 and M. G1 and G2 are preparation 
phases for DNA synthesis (S) and mitosis (M) phases respectively. During G1 and G2 
phases cell growth, doubling of the amount of protein and organelles and preparation for 
the next phase occurs. If the conditions are not appropriate, cells in G1 phase stop cell cycle 
progression and enter into a resting state, known as G0 phase, where they continue 
biological functions but do not go through the rest of the cell cycle. When growth signals are 
received, cells in G0 phase can continue the cycle through the G1 phase [67, 68]. 
The eukaryotic cell cycle is regulated by the coordinated activity of a family of cyclin-
dependent kinases (CDKs). These are positively and negatively regulated by the cyclin and 
CDK inhibitor families [69, 70]. Based on the timing of their appearance in the cell cycle, 
cyclins can be divided into two groups, i.e. the mitotic cyclins A and B and the G1 cyclins of 
the D and E families [71]. Cyclin A promotes both G1/S and G2/M transitions, whereas 
cyclin B1 accumulates in the cytosol during late S phase and G2 and enters the nucleus at 
the onset of mitosis [72]. 
In mammalian cells, there are at least two distinct families of CDK inhibitors: the INK4 and 
the Cip/Kip inhibitors (p21, p27, p57). Both families play regulatory roles during the G1/S 
cell cycle checkpoint [73]. Because of their broader panel of CDKs with which they interact 
[74], the inhibitors of the Cip/Kip family control other checkpoints as well. p21 plays a role 
during the G2/M phase transition [75] and may also mediate S phase [76] and G2 arrest [77]. 
Overall it is correlated with cell cycle arrest before terminal differentiation [78]. Also, p27 
has the capacity to arrest cells in G2 [77]. p57 inhibits cyclin A- and E-associated CDKs and 
therefore regulates G1/S transition and completion of S phase [79] and is primarily 
expressed in terminally differentiated cells [80]. 
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the placenta. In sheep, rats, mice and non-human primates, administration of synthetic 
glucocorticoids during late gestation reduces placental weight. In most of these species, the 
effect of glucocorticoids on the placenta is greater than that on the fetus [13]. Glucocorticoids 
have been implicated in the fusion of cytotrophoblast cells to form the syncytiotrophoblast 
and associated with morphological (accelerated apical microvilli formation, nuclear 
maturation, and increase in cell organelle number) and functional (elevated hCG secretion 
and increased 11β-HSD2 mRNA expression) markers of syncytiotrophoblast differentiation. 
These findings suggest that glucocorticoids stimulate syncytiotrophoblast differentiation 
and maturation [55-57].  
Microarray analysis showed that maternal glucocorticoid administration leads to marked 
changes in the gene expression profile in the placenta. Dexamethasone (Dex) caused a 
decrease in expression of genes involved in cell division such as cyclins A2, B1, D2, CDK 2, 
CDK 4 and M-phase protein kinase along with growth-promoting genes such as epidermal 
growth factor receptor, bone morphogenetic protein 4 and insulin-like growth factor-
binding protein 3. In addition, Dex treatment led to down-regulation of genes involved in 
protein biosynthesis, skeletal development, and collagen metabolism. There was also 
decreased expression of genes involved in cell division, DNA replication, chromosome 
segregation, DNA alkylation, nucleotide and nucleoside biosynthesis, microtubule-based 
processes, B-cell activation and differentiation processes, innate immune response, antigen 
processing and presentation, and complement system [58]. Treatment of rats with 
glucocorticoids restricts placental vascular development via inhibition of the VEGF-A and 
peroxisome proliferator-activated receptor γ (PPARγ) which is regulated by VEGF-A 
expression [59, 60]. In addition, in response to glucocorticoid treatment of either the mother 
or fetus, there are changes in the placental handling of certain amino acids such as 
alanine, glutamine and glutamate. However, there have been few studies on the effects of 
glucocorticoids on amino acid transporters in the placenta of any species to date [61, 62]. 
Additionally, glucocorticoids change the production and metabolism of hormones by the 
placenta such as prostaglandins, placental lactogen, leptin, corticotrophin-releasing 
hormone (CRH), estrogens, progesterone and other progestagens [63, 64]. Glucocorticoids 
also alter the placental activity of various enzymes involved in the synthesis and 
inactivation of steroids and thyroid hormones such as 17,20-lyase, 17α-hydroxylase, 
aromatase, renin and endothelial nitric oxide synthase [63].  
2. The effects of glucocorticoids on placental cell cycle 
Glucocorticoids play a fundamental role in pregnancy with effects on decidualization, 
implantation, placental development, fetal brain development, lung maturation and 
parturition but fetal-placental exposure to maternally administered glucocorticoids may 
lead to abnormalities of fetal and placental growth [15, 19, 65]. The mode of action of 
glucocorticoids in placental growth inhibition has not been determined.  
Human placental development is established by trophoblast invasion into the uterine 
endometrium and its vasculature. The resulting changes will facilitate an increase in 
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intervillous blood flow and, hence, the exchange of nutrients and molecules between 
maternal and fetal blood. The transports as well as metabolic and endocrine functions of 
the placenta reside primarily in the floating villi covered by the syncytiotrophoblast, a 
tissue that results from terminal differentiation of underlying villous cytotrophoblasts 
and their subsequent fusion. Anchoring villi establish physical connection of the placenta 
with the decidua predominantly by a subpopulation of cytotrophoblasts known as EVT. 
They accumulate at the tips of the anchoring villi and form cell columns. Both villous 
and extravillous cytotrophoblast subpopulations arise by proliferation and 
differentiation from stem cells located within the cytotrophoblast layer of the chorionic 
villi [66]. 
On the basis of the immunostaining of the Ki67 antigen, a cell cycle regulator with yet 
unknown role, EVTs have been categorized as the proliferative phenotype, which is 
primarily located in the proximal part, and the invasive phenotype that is located mainly in 
the distal part of cell columns [66]. Current understanding assumes that EVT can 
differentiate, thereby acquiring an invasive phenotype, which eventually enables them to 
invade the maternal decidua and spiral arteries. Thus placental development involves 
proliferation and differentiation of the cytotrophoblasts in a manner that is tightly regulated 
in time and space. 
Eukaryotic cell cycle consists of four phases, G1, S, G2 and M. G1 and G2 are preparation 
phases for DNA synthesis (S) and mitosis (M) phases respectively. During G1 and G2 
phases cell growth, doubling of the amount of protein and organelles and preparation for 
the next phase occurs. If the conditions are not appropriate, cells in G1 phase stop cell cycle 
progression and enter into a resting state, known as G0 phase, where they continue 
biological functions but do not go through the rest of the cell cycle. When growth signals are 
received, cells in G0 phase can continue the cycle through the G1 phase [67, 68]. 
The eukaryotic cell cycle is regulated by the coordinated activity of a family of cyclin-
dependent kinases (CDKs). These are positively and negatively regulated by the cyclin and 
CDK inhibitor families [69, 70]. Based on the timing of their appearance in the cell cycle, 
cyclins can be divided into two groups, i.e. the mitotic cyclins A and B and the G1 cyclins of 
the D and E families [71]. Cyclin A promotes both G1/S and G2/M transitions, whereas 
cyclin B1 accumulates in the cytosol during late S phase and G2 and enters the nucleus at 
the onset of mitosis [72]. 
In mammalian cells, there are at least two distinct families of CDK inhibitors: the INK4 and 
the Cip/Kip inhibitors (p21, p27, p57). Both families play regulatory roles during the G1/S 
cell cycle checkpoint [73]. Because of their broader panel of CDKs with which they interact 
[74], the inhibitors of the Cip/Kip family control other checkpoints as well. p21 plays a role 
during the G2/M phase transition [75] and may also mediate S phase [76] and G2 arrest [77]. 
Overall it is correlated with cell cycle arrest before terminal differentiation [78]. Also, p27 
has the capacity to arrest cells in G2 [77]. p57 inhibits cyclin A- and E-associated CDKs and 
therefore regulates G1/S transition and completion of S phase [79] and is primarily 
expressed in terminally differentiated cells [80]. 
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Despite the importance in understanding the mechanisms controlling proliferation, little is 
known about how cytotrophoblast proliferation is coordinated with differentiation and 
what factors determine whether cytotrophoblast cells divide or differentiate and 
syncytialize. A few studies localized cell cycle regulators that are specifically expressed 
during key transitions and phases [81-83]. 
The hypothesis that the coordinated expression of cell cycle progression and inhibition 
factors will determine whether cytotrophoblasts proliferate or undergo cell cycle arrest or 
cell cycle exit allowing subsequent differentiation was tested by our team. The cell cycle 
promoters cyclin A, cyclin B1, proliferating cell nuclear antigen (PCNA), Ki67 and the cell 
cycle inhibitors p21, p27 and p57 were immunolocalized in tissue sections of first trimester 
pregnancies (weeks 6 and 9-12). Villous cytotrophoblasts were immunolabelled for Ki67 and 
cyclin A but only few were stained with anti-cyclin B1. The syncytiotrophoblast was devoid 
of immunoreactivity for any of the cell cycle progression factors. It expressed especially p21, 
whereas p27 and p57 were predominantly found in villous cytotrophoblasts. PCNA, Ki67, 
cyclin A and cyclin B1 were immunolocalized in proximal and distal EVTs of anchoring villi 
and in EVT which had invaded the upper decidual segments. All EVTs strongly expressed 
p27 and p57, but not p21. These data clearly suggest different functions for p21, p27 and p57 
in placental development with distinct roles for p21 and p57 in syncytiotrophoblast and EVT 
differentiation, respectively. p27 appears to be involved in both the processes. The results 
may also challenge the concept of differential mitotic activity in the proximal and distal 
parts of the first trimester cytotrophoblast cell column, but more functional studies are 
clearly needed. The presence of p27 and p57 in EVT cells, which invade the deciduas deeply, 
may account for the loss of mitogenic potential of these cells [84]. 
Although the architecture of the human and rodent placentas differs, their anatomical structures 
and molecular mechanisms have been compared [85, 86] and analogies drawn between the 
various cell types; furthermore, the molecular mechanisms of placental development are thought 
to be very similar between the two species. Thus, the rodent placenta is increasingly used as a 
model to study mechanisms underlying placental development [85, 87]. 
 
Figure 1. Schematic representation of cell cycle related proteins in rat placenta of our study [88]. 
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We have been used to localize G1 cyclins (D1, D3, E), which are major determinants of 
proliferation, Cip/Kip inhibitors, p53 as a master regulator and proliferating cell nuclear 
antigen in all cell types of the rat term placenta. Schematic representation of cell cycle 
related proteins studied is showed in Figure 1. The proportion of each cell type 
immunolabeled was counted. Cyclin D1 and cyclin D3 were present mostly in cells of the 
fetal aspect of the placenta, whereas the G1/S cyclin E was present only in the spongio- and 
labyrinthine trophoblast populations. Among the Cip/Kip inhibitors, p21 was present only 
in cells of the fetal aspect whereas p27 and p57 were found in all cell types studied. p53 was 
only found in a small proportion of cells with no co-localization of p53 and p21 [88]. 
Schematic representation of our immunohistochemistry results in the rat placenta is showed 
in Figure 2. The data suggest that the cells of the fetal side of the rat placenta still have some 
proliferation potential which is kept in check by expression of the Cip/Kip cell cycle 
inhibitors, whereas cells of the maternal aspect have lost this potential. Apoptosis is only 
marginal in the term rat placenta. In conclusion, proliferation and apoptosis in rat placental 
cells appears controlled mostly by the Cip/Kip inhibitors in late pregnancy. It is still not 
known how coordination mechanisms of proliferation and differentiation are influenced by 
glucocorticoid induced IUGR in the placenta. 
 
Ch: Chorion, LZ: Labyrinth Zone (fetal placenta), JZ: Junctional Zone (maternal placenta) [88]. 
Figure 2. Schematic representation of our immunohistochemistry results in the rat placenta. 
We aimed to investigate the effects of maternally administered synthetic glucocorticoid Dex 
on cell proliferation, cell cycle arrest or apoptosis of placental development. We investigated 
the spatial and temporal immunolocalization of PCNA, Ki67, p27 and p57 in normal and 
Dex-induced IUGR placental development in pregnant rats. PCNA immunolabeling intensity 
in placentas of the control group was statistically significantly higher than that in the Dex-
induced IUGR group placentas on all days in junctional and labyrinth zones (JZ and LZ, 
respectively). We observed decreased Ki67 staining intensity in the labyrinth trophoblasts of 
Dex-induced IUGR placentas compared to controls on day 21. Ki67 immunolabeling intensity 
was higher in the control group than that in the IUGR group placentas on all days in both 
zones except for day 21 in the junctional zone. These differences were statistically significant 
on days 15, 17 and 19 in the junctional zone and on days 13, 15, 17 and 21 in the labyrinth 
zone. Ki67 staining intensity decreased gradually after day 15 in both zones of control and 
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Despite the importance in understanding the mechanisms controlling proliferation, little is 
known about how cytotrophoblast proliferation is coordinated with differentiation and 
what factors determine whether cytotrophoblast cells divide or differentiate and 
syncytialize. A few studies localized cell cycle regulators that are specifically expressed 
during key transitions and phases [81-83]. 
The hypothesis that the coordinated expression of cell cycle progression and inhibition 
factors will determine whether cytotrophoblasts proliferate or undergo cell cycle arrest or 
cell cycle exit allowing subsequent differentiation was tested by our team. The cell cycle 
promoters cyclin A, cyclin B1, proliferating cell nuclear antigen (PCNA), Ki67 and the cell 
cycle inhibitors p21, p27 and p57 were immunolocalized in tissue sections of first trimester 
pregnancies (weeks 6 and 9-12). Villous cytotrophoblasts were immunolabelled for Ki67 and 
cyclin A but only few were stained with anti-cyclin B1. The syncytiotrophoblast was devoid 
of immunoreactivity for any of the cell cycle progression factors. It expressed especially p21, 
whereas p27 and p57 were predominantly found in villous cytotrophoblasts. PCNA, Ki67, 
cyclin A and cyclin B1 were immunolocalized in proximal and distal EVTs of anchoring villi 
and in EVT which had invaded the upper decidual segments. All EVTs strongly expressed 
p27 and p57, but not p21. These data clearly suggest different functions for p21, p27 and p57 
in placental development with distinct roles for p21 and p57 in syncytiotrophoblast and EVT 
differentiation, respectively. p27 appears to be involved in both the processes. The results 
may also challenge the concept of differential mitotic activity in the proximal and distal 
parts of the first trimester cytotrophoblast cell column, but more functional studies are 
clearly needed. The presence of p27 and p57 in EVT cells, which invade the deciduas deeply, 
may account for the loss of mitogenic potential of these cells [84]. 
Although the architecture of the human and rodent placentas differs, their anatomical structures 
and molecular mechanisms have been compared [85, 86] and analogies drawn between the 
various cell types; furthermore, the molecular mechanisms of placental development are thought 
to be very similar between the two species. Thus, the rodent placenta is increasingly used as a 
model to study mechanisms underlying placental development [85, 87]. 
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related proteins studied is showed in Figure 1. The proportion of each cell type 
immunolabeled was counted. Cyclin D1 and cyclin D3 were present mostly in cells of the 
fetal aspect of the placenta, whereas the G1/S cyclin E was present only in the spongio- and 
labyrinthine trophoblast populations. Among the Cip/Kip inhibitors, p21 was present only 
in cells of the fetal aspect whereas p27 and p57 were found in all cell types studied. p53 was 
only found in a small proportion of cells with no co-localization of p53 and p21 [88]. 
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in Figure 2. The data suggest that the cells of the fetal side of the rat placenta still have some 
proliferation potential which is kept in check by expression of the Cip/Kip cell cycle 
inhibitors, whereas cells of the maternal aspect have lost this potential. Apoptosis is only 
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cells appears controlled mostly by the Cip/Kip inhibitors in late pregnancy. It is still not 
known how coordination mechanisms of proliferation and differentiation are influenced by 
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Figure 2. Schematic representation of our immunohistochemistry results in the rat placenta. 
We aimed to investigate the effects of maternally administered synthetic glucocorticoid Dex 
on cell proliferation, cell cycle arrest or apoptosis of placental development. We investigated 
the spatial and temporal immunolocalization of PCNA, Ki67, p27 and p57 in normal and 
Dex-induced IUGR placental development in pregnant rats. PCNA immunolabeling intensity 
in placentas of the control group was statistically significantly higher than that in the Dex-
induced IUGR group placentas on all days in junctional and labyrinth zones (JZ and LZ, 
respectively). We observed decreased Ki67 staining intensity in the labyrinth trophoblasts of 
Dex-induced IUGR placentas compared to controls on day 21. Ki67 immunolabeling intensity 
was higher in the control group than that in the IUGR group placentas on all days in both 
zones except for day 21 in the junctional zone. These differences were statistically significant 
on days 15, 17 and 19 in the junctional zone and on days 13, 15, 17 and 21 in the labyrinth 
zone. Ki67 staining intensity decreased gradually after day 15 in both zones of control and 
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IUGR placentas. Ki67 immunostaining intensities were stronger in the labyrinth zone 
compared to the junctional zone in both groups. Moreover, after day 17, scarcely any Ki67 
immunostaining was obtained in the IUGR placentas in the junctional zone. We found 
stronger p27 immunolabeling intensity in Dex-induced IUGR placentas when compared to 
control placentas in both junctional and labyrinth zones for all gestational days (Table 1) [89]. 
In accordance with this, in another study, it was observed that in the Dex-induced human 
choriocarcinoma JEG-3 cells p27 mRNAs were upregulated [90]. We observed that p57 
immunostaining intensities in Dex-induced IUGR placentas were stronger compared to 
controls in both zones for all gestational days. We found that Dex-induction results in p57 
upregulation in rat placental development [89]. In contrast to our results, p57 was not 
expressed in Dex-induced JEG-3 cells [90]. In another study, we wanted to determine the 
Ser/Thr protein kinase Akt and a MAPK (Mitogen-Activated Protein Kinase) ERK1/2 related 
proliferation and apoptosis mechanisms are influenced by Dex-induced IUGR placentas. 
Thus, we investigated the expression levels and spatio-temporal immunolocalization of Akt, 
p-Akt, ERK1/2 and p-ERK1/2 proteins in normal and Dex treated placental development of 
rats. We found that maternal Dex treatment led to a decrease in ERK1/2 and Akt activation 
during rat placental development together with placental and fetal weight loss. Akt 
activation was significant at junctional zones of the rat placenta, especially at 
spongiotrophoblast cells and giant cells, and reduced after dexamethasone treatment. On the 
other hand, ERK1/2 activation was seen in both junctional and labyrinth zones of the rat 
placentas and was weaker in labyrinth zones of IUGR group placentas. The decrease in 
ERK1/2 and Akt activation may result in cell survival inhibition or apoptosis stimulation. 
Consequently, Dex induced placental and embryonal developmental abnormalities could be 
associated with reduction of Akt and ERK1/2 activation [91]. In another study, decreased 
levels of placental Akt phosphorylation was observed after in utero exposure to Dex [92]. 
Antenatal Dex use is associated with reduction in fetal and placental weight with 
morphological changes in the placenta. Dex-treated mouse placentas showed swollen 
trophoblast cells in both the junctional and labyrinth zones and increased apoptosis of 
trophoblast cells in the junctional zone. Moreover, Dex-treated placentas were hydropic, 
friable and pale [58]. Increasing antenatal corticosteroid exposure was associated with 
villous fibrosis, stromal mineralization, and less frequent villous infarction [93]. In addition, 
treatment with Dex prevented the normal rise in VEGF expression and the associated 
increase in labyrinthine vascularity over the final third of pregnancy. Therefore, Dex 
appears to reduce labyrinth zone growth by preventing the normal development of the fetal 
vasculature within the labyrinth zone [59]. Moreover, microarray analysis showed that Dex 
caused a decrease in expression of genes involved in cell division such as cyclins A2, B1, D2, 
CDK 2, CDK 4 and M-phase protein kinase along with growth-promoting genes such as 
epidermal growth factor receptor, bone morphogenetic protein 4 and insulin-like growth 
factor-binding protein 3 [58]. In addition, 3H-thymidine incorporation assay revealed that 
proliferation of trophoblast cell lines JEG-3 and HTR-8/SV neo and human first-trimester 
primary trophoblasts was time- and dose-dependently inhibited by glucocorticoids [94]. 
Impaired growth in Dex-treated placentas was also characterized by decreased expression of 
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both prolactin-like protein-B and insulin-like growth factor (IGF)-II, particularly in the 
junctional zone of the rat placenta [92]. Dex-treatment increased apoptosis of trophoblast 
cells in mouse and rat placentas. Dex-induced trophoblast apoptosis was mediated through 
activation of caspases 1 and 3 [58, 95]. Apoptosis was also induced in primary cultures of 
third trimester human decidual cells when treated with cortisol, cortisone, or 
dexamethasone [34]. Likewise, Dex was shown to induce both apoptosis and necrosis in 
primary cultures of term human placental trophoblast, in an in vitro model of 
syncytialization and in the SGH-PL4 cell line derived from human extravillous trophoblasts 
by measuring the cytokines TNF-alpha and IFN-gamma using the TUNEL technique, 
Annexin V binding, fluorescence microscopy and ATP/ADP measurements [96]. In another 
study, using a human in vitro term placental explant model, Dex treatment was shown to be 
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Table 1. Immunolabeling intensity changes of PCNA, Ki67, p27 and p57 in the junctional and labyrinth 
zones of placentas of the IUGR group rat placentas compared to control of given gestational day 
(p=<0.05). −, statistically signicantly unchanged; , statistically significantly increased; , statistically 
significantly decreased. 
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IUGR placentas. Ki67 immunostaining intensities were stronger in the labyrinth zone 
compared to the junctional zone in both groups. Moreover, after day 17, scarcely any Ki67 
immunostaining was obtained in the IUGR placentas in the junctional zone. We found 
stronger p27 immunolabeling intensity in Dex-induced IUGR placentas when compared to 
control placentas in both junctional and labyrinth zones for all gestational days (Table 1) [89]. 
In accordance with this, in another study, it was observed that in the Dex-induced human 
choriocarcinoma JEG-3 cells p27 mRNAs were upregulated [90]. We observed that p57 
immunostaining intensities in Dex-induced IUGR placentas were stronger compared to 
controls in both zones for all gestational days. We found that Dex-induction results in p57 
upregulation in rat placental development [89]. In contrast to our results, p57 was not 
expressed in Dex-induced JEG-3 cells [90]. In another study, we wanted to determine the 
Ser/Thr protein kinase Akt and a MAPK (Mitogen-Activated Protein Kinase) ERK1/2 related 
proliferation and apoptosis mechanisms are influenced by Dex-induced IUGR placentas. 
Thus, we investigated the expression levels and spatio-temporal immunolocalization of Akt, 
p-Akt, ERK1/2 and p-ERK1/2 proteins in normal and Dex treated placental development of 
rats. We found that maternal Dex treatment led to a decrease in ERK1/2 and Akt activation 
during rat placental development together with placental and fetal weight loss. Akt 
activation was significant at junctional zones of the rat placenta, especially at 
spongiotrophoblast cells and giant cells, and reduced after dexamethasone treatment. On the 
other hand, ERK1/2 activation was seen in both junctional and labyrinth zones of the rat 
placentas and was weaker in labyrinth zones of IUGR group placentas. The decrease in 
ERK1/2 and Akt activation may result in cell survival inhibition or apoptosis stimulation. 
Consequently, Dex induced placental and embryonal developmental abnormalities could be 
associated with reduction of Akt and ERK1/2 activation [91]. In another study, decreased 
levels of placental Akt phosphorylation was observed after in utero exposure to Dex [92]. 
Antenatal Dex use is associated with reduction in fetal and placental weight with 
morphological changes in the placenta. Dex-treated mouse placentas showed swollen 
trophoblast cells in both the junctional and labyrinth zones and increased apoptosis of 
trophoblast cells in the junctional zone. Moreover, Dex-treated placentas were hydropic, 
friable and pale [58]. Increasing antenatal corticosteroid exposure was associated with 
villous fibrosis, stromal mineralization, and less frequent villous infarction [93]. In addition, 
treatment with Dex prevented the normal rise in VEGF expression and the associated 
increase in labyrinthine vascularity over the final third of pregnancy. Therefore, Dex 
appears to reduce labyrinth zone growth by preventing the normal development of the fetal 
vasculature within the labyrinth zone [59]. Moreover, microarray analysis showed that Dex 
caused a decrease in expression of genes involved in cell division such as cyclins A2, B1, D2, 
CDK 2, CDK 4 and M-phase protein kinase along with growth-promoting genes such as 
epidermal growth factor receptor, bone morphogenetic protein 4 and insulin-like growth 
factor-binding protein 3 [58]. In addition, 3H-thymidine incorporation assay revealed that 
proliferation of trophoblast cell lines JEG-3 and HTR-8/SV neo and human first-trimester 
primary trophoblasts was time- and dose-dependently inhibited by glucocorticoids [94]. 
Impaired growth in Dex-treated placentas was also characterized by decreased expression of 
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both prolactin-like protein-B and insulin-like growth factor (IGF)-II, particularly in the 
junctional zone of the rat placenta [92]. Dex-treatment increased apoptosis of trophoblast 
cells in mouse and rat placentas. Dex-induced trophoblast apoptosis was mediated through 
activation of caspases 1 and 3 [58, 95]. Apoptosis was also induced in primary cultures of 
third trimester human decidual cells when treated with cortisol, cortisone, or 
dexamethasone [34]. Likewise, Dex was shown to induce both apoptosis and necrosis in 
primary cultures of term human placental trophoblast, in an in vitro model of 
syncytialization and in the SGH-PL4 cell line derived from human extravillous trophoblasts 
by measuring the cytokines TNF-alpha and IFN-gamma using the TUNEL technique, 
Annexin V binding, fluorescence microscopy and ATP/ADP measurements [96]. In another 
study, using a human in vitro term placental explant model, Dex treatment was shown to be 
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Table 1. Immunolabeling intensity changes of PCNA, Ki67, p27 and p57 in the junctional and labyrinth 
zones of placentas of the IUGR group rat placentas compared to control of given gestational day 
(p=<0.05). −, statistically signicantly unchanged; , statistically significantly increased; , statistically 
significantly decreased. 
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and increased cell organelle number) and functional (elevated hCG secretion, increased 11β-
HSD2 mRNA expression and reduced cytotrophoblast proliferation markers) of 
syncytiotrophoblast differentiation. These findings suggest that Dex stimulates 
syncytiotrophoblast differentiation and maturation [57]. In another study, BeWo and JEG-3 
choriocarcinoma cell lines used as models for human trophoblast were cultured with another 
synthetic glucocorticoid triamcinolone acetonide (TA). TA altered the number of viable and 
dead cells as well as cyclin B1 expression levels shown by Western blotting and to a lesser 
extent, invasion of BeWo and JEG-3 cell lines determined by Matrigel invasion assay and by 
measuring the secretion (ELISA) of matrix-metalloproteinases (MMP-2, MMP-9) [97].  
3. The effects of glucocorticoids on fetal and placental angiogenesis 
mechanisms 
Angiogenesis is a complex process that may be initiated by a large number of stimuli and 
that is performed through multiple biologic pathways and a variety of molecules. With the 
increased understanding of angiogenesis, it has become clear that many of its pathways are 
parallel and redundant, greatly complicating efforts to interrupt the process. The disruption 
of one pathway most likely does not abolish completely the formation of new blood vessels, 
which may explain the less than perfect clinical results achieved when treating neovascular 
processes with currently available regimens. Combination therapies and drugs that target 
more than one pathway have become more popular and intensively explored. 
Angiogenesis is required for the cyclic processes of endometrial growth, breakdown, and 
repair during the menstrual cycle, and it provides a richly vascularized tissue receptive for 
implantation and placentation [98]. Besides, the formation of new blood vessels is essential 
for organogenesis and successful embryonic and fetal development. 
For many years glucocorticoids have been used in pregnant women for several reasons such 
as risk of premature deliveries or treatment of a variety of medical disorders like bronchial 
asthma, systemic lupus erythematosous etc.. The dosages and types of glucocorticoids 
changes depending on the severity of the symptoms and treatment procedure [99].   
It is reviewed by Hadoka et al. [100] that endogenous GCs contribute to physiological 
angiogenesis mechanisms by regulating the new vessel formation processes. Endothelial 
cells are seem to be a target of glucocorticoid effect as they both express glucocorticoid and 
mineralocorticoid receptors [101, 102]. But overexposure to glucocorticoids during 
pregnancy has adverse effects on placental angiogenesis mechanisms. Therefore these 
steroids should be carefully used in pregnancy.  
Hewitt et al. [59] investigated the impact of increased glucocorticoid exposure on the spatial 
and temporal expression of the endothelial cell-specific mitogen; VEGF and associated 
placental vascularization over the final third of rat pregnancy. They showed that treatment 
with dexamethasone prevented the normal rise in VEGF expression as a LZ specific manner. 
Their data suggest that glucocorticoid induced restriction of fetal and placental growth is 
mediated, in part, via inhibition of placental VEGF expression and associated reduction in 
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placental vascularization. Therefore, dexamethasone appears to reduce LZ growth by 
preventing the normal development of the fetal vasculature within the LZ.  
As it is mentioned in the study above, GCs have adverse effect on placental 
angiogenesis mechanisms. This effect would be related with both angiogenic activity of 
the endothelial cells or maybe related with proliferation or cell survival processes. It 
was reported in a previous study that GCs inhibit tube formation of cultured 
endothelial cells [103] but the molecular mechanisms underlying this effect hasn’t been 
clearly understood [104].  
Recently, Logie et al. [105] reported that GCs do not affect the endothelial cell viability or 
proliferation but tube formation capacity.  This investigation addressed the hypothesis that 
the potent antiangiogenic action of glucocorticoids is due to prevention of tube formation by 
endothelial cells. Cultured human umbilical vein endothelial cells (HUVEC) and aortic 
endothelial cells (HAoEC) were used to determine the influence of glucocorticoids on tube-
like structure (TLS) formation, and on cellular proliferation, viability and migration. 
Dexamethasone or cortisol (at physiological concentrations) inhibited both basal and 
prostaglandinF-2α -induced and VEGF stimulated TLS formation in endothelial cells 
cultured on Matrigel, effects which were blocked with the glucocorticoid receptor antagonist 
RU38486. Glucocorticoids had no effect on endothelial cell viability, migration or 
proliferation. Time-lapse imaging showed that cortisol blocked VEGF-stimulated 
cytoskeletal reorganization and initialization of tube formation. Exposure to glucocorticoids 
reduced the formation of cell-cell contacts rather than increasing degradation of existing 
tubes. They concluded that glucocorticoids interact directly with glucocorticoid receptors on 
vascular endothelial cells (ECs) to inhibit TLS formation. This action, which was conserved 
in ECs from two distinct vascular territories, was due to alterations in cell morphology 
rather than inhibition of EC viability, migration or proliferation. These findings provide 
important insights into the anti angiogenic action of endogenous glucocorticoids in health 
and disease [105]. 
According to the results of an ongoing study of us, Triamcinolone treatment decreased 
VEGF expression in HUVECs. In this study, we tested the hypothesis that IUGR could be 
observed in fetuses as a result of insufficient nutrient transport depending on the 
glucocorticoid effect on placental angiogenesis mechanism that leads to inadequate vessel 
development. HUVECs were cultured at different concentrations (0.5, 5, 50 µmol/L) of the 
synthetic glucocorticoid triamnicinolone acetonide for 48 and 72 hours. After culture, RT-
PCR, ELISA, Western blot and Matrigel experiments were performed. On the other hand, 
dexamethasone was injected to rats during gestation. Placenta and blood samples were 
taken from rats on gestational days 14, 16, 18 and 20.  RT-PCR and Western blot analyses 
were performed on placentas while ELISA test was applied to sera and HUVEC culture 
media. We found that in HUVECs; VEGF, VEGFR1, VEGFR2, Placental Growth Factor 
(PIGF) and Fibroblast Growth Factor (FGF) gene levels on 48 and 72 hours decreased in 50 
mM TA groups compared to control. VEGF protein amount on 48 and 72 hours decreased 
in TA groups compared to control. VEGFR1 protein quantity decreased and VEGFR2 
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and increased cell organelle number) and functional (elevated hCG secretion, increased 11β-
HSD2 mRNA expression and reduced cytotrophoblast proliferation markers) of 
syncytiotrophoblast differentiation. These findings suggest that Dex stimulates 
syncytiotrophoblast differentiation and maturation [57]. In another study, BeWo and JEG-3 
choriocarcinoma cell lines used as models for human trophoblast were cultured with another 
synthetic glucocorticoid triamcinolone acetonide (TA). TA altered the number of viable and 
dead cells as well as cyclin B1 expression levels shown by Western blotting and to a lesser 
extent, invasion of BeWo and JEG-3 cell lines determined by Matrigel invasion assay and by 
measuring the secretion (ELISA) of matrix-metalloproteinases (MMP-2, MMP-9) [97].  
3. The effects of glucocorticoids on fetal and placental angiogenesis 
mechanisms 
Angiogenesis is a complex process that may be initiated by a large number of stimuli and 
that is performed through multiple biologic pathways and a variety of molecules. With the 
increased understanding of angiogenesis, it has become clear that many of its pathways are 
parallel and redundant, greatly complicating efforts to interrupt the process. The disruption 
of one pathway most likely does not abolish completely the formation of new blood vessels, 
which may explain the less than perfect clinical results achieved when treating neovascular 
processes with currently available regimens. Combination therapies and drugs that target 
more than one pathway have become more popular and intensively explored. 
Angiogenesis is required for the cyclic processes of endometrial growth, breakdown, and 
repair during the menstrual cycle, and it provides a richly vascularized tissue receptive for 
implantation and placentation [98]. Besides, the formation of new blood vessels is essential 
for organogenesis and successful embryonic and fetal development. 
For many years glucocorticoids have been used in pregnant women for several reasons such 
as risk of premature deliveries or treatment of a variety of medical disorders like bronchial 
asthma, systemic lupus erythematosous etc.. The dosages and types of glucocorticoids 
changes depending on the severity of the symptoms and treatment procedure [99].   
It is reviewed by Hadoka et al. [100] that endogenous GCs contribute to physiological 
angiogenesis mechanisms by regulating the new vessel formation processes. Endothelial 
cells are seem to be a target of glucocorticoid effect as they both express glucocorticoid and 
mineralocorticoid receptors [101, 102]. But overexposure to glucocorticoids during 
pregnancy has adverse effects on placental angiogenesis mechanisms. Therefore these 
steroids should be carefully used in pregnancy.  
Hewitt et al. [59] investigated the impact of increased glucocorticoid exposure on the spatial 
and temporal expression of the endothelial cell-specific mitogen; VEGF and associated 
placental vascularization over the final third of rat pregnancy. They showed that treatment 
with dexamethasone prevented the normal rise in VEGF expression as a LZ specific manner. 
Their data suggest that glucocorticoid induced restriction of fetal and placental growth is 
mediated, in part, via inhibition of placental VEGF expression and associated reduction in 
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placental vascularization. Therefore, dexamethasone appears to reduce LZ growth by 
preventing the normal development of the fetal vasculature within the LZ.  
As it is mentioned in the study above, GCs have adverse effect on placental 
angiogenesis mechanisms. This effect would be related with both angiogenic activity of 
the endothelial cells or maybe related with proliferation or cell survival processes. It 
was reported in a previous study that GCs inhibit tube formation of cultured 
endothelial cells [103] but the molecular mechanisms underlying this effect hasn’t been 
clearly understood [104].  
Recently, Logie et al. [105] reported that GCs do not affect the endothelial cell viability or 
proliferation but tube formation capacity.  This investigation addressed the hypothesis that 
the potent antiangiogenic action of glucocorticoids is due to prevention of tube formation by 
endothelial cells. Cultured human umbilical vein endothelial cells (HUVEC) and aortic 
endothelial cells (HAoEC) were used to determine the influence of glucocorticoids on tube-
like structure (TLS) formation, and on cellular proliferation, viability and migration. 
Dexamethasone or cortisol (at physiological concentrations) inhibited both basal and 
prostaglandinF-2α -induced and VEGF stimulated TLS formation in endothelial cells 
cultured on Matrigel, effects which were blocked with the glucocorticoid receptor antagonist 
RU38486. Glucocorticoids had no effect on endothelial cell viability, migration or 
proliferation. Time-lapse imaging showed that cortisol blocked VEGF-stimulated 
cytoskeletal reorganization and initialization of tube formation. Exposure to glucocorticoids 
reduced the formation of cell-cell contacts rather than increasing degradation of existing 
tubes. They concluded that glucocorticoids interact directly with glucocorticoid receptors on 
vascular endothelial cells (ECs) to inhibit TLS formation. This action, which was conserved 
in ECs from two distinct vascular territories, was due to alterations in cell morphology 
rather than inhibition of EC viability, migration or proliferation. These findings provide 
important insights into the anti angiogenic action of endogenous glucocorticoids in health 
and disease [105]. 
According to the results of an ongoing study of us, Triamcinolone treatment decreased 
VEGF expression in HUVECs. In this study, we tested the hypothesis that IUGR could be 
observed in fetuses as a result of insufficient nutrient transport depending on the 
glucocorticoid effect on placental angiogenesis mechanism that leads to inadequate vessel 
development. HUVECs were cultured at different concentrations (0.5, 5, 50 µmol/L) of the 
synthetic glucocorticoid triamnicinolone acetonide for 48 and 72 hours. After culture, RT-
PCR, ELISA, Western blot and Matrigel experiments were performed. On the other hand, 
dexamethasone was injected to rats during gestation. Placenta and blood samples were 
taken from rats on gestational days 14, 16, 18 and 20.  RT-PCR and Western blot analyses 
were performed on placentas while ELISA test was applied to sera and HUVEC culture 
media. We found that in HUVECs; VEGF, VEGFR1, VEGFR2, Placental Growth Factor 
(PIGF) and Fibroblast Growth Factor (FGF) gene levels on 48 and 72 hours decreased in 50 
mM TA groups compared to control. VEGF protein amount on 48 and 72 hours decreased 
in TA groups compared to control. VEGFR1 protein quantity decreased and VEGFR2 
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protein quantity increased in a dose- and time-dependent manner. According to ELISA 
results, VEGFR1 secreted by HUVEC cells decreased while VEGFR2 and FGF increased. In 
Matrigel experiments, decreased vessel tube structures were created by HUVEC cells 
exposed for 72 hours to 50 mM TA. The amount of VEGF in Dex treated rat sera 
statistically significantly decreased on days 14, 16 and 20, while there is no difference on 
day 18 compared to control. VEGF protein amount showed a decrease in all gestational 
days of IUGR group compared to control in rat placentas. VEGFR1 decreased in advancing 
pregnancy days of control group while increased in parallel to pregnancy days of IUGR 
group. VEGF and  VEGFR1 gene level was lower at term rat placentas compared to control 
group at gestational day 20. In conclusion our results showed that glucocorticoids had a 
negative effect on angiogenesis mechanism  (Figure 3) via altering the angiogenesis related 
protein and gene expression, and tube formation capacity and angiogenesis related 
proteins in sera  (A.Ozmen, G.Unek, D.K. Korgun, I.Mendilcioğlu and E.T.Korgun 
unpublished). 
 
Figure 3. A possible model for glucocorticoid effect on endothelial cells. In physiological conditions; in 
the case of moderate GC concentrations (left picture), vascular homeostasis is tightly regulated.  VEGF, 
VEGFR1&R2 expression, angiogenic cytokine production, endothelial cell migration, blood flow 
velocity etc… is maintained in a balance in functional endothelial cells. But when GC concentration is 
increased (right picture), endothelial cell are subjected to excess GC. And this GC overexposure results 
with endothelial dysfunction by downregulating VEGF and VEGFR1 expression, upregulating VEGFR2 
expression, altering angiogenic cytokine production and by inhibiting endothelial cell migration etc… 
(vWF: Von Willebrand Factor) 
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In another study of ours, we investigated the effects of glucocorticoids on rat placental 
development depending on the PI3K/Akt and MAPK-ERK1/2 pathways [91]. It was 
observed that, the IUGR group had significantly smaller embryos on day 20 of gestation 
and had smaller placentas on day 14, 16, 18 and 20 compared with control.  Maternal 
dexamethasone treatment led to a significant decrease in Akt activation on day 16, 18, and 
20. Total Akt protein expression was not significantly affected by the treatment. There was 
a significant decrease in ERK1/2 activation on day 18 in IUGR group; on the other hand 
there was a significant increase on day 16. Total ERK1/2 protein expression didn’t show 
any significant difference between groups. We observed that phospho-Akt 
immunolabelings were remarkable in junctional zone in control groups and weaker in 
IUGR groups. Phospho-ERK1/2 immunolabelings were considerable in the junctional and 
labyrinth zones in the control groups and weaker in IUGR groups. We found that ERK1/2 
activity was decreased in the dexamethasone treated IUGR groups. This decrease was 
especially seen in the LZ of the rat placenta. Concerning the importance of Erk1/2 on 
placental vasculature development [106-109], it could be said that the decrease in ERK1/2 
activity might be related with vascular failure and this could result with abnormal 
placental development. Besides it is mentioned in the literature that the PI3K/Akt 
pathway modulates the expression of some angiogenic factors such as nitric oxide and 
angiopoietins. Numerous inhibitors targeting the PI3K/Akt pathway have been 
developed, and these agents have been shown to decrease VEGF secretion and 
angiogenesis. [110]. Therefore, dexamethasone induced decreased Akt phosphorylation 
may negatively affect the placental angiogenesis mechanisms. There are some other 
studies [111, 112] mentioning the effect of GCs on fetal/placental vasculature during 
pregnancy. These studies report that GCs alter the physiological condition of the 
vasculature and leads pathological conditions. Aida et al. [111] determined a significant 
depression of total placental eNOS protein measured by ELISA (betamethasone treated vs 
control) and immunohistochemistry in both syncytiotrophoblast and vascular 
endothelium. In conclusion, maternally administered betamethasone produces a 
consistent decrease in several indices of placental eNOS function that may play a role in 
the altered cardiovascular dynamics and fetal growth retardation produced by 
betamethasone administration in late pregnancy.   
Angiogenesis is tightly regulated by hormones.  Hormones regulate blood vessel growth 
by controlling the production of local chemical mediators, often other hormones, but also 
growth factors, cytokines, enzymes, receptors, adhesion molecules, and metabolic factors. 
As mentioned above, GCs may show their effects directly on endothelial cells or indirectly 
for example by altering cytokine production that may affect placental vasculature. Xu et al. 
2005, [9] studied the effects of GCs on placental cytokine production. Villous explants were 
cultured with increasing concentrations of glucocorticoids (betamethasone and methyl-
prednisolone, 0.0025 mM, 0.25 mM and 25 mM). The dose effect of glucocorticoids on 
cytokine (TNF-α, IL-6 and IL-10) production was examined using ELISA. There was a 
stepwise reduction of TNF-α and IL-6 with increasing doses of betamethasone and methyl-
prednisolone from placentas of women with preeclampsia and normal pregnancy. 
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protein quantity increased in a dose- and time-dependent manner. According to ELISA 
results, VEGFR1 secreted by HUVEC cells decreased while VEGFR2 and FGF increased. In 
Matrigel experiments, decreased vessel tube structures were created by HUVEC cells 
exposed for 72 hours to 50 mM TA. The amount of VEGF in Dex treated rat sera 
statistically significantly decreased on days 14, 16 and 20, while there is no difference on 
day 18 compared to control. VEGF protein amount showed a decrease in all gestational 
days of IUGR group compared to control in rat placentas. VEGFR1 decreased in advancing 
pregnancy days of control group while increased in parallel to pregnancy days of IUGR 
group. VEGF and  VEGFR1 gene level was lower at term rat placentas compared to control 
group at gestational day 20. In conclusion our results showed that glucocorticoids had a 
negative effect on angiogenesis mechanism  (Figure 3) via altering the angiogenesis related 
protein and gene expression, and tube formation capacity and angiogenesis related 
proteins in sera  (A.Ozmen, G.Unek, D.K. Korgun, I.Mendilcioğlu and E.T.Korgun 
unpublished). 
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expression, altering angiogenic cytokine production and by inhibiting endothelial cell migration etc… 
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In another study of ours, we investigated the effects of glucocorticoids on rat placental 
development depending on the PI3K/Akt and MAPK-ERK1/2 pathways [91]. It was 
observed that, the IUGR group had significantly smaller embryos on day 20 of gestation 
and had smaller placentas on day 14, 16, 18 and 20 compared with control.  Maternal 
dexamethasone treatment led to a significant decrease in Akt activation on day 16, 18, and 
20. Total Akt protein expression was not significantly affected by the treatment. There was 
a significant decrease in ERK1/2 activation on day 18 in IUGR group; on the other hand 
there was a significant increase on day 16. Total ERK1/2 protein expression didn’t show 
any significant difference between groups. We observed that phospho-Akt 
immunolabelings were remarkable in junctional zone in control groups and weaker in 
IUGR groups. Phospho-ERK1/2 immunolabelings were considerable in the junctional and 
labyrinth zones in the control groups and weaker in IUGR groups. We found that ERK1/2 
activity was decreased in the dexamethasone treated IUGR groups. This decrease was 
especially seen in the LZ of the rat placenta. Concerning the importance of Erk1/2 on 
placental vasculature development [106-109], it could be said that the decrease in ERK1/2 
activity might be related with vascular failure and this could result with abnormal 
placental development. Besides it is mentioned in the literature that the PI3K/Akt 
pathway modulates the expression of some angiogenic factors such as nitric oxide and 
angiopoietins. Numerous inhibitors targeting the PI3K/Akt pathway have been 
developed, and these agents have been shown to decrease VEGF secretion and 
angiogenesis. [110]. Therefore, dexamethasone induced decreased Akt phosphorylation 
may negatively affect the placental angiogenesis mechanisms. There are some other 
studies [111, 112] mentioning the effect of GCs on fetal/placental vasculature during 
pregnancy. These studies report that GCs alter the physiological condition of the 
vasculature and leads pathological conditions. Aida et al. [111] determined a significant 
depression of total placental eNOS protein measured by ELISA (betamethasone treated vs 
control) and immunohistochemistry in both syncytiotrophoblast and vascular 
endothelium. In conclusion, maternally administered betamethasone produces a 
consistent decrease in several indices of placental eNOS function that may play a role in 
the altered cardiovascular dynamics and fetal growth retardation produced by 
betamethasone administration in late pregnancy.   
Angiogenesis is tightly regulated by hormones.  Hormones regulate blood vessel growth 
by controlling the production of local chemical mediators, often other hormones, but also 
growth factors, cytokines, enzymes, receptors, adhesion molecules, and metabolic factors. 
As mentioned above, GCs may show their effects directly on endothelial cells or indirectly 
for example by altering cytokine production that may affect placental vasculature. Xu et al. 
2005, [9] studied the effects of GCs on placental cytokine production. Villous explants were 
cultured with increasing concentrations of glucocorticoids (betamethasone and methyl-
prednisolone, 0.0025 mM, 0.25 mM and 25 mM). The dose effect of glucocorticoids on 
cytokine (TNF-α, IL-6 and IL-10) production was examined using ELISA. There was a 
stepwise reduction of TNF-α and IL-6 with increasing doses of betamethasone and methyl-
prednisolone from placentas of women with preeclampsia and normal pregnancy. 
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However, IL-10 was not altered in conditioned medium by increasing doses of 
glucocorticoids. In pregnancy, TNF-α can cause direct damage to endothelial cells, increase 
endothelial cell permeability, up-regulate endothelial adhesion molecules (ICAM-1, 
VCAM-1, E-Selectin) and promote vasoconstriction, all of which are identified in the 
pathogenesis of preeclampsia [113]. IL-10 is an immunosuppressive Th2-type cytokine 
which is produced by immune cells including T-cells, monocytes, macrophages, 
granulocytes and NK cells and also trophoblasts. IL-10 has been also shown to be a potent 
inhibitor of Th1 cell proliferation and the production of Th1-type cytokines such as TNF-α 
[114].  
To observe the influence of maternal betamethasone administration for fetal lung 
maturation on the arterial, venous and intracardiac blood flow of the fetus and the uterine 
arteries; twenty-seven women with singleton pregnancies were examined before the first, 
and 30 min and 8, 24, 48 and 72 h after the second of two single doses of 8 mg of 
betamethasone. The blood flow velocity waveforms of the umbilical artery (UA), the middle 
cerebral artery, the uterine arteries, the ductus venosus, the inferior vena cava and the right 
hepatic vein, the pulmonary trunk, the ductus arteriosus and the right and left 
intraventricular inflow of the heart was recorded. The resistance index of the UA showed a 
significant transient decrease 30 min after the second betamethasone dose. The peak systolic 
velocity of the ductus arteriosus increased significantly 30 min after the 2nd dose and then 
returned to non-significant values. No significant change was observed in any of the other 
vessels. So it could be said that Betamethasone causes short-term changes in fetal blood 
flow. However, this effect seems to be mild and reversible and does not appear to 
contraindicate the use of corticosteroids to promote fetal lung maturation [115]. Therefore, it 
could be mentioned that long term dexamethasone usage my result with decreased maternal 
blood velocity which would negatively affect angiogenesis mechanisms as maternal blood 
itself contains angiogenesis related proteins. 
 It is reviewed by Oliver et al. [116] that corticosteroids are believed to act at multiple levels 
of angiogenesis by regulating growth factors, proteases, and blood cell behavior, and have 
shown signicant promise in clinical studies of neovascularization secondary to diabetes, 
age-related macular degeneration (AMD), and ocular histoplasmosis syndrome [117-121]. 
Angiostatic steroids have been proposed to inhibit angiogenesis by altering the capillary 
basement membrane composition, suppressing its dissolution, and inhibiting endothelial 
cell migration, in addition to their capacity of regulating the participation of inammatory 
cells in the neovascular process [122-124]. There is a growing body of evidence that reports 
inhibitive effects of glucocorticoids on angiogenesis mechanisms [105, 125-128] but there is 
limited data about the impact of glucocorticoids on placental angiogenesis mechanisms. 
Glucocorticoid-mediated inhibition of angiogenesis is important in physiology, 
pathophysiology and therapy. However, the mechanisms through which glucocorticoids 
inhibit growth of new blood vessels have not been established. Over-exposure to GCs may 
alter intracellular signaling pathways such as MAPK/ERK1/2 and PI3K/Akt with a 
processes mediated by GR and finally expression of angiogenic proteins could be altered 
(Figure 4). 
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Figure 4. Glucocorticoids might show their effects on angiogenesis mechanisms by altering intracellular 
signal transduction pathways. GCs affect cellular processes via binding Glucocorticoid receptor. MAPK 
and PI3K/Akt (by phosphorylation of several downstream molecules; yellow dots in the picture) 
pathways mediate GC action on placental angiogenesis mechanisms like VEGF, VEGFR1&2 expression 
and endothelial cell cytoskeleton organization etc… (GC; Glucocorticoid, GR; Glucocorticoid Receptor) 
4. The effects of glucocorticoids on placental glucose transporters 
The Glut protein family belongs to the Major Facilitator Superfamily (MFS) of membrane 
transporters [129]. Most Glut proteins catalyze the facilitative (energy-independent) 
bidirectional transfer of their substrates across membranes. Up to now, 14 functional 
mammalian-facilitated hexose carriers (GLUTs) have been characterized by molecular 
cloning [130]. The Glut family members can be grouped into three (Class I, Class II and 
Class III) different classes based on their sequence similarities [131]. The isoforms GLUT1, 3 
and 4 are included in Class I and represent high-affinity transport facilitators.  
The existence of glucose transporters in the placenta have been known for many years. 
GLUT1 protein is present in placental endothelial cells  [132, 133]  and in the basal [132], or 
microvillous membranes of the syncytiotrophoblast  [133-135]. GLUT3 mRNA is distributed 
throughout the cells of villous tissue; GLUT3 protein appears to be expressed only in the 
vascular endothelium and, is not expressed in the syncytiotrophoblast layer of the placenta. 
A strong GLUT4 signal was observed in intravillous stromal cells, appearing to co-localize 
with insulin receptors [136], a discovery which complements the observation of GLUT4 in 
fibroblasts from amnion and chorion [137]. 
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intraventricular inflow of the heart was recorded. The resistance index of the UA showed a 
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velocity of the ductus arteriosus increased significantly 30 min after the 2nd dose and then 
returned to non-significant values. No significant change was observed in any of the other 
vessels. So it could be said that Betamethasone causes short-term changes in fetal blood 
flow. However, this effect seems to be mild and reversible and does not appear to 
contraindicate the use of corticosteroids to promote fetal lung maturation [115]. Therefore, it 
could be mentioned that long term dexamethasone usage my result with decreased maternal 
blood velocity which would negatively affect angiogenesis mechanisms as maternal blood 
itself contains angiogenesis related proteins. 
 It is reviewed by Oliver et al. [116] that corticosteroids are believed to act at multiple levels 
of angiogenesis by regulating growth factors, proteases, and blood cell behavior, and have 
shown signicant promise in clinical studies of neovascularization secondary to diabetes, 
age-related macular degeneration (AMD), and ocular histoplasmosis syndrome [117-121]. 
Angiostatic steroids have been proposed to inhibit angiogenesis by altering the capillary 
basement membrane composition, suppressing its dissolution, and inhibiting endothelial 
cell migration, in addition to their capacity of regulating the participation of inammatory 
cells in the neovascular process [122-124]. There is a growing body of evidence that reports 
inhibitive effects of glucocorticoids on angiogenesis mechanisms [105, 125-128] but there is 
limited data about the impact of glucocorticoids on placental angiogenesis mechanisms. 
Glucocorticoid-mediated inhibition of angiogenesis is important in physiology, 
pathophysiology and therapy. However, the mechanisms through which glucocorticoids 
inhibit growth of new blood vessels have not been established. Over-exposure to GCs may 
alter intracellular signaling pathways such as MAPK/ERK1/2 and PI3K/Akt with a 
processes mediated by GR and finally expression of angiogenic proteins could be altered 
(Figure 4). 
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Figure 4. Glucocorticoids might show their effects on angiogenesis mechanisms by altering intracellular 
signal transduction pathways. GCs affect cellular processes via binding Glucocorticoid receptor. MAPK 
and PI3K/Akt (by phosphorylation of several downstream molecules; yellow dots in the picture) 
pathways mediate GC action on placental angiogenesis mechanisms like VEGF, VEGFR1&2 expression 
and endothelial cell cytoskeleton organization etc… (GC; Glucocorticoid, GR; Glucocorticoid Receptor) 
4. The effects of glucocorticoids on placental glucose transporters 
The Glut protein family belongs to the Major Facilitator Superfamily (MFS) of membrane 
transporters [129]. Most Glut proteins catalyze the facilitative (energy-independent) 
bidirectional transfer of their substrates across membranes. Up to now, 14 functional 
mammalian-facilitated hexose carriers (GLUTs) have been characterized by molecular 
cloning [130]. The Glut family members can be grouped into three (Class I, Class II and 
Class III) different classes based on their sequence similarities [131]. The isoforms GLUT1, 3 
and 4 are included in Class I and represent high-affinity transport facilitators.  
The existence of glucose transporters in the placenta have been known for many years. 
GLUT1 protein is present in placental endothelial cells  [132, 133]  and in the basal [132], or 
microvillous membranes of the syncytiotrophoblast  [133-135]. GLUT3 mRNA is distributed 
throughout the cells of villous tissue; GLUT3 protein appears to be expressed only in the 
vascular endothelium and, is not expressed in the syncytiotrophoblast layer of the placenta. 
A strong GLUT4 signal was observed in intravillous stromal cells, appearing to co-localize 
with insulin receptors [136], a discovery which complements the observation of GLUT4 in 
fibroblasts from amnion and chorion [137]. 
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GLUT proteins’ cell surface expression level, greatly inuences the rate of glucose uptake 
into the cells [131]. Uptake of glucose by the placenta is facilitated primarily by GLUT1 and 
in part by GLUT3 transporters [133, 138-140]. A possible major glucose transfer mechanism 
in the human placental villi may be depicted as follows. Glucose in the maternal 
bloodstream passes the apical microvillous plasma membrane of syncytiotrophoblast cells 
by means of GLUT1. Glucose moves through the cytoplasm of the syncytiotrophoblast by 
simple diffusion and leaves the cytoplasm via GLUT1 in the basal plasma membrane. 
GLUT1 and GLUT3 proteins contribute to the uptake of glucose by placental endothelial 
cells, as well as facilitate the transfer of glucose into and out of the fetal blood vessels in the 
villous core [133, 138-140]. About 25% of glucose entering the placenta is metabolized within 
this tissue; the majority of glucose is passed to the fetus through placental endothelial cells 
[141]. 
Efficient placental (maternal to fetal) transport of glucose is crucial to sustain the normal 
development and survival of the fetus in utero because its own glucose production is 
minimal [142]. The factors regulating transplacental glucose transfer are largely 
unknown.  
In our recent study [143], we showed that Triamcinolone administration at doses of 0.5, 5 
and 50µmol/L, led to a signicant up-regulation of placental GLUT1 and GLUT3 transcripts 
and protein levels in Human Placental Endothelial Cells (HPECs). After several passages, 
the endothelial cells were cultured in the presence or absence (controls) of 0.5, 5 and 
50µmol/L of TA. The lower (0.5 mmol) dose is a concentration in the lower range of doses 
generally used in previous cell culture studies [7] and considered comparable to the doses 
used to promote lung maturation in rats [144]. Other doses (5 and 50 mmol) were used to 
investigate the potentially detrimental effects of glucocorticoid excess. The highest TA dose 
administered to the endothelial cell cultures corresponds to the TA concentration in blood 
resulting after intravenous injection of a dose recommended by the manufacturers for 
therapy in humans. Our Western blot results showed that GC overexposure significantly 
increased placental GLUT1 and GLUT3 protein levels in all experimental groups of HPECs. 
RT-PCR analysis of placental GLUT expressions indicated that both GLUT1 and GLUT3 
mRNA levels were affected by the GC induction. It was supposed that GCs caused an 
increase in placental GLUT proteins and mRNA expression. 
The human placenta is a GC responsive organ consisting of multiple cell types including 
endothelial cells, broblasts and trophoblasts that demonstrate changes in gene 
expression after hormone treatment. However, little is known about the relative 
expression or activity of the Glucocorticoid Receptor among the various placental cell 
types. Previous studies have documented that placental endothelial cells expressed GR 
and Mineralocorticoid Receptor (MR) [101, 102] but the GR regulation of glucose transport 
have not been studied. We found that GR mRNA and protein expression down-regulated 
after 24-h cell culture of HPECs. Our results suggest that GC-mediated down-regulation 
of GR levels occurs through changes in protein and mRNA stability in HPECs after TA 
treatment. The data from the cell culture strengthens the hypothesis that increased GC 
levels specifically modulate GLUT expression via the GR. 
 
The Effects of Glucocorticoids on Fetal and Placental Development 321 
Collectively, we conclude that TA is a potent regulator of HPECs’ GLUT1 and GLUT3 
expression (Figure 5). This effect is mediated by GR. We speculate that GC-induced up-
regulation of the placental glucose transporter systems contributes to the retarded fetal and 
placental growth observed with GC treatment.  
Similarly in a previous study [18], it is reported that exposure to excess glucocorticoids from 
day 15 of gestation modified rodent placental glucose transporter protein expression at day 
21 of gestation in a concentration-dependent manner.  
Dexamethasone treatment from day 15 to day 21 of pregnancy led to fetal 
hypoglycaemia. GLUT1 and GLUT3 protein expression were detectable in the rat 
placenta during late gestation, and dexamethasone treatment from day 15 to day 21 of 
pregnancy significantly decreased placental weight and up-regulated the placental 
protein expression of both glucose transporters during late gestation in a dose-
dependent manner.  
Dexamethasone administration at the lower dose (100µg/kg) led to modest up-regulation of 
placental GLUT1 protein expression, in the absence of any significant change in the protein 
expression of GLUT3. Dexamethasone at the higher dose (200µg/kg) led to significant up-
regulation of the placental expression of both GLUT1 and GLUT3 in rats, with a slightly 
more marked effect on GLUT3 [18]. It is concluded that, depending on the dose 
administered, either maturational glucose transporter isoform switching might be 
accelerated by dexamethasone treatment during late pregnancy or, at a higher dose, 
placental glucose transporter expression would be down-regulated. 
In another study of ours, the glucocorticoid effect on the glucose transporters in the 
diabetic rat placenta was questioned.  It was hypothesized that GCs regulate placental 
glucose transport in many cell types and tissues and depending on this hypothesis the 
relationship between glucose transport and the glucocorticoid metabolism in rat placental 
development of normal and diabetic pregnancy was investigated. The 
immunohistochemical results indicated that GR and GLUT1 are expressed ubiquitously in 
the trophoblast and endothelial cells of the labyrinthine zone. Amounts of GR and GLUT1 
proteins increased towards the end of gestation both in the control and the diabetic 
placenta. However, at days 17 and 19 of gestation, only the placental GR protein was 
significantly increased in the streptozotocin-induced diabetic rats compared to control rats. 
It is mentioned in this study that there might be a relationship between GR and GLUT1 
expressions at the cellular level. GLUT1 does not play a pivotal role in diabetic 
pregnancies. However, placental growth abnormalities during diabetic pregnancy may be 
related with the amount of GR [145].   
It was previously reported by Hahn et al. for the first time, that both GLUT1 and GLUT3 
transcripts and protein were significantly down-regulated in isolated human trophoblast 
cells and in rat placentas by GCs, suggesting regulation at the transcriptional level [7]. 
Hyperglycemia is one of the well known systemic effects following GC treatment. Thus, 
elevated glucose concentrations might have affected placental GLUT expression [146]. 
However, in the rat model, a single injection of TA resulted in only short term 
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GLUT proteins’ cell surface expression level, greatly inuences the rate of glucose uptake 
into the cells [131]. Uptake of glucose by the placenta is facilitated primarily by GLUT1 and 
in part by GLUT3 transporters [133, 138-140]. A possible major glucose transfer mechanism 
in the human placental villi may be depicted as follows. Glucose in the maternal 
bloodstream passes the apical microvillous plasma membrane of syncytiotrophoblast cells 
by means of GLUT1. Glucose moves through the cytoplasm of the syncytiotrophoblast by 
simple diffusion and leaves the cytoplasm via GLUT1 in the basal plasma membrane. 
GLUT1 and GLUT3 proteins contribute to the uptake of glucose by placental endothelial 
cells, as well as facilitate the transfer of glucose into and out of the fetal blood vessels in the 
villous core [133, 138-140]. About 25% of glucose entering the placenta is metabolized within 
this tissue; the majority of glucose is passed to the fetus through placental endothelial cells 
[141]. 
Efficient placental (maternal to fetal) transport of glucose is crucial to sustain the normal 
development and survival of the fetus in utero because its own glucose production is 
minimal [142]. The factors regulating transplacental glucose transfer are largely 
unknown.  
In our recent study [143], we showed that Triamcinolone administration at doses of 0.5, 5 
and 50µmol/L, led to a signicant up-regulation of placental GLUT1 and GLUT3 transcripts 
and protein levels in Human Placental Endothelial Cells (HPECs). After several passages, 
the endothelial cells were cultured in the presence or absence (controls) of 0.5, 5 and 
50µmol/L of TA. The lower (0.5 mmol) dose is a concentration in the lower range of doses 
generally used in previous cell culture studies [7] and considered comparable to the doses 
used to promote lung maturation in rats [144]. Other doses (5 and 50 mmol) were used to 
investigate the potentially detrimental effects of glucocorticoid excess. The highest TA dose 
administered to the endothelial cell cultures corresponds to the TA concentration in blood 
resulting after intravenous injection of a dose recommended by the manufacturers for 
therapy in humans. Our Western blot results showed that GC overexposure significantly 
increased placental GLUT1 and GLUT3 protein levels in all experimental groups of HPECs. 
RT-PCR analysis of placental GLUT expressions indicated that both GLUT1 and GLUT3 
mRNA levels were affected by the GC induction. It was supposed that GCs caused an 
increase in placental GLUT proteins and mRNA expression. 
The human placenta is a GC responsive organ consisting of multiple cell types including 
endothelial cells, broblasts and trophoblasts that demonstrate changes in gene 
expression after hormone treatment. However, little is known about the relative 
expression or activity of the Glucocorticoid Receptor among the various placental cell 
types. Previous studies have documented that placental endothelial cells expressed GR 
and Mineralocorticoid Receptor (MR) [101, 102] but the GR regulation of glucose transport 
have not been studied. We found that GR mRNA and protein expression down-regulated 
after 24-h cell culture of HPECs. Our results suggest that GC-mediated down-regulation 
of GR levels occurs through changes in protein and mRNA stability in HPECs after TA 
treatment. The data from the cell culture strengthens the hypothesis that increased GC 
levels specifically modulate GLUT expression via the GR. 
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Collectively, we conclude that TA is a potent regulator of HPECs’ GLUT1 and GLUT3 
expression (Figure 5). This effect is mediated by GR. We speculate that GC-induced up-
regulation of the placental glucose transporter systems contributes to the retarded fetal and 
placental growth observed with GC treatment.  
Similarly in a previous study [18], it is reported that exposure to excess glucocorticoids from 
day 15 of gestation modified rodent placental glucose transporter protein expression at day 
21 of gestation in a concentration-dependent manner.  
Dexamethasone treatment from day 15 to day 21 of pregnancy led to fetal 
hypoglycaemia. GLUT1 and GLUT3 protein expression were detectable in the rat 
placenta during late gestation, and dexamethasone treatment from day 15 to day 21 of 
pregnancy significantly decreased placental weight and up-regulated the placental 
protein expression of both glucose transporters during late gestation in a dose-
dependent manner.  
Dexamethasone administration at the lower dose (100µg/kg) led to modest up-regulation of 
placental GLUT1 protein expression, in the absence of any significant change in the protein 
expression of GLUT3. Dexamethasone at the higher dose (200µg/kg) led to significant up-
regulation of the placental expression of both GLUT1 and GLUT3 in rats, with a slightly 
more marked effect on GLUT3 [18]. It is concluded that, depending on the dose 
administered, either maturational glucose transporter isoform switching might be 
accelerated by dexamethasone treatment during late pregnancy or, at a higher dose, 
placental glucose transporter expression would be down-regulated. 
In another study of ours, the glucocorticoid effect on the glucose transporters in the 
diabetic rat placenta was questioned.  It was hypothesized that GCs regulate placental 
glucose transport in many cell types and tissues and depending on this hypothesis the 
relationship between glucose transport and the glucocorticoid metabolism in rat placental 
development of normal and diabetic pregnancy was investigated. The 
immunohistochemical results indicated that GR and GLUT1 are expressed ubiquitously in 
the trophoblast and endothelial cells of the labyrinthine zone. Amounts of GR and GLUT1 
proteins increased towards the end of gestation both in the control and the diabetic 
placenta. However, at days 17 and 19 of gestation, only the placental GR protein was 
significantly increased in the streptozotocin-induced diabetic rats compared to control rats. 
It is mentioned in this study that there might be a relationship between GR and GLUT1 
expressions at the cellular level. GLUT1 does not play a pivotal role in diabetic 
pregnancies. However, placental growth abnormalities during diabetic pregnancy may be 
related with the amount of GR [145].   
It was previously reported by Hahn et al. for the first time, that both GLUT1 and GLUT3 
transcripts and protein were significantly down-regulated in isolated human trophoblast 
cells and in rat placentas by GCs, suggesting regulation at the transcriptional level [7]. 
Hyperglycemia is one of the well known systemic effects following GC treatment. Thus, 
elevated glucose concentrations might have affected placental GLUT expression [146]. 
However, in the rat model, a single injection of TA resulted in only short term 
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hyperglycemia, followed by hypoglycemia. This hypoglycemia may be the reason for the 
smaller fetuses and placentas as well as for the markedly reduced weight gain of TA-
treated rats during gestational days 16 and 21.The human trophoblast cells were cultured 
under physiological glucose concentrations, yet their GLUTs were down-regulated similar 
to those in TA-treated rats. Collectively, the investigators concluded that the synthetic GC 
Triamcinolone is a potent regulator of human and rodent placental GLUT1 and GLUT3 
expression. This effect is mediated by the GR. They speculate that GC-induced down-
regulation of the placental glucose transporter systems contributes to the retarded fetal 
and placental growth observed with GC treatment. This would represent a pathogenetic 
mechanism different from that leading to intrauterine growth retardation in the absence 
of GC treatment, in which trophoblast GLUT1 is not altered [134]. However, it is difficult 
to determine the cause and effect relationships, and the growth restriction could occur 
first, followed by an appropriate down-regulation of the transporters so as to match fetal 
size. 
Consistent with this study, it was also reported that GLUT1 and GLUT3 mRNA levels were 
decreased in the dexamethasone treated group in the caruncles of the caw placenta [147]. In 
this study, plasma glucose concentrations of cows carrying a somatic cell clone fetus during 
late pregnancy and GLUT mRNA levels at parturition were examined. Parturition was 
induced by using dexamethasone and some other molecules. Cotyledon and caruncle tissues 
were removed just after parturition and were used for mRNA extraction. In the caruncules 
of the Dex induced parturition group GLUT1 and GLUT3 mRNA levels were decreased 
according to the Clone Pregnancy. 
In another rat model, female pregnant rats were subjected to % 50 food restrictions in order 
to investigate the effect of maternal nutrient on placental GLUTs. In this model fetuses were 
overexposured to glucocorticoids as maternal protein restriction induces it. At day 21 of 
pregnancy plasma corticosterone levels were increased. Correspondingly, placental GLUT3 
protein was decreased, GLUT1 and GLUT4 protein levels were not affected by maternal 
feeding regimen and therefore enhanced corticosterone level [148]. 
Besides placenta, GCs affect glucose transport in a variety of peripheral tissues, such as 
skeletal muscle, adipocytes, and endothelial cells [149-160]. High affinity low capacity GRs 
have been identified in the placenta of various species, including man, rat, and mouse [17, 
35, 161, 162]. This would have important clinical implications, because GC-induced down-
regulation of the placental glucose transport system(s) may contribute to the deleterious 
side-effects of GC treatment during pregnancy, such as the higher incidence of growth-
retarded fetuses [46, 163-165].   
Corticosteroids have also been shown to have major effects on fetal glucose homeostasis 
resulting in long-term persistence of these changes after birth in sheep and rats [166-172]. 
Prenatal corticosteroid exposure of mice resulted in programming of the fetus such that the 
adult progeny exhibited glucose intolerance [170, 171]. In addition, repeated courses of 
maternal corticosteroid administration have been shown to alter fetal glucose homeostasis 
and hepatic enzyme activity in rats [157, 173]. 
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Figure 5. Effect of glucocorticoid overexposure on GLUT1 and GLUT3 expression in placental 
endothelial cells. GCs bind to GR and activate cellular signal transduction pathways. These molecular 
mechanisms remain to be unknown. As a result of GC overexposure GLUT1 and GLUT3 mRNA and 
proteins are increased in placental endothelial cells. Left panel refers possible physiological conditions 
and right panel refers effects of GC overexposure on GLUTs. (GC; Glucocorticoid, GR; Glucocorticoid 
Receptor, GLUT; Glucose Transporter) 
In summary, the effects of glucocorticoids in placental glucose transport mechanisms in not 
fully understood. Further studies are needed to explain this issue. 
5. Conclusion 
Placental and fetal development is effected from glucocorticoids. Physiological 
glucocorticoid concentrations are necessary for healthy implantation, and pregnancy 
processes. On the other hand, glucocorticoid overexposure results with fetal and placental 
defects. Placentas of dexamethasone treated animals are smaller than healthy ones. In IUGR 
group placentas reduced placental proliferation and induced apoptosis seem to be a reason 
for decreased placental weigths. Dexamethasone caused a decrease in expression of genes 
involved in cell division such as cyclins A2, B1, D2, CDK 2, CDK 4 and M-phase protein 
kinase along with growth-promoting genes such as epidermal growth factor receptor. 
Moreover, in IUGR placentas cell cycle promoter proteins PCNA, Ki67 is decreased and cell 
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hyperglycemia, followed by hypoglycemia. This hypoglycemia may be the reason for the 
smaller fetuses and placentas as well as for the markedly reduced weight gain of TA-
treated rats during gestational days 16 and 21.The human trophoblast cells were cultured 
under physiological glucose concentrations, yet their GLUTs were down-regulated similar 
to those in TA-treated rats. Collectively, the investigators concluded that the synthetic GC 
Triamcinolone is a potent regulator of human and rodent placental GLUT1 and GLUT3 
expression. This effect is mediated by the GR. They speculate that GC-induced down-
regulation of the placental glucose transporter systems contributes to the retarded fetal 
and placental growth observed with GC treatment. This would represent a pathogenetic 
mechanism different from that leading to intrauterine growth retardation in the absence 
of GC treatment, in which trophoblast GLUT1 is not altered [134]. However, it is difficult 
to determine the cause and effect relationships, and the growth restriction could occur 
first, followed by an appropriate down-regulation of the transporters so as to match fetal 
size. 
Consistent with this study, it was also reported that GLUT1 and GLUT3 mRNA levels were 
decreased in the dexamethasone treated group in the caruncles of the caw placenta [147]. In 
this study, plasma glucose concentrations of cows carrying a somatic cell clone fetus during 
late pregnancy and GLUT mRNA levels at parturition were examined. Parturition was 
induced by using dexamethasone and some other molecules. Cotyledon and caruncle tissues 
were removed just after parturition and were used for mRNA extraction. In the caruncules 
of the Dex induced parturition group GLUT1 and GLUT3 mRNA levels were decreased 
according to the Clone Pregnancy. 
In another rat model, female pregnant rats were subjected to % 50 food restrictions in order 
to investigate the effect of maternal nutrient on placental GLUTs. In this model fetuses were 
overexposured to glucocorticoids as maternal protein restriction induces it. At day 21 of 
pregnancy plasma corticosterone levels were increased. Correspondingly, placental GLUT3 
protein was decreased, GLUT1 and GLUT4 protein levels were not affected by maternal 
feeding regimen and therefore enhanced corticosterone level [148]. 
Besides placenta, GCs affect glucose transport in a variety of peripheral tissues, such as 
skeletal muscle, adipocytes, and endothelial cells [149-160]. High affinity low capacity GRs 
have been identified in the placenta of various species, including man, rat, and mouse [17, 
35, 161, 162]. This would have important clinical implications, because GC-induced down-
regulation of the placental glucose transport system(s) may contribute to the deleterious 
side-effects of GC treatment during pregnancy, such as the higher incidence of growth-
retarded fetuses [46, 163-165].   
Corticosteroids have also been shown to have major effects on fetal glucose homeostasis 
resulting in long-term persistence of these changes after birth in sheep and rats [166-172]. 
Prenatal corticosteroid exposure of mice resulted in programming of the fetus such that the 
adult progeny exhibited glucose intolerance [170, 171]. In addition, repeated courses of 
maternal corticosteroid administration have been shown to alter fetal glucose homeostasis 
and hepatic enzyme activity in rats [157, 173]. 
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Figure 5. Effect of glucocorticoid overexposure on GLUT1 and GLUT3 expression in placental 
endothelial cells. GCs bind to GR and activate cellular signal transduction pathways. These molecular 
mechanisms remain to be unknown. As a result of GC overexposure GLUT1 and GLUT3 mRNA and 
proteins are increased in placental endothelial cells. Left panel refers possible physiological conditions 
and right panel refers effects of GC overexposure on GLUTs. (GC; Glucocorticoid, GR; Glucocorticoid 
Receptor, GLUT; Glucose Transporter) 
In summary, the effects of glucocorticoids in placental glucose transport mechanisms in not 
fully understood. Further studies are needed to explain this issue. 
5. Conclusion 
Placental and fetal development is effected from glucocorticoids. Physiological 
glucocorticoid concentrations are necessary for healthy implantation, and pregnancy 
processes. On the other hand, glucocorticoid overexposure results with fetal and placental 
defects. Placentas of dexamethasone treated animals are smaller than healthy ones. In IUGR 
group placentas reduced placental proliferation and induced apoptosis seem to be a reason 
for decreased placental weigths. Dexamethasone caused a decrease in expression of genes 
involved in cell division such as cyclins A2, B1, D2, CDK 2, CDK 4 and M-phase protein 
kinase along with growth-promoting genes such as epidermal growth factor receptor. 
Moreover, in IUGR placentas cell cycle promoter proteins PCNA, Ki67 is decreased and cell 
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cycle inhibitor proteins p27 and 57 are increased. Altered MAPK and Akt pathways are also 
unfavorably affected from glucocorticoid treatment. Decreased Akt and MAPK activations 
would result with reduced proliferation and/or induced apoptosis and reduced 
angiogenesis. GCs may affect placental angiogenesis by altering VEGF, VEGFR1 and 
VEGFR2 expression both at protein and gene levels with a direct effect on endothelial cells. 
Besides, without effecting endothelial cell viability and proliferation, GCs may affect 
endothelial cell migration and/or capacity of tube formation. The indirect effects of GCs 
seem to be via altering placental cytokine production processes which have negative effects 
on angiogenesis mechanisms. Another mechanism by which GCs may alter placental 
development is glucose transport mechanisms. It seems that GCs affect Glucose transporters 
via cell type dependent manner. In human endothelial cells GCs will up-regulate GLUT1 
and GLUT3 expression but in trophoblast cells GCs adversely down regulates GLUT1 and 
GLUT3 expression in vitro. 
In summary glucocorticoid overexposure may alter fetal development by altering, in part, 
placental development and function. It is clearly reviewed that placental development, 
proliferation, angiogenesis and glucose transport mechanisms are negatively affected from 
excess maternal glucocorticoid.  
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cycle inhibitor proteins p27 and 57 are increased. Altered MAPK and Akt pathways are also 
unfavorably affected from glucocorticoid treatment. Decreased Akt and MAPK activations 
would result with reduced proliferation and/or induced apoptosis and reduced 
angiogenesis. GCs may affect placental angiogenesis by altering VEGF, VEGFR1 and 
VEGFR2 expression both at protein and gene levels with a direct effect on endothelial cells. 
Besides, without effecting endothelial cell viability and proliferation, GCs may affect 
endothelial cell migration and/or capacity of tube formation. The indirect effects of GCs 
seem to be via altering placental cytokine production processes which have negative effects 
on angiogenesis mechanisms. Another mechanism by which GCs may alter placental 
development is glucose transport mechanisms. It seems that GCs affect Glucose transporters 
via cell type dependent manner. In human endothelial cells GCs will up-regulate GLUT1 
and GLUT3 expression but in trophoblast cells GCs adversely down regulates GLUT1 and 
GLUT3 expression in vitro. 
In summary glucocorticoid overexposure may alter fetal development by altering, in part, 
placental development and function. It is clearly reviewed that placental development, 
proliferation, angiogenesis and glucose transport mechanisms are negatively affected from 
excess maternal glucocorticoid.  
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1. Introduction 
Glucocorticoids are steroid hormones synthesized in the adrenal gland cortex, and most of 
their physiological effects are mediated by the glucocorticoid receptor (GR), that acts as a 
ligand-dependent transcription factor. Coordinate changes in metabolism under 
glucocorticoid influence provide energy that is instantly and selectively available to vital 
organs, an enables them to deal with immediate environmental demands, at the expense of 
anabolic pathways, such as bone formation, reproduction, immunological responses and 
other, that are being blunted or delayed, under glucocorticoid influence [1-3]. 
During fetal development the synthesis of adrenal glucocorticoids precedes the 
establishment of a definitive structure of the gland. In rats, secretion of the main 
glucocorticoid – corticosterone starts as early as on day 13 of development [4] (term=22 
days, short gestation period), while in humans secretion of the main glucocorticoid – cortisol 
starts in the 8th week of pregnancy (term=40 weeks, long gestation period) [5]. 
Glucocorticoid receptor mRNA is present in the tissue derivatives of all three germ layers 
from fetal day 13 onwards, and increases gradually during rat fetal development [6]. 
Human fetal tissues express GR at the gestational age of 6 weeks, meaning that the 
machinery for hormone action is prepared at the early stages of development [5]. These facts 
suggest that endogenous glucocorticoids produced by the fetal adrenal glands have a crucial 
role in fetal growth and the development of individual fetal tissues [7]. In response to the 
prepartum rise in glucocorticoids a wide variety of changes known as “preparation for 
birth” occurs, meaning that the maturational changes in many fetal tissues, essential for 
neonatal survival, are intensified during the last third of gestation. Namely, circulating 
glucocorticoids induce fetal lung maturation and surfactant production, trigger a variety of 
physiological effects on brain cell differentiation and synaptogenesis, stimulate the 
production of hepatic gluconeogenic enzymes, affect pancreatic -cell development and 
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insulin content, influence renal development and affect the maturation of the immune 
system [8-10]. Metabolic, cardiovascular and immune adaptations under glucocorticoid 
influence are fundamental to successfully overcoming birth-related stress and postnatal 
adaptation of the newborn to environmental challenges [11, 12].    
Environmental conditions influence the prevailing nutritional and endocrine status in 
mothers and fetuses. Numerous animal and human studies have shown that adverse 
environmental conditions during pregnancy, such as maternal undernutrition [13, 14], stress 
[15, 16], illness, placental insufficiency [17, 18], as well as prenatal glucocorticoid exposure 
[19, 20] affect fetal development and postnatal outcome. Changes in the maternal 
hypothalamic-pituitary-adrenal (HPA) activity, transplacental diffusion of nutrients, 
hormones and growth factor supply, potently affect the fetal HPA axis influencing 
glucocorticoid output as well as other developing systems [21, 22]. Gestational age, at which 
an insult occurs, its nature and intensity, determines the specific tissue or organ which will 
be affected by the insult. Glucocorticoids are the key mediators between maternal 
environment and the fetus, and as such are involved in adaptations of the fetus to predicted 
postnatal environment. Even transient changes in glucocorticoid levels could have long-
lasting consequences. The outcome might be growth retardation and change in the 
developmental trajectory, in the direction that best suited to the expected environment [23, 
24]. This phenomenon is known as programming. The adaptations caused by suboptimal 
intrauterine conditions are appropriate if the predicted and actual postnatal environments 
match, and lead to survival to reproduce in a deprived environment [25, 26]. If there is a 
mismatch between the environment predicted and the actual environment experienced 
postnatally, adaptations are inappropriate and result in the development of disease like 
hypertension, ischemic heart disease, glucose intolerance, insulin resistance and type 2 
diabetes [27-29].  
In this chapter the latest findings, with clear statements from the literature, as well as own 
results regarding the endocrine mechanisms of intrauterine programming mediated by 
glucocorticoids will be analyzed. The causal relationship between a prenatally programmed 
endocrine axes and their postnatal functioning that affect growth, stress response, 
metabolism and reproduction will be discussed. In order to better understand mechanisms 
of fetal glucocorticoid programming of endocrine axes, special attention will be paid to key 
points of their development.   
2. Development of endocrine axses 
2.1. Development of hipothalamic-pituitary-adrenal axis 
Functional differentiation of anterior pituitary cells is under the control of transcription 
factors and their cofactors. The transcription factors expressed in early pituitary 
development such as Rpx/Hesx1, Ptx1, Ptx2, Lhx3 regulate the formation of Rathke’s pouch 
and maintain the formation of the baseline cellular structure. Signaling between the 
developing hypothalamus and the Rathe's pouch is also involved in the initial formation of 
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pituitary primordia and further differentiation of the pituitary gland. Hypothalamic BMP 4 
and FGF 8 are required for the activation of expression and maintenance of expression of the 
early transcriptional factors in the pouch. The lineage of adrenocorticotropin (ACTH) 
producing cells arises first during organogenesis, and thus represents a separate lineage. 
Pituitary homeobox 1 (Ptx1/Pitx1) was reported as factor for differentiation towards 
proopiomelanocortin (POMC) cells [30]. In the fetal pituitary the first cells that are 
immunopositive for ACTH can be found on fetal day 13 in the pars tuberalis anlage, 
whereas ACTH immunostaining is found 1 day later in the pars distalis [31]. The pars 
intermedia of the fetal rat pituitary is the last part to display ACTH staining [32]. Although 
pituitary precursor cells are influenced by spatial cues and extrinsic signals, for the initiation 
of ACTH synthesis in the fetal pituitary, a certain degree of autonomy exists. Moreover, 
ACTH immunostaining was found in 11-day-old fetal rat pituitary primordia cultured for 4 
days in a serum-free medium, thus without endocrine or neuroendocrine signals [33]. 
Furthermore, ACTH-containing cells were detected in anencephalic human fetuses [34].  
In the next stage of differentiation of ACTH-producing cells, the hypothalamic 
(corticotropin-releasing hormone) CRH control over ACTH cells has an indispensable 
role. In rats, the appearance of hypothalamic CRH-containing neurons occurs in lateral 
hypothalamic areas and in the paraventricular nucleus (PVN) on days 15.5 and 16.5 of 
gestation, respectively, whereas beaded fibers are visible in the external layer of the 
median eminence on day 17.5 of gestation [35]. Expression of CRH is correlated with a 
progressive rise in ACTH in the fetal circulation. A progressive 10-fold increase in ACTH 
concentration occurs in the pars distalis on days 17–20 of gestation [36], which suggests a 
crucial role of the developing hypothalamus. From the 20th day of gestation until term, the 
ACTH concentration remains unchanged. The existence of a mechanism that overcomes 
the negative feedback effect of elevated glucocorticoid levels on POMC gene expression 
during late pregnancy was demonstrated [37]. From that period onwards, ACTH is stored 
in the fetal pituitary gland as a readily releasable pool. Its location near the fenestrated 
capillary network enables momentary depletion of significant amounts of ACTH, and a 
subsequent considerable increase in ACTH concentration in the circulation, if 
physiologically demanded [38].  
The cells of the adrenal cortex arise early in development due to the local proliferation of 
cells from the splanchnic mesoderm. The genes coding the orphan nuclear receptors SF-1 
and DAX-1 control the early fetal adrenal cortex development. Knockout mice for these 
genes manifest adrenal and gonadal agenesis, gonadotropin deficiency and the absence of 
the hypothalamic ventromedial nucleus [39]. The potential for steroid synthesis occurs early, 
in 12-day-old rat fetuses [40]. In the later stages of fetal life, ACTH controls growth and 
development, as well as steroidogenic maturation of the adrenal glands [41]. Histological 
analysis of a near term rat fetal adrenal glands showed that the main part of the gland is 
steroidogenic tissue composed of a zona glomerulosa (ZG) and an inner zone (IZ), while the 
number of migrating chromoblasts is still modest [42]. Both cortical zones are functionally 
competent and able to produce aldosterone and corticosterone in 19-day-old fetuses [43]. 
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insulin content, influence renal development and affect the maturation of the immune 
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pituitary primordia and further differentiation of the pituitary gland. Hypothalamic BMP 4 
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analysis of a near term rat fetal adrenal glands showed that the main part of the gland is 
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number of migrating chromoblasts is still modest [42]. Both cortical zones are functionally 
competent and able to produce aldosterone and corticosterone in 19-day-old fetuses [43]. 
The proliferative activity of adrenocortical cells is most intensive in the outer portion of the 
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glands, in the subcapsular ZG region and outer portion of IZ from where the cells migrated 
centripetally [44]. A balance between proliferation and cell death enables proper functioning 
and integrity of the developing adrenal glands. Programmed cell death appears to occur in 
the inner cortical layers, where many resident macrophages are present [4], as well as in the 
resorption zones and giant cells [45, 46].  
The development of the human adrenal glands exhibits a number of important differences 
in histological organization and steroidogenic activity in relation to species with a short-
term gestation period. The primordium of the human fetal adrenal glands can be recognized 
by 3–4 weeks of gestation, but by the 8th week of embryonic development the adrenal cortex 
is clearly identifiable with its characteristic zonal partitioning [47]. The principal steroids of 
primate fetal adrenal gland, i.e. fetal zone situated in the inner part of the gland, are 
dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). DHEA serves as a substrate 
for placental estrone and estradiol production. Rapid growth of the fetal adrenal cortex, 
especially the fetal zone, with a significant increase in steroidogenic activity begins after 
week 10 of gestation and continues until term [47]. The definitive zone, positioned at the 
peripheral part of the gland, is steroidogenically inert, at last until the second trimester of 
pregnancy. After this period mineralocorticoid production were found, although 
aldosterone synthesis in the fetal adrenals is in poor correlation with plasma rennin activity. 
The transitional zone that becomes distinguishable between fetal and definitive zone at the 
end of the second trimester of pregnancy represents a precursor of the adult zona fasciculata 
(ZF). The expression of enzymes 3β hydroxysteroid dehydrogenase (3βHSD) and 
cytochrome P450 17α-hydroxylase/lyase (CYP17) in the transitional zone enables the 
capacity for cortisol production [48]. In the initial phase, the fetal adrenals begin to produce 
cortisol between weeks 10 and 20 of gestation, possibly utilizing progesterone as a 
precursor. However, de novo synthesis of cortisol from cholesterol is established fairly late in 
gestation, leading to a remarkable increase in cortisol concentrations in the third trimester. 
Immediately after birth, the fetal zone of the adrenal cortex degenerates extensively, 
whereas the ZF matures in the subsequent period. [48]. Although the presence of ACTH is 
established in circulation from week 15 of gestation, cortisol and androgen production by 
the definitive and fetal zone are maximally stimulated by circulating ACTH from 
midgestation [49].  
The functional state of the fetal HPA axis is important for several reasons. Firstly, 
glucocorticoids play a role in the maturation of numerous organs necessary for intrauterine 
development and extrauterine existence. Organ systems involved in reaching metabolic 
homeostasis, stress response and electrolyte balance in outer space are strongly controlled 
by glucocorticoids [50]. Secondly, the fetal HPA negative feedback mechanism begins to 
operate between days 15 and 17 of rat gestation [51]. Thus, near term fetuses are able to 
regulate their own homeostasis and glucocorticoid production in response to different 
maternal stressors [52] and adverse conditions [37]. Finally, the fetal HPA axis activity 
strongly affects the timing of parturition [48]. In a number of species at the end of gestation 
there is an increase in HPA activity, with increased plasma glucocorticoid levels that reflects 
on the placental trophoblast cells, causing enhanced output of prostaglandins [37]. The 
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effects of prostaglandins on the myometrium associated with increased oxytocin activity 
represent an important step in the initiation of birth [50].   
2.1.1. Effects of glucocorticoids during fetal development  
Strictly defined spatial and temporal effects of glucocorticoids are actually determined by 
the previous appearance of the GR. In situ hybridization histochemistry revealed GR gene 
expression in the tissue derivatives of all three germ layers. The facts that intense GR mRNA 
labeling happened just before the final differentional step for each glucocorticoid target 
tissue, and that upon differentiation reduced amounts of GR mRNA were found further 
support the crucial morphogenic role of glucocorticoids during fetal development [6].   
Sufficient glucocorticoid levels are essential for the normal maturation of many parts of CNS 
during the prenatal period. In general, glucocorticoids act on neuronal maturation, 
replication, differentiation, and programmed cell death [8, 12]. In parallel with reducing the 
rate of neuronal replication, glucocorticoids promote the differentiation of central 
noradrenergic, serotonergic and dopaminergic neurons, enhance axonal growth, dendritic 
arborisation and synaptogenesis in a regionally selective manner, and control programmed 
cell death [53, 54].  
Glucocorticoids promote the differentiation of sympathoadrenal precursors, initially 
expressed multiple neuronal markers, into endocrine chromaffin cells in the adrenal gland 
medulla. As sympathoadrenal precursors invade the primordium of the fetal adrenal gland 
and migrate centripetally, they are exposed to adrenal steroids. The initial adrenaline 
synthesis occurs in parallel with a sharp rise in the adrenal tissue and plasma glucocorticoid 
concentrations, and the appearance of GR in the sympathoadrenal precursor cells in 17-day-
old rat fetuses [55]. Thus, glucocorticoids represent an important signal for the induction 
and maintenance of adrenaline synthesis in the adrenal medulla, but initial induction of the 
adrenaline-synthesizing enzyme, phenylethanolamine-N-methyltransferase is rather 
determined by a cell-intrinsic timed process in the chromaffin precursors [56]. 
Glucocorticoids accelerate lung maturation as they speed up the thinning of the double 
capillary loop to form the thin gas exchanging walls of the alveoli. By enhancing the 
production of surfactant by type II pneumocytes, glucocorticoids allow the newborn to 
draw its first breath and enable the start of the breathing process [57].  
In the fetal liver, glucocorticoids promote the activity of the key gluconeogenic enzyme 
systems and hepatic glycogen deposition in preparation for the nutritional transition at 
birth. Inability of the adrenalectomised sheep fetuses to induce glucogenesis during extreme 
circumstances such as maternal undernutrition with reductions in hepatic glycogen content 
was associated with lower circulating concentrations of cortisol [10]. It might be concluded 
that birth-related stress and subsequent environmental challenges trigger glucocorticoid 
actions essentially involved in the activation of fetal glucogenesis and glucose availability 
necessary for maintaining homeostasis after birth. 
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gestation, leading to a remarkable increase in cortisol concentrations in the third trimester. 
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there is an increase in HPA activity, with increased plasma glucocorticoid levels that reflects 
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the previous appearance of the GR. In situ hybridization histochemistry revealed GR gene 
expression in the tissue derivatives of all three germ layers. The facts that intense GR mRNA 
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tissue, and that upon differentiation reduced amounts of GR mRNA were found further 
support the crucial morphogenic role of glucocorticoids during fetal development [6].   
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during the prenatal period. In general, glucocorticoids act on neuronal maturation, 
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cell death [53, 54].  
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expressed multiple neuronal markers, into endocrine chromaffin cells in the adrenal gland 
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and migrate centripetally, they are exposed to adrenal steroids. The initial adrenaline 
synthesis occurs in parallel with a sharp rise in the adrenal tissue and plasma glucocorticoid 
concentrations, and the appearance of GR in the sympathoadrenal precursor cells in 17-day-
old rat fetuses [55]. Thus, glucocorticoids represent an important signal for the induction 
and maintenance of adrenaline synthesis in the adrenal medulla, but initial induction of the 
adrenaline-synthesizing enzyme, phenylethanolamine-N-methyltransferase is rather 
determined by a cell-intrinsic timed process in the chromaffin precursors [56]. 
Glucocorticoids accelerate lung maturation as they speed up the thinning of the double 
capillary loop to form the thin gas exchanging walls of the alveoli. By enhancing the 
production of surfactant by type II pneumocytes, glucocorticoids allow the newborn to 
draw its first breath and enable the start of the breathing process [57].  
In the fetal liver, glucocorticoids promote the activity of the key gluconeogenic enzyme 
systems and hepatic glycogen deposition in preparation for the nutritional transition at 
birth. Inability of the adrenalectomised sheep fetuses to induce glucogenesis during extreme 
circumstances such as maternal undernutrition with reductions in hepatic glycogen content 
was associated with lower circulating concentrations of cortisol [10]. It might be concluded 
that birth-related stress and subsequent environmental challenges trigger glucocorticoid 
actions essentially involved in the activation of fetal glucogenesis and glucose availability 
necessary for maintaining homeostasis after birth. 
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By combining in vitro studies with in vivo investigations in mice lacking the GR in the whole 
organism or in specific pancreatic cell populations, it has been shown that glucocorticoids 
are important hormones in pancreatic development. Acting before insulin expression onset, 
glucocorticoids decreased the differentiation of the embryonic pancreas into β-cells favoring 
acinar cells differentiation. Deletion of the GR in pancreatic precursor cells led to increased 
β-cell mass. Thus, glucocorticoids unable β-cells mass expansion in later stages, by 
modifying the balance of specific transcription factors, mostly Pdx-1 [9]. At birth, as the 
placental source of glucose is lost, tight glycemic control must be established. A prepartum 
rise in glucocorticoid levels in fetal horse and sheep increases pancreatic β cells sensitivity to 
glucose and influences the fetal insulin level, enabling active regulation of the glucose level 
after birth, and thus the transition to enteral supply [10, 22].  
The highest expression of the GR mRNA was identified during early kidney development in 
the developing glomeruli, epithelial cells of the proximal and distal renal tubule, and the 
central collecting duct. Reduction of GR levels in the fully differentiated glomeruli pointed 
out the importance of glucocorticoids during a defined period of establishment of the 
definitive renal structure and function [5].  
Effective thermoregulation in response to cold exposure in the extrauterine environment 
post birth is crucial to prevent hypothermia in newborns. The expression of mitochondrial 
uncoupling protein (UCP), that catalyzes adaptive thermogenesis in mammalian brown 
adipose tissue increases dramatically during the final week of gestation in fetal adipose 
tissue [58]. The late-gestation augment in fetal plasma glucocorticoid levels as well as 
application of synthetic glucocorticoids enhance mitochondrial UCP expression, suggesting 
that glucocorticoids are crucially involved in increasing the thermogenic potential of fetal 
adipose tissue near term [59, 60].  
2.2. Development of the somatotropic axis 
Growth hormone (GH) is secreted from the anterior pituitary gland under the control of 
two hypothalamic hormones: the releasing hormone is growth hormone-releasing 
hormone (GHRH), and the release-inhibiting hormone is somatostatin (SRIH). In addition 
to these two neurohormones, a number of factors such as free fatty acids, acetylcholine, 
amino acids, opiates, glucocorticoids and some neuropeptides also have direct or indirect 
effects on GH release. Most of the metabolic actions of GH are mediated by insulin-like 
growth factor I (IGF-I), which is produced in many different tissues, with most of the 
circulating IGF-I being derived from the liver. IGF-I has anabolic as well as metabolic 
effects in many cell types, acting through autocrine, paracrine and classical endocrine 
mechanisms. IGF signaling has been recognized as one of the major molecular regulators 
of cell growth and proliferation [61]. Moreover, it is generally accepted that GH, by 
controlling important aspects of IGF activity in many tissues and cell types of mammals, 
is able to coordinate somatic growth in a defined spatio-temporal manner at the whole 
body level [62]. IGF signaling, however, not only regulates growth but also affects 
differentiation and may, through epigenetic processes, steer adult cell function as a result 
of particular conditions during postnatal development [63]. 
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In rat, GHRH neurons are detected at the 16th day of fetal development [64], while SRIH 
mRNA in the periventricular nucleus of the hypothalamus is expressed on the 14th fetal 
day [65]. Initial pituitary GH expression is detected on day 15 of gestation using sensitive 
methods such as the reverse transcriptase-polymerase chain reaction (RT-PCR) [66]. In the 
following phase of GH cell development the expression of Pit-1 occurs. Pit-1 is a pituitary-
specific transcriptional factor that mediates cell proliferation and differentiation into 
specific hormone-producing cell types – thyrotropes, somatotropes or lactotropes [67]. 
During this period, the quantity of GH transcripts remains at an extremely low level. A 
marked increase in cell number and GH production occurs between days 18 and 19 of 
fetal development [68]. The expression of the GHRH receptor also occurs on fetal day 19 
in rats [69, 70]. 
It has been considered that pituitary GH promotes and controls fetal development  
and body weight by stimulating the family of hepatic growth factors. Recent 
investigations showed that extrapituitary GH as well as local production of growth factors 
had great paracrine/autocrine influence on fetal developmental processes and 
differentiation. The expression of GH and GH receptor in a wide variety of tissues is 
established before the pituitary gland and circulatory system become functional [71].  
In rats and mice a contribution of the pituitary GH to growth, development and body 
weight has been demonstrated postnatally, during the second week of life [72]. The 
influence of pituitary GH on normal growth and body weight in near-term fetuses, 
immediately after the GH cells become functional, is still difficult to understand and not 
well defined. 
In humans, GH cells are evident at 8 weeks of gestation, with abundant immunoreactive 
cytoplasmic GH expression. Plasma GH concentrations are highest at midgestation and 
thereafter fall until term. The pattern of ontogenesis of plasma GH reflects the progressive 
maturation of hypothalamic–pituitary and forebrain function. The responses of GH to SRIH 
and GHRH are mature at term in human infants [73].   
IGF-1 and IGF-2 mRNA transcripts are present in virtually all fetal tissues [74]. Both IGFs 
are also detected in the fetal circulation from early gestation, but the plasma concentrations 
of IGF-II are 3–10 fold higher than those of IGF-I during late gestation [75]. They are present 
in serum and other extracellular fluids associated with highly specific binding proteins (IGF 
binding proteins (IGFBPs)). In the fetus, IGFs are predominantly complexed with IGFBP-1 
and -2, and the liver is the predominant production site for these IGFBPs [76]. Tissue and 
plasma IGF-II are higher in the fetus than in newborn or adult animals in most species [77]. 
In rodents, IGF-II expression disappears from most tissues except the brain by weaning, 
with the consequence that IGF-II is virtually undetectable in adult plasma [78]. In contrast, 
plasma IGF-I levels increase rapidly after birth, primarily as a result of the onset of GH 
stimulated IGF-I production by the liver [79], since IGF regulation is GH-independent 
during the fetal period [74]. There is, therefore, a shift in IGF predominance from IGF-II 
before birth to IGF-I after birth, which has led to the concept that IGF-II is the IGF primarily 
responsible for fetal growth [80].  
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2.3. Development of hypothalamic-pituitary-thyroid axis 
The development of thyroid-stimulating hormone (TSH) cells in the fetal rat pituitary pars 
distalis is determined by the expression of Pit-1 and TEF transcription factors [67]. 
Differentiation from precursor cells enables detection of TSH cells mRNA on day 15 of 
gestation [81], while immunocytochemically recognized TSH cells can be observed in 16.5- 
to 17.5-day-old fetuses. TSH cells were few in 17.5-day-old rat fetuses, but their number 
increased thereafter, particularly during the 2nd week after birth [68].   
In the rat fetal hypothalamus, thyrotropin-releasing hormone (TRH), which promotes 
prompt synthesis and secretion of anterior pituitary TSH, is first detected on the 16th day of 
gestation [82]. The destruction of paraventricular nuclei (PVN), which contain TRH 
neuronal cell bodies, results in a significant decrease in anterior pituitary TSHβ- and α-
subunit mRNA levels, as well as in serum TSH concentrations [83]. During the fetal period a 
major influence of TSH is to control the morphological and functional maturation of the fetal 
thyroid gland.      
The thyroid gland is derived from the fusion of a medial outpouching from the floor of the 
primitive pharynx and bilateral evaginations of the fourth pharyngeal pouch, giving rise to 
the precursors of follicular (thyroxine-producing cells) and parafollicular (calcitonin-
producing C cells) cells. Coordinate action of numerous transcription factors is involved in 
thyroid morphogenesis. Titf1, Hhex, Pax8 and Foxe1 are expressed in the rat just prior to the 
first appearance of the thyroid diverticulum on fetal day 9.5–10, controlling the 
proliferation, survival and migration of precursor cells [84]. Targeted disruption of Titf1 in 
mice results in total absence of the thyroid tissue, while the lack of Pax8 results in follicle 
agenesis, with the remaining tissue being composed almost exclusively of C-cells [85, 86].  
In rats on fetal day 17 significant growth and rapid functional and structural development 
of the thyroid gland are established. The first appearance of follicles, iodine organification 
and thyroid hormonogenesis occur in parallel with a marked increase of TSH in fetal 
circulation and the expression of TSH receptors (TSHR) in thyroid tissue. Thus, 
upregulation of TSHR gene expression by TSH in fetuses is crucial for further maturation of 
the thyroid [81].    
Deiodinase enzymes provide biologically active triiodothyronine (T3) to developing tissues 
by activating and/or deactivating systemic serum thyroid hormones (TH). Three types of 
iodothyronine deiodinases (D1, D2, D3) have been identified, which differ in tissue 
distribution, substrate specificity and sensitivity to inhibiting compounds [87].  Expression 
of D1 is low through gestation, while D2 and D3 are the major isoforms in the fetus [88]. D2 
is the activating enzyme that catalyzes the removal of one iodide from the outer tyrosine 
ring of thyroxine (T4) and production of active T3. D3 is the inactivating enzyme that 
catalyzes the cleaving of one iodide from the inner tyrosine rings of T4 or T3, thus 
generating reverse T3 (rT3) or T2. Action of D2 and D3 preserves the safe level of T3 in the 
developing brain and the pituitary [87], while the activity of D3 in the utero-placental unit 
protects fetal tissues against high maternal T4 concentrations. Local tissue deiodinase 
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activity is essential for compensation and adaption to potential malfunctions in the fetal 
hypothalamic-pituitary-thyroid (HPT) axis, i.e. in the case of congenital hypothyroidism and 
normal maternal T4, the transfer of the latter, together with increased brain D2 activity, 
protects the fetal brain from T3 deficiency [89]. 
In humans, thyroid gland reaches maturity by the 11th–12th week of gestation, when tiny 
follicle precursors with thyroglobulin in follicular space can be seen and iodine binding is 
detected. In this period both T4 and T3 are measurable in fetal serum [90]. At this stage of 
early development maternal T4 transplacental passage contributes to the fetal hormonal 
status, which is essential for normal early fetal neurogenesis. In the later stages of 
development, if fetal thyroid function is normal, placental TH passage is relatively limited 
due to the presence of D3 [91]. The increase in total T4 and free T4 levels between weeks 18 
and 36 of gestation indicates maturation of the HPT axis function, with the establishment of 
feedback control about midgestation.  
2.4. Development of the endocrine pancreas   
The embryogenesis of pancreas is mediated by a series of transcription factors involved in 
morphogenesis. The expression of Pdx1 has been found early in organ formation, in cells that 
give rise to endocrine and exocrine cells of the mouse neonatal pancreas. In Pdx1 null mice 
pancreas agenesis occurs. The appearance of insulin and glucose transporter GLUT2 is also 
regulated by this transcription factor [92]. Transcription factors Hlxb9 and Isl1 are necessary 
for the initial induction of Pdx1. Hlxb9 is observed during the formation of pancreatic anlage 
and later during the differentiation of β cells. Neurogenin 3 has been identified as the key 
regulator of endocrine development, giving rise to all pancreatic endocrine lineages [93].  
The pancreas arises from a multipotent endodermal cell population that will produce ductal, 
exocrine and endocrine cells [94]. The human fetal pancreas develops during the 5th week of 
gestation, while endocrine cells are identifiable by the 8th or 9th week of gestation. Scattered 
single endocrine cells are recognized to produce insulin (β-cell), glucagon (α-cells), 
somatostatin (δ-cells) and pancreatic polypeptide (PP cells). Clusters of epithelial endocrine 
cells form primitive islets of Langerhans a few weeks later, in parallel with the expression of 
neural adhesion molecule (N-CAM) [95]. The largest expansion of the β-cell mass has been 
shown to take place in the second half of prenatal development, from approximately 20 
weeks in humans. This developmental period is critical to achieve a β-cell mass required to 
ensure proper insulin secretion throughout life. It is thought to result from β-cell neogenesis 
from rapidly dividing undifferentiated progenitor cells [96]. Thereafter, some degree of β-
cell expansion persists at least until adolescence due to β-cell neogenesis, mitosis and 
perhaps to transdifferentiation of α-cells, acinar or ductal cells [97].   
During the development of insulin-expressing cells there is a changing phenotype, from 
progenitor cells to immature β-cells, and finally, to mature adult β-cells. Using gene 
expression and immunohistochemistry, differences among late-embryonic, neonatal, and 
adult β-cells were found in a series of markers with transient expression patterns during the 
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perinatal period. Of these, cytokeratin-19, matrix metalloproteinase-2 and surfactant 
protein-D can be considered as true markers of new and immature β-cells, as their 
expression is transient and not entirely synchronous, but absent in adults [98]. Sympathetic 
innervation and vascularization of islets play important roles in normal islet morphogenesis 
during prenatal life, and have trophic effects on β-cells survival, maturation and insulin 
secretion [99].   
Human and rodent fetal islets are insensitive to glucose, as fetal β-cells do not discriminate 
between different glucose levels, despite adequate insulin reserves. Relative functional 
immaturity in utero was also recorded in response to circulating amino acids, particularly 
leucine, catecholamines and neural stimulation, with regard to the capacity to secrete both 
insulin and glucagon [100]. For blunted capacity for insulin and glucagon secretion several 
causes are proposed. Firstly, during fetal development in mammals glucose homeostasis is 
mainly achieved by the mother because of a constant supply of glucose by placental transfer 
through facilitated diffusion. Secondly, the mechanisms that mediate insulin secretion in 
adults are immature in fetuses, meaning that the production of cAMP is decreased, 
expression of glucose transporter GLUT2 is lower and expression of voltage-gated L-type 
Ca2+ channels is diminished in β-cells [100, 101]. Furthermore, generalized immaturity of the 
metabolic enzyme expression in pancreatic β-cells during the fetal and neonatal period in 
the rat has been recorded. Lower expression levels of the metabolic enzyme genes such as 
malate dehydrogenase, glycerol-3-phosphate dehydrogenase, glutamate oxaloacetate 
transaminase and pyruvate carboxylase were established and confirmed by quantitative 
PCR during fetal development and several weeks after birth than in adults [102]. During 
fetal life GH might be involved in the process of β-cell mass expansion and maturation that 
finally leads to an effective response to hyperglycaemia [103].   
2.5. Development of the hypothalamic-pituitary-gonadal axis 
Reproductive physiology in mammals is centrally regulated through the hypothalamic–
pituitary–gonadal (HPG) axis and depends on gonadotropin-releasing hormone (GnRH). 
GnRH, a decapeptide, is released into the hypophyseal portal vasculature from axon 
terminals at the median eminence and binds to the GnRH receptor (GnRHR), which is 
specifically expressed in gonadotrope cells in the anterior pituitary gland. GnRH signaling 
controls the biosynthesis and release of luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH), which in turn regulate the development and activity of the ovaries and 
testes. LH and FSH, together with TSH, are heterodimeric glycoproteins composed of a 
common α-subunit (αGSU) and a hormone-specific β-subunit (LHβ, FSHβ).  
The crucial maturation events at the hypothalamic–pituitary level are the onset of GnRH 
synthesis, access of GnRH to the hypothalamic–hypophysial circulation, appearance of 
GnRH receptors in the pituitary gonadotropes, and the onset of gonadotropin synthesis and 
secretion. Traces of GnRH in whole rat brain extracts were detected as early as on day 12 of 
gestation, and by the 17th day of gestation immunoreactive GnRH cells within the brain were 
distributed in a pattern similar to that of the adult, projecting neurosecretory axons to the 
median eminence [104].  
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Although gonadotrope is the last cell type in the anterior pituitary to reach maturation with 
the expression of terminal differentiation markers LHβ, FSHβ, and GnRHR, αGSU is the 
first pituitary hormone transcript expressed during development. In mice, it is first detected 
at fetal day 10.5 in the most ventral region of Rathke’s pouch [105]. Gonadotrope specific 
expression of αGSU is regulated by SF1, which plays essential roles at multiple levels of the 
reproductive axis, reviewed in [106]. However, no single transcription factor has been 
demonstrated to be necessary and sufficient for gonadotrope lineage commitment [107]. In 
the rat pituitary, on fetal day 16 rare LHβ were detected by in situ hybridization. Many more 
cells hybridizing LHβ and FSHβ were observed on day 17. At this stage, the fetal pituitary 
gland becomes GnRH responsive [104]. Recently, it has been shown that two types of 
gonadotropes may become responsive to GnRH at different time points during 
development [108].  
In humans, fetal pituitary gonadotropins are secreted as early as at 12 weeks of gestation. 
Marked rises in the pituitary and plasma concentrations of FSH and LH are observed during 
the second trimester of gestation, and significantly higher levels of circulating 
gonadotropins are detected in female than in male fetuses [109]. 
Gonad development is a unique system in which a single rudimentary tissue can be induced 
to form one of two different organs, the ovary or the testis. The gonads originate from the 
thickening of the ventrolateral epithelium along the embryonic mesonephros surface, called 
the genital ridge, and in mice are visible at fetal day 10. Proliferation of these epithelial cells 
gives rise to somatic cells of the gonad. By contrast, the germ cell lineage arises outside the 
urogenital ridge before the formation of gonads. Mouse primordial germ cells (PGCs) are 
specified in the epiblast, and are first detected at about fetal day 7.25 using alkaline 
phosphatase as a marker [110]. PGCs proliferate and migrate through the gut mesentery into 
the urogenital ridge, populating the gonads between the 10th and 11th day of fetal 
development. The exact trigger that initiates PGCs migration to the genital ridge and the 
chemoattractants that are required for the directional movement toward the genital ridge 
are slowly beginning to be understood [111]. 
In mammals, the choice between the male or the female gonad, is initiated by a single gene 
on the Y chromosome, Sry (sex-determining region of the Y chromosome). Sry is expressed 
in the somatic cells of the XY gonad between 10.5 and 12.0 of gestation [112] and encodes a 
putative transcription factor that acts as a genetic switch for male development. The Sry 
protein is expressed in each pre-Sertoli cell during a narrow window of several hours in the 
period of gonadal differentiation, between fetal days 10.5 and 12.5, resulting in up-
regulation of Sox9, the major gene transcriptionally downstream of Sry [113]. If Sry is 
expressed in the rudimentary gonad, either from the Y chromosome or from an ectopic 
transgene, a testis forms [114]. If Sry is not expressed, as in XX individuals or in cases where 
Sry is mutated or deleted, an ovary forms [115]. Based on this, it was believed that the 
presence of Sry actively caused testis development to occur, and that in the absence of Sry 
the ovary developed passively (i.e. the so-called “default” pathway). Recent discoveries 
have now made it clear that early ovarian development is an active process that involves the 
interaction and competition of multiple signaling pathways that specify male or female 
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development. The two alternative sex fates are thought to emerge through the antagonistic 
activities of sex-specific transcription factors in a restricted number of gonadal cells. This 
initial cell fate decision is further expanded by extracellular non-cell-autonomous signals 
that promote one developmental program, while at the same time suppressing the other 
[116]. Studies have identified two secreted factors, Wnt4 and follistatin, which are required 
during early gonad development to repress the aspects of testis differentiation in XX 
gonads, reviewed in [111]. 
By fetal day 13.5, germ cells in XX and XY gonads have taken different developmental  
paths. In XY gonads germ cells undergo mitotic arrest as prospermatogonia, whereas in  
XX gonads the germ cells enter the prophase of the first meiotic division. The fate of  
germ cells is dependent on the somatic environment, and not on the chromosomal sex  
of the germ cells [117]. Thus, signals from adjacent somatic cells must direct the 
differentiation of germ cells in the embryonic gonads, although these signals have not been 
identified. 
The onset of gonadal endocrine activity is very clearly sexually dimorphic. During 
embryogenesis, male differentiation requires the secretion of three testicular hormones. 
Anti-Müllerian hormone (AMH), produced by fetal Sertoli cells, induces regression of the 
Müllerian ducts. Testosterone, produced by Leydig cells, promotes the development of 
Wolffian duct derivatives and masculinization of the external male genitalia. Finally, 
insulin-like 3 (Insl3) mediates transabdominal testicular descent into the scrotum [118]. The 
action of LH and production of testosterone start simultaneously in the rat testis on fetal day 
15.5 [119]. In females, differentiation occurs when the absence of AMH allows development 
of Müllerian structures. The lack of androgens permits degeneration of Wolffian ducts, and 
the absence of Insl3 maintains the gonads in the abdomen. In the ovary, the responsiveness 
to LH appears postnatally at the end of the first week of life [120] concomitantly with the 
onset of steroidogenesis [121]. Functional FSH receptors can be detected some days earlier in 
the perinatal rat ovary, at the age of 4–5 days [122]. 
Steroid hormones play a crucial role in fetal gonadal development and ovarian cell 
wellbeing. Estrogen action is needed for normal ovarian development, follicle survival and 
the regulation of female reproduction. The role of estrogens in female sexual development 
has been demonstrated in many studies utilizing mice lacking functional estrogen receptors 
or estrogen-converting enzymes [123, 124]. However, the developmental role of estrogens in 
human fetal ovaries is not well known. In contrast, testicular hormones are crucial for 
testicular formation and function, i.e. induction and maintenance of the male phenotype at 
all stages of development. 
In humans ovarian development starts at around the 5th week of gestation, when primordial 
germ cells migrate into the undifferentiated gonad. Thereafter, the germ cells undergo 
multiple mitotic divisions, and the number of oogonia reaches its peak by the 20th week of 
development. At this time about 7–8 million germ cells are present in the ovary [125]. 
Simultaneously with mitotic divisions, starting around the fetal age of 11–12 weeks, 
primordial germ cells begin to enter meiosis [126]. After the 10th week of gestation granulosa 
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cell precursors start to form, and at 24 weeks of development almost all oocytes are 
enveloped in a primordial follicle structure [127]. The human fetus is exposed to high 
concentrations of maternal and placental estrogens, and estrogens are produced in several 
fetal tissues [128, 129]. However, minimal amounts of fetal circulating estrogens are 
produced in the fetal ovarian follicles [109].  
In the human male at 7 weeks of gestation, the presence of germ cells in the embryonic 
gonadal ridge and of coelomic epithelial cells that give rise to Sertoli cells was observed. 
This was followed by the appearance of Sertoli cells in the testicular tubules and of Leydig 
cells at 9 weeks, and also by the appearance of vascular endothelial cells and peritubular 
myoid cells at 12 weeks [130]. The production of testosterone peaks at around 11 or 12 to 14 
weeks of gestation, as determined by measurements in the testis and fetal blood [131]. 
Between weeks 12 and 20, serum testosterone levels in the male fetus are from 3- to 8-fold 
higher than in the female [132]. 
3. Programming 
During development, there are critical periods in the course of which a system or an organ 
has to mature. The critical periods are defined by the epochs of rapid cell division within an 
organ, and different organs develop at different rates and different times. At these critical 
periods organs are especially vulnerable to challenges such as decreased oxygenation, 
nutrient supply, and altered hormone exposure. If adverse conditions are experienced in the 
window of vulnerability, then the trajectory of development of the responding organ may 
be changed in ways that result in persistent malfunction. The concepts of “nutritional 
programming”, “fetal programming”, “fetal origins of adult disease”, “developmental 
origins of health and disease”, “developmental induction”, and “developmental 
programming” [26, 133-135] imply that some stimulus or an insult at these critical, restricted 
periods in development has long-lasting consequences, setting in train a series of events that 
culminate in the adult onset of disordered function, while the same environmental stimulus 
outside that critical period induces only reversible changes. The concept evolved from 
human epidemiological studies that have shown that impaired intrauterine growth is 
associated with an increased incidence of metabolic, cardiovascular and other diseases in 
later life. Low birth weight, in particular, has been linked to hypertension, glucose 
intolerance, insulin resistance, type 2 diabetes, dyslipidaemia, obesity and reproductive 
disorders in the adult (Figure 1) [133]. The Dutch famine, a unique “natural experiment” 
with a well-defined period of food shortage in an otherwise well-nourished population, has 
shown that maternal undernutrition during gestation compromises health in later life, and 
that these long-term effects depend on its timing during gestation [136]. Intrauterine growth 
retardation (IUGR) and/or delays in attaining motor, verbal and social skills were recorded 
in the offspring of mothers exposed to the influence of a large variety of ”stresses” such as 
loud, unanticipated noise (as experienced by people living under the flight paths of busy 
airports) and living in a country preparing for and ultimately going to war (e.g. the six-day 
Israeli war) [137]. 
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development. The two alternative sex fates are thought to emerge through the antagonistic 
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cell precursors start to form, and at 24 weeks of development almost all oocytes are 
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later life. Low birth weight, in particular, has been linked to hypertension, glucose 
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Figure 1. Maternal undernutrition or stress increase maternal glucocoticoid levels and decrease the rate 
of their inactivation by 11ß-HSD2 in the placenta that results in fetal glucocorticoid overexposure. The 
synthetic glucocorticoids pass through the enzymatic placental barrier and reach the fetal circulation. 
Consequences of fetal glucocorticoid overexposure are growth retardation and programming of 
endocrine axes with long-term effects. HPA-hypothalamic-pituitary-adrenal axis; GC-glucocorticoids; 
synGC-synthetic glucocorticoids; 11ß-HSD2-11ß-hydroxysteroid dehydrogenase type 2; SA-
somatotropic axis; HPT-hypothalamic-pituitary-thyroid axis; EP-endocrine pancreas; HPG- 
hypothalamic-pituitary-gonadal axis.      
The concept of programming has been tested experimentally in numerous species using a 
wide range of experimental approaches to impair fetal growth. Some of the most commonly 
used experimental models are maternal undernutrition (calorie restriction, protein 
deprivation, iron deficiency), placental insufficiency and exposure to glucocorticoids that 
includes maternal stress, maternal treatment with synthetic glucocorticoids and inhibition of 
placental 11ß-hydroxysteroid dehydrogenase (11β-HSD2) (Figure 1) [138].  
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Majority of these experimental models ultimately result in fetal glucocorticoid 
overexposure, since they mediate the programming effects of nutritional and other 
environmental challenges during pregnancy [139]. Maternal low-protein diet and placental 
11β-HSD2 deficiency cause fetal growth restriction via distinct pathways but with a 
common component: overexposure of fetoplacental tissues to glucocorticoids. Whatever the 
source, glucocorticoids play an important role in the regulation of fetal growth, and through 
this in developmental programming [140]. Glucocorticoids are growth inhibitory and affect 
development of all the tissues and organ systems that are at increased risk of adult 
pathophysiology when fetal growth is impaired [11]. Glucocorticoids signal adverse 
intrauterine conditions and adapt fetal development to ensure the maximum chances of 
survival both in utero and at birth. They act at cellular and molecular levels to induce 
changes in tissue growth and differentiation by direct and indirect mechanisms. At the 
cellular level, glucocorticoid exposure in utero alters receptors, enzymes, ion channels and 
transporters in a wide range of different cell types during late gestation. They also change 
the expression of various growth factors, cytoarchitectural proteins, binding proteins and 
components of the intracellular signaling pathways [139]. These changes will influence the 
basal functioning of the cell and its responses to endocrine, metabolic and other stimuli, 
with consequences for its size, proliferation rate and terminal differentiation. In addition to 
these direct effects, glucocorticoids can act indirectly on tissue proliferation and 
differentiation through changes in the cellular secretion of proteins, hormones, growth 
factors and metabolites [139]. 
Another major mechanism by which glucocorticoids act on physiological systems is through 
changes in hormone bioavailability. They alter the production and secretion by the placenta 
and fetal endocrine glands of a number of hormones, such as estrogen, insulin, gastrin, 
neuropeptide Y, angiotensin II, T3, noradrenaline and adrenaline. They also regulate 
hormone receptor densities and the activities of several enzymes involved in activating and 
inactivating hormones in the fetal tissues. One of the recently proposed mechanisms of 
programming, with particular emphasis on glucocorticoids, is epigenetic programming. 
Glucocorticoids act as epigenetic signals that allow transgenerational transmission of non-
genomic factors important in developing the optimal phenotype for survival to reproductive 
age [141]. The consequences of fetal overexposure to either endogenous or exogenous 
glucocorticoids lead to hypertension, glucose intolerance, insulin resistance, and 
abnormalities in the HPA function after birth [142].  
3.1. Placental 11ß-hydroxysteroid dehydrogenase 2 (11ß-HSD2)  
Transcriptional activation of GR is known to be determined by intracellular glucocorticoid 
availability that is regulated by two distinct isoforms of the enzyme 11ß-HSD. These 
enzymes control the first critical step for GR activation and target gene expression, while the 
process has been termed pre-receptor ligand control [2]. 11ß-HSD1 is NADPH-dependent 
with reductase activity, converting cortisone to the bioactive cortisol in the human, and 11-
dehydrocorticosterone to corticosterone in the rat. 11ß-HSD2 is NAD-dependent and 
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Majority of these experimental models ultimately result in fetal glucocorticoid 
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common component: overexposure of fetoplacental tissues to glucocorticoids. Whatever the 
source, glucocorticoids play an important role in the regulation of fetal growth, and through 
this in developmental programming [140]. Glucocorticoids are growth inhibitory and affect 
development of all the tissues and organ systems that are at increased risk of adult 
pathophysiology when fetal growth is impaired [11]. Glucocorticoids signal adverse 
intrauterine conditions and adapt fetal development to ensure the maximum chances of 
survival both in utero and at birth. They act at cellular and molecular levels to induce 
changes in tissue growth and differentiation by direct and indirect mechanisms. At the 
cellular level, glucocorticoid exposure in utero alters receptors, enzymes, ion channels and 
transporters in a wide range of different cell types during late gestation. They also change 
the expression of various growth factors, cytoarchitectural proteins, binding proteins and 
components of the intracellular signaling pathways [139]. These changes will influence the 
basal functioning of the cell and its responses to endocrine, metabolic and other stimuli, 
with consequences for its size, proliferation rate and terminal differentiation. In addition to 
these direct effects, glucocorticoids can act indirectly on tissue proliferation and 
differentiation through changes in the cellular secretion of proteins, hormones, growth 
factors and metabolites [139]. 
Another major mechanism by which glucocorticoids act on physiological systems is through 
changes in hormone bioavailability. They alter the production and secretion by the placenta 
and fetal endocrine glands of a number of hormones, such as estrogen, insulin, gastrin, 
neuropeptide Y, angiotensin II, T3, noradrenaline and adrenaline. They also regulate 
hormone receptor densities and the activities of several enzymes involved in activating and 
inactivating hormones in the fetal tissues. One of the recently proposed mechanisms of 
programming, with particular emphasis on glucocorticoids, is epigenetic programming. 
Glucocorticoids act as epigenetic signals that allow transgenerational transmission of non-
genomic factors important in developing the optimal phenotype for survival to reproductive 
age [141]. The consequences of fetal overexposure to either endogenous or exogenous 
glucocorticoids lead to hypertension, glucose intolerance, insulin resistance, and 
abnormalities in the HPA function after birth [142].  
3.1. Placental 11ß-hydroxysteroid dehydrogenase 2 (11ß-HSD2)  
Transcriptional activation of GR is known to be determined by intracellular glucocorticoid 
availability that is regulated by two distinct isoforms of the enzyme 11ß-HSD. These 
enzymes control the first critical step for GR activation and target gene expression, while the 
process has been termed pre-receptor ligand control [2]. 11ß-HSD1 is NADPH-dependent 
with reductase activity, converting cortisone to the bioactive cortisol in the human, and 11-
dehydrocorticosterone to corticosterone in the rat. 11ß-HSD2 is NAD-dependent and 
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catalyzes the rapid metabolism of cortisol and corticosterone to inactive 11-keto forms, 
cortisone and 11-dehydrocorticosterone, respectively [143]. These enzyme systems function 
in most fetal gucocorticoid sensitive tissues modulating ligand access to GR. This is 
especially important for mineralocorticoid sensitive tissues. In the developing kidney, for 
example, in the presence of 11ß-HSD2, cortisol was efficiently metabolised to inert cortisone, 
which does not bind to receptors allowing aldosterone action. As a consequence, sodium 
retention, potassium loss and hypertension are prevented [5]. 
11ß-HSD2 is highly expressed in the placenta, in the syncytiotrophoblast in humans, and in 
the labyrinthine zone in rodents, i.e. at the interface between maternal and fetal circulations. 
Besides the mentioned function, it has an additional role in the placenta: it selectively 
regulates passage of glucocorticoids from the mother to the fetus, since highly lipophilic 
glucocorticoid molecules are able to pass freely across the placenta [144, 145]. As 
glucocorticoid levels are significantly lower in the fetus than in the mother, the 11ß-HSD2 
placental enzymatic barrier prevents most of the maternal glucocorticoids from reaching the 
fetus, protecting the very sensitive fetal tissues from high glucocortivoid levels during 
development. Although 11ß-HSD2 limits fetal exposure to maternal glucocorticoids, a 
certain amount avoids enzymatic inactivation and reaches the fetus [146]. 11ß-HSD2 
maintains a gradient of glucocorticoids from the maternal to the fetal circulation, although 
its magnitude varies between species. There is a positive correlation between the materno-
fetal gradient and the activity of placental 11ß-HSD2 [139].    
Reduced 11ß-HSD2 placental activity results in higher levels of glucocorticoids reaching the 
fetus, which induces growth retardation and program later disease susceptibility (Figure 1). 
In rats the lowest placental 11ß-HSD2 activity caused the highest fetal exposure to maternal 
glucocorticoids is seen in the smallest fetuses with the largest placenta [146]. In addition, 
low levels of 11ß-HSD2 placental activity decrease birth weight in humans, and can lead to 
adult hypertension [143]. Furthermore, in 11ß-HSD2 knockout mice fetal weight is 
significantly reduced in relation to wild type controls, as a consequence, not only of the 
increased fetal exposure to maternal glucocorticoids, but also altered placental function, i.e. 
decreased transport of nutrients. Thus, absence of 11β-HSD2 compromises not only fetal but 
also placental growth, function and morphology, representing an additional mechanism of 
fetal programming [147]. Since maternal glucocorticoid levels are significantly higher then 
those in the fetus, even modest perturbations of the placental 11β-HSD2 levels or activity 
can have a profound impact on fetal glucocorticoid exposure [148]. Inhibition of 11β-HSD2 
activity by the application of carbenoxolone to gravid females, a potent inhibitor of 11β-
HSD2, reduces birth weight in rats and elevates blood pressure in the adult rat offspring. 
These effects require the presence of maternal adrenal products, since carbenoxolone given 
to adrenalectomized pregnant rats had no effect on birth weight or blood pressure [149].  
Placental 11ß-HSD2 can be avoided by the application of synthetic glucocorticoids. It has 
been demonstrated that treatment of pregnant rats with dexamethasone and betamethasone, 
synthetic glucocorticoids that are poorly metabolized by the enzyme, results in reduced 
birth weight, higher activity of the HPA axis and elevated blood pressure in the adult 
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offspring (Figure 1) [143]. Synthetic glucocorticoids have been shown to up-regulate the 
activity of 11ß-HSD2, and, hence, amplify the placental barrier for physiological 
glucocorticoids [150]. 
It can be concluded that fetuses are protected from environmental perturbations by an 
enzymatic placental barrier that, by regulating fetal exposure to maternal glucocorticoids, 
crucially determines foeto-placental growth. Its deficiency causes programming effects in 
the offspring.  
3.2. Stress during pregnancy and maternal undernutrition 
Exposure to stress during pregnancy has been associated with offspring behavior, 
morphology, physiology, and immunology [151]. Although the mechanisms by which 
stress during pregnancy can influence the development of the offspring are not entirely 
known, elevation of the maternal glucocorticoid levels after stress exposure could be the 
first step in early life programming that predisposes individuals to several illnesses and 
psychiatric disorders. Maternal exposure to alcohol, repeated restraint stress, electric tail 
shocks, and undernutrition during pregnancy induced a corticosterone increase [152, 153]. 
In the offspring of these mothers growth retardation with altered function of the HPA axis 
and glucocorticoid responses under stress challenge, hyperglycemia and other 
dysfunctions related to type 2 diabetes, as well as hypertension were established (Figure 
1) [14, 15, 153].   
Adrenalectomy, as a blockade of the maternal stress-induced corticosterone secretion, 
suppresses the changes established in the offspring of prenatally stressed dams. The 
effects of repeated restraint stress during pregnancy on the offspring HPA axis activity 
and hippocampal mineralocorticoid receptor (MR) level are suppressed by 
adrenalectomy, while the administration of corticosterone to adrenalectomised mothers 
reinstates the effects induced by prenatal stress [153]. Furthermore, a pharmacological 
blockade of the maternal glucocorticoid synthesis with metyrapone also prevented 
hypertension, which is induced by fetal exposure to maternal low-protein diet [154]. 
Adrenalectomy carried out during pregnancy (without stress exposure), although it 
causes the opposite result in relation to stress exposure due to circulating corticosterone 
levels, also affects offspring development. Maternal adrenalectomy performed during 
gestation results in a compensatory increase in fetal corticosterone levels [152], decreases 
body weight in both male and female offspring, while the HPA axis shows a sex-specific 
pattern of vulnerability. In females, a dramatic increase in hypothalamic CRH and GR 
mRNA levels was established on day 14 [155]. All this together points out that  
highly regulated maternal glucocorticoids are indispensable during normal fetal 
development.   
Various types of stress applied during gestation cause a broad spectrum of effects in the 
offspring at any age. Effects of prenatal stress caused by the restraining of pregnant rats 
influence the development of fetal hypothalamic PVN neurons in a duration-dependent 
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offspring (Figure 1) [143]. Synthetic glucocorticoids have been shown to up-regulate the 
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1) [14, 15, 153].   
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and hippocampal mineralocorticoid receptor (MR) level are suppressed by 
adrenalectomy, while the administration of corticosterone to adrenalectomised mothers 
reinstates the effects induced by prenatal stress [153]. Furthermore, a pharmacological 
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Adrenalectomy carried out during pregnancy (without stress exposure), although it 
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gestation results in a compensatory increase in fetal corticosterone levels [152], decreases 
body weight in both male and female offspring, while the HPA axis shows a sex-specific 
pattern of vulnerability. In females, a dramatic increase in hypothalamic CRH and GR 
mRNA levels was established on day 14 [155]. All this together points out that  
highly regulated maternal glucocorticoids are indispensable during normal fetal 
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Various types of stress applied during gestation cause a broad spectrum of effects in the 
offspring at any age. Effects of prenatal stress caused by the restraining of pregnant rats 
influence the development of fetal hypothalamic PVN neurons in a duration-dependent 
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manner. Long-lasting stress causes neurotoxic changes of the fetal PVN neurons, including 
CRH neurons that showed significantly shorter total length of the neuronal processes and an 
increased number of apoptotic cells. On the contrary, short-lasting stress facilitates the 
development of these fetal PVN neurons that showed enhanced CRH messenger RNA 
expression, while the varicosities of CRH-containing axons at the median eminence revealed 
more mature morphology. A greater degree of neuronal differentiation, as manifested by an 
increase in both the number of branch points and the total length of the processes from the 
cell body, was also demonstrated [156]. 
Chronic maternal restraint stress during late gestation decreases placental 11β-HSD2 
expression and activity, and reduces body weight in rat fetuses at term. These alterations 
were associated with reduced pancreatic β-cell mass, growth hormone level, and decreased 
glucose concentration in fetal plasma [18]. Other results established hyperglycaemia, 
glucose intolerance and decreased basal leptin levels in prenatally stressed aged male rats as 
dysfunctions related to type 2 diabetes mellitus [15]. These data suggest that maternal stress 
and later dysfunctions such as type 2 diabetes could be linked to the restricted fetal growth 
and the adverse glucocorticoid environment in utero as the consequences of decreased 
placental 11β-HSD2 expression.  
Observations from animal and human studies have linked maternal nutritional status and 
fetal growth retardation with the programming of hypertension and coronary heart disease 
in later life [27]. In the ewe, undernutrition in early pregnancy leads to placental 
enlargements, as adaptation to extract more nutrients. There is a correlation between 
placental weight and systolic blood pressure in adults that tends to rise as placental weight 
increases [157]. Mild protein restriction during pregnancy attenuates placental 11β-HSD2 
expression which leads to overexposure of the fetus to maternal glucocorticoids (Figure 1) 
[14, 143]. Intrauterine growth retardation and disturbed development of the HPA axis 
appear as an outcome [15]. In addition, in the adult offspring subjected to maternal 
undernutrition during pregnancy persistently elevated expression of GR and decreased 
expression of 11β-HSD2 in the kidney, liver and brain mediated tissue-specific increases in 
glucocorticoid action. These changes represent potentially important mechanisms 
contributing to the programming of hypertension in utero [158].    
As presented, it has so far been established that certain types of stress affect the reduction 
of placental 11β-HSD2 expression in rats, suggesting that the fetus and placenta are 
exposed to excessive amounts of glucocorticoids. Thus, deficiency of the placental barrier 
to maternal glucocorticoids may represent a common pathway between the maternal 
environment and feto-placental programming of later disease [12, 18]. Secondly, 
disturbances in placental growth and function, as a consequence of maternal stress 
exposure, decrease fetal nutrient supply and may further contribute to suboptimal fetal 
growth [14, 145]. Both changes, i.e. the reduced maternal glucocorticoid inactivation and 
decreased nutritional supply reflect on the HPA axis activity in fetuses and offspring, 
although the HPA axis response is differentially affected by the gestational stress 
procedure (Figure 1) [151]. Thus, the fetal HPA axis is a possible primary target and is 
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intricately involved in early life disturbance caused by maternal stress exposure with far-
reaching physiological consequences. 
3.3. Antenatal glucocorticoid therapy       
Because glucocorticoids have potent influence on maturation of fetal lung and other 
tissues they have been used for more than 40 years in human pregnancies at risk of 
preterm delivery. Use of antenatal corticosteroid therapy reduced the complications 
associated with preterm delivery such as neonatal respiratory distress syndrome (RSD), 
periventricular hemorrhage, necrotizing enterocolitis and, most importantly, neonatal 
mortality [159]. According to the National Institute of Health [160] all fetuses between the 
24th and 34th week of gestation at risk of preterm delivery should be considered as 
candidates for the beneficial effects of antenatal glucocorticoid treatment. The 
recommended treatment consists of two doses of 12 mg betamethasone given 24 h apart, 
or alternative regimen of four doses of 6 mg dexamethasone given 12 h apart [161]. 
However, antenatal glucocorticoid therapy may produce growth retardation, affective 
and cognitive disturbances as well as other disorders in children and adults [162], thus the 
question of the relative risk and benefit of repetitive courses of prenatal glucocorticoid 
administration is still open (Figure 1).      
Furthermore, the effects of prenatal glucocorticoid administration in cases of congenital 
adrenal hyperplasia (CAH) that must begin early in the first trimester to be effective in 
preventing female genital ambiguity are not completely known. CAH is an inherited 
disease in which a disordered steroidogenic enzyme P450C21 diverts adrenal steroid 
synthesis away from cortisol toward androgen. As a consequence girls are masculinized, 
because the adrenal glands secrete large amounts of androgens during prenatal 
development. Dexamethasone treatment should be introduced very early in pregnancy, 
before the seventh week of gestation, with the aim to increase fetal glucocorticoid 
concentrations, thus suppressing the elevated ACTH level that drives adrenal androgen 
production [146, 163]. 
In obstetric practice different synthetic glucocorticoids are used: dexamethasone, 
betamethasone, or prednisolone. Synthetic glucocorticoids are slightly different from their 
endogenous equivalents in chemical structure. Dexamethasone and bethamethasone both 
have the additional 9α-fluoro groups, and 16β- or 16α-methyl groups, respectively [164]. 
Prednisolone differs from cortisol by a 1-dehydro configuration (Figure 2). The choice of 
the concrete drug use will depend on its biological half-life, which represents the time that 
passes until one half of the initial drug concentration has disappeared from the blood [165]. 
Physiological and synthetic glucocorticoids have been divided into short-, medium- and 
long-acting substances dependent on the duration of measurable biological half-life [165]. 
Cortisol belongs to the short-acting category with the biological half-life of 8–12 h, 
prednisolone belongs to the medium-acting category with the half-life of 12–36 h, while 
dexamethasone and betamethasone have long-acting properties, ranging between 36 and 54 
h [165].   
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Figure 2. The structural formulas of natural (cortisol, cortocosterone) and synthetic glucocorticoids. 
The biological activity of glucocorticoids is partly determined by the rate and selectivity of 
protein binding, because only the unbound glucocorticoids fraction is biologically active. 
Gayrard et al. [166] have found that the plasma free cortisol concentrations (6% to 14%), 
corticosteroid-binding globulin (CBG)-bound (67% to 87%) and albumin-bound (7% to 19%) 
concentrations are similar within species. Cortisol binding decreases as its concentration 
increases [167]. In human plasma, betamethasone and dexamethasone bind predominantly 
to albumin, which has high capacity but low affinity for ligating, while both steroids bind 
only marginally to CBG [167]. Dexamethasone displays higher protein affinity than 
betamethasone. The potency of glucocorticoids in a biological system also depends on its 
affinity for its receptor. Genomic potency of betamethasone was reported to be moderately 
higher than that of dexamethasone, while both steroids have a 25-fold higher affinity to the 
GR than cortisol [168]. 
4. Programming of endocrine axes 
4.1. Programming of the fetal hypothalamic-pituitary-adrenal axis  
The HPA axis is particularly sensitive to glucocorticoid levels. Fetal exposure to excessive 
glucocorticoids, natural or synthetic, can occur via a number of mechanisms including 
maternal stress, undernutrition as well as maternal antenatal treatment. As previously 
noted, synthetic glucocorticoids such as dexamethasone and betamethasone pass easily 
through the placental barrier avoiding the placental enzyme 11β-HSD2 [7], while maternal 
stress and undernutrition affect the same enzyme, resulting in increased fetal exposure to 
maternal glucocorticoids [18]. As the increased fetal exposure to glucocorticoids occurs 
during a critical period of the HPA axis development, when its control is just setting up, 
permanent alterations in the basal and stress induced HPA axis activity and regulation 
occur in the offspring, and sustain throughout life. Crucial changes that underlie the 
programming of the HPA axis will be presented below. Additionally, disturbances of the 
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complex maturational process such as HPA axis development that have far-reaching 
immediate and delayed physiological effects will be discussed later.     
The hippocampus represents a major inhibitory input to the HPA axis function. This is the 
point where glucocorticoid feedback, via GR an MR in the hippocampus and GR in the 
hypothalamic PVN and anterior pituitary, inhibits further HPA activity [169]. Thus, the 
balance between GR and MR in the hippocampus is an important factor in determining the 
HPA axis feedback sensitivity. Prenatal dexamethasone exposure alters GR and MR 
expression in the developing limbic system of guinea pig fetuses in both a region-specific 
and a sex-specific manner. After a single dexamethasone dose, female fetuses exhibited a 
significant increase in MR and GR mRNA levels in the CA1 and CA2 regions of the 
hippocampus and MR mRNA in the dentate gyrus [170]. Other results showed that multiple 
dexamethasone administration during pregnancy led to a marked increase in hippocampal 
GR and MR mRNA levels in male fetuses [171]. In mice, a single course of dexamethasone 
transiently reduced MR mRNA expression in the fetal hippocampus [172]. In addition, 
prenatal stress, or dexamethasone exposure are implicated in the development of rat 
hippocampal GR and MR in the offspring. In rat offspring exposed to glucocorticoid excess 
during late pregnancy permanently attenuated GR and MR mRNA expression in specific 
hippocampal regions reduced sensitivity to glucocorticoids [173]. The administration of 
betamethasone to pregnant sheep resulted in significant increases in MR and 11-βHSD2 
gene expression in adult animals, reflecting a possible role for the locally produced 
glucocorticoids within the hippocampus, and the potential for long term alterations in HPA 
function [20].  
At the level of the hypothalamic PVN, significantly decreased amounts of CRH mRNA were 
seen in male fetuses and female offspring after treatment of guinea pig mothers with 
dexamethasone or betamethasone, supporting the idea that synthetic glucocorticoids enter 
the fetal brain and inhibit central drive to the fetal HPA axis [171]. In addition, it has been 
shown that prenatal dexamethasone treatment induces a clear delay in increment of CRH in 
the external zone of the median eminence [174]. Morphometric analyses of rat PVN 
neurosecretory cells at eight distinct subdivisions indicate that dexamethasone given to 
pregnant dams causes significant changes in PVN neurosecretory cells in 20-day-old fetuses 
as well as in neonatal offspring. Significantly decreased neurosecretory cell nuclei volume 
and number in PVN, due to decreased proliferative activity, were found at the levels were 
parvocellular neurons are present, i.e. where CRH neurons are dominant [175, 176]. On the 
other hand, removal of maternal adrenals at day 16 of gestation significantly affected the 
size of neurosecretory cells in different subgroups of fetal PVN. These effects persisted 
during the neonatal period [177], confirming that prenatal glucocorticoid exposure alters the 
development and function of prenatal and neonatal PVN.  
Prenatal glucocorticoid application alters the monoaminergic transmitter systems involved 
in the regulation of GR expression in the brain. Significant differences in the turnovers of 
serotonin, dopamine and noradrenaline contents between the weeks 3 and 14 of life were 
found in a wide area in the rat brain [54]. Thus, developmental alterations of 
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function [20].  
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seen in male fetuses and female offspring after treatment of guinea pig mothers with 
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the fetal brain and inhibit central drive to the fetal HPA axis [171]. In addition, it has been 
shown that prenatal dexamethasone treatment induces a clear delay in increment of CRH in 
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other hand, removal of maternal adrenals at day 16 of gestation significantly affected the 
size of neurosecretory cells in different subgroups of fetal PVN. These effects persisted 
during the neonatal period [177], confirming that prenatal glucocorticoid exposure alters the 
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monoaminergic neurons, that represent major modulators of the HPA axis function, 
influence endocrine response in the adult offspring. The data suggest that key targets for 
programming include GR gene expression and the CRH system [178]. 
Antenatal treatment with synthetic glucocorticoids affects pituitary development and the 
differentiation of hormone-producing cell types during the fetal period as well as after birth. 
A significant reduction in fetal ACTH cell volume and number was demonstrated in 19 and 
21-day-old fetuses after multiple prenatal dexamethasone administration (Figure 3) [38, 42]. 
Dexamethasone decreased the rate of division of both immature cells and the existing fetal 
ACTH in the period when its proliferation was most intensive, on day 19 of fetal 
development [179], thus leaving long lasting consequences. Multiple dexamethasone 
exposure during pregnancy affects the ultrastructure of ACTH cells, which in the Golgi 
complex show much lower presence of specific granules as well as dilation of the 
endoplasmatic reticulum [180]. Decreased morphometric parameters of the ACTH cells and 
their changed ultrastructure resulted in significantly reduced plasma ACTH levels in fetuses 
and neonatal offspring after multiple dexamethasone administration during pregnancy [180, 
181]. On the contrary, a single dose of dexamethasone, given to pregnant rats on day 16 of 
gestation, suppressed the synthetic activity of fetal ACTH cells, but in the early neonatal 
period this suppression was followed by stimulation of ACTH secretion and increased 
circulating ACTH levels [182]. Other results showed that following antenatal exposure to 
synthetic glucocorticoids in juvenile males POMC mRNA and CRH receptor mRNA on the 
pituitary level were increased [183].     
 
 
Figure 3. a) Intensive immunopositivity of ACTH cells located near the capillary network is 
characteristic for 21-day-old fetus. b) Decreased size, immunopositivity and number of ACTH cells in 
21-day-old fetuses after maternal dexamethasone administration. Bar - 25 m. 
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After maternal glucocorticoid exposure the absence of peaks in ACTH blood concentration 
in near term (19-day-old) fetuses reduces ACTH-trophic support and reflects on the adrenal 
glands structure and functional activity [42]. Administration of a single or multiple 
dexamethasone dose to pregnant rats induced a significant decrease in adrenal glands 
weight, volume of whole adrenal glands, as well as average volume and total number of 
cells in near term fetuses and neonatal rat offspring, a consequence of the decreased 
proliferative activity of adrenocortical cells [45, 46]. Interestingly, in 19-day-old fetuses the 
proliferative activity of adrenocortical cells that is most intensive in the outer portion of the 
fetal adrenal glands is markedly reduced in ZG. The proliferation rate of adrenocortical cells 
in IZ was not affected by prenatal dexamethasone application [42], suggesting that different 
sensitivity and/or responses of the proliferating cells in ZG and the outer portion of IZ to 
external stimuli could be a possible mechanism for the formation and maintenance of the 
zonal structure of the adrenal cortex [184].  
In the rat adrenal glands of fetuses and pups of dexamethasone treated dams, during during 
the early neonatal period adrenocortical cells in various stages of degeneration were 
abundant, especially near the central part of the gland where zona reticularis (ZR) begins to 
differentiate. Resorption zones with lymphocytic infiltrations and presence of macrophages 




Figure 4. a) Zona glomerulosa (ZG) with numerous dividing cells (→), inner zone (IZ) with 
lymphocytes (black arrowheads), cellular interspaces, and centrally positioned group of chromoblasts 
(CH) are seen in adrenal gland of 21-day-old fetus. b) Decreased number of proliferating cells (→) in the 
adrenal gland of 21-day-old fetuses from gravid females treated with dexamethasone. Infiltration of 
lymphocytes (black arrowheads) and giant cells (white arrowheads) are indications of intensive tissue 
remodeling. Bar - 100 m. 
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structure is affected by prenatal glucocorticoid exposure (Figure 4) [45, 46]. In the juvenile 
period, decreased expression of steroidogenic enzyme CYP17 after antenatal exposure to 
synthetic glucocorticoids has been established, reflecting the persistence of the adrenal 
glands functional changes [183]. 
The influence of a single dexamethasone treatment given to gravid females resulted in  
the decreased volume of adrenal medulla and the number of chromaffin cells that persisted 
during the fetal and neonatal period. Decreased proliferation of chromaffin cells during  
the fetal and early neonatal period was followed by significantly higher values in relation to 
controls during the second neonatal week, indicating the capacity of the adrenal  
gland medulla to recover [185]. Multiple dexamethasone doses applied during pregnancy 
exert a more potent inhibitory effect. A reduced number of chromaffin cells and significantly 
decreased adrenaline content in the adrenals were seen in 14-day-old neonatal  
offspring [181].  
As pointed out, the consequences of fetal glucocorticoid exposure occur at the level  
of central regulation, pituitary ACTH cells and the adrenal gland, causing programming 
effects on HPA axis function in later life. In offspring HPA axis activity may be changed  
in different directions under basal conditions and after stress challenge [186].  
Permanently elevated basal plasma glucocorticoid levels [178, 187], greater glucocorticoid 
response to stress [54] as well as blunted HPA axis response to stress [183] have been 
established in offspring following antenatal exposure to synthetic glucocorticoids. In 
addition, antenatal glucocorticoid treatment programs HPA function in the adult offspring 
in a sex-specific manner [188]. Programming of the fetal HPA axis, although it could have 
had an adverse postnatal outcome, actually demonstrated the amazing plasticity of the HPA 
axis.  
Exposure to stress or glucocorticoids, exogenous or endogenous, causes fetal growth 
retardation and low birth weight in parallel with deregulation of the HPA axis during the 
life cycle [139]. Additionally, there is a correlation between the natural variation in body 
weight and the HPA axis function in offspring. In adult pigs that were low-weight at birth 
and remained small after birth altered HPA axis function has been recorded in later life, i.e. 
elevated adrenal responsiveness to insulin-induced hypoglycaemia [189]. Thus, it can be 
concluded that growth retardation and programming of the HPA axis are two mutually 
dependent processes that actually represent the modality by which prenatal environment 
influences adult stress-related diseases (Figure 1).  
It has been shown that in rodents, effects of programming can be induced by insults even 
in neonatal period of life. One of the striking characteristics of the HPA axis is the stress 
hypo-responsive period during the first 2 weeks of life for species that are immature at 
birth, such as rats and mice. During the stress hypo-responsive period there is low basal 
corticosterone secretion and the inability to increase corticosterone in response to mild 
stressors, in order to protect the developing nervous system from glucocorticoid excess. 
Thus, neonatal glucocorticoid exposure and early life experience that activate the HPA 
 
Prenatal Glucocorticoids: Short-Term Benefits and Long-Term Risks 361 
axis have programming effects on HPA axis organization and functioning during the life 
cycle. Postnatal handling attenuated HPA response to stress in adult animals. Most likely 
this is an indirect effect, caused by altered maternal behavior which results in increased 
licking and grooming of pups by the dam. It is considered that serotonin plays a crucial 
role in the persistence of the handling effect through increased hippocampal GR levels 
[190]. Similarly, as adults, the offspring of mothers that exhibited more licking and 
grooming of pups during the first 10 days of life showed reduced HPA axis stress 
response due to increased hippocampal GR mRNA expression and decreased levels of 
hypothalamic CRH mRNA [191]. On the other hand, maternal separations during the 
critical periods of hippocampal development can disrupt hippocampal cytoarchitecture 
and neurogenesis in a stable manner, with stress hyper-responsiveness observed in these 
animals as adults [192, 193].  
4.2. Programming of the somatotropic axis  
Programming of the somatotropic axis (GH-IGF axis) is known to be induced by transient 
events in early postnatal life. The best described example is the effect of transient neonatal 
manipulation of sex steroids to permanently alter subsequent GH secretion to resemble the 
pattern of GH secretion of the opposite sex in rodents [194]. Intrauterine programming of 
the somatotropic (GH-IGF) axis is still not fully understood, despite its importance in 
postnatal growth and metabolism. Synthetic activity, storage, and proliferation of rat 
pituitary GH cells, indicated by the significant increase in GH cell immunopositivity, size, 
and number per volume and unit of area, rise markedly from the 19th till the 21st fetal day 
[195]. This corresponds with an increase in plasma corticosterone concentration in near term 
rat fetuses [46]. It has been shown that dexamethasone administered during the last week of 
pregnancy has a maturational effect on pituitary GH cells in rats [196]. Dexamethasone 
induced GHRHR mRNA expression and accumulation in the fetal rat pituitary gland [70] 
and amplified the stimulatory influence of GHRH. As a consequence, dexamethasone 
induced GH cells to synthesize and release more GH, leading to increases in GH cell size 
and immunopositivity (Figure 5) [196]. Corticosterone-induced GH cell differentiation 
involves GH expression in cells not expressing GH mRNA previously [197]. Moreover, 
dexamethasone can induce GH progenitors to start GH synthesis one day earlier than in 
normal fetuses. In vitro findings suggested that incubation of the pituitary gland with 
dexamethasone for 24 h increased GH mRNA on fetal day 18 to a level nearly identical to 
that in intact 19-day-old fetuses [70]. In humans, low-weight babies have high basal GH and 
low IGF-I concentrations at birth, with an increased GH response to GHRH [198]. These 
altered concentrations are maintained during early childhood and are accompanied by 
changes in the pattern of GH secretion. By early adulthood, urinary GH excretion, which 
reflects GH secretion, is low in men and women with low birth weights, but in old age birth 
weight is unrelated to either urinary GH excretion or the GH secretory profile [198]. Low 
birth weight is associated with decreased IGF-I, IGF-II and IGFBP-3, and elevated levels of 
IGFBP-1 [199]. 
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structure is affected by prenatal glucocorticoid exposure (Figure 4) [45, 46]. In the juvenile 
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the decreased volume of adrenal medulla and the number of chromaffin cells that persisted 
during the fetal and neonatal period. Decreased proliferation of chromaffin cells during  
the fetal and early neonatal period was followed by significantly higher values in relation to 
controls during the second neonatal week, indicating the capacity of the adrenal  
gland medulla to recover [185]. Multiple dexamethasone doses applied during pregnancy 
exert a more potent inhibitory effect. A reduced number of chromaffin cells and significantly 
decreased adrenaline content in the adrenals were seen in 14-day-old neonatal  
offspring [181].  
As pointed out, the consequences of fetal glucocorticoid exposure occur at the level  
of central regulation, pituitary ACTH cells and the adrenal gland, causing programming 
effects on HPA axis function in later life. In offspring HPA axis activity may be changed  
in different directions under basal conditions and after stress challenge [186].  
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addition, antenatal glucocorticoid treatment programs HPA function in the adult offspring 
in a sex-specific manner [188]. Programming of the fetal HPA axis, although it could have 
had an adverse postnatal outcome, actually demonstrated the amazing plasticity of the HPA 
axis.  
Exposure to stress or glucocorticoids, exogenous or endogenous, causes fetal growth 
retardation and low birth weight in parallel with deregulation of the HPA axis during the 
life cycle [139]. Additionally, there is a correlation between the natural variation in body 
weight and the HPA axis function in offspring. In adult pigs that were low-weight at birth 
and remained small after birth altered HPA axis function has been recorded in later life, i.e. 
elevated adrenal responsiveness to insulin-induced hypoglycaemia [189]. Thus, it can be 
concluded that growth retardation and programming of the HPA axis are two mutually 
dependent processes that actually represent the modality by which prenatal environment 
influences adult stress-related diseases (Figure 1).  
It has been shown that in rodents, effects of programming can be induced by insults even 
in neonatal period of life. One of the striking characteristics of the HPA axis is the stress 
hypo-responsive period during the first 2 weeks of life for species that are immature at 
birth, such as rats and mice. During the stress hypo-responsive period there is low basal 
corticosterone secretion and the inability to increase corticosterone in response to mild 
stressors, in order to protect the developing nervous system from glucocorticoid excess. 
Thus, neonatal glucocorticoid exposure and early life experience that activate the HPA 
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axis have programming effects on HPA axis organization and functioning during the life 
cycle. Postnatal handling attenuated HPA response to stress in adult animals. Most likely 
this is an indirect effect, caused by altered maternal behavior which results in increased 
licking and grooming of pups by the dam. It is considered that serotonin plays a crucial 
role in the persistence of the handling effect through increased hippocampal GR levels 
[190]. Similarly, as adults, the offspring of mothers that exhibited more licking and 
grooming of pups during the first 10 days of life showed reduced HPA axis stress 
response due to increased hippocampal GR mRNA expression and decreased levels of 
hypothalamic CRH mRNA [191]. On the other hand, maternal separations during the 
critical periods of hippocampal development can disrupt hippocampal cytoarchitecture 
and neurogenesis in a stable manner, with stress hyper-responsiveness observed in these 
animals as adults [192, 193].  
4.2. Programming of the somatotropic axis  
Programming of the somatotropic axis (GH-IGF axis) is known to be induced by transient 
events in early postnatal life. The best described example is the effect of transient neonatal 
manipulation of sex steroids to permanently alter subsequent GH secretion to resemble the 
pattern of GH secretion of the opposite sex in rodents [194]. Intrauterine programming of 
the somatotropic (GH-IGF) axis is still not fully understood, despite its importance in 
postnatal growth and metabolism. Synthetic activity, storage, and proliferation of rat 
pituitary GH cells, indicated by the significant increase in GH cell immunopositivity, size, 
and number per volume and unit of area, rise markedly from the 19th till the 21st fetal day 
[195]. This corresponds with an increase in plasma corticosterone concentration in near term 
rat fetuses [46]. It has been shown that dexamethasone administered during the last week of 
pregnancy has a maturational effect on pituitary GH cells in rats [196]. Dexamethasone 
induced GHRHR mRNA expression and accumulation in the fetal rat pituitary gland [70] 
and amplified the stimulatory influence of GHRH. As a consequence, dexamethasone 
induced GH cells to synthesize and release more GH, leading to increases in GH cell size 
and immunopositivity (Figure 5) [196]. Corticosterone-induced GH cell differentiation 
involves GH expression in cells not expressing GH mRNA previously [197]. Moreover, 
dexamethasone can induce GH progenitors to start GH synthesis one day earlier than in 
normal fetuses. In vitro findings suggested that incubation of the pituitary gland with 
dexamethasone for 24 h increased GH mRNA on fetal day 18 to a level nearly identical to 
that in intact 19-day-old fetuses [70]. In humans, low-weight babies have high basal GH and 
low IGF-I concentrations at birth, with an increased GH response to GHRH [198]. These 
altered concentrations are maintained during early childhood and are accompanied by 
changes in the pattern of GH secretion. By early adulthood, urinary GH excretion, which 
reflects GH secretion, is low in men and women with low birth weights, but in old age birth 
weight is unrelated to either urinary GH excretion or the GH secretory profile [198]. Low 
birth weight is associated with decreased IGF-I, IGF-II and IGFBP-3, and elevated levels of 
IGFBP-1 [199]. 
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Figure 5. a) Pituitary GH cells of control 21-day-old fetus. b) Intensive immunostaining of GH cells in 
21-day-old fetuses after maternal dexamethasone treatment. Bar - 25 m. 
In the fetus, IGF-I together with insulin, acts as a signal of nutrient plenty at the cellular 
level and promotes tissue growth in line with substrate availability in the fetus [24]. In 
fetal sheep, concentrations of insulin and IGF-I rise with increasing fetal concentrations of 
glucose over the normal range of values induced by variations in maternal nutritional 
state. The rise in fetal plasma IGF-I probably reflects overspill of IGF-I produced by a 
number of different fetal tissues, since IGF-I is primarily a paracrine growth factor in 
utero. In contrast, the concentrations of cortisol rise as fetal glucose levels decline [200]. 
Fetal undernutrition induced by maternal dietary manipulation, placental insufficiency 
and restriction of uterine blood flow, all reduce the circulating levels and tissue 
expression of IGF-I [200]. Glucocorticoids affect the expression of Igf1 and Igf2 genes, 
although their effects are tissue and Igf-specific. In fetal sheep, cortisol up- and down-
regulates Igf1 gene expression in the liver and skeletal muscle, respectively, whereas it 
down-regulates Igf2 gene expression in these tissues. These changes in tissue expression 
occur both in response to exogenous cortisol infusion before term, and when fetal cortisol 
levels rise endogenously during the immediate prepartum period [200]. The cortisol-
induced changes in tissue Igf gene expression are also accompanied by decreases in the 
fetal growth rate and, close to term, by a fall in plasma IGF-II levels [77, 201]. Cortisol, 
therefore, appears to initiate the switch from paracrine IGF production in utero to the 
hepatic production of endocrine IGF-I characteristic of the postnatal animal. 
Glucocorticoids may act on Igf gene expression either directly or indirectly, through 
changes in the GH receptor gene expression [79] and/or via other transcription factors or 
cortisol-dependent hormones, such as T3 [202]. This premature transition from IGF-II to 
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IGF-I production has beneficial effects on tissue differentiation, should delivery occur 
before full term. However, if delivery is not stimulated prematurely, the glucocorticoid-
induced switch from the fetal to the adult mode of somatotrophic regulation may lead to 
inappropriate changes in cell proliferation and differentiation in utero with adverse 
sequelae both at birth and much later in life [200]. The reduced axial growth and reduced 
femur and tibia length reported in juvenile rats prenatally exposed to dexamethasone 
could serve as an illustration [203]. Altogether, the long-term consequences of such fetal 
changes in the GH-IGF axis are yet not fully understood in terms of functional adaptation 
or diseases. However, glucocorticoid-induced alterations might appear as potentially 
beneficial for short-term survival in an environment of shortage of nutritional resources. 
After birth, normalization of insulin, IGFs and IGFPs occurs. During this period, when 
suddenly exposed to increased concentrations of insulin and IGF-1, tissues chronically 
depleted of these two hormones during fetal life may counteract the hike by developing 
insulin resistance as a metabolic defense against developing hypoglycemia [204]. 
Therefore, infants with low birth weight who show early and complete growth recovery 
could be at higher risk for the occurrence of the metabolic syndrome in adulthood. 
Indeed, recent results in rats have shown permanent and sexually dimorphic changes in 
the expression of genes involved in the GH-IGF axis in animals that were weaned on to a 
high fat diet [203].  
4.3. Programming of the hypothalamic-pituitary-thyroid axis   
Glucocorticoid milieu strongly influences HPT axis activity during critical developmental 
periods. Prenatal alterations in glucocorticoid levels, caused by the application of synthetic 
glucocorticoids, maternal undernutrition or adrenalectomy, reflect on the fetal, neonatal and 
adult HPT axis structure and function.     
Unbiased estimation of the cell number applying a design-based modern stereological 
approach revealed that maternal dexamethasone treatment significantly decreased pituitary 
TSH cell number in near term fetuses. This result together with the strong immunopositivity 
of TSH cells, and the fact that the decreased number of TSH cells sustains serum TSH 
concentrations at the control level, indicates that glucocorticoids exert a maturation-
promoting effect on fetal TSH cells enhancing TSH synthesis (Figure 6) [205]. In sheep 
fetuses, antenatal glucocorticoid administration induced an increase in the circulating T3 
concentration. Tissue-specific changes in deiodinase enzyme activities show stimulation of 
hepatic D1 activity with consequent increases in hepatic T3 production, as well as decreased 
T3 clearance by suppression of D3 enzymes in the kidney and placenta [206]. In the brain, 
glucocorticoid application stimulated TH activity during a period between gestational day 
20 and neonatal day 12 that largely overlaps with the transient window in time during 
which brain development is TH sensitive [207]. On the contrary, maternal undernutrition 
during the gestational period results in lower serum T3 and higher serum reverse T3 
concentrations in neonatal pups [208].   
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IGF-I production has beneficial effects on tissue differentiation, should delivery occur 
before full term. However, if delivery is not stimulated prematurely, the glucocorticoid-
induced switch from the fetal to the adult mode of somatotrophic regulation may lead to 
inappropriate changes in cell proliferation and differentiation in utero with adverse 
sequelae both at birth and much later in life [200]. The reduced axial growth and reduced 
femur and tibia length reported in juvenile rats prenatally exposed to dexamethasone 
could serve as an illustration [203]. Altogether, the long-term consequences of such fetal 
changes in the GH-IGF axis are yet not fully understood in terms of functional adaptation 
or diseases. However, glucocorticoid-induced alterations might appear as potentially 
beneficial for short-term survival in an environment of shortage of nutritional resources. 
After birth, normalization of insulin, IGFs and IGFPs occurs. During this period, when 
suddenly exposed to increased concentrations of insulin and IGF-1, tissues chronically 
depleted of these two hormones during fetal life may counteract the hike by developing 
insulin resistance as a metabolic defense against developing hypoglycemia [204]. 
Therefore, infants with low birth weight who show early and complete growth recovery 
could be at higher risk for the occurrence of the metabolic syndrome in adulthood. 
Indeed, recent results in rats have shown permanent and sexually dimorphic changes in 
the expression of genes involved in the GH-IGF axis in animals that were weaned on to a 
high fat diet [203].  
4.3. Programming of the hypothalamic-pituitary-thyroid axis   
Glucocorticoid milieu strongly influences HPT axis activity during critical developmental 
periods. Prenatal alterations in glucocorticoid levels, caused by the application of synthetic 
glucocorticoids, maternal undernutrition or adrenalectomy, reflect on the fetal, neonatal and 
adult HPT axis structure and function.     
Unbiased estimation of the cell number applying a design-based modern stereological 
approach revealed that maternal dexamethasone treatment significantly decreased pituitary 
TSH cell number in near term fetuses. This result together with the strong immunopositivity 
of TSH cells, and the fact that the decreased number of TSH cells sustains serum TSH 
concentrations at the control level, indicates that glucocorticoids exert a maturation-
promoting effect on fetal TSH cells enhancing TSH synthesis (Figure 6) [205]. In sheep 
fetuses, antenatal glucocorticoid administration induced an increase in the circulating T3 
concentration. Tissue-specific changes in deiodinase enzyme activities show stimulation of 
hepatic D1 activity with consequent increases in hepatic T3 production, as well as decreased 
T3 clearance by suppression of D3 enzymes in the kidney and placenta [206]. In the brain, 
glucocorticoid application stimulated TH activity during a period between gestational day 
20 and neonatal day 12 that largely overlaps with the transient window in time during 
which brain development is TH sensitive [207]. On the contrary, maternal undernutrition 
during the gestational period results in lower serum T3 and higher serum reverse T3 
concentrations in neonatal pups [208].   
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Figure 6. a) Numerous TSH cells characteristic for pituitary of 21-day-old fetus. b) Decreased number of 
TSH cells, with intense immunopositivity was observed in 21-day-old fetuses after maternal 
dexamethasone administration. Bar - 25 m. 
Alteration of the glucocorticoid milieu caused by maternal adrenalectomy influences HPT 
axis functioning in adult offspring. Decreased hypothalamic TRH mRNA levels and 
increased plasma TSH levels recorded in both male and female adult offspring of 
adrenalectomized dams were reversed by the administration of corticosterone to the 
pregnant adrenalectomized dam. The decreased plasma T3 concentrations in female 
offspring, which were reversed by the administration of higher levels of corticosterone to 
the adrenalectomized pregnant rats, suggest that the adult HPT axis responded to variations 
in maternal glucocorticoid milieu in a sex-specific manner [209].   
Importantly, TH per se are potent programming factors. Fetal and neonatal 
hyperthyroidism or hypothyroidism results in programming of the HPT function. During 
critical periods, TSH secretion is suppressed by an excess of TH, but cannot be increased 
despite the marked lowering of circulating TH caused by perinatal propylthiouracil 
administration. More importantly, perinatal thyroid status "programs" its own future 
reactivity, so that early hypothyroidism results in reduced T4 and T3 levels in adulthood, 
despite normal levels of TSH [210].   
TH influence the accretion, differentiation and metabolism of many tissues and cell types 
during development in a time-dependent manner. The effects of its deficiency during critical 
periods, when the tissues still have some plasticity and are in a higher proliferating and 
differentiating stage, are thus notable, often permanent. Fetal hypothyroidism leads to 
asymmetrical growth retardation, with reduction in muscle mass [211]. Fetal metabolism 
and utilization of oxygen, as well as bone tissue growth were adversely affected by TH 
deficiency in utero [211]. A well known example is that hypothyroidism during the period 
of thyroid-dependent brain development, in fetuses and during infancy, causes permanent 
mental retardation [212]. Thus, the structure and function of TH-dependent tissues, 
determined during critical periods by the striking effects of TH action [139], might be the 
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cause of different (patho)physiological alterations which manifest during the life cycle. The 
potent influence of glucocorticoids on serum TH concentrations and the TH tissue 
bioavailability in the same period represents an important additional cause of the 
programming events recorded in different tissues.  
4.4. Programming of endocrine pancreas 
A number of epidemiological and clinical studies demonstrate an association between low 
birth weight and an increased incidence of metabolic, cardiovascular and other diseases in 
adult life. Adverse intrauterine environment caused by inadequate maternal nutrition status 
[13], poor placental function [17], maternal stress [15] or treatment with synthetic 
glucocorticoids [187] is linked with impaired intrauterine growth and increased rates of 
metabolic diseases such as type 2 diabetes in adulthood.   
The increased fetal glucocorticoid exposure observed during and after suboptimal 
conditions, triggers cell differentiation in many of the tissues, resetting the set points of 
metabolic homeostasis and endocrine axes and in most individual fetal tissues leads to 
weight reduction, restricted fetal growth and decreased birth weight [24]. Glucocorticoids 
therefore switch the cell cycle from tissue accretion to tissue differentiation in preparation 
for delivery. At the same time, glucocorticoids are involved in the programming of the HPA 
axis during critical periods, causing structural and functional changes specified in the above 
section. Alterations in the feedback sensitivity of the fetal HPA axis, as adaptation to 
suboptimal conditions, mostly result in enhanced HPA axis activity postnatally, under basal 
conditions or after stress challenge, with elevated glucocorticoid levels [21]. These changes 
are in close association with the programming of susceptibility in the fetus to develop 
metabolic syndrome in later life. Indeed, hyperactivity of the HPA axis with chronically 
elevated glucocorticoids is positively correlated with the metabolic syndrome, which 
includes a cluster of symptoms such as hyperglycemia, hyperinsulinemia, or insulin 
resistance. Dyslipidemia, hyperleptinemia, raised serum triglycerides, lowered serum high-
density lipoprotein cholesterol, and high blood pressure have also been recorded. All of 
those risk factors are a prelude to the development of diseases such as type 2 diabetes, 
atherosclerosis and cardio-vascular complications [28].  
Suboptimal conditions in utero lead to changes in the endocrine environment which 
influence fetal development so that its nutrient requirements are decreased and a thrifty 
phenotype is produced to maximize its chances for survival. These short-term beneficial 
adaptations may be maladaptive in postnatal life, contributing to poor health outcomes [26]. 
If postnatal nutrient availability is better than predicted, metabolic dysfunctions occur, as 
the organism is not adapted to cope with excessive caloric intake in later life. The association 
of low birth weight with early postnatal catch-up growth, in situations where discrepancies 
between the pre- and postnatal environment are significant, adversely affects body 
composition, producing increased susceptibility to non-insulin dependent type 2 diabetes. 
But if environmental conditions remain unchanged, and the offspring of mothers on a low 
protein diet continue with the low protein diet during lactation, development of the 
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cause of different (patho)physiological alterations which manifest during the life cycle. The 
potent influence of glucocorticoids on serum TH concentrations and the TH tissue 
bioavailability in the same period represents an important additional cause of the 
programming events recorded in different tissues.  
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A number of epidemiological and clinical studies demonstrate an association between low 
birth weight and an increased incidence of metabolic, cardiovascular and other diseases in 
adult life. Adverse intrauterine environment caused by inadequate maternal nutrition status 
[13], poor placental function [17], maternal stress [15] or treatment with synthetic 
glucocorticoids [187] is linked with impaired intrauterine growth and increased rates of 
metabolic diseases such as type 2 diabetes in adulthood.   
The increased fetal glucocorticoid exposure observed during and after suboptimal 
conditions, triggers cell differentiation in many of the tissues, resetting the set points of 
metabolic homeostasis and endocrine axes and in most individual fetal tissues leads to 
weight reduction, restricted fetal growth and decreased birth weight [24]. Glucocorticoids 
therefore switch the cell cycle from tissue accretion to tissue differentiation in preparation 
for delivery. At the same time, glucocorticoids are involved in the programming of the HPA 
axis during critical periods, causing structural and functional changes specified in the above 
section. Alterations in the feedback sensitivity of the fetal HPA axis, as adaptation to 
suboptimal conditions, mostly result in enhanced HPA axis activity postnatally, under basal 
conditions or after stress challenge, with elevated glucocorticoid levels [21]. These changes 
are in close association with the programming of susceptibility in the fetus to develop 
metabolic syndrome in later life. Indeed, hyperactivity of the HPA axis with chronically 
elevated glucocorticoids is positively correlated with the metabolic syndrome, which 
includes a cluster of symptoms such as hyperglycemia, hyperinsulinemia, or insulin 
resistance. Dyslipidemia, hyperleptinemia, raised serum triglycerides, lowered serum high-
density lipoprotein cholesterol, and high blood pressure have also been recorded. All of 
those risk factors are a prelude to the development of diseases such as type 2 diabetes, 
atherosclerosis and cardio-vascular complications [28].  
Suboptimal conditions in utero lead to changes in the endocrine environment which 
influence fetal development so that its nutrient requirements are decreased and a thrifty 
phenotype is produced to maximize its chances for survival. These short-term beneficial 
adaptations may be maladaptive in postnatal life, contributing to poor health outcomes [26]. 
If postnatal nutrient availability is better than predicted, metabolic dysfunctions occur, as 
the organism is not adapted to cope with excessive caloric intake in later life. The association 
of low birth weight with early postnatal catch-up growth, in situations where discrepancies 
between the pre- and postnatal environment are significant, adversely affects body 
composition, producing increased susceptibility to non-insulin dependent type 2 diabetes. 
But if environmental conditions remain unchanged, and the offspring of mothers on a low 
protein diet continue with the low protein diet during lactation, development of the 
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metabolic phenotype is prevented. The “predictive adaptive response” hypothesis proposes 
that the degree of mismatch between the pre- and postnatal environments is a major 
determinant of subsequent disease, and leads to the premise that adult disease arises in utero 
[28, 213].  
The thrifty phenotype is not able to respond to unexpected environmental conditions 
because the changes in metabolic tissues established during critical periods are directed 
towards low nutritional demands. The fetus adapts to an adverse intrauterine milieu 
through changes that permanently affect the pancreas, muscles, adipose tissue, and liver 
structure and function, which are involved in the pathogenesis of obesity and type 2 
diabetes [25]. 
Progressive reduction in insulin-producing β-cell mass is observed in rats with restricted 
fetal growth [214]. There is evidence that prenatal caloric restriction during pregnancy 
causes alteration in pancreatic islet neogenesis by decreasing the β-cell precursor pool [215], 
while maternal protein restriction in rats lowers β-cell proliferation and/or increases 
apoptosis rates in the fetal endocrine pancreas [215, 216]. Permanent reductions in β-cell 
mass and its functional efficiency, although achieved by different mechanisms, result in 
glucose intolerance in adulthood [214]. Nutritional deprivation as severe stress induces a 
rise in both maternal and fetal corticosterone levels, which in turn are responsible for the 
observed effects [217].       
Prenatal stress that induces a restriction in intrauterine growth in aged male rats causes 
hyperglycemia, glucose intolerance, and decreased basal leptin levels. Again, an adverse 
glucocorticoid environment during critical periods might be the underlying mechanism that 
mediates long-lasting disturbances in feeding behavior and dysfunctions related to type 2 
diabetes [15].   
Overexposure to exogenous glucocorticoids during different stages of development reduces 
β-cell mass in the fetal endocrine pancreas: impairment of β-cell commitment is recorded in 
fetuses exposed to glucocortiocoid during the last week of gestation, while glucocorticoids 
treatment throughout gestation lowers β-cell proliferation and impairs islet vascularization 
[218]. Glucocorticoid excess during the last week of gestation leads to lower levels of insulin 
expression in the β-cells of 3-week-old offspring via a mechanism that involves down-
regulation of Pdx-1, the transcription factor that initiates and promotes β-cells development 
[219]. Programming of the functional capacity of pancreatic β-cell mass by adverse 
intrauterine conditions increases susceptibility to type 2 diabetes during adulthood that is 
especially evident if offspring when they are challenged with nutritional abundance. As 
during adulthood the majority of β-cells are formed through proliferation of the existing 
cells [220], smaller β-cell mass in the newborn means fewer β-cells will be available for 
renewal during life, which increases the risk of developing glucose intolerance or diabetes 
[221].  
Impaired insulin action at the major sites of glucose utilization, such as skeletal muscles, 
liver and adipose tissue, further predisposes to a later diabetic state. Excess prenatal 
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glucocorticoid exposure, uteroplacental insufficiency as well as maternal low protein diet 
in the perinatal period prepare skeletal muscle metabolism for poor metabolic conditions 
in later life [22, 25, 213]. These changes include up-regulation of GR expression that 
determines higher muscle glucocorticoid sensitivity, with the promotion of protein 
breakdown and blunted protein synthesis in muscles [222]. Prenatal growth restriction 
caused by adverse intrauterine conditions of different etiology has a long-term influence 
on adiposity. Redistribution of body fat from the periphery to the central or visceral 
deposits that have a relatively higher level of GR expression and are thus more sensitive 
to glucocorticoid action is established in adult rats and sheep prenatally exposed to 
glucocorticoid excess [223-225], contributing to decreased insulin sensitivity and blunted 
glucose intake [2]. Adipocytes from 15-month-old low-protein rat offspring are also 
resistant to the antilipolytic action of insulin and insulin-induced glucose uptake [25]. It 
can be concluded that adverse conditions during critical periods may program adipocyte 
metabolism to give rise to later obesity and type 2 diabetes, especially when challenged 
postnatally with a hypercaloric diet [226]. Suboptimal conditions during fetal 
development program an increased level of liver GR expression that enables much higher 
glucocorticoid impact in diabetic animals [227]. Down-regulation of glucokinase activity 
in parallel with decreased liver glucose uptake, and up-regulation of gluconeogenic 
enzyme activities, notably phosphoenolpyruvate carboxykinase which catalyzes a rate-
limiting step in gluconeogenesis, have been established in rats exposed to excessive 
glucocorticoids in utero [25, 228]. The programming effects established in glucocorticoid 
overexposed fetuses with restricted growth are thus directed toward enhanced glucose 
production and reduced glucose utilization in the liver and other peripheral tissues in 
adulthood, and represent the structural and physiological basis of the development of 
type 2 diabetes [19].    
4.5. Programming of hipothalamic-pituitary-gonadal axis 
Steroid hormone excess during fetal life, including glucocorticoids and sex hormones, is 
well known to induce permanent alterations in the physiology of the adult HPG axis in 
both sexes [229]. The majority of data describing the effects of elevated levels of 
glucocorticoids on the HPG axis and possible mechanisms, come from studies in adults, 
and there are only limited data on fetal effects. It has been known that the HPA axis, 
when activated by stress, exerts an inhibitory effect on the female and male reproductive 
system. Reallocation of resources during the stress response suppresses the reproductive 
axis, which gives higher priority to an individual’s survival rather than the maintenance 
of species. This effect is responsible for the “hypothalamic amenorrhea of stress” in 
females, which is observed in anxiety and depression, malnutrition, eating disorders and 
chronic excessive exercise, and the hypogonadism in Cushing’s syndrome [230]. Stressors 
trigger a rise in glucocorticoids that suppress reproductive functions along the HPG axis 
[3]. Glucocorticoids decrease expression of GnRH mRNA [231] in the hypothalamus, and 
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metabolic phenotype is prevented. The “predictive adaptive response” hypothesis proposes 
that the degree of mismatch between the pre- and postnatal environments is a major 
determinant of subsequent disease, and leads to the premise that adult disease arises in utero 
[28, 213].  
The thrifty phenotype is not able to respond to unexpected environmental conditions 
because the changes in metabolic tissues established during critical periods are directed 
towards low nutritional demands. The fetus adapts to an adverse intrauterine milieu 
through changes that permanently affect the pancreas, muscles, adipose tissue, and liver 
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glucocorticoid environment during critical periods might be the underlying mechanism that 
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cells [220], smaller β-cell mass in the newborn means fewer β-cells will be available for 
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glucocorticoid exposure, uteroplacental insufficiency as well as maternal low protein diet 
in the perinatal period prepare skeletal muscle metabolism for poor metabolic conditions 
in later life [22, 25, 213]. These changes include up-regulation of GR expression that 
determines higher muscle glucocorticoid sensitivity, with the promotion of protein 
breakdown and blunted protein synthesis in muscles [222]. Prenatal growth restriction 
caused by adverse intrauterine conditions of different etiology has a long-term influence 
on adiposity. Redistribution of body fat from the periphery to the central or visceral 
deposits that have a relatively higher level of GR expression and are thus more sensitive 
to glucocorticoid action is established in adult rats and sheep prenatally exposed to 
glucocorticoid excess [223-225], contributing to decreased insulin sensitivity and blunted 
glucose intake [2]. Adipocytes from 15-month-old low-protein rat offspring are also 
resistant to the antilipolytic action of insulin and insulin-induced glucose uptake [25]. It 
can be concluded that adverse conditions during critical periods may program adipocyte 
metabolism to give rise to later obesity and type 2 diabetes, especially when challenged 
postnatally with a hypercaloric diet [226]. Suboptimal conditions during fetal 
development program an increased level of liver GR expression that enables much higher 
glucocorticoid impact in diabetic animals [227]. Down-regulation of glucokinase activity 
in parallel with decreased liver glucose uptake, and up-regulation of gluconeogenic 
enzyme activities, notably phosphoenolpyruvate carboxykinase which catalyzes a rate-
limiting step in gluconeogenesis, have been established in rats exposed to excessive 
glucocorticoids in utero [25, 228]. The programming effects established in glucocorticoid 
overexposed fetuses with restricted growth are thus directed toward enhanced glucose 
production and reduced glucose utilization in the liver and other peripheral tissues in 
adulthood, and represent the structural and physiological basis of the development of 
type 2 diabetes [19].    
4.5. Programming of hipothalamic-pituitary-gonadal axis 
Steroid hormone excess during fetal life, including glucocorticoids and sex hormones, is 
well known to induce permanent alterations in the physiology of the adult HPG axis in 
both sexes [229]. The majority of data describing the effects of elevated levels of 
glucocorticoids on the HPG axis and possible mechanisms, come from studies in adults, 
and there are only limited data on fetal effects. It has been known that the HPA axis, 
when activated by stress, exerts an inhibitory effect on the female and male reproductive 
system. Reallocation of resources during the stress response suppresses the reproductive 
axis, which gives higher priority to an individual’s survival rather than the maintenance 
of species. This effect is responsible for the “hypothalamic amenorrhea of stress” in 
females, which is observed in anxiety and depression, malnutrition, eating disorders and 
chronic excessive exercise, and the hypogonadism in Cushing’s syndrome [230]. Stressors 
trigger a rise in glucocorticoids that suppress reproductive functions along the HPG axis 
[3]. Glucocorticoids decrease expression of GnRH mRNA [231] in the hypothalamus, and 
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are associated with alterations in both FSH and LH cells [232, 233]. Glucocorticoids also 
affect gonads directly. It has been reported that dexamethasone inhibits ovarian function 
in immature female rats and the differentiation of granulosa cells by FSH [234]. In the 
testis, elevated levels of glucocorticoids suppress testosterone biosynthesis [3]. 
Additionally, dexamethasone induces apoptosis of tubules and germ cells in adult rat 
testis [235].  
Elevation of maternal glucocorticoids induced by maternal stress, undernutrition or 
exogenously administered dexamethasone or betamethasone, along with IUGR  
cause alterations in HPG axis function in male and female offspring. The major alterations 
reported were related to changed sexual behavior, delayed puberty, and delayed 
development of the gonads. In rats, exposure to prenatal stress demasculinizes  
and feminizes the behavior of the male offspring. When dams are restrained under  
bright light from days 14 to 21 of gestation, the male offspring display reduced  
anogenital distance and lower testis weight at birth compared to controls [18, 236],  
which could predict impaired sexual activity at adulthood [237]. Prenatal treatment  
with glucocorticoids caused the disappearance of sexual dimorphism of aromatase 
activity in the brain preoptic area of rat pups in early postnatal life [238].  
Prenatal bethamethasone treatment diminished the testosterone peak in male pups, a 
peak crucial for brain sexual differentiation. As a consequence, this prenatal  
treatment may have impaired the hypothalamus–pituitary axis, thus reducing production 
of testosterone in adulthood and altering the partner preference and sexual  
behavior [239]. 
It has been reported that maternal protein restriction altered the key components of 
pregnant maternal steroid endocrinology, as well as the endocrinology of the offspring. 
Maternal corticosterone and testosterone levels were elevated, which resulted in an 
increased anogenital distance in males [240].  In females exposed to protein restriction 
during development the onset of puberty was delayed and the cycle length was increased 
[241]. The decrease of LH and slight, but not significant, decrease of FSH levels was 
detected in adult females that experienced maternal protein restriction at some stage of 
development. Together with the increases in testosterone levels at 1 year, this presage 
potential reproductive problems, including changes in the ovarian cycle [241]. Maternal 
protein restriction leads to similar changes in reproductive hormones in the male 
offspring [240], indicating that a major effect of the challenge imposed on the developing 
offspring is to alter hypothalamic–pituitary endocrine function. The reproductive function 
aged more rapidly in females that had been exposed to protein restriction during 
development [241]. Testicular and ovarian growth was drastically retarded, and the onset 
of puberty was delayed in male and female rats prenatally exposed to maternal food 
restriction [242]. In addition, the ovulation rate in adulthood was reduced in female sheep 
that experienced undernutrition during the prenatal period [243]. The suggested main 
mechanism by which maternal calorie restriction induced delay of puberty in the female 
offspring is that decreased function of the kisspeptin system retards the development of 
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reproductive function and the onset of puberty. Hypothalamic levels of Kiss1 mRNA were 
decreased in prenatally undernourished rats, and the replacement of kisspeptin 
normalized the timing of vaginal opening in these females [244]. However, this 
mechanism is not responsible for delaying puberty in dexamethasone-induced IUGR 
females, since the levels of Kiss1 mRNA were not altered [245]. On the other hand, 
alterations of ovarian functions found in dexamethasone-induced IUGR rats, can affect 
sexual maturation [246]. As ovarian weight in the dexamethasone-induced IUGR rats was 
lower than in the controls during the prepubertal period (postnatal day 28), but not on the 
day of vaginal opening, the retardation of ovarian function development might be 
involved in the delayed onset of puberty [245]. Smith and Waddell [247] have shown that 
variations in fetal glucocorticoid exposure across the normal physiological range are 
capable of influencing the timing of subsequent puberty. Puberty was substantially 
delayed by increased exposure to glucocorticoids, which was most clearly evident in 
female offspring. Of particular importance were the observations that increased exposure 
of the fetus to endogenous maternal glucocorticoids (via inhibition of placental 11β-HSD 
by carbenoxolone treatment) delayed puberty in the female offspring, whereas an 
experimental reduction in fetal glucocorticoid exposure (by maternal metyrapone 
treatment) advanced puberty in the male offspring [247].  
When higher multiple doses of dexamethasone were administered to dams between the  
16th and 18th day of gestation, a significant reduction in body weight was recorded in near-
term fetuses that persisted till the peripubertal period of life. The volume of pituitaries of the 
exposed females were also significanly reduced till the peripubertal period. The  
absolute number of both types of gonadotropic cells, obtained by design-based stereological 
methods, was decreased in the pituitaries of exposed females (Figure 7). As the pituitaries, 
the ovaries of exposed females were smaller than that of controls (Figure 8).  
Significant decrease in healthy, but an increase in atretic primordial follicles was observed in 
neonatal period (at 5 days of age) [246]. Alterations in the number of healthy and 
degenerated germinative cells were evident in fetuses as well, and sustained  
till the peripubertal period of life. Since the puberty was delayed in females exposed 
prenatally to dexamethasone, no corpora lutea were seen in their ovaries. In contrast, 3-5 
corpora lutea were present in the ovaries of control females (Figure 8). However, the  
process of folliculogenesis remained unchanged, since the follicles at all stages of 
development seen in the ovaries of control females in the neonatal [246], infantile and 
peripubertal period, were present in the ovaries of females prenatally exposed to high levels 
of glucocorticoids. Therefore, a clear programming effect of dexamethasone was detected in 
the female HPG axis. It has been shown that glucocorticoids mediate changes in the 
dynamic balance between mitosis and apoptosis [248], and may be a mechanism for the 
control of total cell number in developing tissues and organs [249, 250]. This could be one of 
the mechanisms by which glucocorticoid overexposure affects the hypothalamic–pituitary–
ovarian axis.  
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offspring [240], indicating that a major effect of the challenge imposed on the developing 
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mechanism is not responsible for delaying puberty in dexamethasone-induced IUGR 
females, since the levels of Kiss1 mRNA were not altered [245]. On the other hand, 
alterations of ovarian functions found in dexamethasone-induced IUGR rats, can affect 
sexual maturation [246]. As ovarian weight in the dexamethasone-induced IUGR rats was 
lower than in the controls during the prepubertal period (postnatal day 28), but not on the 
day of vaginal opening, the retardation of ovarian function development might be 
involved in the delayed onset of puberty [245]. Smith and Waddell [247] have shown that 
variations in fetal glucocorticoid exposure across the normal physiological range are 
capable of influencing the timing of subsequent puberty. Puberty was substantially 
delayed by increased exposure to glucocorticoids, which was most clearly evident in 
female offspring. Of particular importance were the observations that increased exposure 
of the fetus to endogenous maternal glucocorticoids (via inhibition of placental 11β-HSD 
by carbenoxolone treatment) delayed puberty in the female offspring, whereas an 
experimental reduction in fetal glucocorticoid exposure (by maternal metyrapone 
treatment) advanced puberty in the male offspring [247].  
When higher multiple doses of dexamethasone were administered to dams between the  
16th and 18th day of gestation, a significant reduction in body weight was recorded in near-
term fetuses that persisted till the peripubertal period of life. The volume of pituitaries of the 
exposed females were also significanly reduced till the peripubertal period. The  
absolute number of both types of gonadotropic cells, obtained by design-based stereological 
methods, was decreased in the pituitaries of exposed females (Figure 7). As the pituitaries, 
the ovaries of exposed females were smaller than that of controls (Figure 8).  
Significant decrease in healthy, but an increase in atretic primordial follicles was observed in 
neonatal period (at 5 days of age) [246]. Alterations in the number of healthy and 
degenerated germinative cells were evident in fetuses as well, and sustained  
till the peripubertal period of life. Since the puberty was delayed in females exposed 
prenatally to dexamethasone, no corpora lutea were seen in their ovaries. In contrast, 3-5 
corpora lutea were present in the ovaries of control females (Figure 8). However, the  
process of folliculogenesis remained unchanged, since the follicles at all stages of 
development seen in the ovaries of control females in the neonatal [246], infantile and 
peripubertal period, were present in the ovaries of females prenatally exposed to high levels 
of glucocorticoids. Therefore, a clear programming effect of dexamethasone was detected in 
the female HPG axis. It has been shown that glucocorticoids mediate changes in the 
dynamic balance between mitosis and apoptosis [248], and may be a mechanism for the 
control of total cell number in developing tissues and organs [249, 250]. This could be one of 
the mechanisms by which glucocorticoid overexposure affects the hypothalamic–pituitary–
ovarian axis.  
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Figure 7. Immunohistochemically stained FSH cells in the pituitaries of control (a-d), and females 
prenatally exposed to dexamethasone (e-h). FSH cells were examined in different periods of life: in 
nearm-term fetal period (a, e), neonatal (b, f), infantile (c, g) and peripubertal period (d, h). In all 
examined periods the number of FSH cells was lower in the pituitaries of dexamethasone exposed 
females compared to controls. Bar - 20 μm. 
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Figure 8. Ovaries of control (a-d), and females prenatally exposed to dexamethasone (e-h). Ovaries 
were examined in different periods of life: in nearm-term fetal period (a, e), neonatal (b, f), infantile (c, 
g) and peripubertal period (d, h) and they were smaller in dexamethasone exposed females. Numerous 
primordial follicles (dashed line) are present in the ovaries of control females, while they were fewer in 
number in the ovaries of dexamethasone exposed rats in all examined periods of life. Bar - 200 μm. In b) 
and f) bar - 20 μm. 
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Maternal bethamethasone administration affected the morphological development of the 
testes in male sheep fetuses, by reducing the length of testicular cords, the amount of 
interstitial tissue and testicular weight. Because interstitial tissue is primarily made up of 
Leydig cells, it is possible that betamethasone altered Leydig cell development. In contrast, 
there was no inhibitory effect on Sertoli cell number. This could be a result of the direct 
influence of the glucocorticoid used, since the presence of glucocorticoid receptor was 
demonstrated in ovine fetal Leydig cells, while the level of glucocorticoid receptor 
expression in Sertoli cells was low [251]. 
Fetal overexposure to glucocrticoids without any doubt has programming effects on the HPG 
axis, and reproduction in later life is thus impaired in both sexes. However, the mechanism of 
HPG programming is yet to be elucidated. The time interval between the exact insult and a 
fully functioning HPG axis is long, and prone to influences and interplay with other endocrine 
axes that are also altered by glucocrticoid overexposure. For example, an impaired 
somatotropic axis negatively affects reproduction. Somatostatin treatment inhibits pituitary 
gonadotropic cells and initial folliculogenesis in the ovaries of infant, peripubertal and adult 
females [252-257]. Polycystic ovary syndrome (PCOS) is of great importance, owing to its 
prevalence in up to 10% of the women population of reproductive age. Besides being 
characterized by perturbed gonadotropin secretion and excess production of androgens, PCOS 
shares a lot of commons with the metabolic syndrome. Metabolic syndrome is also believed to 
be of fetal origin and the result of programming in which glucocorticoids play a crucial role 
[213]. The short-term benefits of glucocorticoid exposure are also difficult to establish due to 
physiological dormancy of the system till puberty. The maturational effect of glucocorticoids is 
evident in the pituitary and in the ovary, since fetal overexposure induces a decreased volume 
of these glands, and of the absolute number of gonadotrops and ovarian somatic and 
germinative cells till puberty (Figure 1).  
5. Conclusion 
Glucocorticoids have a powerful influence on growth, maturation and tissue remodeling 
during fetal development. Their use in human pregnancies at risk of preterm delivery 
reduces neonatal mortality and morbidity. Glucocorticoids are also the key mediators 
between the maternal environment and the fetus, and their levels rise, in the mother and in 
the fetus, when the conditions are suboptimal. They reduce fetal growth, force maturational 
processes and provoke permanent changes in physiological systems in order to adapt the 
fetus to an adverse postnatal environment and ensure the maximum chances of survival at 
birth. These short-term beneficial effects of prenatal glucocorticoids are, at the same time, 
the ones that increase the long-term risks of dysregulation of the metabolic function and 
endocrine axes, including stress response, growth and reproduction. 
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1. Introduction 
The placenta, essential for normal fetal development by providing adequate nutrients to 
allow appropriate growth and maturation of the fetus in preparation for birth, is also a 
‘protective’ barrier in the sense that it prevents entry into the fetal circulation of substances 
that are either toxic, or that drive fetal growth at inappropriate rates. An important aspect of 
this ‘filtering’ function of the placenta is limiting the entry of glucocorticoids of maternal 
origin into the fetal compartment. This is achieved by the presence of enzymes, transporters 
and receptors collectively termed the ‘placental glucocorticoid barrier’ [1-4]. 
Antenatal glucocorticoids are routinely administered to the mother for the treatment of a 
variety of pregnancy and fetal complications. Asthmatic women often experience an 
increase in severity of their symptoms during pregnancy leading to increased use of 
glucocorticoids. The threat of preterm birth results in administration of the synthetic 
glucocorticoid, betamethasone, to rapidly mature fetal organs (especially, the lungs) to 
promote survival. Further, stressful events during pregnancy such as natural disasters and 
famines for example, expose fetuses to higher than normal levels of maternally secreted 
glucocorticoids.  
The effects of exposure to high levels of glucocorticoids during fetal development have now 
been well described [1, 5-9], and the advantages (e.g., maturation of lung surfactant 
production and increased hepatic glycogen deposition) are offset by effects that limit fetal 
growth and induce perturbations of brain growth and perfusion [1, 10-11]. However, while 
fetal/neonatal effects have been intensively investigated, the consequences of glucocorticoid 
excess on placental structure and function has received little attention to date. The 
knowledge that male fetuses are more likely to be affected negatively following events that 
usually increase fetal glucocorticoid exposure, has alerted researchers to the possibility that 
such sex-related effects could arise in the placenta. This chapter will describe the differences 
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The placenta, essential for normal fetal development by providing adequate nutrients to 
allow appropriate growth and maturation of the fetus in preparation for birth, is also a 
‘protective’ barrier in the sense that it prevents entry into the fetal circulation of substances 
that are either toxic, or that drive fetal growth at inappropriate rates. An important aspect of 
this ‘filtering’ function of the placenta is limiting the entry of glucocorticoids of maternal 
origin into the fetal compartment. This is achieved by the presence of enzymes, transporters 
and receptors collectively termed the ‘placental glucocorticoid barrier’ [1-4]. 
Antenatal glucocorticoids are routinely administered to the mother for the treatment of a 
variety of pregnancy and fetal complications. Asthmatic women often experience an 
increase in severity of their symptoms during pregnancy leading to increased use of 
glucocorticoids. The threat of preterm birth results in administration of the synthetic 
glucocorticoid, betamethasone, to rapidly mature fetal organs (especially, the lungs) to 
promote survival. Further, stressful events during pregnancy such as natural disasters and 
famines for example, expose fetuses to higher than normal levels of maternally secreted 
glucocorticoids.  
The effects of exposure to high levels of glucocorticoids during fetal development have now 
been well described [1, 5-9], and the advantages (e.g., maturation of lung surfactant 
production and increased hepatic glycogen deposition) are offset by effects that limit fetal 
growth and induce perturbations of brain growth and perfusion [1, 10-11]. However, while 
fetal/neonatal effects have been intensively investigated, the consequences of glucocorticoid 
excess on placental structure and function has received little attention to date. The 
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usually increase fetal glucocorticoid exposure, has alerted researchers to the possibility that 
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that exist between a male and female placenta with respect to the glucocorticoid barrier, and 
summarise current human clinical and experimental animal work that has explored the 
differential response of the placenta of a male and female fetus to glucocorticoid exposure.  
2. The placental glucocorticoid barrier 
While glucocorticoids are essential for the development of many organs, during 
pregnancy, the placenta acts as a barrier to prevent excess entry of maternal glucocorticoids 
into the fetal compartment [12-14]. This placental barrier to glucocorticoids is achieved 
predominantly by the presence of 11β-hydroxysteriod dehydrogenase type 2 (11βHSD2), 
which converts the biologically active glucocorticoid (cortisol in humans, corticosterone in 
mice and rats) to its physiologically inert form [2]. The placental ‘barrier’ is not complete, 
and under normal conditions a proportion (~10-15%) of maternal glucocorticoids reaches 
the fetal circulation [2]. While 11βHSD2 is the major component of the placental 
glucocorticoid barrier, other proteins contained within the placenta may also help to limit 
the transfer of maternal glucocorticoid to the fetus. The multi-drug resistance P-
glycoprotein (ABCB1) is a membrane-bound protein, which mediates the efflux of 
glucocorticoids out of the placenta back into the maternal circulation, thus reducing the 
amount of glucocorticoids able to diffuse down the concentration gradient into the fetal 
circulation [15-17].  
The response of the placenta itself to glucocorticoids is mediated by the glucocorticoid (GR) 
and mineralocorticoid receptor [18]. The most prominent isoform of the GR, both in the 
placenta and throughout the whole body, is GRα. This isoform mediates the biological 
effects of glucocorticoids, which include cell growth, proliferation and differentiation [19]. 
The placenta has not generally been considered a mineralocorticoid target tissue, however 
work by Driver et al [20] has suggested that placental trophoblast cells express a functional 
mineralocorticoid receptor, which is in part responsible for the transport of sodium across 
the placenta [20]. Because of the limited data on the role of the mineralocorticoid receptor in 
the placenta, our discussion will focus primarily on GR mediated effects. 
3. Causes of elevated glucocorticoids during pregnancy 
There are many circumstances during pregnancy in which the circulating levels of maternal 
glucocorticoids are elevated, resulting in placental and fetal exposure to excess 
glucocorticoids. The glucocorticoids within the maternal system can either be endogenous, 
originating from within the mother; or exogenous, where the glucocorticoid has been 
administered to the mother as a drug or treatment. Exogenous glucocorticoids are generally 
synthetic, such as betamethasone, dexamethasone or prednisone. The period of time when 
maternal, and therefore fetal and placental glucocorticoid levels, are elevated will vary 
considerably depending on the clinical circumstance, and effects arising from either acute or 
chronic exposures have been identified. Thus, the type of glucocorticoid, duration of 
exposure, and time in gestation need to be taken into account when determining the 
consequences for the fetus and placenta. 
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3.1. Exposure to natural glucocorticoids 
Periods of stress, both physical (illness, excess exercise, famine/under nutrition) or 
psychological (anxiety) in origin, result in the elevation of endogenous glucocorticoids [21]. 
While cortisol can cross the placenta, it is a good substrate for 11βHSD2, and is readily 
catalysed by this enzyme under normal levels. However, when levels of cortisol are 
elevated, the barrier is overwhelmed and more cortisol is able to cross the placenta into the 
fetal circulation [4]. Deleterious effects of excess endogenous glucocorticoids on the fetus 
and newborn have been well documented [3, 6, 22-25]. These effects are greater for male 
fetuses. For example, males have been shown to have greater instances of in utero mortality 
and also increased likelihood of childhood and adult morbidity and mortality [21, 26]. An 
epidemiology study that examined women who were pregnant at the time of the 2001 
terrorist attacks on the World Trade Centre found that there was a higher incidence of low 
birth weight babies for women who were residing in New York at the time. The greatest 
proportion of these low birth weight babies came from women who were in their first or 
second trimester at the time of the attacks [27]. These studies also revealed an increased 
incidence of male fetal death in New York after September 2001 [28-29]. High maternal 
stress and thus fetal exposure of cortisol are thought to be the cause of these poor fetal 
outcomes.  
3.2. Exposure to synthetic glucocorticoids 
Antenatal glucocorticoids are routinely administered to the mother for the treatment of a 
variety of pregnancy and fetal complications. Women who suffer from asthma are required 
to continue their glucocorticoid medication for the ongoing treatment/prevention of their 
symptoms, which in 33% of cases worsen during pregnancy [30-31]. Women whose babies 
are at risk of congenital adrenal hyperplasia are administered antenatal glucocorticoid 
treatment to return fetal adrenal hormone levels to normal and thus virilisation (the 
abnormal development of male sexual characteristics in a female) and fertility problems are 
prevented [32]. Further, pregnant mothers threatening preterm birth (~7-10% of all 
pregnancies), receive antenatal glucocorticoids, to mature the lungs of the fetus prior to 
birth to reduce neonatal morbidity and mortality [25]. As for cortisol, synthetic 
glucocorticoids can be catalysed by 11βHSD2, however they are a poor substrate for the 
enzyme, and more freely cross the placenta than cortisol [33]. The presence of excess 
maternal glucocorticoids can have positive effects on fetal development and maternal health 
and in many situations cannot be avoided. The National Institute of Health recommend 
treatment of all women at risk of preterm delivery, between 24 and 34 weeks of gestation, 
with synthetic glucocorticoids to prematurely mature fetal organs, primarily the lung, to 
improve neonatal survival [8]. Therefore a large proportion of this population of babies, are 
exposed to single, and sometimes multiple courses of synthetic glucocorticoids in the period 
leading up to birth [25]. While antenatal glucocorticoids are the most effective treatment for 
improving preterm birth survival rates, the scientific community continues to question 
whether the use of glucocorticoids to reduce the morbidity and mortality associated with 
preterm birth, is worth the risk of the potential negative outcomes on metabolism and 
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that exist between a male and female placenta with respect to the glucocorticoid barrier, and 
summarise current human clinical and experimental animal work that has explored the 
differential response of the placenta of a male and female fetus to glucocorticoid exposure.  
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amount of glucocorticoids able to diffuse down the concentration gradient into the fetal 
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The response of the placenta itself to glucocorticoids is mediated by the glucocorticoid (GR) 
and mineralocorticoid receptor [18]. The most prominent isoform of the GR, both in the 
placenta and throughout the whole body, is GRα. This isoform mediates the biological 
effects of glucocorticoids, which include cell growth, proliferation and differentiation [19]. 
The placenta has not generally been considered a mineralocorticoid target tissue, however 
work by Driver et al [20] has suggested that placental trophoblast cells express a functional 
mineralocorticoid receptor, which is in part responsible for the transport of sodium across 
the placenta [20]. Because of the limited data on the role of the mineralocorticoid receptor in 
the placenta, our discussion will focus primarily on GR mediated effects. 
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There are many circumstances during pregnancy in which the circulating levels of maternal 
glucocorticoids are elevated, resulting in placental and fetal exposure to excess 
glucocorticoids. The glucocorticoids within the maternal system can either be endogenous, 
originating from within the mother; or exogenous, where the glucocorticoid has been 
administered to the mother as a drug or treatment. Exogenous glucocorticoids are generally 
synthetic, such as betamethasone, dexamethasone or prednisone. The period of time when 
maternal, and therefore fetal and placental glucocorticoid levels, are elevated will vary 
considerably depending on the clinical circumstance, and effects arising from either acute or 
chronic exposures have been identified. Thus, the type of glucocorticoid, duration of 
exposure, and time in gestation need to be taken into account when determining the 
consequences for the fetus and placenta. 
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psychological (anxiety) in origin, result in the elevation of endogenous glucocorticoids [21]. 
While cortisol can cross the placenta, it is a good substrate for 11βHSD2, and is readily 
catalysed by this enzyme under normal levels. However, when levels of cortisol are 
elevated, the barrier is overwhelmed and more cortisol is able to cross the placenta into the 
fetal circulation [4]. Deleterious effects of excess endogenous glucocorticoids on the fetus 
and newborn have been well documented [3, 6, 22-25]. These effects are greater for male 
fetuses. For example, males have been shown to have greater instances of in utero mortality 
and also increased likelihood of childhood and adult morbidity and mortality [21, 26]. An 
epidemiology study that examined women who were pregnant at the time of the 2001 
terrorist attacks on the World Trade Centre found that there was a higher incidence of low 
birth weight babies for women who were residing in New York at the time. The greatest 
proportion of these low birth weight babies came from women who were in their first or 
second trimester at the time of the attacks [27]. These studies also revealed an increased 
incidence of male fetal death in New York after September 2001 [28-29]. High maternal 
stress and thus fetal exposure of cortisol are thought to be the cause of these poor fetal 
outcomes.  
3.2. Exposure to synthetic glucocorticoids 
Antenatal glucocorticoids are routinely administered to the mother for the treatment of a 
variety of pregnancy and fetal complications. Women who suffer from asthma are required 
to continue their glucocorticoid medication for the ongoing treatment/prevention of their 
symptoms, which in 33% of cases worsen during pregnancy [30-31]. Women whose babies 
are at risk of congenital adrenal hyperplasia are administered antenatal glucocorticoid 
treatment to return fetal adrenal hormone levels to normal and thus virilisation (the 
abnormal development of male sexual characteristics in a female) and fertility problems are 
prevented [32]. Further, pregnant mothers threatening preterm birth (~7-10% of all 
pregnancies), receive antenatal glucocorticoids, to mature the lungs of the fetus prior to 
birth to reduce neonatal morbidity and mortality [25]. As for cortisol, synthetic 
glucocorticoids can be catalysed by 11βHSD2, however they are a poor substrate for the 
enzyme, and more freely cross the placenta than cortisol [33]. The presence of excess 
maternal glucocorticoids can have positive effects on fetal development and maternal health 
and in many situations cannot be avoided. The National Institute of Health recommend 
treatment of all women at risk of preterm delivery, between 24 and 34 weeks of gestation, 
with synthetic glucocorticoids to prematurely mature fetal organs, primarily the lung, to 
improve neonatal survival [8]. Therefore a large proportion of this population of babies, are 
exposed to single, and sometimes multiple courses of synthetic glucocorticoids in the period 
leading up to birth [25]. While antenatal glucocorticoids are the most effective treatment for 
improving preterm birth survival rates, the scientific community continues to question 
whether the use of glucocorticoids to reduce the morbidity and mortality associated with 
preterm birth, is worth the risk of the potential negative outcomes on metabolism and 
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neurodevelopment seen within these babies during childhood and into adulthood [9]. While 
the consensus is currently ‘yes’, the guidelines for women threatening preterm birth state 
that only a single, and not multiple doses of glucocorticoids, should be given until more 
convincing data of the benefits of multiple doses are obtained [34]. Much work is examining 
the outcomes of antenatal glucocorticoids for the fetus, however the effect of glucocorticoids 
on the placenta, including the potential sex-specific effects, need to be considered as these 
may contribute to, or compound, the fetal outcomes. 
4. Excess glucocorticoids and the programming of disease  
The Barker Hypothesis of Developmental Origins of Health and Disease (DoHaD) states that 
diseases, such as coronary heart disease, hypertension and diabetes, may be consequences of 
in utero 'programming', whereby a stimulus or insult at a critical, sensitive ‘window’ of fetal 
life results in long-term changes in structure, physiology or metabolism, leading to diseases 
later in life [35]. These stimuli are likely to be mediated via a number of different hormones 
and immune factors, but glucocorticoids have been singled out as one of the most prevalent 
factors. Epidemiological and experimental animal studies have revealed that excess 
glucocorticoids in utero can be linked to the development of diseases such as hypertension 
[36-42], depression [43], cardiovascular disease [44], diabetes [45-46] and attention deficit 
disorders [23, 47]. Further, the outcomes or the severity of these diseases are worse if the 
offspring affected are male [37-39, 48-51].  
Recently, a role for the placenta in mediating developmental programming of excess 
glucocorticoids and other in utero events has been suggested [44, 47, 52-55]. The size (both 
absolute and relative to fetal size), shape, and vascular development of the placenta have all 
been identified as potential predictors of adult onset diseases. For instance, a small baby with 
a large placenta has a relative risk of adult hypertension 3 times that of a large baby with a 
normal placental size [44]. Further, the abolition of a gene vital for placental, but not cardiac 
vascular development (HOXA13) has been shown to be embryonic lethal in mice, indicating 
that placental hemodynamics play an important role in the development of the heart, and 
alterations may lead to the development of cardiovascular problems later in life [56]. 
5. Susceptibility of the placenta to negative outcomes from glucocorticoid 
exposure 
There are several reasons for the susceptible of the placenta to adverse outcomes caused by 
excess glucocorticoid exposure. I.) The placenta is in direct contact with the maternal 
circulation and thus is directly bathed in circulating maternal glucocorticoids. II.) One of the 
main roles of the placenta, as described above, is as a barrier to prevent fetal exposure to excess 
glucocorticoids; therefore the placenta may be directly altered by the glucocorticoid exposure 
before 11βHSD2 is able to convert these to their inactive metabolites [57]. III.) The structural 
development of the placenta occurs through a series of branching events, particularly the 
placental vasculature. This branching occurs similarly in other organs, such as the lung and 
kidney, which are particularly vulnerable to excess glucocorticoid exposure during periods of 
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extensive branching [58-60]. Indeed in the evolution of the placenta, the genetic pathways that 
regulate branching morphogenesis in these other organs has been utilised by the placenta [61-
65]. Hence a similar susceptibility could be expected for the placenta.  
6. Sex-specific placental regulation of glucocorticoids 
The placental is primarily derived from embryonic tissue and therefore has the same genetic 
content as the fetus. In recent studies examining both human and animal models, a number of 
fundamental differences between the placenta of a male and female fetus have been 
uncovered. Differences in placental proportions [66] and surface area [67] have been noted in 
placentas of males and females. Specifically, females have been shown to have a greater 
exchange region of the placenta compared to males [66], and within this exchange region, 
females have been reported to have a larger surface area [67]. Expression of genes and proteins 
known to have fundamental roles in controlling placental development [66], nutrient transfer, 
and other placental functions [68-71] differ between a male and female placenta. Specifically, 
placentas of male fetuses have been reported to have higher levels of the glucose transporter 
[66], higher levels of epidermal growth factor binding protein at term [68], but lower levels of 
activity of the sodium-hydrogen exchanger [70]. Levels of pregnancy hormones, produced by 
the placenta, differ for a male and female. For example, maternal serum human chorionic 
gonadotrophin levels are significantly higher in pregnancies carrying a female fetus from as 
early as 3 weeks of pregnancy [72]. Placental levels of progesterone also differ for a male and 
female fetus in many species, with a study in the gray seal, for example, showing higher levels 
in females than males [73]. Because progesterone is primarily of placental origin, these 
differences provide further evidence of the fundamental differences that exist in the placenta 
of a male and female fetus. Further, the placenta of a male and female fetus have also been 
shown to respond differently to adverse in utero environments including maternal under-
nutrition/famine [74] and in utero infection [75]. For example, female placentas demonstrated 
more striking alterations in gene expression in response to restrictions in maternal diet than 
male placentas when examined by microarray analysis. Further, placentas of male fetuses 
exhibited a greater immunologicial reaction (greater expression of TNFa, IL-10, and PTGS2) to 
simulated in utero infection. Whether these responses differ because of the fundamental 
differences that exist between the sexes remains unknown. 
Normal physiological glucocorticoid levels: During pregnancy, the term female placenta 
has significantly higher expression of the GR [31] and 11βHSD2 activity [76] than placentas 
of male fetuses. Glucocorticoids are known to negatively regulate GR expression [66, 77], 
therefore the higher GR expression within placentas of female fetuses may be physiological 
evidence that the female fetal–placental unit is exposed to less bioactive cortisol at term than 
the male. A downstream consequence of lower glucocorticoid levels may be an enhanced 
immune response. The activation of the fetal immune system is associated with the 
activation of the fetal hypothalamic pituitary adrenal axis, which results in the production of 
glucocorticoids, which in turn modulate the inflammatory response. Glucocorticoids 
function in a negative feedback loop with the hypothalamic pituitary adrenal axis, such that 
high glucocorticoid levels suppressing immune function [78]. It has been suggested that this 
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neurodevelopment seen within these babies during childhood and into adulthood [9]. While 
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convincing data of the benefits of multiple doses are obtained [34]. Much work is examining 
the outcomes of antenatal glucocorticoids for the fetus, however the effect of glucocorticoids 
on the placenta, including the potential sex-specific effects, need to be considered as these 
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normal placental size [44]. Further, the abolition of a gene vital for placental, but not cardiac 
vascular development (HOXA13) has been shown to be embryonic lethal in mice, indicating 
that placental hemodynamics play an important role in the development of the heart, and 
alterations may lead to the development of cardiovascular problems later in life [56]. 
5. Susceptibility of the placenta to negative outcomes from glucocorticoid 
exposure 
There are several reasons for the susceptible of the placenta to adverse outcomes caused by 
excess glucocorticoid exposure. I.) The placenta is in direct contact with the maternal 
circulation and thus is directly bathed in circulating maternal glucocorticoids. II.) One of the 
main roles of the placenta, as described above, is as a barrier to prevent fetal exposure to excess 
glucocorticoids; therefore the placenta may be directly altered by the glucocorticoid exposure 
before 11βHSD2 is able to convert these to their inactive metabolites [57]. III.) The structural 
development of the placenta occurs through a series of branching events, particularly the 
placental vasculature. This branching occurs similarly in other organs, such as the lung and 
kidney, which are particularly vulnerable to excess glucocorticoid exposure during periods of 
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extensive branching [58-60]. Indeed in the evolution of the placenta, the genetic pathways that 
regulate branching morphogenesis in these other organs has been utilised by the placenta [61-
65]. Hence a similar susceptibility could be expected for the placenta.  
6. Sex-specific placental regulation of glucocorticoids 
The placental is primarily derived from embryonic tissue and therefore has the same genetic 
content as the fetus. In recent studies examining both human and animal models, a number of 
fundamental differences between the placenta of a male and female fetus have been 
uncovered. Differences in placental proportions [66] and surface area [67] have been noted in 
placentas of males and females. Specifically, females have been shown to have a greater 
exchange region of the placenta compared to males [66], and within this exchange region, 
females have been reported to have a larger surface area [67]. Expression of genes and proteins 
known to have fundamental roles in controlling placental development [66], nutrient transfer, 
and other placental functions [68-71] differ between a male and female placenta. Specifically, 
placentas of male fetuses have been reported to have higher levels of the glucose transporter 
[66], higher levels of epidermal growth factor binding protein at term [68], but lower levels of 
activity of the sodium-hydrogen exchanger [70]. Levels of pregnancy hormones, produced by 
the placenta, differ for a male and female. For example, maternal serum human chorionic 
gonadotrophin levels are significantly higher in pregnancies carrying a female fetus from as 
early as 3 weeks of pregnancy [72]. Placental levels of progesterone also differ for a male and 
female fetus in many species, with a study in the gray seal, for example, showing higher levels 
in females than males [73]. Because progesterone is primarily of placental origin, these 
differences provide further evidence of the fundamental differences that exist in the placenta 
of a male and female fetus. Further, the placenta of a male and female fetus have also been 
shown to respond differently to adverse in utero environments including maternal under-
nutrition/famine [74] and in utero infection [75]. For example, female placentas demonstrated 
more striking alterations in gene expression in response to restrictions in maternal diet than 
male placentas when examined by microarray analysis. Further, placentas of male fetuses 
exhibited a greater immunologicial reaction (greater expression of TNFa, IL-10, and PTGS2) to 
simulated in utero infection. Whether these responses differ because of the fundamental 
differences that exist between the sexes remains unknown. 
Normal physiological glucocorticoid levels: During pregnancy, the term female placenta 
has significantly higher expression of the GR [31] and 11βHSD2 activity [76] than placentas 
of male fetuses. Glucocorticoids are known to negatively regulate GR expression [66, 77], 
therefore the higher GR expression within placentas of female fetuses may be physiological 
evidence that the female fetal–placental unit is exposed to less bioactive cortisol at term than 
the male. A downstream consequence of lower glucocorticoid levels may be an enhanced 
immune response. The activation of the fetal immune system is associated with the 
activation of the fetal hypothalamic pituitary adrenal axis, which results in the production of 
glucocorticoids, which in turn modulate the inflammatory response. Glucocorticoids 
function in a negative feedback loop with the hypothalamic pituitary adrenal axis, such that 
high glucocorticoid levels suppressing immune function [78]. It has been suggested that this 
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may contribute to the increased viability of female fetuses exposed to a sub-optimal in utero 
environment, compared to males, who are particularly vulnerable to changes in the 
maternal environment in which increased levels of glucocorticoids are often seen [79] (see 
above).  
Response to excess glucocorticoids: The adverse effects of glucocorticoids during 
pregnancy on placental weight in the human have been reported as early as 1977 by Koppe 
and others [80]. Since then, a number of studies, in both humans and animal models, have 
demonstrated that excess glucocorticoids during gestation have a wide range of 
consequences for the placenta, which impact its structure and function, ultimately impacting 
the fetus [22, 81-91]. Recently, these consequences have been shown to occur in a sex-specific 
manner. 
Human evidence 
Evidence is beginning to emerge from studies in the clinical setting demonstrating that 
human placentas are sexually dimorphic in their regulation of normal glucocorticoid levels 
and these differences are exacerbated in response to excess maternal glucocorticoids. Much 
of this clinical evidence is arising from the work of Clifton and colleagues, who focus on 
identifying the effect of glucocorticoids on fetal and placental development, by studying 
mothers who suffer from asthma and thus use inhaled glucocorticoid treatments throughout 
their pregnancy. Asthma affects between 3% and 12% of pregnant women worldwide and 
the prevalence among pregnant women is rising [92]. It is well recognised that women (and 
their babies) with asthma are at increased risk of poor pregnancy outcomes [93]. Clifton and 
colleagues have also examined preterm babies and the consequences of excess 
glucocorticoid exposure on their placentas.  
6.1. Effect of glucocorticoids on placental development and other pathways 
Female babies born to asthmatic mothers, who utilised inhaled glucocorticoid treatments to 
manage their symptoms, were found to be growth-reduced unlike male babies born to 
asthmatic mothers, who were normally grown, despite similar cord blood cortisol levels 
[76]. Placentas of male and female babies born to these mothers, had reduced vascularisation 
within the placental villi, resulting in reduced absolute fetal capillary volume [94], although 
this was most striking in placentas of male fetuses. Further, placentas of glucocorticoid-
exposed males also had a reduced fetal capillary length [94], which was not observed in 
placentas of female fetuses. The authors speculate that glucocorticoid treatment may 
adversely affect placental vasculogenesis and/or angiogenesis by causing endothelial cell 
rounding and capillary regression, an observation made in other tissues after glucocorticoid 
exposure [95-97]. These effects may be mediated by members of the vascular endothelial 
growth factor family or inflammatory cytokines, both of which play a key role in placental 
vasculogenesis and angiogenesis [98]. The observed changes in placental morphometry in 
male placentas would be expected to affect placental heamodynamics, however the absence 
of these changes in the female placenta do not adequately explain the reduced fetal growth 
of the female fetus in this high glucocorticoid environment. 
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A study by Stark et al [99], examined the placental pro-: anti-oxidant balance in response to 
antenatal betamethasone in placentas of preterm babies. Glucocorticoids have previously 
been shown to influence fetal reactive oxygen species production and antioxidant defences 
[100-101]. These pathways are involved in preparing the fetus for the increase in free oxygen 
radical generation which is experienced during the fetal to neonatal transition [102]. Stark 
and colleagues observed that a pro-oxidant state was present in placentas of male fetuses, 
but not females following glucocorticoid exposure. Specifically, they reported that males 
had higher levels of the oxidative stress marker, protein carbonyl and a decreased level of 
the anti-oxidant enzyme, glutathione peroxidase. The authors suggested that these findings 
could contribute to the patho-physiologic processes underlying oxygen radical diseases of 
the newborn [99]; conditions known to exhibit a male excess [103]. 
6.2. Sex-specific effects of excess glucocorticoids on the placental glucocorticoid 
barrier 
As the placental glucocorticoid barrier demonstrates sexually dimorphic regulation under 
normal conditions, and the placental response to glucocorticoids is crucial in determining 
fetal growth outcomes, the effect of excess maternal glucocorticoids on this barrier have 
been investigated. The expression of the GR within the placenta of male and female fetuses 
is reported to be sexually dimorphic under normal conditions (females having higher 
expression levels), whereas the response of GR to excess glucocorticoids is similar between 
the sexes [77].  
In preterm babies, whose mothers received antenatal betamethasone, the activity of 
placental 11βHSD2 (predominant component of the glucocorticoid barrier) was reduced in 
placentas of male fetuses only [104]. This reduction in 11βHSD2 activity would be expected 
to compound the already increased exposure of the male fetus to cortisol brought about by 
the decreased term 11βHSD2 activity within male placentas during a normal pregnancy 
[76]. This may further compound the reduced immune function in male fetuses, thus 
increasing their susceptibility to disease. Further, glucocorticoids are important for fetal 
adrenal development [104]. Male preterm babies exposed to excess glucocorticoids in utero, 
have less adrenal activity than female preterm babies exposed to similar levels of 
glucocorticoids [104], which may explain the increased risk of morbidity and mortality of 
preterm male babies. We are unaware of any studies that have investigated the other 
members of the placental glucocorticoid barrier (MR and ABCB1) and their sexually 
dimorphic response to excess glucocorticoid exposure. 
Animal models of glucocorticoid exposure 
The effects of excess maternal glucocorticoid exposure, on placental growth and 
development, has been investigated using a range of animal models including the sheep 
[105-106], rat [85], mouse [107] and spiny mouse [66]. Most of these studies have utilised 
synthetic glucocorticoids (namely dexamethasone or betamethasone) and been designed to 
mimic the level of exposure experienced by the preterm infant. However, there are also a 
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may contribute to the increased viability of female fetuses exposed to a sub-optimal in utero 
environment, compared to males, who are particularly vulnerable to changes in the 
maternal environment in which increased levels of glucocorticoids are often seen [79] (see 
above).  
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pregnancy on placental weight in the human have been reported as early as 1977 by Koppe 
and others [80]. Since then, a number of studies, in both humans and animal models, have 
demonstrated that excess glucocorticoids during gestation have a wide range of 
consequences for the placenta, which impact its structure and function, ultimately impacting 
the fetus [22, 81-91]. Recently, these consequences have been shown to occur in a sex-specific 
manner. 
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Evidence is beginning to emerge from studies in the clinical setting demonstrating that 
human placentas are sexually dimorphic in their regulation of normal glucocorticoid levels 
and these differences are exacerbated in response to excess maternal glucocorticoids. Much 
of this clinical evidence is arising from the work of Clifton and colleagues, who focus on 
identifying the effect of glucocorticoids on fetal and placental development, by studying 
mothers who suffer from asthma and thus use inhaled glucocorticoid treatments throughout 
their pregnancy. Asthma affects between 3% and 12% of pregnant women worldwide and 
the prevalence among pregnant women is rising [92]. It is well recognised that women (and 
their babies) with asthma are at increased risk of poor pregnancy outcomes [93]. Clifton and 
colleagues have also examined preterm babies and the consequences of excess 
glucocorticoid exposure on their placentas.  
6.1. Effect of glucocorticoids on placental development and other pathways 
Female babies born to asthmatic mothers, who utilised inhaled glucocorticoid treatments to 
manage their symptoms, were found to be growth-reduced unlike male babies born to 
asthmatic mothers, who were normally grown, despite similar cord blood cortisol levels 
[76]. Placentas of male and female babies born to these mothers, had reduced vascularisation 
within the placental villi, resulting in reduced absolute fetal capillary volume [94], although 
this was most striking in placentas of male fetuses. Further, placentas of glucocorticoid-
exposed males also had a reduced fetal capillary length [94], which was not observed in 
placentas of female fetuses. The authors speculate that glucocorticoid treatment may 
adversely affect placental vasculogenesis and/or angiogenesis by causing endothelial cell 
rounding and capillary regression, an observation made in other tissues after glucocorticoid 
exposure [95-97]. These effects may be mediated by members of the vascular endothelial 
growth factor family or inflammatory cytokines, both of which play a key role in placental 
vasculogenesis and angiogenesis [98]. The observed changes in placental morphometry in 
male placentas would be expected to affect placental heamodynamics, however the absence 
of these changes in the female placenta do not adequately explain the reduced fetal growth 
of the female fetus in this high glucocorticoid environment. 
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radical generation which is experienced during the fetal to neonatal transition [102]. Stark 
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the anti-oxidant enzyme, glutathione peroxidase. The authors suggested that these findings 
could contribute to the patho-physiologic processes underlying oxygen radical diseases of 
the newborn [99]; conditions known to exhibit a male excess [103]. 
6.2. Sex-specific effects of excess glucocorticoids on the placental glucocorticoid 
barrier 
As the placental glucocorticoid barrier demonstrates sexually dimorphic regulation under 
normal conditions, and the placental response to glucocorticoids is crucial in determining 
fetal growth outcomes, the effect of excess maternal glucocorticoids on this barrier have 
been investigated. The expression of the GR within the placenta of male and female fetuses 
is reported to be sexually dimorphic under normal conditions (females having higher 
expression levels), whereas the response of GR to excess glucocorticoids is similar between 
the sexes [77].  
In preterm babies, whose mothers received antenatal betamethasone, the activity of 
placental 11βHSD2 (predominant component of the glucocorticoid barrier) was reduced in 
placentas of male fetuses only [104]. This reduction in 11βHSD2 activity would be expected 
to compound the already increased exposure of the male fetus to cortisol brought about by 
the decreased term 11βHSD2 activity within male placentas during a normal pregnancy 
[76]. This may further compound the reduced immune function in male fetuses, thus 
increasing their susceptibility to disease. Further, glucocorticoids are important for fetal 
adrenal development [104]. Male preterm babies exposed to excess glucocorticoids in utero, 
have less adrenal activity than female preterm babies exposed to similar levels of 
glucocorticoids [104], which may explain the increased risk of morbidity and mortality of 
preterm male babies. We are unaware of any studies that have investigated the other 
members of the placental glucocorticoid barrier (MR and ABCB1) and their sexually 
dimorphic response to excess glucocorticoid exposure. 
Animal models of glucocorticoid exposure 
The effects of excess maternal glucocorticoid exposure, on placental growth and 
development, has been investigated using a range of animal models including the sheep 
[105-106], rat [85], mouse [107] and spiny mouse [66]. Most of these studies have utilised 
synthetic glucocorticoids (namely dexamethasone or betamethasone) and been designed to 
mimic the level of exposure experienced by the preterm infant. However, there are also a 
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large number of studies using glucocorticoids at other developmental time points including 
very early in gestation. When considering the data generated from animal models, it is 
important to take into consideration not only the timing of glucocorticoid exposure but also 
the timing of placental and fetal development in the species being used, as there is 
considerable variation in placental development and overall structure between species. 
Many of these studies, particularly those in the sheep and rat, have not analysed data 
according to fetal sex. However a couple of recent studies in the mouse and spiny mouse 
have demonstrated markedly different outcomes in placental development and gene 
expression in placentas of males and females suggesting that alterations occurring within 
the placenta, following glucocorticoid exposure, are dependent upon fetal sex.  
Sheep 
The sheep placenta is made up of 60-70 individual placentomes called cotyledons, which are 
cup shaped structures with fetal tissue surrounded by maternal tissue. Administration of 
dexamethasone for 48 hours between 64-66 days of gestation (term=145-150 days) resulted in 
generally larger cotyledons with overgrowth of the fetal tissue when the placenta was 
examined at completion of the infusion [105]. However, this was not observed in other 
studies using betamethasone later in gestation (around 100 days of gestation) [108]. 
Unfortunately, neither of these studies separated data according to fetal sex. In another 
study, pregnant ewes received intramuscular injections of dexamethasone on day 40 and 41 
of gestation and the placentas were examined at day 50, 100 or 140 days of gestation. In this 
case, data was analysed separately for males and females and whilst dexamethasone 
exposure significantly increased placental 11βHSD2 mRNA levels in males compared with 
controls at 50 and 140 days, in female placentas, levels were not altered by the 
dexamethasone exposure [106].  
Rat 
Dexamethasone exposure during late pregnancy has been shown to significantly reduce 
placental weight in the rat [91, 109]. This was associated with reduced expression of vascular 
endothelial growth factors (VEGF) and placental vascularisation [91] along with altered 
insulin like growth factor II expression. Neither of these studies looked at sex-specific 
effects. 
Mouse  
Given the extensive use of the mouse for development studies, it is somewhat surprising that 
there has been little research of the effects of glucocorticoids on the mouse placenta. We have 
recently shown that dexamethasone exposure for 2 days around mid-gestation (day 12.5-14.5 
of gestation, term=20 days) caused decreases in fetal body weight at day 14.5, but placental 
weight was only reduced in placentas from female fetuses [107]. These changes in placental 
growth were associated with sex-specific changes in placental gene and protein expression: at 
day 14.5, the placentas from female fetuses had higher mRNA levels of expression of 
11βHSD2 and VEGF, whilst protein levels of Mitogen-activated protein kinase were 
significantly reduced. By day 17.5, some 3, days after cessation of the dexamethasone, fetal 
 
Sex-Specific Effects of Prenatal Glucocorticoids on Placental Development  399 
and placental weights are restored but levels of 11βHSD2 protein are elevated in the 
placentas of female fetuses. These sex-specific changes in gene and protein levels were not 
present for nutrient transporters such as glucose transporter 1 and 3 or the major amino acid 
transports [107]. 
Spiny mouse 
We have also utilised a precocial rodent, the spiny mouse (Acomys cahirinus), in which the 
natural circulating glucocorticoid is cortisol, not corticosterone like other rodents [110], to 
explore sex-specific effects of glucocorticoids on the placenta. O’Connell et al [66] examined 
the immediate and long-term consequences of excess maternal glucocorticoids 
(dexamethasone) administered for a short time (60h) at mid-gestation (day 20, term is 39 
days) on placental structure and gene expression. The immediate consequences of 
glucocorticoid administration were similar between male and female placentas. However, 
two-weeks post-treatment (day 37), the transcriptional and structural response of the 
placenta was dependent on the sex of the fetus. Placentas of male fetuses were found to 
have an increase in the expression of a gene involved in placental patterning, glial cell 
missing 1 gene; GCM1, but also decreases in the expression of the primary placental glucose 
transporter (solute carrier family 2 (facilitated glucose transporter), member 1; SLC2A1). 
Placentas of male fetuses also had decreased amounts of maternal blood sinusoids, which 
are involved in the drawing of nutrient poor blood away from the placenta and back into 
the maternal circulation. Placentas of female fetuses were observed to have increased 
glucose transporter expression, and an increased amount of maternal blood sinusoids, in 
other words, the response of a female placenta to excess glucocorticoids was opposite to that 
of a male. This study highlights that while the immediate response to excess glucocorticoids 
may be the same for both sexes in this species, these may persist or evolve within the 
placenta differently, depending on the sex of the fetus [66]. 
7. Significance 
There is now a growing body of evidence to suggest that the placenta of a male and female 
differs and that this may underlie the greater vulnerability of males to stressors that occur 
during pregnancy. Here we provided evidence that the placental response to changes in 
maternal glucocorticoid status differs depending on the sex of the fetus and raises the 
important question: are differences in fetal outcomes driven by the fetus itself or the 
placenta. We suggest that the placenta should become an organ of greater interest to 
clinical obstetrics and perinatology, particularly with respect to how the placenta may 
function differently for a male and female fetus during periods of high glucocorticoid 
exposure.  
With respect to the clinical use of glucocorticoids, the different response of a male and 
female to even a small dose of synthetic glucocorticoids must be followed up in a large 
clinical based study. At least from experimental data, the question has been raised, “Should 
the sex of the fetus be taken into consideration when synthetic glucocorticoids are 
administered during pregnancy”? 
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insulin like growth factor II expression. Neither of these studies looked at sex-specific 
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recently shown that dexamethasone exposure for 2 days around mid-gestation (day 12.5-14.5 
of gestation, term=20 days) caused decreases in fetal body weight at day 14.5, but placental 
weight was only reduced in placentas from female fetuses [107]. These changes in placental 
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and placental weights are restored but levels of 11βHSD2 protein are elevated in the 
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may be the same for both sexes in this species, these may persist or evolve within the 
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differs and that this may underlie the greater vulnerability of males to stressors that occur 
during pregnancy. Here we provided evidence that the placental response to changes in 
maternal glucocorticoid status differs depending on the sex of the fetus and raises the 
important question: are differences in fetal outcomes driven by the fetus itself or the 
placenta. We suggest that the placenta should become an organ of greater interest to 
clinical obstetrics and perinatology, particularly with respect to how the placenta may 
function differently for a male and female fetus during periods of high glucocorticoid 
exposure.  
With respect to the clinical use of glucocorticoids, the different response of a male and 
female to even a small dose of synthetic glucocorticoids must be followed up in a large 
clinical based study. At least from experimental data, the question has been raised, “Should 
the sex of the fetus be taken into consideration when synthetic glucocorticoids are 
administered during pregnancy”? 
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1. Introduction 
‘Pregnancy loss’ can be defined as the failure by the gestational processes to result in the 
birth of a viable neonate. Miscarriage is defined as the end of pregnancy before the fetus 
reaches viability, a condition in turn depending on other variables, among which gestational 
age, birth weight and maturity, as well as the quality of assistance. Therefore to set, as it is 
done, at 24 weeks the term before which any birth should be classified as abortion is 
inadequate, because around this time some fetuses survive. On the other hand, preterm 
birth, that is strictly related with adverse infant outcome in terms of survival and quality of 
life, is defined as birth at less than 37 weeks. However it will be recognized that while up to 
the half of the second trimester no foetus at the moment can survive outside the maternal 
environment, during the third trimester, rather than from gestational age by itself, 
pregnancy loss will mainly depend on the pathologic condition leading to premature 
delivery. Recurrent miscarriage refers to the occurrence of three or even two (von Eye 
Corleta, 2010) consecutive pregnancy losses. The attempt to distinguish sporadic from 
repeated abortion stems from the believe that they may have different causes. Nevertheless, 
although it may be difficult to establish the pathogenic mechanism in single cases, in general 
it is much better understood today, and it is basically always the same: therefore it appears 
that separating sporadic from recurrent abortion is no longer needed. Indeed, pregnancy 
loss can occur at any time throughout gestation and labour as a consequence of a number of 
pathologic conditions widely recognizing two background pathways, namely the 
impairment of the blood supply to the foetus and the stimulation of uterine contractions. In 
the majority of the cases, such complications are triggered by an either pre-existent or 
acquired inflammatory mechanism. For instance, maternal rheumatic diseases represent a 
well known condition leading to poor pregnancy outcome (Spinillo et al., 2012), although, as 
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1. Introduction 
‘Pregnancy loss’ can be defined as the failure by the gestational processes to result in the 
birth of a viable neonate. Miscarriage is defined as the end of pregnancy before the fetus 
reaches viability, a condition in turn depending on other variables, among which gestational 
age, birth weight and maturity, as well as the quality of assistance. Therefore to set, as it is 
done, at 24 weeks the term before which any birth should be classified as abortion is 
inadequate, because around this time some fetuses survive. On the other hand, preterm 
birth, that is strictly related with adverse infant outcome in terms of survival and quality of 
life, is defined as birth at less than 37 weeks. However it will be recognized that while up to 
the half of the second trimester no foetus at the moment can survive outside the maternal 
environment, during the third trimester, rather than from gestational age by itself, 
pregnancy loss will mainly depend on the pathologic condition leading to premature 
delivery. Recurrent miscarriage refers to the occurrence of three or even two (von Eye 
Corleta, 2010) consecutive pregnancy losses. The attempt to distinguish sporadic from 
repeated abortion stems from the believe that they may have different causes. Nevertheless, 
although it may be difficult to establish the pathogenic mechanism in single cases, in general 
it is much better understood today, and it is basically always the same: therefore it appears 
that separating sporadic from recurrent abortion is no longer needed. Indeed, pregnancy 
loss can occur at any time throughout gestation and labour as a consequence of a number of 
pathologic conditions widely recognizing two background pathways, namely the 
impairment of the blood supply to the foetus and the stimulation of uterine contractions. In 
the majority of the cases, such complications are triggered by an either pre-existent or 
acquired inflammatory mechanism. For instance, maternal rheumatic diseases represent a 
well known condition leading to poor pregnancy outcome (Spinillo et al., 2012), although, as 
 The Author(s). Licensee InTech. This chapter is distributed under he terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
 
Glucocorticoids – New Recognition of Our Familiar Friend 408 
it will be explained ahead, abortion can also represent the only pathologic expression of 
functional changes resembling inflammation confined at the uterine mucosa level. At this 
regard, one basic need in approaching the role of glucocorticoids (GCs) in medicine is 
represented by a reappraisal to the concept itself of inflammation. This, indeed, based on 
our background medical education, is characterized by classical signs and symptoms (rubor, 
calor, tumor, dolor and functio laesa) as well as by several hemato-chemical and histological 
features. However, the cytokines and prostanoids that trigger inflammation are also 
involved in the regulation of important physiologic functions, among which social 
behaviour of cells (Biondi et al., 2006), angiogenesis (Suffee et al., 2011), haemostasis 
(Salgado et al., 1994) and smooth muscle contraction (Shynlova et al., 2009). In obstetrics, 
processes such as implantation and labour are under the control of these mediators, the 
imbalance of which is able to deviate a physiological function towards an inflammatory 
disease, leading to a wide number of gestational complications, from abortion (Saini et al, 
2011) to foetal malformation (Sljivic et al., 2006), intra-uterine growth restriction (Eastabrook 
et al., 2008), abruptio placentae (Nath et al., 2007), premature delivery (Romero et al., 2002), 
as well as hyaline membrane disease (Cheah et al., 2005), necrotizing entero-colitis (Xu et al., 
2011) and hypoxic ischemic encephalopathy of the newborn (Liu et al., 2010). Such a 
cytokine and prostanoid imbalance may therefore represent the early change for an 
eventual, future inflammation. Surprisingly, instead, implantation and labour themselves 
are often named as a sort of inflammatory process, thus implying that a pathologic event 
may be beneficial to human health: such a pointless unsafe concept should be better 
avoided. Indeed, besides its intrinsic contradiction, it represents an obstacle to the liberal use 
of some anti-inflammatory drugs, among which GCs, aimed at re-balancing the above 
mentioned mediators for preventing harmful complications. There is a further point of 
primary significance to be considered before entering into the specific field of pregnancy 
regulators, and it deals with the causal relationship between inflammation and infection. At 
this regard, it is generally accepted that it is the latter to trigger the first, while, based on a 
number of considerations, at least in some cases the opposite is true. Indeed, most bacteria 
responsible for infection belong to the saprophytic flora, thus suggesting that their shift to 
pathogen may be a consequence of an environmental alteration, possibly linked with a 
cytokine-prostanoid imbalance that leads to the inflammatory response. Such a view is 
strongly supported in obstetrics, thanks to the fundamental work of professor Romero 
showing that premature delivery, an ominous condition of pregnancy often complicated by 
infection, is preceded by an inflammation of gestational tissues: ‘the foetal inflammatory 
response syndrome’, that will be explained in a more detailed manner ahead. Being, to the 
best of our knowledge, the Romero’s syndrome the first clinical demonstration of a reversed 
causal relationship between infection and inflammation, it represents a milestone suggesting 
to search for similar pathogenic mechanisms in other fields of medicine. In the meantime, it 
opens to debate upon the role and priority of the drugs currently used in the management of 
such disease, namely GCs, antibiotics and non steroidal anti-inflammatory compounds. 
2. Mediators of physiological pregnancy 
Based on the above considerations, we proceed now to analyze the pro- as well as the anti-
inflammatory mediators of physiological pregnancy. Cytokines found at the maternal-foetal 
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interface include interferons (IFNs), interleukins (ILs), leukaemia inhibitory factor (LIF), 
tumour necrosis factors (TNFs), transforming growth factors (TGFs), colony stimulating 
factors (CSFs), vascular endothelial growth factors (VEGFs) and many others (Chaouat et al., 
2007). Although a prevalence of pro-inflammatory cytokines are found during the early 
stages of pregnancy, the action of the anti-inflammatory is needed as well. For instance, LIF 
and IL-6 are required for a successful implantation in mice (Robb et al., 1998), but the lack of 
activity of IL-11 results in reduced fertility (White et al.,2004).  
With the aim to shed light upon the complex network of reciprocal influences between 
cytokines and prostanoids from one side and their trophoblastic target form the other, we 
provide a more detailed description as regards the macrophage migration inhibitory factor 
(MIF) system, the interleukin-1 system (IL-1), the Toll-like receptors (TLRs) and the  
chemicals known as “endocrine disruptors” (EDs). (Figure 1). 
2.1. MIF 
The need for a balanced action of cytokines, whether or not of the inflammatory type, is 
confirmed looking at the macrophage migration inhibitory factor (MIF) system. MIF 
stimulates the production of a large panel of pro-inflammatory molecules, such as TNFα, 
IFNγ, IL-1β, IL-2, IL-6, IL-8 (Calandra et al., 1995) as well as nitric oxide (NO) (Cunha et al., 
1993), matrix metalloproteinases (MMPs) and products of the arachidonic acid pathway 
(Calandra et al., 2003). MIF protein and mRNA are expressed by first trimester human 
villous and extra-villous trophoblast, the protein being also found in term placenta, amniotic 
fluid and maternal serum (Ietta et al. 2002). Their levels are higher at the beginning of first 
trimester to decline later on. Moreover, they are up-regulated by low oxygen tension, 
comparable to the values occurring at the very early stage of pregnancy (Ietta et al., 2007). 
Trophoblast MIF reduces the cytotoxicity of decidual natural killer (NK) cells (Arcuri et al., 
2006), and intraperitoneal injection of rMIF to pregnant mice induces an increase of 
endometrial alpha(v),beta-3-integrin subunits and VEGF expression, that are markers of 
uterine receptivity (Bondza et al., 2008). Accordingly, pregnant MIF-treated mice show an 
enhanced rate of implanted embryos with respect to controls (Bondza et al., 2008), although 
fertility is not impaired in MIF knock-out mice (Fingerle-Rowson et al., 2003).  
2.2. IL-1  
The IL-1 system represents a further regulator of uterine receptivity and embryo 
implantation At the implantation site, immunoreactive IL-1β was detected in the villous and 
extravillous trophoblast as well as in the maternal decidual cells (Paulesu et al. 2010). 
Moreover, interleukin-1 receptor type 1 (IL-1R tI) is expressed by the syncytiotrophoblast, 
supporting the stimulatory effect of IL-1β on human chorionic gonadotropin (hCG) release 
(Masuhiro et al., 1991). IL-1 has been reported to stimulate different cytokines in the 
endometrium, including IL-6, IL-8, LIF and TNF-α, as well as the expression of 
prostaglandins (PGs)-2 and -2α and their receptor EP1 (Minas et al., 2005). The presence of 
IL-1α and IL-1β in the embryo culture medium has been correlated with successful 
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it will be explained ahead, abortion can also represent the only pathologic expression of 
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et al., 2008), abruptio placentae (Nath et al., 2007), premature delivery (Romero et al., 2002), 
as well as hyaline membrane disease (Cheah et al., 2005), necrotizing entero-colitis (Xu et al., 
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of some anti-inflammatory drugs, among which GCs, aimed at re-balancing the above 
mentioned mediators for preventing harmful complications. There is a further point of 
primary significance to be considered before entering into the specific field of pregnancy 
regulators, and it deals with the causal relationship between inflammation and infection. At 
this regard, it is generally accepted that it is the latter to trigger the first, while, based on a 
number of considerations, at least in some cases the opposite is true. Indeed, most bacteria 
responsible for infection belong to the saprophytic flora, thus suggesting that their shift to 
pathogen may be a consequence of an environmental alteration, possibly linked with a 
cytokine-prostanoid imbalance that leads to the inflammatory response. Such a view is 
strongly supported in obstetrics, thanks to the fundamental work of professor Romero 
showing that premature delivery, an ominous condition of pregnancy often complicated by 
infection, is preceded by an inflammation of gestational tissues: ‘the foetal inflammatory 
response syndrome’, that will be explained in a more detailed manner ahead. Being, to the 
best of our knowledge, the Romero’s syndrome the first clinical demonstration of a reversed 
causal relationship between infection and inflammation, it represents a milestone suggesting 
to search for similar pathogenic mechanisms in other fields of medicine. In the meantime, it 
opens to debate upon the role and priority of the drugs currently used in the management of 
such disease, namely GCs, antibiotics and non steroidal anti-inflammatory compounds. 
2. Mediators of physiological pregnancy 
Based on the above considerations, we proceed now to analyze the pro- as well as the anti-
inflammatory mediators of physiological pregnancy. Cytokines found at the maternal-foetal 
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interface include interferons (IFNs), interleukins (ILs), leukaemia inhibitory factor (LIF), 
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2007). Although a prevalence of pro-inflammatory cytokines are found during the early 
stages of pregnancy, the action of the anti-inflammatory is needed as well. For instance, LIF 
and IL-6 are required for a successful implantation in mice (Robb et al., 1998), but the lack of 
activity of IL-11 results in reduced fertility (White et al.,2004).  
With the aim to shed light upon the complex network of reciprocal influences between 
cytokines and prostanoids from one side and their trophoblastic target form the other, we 
provide a more detailed description as regards the macrophage migration inhibitory factor 
(MIF) system, the interleukin-1 system (IL-1), the Toll-like receptors (TLRs) and the  
chemicals known as “endocrine disruptors” (EDs). (Figure 1). 
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The need for a balanced action of cytokines, whether or not of the inflammatory type, is 
confirmed looking at the macrophage migration inhibitory factor (MIF) system. MIF 
stimulates the production of a large panel of pro-inflammatory molecules, such as TNFα, 
IFNγ, IL-1β, IL-2, IL-6, IL-8 (Calandra et al., 1995) as well as nitric oxide (NO) (Cunha et al., 
1993), matrix metalloproteinases (MMPs) and products of the arachidonic acid pathway 
(Calandra et al., 2003). MIF protein and mRNA are expressed by first trimester human 
villous and extra-villous trophoblast, the protein being also found in term placenta, amniotic 
fluid and maternal serum (Ietta et al. 2002). Their levels are higher at the beginning of first 
trimester to decline later on. Moreover, they are up-regulated by low oxygen tension, 
comparable to the values occurring at the very early stage of pregnancy (Ietta et al., 2007). 
Trophoblast MIF reduces the cytotoxicity of decidual natural killer (NK) cells (Arcuri et al., 
2006), and intraperitoneal injection of rMIF to pregnant mice induces an increase of 
endometrial alpha(v),beta-3-integrin subunits and VEGF expression, that are markers of 
uterine receptivity (Bondza et al., 2008). Accordingly, pregnant MIF-treated mice show an 
enhanced rate of implanted embryos with respect to controls (Bondza et al., 2008), although 
fertility is not impaired in MIF knock-out mice (Fingerle-Rowson et al., 2003).  
2.2. IL-1  
The IL-1 system represents a further regulator of uterine receptivity and embryo 
implantation At the implantation site, immunoreactive IL-1β was detected in the villous and 
extravillous trophoblast as well as in the maternal decidual cells (Paulesu et al. 2010). 
Moreover, interleukin-1 receptor type 1 (IL-1R tI) is expressed by the syncytiotrophoblast, 
supporting the stimulatory effect of IL-1β on human chorionic gonadotropin (hCG) release 
(Masuhiro et al., 1991). IL-1 has been reported to stimulate different cytokines in the 
endometrium, including IL-6, IL-8, LIF and TNF-α, as well as the expression of 
prostaglandins (PGs)-2 and -2α and their receptor EP1 (Minas et al., 2005). The presence of 
IL-1α and IL-1β in the embryo culture medium has been correlated with successful 
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implantation after in vitro fertilization (Karagouni et al., 1998). Later studies of endometrial 
secretions from women before embryo transfer showed the association of lower levels of IL-
1β with clinical pregnancy (Boomsma et al., 2009). Since IL-1β and TNFα are significantly 
related to clinical pregnancy and not embryo implantation, it was suggested that these two 
cytokines are not associated with the initial apposition and adhesion of the embryo 
(Boomsma et al., 2009). An inappropriate ratio of IL-1β to IL-α and higher IL-1R tI are 
involved in the establishment of ectopic pregnancy in the oviduct (Huang et al., 2005). IL-1β 
mediates the paracrine effect of PG synthesis by inducing COX-2 (Pellicer et al., 2002), and 
IL-1α induces the production of MMP-1 in stromal fibroblast and raises the activity of MMP-
9 in trophoblast (Pellicer et al., 2002). Moreover, it has been shown that trophoblast reduces 
the secretion of pro-inflammatory cytokines IL-1β, IL-6 and TNFα elicited by low (0.1 
μg/mL), but not high, doses lipopolysaccharide (LPS)-activated monocytes (Fest et al., 2007). 
As the female genital tract is opened to the external environment, cytokine release by 
gestational tissue can be influenced by external factors. For instance, exposure to seminal 
plasma factors including TGFβ1 stimulates cytokine production by uterine epithelial cells, 
with consequent recruitment and activation of macrophages, granulocytes and dendritic 
cells in the underlying stroma (Gopichandran et al., 2006).  
2.3. TLRs 
Cytokine release by gestational tissue is further regulated through the action of specific 
receptors for pathogen-associated molecular patterns, named Toll-like receptors (TLRs). 
These are present in the epithelial lining as well as in the underlying connective stroma of 
the human female reproductive tract (Hirata et al., 2007). TLR2 and TLR4 have been 
detected in villous and extra-villous, but not in syncytial first trimester trophoblast, TLR6, 
instead, is absent in the first but present in the third trimester trophoblast (Mitsunari et al., 
2006).  Binding of TLRs with microbial antigens activates the release of pro-inflammatory 
cytokines, possibly interfering with their physiological gestational balance (Schaefer et al., 
2005). In addition to the above mentioned factors, also stress, nutrition, metabolic status, 
drugs and environmental chemicals (Arck et al., 2008), as well as genetic conditions are 
known to influence gestational cytokine and prostanoids. 
2.4. EDs 
Some chemicals defined as “endocrine disruptors” (EDs) are able to act like natural 
estrogens, interfering with reproductive processes. For instance, it has been recently shown 
that the ED para-nonylphenol (p-NP) affects trophoblast cytokine secretion as well as cell 
differentiation and apoptosis (Bechi et al., 2010). In addition to cytokines and prostanoids, 
also the cellular components of the immune system are involved in the regulation of 
physiological pregnancy. Among these, NK cells, that are large granular lymphocytes 
constituting 10-15% of their total circulating number. Even though their main activity is 
citotoxicity of target cells, in normal pregnancy they provide benefit by secreting cytokines, 
chemokines and angiogenetic factors which are needed for pregnancy success (Santoni et al., 
2008). There is a further class of NK at the decidual level, named uterine NK (uNK), which 
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are provided with phenotypic markers different from peripheral (pNK). uNK cells seem to 
be necessary for pregnancy success by producing factors that modulate trophoblast invasion 
and placental vascularization (Saito et al., 1993).  
All above evidences outline the concept that there is no single substance, or mediator, or cell 
type that can be specifically identified as either detrimental or protective towards 
physiological pregnancy, but rather that it is their imbalance which can lead to an 
unfavourable outcome.  
 
Figure 1. Influences of MIF and IL-1 systems on cytokine network in physiologic pregnancy 
3. Hormone regulation of gestational cytokines and prostanoids 
Pregnancy can be defined as a vascular  phenomenon under the control of steroid 
hormones. Indeed nearly all above mentioned mediators are directly or indirectly able to 
interfere with the maternal uterine arteries changes aimed at increasing the foetal blood 
supply, and they are largely influenced by steroids. Therefore we will look now at the 
experimental results supporting the specific role of estrogen, progesterone and 
glucocorticoids in the control of the mediators of gestational functions. In particular, as 
progesterone and glucocorticoids actions are higly impaired by the abortive drug named 
mifepristone, we will compare influence of such compounds upon some gestational 
regulators and functions. Such a comparison should better address to understand the nature 
of both hormonal protection and drug impairment of pregnancy, provided that their action 
mechanisms lead to opposite regulatory consequences.   
3.1. Estrogen and progesterone  
Estradiol and progesterone exert an important role in the regulation of a number of the 
factors involved in gestational processes thus avoiding harmful inflammatory response 
(Dekel et al., 2010). By doing so, these hormones also modulate epithelial cells ability to 
respond to pathogenic microbes. Indeed estradiol suppresses the secretion of MIF, TNFα, 
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implantation after in vitro fertilization (Karagouni et al., 1998). Later studies of endometrial 
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9 in trophoblast (Pellicer et al., 2002). Moreover, it has been shown that trophoblast reduces 
the secretion of pro-inflammatory cytokines IL-1β, IL-6 and TNFα elicited by low (0.1 
μg/mL), but not high, doses lipopolysaccharide (LPS)-activated monocytes (Fest et al., 2007). 
As the female genital tract is opened to the external environment, cytokine release by 
gestational tissue can be influenced by external factors. For instance, exposure to seminal 
plasma factors including TGFβ1 stimulates cytokine production by uterine epithelial cells, 
with consequent recruitment and activation of macrophages, granulocytes and dendritic 
cells in the underlying stroma (Gopichandran et al., 2006).  
2.3. TLRs 
Cytokine release by gestational tissue is further regulated through the action of specific 
receptors for pathogen-associated molecular patterns, named Toll-like receptors (TLRs). 
These are present in the epithelial lining as well as in the underlying connective stroma of 
the human female reproductive tract (Hirata et al., 2007). TLR2 and TLR4 have been 
detected in villous and extra-villous, but not in syncytial first trimester trophoblast, TLR6, 
instead, is absent in the first but present in the third trimester trophoblast (Mitsunari et al., 
2006).  Binding of TLRs with microbial antigens activates the release of pro-inflammatory 
cytokines, possibly interfering with their physiological gestational balance (Schaefer et al., 
2005). In addition to the above mentioned factors, also stress, nutrition, metabolic status, 
drugs and environmental chemicals (Arck et al., 2008), as well as genetic conditions are 
known to influence gestational cytokine and prostanoids. 
2.4. EDs 
Some chemicals defined as “endocrine disruptors” (EDs) are able to act like natural 
estrogens, interfering with reproductive processes. For instance, it has been recently shown 
that the ED para-nonylphenol (p-NP) affects trophoblast cytokine secretion as well as cell 
differentiation and apoptosis (Bechi et al., 2010). In addition to cytokines and prostanoids, 
also the cellular components of the immune system are involved in the regulation of 
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constituting 10-15% of their total circulating number. Even though their main activity is 
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chemokines and angiogenetic factors which are needed for pregnancy success (Santoni et al., 
2008). There is a further class of NK at the decidual level, named uterine NK (uNK), which 
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are provided with phenotypic markers different from peripheral (pNK). uNK cells seem to 
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and placental vascularization (Saito et al., 1993).  
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type that can be specifically identified as either detrimental or protective towards 
physiological pregnancy, but rather that it is their imbalance which can lead to an 
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Moreover the hormone stimulates IL-1β secretion in LPS-activated human uterine 
monocytes and down-regulates protein-expression of IL-1RtI, thus inhibiting the IL-1β-
mediated inflammatory response. In chorionic explants MIF secretion is dose-dependently 
modulated by 17β-estradiol (E2) (Ietta et al., 2010). As for progesterone, it favours the 
secretion of IL-3, IL-4, IL-5 and IL-10, that are reported to inhibit the Th1 response (Pioli et 
al., 2006). Interestingly, however, dydrogesterone induction of a Th1 to Th2 cytokine shift is 
also expressed by inhibition of IFN-γ and TNF-α but up-regulation of the production of IL-4 
and IL-6. It happens therefore that, given a protective action of progesterone against 
abortion, IL6, that is able to trigger PG release, thus leading to abortion or premature 
delivery, being up-regulated by the hormone, should be considered protective in the context 
of early pregnancy! (Raghupathy et al., 2005).  
3.2. Mifepristone  
The complexity of the relation between cytokine balance and pregnancy outcome is further 
expressed by comparison of mifepristone (Ru486), betamethasone and progesterone action 
mechanisms. As for the antiprogestational action of Ru486, the mechanism by which it 
inactivates the progesterone receptor (PR) is not completely clarified (Leonhardt et al., 2002). 
However it appears that its abortive action could be in some way related with an influence 
on cytokines, as repeated administration of the drug significantly enhances the serum 
production of TNFα and IFNγ while prolonging LPS-induced depressive-like behaviour in 
rats (Wang et al., 2011), although it does not exert the same effect in mice (Yang et al., 2008). 
RU486 also stimulates the expression of IL-6 and LIF protein in human villous trophoblast 
and stroma cells in early pregnancy, thus questioning the supposed IL6 protective role (Pei 
et al., 2010). Indeed, while opening to debate the action mechanism of progestogens, GCs 
and their antagonists at the level of gestational tissues, such contradictory observations do 
not clarify (whether or not inflammatory) the role of IL6 in pregnancy. RU486 counteracts 
the hyper-polarization of cell membranes as well as the inhibition of gap-junctions 
responsible for uterine contraction exerted by the hormone (Garfield et al., 1988). It also 
stimulates the release of PG and impairs the PG-dehydrogenase activity (Norman et al., 
1991). As a consequence, the uterine sensibility to PG is significantly enhanced. Accordingly, 
the capacity of the drug alone to induce abortion is low, while it raises up to 95% when 
followed by PG administration (Grimes, 1997). Therefore, once again, it appears that early 
abortion of an otherwise normal pregnancy is mainly obtained by smooth muscle 
contraction (and therefore by impairment of utero-placental blood perfusion), rather than by 
a disturbance of the cellular mechanisms of implantation. However, the antiglucocorticoid 
nature of RU486 is also well characterized. Indeed, it binds to the glucocorticoid receptor 
(GR), and oral administration of the drug results in a dose-dependent activation of the 
hypothalamic-pituitary-adrenal (HPA) axis (Gaillard et al., 1984). Despite the compensatory 
increase in the serum cortisol concentration, in patients undergoing medical termination of a 
first trimester pregnancy the net effect of this compound is a profound suppression of 
circulating GC bioactivity (Heikinheimo et al.; 2003). Given the power of the anti-GC 
activity of RU486, the question arises whether its abortive action is also due to this property. 
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Furthermore it is interesting to ascertain whether such an action is to be ascribed to the 
disturbance of intercellular communication at the earliest stage of blastocyst implantation or 
to impairment of blood perfusion later on. Indeed, among the potentially positive effects of 
GC in early pregnancy, promotion of trophoblast growth and invasion have been suggested, 
along with stimulation of hCG secretion and suppression of NK cells (Michael & 
Papageorghiou; 2008). By modulating extravillous trophoblast proliferation and invasion, in 
fact GC may directly influence the capacity of chorionic villi to modify the structure of 
maternal spiral arteries, a change aimed at meeting the needs of embryo oxygenation and 
growth. The initial process of invasion belongs to the cross-talk between trophoblast and 
uterine decidua. Blastocyst attachment appears to be regulated by cell surface signalling 
molecules among which integrins and bronectin. At physiological concentrations (100 
nmol/l), GCs can suppress the expression of trophoblast integrins while their effects on 
fibronectin expression are tissue-specic (Burrows et al., 1996). For instance, in human 
pregnancy at term, dexamethasone suppresses bronectin expression cytotrophoblasts and 
amnion while it acts in synergy with transforming growth factor-b towards up-regulation in 
matched samples of chorion and placental mesenchymal cells (Guller et al., 1995). Moreover, 
trophoblast functions are regulated by gap-junctional intercellular communication (GJIC) 
(Malassiné & Cronier, 2005). Gap junctions (GJ) are membrane channels which span the 
intercellular space, providing a pathway for the exchange of signalling molecules such as 
second messengers and siRNA. Said channels are constituted by the association of two 
hemi-channels, termed connexons, each composed of six connexin (Cx) subunits. 
Trophoblast Cx expression is modulated by hCG and estradiol, and GCs have been shown 
to enhance trophoblast GJIC in human pregnancy at term (Cronier et al., 1998). We have 
recently demonstrated that betamethasone selectively modifies trophoblast GR and Cx 
expression, enhancing the GRα isoform without affecting GRβ, and inhibiting Cx40 
expression while increasing that of Cx43 and 45. Furthermore, betamethasone exerts an 
inhibitory action on cell proliferation. This result could be at least partly due to the 
inhibitory effect of the reduced expression of Cx40, coupled with an upregulation of Cx43. 
Indeed, it has been reported that Cx40 is involved in trophoblast proliferation (Winterhager 
et al. 1999; Nishimura et al. 2004), and that Cx43 upregulation is associated with an inhibition 
of JEG-3 cell proliferation (Kibschull et al. 2008). By modulating extravillous trophoblast 
proliferation and invasion, GCs may directly influence the capacity of chorionic villi to 
modify the structure of maternal spiral arteries, a change aimed at meeting the needs of 
embryo oxygenation and growth. 
RU-486, in spite of its anti-GR property, does not contrast this effect of betamethasone. On 
the contrary, it induces responses similar to those of the hormone. As for progesterone, it 
shows the same effect as betamethasone on Cx expression, while it does not affect 
proliferation. RU-486 does not antagonize the progesterone effect as well. These results, by 
confirming that neither the abortive action of RU486 nor the protective action of GCs are 
obtained through their influence on trophoblast Cx expression, along with the other above 
mentioned evidences, do not exclude that the abortive mechanism of the drug may be also 
linked to its anti-glucocorticoid action at a level other than Cx (Cervellati et al., 2011). 
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Moreover the hormone stimulates IL-1β secretion in LPS-activated human uterine 
monocytes and down-regulates protein-expression of IL-1RtI, thus inhibiting the IL-1β-
mediated inflammatory response. In chorionic explants MIF secretion is dose-dependently 
modulated by 17β-estradiol (E2) (Ietta et al., 2010). As for progesterone, it favours the 
secretion of IL-3, IL-4, IL-5 and IL-10, that are reported to inhibit the Th1 response (Pioli et 
al., 2006). Interestingly, however, dydrogesterone induction of a Th1 to Th2 cytokine shift is 
also expressed by inhibition of IFN-γ and TNF-α but up-regulation of the production of IL-4 
and IL-6. It happens therefore that, given a protective action of progesterone against 
abortion, IL6, that is able to trigger PG release, thus leading to abortion or premature 
delivery, being up-regulated by the hormone, should be considered protective in the context 
of early pregnancy! (Raghupathy et al., 2005).  
3.2. Mifepristone  
The complexity of the relation between cytokine balance and pregnancy outcome is further 
expressed by comparison of mifepristone (Ru486), betamethasone and progesterone action 
mechanisms. As for the antiprogestational action of Ru486, the mechanism by which it 
inactivates the progesterone receptor (PR) is not completely clarified (Leonhardt et al., 2002). 
However it appears that its abortive action could be in some way related with an influence 
on cytokines, as repeated administration of the drug significantly enhances the serum 
production of TNFα and IFNγ while prolonging LPS-induced depressive-like behaviour in 
rats (Wang et al., 2011), although it does not exert the same effect in mice (Yang et al., 2008). 
RU486 also stimulates the expression of IL-6 and LIF protein in human villous trophoblast 
and stroma cells in early pregnancy, thus questioning the supposed IL6 protective role (Pei 
et al., 2010). Indeed, while opening to debate the action mechanism of progestogens, GCs 
and their antagonists at the level of gestational tissues, such contradictory observations do 
not clarify (whether or not inflammatory) the role of IL6 in pregnancy. RU486 counteracts 
the hyper-polarization of cell membranes as well as the inhibition of gap-junctions 
responsible for uterine contraction exerted by the hormone (Garfield et al., 1988). It also 
stimulates the release of PG and impairs the PG-dehydrogenase activity (Norman et al., 
1991). As a consequence, the uterine sensibility to PG is significantly enhanced. Accordingly, 
the capacity of the drug alone to induce abortion is low, while it raises up to 95% when 
followed by PG administration (Grimes, 1997). Therefore, once again, it appears that early 
abortion of an otherwise normal pregnancy is mainly obtained by smooth muscle 
contraction (and therefore by impairment of utero-placental blood perfusion), rather than by 
a disturbance of the cellular mechanisms of implantation. However, the antiglucocorticoid 
nature of RU486 is also well characterized. Indeed, it binds to the glucocorticoid receptor 
(GR), and oral administration of the drug results in a dose-dependent activation of the 
hypothalamic-pituitary-adrenal (HPA) axis (Gaillard et al., 1984). Despite the compensatory 
increase in the serum cortisol concentration, in patients undergoing medical termination of a 
first trimester pregnancy the net effect of this compound is a profound suppression of 
circulating GC bioactivity (Heikinheimo et al.; 2003). Given the power of the anti-GC 
activity of RU486, the question arises whether its abortive action is also due to this property. 
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Furthermore it is interesting to ascertain whether such an action is to be ascribed to the 
disturbance of intercellular communication at the earliest stage of blastocyst implantation or 
to impairment of blood perfusion later on. Indeed, among the potentially positive effects of 
GC in early pregnancy, promotion of trophoblast growth and invasion have been suggested, 
along with stimulation of hCG secretion and suppression of NK cells (Michael & 
Papageorghiou; 2008). By modulating extravillous trophoblast proliferation and invasion, in 
fact GC may directly influence the capacity of chorionic villi to modify the structure of 
maternal spiral arteries, a change aimed at meeting the needs of embryo oxygenation and 
growth. The initial process of invasion belongs to the cross-talk between trophoblast and 
uterine decidua. Blastocyst attachment appears to be regulated by cell surface signalling 
molecules among which integrins and bronectin. At physiological concentrations (100 
nmol/l), GCs can suppress the expression of trophoblast integrins while their effects on 
fibronectin expression are tissue-specic (Burrows et al., 1996). For instance, in human 
pregnancy at term, dexamethasone suppresses bronectin expression cytotrophoblasts and 
amnion while it acts in synergy with transforming growth factor-b towards up-regulation in 
matched samples of chorion and placental mesenchymal cells (Guller et al., 1995). Moreover, 
trophoblast functions are regulated by gap-junctional intercellular communication (GJIC) 
(Malassiné & Cronier, 2005). Gap junctions (GJ) are membrane channels which span the 
intercellular space, providing a pathway for the exchange of signalling molecules such as 
second messengers and siRNA. Said channels are constituted by the association of two 
hemi-channels, termed connexons, each composed of six connexin (Cx) subunits. 
Trophoblast Cx expression is modulated by hCG and estradiol, and GCs have been shown 
to enhance trophoblast GJIC in human pregnancy at term (Cronier et al., 1998). We have 
recently demonstrated that betamethasone selectively modifies trophoblast GR and Cx 
expression, enhancing the GRα isoform without affecting GRβ, and inhibiting Cx40 
expression while increasing that of Cx43 and 45. Furthermore, betamethasone exerts an 
inhibitory action on cell proliferation. This result could be at least partly due to the 
inhibitory effect of the reduced expression of Cx40, coupled with an upregulation of Cx43. 
Indeed, it has been reported that Cx40 is involved in trophoblast proliferation (Winterhager 
et al. 1999; Nishimura et al. 2004), and that Cx43 upregulation is associated with an inhibition 
of JEG-3 cell proliferation (Kibschull et al. 2008). By modulating extravillous trophoblast 
proliferation and invasion, GCs may directly influence the capacity of chorionic villi to 
modify the structure of maternal spiral arteries, a change aimed at meeting the needs of 
embryo oxygenation and growth. 
RU-486, in spite of its anti-GR property, does not contrast this effect of betamethasone. On 
the contrary, it induces responses similar to those of the hormone. As for progesterone, it 
shows the same effect as betamethasone on Cx expression, while it does not affect 
proliferation. RU-486 does not antagonize the progesterone effect as well. These results, by 
confirming that neither the abortive action of RU486 nor the protective action of GCs are 
obtained through their influence on trophoblast Cx expression, along with the other above 
mentioned evidences, do not exclude that the abortive mechanism of the drug may be also 
linked to its anti-glucocorticoid action at a level other than Cx (Cervellati et al., 2011). 
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Moreover, as for the nature of the events leading to pregnancy loss, it appears that it is not 
to be ascribed to the disturbance of intercellular communication at the earliest stage of 
blastocyst implantation, but rather to the impairment of blood perfusion and triggering of 
uterine contractions obtained through an intensive prostaglandin administration later on. If 
the enhanced responsiveness of myometrium to prostaglandins, that represents the main 
abortive action of mifepristone, derives from the anti-progesterone or anti-GCs effects, or 
even both or none of them, remains to be ascertained.  
3.3. Influence of GCs on TLR and MIF 
Further examples of the regulatory actions of GCs are down-regulation of TLR expression, 
suppression of pro-inflammatory and up-regulation of anti-inflammatory cytokines by 
dexamethasone in primary isolated murine liver cells (Broering et al., 2011), as well as 
inhibition of the human pro-IL-lβ gene by decreasing DNA binding of transactivators to the 
signal-responsive enhancer (Waterman et al., 2006). It is interesting to observe that the GR 
can be influenced even independently from GCs. Indeed the unliganded GR attenuates 
TNF-α stimulated IL-6 transcription by a mechanism involving selective phosphorylation 
and recruitment of the unliganded GR and GRIP-1 to the IL-6 promoter. It is suggested that 
such an autoregulatory mechanism may prevent overproduction of IL-6 in the endocervix, 
possibly protecting against negative effects of excessive inflammation (Verhoog et al., 2011). 
However GCs are also reported to induce, rather than to inhibit, the secretion of MIF 
(Calandra et al., 1995), thus counteracting the hormone inhibition of pro-inflammatory 
cytokine production. Such an influence is an example of particular relevance in 
understanding the nature of a balanced protective action against pregnancy loss.  
3.4. Trans-placental passageand  action site  of GCs 
A further matter of debate is represented by the regulation of GCs passage into the foetal 
circulation by placental 11β-hydroxy-dehydrogenase type 2 (11β-HSD2), the level of 
expression and activity of which is determined by a delicate balance between stimulatory 
and inhibitory influences. Studies of human and other primate placentas or derived 
trophoblast cells have shown that placental 11β-HSD2 activity is reduced by progesterone, 
estrogen, NO, PGs, proinflammatory cytokines and infections, β-adrenoceptor agonists, 
hypoxia and peroxisome proliferator-activated receptor δ agonists. Conversely, placental 
11β-HSD2 activity is stimulated by GCs, retinoids and activators of the pathway that 
includes cyclic AMP and protein kinase A (Seckl et al., 2007). Moreover, the exposure of 
foetal tissues to cortisol may be determined locally by 11β-HSD isoenzymes within the 
foetus, rather than simply by GC metabolism at the materno-fetal interface (McNeil et al., 
2007). In the trophoblast cells, (the most abundant site of 11β-HSD1), cortisol up-regulates 
enzyme expression inducing promoter activity, and the effect is enhanced by IL-1β. This 
suggests that more biologically active GCs could be generated in the foetal membranes in 
the presence of infection, which may consequently feed forward in up-regulation of PG 
synthesis. Intriguingly, foetal membranes are a major site of PG synthesis during pregnancy 
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(Li et al., 2006), the production of which has been reported to be increased by GCs (Sun et al., 
2003). However, such stimulatory actions of GCs on the biosynthetic pathways of PG, rather 
than simply suggesting adverse clinical outcomes, sharpen the complexity of the hormonal 
regulatory influence upon the internal homeostasis of organic functions, as they, as it will be 
said ahead, adequately administrated, ultimately contribute to shift the complicate network 
of cytokines and prostanoids towards a beneficial direction. All above evidences indicate 
nothing more than the regulation of gestational processes to rely upon an extremely high 
number of mediators under physiological hormonal control, that are influenced by both 
maternal and foetal conditions (either congenital or acquired), as well as by external factors 
able to modify utero-placental perfusion and myometrial quiescence. As pregnancy loss can 
occur at any time during gestation and labour, it follows that the outcome of pregnancy will 
depend on the grade and time of the regulators derangement. In other words, speaking of 
pregnancy loss, there is no difference between the pathogenic mechanism of abortion and 
that of premature delivery, other than the first to happen very early, the second at a time 
when the foetus may have already reached the capacity to survive. 
4. Direct and indirect relationship between inflammation and pregnancy 
loss 
Aetiology of pregnancy loss includes chromosomal, anatomical, hormonal, immunological 
and endocrinological abnormalities, but in most cases the cause remains unexplained. It is 
frequently claimed that an inflammatory microenvironment is required for adequate tissue 
remodelling during implantation and the early phase of pregnancy (Challis et al., 2009). On 
the contrary, the second trimester is characterized by a prevalence of anti-inflammatory 
signals. An inflammatory pattern is then required near term of pregnancy to induce labour 
contractions and cervical dilatation (Paulesu et al., 2010). At this regard, for instance, we 
have demonstrated the presence on human amnion-derived WISH cells of binding sites for 
formyl-methionyl-leucyl-phenylalanine (fMLP), the classical chemotactic receptor for N-
formyl peptides. fMLP induces a significant increase of PGE2 release by these human 
amnion-derived cells. Such a response in turn is impaired by COX, phospholipase A2, and 
phospholipase C inhibitors (Biondi et al., 2001). Furthermore we have shown that labouring 
amniotic membranes express both high- and low-affinity specific receptors for 3H-fMLP, 
while only the low-affinity are found in non-labouring tissue, and that the peptide is able to 
significantly increase PG synthesis in perifused amnion fragments from labouring and non-
labouring women. (Buzzi et al., 1999). Nevertheless, abnormal inflammatory events may 
lead to adverse pregnancy outcomes, such as implantation failure, pregnancy loss, 
preeclampsia, preterm labour, intrauterine growth restriction (IUGR), and foetal 
inflammatory syndrome (Kwak-Kim et al., 2010). Disregulation of cell function mediators 
can simply derive from genetic conditions, with no need for infectious or inflammatory 
external stimuli. Indeed, it has been reported that polymorphisms in immunoregulatory 
genes IL10, MBL2, TNFRSF6 and TGFB1 may influence susceptibility to chorioamnionitis 
(Annells et al., 2005), and common genetic variants in proinflammatory cytokine genes, such 
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Moreover, as for the nature of the events leading to pregnancy loss, it appears that it is not 
to be ascribed to the disturbance of intercellular communication at the earliest stage of 
blastocyst implantation, but rather to the impairment of blood perfusion and triggering of 
uterine contractions obtained through an intensive prostaglandin administration later on. If 
the enhanced responsiveness of myometrium to prostaglandins, that represents the main 
abortive action of mifepristone, derives from the anti-progesterone or anti-GCs effects, or 
even both or none of them, remains to be ascertained.  
3.3. Influence of GCs on TLR and MIF 
Further examples of the regulatory actions of GCs are down-regulation of TLR expression, 
suppression of pro-inflammatory and up-regulation of anti-inflammatory cytokines by 
dexamethasone in primary isolated murine liver cells (Broering et al., 2011), as well as 
inhibition of the human pro-IL-lβ gene by decreasing DNA binding of transactivators to the 
signal-responsive enhancer (Waterman et al., 2006). It is interesting to observe that the GR 
can be influenced even independently from GCs. Indeed the unliganded GR attenuates 
TNF-α stimulated IL-6 transcription by a mechanism involving selective phosphorylation 
and recruitment of the unliganded GR and GRIP-1 to the IL-6 promoter. It is suggested that 
such an autoregulatory mechanism may prevent overproduction of IL-6 in the endocervix, 
possibly protecting against negative effects of excessive inflammation (Verhoog et al., 2011). 
However GCs are also reported to induce, rather than to inhibit, the secretion of MIF 
(Calandra et al., 1995), thus counteracting the hormone inhibition of pro-inflammatory 
cytokine production. Such an influence is an example of particular relevance in 
understanding the nature of a balanced protective action against pregnancy loss.  
3.4. Trans-placental passageand  action site  of GCs 
A further matter of debate is represented by the regulation of GCs passage into the foetal 
circulation by placental 11β-hydroxy-dehydrogenase type 2 (11β-HSD2), the level of 
expression and activity of which is determined by a delicate balance between stimulatory 
and inhibitory influences. Studies of human and other primate placentas or derived 
trophoblast cells have shown that placental 11β-HSD2 activity is reduced by progesterone, 
estrogen, NO, PGs, proinflammatory cytokines and infections, β-adrenoceptor agonists, 
hypoxia and peroxisome proliferator-activated receptor δ agonists. Conversely, placental 
11β-HSD2 activity is stimulated by GCs, retinoids and activators of the pathway that 
includes cyclic AMP and protein kinase A (Seckl et al., 2007). Moreover, the exposure of 
foetal tissues to cortisol may be determined locally by 11β-HSD isoenzymes within the 
foetus, rather than simply by GC metabolism at the materno-fetal interface (McNeil et al., 
2007). In the trophoblast cells, (the most abundant site of 11β-HSD1), cortisol up-regulates 
enzyme expression inducing promoter activity, and the effect is enhanced by IL-1β. This 
suggests that more biologically active GCs could be generated in the foetal membranes in 
the presence of infection, which may consequently feed forward in up-regulation of PG 
synthesis. Intriguingly, foetal membranes are a major site of PG synthesis during pregnancy 
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(Li et al., 2006), the production of which has been reported to be increased by GCs (Sun et al., 
2003). However, such stimulatory actions of GCs on the biosynthetic pathways of PG, rather 
than simply suggesting adverse clinical outcomes, sharpen the complexity of the hormonal 
regulatory influence upon the internal homeostasis of organic functions, as they, as it will be 
said ahead, adequately administrated, ultimately contribute to shift the complicate network 
of cytokines and prostanoids towards a beneficial direction. All above evidences indicate 
nothing more than the regulation of gestational processes to rely upon an extremely high 
number of mediators under physiological hormonal control, that are influenced by both 
maternal and foetal conditions (either congenital or acquired), as well as by external factors 
able to modify utero-placental perfusion and myometrial quiescence. As pregnancy loss can 
occur at any time during gestation and labour, it follows that the outcome of pregnancy will 
depend on the grade and time of the regulators derangement. In other words, speaking of 
pregnancy loss, there is no difference between the pathogenic mechanism of abortion and 
that of premature delivery, other than the first to happen very early, the second at a time 
when the foetus may have already reached the capacity to survive. 
4. Direct and indirect relationship between inflammation and pregnancy 
loss 
Aetiology of pregnancy loss includes chromosomal, anatomical, hormonal, immunological 
and endocrinological abnormalities, but in most cases the cause remains unexplained. It is 
frequently claimed that an inflammatory microenvironment is required for adequate tissue 
remodelling during implantation and the early phase of pregnancy (Challis et al., 2009). On 
the contrary, the second trimester is characterized by a prevalence of anti-inflammatory 
signals. An inflammatory pattern is then required near term of pregnancy to induce labour 
contractions and cervical dilatation (Paulesu et al., 2010). At this regard, for instance, we 
have demonstrated the presence on human amnion-derived WISH cells of binding sites for 
formyl-methionyl-leucyl-phenylalanine (fMLP), the classical chemotactic receptor for N-
formyl peptides. fMLP induces a significant increase of PGE2 release by these human 
amnion-derived cells. Such a response in turn is impaired by COX, phospholipase A2, and 
phospholipase C inhibitors (Biondi et al., 2001). Furthermore we have shown that labouring 
amniotic membranes express both high- and low-affinity specific receptors for 3H-fMLP, 
while only the low-affinity are found in non-labouring tissue, and that the peptide is able to 
significantly increase PG synthesis in perifused amnion fragments from labouring and non-
labouring women. (Buzzi et al., 1999). Nevertheless, abnormal inflammatory events may 
lead to adverse pregnancy outcomes, such as implantation failure, pregnancy loss, 
preeclampsia, preterm labour, intrauterine growth restriction (IUGR), and foetal 
inflammatory syndrome (Kwak-Kim et al., 2010). Disregulation of cell function mediators 
can simply derive from genetic conditions, with no need for infectious or inflammatory 
external stimuli. Indeed, it has been reported that polymorphisms in immunoregulatory 
genes IL10, MBL2, TNFRSF6 and TGFB1 may influence susceptibility to chorioamnionitis 
(Annells et al., 2005), and common genetic variants in proinflammatory cytokine genes, such 
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as some selected TNF/LTA haplotypes,  increase the risk for spontaneous preterm birth 
(Engel et al., 2005). 
4.1. The Th1/Th2 paradigm 
It has been suggested that a successful pregnancy may be a Th2 type phenomenon, whereas 
a Th1-type prevalence could be detrimental (Kwak-Kim et al., 2003). Immune regulation of 
pregnancy is mediated by TH1, TH2 and macrphages throughout the release of a number of 
cytokines (Table 1). Women with recurrent pregnancy loss have higher peripheral 
concentrations of certain Th1 cytokines (IL-2, TNF-α, TNF-β, IFN-γ) and lower 
concentrations of Th2 (IL-4, -5, -6, -10) when compared with successful pregnancy. Th1 
cytokines, especially IFN-γ, may activate endothelial cell procoagulants and cause 
thrombotic and inflammatory reactions at the utero-placental level (Clark et al 1998). As for 
the mechanism by which thrombotic changes are induced, it has been reported an increased 
expression of pro-coagulant Fg12 in trophoblast cells from failing pregnancy (Knackstedt et 
al., 2001). Fg12 is a glycoprotein able to directly cleave prothrombin to thrombin, leading to 
fibrin deposition. Th1 cytokines up regulate this procoagulant, with consequent activation of 
the coagulation system and disruption of vascular supply to the placenta. On the contrary, 
Th2 system can hamper this process, suppressing Th1 response (Saini et al., 2011). Among 
proinflammatory cytokines, TNF-α is of particular interest. Indeed, even though a low 
concentration is required for successful implantation, it also causes trophoblast apoptosis in 
combination with Th1 cytokines such INF-γ. The cytokine could even be involved in 
pregnancy loss by impairing utero-placental perfusion. A recent study on mouse (Renaud et 
al., 2011) reported a causal link between maternal inflammation induced by LPS 
administration and impaired placental perfusion. LPS administration determined a 
disseminated intravascular coagulation(DIC)-like condition, with clot formation within 
uterine vessels, decreased diastolic uterine artery flow velocity and evidence of prominent 
diastolic notches, resulting in placental and foetal hypoxia. Many biological effects of LPS 
are mediated by TNF-α. Oppositely, IL-10 administration decreased serum level of TNF-α, 
preventing pregnancy loss after LPS exposure. Cytokines of the IL-1 system (IL-1α, IL-1β 
and IL-1 receptor antagonist) are an important regulatory element of the Th1/Th2 balance. 
They have been implicated in implantation, and trophoblastic cells proliferation and 
invasion (Wang et al., 2002). On the other hand, it is interesting to note that IL-1 system can 
also function as a co-stimulator for Th2 response. Therefore, altered decidual IL-1β 
production may cause a reduction in Th2-type cytokine production, contributing to early 
pregnancy failure. The Th1/Th2 paradigm has recently been expanded into the 
Th1/Th2/Th17 and Treg (T regulatory cells) one (Peck et Mellins, 2010). Indeed increased 
peripheral and decidual levels of Th17 cells and their related factors (IL-17, IL-23 and -
retinoid orphan nuclear receptor (RORC) have been reported in women with unexplained 
recurrent spontaneous abortion (RSA) (Wang et al., 2010). In addition, an inverse 
relationship between Th17 cells and Treg cells in the peripheral blood and decidua 
lymphocytes in unexplained RSA has been found. Treg cells are defined by secretion of 
TGF-β and IL10 and the presence of intracellular transcription factor FoxP3. Studies in  
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 Inflammatory reactions 
 Thrombotic events through up-regulation of 
Fg12 
 Trophoblastic apoptosis, inhibition of 
trophoblast cell growth and metabolic activity 
 Promotion of syncytium formation and 







 Anti-inflammatory action 
 Enhancement of hCG secretion 
 Stimulation of growth and differentiation of 
trophoblast 
Macrophage 
IL1 system (IL1α, IL1β, 
IL1ra) 
LIF 
 Stimulation of trophoblast differentiation (LIF) 
Table 1. Immune regulation of pregnancy. 
animal models (Thuere at al., 2007) have shown that Treg cells are essential for maternal 
tolerance of the conceptus, and that they exert suppressive actions in the peri-implantation 
phase. In women, inadequate number of Treg cells or their functional deficiency are linked 
with infertility, miscarriage and pre-eclampsia (Guerin et al., 2009). It is suggested that 
impaired Treg function could lead to increased Th1 cytokines (Jin et al., 2009). Nevertheless 
there are conflicting reports regarding the inflammation state in early pregnancy loss, 
suggesting adequate balance for Th1/Th2 cytokines, although with a slight shift toward Th2 
immunity in successful pregnancy (Saini et al., 2011). A recent study (Calleja-Agius et al., 
2012) confirmed an inflammatory state (higher pro-inflammatory cytokines) in normal 
pregnancy compared with the non pregnant state, which may be disrupted during 
miscarriage. The study revealed in euploid miscarriage a shift toward Th1 immune response 
(higher TNF-α/IL-6 ratio) at 6-9 weeks, but a lower TNF-α/IL 10 and IFN-γ/IL10 ratios in the 
late first trimester compared to normal pregnancy. At this regard it must be noted that the 
classification of IL-6 remains controversial, as some authors consider it as a Th2 mediator 
due to its anti-inflammatory properties possibly involved in new vessels generation and 
tissue remodelling associated with placentation (Jauniaux at al., 1996). A further evidence 
for an influence of inflammatory mediators in pregnancy is represented by the behaviour of 
maternal serum MIF (Yamada et al., 2002). Indeed, MIF concentrations in recurrent abortion 
women with subsequent miscarriage and normal foetal karyotype were lower than those in 
women with history of RSA with subsequent live birth and those in normal pregnant 
women. Moreover, MIF acts as an immunosuppressive factor by inhibiting NK cell activity. 
Since women with RPL and unexplained infertility have increased peripheral blood NK cells 
and increased NK cytotoxic activity (Yamada et al., 2001), low levels of MIF could lead to 
insufficient inhibition of NK cell activity and altered cytokines production with impairment 
of trophoblast proliferation, embryo development, and angiogenesis within placenta. One 
 
Glucocorticoids – New Recognition of Our Familiar Friend 416 
as some selected TNF/LTA haplotypes,  increase the risk for spontaneous preterm birth 
(Engel et al., 2005). 
4.1. The Th1/Th2 paradigm 
It has been suggested that a successful pregnancy may be a Th2 type phenomenon, whereas 
a Th1-type prevalence could be detrimental (Kwak-Kim et al., 2003). Immune regulation of 
pregnancy is mediated by TH1, TH2 and macrphages throughout the release of a number of 
cytokines (Table 1). Women with recurrent pregnancy loss have higher peripheral 
concentrations of certain Th1 cytokines (IL-2, TNF-α, TNF-β, IFN-γ) and lower 
concentrations of Th2 (IL-4, -5, -6, -10) when compared with successful pregnancy. Th1 
cytokines, especially IFN-γ, may activate endothelial cell procoagulants and cause 
thrombotic and inflammatory reactions at the utero-placental level (Clark et al 1998). As for 
the mechanism by which thrombotic changes are induced, it has been reported an increased 
expression of pro-coagulant Fg12 in trophoblast cells from failing pregnancy (Knackstedt et 
al., 2001). Fg12 is a glycoprotein able to directly cleave prothrombin to thrombin, leading to 
fibrin deposition. Th1 cytokines up regulate this procoagulant, with consequent activation of 
the coagulation system and disruption of vascular supply to the placenta. On the contrary, 
Th2 system can hamper this process, suppressing Th1 response (Saini et al., 2011). Among 
proinflammatory cytokines, TNF-α is of particular interest. Indeed, even though a low 
concentration is required for successful implantation, it also causes trophoblast apoptosis in 
combination with Th1 cytokines such INF-γ. The cytokine could even be involved in 
pregnancy loss by impairing utero-placental perfusion. A recent study on mouse (Renaud et 
al., 2011) reported a causal link between maternal inflammation induced by LPS 
administration and impaired placental perfusion. LPS administration determined a 
disseminated intravascular coagulation(DIC)-like condition, with clot formation within 
uterine vessels, decreased diastolic uterine artery flow velocity and evidence of prominent 
diastolic notches, resulting in placental and foetal hypoxia. Many biological effects of LPS 
are mediated by TNF-α. Oppositely, IL-10 administration decreased serum level of TNF-α, 
preventing pregnancy loss after LPS exposure. Cytokines of the IL-1 system (IL-1α, IL-1β 
and IL-1 receptor antagonist) are an important regulatory element of the Th1/Th2 balance. 
They have been implicated in implantation, and trophoblastic cells proliferation and 
invasion (Wang et al., 2002). On the other hand, it is interesting to note that IL-1 system can 
also function as a co-stimulator for Th2 response. Therefore, altered decidual IL-1β 
production may cause a reduction in Th2-type cytokine production, contributing to early 
pregnancy failure. The Th1/Th2 paradigm has recently been expanded into the 
Th1/Th2/Th17 and Treg (T regulatory cells) one (Peck et Mellins, 2010). Indeed increased 
peripheral and decidual levels of Th17 cells and their related factors (IL-17, IL-23 and -
retinoid orphan nuclear receptor (RORC) have been reported in women with unexplained 
recurrent spontaneous abortion (RSA) (Wang et al., 2010). In addition, an inverse 
relationship between Th17 cells and Treg cells in the peripheral blood and decidua 
lymphocytes in unexplained RSA has been found. Treg cells are defined by secretion of 
TGF-β and IL10 and the presence of intracellular transcription factor FoxP3. Studies in  
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 Inflammatory reactions 
 Thrombotic events through up-regulation of 
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trophoblast cell growth and metabolic activity 
 Promotion of syncytium formation and 







 Anti-inflammatory action 
 Enhancement of hCG secretion 
 Stimulation of growth and differentiation of 
trophoblast 
Macrophage 
IL1 system (IL1α, IL1β, 
IL1ra) 
LIF 
 Stimulation of trophoblast differentiation (LIF) 
Table 1. Immune regulation of pregnancy. 
animal models (Thuere at al., 2007) have shown that Treg cells are essential for maternal 
tolerance of the conceptus, and that they exert suppressive actions in the peri-implantation 
phase. In women, inadequate number of Treg cells or their functional deficiency are linked 
with infertility, miscarriage and pre-eclampsia (Guerin et al., 2009). It is suggested that 
impaired Treg function could lead to increased Th1 cytokines (Jin et al., 2009). Nevertheless 
there are conflicting reports regarding the inflammation state in early pregnancy loss, 
suggesting adequate balance for Th1/Th2 cytokines, although with a slight shift toward Th2 
immunity in successful pregnancy (Saini et al., 2011). A recent study (Calleja-Agius et al., 
2012) confirmed an inflammatory state (higher pro-inflammatory cytokines) in normal 
pregnancy compared with the non pregnant state, which may be disrupted during 
miscarriage. The study revealed in euploid miscarriage a shift toward Th1 immune response 
(higher TNF-α/IL-6 ratio) at 6-9 weeks, but a lower TNF-α/IL 10 and IFN-γ/IL10 ratios in the 
late first trimester compared to normal pregnancy. At this regard it must be noted that the 
classification of IL-6 remains controversial, as some authors consider it as a Th2 mediator 
due to its anti-inflammatory properties possibly involved in new vessels generation and 
tissue remodelling associated with placentation (Jauniaux at al., 1996). A further evidence 
for an influence of inflammatory mediators in pregnancy is represented by the behaviour of 
maternal serum MIF (Yamada et al., 2002). Indeed, MIF concentrations in recurrent abortion 
women with subsequent miscarriage and normal foetal karyotype were lower than those in 
women with history of RSA with subsequent live birth and those in normal pregnant 
women. Moreover, MIF acts as an immunosuppressive factor by inhibiting NK cell activity. 
Since women with RPL and unexplained infertility have increased peripheral blood NK cells 
and increased NK cytotoxic activity (Yamada et al., 2001), low levels of MIF could lead to 
insufficient inhibition of NK cell activity and altered cytokines production with impairment 
of trophoblast proliferation, embryo development, and angiogenesis within placenta. One 
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more pathway leading from inflammation to pregnancy loss acts via the complement 
system that induces recruitment and activation of inflammatory cells. Antiphospholipid 
(aPL) antibodies are able to trigger complement system response within decidual tissue, 
thus inducing inflammation and foetal damage (Salmon & Girardi, 2008). Recruitment of 
inflammatory cells creates a placental proinflammatory amplification loop, eventually 
leading to thrombosis, hypoxia, and neutrophil infiltration. Accordingly, increased 
complement activation is associated with recurrent abortion pre-eclampsia and IUGR 
(Tincani et al., 2009). A pathogenic mechanism has been postulated for recurrent abortion 
involving NK cells (Laird et al., 2003). Several studies reported a higher concentration of 
uNK and pNK as well as a higher proportion of activated pNK in women with history of 
RSA (Radysh & Chernyshov, 2005). 
5. Classical treatment and drugs for preventing pregnancy loss 
5.1. Progesterone 
Progesterone is secreted by the corpus luteum and the placenta and is necessary for 
successful implantation and eventually the maintenance of pregnancy. Progesterone is 
prescribed in 13-40% of women with threatened miscarriage, according to published series 
because it is expected to support a potentially deficient corpus luteum and induce relaxation 
of a cramping uterus (Rai & Regan, 2006). This benefit of the hormone could be explained by 
its immmunomodulatory actions in inducing a pregnancy-protective shift from pro-
inflammatoryTh-1 cytokine responses to a more favourable anti-inflammatory Th-2 cytokine 
response (Raghupathy et al., 2009). The first trial using progesterone for such women was 
published in the BMJ in 1953 (Swyer & Daley, 1953) and was followed over the decades by 
several small trials. However, uncertainty remains about the evidence. The latest 
randomized controlled trial (Haas & Ramsey, 2008) to assess progesterone support for 
pregnancy showed that it did not reduce the sporadic miscarriage rate. However, in a 
subgroup analysis of trials involving women with recurrent miscarriage, progesterone 
treatment appeared to offer a statistically significant decrease in miscarriage rate compared 
with placebo or no treatment (OR 0.38, 95% CI 0.2–0.7). Nevertheless, in order to understand 
the limited clinical utility of the conclusions derived from some sort of statistical analysis, it 
is to be noted that this meta-analysis was based on three small controlled studies, none of 
which detected a significant improvement in pregnancy outcome! A large multicenter study 
(PROMISE) is currently under way to assess the benefit of progesterone supplementation in 
women with unexplained recurrent miscarriage. The trial is expected to report in 2013. At 
present, progesterone administration is not recommended for unexplained recurrent 
miscarriage (Coomarasamy  et al., 2011).  
5.2. Aspirin 
Aspirin is largely used in pregnancy because it is believed to increase blood flow to the 
embryo, act on unrecognized thrombophilias and prevent miscarriage. Pregnancy itself is a 
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hyper-coaguable state associated with increased levels of procoagulant factors and 
decreased levels of naturally occurring anticoagulants such as protein S (Comp et al., 1986). 
Microthrombi are a common finding in the placental vasculature of women with recurrent 
miscarriage (Rushton, 1988). PGs appear to be essential for implantation, although and 
exogenous administration of high doses induces abortion: the maintenance of pregnancy 
may be dependent on a mechanism that suppresses prostaglandin synthesis. Aspirin, which 
suppresses COX, has the potential to support this mechanism. Moreover, the maintenance of 
pregnancy is said to depend on a shift of pro-inflammatory to anti-inflammatory cytokines. 
At this regard, aspirin and other antiplatelet agents have been shown to play a role in the 
inhibition of pro-inflammatory cytokines, such as TNFα and IL-8. In stroke (Al-Bahrani et 
al., 2007), TNFα induces thrombin generation and IL-8 causes polymorph accumulation 
(Schraufstatter et al., 2003). Polymorphs react with fibrin and damaged tissues to form clots. 
However, at present, no report in the medical literature confirms a role for aspirin in 
preventing recurrent pregnancy loss. Furthermore, it doesn’t confer a significant benefit in 
anti-phospholipid (aPL) syndrome (Pattison et al., 2000) even if the live birth rate increases 
significantly when heparin is added to treatment. The syndrome is assumed to be 
responsible for pregnancy loss by causing thrombosis in the small blood vessels of the 
decidua, leading to subsequent foetal demise. In unexplained pregnancy loss, aspirin had no 
beneficial effect except for in late pregnancy losses, in cases where hereditary 
thrombophilias were not excluded. Since there is no study of aspirin in this condition, it’s 
suggested that the positive effects in advanced pregnancy may be due to the action of the 
drug in such patients (Rai et al., 2000). Nevertheless, the lack of the evidence of any efficacy 
against RSA, coupled with a reported increased risk of miscarriage and foetal gastroschisis, 
contraindicate prescribing aspirin in early pregnancy (Carp HJ, 2009).  
5.3. COX inhibitors 
COX inhibitors impair uterine contractility, are easily administered and have fewer 
maternal side-effects compared to conventional tocolytics. However, they are not devoid of 
adverse effects on the foetus and newborn. Indeed, increased neonatal complications 
including oligohydramnios, renal failure, necrotizing enterocolitis, intraventricular 
haemorrhage, and closure of the patent ductus arteriosus have been reported with the use of 
the non-selective COX inhibitor indomethacin (Abou-Ghannam et al. 2011). A recent review 
includes outcome data from 13 trials for a total of 713 women. with use of indomethacin in 
10. When compared with placebo, indomethacin alone resulted in a reduction in birth before 
37 weeks gestation, with an increase in gestational age and birth weight. Compared to any 
other tocolytic, COX inhibition resulted also in reduced maternal drug reaction requiring 
cessation of treatment. A comparison of non-selective COX inhibitors versus any COX-2 
inhibitor did not demonstrate any difference in maternal or neonatal outcomes. However, 
due to small numbers, all estimates are imprecise and need to be interpreted with caution. 
Overall, until now there is insufficient information about the role of COX inhibition for 
women in preterm labour (King et al., 2005).  
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the limited clinical utility of the conclusions derived from some sort of statistical analysis, it 
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suggested that the positive effects in advanced pregnancy may be due to the action of the 
drug in such patients (Rai et al., 2000). Nevertheless, the lack of the evidence of any efficacy 
against RSA, coupled with a reported increased risk of miscarriage and foetal gastroschisis, 
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5.4. Antibiotics 
As for antibiotics, their role against infection of the chorioamnionic membranes in preterm 
labour has been extensively investigated. In these cases, the mechanism by which uterine 
contractions take place is supposed to be the release of microbial products into the amniotic 
fluid (Gibbs et al., 1992). There seems to be substantial agreement on the efficacy of 
antibiotic therapy in the prevention of preterm delivery when there is evidence of infection 
(Kirshbaum T, 1993), but its utility in idiopathic preterm labour is controversial (Cox et al., 
1996). Nevertheless, antibiotics can have beneficial influences not only for their 
antimicrobial properties but also through a direct tocolytic action on tissues. Indeed, as it 
will be explained ahead, some among them have the capacity to directly inhibit amniotic IL-
6 and PGE2 release, thus offering an explanation for a beneficial response in cases of 
preterm labour even in the absence of bacterial infection. (Vesce et al., 1998;2004). 
5.5. Heparin 
Successful pregnancy depending on trophoblast invasion into the uterine vasculature, 
inadequate placentation and damage to the spiral arteries with impaired flow and 
prothrombotic changes lead to pregnancy complications that become even more dangerous 
in hyper-coagulable states. Such complications benefit from prophylactic low molecular 
weight heparin (LMWH) and unfractionated heparin (UFH), in spite of several drawbacks 
to their use, including the costs,  discomfort of daily injections, risks of bleeding, skin 
reactions, and thrombocytopenia (Howard, 2009). Indeed, there is general agreement that 
women with recurrent loss and persistent aPL antibodies positivity should receive 
antepartum prophylaxis with UFH or LMWH in combination with aspirin (Bates et al., 
2008), while, at present, it is claimed that antithrombotic therapy should not be advocated 
for unexplained recurrent miscarriage in women without an underlying thrombophilia. 
(Clark et al., 2010). However, although a protective effect in women with heritable 
thrombophilia is not to be excluded, the British Committee for Standards in Haematology 
has recently recommended against the antithrombotic therapy in pregnant women with a 
history of loss based on the results of testing for inherited thrombophilia (Baglin et al., 2010). 
Low-molecular-weight instead of unfractionated heparin is recommended for the 
prevention and treatment of venous thromboembolism in pregnant women (Guyatt et al., 
2012). In acute cases, anticoagulants should be continued for at least 6 weeks postpartum, 
for a minimum total duration of the therapy of 3 months. For women who fulfil the 
laboratory and clinical criteria for aPL antibodies syndrome and history of three or more 
pregnancy losses, is recommended antepartum administration of prophylactic or 
intermediate-dose UFH, or prophylactic (LMWH), combined with low-dose aspirin (75-100 
mg/d) over no treatment. For women with inherited thrombophilia and a history of 
pregnancy complications, as well as for those with two or more miscarriages, but without 
aPL antibodies syndrome or thrombophilia, it is recommended against antithrombotic 
prophylaxis. (Guyatt et al., 2012).  
The Role of Glucocorticoids in Pregnancy: Four Decades  
Experience with Use of Betamethasone in the Prevention of Pregnancy Loss 421 
5.6. Immunotherapy 
Idiopathic recurrent miscarriage has traditionally been associated with alloimmune factors, 
in which uterine CD56+/16 NK cells have been implicated (Quenby et al., 1999). In vitro 
studies suggest that pregnancy may result in uterine T-cell activation along the Th-2 
pathway, resulting in blocking antibodies which mask trophoblast antigens (Wegmann et 
al., 1993). Activation along the Th-1 pathway, instead, results in the production of abortive 
cytokines (Raghupathy et al., 2000). Maternal HY-restricting HLA class II alleles are 
associated with a decreased chance of a live birth in women with secondary recurrent 
miscarriage with a firstborn boy (Nielsen et al., 2009). Although such mechanisms are 
intriguing, there is a paucity of validated tests to assess the maternal immune response in 
pregnancy. Despite this, active and passive immunotherapeutic trials for idiopathic 
recurrent miscarriage have been reported. Paternal mononuclear cell immunization has 
been proved not to be effective (Scott, 2003). It is believed that passive immunotherapy with 
intravenous immunoglobulin (IVIG) may offer benefit in idiopathic secondary (at least one 
prior ongoing pregnancy), but not idiopathic primary (no prior ongoing pregnancy) 
recurrent miscarriage (Christiansen et al., 2002). However, such conclusions must be taken 
with caution because of small heterogeneous sample size. Moreover, IVIG is a highly 
purified and virally inactivated fractionated blood product made from pooled human 
plasma, which makes it costly to use and not without risk. Overall, the efficacy of IVIG in 
women with a history of idiopathic secondary recurrent miscarriage remains controversial, 
as no significant effect of treatment in these patients was found (Stephenson et al., 2010). 
6. Influence of glucocorticoids on foetal development  
6.1. Prenatal administration of GCs and HPA function 
Several studies in animals have shown that prenatal administration of GCs can cause 
hormonal changes in the foetus. Epidemiologic research in human even suggested that these 
may have long-term consequences on health in adult life. This concept is termed ‘early life 
programming’ (Seckl, 2004). Great importance is given to the influence of GCs on foetal 
HPA axis. Several studies assessed basal HPA function in the feto-placental unit by 
measuring markers of its activity in cord blood and amniotic fluid during gestation and at 
birth. Compared with unexposed healthy foetuses, cortisol concentrations were significantly 
lower in otherwise healthy foetuses exposed to synthetic GCs, with values decreasing to the 
10% of the controls. These results, however, refer to premature foetuses, which receive 24 
mg betamethasone within 24 hours before being delivered (Kajantie et al., 2004). In foetuses 
of asthmatic mothers who refrained from taking synthetic GCs during pregnancy, cortisol 
concentrations were even higher compared to those of healthy controls (Murphy et al., 
2002). As for placental CRH mRNA, it was slightly higher in asthmatic patients not treated 
with synthetic GCs. However, treated cases exhibit normal levels irrespective of the 
treatment dose. Similar to cortisol, ACTH, DHEA and DHEA-S (Parker et al., 1996) 
concentrations were reduced in treated foetuses.  
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6.2. Metabolic changes induced by prenatal GCs 
The alteration of the HPA activity seems to be closely related to the changes in glucose 
homeostasis and obesity. In rodent models, administration of dexamethasone leads to 
permanent hyperglycaemia and hyperinsulinaemia in the offspring (Nyirenda et al., 1998) 
with life-long elevations in the activity of phosphoenolpyruvate carboxykinase (PEPCK), the 
enzyme involved in gluconeogenesis. This metabolic effect is correlated with the exposure 
time,  and  week  3  of  gestation  appears  to  be  a  critical  window for inducing long-term 
metabolic changes. Similar alterations of glucose homeostasis have been reported in both 
sheep and non-human primates (de Vries et al., 2007).  Although the molecular mechanisms 
underlying these changes in offspring glucose metabolism have not been fully clarified, the 
alterations in HPA activity are certainly implicated, as the animals have increased levels of 
circulating corticosterone, decreased GR expression in the hippocampus, the site of central 
negative feedback, and increased peripheral GR expression in insulin-sensitive target tissues 
including liver and muscle in the rat (Nyirenda et al., 1998; Cleasby et al., 2003). The increased 
PEPCK expression is regulated by transcription factors, including members of the HNF 
(hepatocyte nuclear factor) and GR that bind to the PEPCK gene promoter. The expression of 
these factors is increased in liver of rats treated with dexamethasone (Nyirenda et al., 1998), 
suggesting that the observed increase in PEPCK may be a secondary effect. Thus, changes in 
key transcription factors may underlie permanent changes in glucose metabolism. The 
influence of prenatal GCs is also expressed in the foetal pancreas. GC signalling is important in 
pancreatic beta cell development, with potential underlying mechanisms including their 
interaction with the transcription factors that control proliferation and differentiation of the 
Langerhans islets cells (Gesina et al., 2006). Among these, IGF (insulin-like growth factor) 2, 
the IGF receptor, and several IGF binding proteins (Hill et al., 2000) may lead to a decreased 
insulin secretion, with consequent hyperglycaemia in adult life. Prenatal GC exposure is also 
associated with alterations in fat distribution and function. Offspring of rats treated with 
dexamethasone during days 8, 10 and 12 of pregnancy have increased intra-abdominal fat 
depots, and a parallel increase in circulating leptin levels (Dahlgren et al., 2001). Moreover, 
treatment of rats with dexamethasone in the last week of pregnancy leads to an increase in GR 
expression in visceral adipose tissue and alterations in fat metabolism which may contribute to 
insulin resistance (Cleasby et al., 2003). Recent evidence also shows that the activity of 11β-
HSD type 1 may be ‘programmed’ by prenatal GC therapy. Indeed, a brief antenatal exposure 
to GCs in pregnant marmosets resulted in up-regulation of 11β-HSD1 mRNA expression and 
activity in subcutaneous, but not visceral, fat of the offspring (Nyirenda et al., 2009). The 
increase in 11β-HSD1 occurred before the animals developed obesity or overt features of the 
metabolic syndrome. This up-regulation of 11β-HSD1 suggests a novel mechanism underlying 
the foetal origins of obesity.  
6.3. The impact of GCs on foetal bone 
Another interesting field of research is represented by the influence of prenatal GCs on 
foetal bone. Indeed, GCs are known to affect skeletal growth and adult bone metabolism, 
but their impact on foetal bone remains to be elucidated. Some Authors (Swolin-Eide et al., 
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2002) reported prenatal dexamethasone exposure to affect skeletal growth in rats. 
Dexamethasone-exposed male but not female rat offspring showed transient increases in 
crown–rump length and tibia and femur lengths at 3–6 weeks of age. In contrast, the cortical 
bone dimensions were altered in 12-week-old female but not male, and the areal bone 
mineral densities of the long bones and the spine were unchanged in both male and female 
suggesting a gender specific effect. Following these results, research was addressed to 
investigate some biochemical markers of bone turnover such as 4,5 carboxy-terminal 
propeptide of type I procollagen (PICP) and cross-linked carboxy-terminal telopeptide of 
type I collagen (ICTP). A single course of antenatal corticosteroids reduced umbilical cord 
levels of PICP without influence on ICTP (Korakaki et al., 2007). Instead, according to other 
Authors (Fonseca et al., 2009), umbilical cord serum levels of ICTP, the marker for foetal 
bone resorption, decreased only when the doses were ≥ 4.  
6.4. Conclusion 
Overall, it appears that, in animals, programming effects of GCs exposure during gestation 
involve: 
- hyperglycaemia throughout a gluconeogenesis enzyme modulation coupled with a 
decreased growth of pancreatic islets;  
- increased deposition of visceral fat related with an increase in circulating levels of leptin 
and expression of GR in the fat tissue; 
- gender-specic manner stimulation of bone growth without influence on 
mineralization. 
However, the results of these experimental studies, performed on a variety of animal 
species, using high doses and different types of GC, cannot be extended to human 
pregnancy, that is provided with distinct metabolising capacity at the utero-placental level. 
Indeed, GCs are largely prescribed for a variety of maternal and foetal conditions during 
human pregnancy, where none of the above reported complications and side effects have 
been confirmed. The absolute indications for using these compounds are Addison syndrome 
and hypopituarism. Furthermore, they are largely utilized for maternal asthma, collagen 
disease, ulcerative colitis, regional enteritis, and need of immunosuppression. Moreover, 
there is a number of specific indications to early administration for pregnancy-induced 
pathology. Among these foetal atrio-ventricular block, congenital adrenal hyperplasia, cystic 
adenomatoid malformation of the lung, alloimune thrombocytopenia, recurrent pregnancy 
loss and antiphospholipid antibody syndrome. In addition, clinical conditions that benefit 
from use of GCs in advanced pregnancy are related with premature delivery, aimed at the 
prevention of neonatal respiratory distress syndrome, intraventricular haemorrhage and 
necrotizing enterocolitis (Lunghi et al., 2010). All above conditions provide evidence for 
substantial advantages in foetal and maternal prognosis of prenatal administration of GCs, 
compared to feared, but unproved, side effects such as malformation and intrauterine 
growth restriction. At this regard, it has been reported that triamcinolone acetonide, a 
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2002) reported prenatal dexamethasone exposure to affect skeletal growth in rats. 
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been confirmed. The absolute indications for using these compounds are Addison syndrome 
and hypopituarism. Furthermore, they are largely utilized for maternal asthma, collagen 
disease, ulcerative colitis, regional enteritis, and need of immunosuppression. Moreover, 
there is a number of specific indications to early administration for pregnancy-induced 
pathology. Among these foetal atrio-ventricular block, congenital adrenal hyperplasia, cystic 
adenomatoid malformation of the lung, alloimune thrombocytopenia, recurrent pregnancy 
loss and antiphospholipid antibody syndrome. In addition, clinical conditions that benefit 
from use of GCs in advanced pregnancy are related with premature delivery, aimed at the 
prevention of neonatal respiratory distress syndrome, intraventricular haemorrhage and 
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compared to feared, but unproved, side effects such as malformation and intrauterine 
growth restriction. At this regard, it has been reported that triamcinolone acetonide, a 
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synthetic glucocorticoid, induces cleft palate resulting from poor development of palatal 
shelves in mice (Furukawa et al., 2004). Nevertheless, direct extrapolation to humans of 
teratogenic effects of GCs in animals is tenuous. Indeed, a prospective controlled cohort 
study, based on self-reported drug exposure and maternal interview as a source, collected 
311 pregnancies receiving systemic use of different GCs in the first trimester. The rate of 
major congenital anomalies was compared to that of 790 controls that were counselled for 
non-teratogenic exposure. There was no case of oral cleft and no pattern of anomalies 
among the GCs exposed group, supporting the opinion that these hormones do not 
represent a major teratogenic risk in humans (Gur et al.,2004). A survey of the literature 
concerning 468 pregnant women treated with corticosteroids outside the transplant setting 
demonstrated an overall malformation rate of 3.5%, thus within the expected incidence in 
the general population (Danesi & Del Tacca, 2004). Moreover, a study on more than 6600 
infants reported that maternal exposure to orally inhaled budesonide during pregnancy is 
not associated with an increased risk of congenital malformations or other adverse foetal 
outcomes (Rahimi et al., 2006). As for foetal growth, a systematic review of animal studies 
examining the association of GCs on birth outcome reported a reduction in birth weight 
(Aghajafari, 2002). However, it should be considered that animal experiments 
demonstrating negative effects employed doses equivalent to 20-100 times a ‘replacement’ 
dose of steroids for a human patient. Nevertheless studies in human were addressed to 
assess both the effect of early exposure protracted for a long time and that of late 
administration for preventing the complications of premature delivery. Interestingly, 
although a recent study suggests that foetal growth becomes sensitive to GCs when the 
treatment starts early and is prolonged for a long time (Gur et al., 2004), dexamethasone 
given from the 10th week throughout pregnancy in the presence of female foetuses affected 
by 21-hydroxylase deficiency did not influence weight, length and head circumference of 
the newborns (Carlson et al., 1999). As for advanced pregnancy, randomized controlled 
studies have shown that treatment for preventing respiratory distress syndrome of the 
neonate leads to birth weight reduction only after four or more courses, and that these 
parameters normalized by the time of hospital discharge (Bonanno et al., 2007). Moreover, a 
meta-analysis of five trials in which 2028 pregnant women were treated with GCs in late 
pregnancy found no significant effect on birth weight (Crowther et al., 2007). Two main 
exceptions can be raised towards human clinical studies: first, the time elapsing between 
administration of the drug and delivery appears to be too short to influence foetal growth; 
second, obstetrical diseases affecting foetal growth are necessarily included in the study 
sample, and therefore it is not possible to discriminate their influence from that of the 
hormone. The only way to avoid such a bias should be to administrate GC to healthy 
volunteers along the course of physiological pregnancy, something that happened to us in 
some way to do, in our long experience with low dose betamethasone therapy throughout 
gestation (see ahead). Based on our results, there is no persuasive evidence for any adverse 
effect neither of long duration low dose (see ahead), nor of short duration high dose GC on 
foetal growth. 
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7. Need and rules for antibiotic and glucocorticoid therapy in advanced 
pregnancy: The foetal inflammatory response syndrome. 
We have previously treated in a more detailed manner the main indications to 
glucocorticoid therapy in human pregnancy (Lunghi et al., 2010). Nevertheless, for the 
purposes of the present chapter, it is necessary to stress the concepts dealing with the 
“Foetal Inflammatory Response Syndrome” (FIRS) (Romero et al., 1998). Indeed, being 
paradigmatic of the negative effects of inflammation on pregnancy, it offers the chance to 
clarify the rationale for the appropriate use of GCs and antibiotics for preventing harmful 
complications. FIRS is defined as a systemic inflammation characterized by an elevation of 
foetal plasma IL-6. In this syndrome a foetal plasma IL-6 level above 11 pg/ml is a major 
independent risk factor for the subsequent development of severe neonatal morbidity. Such 
a condition can be found even in the absence of microbial invasion of the amniotic cavity 
and any other sign of infection, as a foetal immune reaction characterized by increase in 
monocyte and neutrophil activation, and without correlation with maternal plasma or 
amniotic fluid concentration of the cytokine. It has been suggested that the foetus uses the 
effector limb of the immune response via the secretion of pro-inflammatory cytokines to 
signal the onset of labour and exit a hostile intrauterine environment (Romero et al., 1998). 
Whatever its teleological meaning, FIRS, also expressed by increased concentrations of foetal 
MMP-9, an enzyme involved in the digestion of type IV collagen and in the patho-
physiology of preterm premature rupture of the membranes, can progress towards multiple 
organ dysfunction. (Romero et al., 2002). A further enzyme involved in such inflammatory 
process is MMP-8. Indeed an elevated MMP-8 concentration (>23 ng/mL), is present in 81% 
of the cases with cervical insufficiency, while a positive microbial culture is found only in 
8%. These results indicate that, regardless of the eventual microbial involvement, 
inflammation is a risk factor for impending preterm delivery (Lee et al., 2008). Overall, the 
evidences above speak in favour of a leading role of inflammation in the pathogenesis not 
only of premature birth, but also of ominous perinatal complications such as respiratory 
distress syndrome (RDS), cerebral haemorrhage and necrotizing enterocolitis (NEC). 
Evidently, in this perspective, the causal role of infection appears substantially scaled. 
Accordingly, there is no evidence for a clear benefit of antibiotic treatment in infectious 
conditions that are associated with premature delivery, such as bacterial vaginosis and 
urinary infections (McDonald et al., 2007). In addition, treating women at risk with 
antibiotics does not reduce the incidence of subsequent of preterm delivery (Simcox et al., 
2007), and among women with Group B streptococcal bacteriuria, exposure to additional 
antibiotics even increases the risk (Anderson et al., 2008). Conflicting reports do not clarify 
the role of prophylactic antibiotic therapy for inhibiting preterm labour. For instance, one 
meta-analysis including 11 trials on 7428 women with intact membranes showed a 
reduction in maternal infection, but failed to demonstrate benefit or harm for the neonatal 
outcome (King et al., 2002). On the contrary routine antibiotic prophylaxis during the second 
or third trimester of pregnancy reduces the risk of pre-labour rupture of the membranes, 
with beneficial effects on birth weight and the risk of postpartum endometritis in high risk 
women, according to a further meta-analysis (Thinkhamrop et al., 2002). As regards to the 
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although a recent study suggests that foetal growth becomes sensitive to GCs when the 
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given from the 10th week throughout pregnancy in the presence of female foetuses affected 
by 21-hydroxylase deficiency did not influence weight, length and head circumference of 
the newborns (Carlson et al., 1999). As for advanced pregnancy, randomized controlled 
studies have shown that treatment for preventing respiratory distress syndrome of the 
neonate leads to birth weight reduction only after four or more courses, and that these 
parameters normalized by the time of hospital discharge (Bonanno et al., 2007). Moreover, a 
meta-analysis of five trials in which 2028 pregnant women were treated with GCs in late 
pregnancy found no significant effect on birth weight (Crowther et al., 2007). Two main 
exceptions can be raised towards human clinical studies: first, the time elapsing between 
administration of the drug and delivery appears to be too short to influence foetal growth; 
second, obstetrical diseases affecting foetal growth are necessarily included in the study 
sample, and therefore it is not possible to discriminate their influence from that of the 
hormone. The only way to avoid such a bias should be to administrate GC to healthy 
volunteers along the course of physiological pregnancy, something that happened to us in 
some way to do, in our long experience with low dose betamethasone therapy throughout 
gestation (see ahead). Based on our results, there is no persuasive evidence for any adverse 
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The Role of Glucocorticoids in Pregnancy: Four Decades  
Experience with Use of Betamethasone in the Prevention of Pregnancy Loss 425 
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conflicting results of clinical studies about the administration of antibiotics in the prevention 
and cure of preterm delivery, it must be said that their Authors did not take into account the 
direct anti-inflammatory capacity that some of them are able to exert on gestational tissues. 
Indeed, we have demonstrated that ampicillin inhibits PGE release from amnion tissue in 
vitro, either in basal condition or upon addition of arachidonic acid or oxytocin to the 
medium (Vesce et al., 1998). Furthermore, it strongly reduces IL-6 level in amniotic fluid of 
patients sampled 4 hours after drug administration (Vesce et al., 2004). Ceftriaxone and 
gentamycin significantly and reversibly inhibit both basal and arachidonic acid- or oxytocin-
stimulated PGE release from amnion, although to a lesser extent compared with ampicillin. 
On the contrary tetracycline and erythromycin do not influence the PG output. Of key 
importance from a clinical standpoint, the inhibitory effect of ampicillin is enhanced in an 
additive manner by ceftriaxone, reduced by gentamycin, and abolished by tetracycline and 
erythromycin (Vesce F et al., 1999). The above evidences indicate that, at least in pregnancy, 
the inhibitory action of β-lactamines on amniotic IL-6 and PGE release could be of value 
independently from their antibacterial action. Conversely, the classes of antibiotics that do 
not exert any inhibition on PGE release should not be used when preterm labour is not 
induced through a bacterial mediation. Furthermore, in cases of premature labour of 
inflammatory origin subsequently complicated by superimposed infection, macrolides 
addition to β-lactamines may eradicate infection, but it does not counteract the triggering 
pathogenic mechanism. In other words, in interpreting the efficacy of antibiotics in the 
management of premature labour, it is mandatory to know whether or not they directly 
inhibit inflammatory cytokines and prostanoids. It has been claimed that antibiotic therapy 
of premature labour in the presence of infection leads to the release of microbial products 
which may exacerbate the cytokine response and worsen the clinical picture. It has been also 
hypothesized that a similar scenario may occur in patients with microbial invasion of 
decidua and amniotic cavity. Such an initial worsening of the inflammatory response may 
accelerate the process of premature parturition and foetal damage. Nevertheless, it has been 
also suggested that transient down-regulation of the effects of the inflammatory response 
would permit the time that is required to eradicate the infectious process, without injury to 
the foetus. Indeed, anti-inflammatory cytokines, antibody to macrophage migration 
inhibitory factor and antioxidants, may also play a role in preventing delivery, neonatal 
injury, and long-term perinatal morbidity. Accordingly, a combination of antibiotics and 
immunomodulators (dexamethasone and indomethacin), in experimental premature labour 
induced by intra-amniotic inoculation with group B streptococci. in non human pregnant 
primates, was effective to eradicate infection, suppress the inflammatory response, and 
prolong gestation (Tsuzuki et al., 2009). One more aspect needs to be clarified before 
reporting our experience with use of low dose betamethasone for the prevention of 
pregnancy loss, and it deals with the necessity to discriminate the pathogenic role of 
prematurity from inflammation and hypoxia.  Indeed, prematurity is still reported 
everywhere as the leading cause of perinatal morbidity and mortality (Mwaniki et al., 2012). 
Such a concept is obviously provided with some validity, but in the general contest of 
pregnancy complications it needs to be adequately scaled. Basically, it appears to stem from 
the link between prematurity and hyaline membrane disease (HMD) of the lung, an 
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ominous disease that is ascribed to the failure of immature type II alveolar cells to produce 
sufficient surfactant (i. e. lecithin). As betamethasone was historically recognized to be able 
to prevent HMD, its efficacy was intended as a sort of “maturational promotion”. However, 
there are good reasons to believe that the main pathogenic mechanism is rather of a 
hypoxic-inflammatory type. Indeed, premature foetuses express RDS of diverse intensity at 
the same gestational age, in relation with the grade of the pathology causing premature 
birth. Pregnancy complications leading to premature birth are largely a consequence of an 
inflammatory mechanism. Accordingly, prematurity is characterized by two other 
complications, i. e. NEC and encephalopathy, marked by high levels of inflammatory 
cytokines that also benefit from the action of betamethasone. Finally, the drug efficacy is 
limited to its timely prenatal administration, as it lacks when the hormone is given after 
birth, suggesting that it stimulates the production of an extra amount surfactant at a level 
other than the foetal alveoli that is subsequently delivered to the lung before birth thru 
gasping efforts a typical feature of foetal hypoxia. As we have demonstrated, the site of 
lecithin release in the foetal compartment is represented by amnion tissue (Vesce F et al., 
1992). Based on these considerations, chronic intrauterine distress appears to play a major 
role compared to gestational age in the pathogenic mechanism of the ‘prematurity’ 
syndrome. Indeed, all above evidences indicates that FIRS proceeds from inflammatory 
processes endowed themselves with the capacity to lead to all above mentioned dangerous 
perinatal complications, infection included. Timely addition of GCs addressed to rebalance 
cytokines and prostanoids regulating the inflammatory response, represents therefore an 
unavoidable therapeutic approach.  
8. Personal experience with low-dose betamethasone administration 
throughout pregnancy for prevention of pregnancy loss 
The clinical observations by the corresponding author of the present chapter regarding 
pregnancy loss begun during the early seventies, when progesterone therapy was the main 
choice in cases of either threatened or recurrent abortion at the Department of Obstetrics 
and Gynaecology of Ferrara University. However, as ultrasounds became available, it 
clearly appeared to the echographers that, based on the above mentioned theoretical 
benefits, the drug was given blindly, even to patient with missed abortion as well as to those 
who never would have needed it. Indeed, there was no practical way (as it still substantially 
lacks today) to investigate the causes of abortion in single cases, and the explanation given 
to the patient dealt almost invariably with either corpus luteum deficiency or aneuploidy. 
Soon after we were informed that corticosteroids had been occasionally used successfully in 
patients with recurrent abortion when an “immunological basis” for rejection of the 
conceptus was hypothesized (Professor Denis Hawkins, of London, personal 
communication). In addition, administration of cortisone 25-75 mg/day up to 64 days during 
the first trimester for the treatment of hyperemesis had already been reported long before 
(Wells, 1953). At that stage, after observing many more cases of recurrent abortion, all 
treated with various regimens of progesterone, we concluded that there was no reason for 
further giving this drug to such women. The first case of recurrent abortion occasionally 
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treated with betamethasone was 34 years ago a patient with bronchial asthma that, in spite 
of progesterone therapy, had experienced three early pregnancy losses. Subsequently she 
had gone through two years of anovulatory sterility, followed by several attempts to 
medical induction of ovulation, all ended in ovarian hyperstimulation syndrome. This 
patient was therefore counselled to assume 0.5 mg betamethasone daily for the next three 
months for treating asthma, and she started a spontaneous pregnancy one month later. Once 
adequately informed of a possible protective action of the hormone, she accepted to 
continue with the same regimen up to the end of pregnancy, when she delivered a normal 
foetus. Such a successful outcome encouraged us to cautiously adopt over the years low dose 
betamethasone therapy in all our patients with history of recurrent abortion previously 
unsuccessfully treated with progesterone. Furthermore, as we became aware of the high 
efficacy of the hormone, we extended its use to some other cases where protection of the first 
pregnancy was advisable even in the absence of previous pregnancy loss. These included, for 
instance, women of advanced age with or without previous sterility. We may say that there are 
several reasons for such a policy. The first one is represented by the lack of efficacy of 
progesterone in our experience, coupled with the tenuous and controversial evidence of a 
protective role in the above reported literature. A further point in favour of preventive GCs 
administration is that there are women who will not have the chance of a second pregnancy, 
and therefore they are suitable for prevention of possible inflammatory complications, for the 
timely diagnosis of which there are no available tests in the clinical practice. Indeed, as it 
became clear later on, GCs regulate the inflammatory process by modulating cytokine 
production (IL-6 and TNFα) (Thum et al., 2008) and decreasing maternal NK population 
(Quenby et al., 2005), two among the good reasons to adopt them in the clinical management 
of these cases. The study of this particular mechanism of GC in early pregnancy has been 
enhanced in the last years the focus being directed on prednisolone, the role of which in the 
prevention of recurrent pregnancy loss is currently under trial (Thang et al., 2009). However, 
its pharmacokinetic characteristics require a high dose to obtain the therapeutic effect. For 
instance, in  the  case  reported  by  Quenby  et  al. (2003), a  patient with  history  of  14  
consecutive abortions between the 8th and 10th week of gestation, first received 5 mg/day  pre-
conceptual prednisolone, leading to 5 further abortions. Only when the dose was raised up to 
20 mg/day she became able to deliver a preterm viable baby. Indeed, as it has been explained 
above, the trans-placental passage of the drug is highly impaired by 11-β-HSD isoenzymes. By 
contrast, compared to prednisolone, betamethasone is little metabolized by the placenta and it 
is ten times more effective (Burton & Waddell, 1999). Therefore, we decided to focus on 
betamethasone that is extensively used in advanced pregnancy for prevention of neonatal 
respiratory distress syndrome (Sotiriadis et al., 2009) but it is not adopted in early pregnancy, 
due to all above mentioned possible negative influences in animals, although they have not 
been confirmed in humans. Taking into account all these evidences, we choose to administer a 
low dose betamethasone, in order to obtain a better protective effect on pregnancy, avoiding at 
the same time significant maternal dose-dependent side effects. In our experience this 
therapeutic approach proved to be coupled with great efficacy and lack of significant 
complications. We treated over 200 cases until today, as other pregnancies are going on at the 
moment, the main indication being a history of recurrent pregnancy loss. There were cases in 
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which the usual dose of 0.5 mg/day was ineffective to prevent abortion, and it was doubled 
during the subsequent pregnancy, to be increased up to 2 mg/day month by month, due to 
heavy bleeding around the time of the expected menstrual flow. These cases, not included in 
the sample below, ultimately ended with the birth of healthy babies around term. As expected, 
there were cases of pregnancy complications, such as premature delivery, IUGR, preeclampsia, 
abruptio placentae, gestational diabetes, that were handled with the standard obstetric care. 
Indeed, betamethasone does not represent the panacea for every adverse gestational condition. 
Overall, besides the high effectiveness of the therapy in preventing pregnancy loss, we can 
testify that neither foetal malformations nor significant maternal or foetal adverse effect of 
betamethasone were observed. No chance of a prospective randomized case-control study was 
offered at our Institution, in order to statistically prove the greater efficacy of betamethasone 
compared to other therapies. However we were able to analyze retrospectively a total of 101 
treated patients as regards to some foetal biometric parameters and birth weight. Furthermore 
we performed two prospective studies aimed at verify two relevant end-points provided with 
physio-pathologic and clinical implications: 
- the possible positive correlation of foetal growth restriction with maternal peripheral 
NK cells concentration; 
- the possible efficacy of low-dose betamethasone therapy in decreasing the   maternal 
peripheral NK cells concentration. 
Our retrospective analysis includes 166 patients admitted to the Section of Obstetrics and 
Gynaecology of Ferrara University from the late seventies to 2010. The population was 
divided into three groups:  
- (Group A): 80 patients treated by low dose betamethasone (0, 5 mg/daily) throughout 
pregnancy for previous history of recurrent miscarriage; 
- (Group B): 65 patients with physiological pregnancy; 
- (Group C): 21 patients affected by rheumatologic disease treated by prednisone (4-16 
mg/daily).  
Foetal growth was assessed by measuring the weight, head circumference and length at the 
birth. First data evaluation revealed neonatal weight and length significantly lower in the 
treated groups (2843,5 g and 48,14 cm in group A; 3262,92 g and 49,93 cm in group B; 
2901,90 g and 49,67 in group C (Figure 2). Instead the head circumference was not 
statistically different among three groups (respectively 33.6 cm, 34.03 cm and 34.3 cm). 
However in evaluating biometric parameters of the newborns, the pathological conditions of 
pregnancy that may lead to foetal growth restriction must be considered (Grivell et al., 
2009). Among these, premature delivery, pre-eclampsia, gestational diabetes, 
hypothyroidism and bronchial asthma (Murphy & Gibson, 2011; Mitanchez, 2010; Krassas et 
al., 2010). Therefore, to get a more accurate evidence of the effect of betamethasone alone on 
foetal growth, we normalized the study population by excluding 26 patients suffering from 
the above mentioned diseases. By doing so, as expected, the differences among the neonatal 
biometric parameters were no more significant in the three groups (3144 g, 3262 g and 3171 
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g respectively for the birth weight; 49.73 cm, 49.3 cm and 49.63 cm for the neonatal length; 
34.25 cm, 34.03 cm and 34.53 cm for the head circumference) (Figure 3).  
 
Figure 2. Distribution of birth weight in three groups. Group A (treated by betamethasone): 2843,5 g; 
Group B (physiologic pregnancy): 3262,92 g; Group C (rheumatologic diseases): 2901,90 g. 
 
Figure 3. Distribution of birth weight in three groups after normalization of the study population. 
Group A (treated by betamethasone): 3144 g; Group B (physiologic pregnancy) 3262 g; Group C 
(rheumatologic diseases): 3171 g. 
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Moreover, by analyzing the distribution of birth weight values, we observed that one third 
of the newborns reached a weight higher than the fiftieth percentile in the treated group. 
Being all the patients upon the same betamethasone regimen, such an observation confirms 
that the cause of decreased neonatal weight should be ascribed to factors other than the 
hormone. The result of our attempt to homogenize the study sample highlights the need to 
take with caution the conclusions of other reports where different classes of patients were 
accidentally mixed up. As a matter of fact, most cases of GCs administration reported in the 
literature belong to pathologic conditions leading by themselves to foetal growth restriction 
(Davis et al., 2009; Kumar & Seshadri, et al., 2005). Coming to our first prospective study, we 
must recall that impairment of foetal oxygenation and growth, besides being linked with the 
above mentioned influences of unbalanced cytokines on utero-placental perfusion, is also 
reflected in the correlation between high values of uNK and IUGR (Williams et al., 2009). 
Therefore we decided to analyze the circulating lymphocyte subsets, mainly to search for a 
correlation between peripheral maternal NK concentration and foetal growth restriction. 
Such a possible link, to our knowledge never investigated before, could open the way to a 
practical test for the early diagnosis of a harmful complication. We selected ten pregnant 
women with a history of a successful pregnancy as a control group (group 1), plus ten with 
a diagnosis of IUGR, i.e. with foetal ultrasound biometric parameters below the 10th 
percentile (group 2). The course of pregnancy was normal in both groups, ending in 
spontaneous or elective caesarean delivery at term. Fresh blood samples drawn during the 
third trimester were analyzed at the Laboratory of the Haematological Unit of Ferrara 
University. Our study demonstrates that the number of peripheral leukocytes, the number 
of lymphocytes and their percentage were constant (p<0,75; p<0,93; p<0,49) while significant 
changes are observed for the NK cells. In particular: 
 Significantly higher NK percentage (% CD56+ cells) in group 2 (20,9) compared to group 
1 (15,1) (p<0,01) (Figure 4);  
 No significant increase in NK total number (CD56+  U/μl cells) (419,6) in group 2 
compared to group 1  (341,4 ) (p< 0,10); 
 Significantly higher percentage NK subset (CD2+CD56+ cells) in group 2 (18,8) 
compared to group 1 (13,4) (p<0.02) (Figure 5). 
By analyzing the other lymphocyte subsets, we observed a non significant CD4+ T decrease 
along with a CD8+ T increase, with a consequent decrease of their ratio. Moreover, there 
were no differences in the absolute count and percentage of the following lymphocyte 
subsets: T(CD3+) lymphocytes, T activated lymphocytes (CD3+ HLA-DR+), CD45 leukocytes, 
HLA-DR cells and B lymphocytes (CD19+ e CD19+CD5+). 
Therefore, increased peripheral NK percentage was the only significant feature of 
lymphocyte subset linked with IUGR in our study sample. Subsequently, with the aim to 
contribute to a better knowledge of the basic mechanisms of GCs protection, we evaluated 
the influence of betamethasone on the percentage of maternal pNK and other components of 
the lymphocyte subset in women with history of RSA. The patients with known anatomical, 
hormonal, genetic, infectious, autoimmune causes of abortion, as well as those with 
psychiatric disease were excluded from the study. Ten pregnant women with history of RSA  
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must recall that impairment of foetal oxygenation and growth, besides being linked with the 
above mentioned influences of unbalanced cytokines on utero-placental perfusion, is also 
reflected in the correlation between high values of uNK and IUGR (Williams et al., 2009). 
Therefore we decided to analyze the circulating lymphocyte subsets, mainly to search for a 
correlation between peripheral maternal NK concentration and foetal growth restriction. 
Such a possible link, to our knowledge never investigated before, could open the way to a 
practical test for the early diagnosis of a harmful complication. We selected ten pregnant 
women with a history of a successful pregnancy as a control group (group 1), plus ten with 
a diagnosis of IUGR, i.e. with foetal ultrasound biometric parameters below the 10th 
percentile (group 2). The course of pregnancy was normal in both groups, ending in 
spontaneous or elective caesarean delivery at term. Fresh blood samples drawn during the 
third trimester were analyzed at the Laboratory of the Haematological Unit of Ferrara 
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changes are observed for the NK cells. In particular: 
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 Significantly higher percentage NK subset (CD2+CD56+ cells) in group 2 (18,8) 
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along with a CD8+ T increase, with a consequent decrease of their ratio. Moreover, there 
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subsets: T(CD3+) lymphocytes, T activated lymphocytes (CD3+ HLA-DR+), CD45 leukocytes, 
HLA-DR cells and B lymphocytes (CD19+ e CD19+CD5+). 
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Figure 4. Comparison of  pNK percentage (% CD56 +) between patients with adequate foetal growth 
(Group 1) and those with growth restriction (Group 2)  
 
 
Figure 5. Comparison of the mean value of the CD2 + CD56 + subset percentage between patients with 
adequate foetal growth (Group 1) and those with growth restriction (Group 2).    
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were consecutively recruited (group 1). They were given oral betamethasone 0.5mg/daily 
from the fifth week of pregnancy until delivery. Ten normal pregnant women with previous 
history of successful pregnancies served as a control group (group 2). Blood samples were 
drawn at each one of the three trimesters (t1-first trimester, t2-second, t3-third). Fresh 
samples were analyzed at the Laboratory of the Haematology Unit of Ferrara University. 
The comparison between the two groups showed that lymphocytes percentage was 
significantly lower upon betamethasone therapy only in the third trimester (p-value =0,035). 
The percentage of T CD4+ cells in the third trimester was higher in treated women (46,4%) 
compared with controls (42,2%) (p-value =0,031), while that of T CD8+ cells was significantly 
lower in RSA in the second and in the third trimester. Comparison of CD2+, CD3+, CD5+, 
CD19+, CD45+, CD3+HLA-DR+ and CD19+CD5+ cells percentage between groups revealed 
no difference. As for NK, during the first trimester their percentage in RSA did not differ 
from that of the controls (gr1=15,0%, gr2=15,3%). However in the second trimester it became 
significantly lower (gr1=15,2%, gr2=17,6%, p-value=0,045). In the third trimester, despite a 
drop of their percentage (reaching 12,0%), only the absolute NK count decrease reached 
statistical significance. The percentage of NK subset CD2+CD56+ in the second and third 
trimester was significantly lower in group 1 (Figure 6). Our data on controls show the 
absence of significant changes in leukocyte and NK count and percentage throughout 
pregnancy. Coming to leukocyte subsets, we registered a lymphocytes decrease in the 
second trimester and a subsequent raise in the third, and a T CD4+ lymphocytes decrease 
with a T CD8+ increase throughout pregnancy. All together, these results substantially agree 
with the previous studies on physiologic pregnancy (Radysh et al., 2005). 
 
Figure 6. Trend of CD56 + cells U / l in group 1 and group 2 in the three trimesters. Time = 1.0 1^ 
trimester, 2.0 = 2^ trimester, 3.0 = 3^ trimester. Gr1 = normal pregnancy, Gr.2 = pregnancy with history 
of RSA treated with betamethasone 
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In the present study, moreover, we found that chronic low dose betamethasone 
administration leads to a significant decrease of leukocyte total number. Such behaviour is 
opposite to the well known leukocyte increase that follows 24 mg betamethasone 
administration during the third trimester for the prevention of hyaline membrane disease of 
the newborn. In addition, the lymphocytes percentage decrease caused by betamethasone 
reached statistical significance compared with controls in the third trimester. Such a result is 
likely to be related to the reduction of pNK. In treated cases NK percentage and number 
during the second and third trimester respectively reached lower values compared to 
controls. However, their values during the first trimester did not differ. Since it has been 
reported that women with history of RSA have a higher peripheral NK percentage, the 
absence of a difference between treated cases and physiological pregnancies during the first 
trimester in our data can be interpreted as an effect of betamethasone administration. In 
other words, betamethasone in RSA was able to decrease NK to values equal to (first 
trimester) and lower than (second and third) those in physiological pregnancy.  With regard 
to the other lymphocyte subsets, it had been reported that women with RSA have a higher T 
cytotoxic CD8+ and T activated cells (CD3+HLA-DR+) percentage as compared to 
physiological pregnancy. Our work showed that betamethasone is able to decrease T CD8+ 
percentage to the same or even lower values compared to physiological pregnancy. In 
addition, we found no differences for T activated cells, between physiological pregnancy 
and treated RSA group, probably due to a suppressive action of the hormone. Previous 
studies demonstrated a CD19+CD5+ decrease in normal pregnancy. These are B 
lymphocytes producing auto-antibodies, and their percentage typically raises in RSA and in 
ANA positive women. Indeed, their percentage is reported to fall from 4,17% in the first 
trimester to 1,92% in the third. In contrast, we did not find any difference in CD19+CD5+ 
percentage between the 2 groups. In conclusion, our research shows that 0.5 mg/day 
betamethasone therapy throughout pregnancy in RSA women reduces pNK cells, 
CD19+CD5+ and CD3+HLA-DR+ lymphocytes. Such a finding, based on the above reported 
data in the literature, suggests that, besides the possible rebalancing effect of the drug upon 
the inflammatory cytokines at the implantation site, successful outcome probably derives 
also from an action on the cellular components of the immune system. It is noteworthy that 
the clinical result is obtained with use of a low dose that proved to be harmless for the 
foetus and devoid of maternal side effects. 
9. Conclusive remarks 
We have reported in the present chapter the regulation of the gestational processes as it 
appears from the data in the literature. Pregnancy can be essentially interpreted as a 
vascular phenomenon resulting from a balanced activation and release of a great number of 
mediators upon hormonal control. Corpus luteum progesterone is required before 
conception in order to adapt the uterine decidua to the subsequent early phase of 
implantation. However it was shown long ago that from the seventh week onward the 
corpus luteum is no more needed, as at this stage castration becomes unable to interrupt 
pregnancy. In spite of such evidence, the hormone is extensively used for prevention of 
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abortion, and it keeps on being advocated even later on (Lucovnik et al., 2011), mainly based 
on its immuno-modulatory and myometrial relaxing effects. Recent research shed light on a 
more relevant cause of pregnancy loss than progesterone deficiency that is represented by 
inflammation at any stage of the gestational process. It can be triggered along a number of 
pathways, infection included. Nevertheless, infection, although accounting for ominous 
complications, has been found in some cases to represent a consequence rather than the 
cause of gestational inflammation. Inflammatory changes appear quite often to derive from 
a derangement of cytokines and prostanoids involved in the regulation of gestational 
physiological processes. A great number of cell function mediators has been found to be 
linked either with favourable outcome or with pregnancy loss, depending on the 
experimental model as well as on the gestational stage, but none can be identified alone as 
the keystone, successful pregnancy appearing the result of a balanced action of all mediators 
together. On the contrary, their imbalance leads to the activation of blood coagulation and 
stimulation of uterine contraction, the basic mechanisms for any pregnancy loss, aneuploid 
included (Vesce et al., 1996; Vesce et al., 2001; Vesce 2002). Myometrial activity is triggered 
by the release of prostanoids, mainly PGs of the E type, upon the action of many unbalanced 
cytokines. During the first trimester such abnormalities are confined to the feto-placental 
unit, while from late second to the third they can involve the maternal organism as well, 
leading to the variable clinical signs of preeclampsia. Outcome of pregnancy depends on the 
time of onset, the grade and the duration of cytokine imbalance. Moreover it must be 
considered that the maternal vascular adaptation is induced by the foetus itself, through the 
action of mediators released by trophoblastic cells on the uterine spiral arteries, and that 
even apparently late complications, such as preeclampsia, derive their origin from early 
foetal inadequacy (Vesce et al., 1997) Derangement of such mediators largely recognizing an 
inflammatory pathogenic mechanism, and low dose betamethasone being devoid of 
significant foetal side effects, there is no reason for administrating the glucocorticoids whose 
transfer to the foetus is highly impaired by 11β-HSD iso-enzymes. Indeed two possible 
scenarios can be identified:  
- the trophoblast is able to modify the uterine vessels, but the unfavourable decidual 
environment impairs such a potential capacity; 
- the maternal environment is favourable, but the trophoblast is unable to correctly 
operate. 
In either one of the cases, there are several possible treatments that, like in any other disease, 
can be classified as symptomatic or etiological: the first are addressed to counteract uterine 
contractions and blood clotting, the second aimed at rebalancing maternal, as well as foetal, 
cytokine derangement that leads to abnormal prostanoids release. However, none of the 
available therapeutic options is able to reverse endothelial damage, once it is already 
established. Moreover, only etiological therapies are provided with the capacity to prevent 
the clinical pictures of pregnancy loss in high risk cases.   Therefore, once the risk identified, 
etiological prevention and cure must start as early as possible, in some cases even before 
conception, and last enough to ensure foetal survival. In our opinion, GCs are the best 
preventive choice, as they represent the natural controller of the cross-talk that trophoblast 
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a derangement of cytokines and prostanoids involved in the regulation of gestational 
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conception, and last enough to ensure foetal survival. In our opinion, GCs are the best 
preventive choice, as they represent the natural controller of the cross-talk that trophoblast 
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entertains with maternal cells, throughout their entangled cytokine network. In this 
perspective, their efficacy is not to be intended simply as the result of a mere anti-
inflammatory action, but rather as a complex direct and indirect regulatory influence on the 
mediators of cell functions. For instance, betamethasone, from one hand directly down-
regulates the synthesis of inflammatory cytokines, while from the other it indirectly does the 
opposite by stimulating the MIF system. Unfortunately, in spite of the clinical evidence of 
the lack of significant maternal and foetal side effects of appropriate doses extensively 
reported in the literature, coupled with the great therapeutic benefits in life-threatening 
pregnancy complications, the concern for a negative impact on foetal morphogenesis and 
growth, mainly derived from experiments in animals with use of high doses, still impairs 
the correct adoption of GCs in the prevention of gestational risk. In the present chapter we 
reported some data from our long term use of low dose betamethasone throughout 
gestation for the prevention of pregnancy loss. Basically it is justified by the concept that 
pregnancy loss is the results of a cytokine imbalance possibly leading to inflammation, a 
derangement for which the use of progesterone is clinically proved to be either unsuitable or 
ineffective. In our experience, low dose betamethasone therapy is provided with great 
efficacy and devoid of significant foetal and maternal side effects. It will keep on 
representing the first choice therapy for protection of pregnancy in our practice.             
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1. Introduction 
1.1. Glucocorticoids discovery started 160 years ago 
Glucocorticoids are subclass from corticosteroids. The other subclass of corticosteroids is 
mineralocorticoids. Historically, the discovery of glucocorticoids has been commenced 
during the early of last century. In fact, glucocorticoids have revealed themselves by their 
absence. In 1849, Thomas Addison, who was a physician at Guy`s Hospital in London, had 
noticed that certain patients were presenting with a cluster of characteristic clinical picture 
including anemia, weakness, peculiar dark skin color and eventually death (1). He 
presented his observation on 11 cases at the South London medical society meeting. In 1855 
he published monograph entitled (On the Constitutional and Local Effects of Disease of the 
Supra-Renal capsules), (2, 3). 100 years later, Dr Philip Hench with a collaborated work with 
Edward Kendall, Professor of Physiological Chemistry, were both at Mayo Clinic which was 
first rheumatic disease service, had extracted “substance X” and in 21 September 1948 first 
injection of substance X was given to 29 years old lady who was suffering from severe, 
erosive arthropathies and became able to walk out of the hospital after 4 days of treatment. 
Dr Hench then named substance X Cortisone and shared the Nobel prize with professor 
Kendall in 1950 (4). 
1.2. Glucocorticoids characteristics 
Glucocorticoids (GCs) are belonging to the steroid group of the hormones that bind to the 
glucocorticoid receptor, which is present in almost all cells (5). This is the reason why the 
GCs play wide range of vital physiological roles in the human and other vertebrate bodies 
(6, 7). They play pivotal role in modulation and regulation of metabolism (8), immune 
system reaction (9, 10) and more significantly they are essential for normal development and 
cognition (11). 
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1.2.1. Biochemical characteristics 
To know how GCs exerts their wide range effects, it is crucial to know about their structure 
and the synthesis pathway. GCs are one of the steroid hormones group. All steroid 
hormones are derived from cholesterol. These include: sex hormones (Testosterone, estrone 
(E1), estradiol (E2), estriol (E3), and progesterone) adrenal cortex hormones (Cortisone, the 
main glucocorticoid and Aldosterone, the main mineralocorticoid) in addition to vitamin D. 
It is essential to know that androgens are the synthetic precursors of estrogens which 
mediated mainly by a specific cytochrome P 450 enzyme named aromatase. Each one of 
these steroid hormones can be a product and precursor in the same time. This is the reason 
why any defect in the synthesis of one steroid hormone will lead to derangement in the 
synthesis of the other hormones. For instance, in congenital adrenal hyperplasia (CAH), an 
autosomal recessive gene defect of the enzyme 21-hydroxylase, there will be blocked 
synthesis of aldosterone and cortisol pathways. Subsequently, all precursors will be directed 
toward androgenic pathway which does not involve 21-hydroxylation and eventually lead 
to excess production of androgens (Figure 1). Fetus with this congenital disease will be 
exposed to high levels of androgens as early as 3 months of gestation and hence during a 
critical window of sexual differentiation. As a result a female fetus will develop an 
ambiguous genitalia or male external genitalia under the influences of adrenal androgens. 
However, this is associated with varying degrees of GCs and mineralocorticoids 
deficiencies. In severe cases there will be salt wasting with low sodium and potassium in 
serum due to aldosterone deficiency (12). Currently, all neonates in the most of world are 
screened for CAH by measuring 17-Hydroxyprogesteron (17-OHP) in filter-paper blood 
samples at week one of life. An elevated 17-OHP indicated affected baby. Recently, there are 
promising clinical trials in prenatal diagnosis and treatments of such condition by giving the 
mother dexamethasone injections to prevent increased secretion of Adreno-Cortico-Tropic 
Hormone (ACTH) and subsequently adrenal androgens(13-17). 
1.2.2. Physiological characteristics 
GCs are needed mainly for energy where as mineralocorticoids are needed for mineral 
balance. GCs regulates wide range of cellular, molecular and the physiological processes in 
human body that are crucial for life such as growth, reproduction, essential metabolism, 
immune responses and inflammatory reactions, as well as central nervous system and 
cardiovascular functions (19-22). For all these roles to be achieved, adrenal GCs is 
considered as a ring which coupled with many other rings to form an integrated chain that 
acts in coordination, this chain is the hypothalamus-pituitary- adrenal axis. 
1.2.2.1. Hypothalamus-pituitary-adrenal axis (HPA axis) 
HPA axis serves as a master that controls major body systems and is considered as a main 
connecting pathway between central nervous system and endocrine system. It regulates 
majority of physiological function as well as it maintains homeostasis in acute stress. In the 
later situation, the brain will signal the stress to the paraventricular nucleus (PVN) in the 
hypothalamus which eventually secretes corticotrophin releasing hormone (CRH). CRH is 
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then transported through hypophyseal portal system to the pituitary gland and induces the 
conversion of pro-opiomelanocortin into ACTH as well as its secretion from anterior 
pituitary to the systemic circulation. ACTH is the primary regulator of adrenal cortical 
steroidogenesis. ACTH will induce the synthesis of adrenal steroids (GCs and androgens) in 
zonae fasciculate and reticularis of adrenal cortex (Figure 1). The ACTH itself is under the 
influences of negative feedback inhibition which exerted by the plasma levels of circulating 
free GCs (Figure 2). 
 
Figure 1. Adrenal gland steroidogenesis. The synthesis of adrenal steroids is started by transfer of 
cholesterol either from blood or from adrenal gland lipid droplets into mitochondria where it will be 
converted to pregnenolone. In zona glomerulosa pregnenolone will be hydroxylated to corticosterone 
and further oxidized to aldosterone where as in zona fasciculate and zona reticularis it will be 
hydoxylated to cortisol or undergoes cleavage to form the main adrenal androgen (DHEA). HSD: 
Hydroxysteroid Dehydrogenase, OH: Hydroxylase, (18). Adrenal androgen synthesis is increased about 
age of 8 years, independent of gonads and puberty, and responsible for pubic and axillary hair growth 
and termed adrenarche. 
1.2.2.2. Molecular mechanisms of GCs action 
GCs secretion from zona fasciculata up on ACTH stimulation is not a continuance process 
but rather in a specific pattern known as circadian rhythm. Once GCs in circulation, 95% of 
them will be bound to a carrier proteins: 80–90% to corticosteroid binding globulin (CBG) 
and 10–15% to albumin, leaving only about 5% as active unbound cortisol (23). The free 
cortisol is the one which mediates the biological effect of GCs since it is able to diffuse 
through the cell membrane freely. The GCs are metabolized in liver by reduction followed 
by conjugation rendering them water soluble and ready for renal excretion in urine. Both 
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liver and kidney contain the enzyme 11 β-Hydroxysteroid dehydrogenase (11 β-HSD).There 
is two isoforms of this enzyme which catalyzes the opposite reactions. 11 β-Hydroxysteroid 
Dehydrogenase-2 (11 β-HSD 2) will inactivate the cortisol by converting it into cortisone. 
The 11 β-Hydroxysteroid dehydrogenase-1 (11 β-HSD 1) will convert inactive cortisone into 
cortisol. The net result will determine the plasma level of active cortisol in the body (24). 
 
Figure 2. Schematic representation of Hypothalamic-pituitary-adrenal axis. PVN: Paraventricular 
nucleus, CRH: Corticotrophin releasing hormone, ACTH: Adrenocorticotropic hormone, : 
Inhibition, :Stimulation  
Once free GCs defused through the plasma membrane of the target cell they will bind to 
intra-cytoplasmic receptors called glucocorticoids receptor (GR). GR-GCs complex will be 
now translocated to the nucleus and bind to glucocorticoids responsive elements (GRE) in 
the promoter of the target gene (Figure 3). 
Human GR is 94 kDa protein which belongs to nuclear receptors known as 
Steroid/Thyroid/Retinoic acid superfamily and characterizing by being a ligand-dependent 
transcription factors that induce or suppress target gene expression (25). GCs are also able to 
alter gene expression of target genes independently to DNA-binding, but through 
interaction with other transcription factors, such as nuclear factor- κB, activator protein-1, 
p53 and signal transducers and activators of transcription (25). 
Interestingly, there are two isoforms of GR, alpha (α) and beta (β) (26, 27). The GR-α is the 
one which is able to bind with glucocorticoids and subsequently to the GCs responsive 
element (GRE) of the DNA promoter region on the target gene. However, GR-β has no such 
ability to bind to GCs but its main role thought to be inhibitory to GR-α action by 
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expression of GR-β is responsible for tissue sensitivity and resistance to GCs. Clinically, 
pathological conditions such as hypertension, rheumatoid arthritis, systemic lupus 
erythmatosis, ischemic heart disease and nasal carriage of Staphylococcus aureus are all 
associated with GR-β protein over-expression (29). 
 
Figure 3. Representation of how glucocorticoid hormone enters to the cell and bind to intracellular 
glucocorticoids receptors (GR). Up on binding to GR they dissociate from heat shock proteins (HSP). 
The glucocorticoids-receptor complex enters the nucleus and bind to glucocorticoids responsive 
element (GRE) in the promoter of the responsive gene (25). Lastly, GR exit nucleus and recycled along 
with the HSP in the cytoplasm. 
2. Tissue responses to glucocorticoids 
As mentioned earlier that GR exist in almost every human cell, then we should not get 
surprised to observe the profound molecular, cellular, metabolic and other known biological 
events modulation in response to GCs excess or deficiency. Notwithstanding, for more 
understanding of these complex relationship and the huge difference in the treatment-
response equation we categorized the human tissue into adult or mature human tissue and 
fetal or immature human tissue. 
2.1. Adult (mature) tissue response to glucocorticoids 
Adult cells and tissue characterized by being fully differentiated and mature. Therefore, 
influences will mainly affect their function.  
2.1.1. Immune system 
It is well established that the first medical use of GCs 60 years ago was for inflammation and 
autoimmune disease (30). GCs have significant influences on both cellular and humeral 
 
Glucocorticoids – New Recognition of Our Familiar Friend 452 
liver and kidney contain the enzyme 11 β-Hydroxysteroid dehydrogenase (11 β-HSD).There 
is two isoforms of this enzyme which catalyzes the opposite reactions. 11 β-Hydroxysteroid 
Dehydrogenase-2 (11 β-HSD 2) will inactivate the cortisol by converting it into cortisone. 
The 11 β-Hydroxysteroid dehydrogenase-1 (11 β-HSD 1) will convert inactive cortisone into 
cortisol. The net result will determine the plasma level of active cortisol in the body (24). 
 
Figure 2. Schematic representation of Hypothalamic-pituitary-adrenal axis. PVN: Paraventricular 
nucleus, CRH: Corticotrophin releasing hormone, ACTH: Adrenocorticotropic hormone, : 
Inhibition, :Stimulation  
Once free GCs defused through the plasma membrane of the target cell they will bind to 
intra-cytoplasmic receptors called glucocorticoids receptor (GR). GR-GCs complex will be 
now translocated to the nucleus and bind to glucocorticoids responsive elements (GRE) in 
the promoter of the target gene (Figure 3). 
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Steroid/Thyroid/Retinoic acid superfamily and characterizing by being a ligand-dependent 
transcription factors that induce or suppress target gene expression (25). GCs are also able to 
alter gene expression of target genes independently to DNA-binding, but through 
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p53 and signal transducers and activators of transcription (25). 
Interestingly, there are two isoforms of GR, alpha (α) and beta (β) (26, 27). The GR-α is the 
one which is able to bind with glucocorticoids and subsequently to the GCs responsive 
element (GRE) of the DNA promoter region on the target gene. However, GR-β has no such 
ability to bind to GCs but its main role thought to be inhibitory to GR-α action by 
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expression of GR-β is responsible for tissue sensitivity and resistance to GCs. Clinically, 
pathological conditions such as hypertension, rheumatoid arthritis, systemic lupus 
erythmatosis, ischemic heart disease and nasal carriage of Staphylococcus aureus are all 
associated with GR-β protein over-expression (29). 
 
Figure 3. Representation of how glucocorticoid hormone enters to the cell and bind to intracellular 
glucocorticoids receptors (GR). Up on binding to GR they dissociate from heat shock proteins (HSP). 
The glucocorticoids-receptor complex enters the nucleus and bind to glucocorticoids responsive 
element (GRE) in the promoter of the responsive gene (25). Lastly, GR exit nucleus and recycled along 
with the HSP in the cytoplasm. 
2. Tissue responses to glucocorticoids 
As mentioned earlier that GR exist in almost every human cell, then we should not get 
surprised to observe the profound molecular, cellular, metabolic and other known biological 
events modulation in response to GCs excess or deficiency. Notwithstanding, for more 
understanding of these complex relationship and the huge difference in the treatment-
response equation we categorized the human tissue into adult or mature human tissue and 
fetal or immature human tissue. 
2.1. Adult (mature) tissue response to glucocorticoids 
Adult cells and tissue characterized by being fully differentiated and mature. Therefore, 
influences will mainly affect their function.  
2.1.1. Immune system 
It is well established that the first medical use of GCs 60 years ago was for inflammation and 
autoimmune disease (30). GCs have significant influences on both cellular and humeral 
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immunity. They induce plasma cell immunoglobuline production and secretion and hence 
enhance humeral immunity (31). With regard to cellular immunity, GCs induce T-cell 
lymphocytosis (32), basophil apoptosis and neutrophilia by increasing bone marrow release 
of polymorphic neutrophils and decrease their migration to the inflammatory site (33, 34). 
Moreover, GCs enhances the phagocytosis and hence maximize the tissue clearance ability 
of the microorganisms and foreign antigens (35). It has been recently revealed that GCs can 
exert their immune-function manipulation at gene expression level. Galon and colleagues 
found that GCs significantly suppress the proinflamatory cytokines (IL1b, TNFa, IL-6, IL-8, 
IL- 12, IL-18) and chemokines gene expression where as the gene expression of anti-
inflammatory cytokines (IL-10 and TGFb) are up-regulated (22). 
2.1.2. Musculoskeletal system 
It is known, from long history of GCs use, that prolonged high doses of GCs results in bone 
mineralization depletion with subsequent osteoporosis (36). As a result bone formation will 
be decreased and resorption will be increased (37-41). Bone loss occur in the first few 
months of treatment and can be improved after cessation of treatment (42-44). Importantly, 
the GCs induced-osteoporosis can be prevented by calcium and vitamin D supplementation 
along with GCs treatment course (45). GCs will also cause proximal myopathy which is dose 
dependent and again improves with discontinuation of treatment (46). GCs treatment 
increases the risk of femoral head avascular necrosis through a not well established 
mechanism, although some preliminary evidence pointing to venous endothelial injury (47, 
48). 
2.1.3. Vascular system 
Use of GCs is associated with increased risk of ischemic heart disease and heart failure by 
increasing the occurrence of hypertension, hyperglycemia, dyslipideamia and obesity (49, 
50). Rapid GCs infusion especially in patients with renal and cardiac co-morbidity was 
associated with sudden death (51). 
2.1.4. Serum lipid levels 
There are conflicting results from different studies regarding GCs induced hyperlipideamia. 
Berg and Nilsson-Ehle found that GCs may induce hyperlipideamia through ACTH 
suppression (52). Whereas others found that GCs may induce favorable lipid profiles in 
patients aged 60 years or more (53). 
2.1.5. Serum glucose levels 
GCs are considered diabetogenic hormones. Patients receiving therapeutic doses of GCs will 
have deranged plasma glucose level and even frank diabetes in glucose intolerant 
individuals (54, 55). The GCs-induced hyperglycemia is mainly due to reduced glucose 
peripheral disposal along with increased hepatic gluconeogenesis (56). 
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2.1.6. Central nervous system 
Prolonged use of high doses of GCs is associated with marked behavioral and cognitive 
deficits. These disorders are more prevalent in those who have risk factors such as pre-
existing psychiatric disorders, family history of depression or alcoholism (57). These 
disturbances are ranging from sleeping disturbances, insomnia, to hypomania, depression 
and psychosis (58) as well as memory disturbances (59). Recently, more evidences are 
accumulated to affirm the relationship between exposure to high GCs and impaired 
cognition. Ioannis and others found that chronic stress, through high endogenous GCs, 
precipitate cognitive impairment and Alzheimer's like disease (60). 
2.1.7. Gastrointestinal system 
Gastritis, peptic ulceration, and gastrointestinal hemorrhage all have been found to 
complicate GCs therapy especially if non-steroidal anti-inflammatory drugs are used 
concomitantly (61). Although, Chrousos and collegues indicated that GCs therapy could be 
related to acute pancreatitis in GCs user (62), but more recent studies have proven the 
opposite that GCs are not an etiological factor (63). 
2.2. Fetal (Immature) tissue responses to glucocorticoids 
Human intrauterine development is divided mainly into three stages: Zygote, from 
fertilization to implantation, embryo, from implantation to 8 weeks and fetus, from 8 weeks 
till term. The embryo and fetal tissues are characterized by rapid division and growth 
rendering them very susceptible to environmental influences and easily adaptive. 
2.2.1. Short term effects of GCs over exposure in fetal life 
2.2.1.1. Fetal over exposure to endogenous GCS 
Fetal plasma GCs are mainly of maternal adrenal origin (64). This is essentially because of the 
biochemical, “partial” barrier role played by the placenta. The placenta contains the enzyme 11 
β-HSD 2 which is responsible for inactivation of maternal cortisol into cortisone (Section 1.2.2) 
and hence maintains a normal feto-maternal concentration gradient of the hormone (65). This 
concentration gradient is species specific where it reaches 180 ng/ml in human; it is only 2 and 
15 ng/ml in sheep and pig respectively (66). Therefore, we can assume that fetal exposure to 
maternal GCs is, at least partly, dependent on the placental activity of this enzyme. This is 
supported by the finding that in human umbilical cord blood cortisone/cortisol ratio, as a 
marker of placental 11 β-HSD 2, and the enzyme activity itself and its mRNA expression were 
lower in human pregnancies which complicated by intrauterine growth restriction (IUGR) (67) 
and each unit increase in cortisol/cortisone ratio was found to be associated with 1.6 mm Hg 
higher systolic blood pressure at 3 years of age (68).  
GCs are essential for optimal fetal tissue maturation. GR are expressed in brain (69) where it 
is essential for development of neurons, the building unit in CNS, as well as the formation of 
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immunity. They induce plasma cell immunoglobuline production and secretion and hence 
enhance humeral immunity (31). With regard to cellular immunity, GCs induce T-cell 
lymphocytosis (32), basophil apoptosis and neutrophilia by increasing bone marrow release 
of polymorphic neutrophils and decrease their migration to the inflammatory site (33, 34). 
Moreover, GCs enhances the phagocytosis and hence maximize the tissue clearance ability 
of the microorganisms and foreign antigens (35). It has been recently revealed that GCs can 
exert their immune-function manipulation at gene expression level. Galon and colleagues 
found that GCs significantly suppress the proinflamatory cytokines (IL1b, TNFa, IL-6, IL-8, 
IL- 12, IL-18) and chemokines gene expression where as the gene expression of anti-
inflammatory cytokines (IL-10 and TGFb) are up-regulated (22). 
2.1.2. Musculoskeletal system 
It is known, from long history of GCs use, that prolonged high doses of GCs results in bone 
mineralization depletion with subsequent osteoporosis (36). As a result bone formation will 
be decreased and resorption will be increased (37-41). Bone loss occur in the first few 
months of treatment and can be improved after cessation of treatment (42-44). Importantly, 
the GCs induced-osteoporosis can be prevented by calcium and vitamin D supplementation 
along with GCs treatment course (45). GCs will also cause proximal myopathy which is dose 
dependent and again improves with discontinuation of treatment (46). GCs treatment 
increases the risk of femoral head avascular necrosis through a not well established 
mechanism, although some preliminary evidence pointing to venous endothelial injury (47, 
48). 
2.1.3. Vascular system 
Use of GCs is associated with increased risk of ischemic heart disease and heart failure by 
increasing the occurrence of hypertension, hyperglycemia, dyslipideamia and obesity (49, 
50). Rapid GCs infusion especially in patients with renal and cardiac co-morbidity was 
associated with sudden death (51). 
2.1.4. Serum lipid levels 
There are conflicting results from different studies regarding GCs induced hyperlipideamia. 
Berg and Nilsson-Ehle found that GCs may induce hyperlipideamia through ACTH 
suppression (52). Whereas others found that GCs may induce favorable lipid profiles in 
patients aged 60 years or more (53). 
2.1.5. Serum glucose levels 
GCs are considered diabetogenic hormones. Patients receiving therapeutic doses of GCs will 
have deranged plasma glucose level and even frank diabetes in glucose intolerant 
individuals (54, 55). The GCs-induced hyperglycemia is mainly due to reduced glucose 
peripheral disposal along with increased hepatic gluconeogenesis (56). 
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2.1.6. Central nervous system 
Prolonged use of high doses of GCs is associated with marked behavioral and cognitive 
deficits. These disorders are more prevalent in those who have risk factors such as pre-
existing psychiatric disorders, family history of depression or alcoholism (57). These 
disturbances are ranging from sleeping disturbances, insomnia, to hypomania, depression 
and psychosis (58) as well as memory disturbances (59). Recently, more evidences are 
accumulated to affirm the relationship between exposure to high GCs and impaired 
cognition. Ioannis and others found that chronic stress, through high endogenous GCs, 
precipitate cognitive impairment and Alzheimer's like disease (60). 
2.1.7. Gastrointestinal system 
Gastritis, peptic ulceration, and gastrointestinal hemorrhage all have been found to 
complicate GCs therapy especially if non-steroidal anti-inflammatory drugs are used 
concomitantly (61). Although, Chrousos and collegues indicated that GCs therapy could be 
related to acute pancreatitis in GCs user (62), but more recent studies have proven the 
opposite that GCs are not an etiological factor (63). 
2.2. Fetal (Immature) tissue responses to glucocorticoids 
Human intrauterine development is divided mainly into three stages: Zygote, from 
fertilization to implantation, embryo, from implantation to 8 weeks and fetus, from 8 weeks 
till term. The embryo and fetal tissues are characterized by rapid division and growth 
rendering them very susceptible to environmental influences and easily adaptive. 
2.2.1. Short term effects of GCs over exposure in fetal life 
2.2.1.1. Fetal over exposure to endogenous GCS 
Fetal plasma GCs are mainly of maternal adrenal origin (64). This is essentially because of the 
biochemical, “partial” barrier role played by the placenta. The placenta contains the enzyme 11 
β-HSD 2 which is responsible for inactivation of maternal cortisol into cortisone (Section 1.2.2) 
and hence maintains a normal feto-maternal concentration gradient of the hormone (65). This 
concentration gradient is species specific where it reaches 180 ng/ml in human; it is only 2 and 
15 ng/ml in sheep and pig respectively (66). Therefore, we can assume that fetal exposure to 
maternal GCs is, at least partly, dependent on the placental activity of this enzyme. This is 
supported by the finding that in human umbilical cord blood cortisone/cortisol ratio, as a 
marker of placental 11 β-HSD 2, and the enzyme activity itself and its mRNA expression were 
lower in human pregnancies which complicated by intrauterine growth restriction (IUGR) (67) 
and each unit increase in cortisol/cortisone ratio was found to be associated with 1.6 mm Hg 
higher systolic blood pressure at 3 years of age (68).  
GCs are essential for optimal fetal tissue maturation. GR are expressed in brain (69) where it 
is essential for development of neurons, the building unit in CNS, as well as the formation of 
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synapses by facilitating cortisone-induced axons and dendrites remodeling and neurons 
myelination (70). Human nervous system development during fetal life is a complex process 
where extensive proliferation of neurons occurs after initial migration between week 8 and 
16 of gestation (71) to reach, at 28 weeks, approximately 40 % higher than total number of 
neurons in adult (72). These enormous numbers of neurons start to be connected by an 
extensive network of synapses where between 24 and 34 weeks of gestation more that 10,000 
new synapses per second are formed (73). Therefore, exposure to altered plasma level of 
cortisone during these stages of development and vulnerability is able to alter the basic 
structure and subsequently the function of the CNS (74). The Maternal and fetal HPA axis 
are independent (Figure 4 ) where maternal cortisol is prevented to enter fetal compartment 
by placental 11 β-HSD 2 until late gestation where placental enzyme drops sharply and 
allow high levels of maternal free cortisol to enhance fetal lung, CNS and other tissue 
maturation (75). However, the placenta secretes placental corticotrophin releasing hormone 
(P-CRH) which is the major, if not the only, mean of cross talk between maternal and fetal 
HPA axis. As mentioned earlier (Section 1.2.2) that maternal cortisol is exerting negative 
feedback inhibition on her hypothalamus release of CRH, on contrast, it induces P-CRH 
secretion as pregnancy advances (76) which in turn will increase maternal and fetal adrenal 
cortisol secretion (77, 78). 
Therefore, maternal either biological stress, like nutritional deprivation, immune reaction, 
hypertension, or psychological stress will be associated with high maternal cortisol and P-
CRH which disrupt fetal nervous system development and affect postnatal cognitive and 
neuromuscular function. High P-CRH, as a marker of maternal stress, during third trimester 
associated with weak fetal responsiveness to noval stimuli (79). Postnataly, there is 
significant reduction in physical and neuromuscular development in neonates who exposed 
to higher maternal cortisol as well as P-CRH during second and third trimester respectively 
(80). Those neonates also express prolonged cortisol response to stress, which similar to the 
effect of synthetic prenatal GCs (81). Interestingly, these behavioral, cognitive and 
neuromuscular deficiency of offspring exposed to endogenous maternal GCs were 
accompanied by reduction in the volume of the areas responsible for these functions (82, 83).  
Immune system disorder also noted in offspring exposed to maternal prenatal stress with 
higher incidence of childhood skin, respiratory and other general infections and increased 
antibiotics use (84). In addition, they have increased body weight which was significantly 
apparent at age of 10 years (85). More specifically, maternal high CRH during second 
trimester was found to be associated with offspring adiposity at age of 3 years (86). 
2.2.1.2. Antenatal synthetic steroid (dexamethasone and betamethsone) exposure 
Maternal administration of synthetic GCs such as dexamethasone and betamethasone, 
which are poor substrates for 11 β-HSD 2 (87), during pregnancy can cross the placenta (88) 
in quantities sufficient to induce immediate fetal changes such as reduction in umbilical 
artery pulsatility index and improved velocity (89) along with transient suppression of fetal 
breathing and fetal movement resulting in lowering the score of biophysical profile (90). 11 
β-HSD 2 is expressed mainly in placental cytotrophoblasts, the progenitors, only upon 
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syncytialization into syncytiotrophoblasts (91). Li and colleagues found that up on 
syncytialization the expressions of SP1 transcription factor as well as the cAMP pathway are 
markedly activated (91). 
 
Figure 4. Fetal and maternal HPA axes are two independent systems. The P-CRH stimulates the 
production of both maternal and fetal cortisol. Maternal cortisol has negative feedback inhibition on her 
CRH and ACTH but exerts positive feedback stimulation on P-CRH. Placental 11 β-HSD 2 inactivates 
maternal cortisol into cortisone and hence partially protects the fetus from endogenous maternal GCs 
over exposure. H: Hypothalamus, P: Pituitary, HPA: Hypothalamo-Pituitary-Adrenal, P-CRH: Placental 
Corticotrophin Releasing Hormone, ACTH: Adreno-Corticotrophic Hormone, 11 β-HSD 2:11-β-
Hydroxysteroid dehydrogenase-2, GCs:Glucocorticoids, M-Cortisol: Maternal cortisol, M-Cortisone: 
Maternal cortisone, PVN: Paraventricular nucleus, : Inhibition, : Stimulation. 
GCs are strong inducers of HLA-G gene expression in choriocarcinoma JEG-3 cell lines. The 
HLA-G molecules play a pivotal role in regulating feto-maternal interface and essential for 
protecting the allogenic fetus from maternal immune attack (92). 
After the finding that surfactant deficiency in premature infants (less than 37 weeks of 
gestation) is the leading cause of respiratory distress syndrome (RDS) in 1959 (93) and high 
mortality rate among preterm infants because of this lung immaturity (94, 95) a continuous 
work was done to prevent such fatal condition. Clinically, GCs has been used to prevent 
neonatal respiratory distress syndrome successfully (96). Thereafter, many studies found 
that maternal treatment of GCs will significantly decrease neonatal death due to reduction 
of intraventricular haemorrhage and necrotising enterocolitis beside reduction in RDS (97, 
98). However, randomized controlled trials shown that no differences in the effectiveness of 
both dexamethasone and betamethasone in reducing the rate of respiratory distress 
syndrome, need for vasopressor therapy, necrotizing enterocolitis, retinopathy of 
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synapses by facilitating cortisone-induced axons and dendrites remodeling and neurons 
myelination (70). Human nervous system development during fetal life is a complex process 
where extensive proliferation of neurons occurs after initial migration between week 8 and 
16 of gestation (71) to reach, at 28 weeks, approximately 40 % higher than total number of 
neurons in adult (72). These enormous numbers of neurons start to be connected by an 
extensive network of synapses where between 24 and 34 weeks of gestation more that 10,000 
new synapses per second are formed (73). Therefore, exposure to altered plasma level of 
cortisone during these stages of development and vulnerability is able to alter the basic 
structure and subsequently the function of the CNS (74). The Maternal and fetal HPA axis 
are independent (Figure 4 ) where maternal cortisol is prevented to enter fetal compartment 
by placental 11 β-HSD 2 until late gestation where placental enzyme drops sharply and 
allow high levels of maternal free cortisol to enhance fetal lung, CNS and other tissue 
maturation (75). However, the placenta secretes placental corticotrophin releasing hormone 
(P-CRH) which is the major, if not the only, mean of cross talk between maternal and fetal 
HPA axis. As mentioned earlier (Section 1.2.2) that maternal cortisol is exerting negative 
feedback inhibition on her hypothalamus release of CRH, on contrast, it induces P-CRH 
secretion as pregnancy advances (76) which in turn will increase maternal and fetal adrenal 
cortisol secretion (77, 78). 
Therefore, maternal either biological stress, like nutritional deprivation, immune reaction, 
hypertension, or psychological stress will be associated with high maternal cortisol and P-
CRH which disrupt fetal nervous system development and affect postnatal cognitive and 
neuromuscular function. High P-CRH, as a marker of maternal stress, during third trimester 
associated with weak fetal responsiveness to noval stimuli (79). Postnataly, there is 
significant reduction in physical and neuromuscular development in neonates who exposed 
to higher maternal cortisol as well as P-CRH during second and third trimester respectively 
(80). Those neonates also express prolonged cortisol response to stress, which similar to the 
effect of synthetic prenatal GCs (81). Interestingly, these behavioral, cognitive and 
neuromuscular deficiency of offspring exposed to endogenous maternal GCs were 
accompanied by reduction in the volume of the areas responsible for these functions (82, 83).  
Immune system disorder also noted in offspring exposed to maternal prenatal stress with 
higher incidence of childhood skin, respiratory and other general infections and increased 
antibiotics use (84). In addition, they have increased body weight which was significantly 
apparent at age of 10 years (85). More specifically, maternal high CRH during second 
trimester was found to be associated with offspring adiposity at age of 3 years (86). 
2.2.1.2. Antenatal synthetic steroid (dexamethasone and betamethsone) exposure 
Maternal administration of synthetic GCs such as dexamethasone and betamethasone, 
which are poor substrates for 11 β-HSD 2 (87), during pregnancy can cross the placenta (88) 
in quantities sufficient to induce immediate fetal changes such as reduction in umbilical 
artery pulsatility index and improved velocity (89) along with transient suppression of fetal 
breathing and fetal movement resulting in lowering the score of biophysical profile (90). 11 
β-HSD 2 is expressed mainly in placental cytotrophoblasts, the progenitors, only upon 
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syncytialization into syncytiotrophoblasts (91). Li and colleagues found that up on 
syncytialization the expressions of SP1 transcription factor as well as the cAMP pathway are 
markedly activated (91). 
 
Figure 4. Fetal and maternal HPA axes are two independent systems. The P-CRH stimulates the 
production of both maternal and fetal cortisol. Maternal cortisol has negative feedback inhibition on her 
CRH and ACTH but exerts positive feedback stimulation on P-CRH. Placental 11 β-HSD 2 inactivates 
maternal cortisol into cortisone and hence partially protects the fetus from endogenous maternal GCs 
over exposure. H: Hypothalamus, P: Pituitary, HPA: Hypothalamo-Pituitary-Adrenal, P-CRH: Placental 
Corticotrophin Releasing Hormone, ACTH: Adreno-Corticotrophic Hormone, 11 β-HSD 2:11-β-
Hydroxysteroid dehydrogenase-2, GCs:Glucocorticoids, M-Cortisol: Maternal cortisol, M-Cortisone: 
Maternal cortisone, PVN: Paraventricular nucleus, : Inhibition, : Stimulation. 
GCs are strong inducers of HLA-G gene expression in choriocarcinoma JEG-3 cell lines. The 
HLA-G molecules play a pivotal role in regulating feto-maternal interface and essential for 
protecting the allogenic fetus from maternal immune attack (92). 
After the finding that surfactant deficiency in premature infants (less than 37 weeks of 
gestation) is the leading cause of respiratory distress syndrome (RDS) in 1959 (93) and high 
mortality rate among preterm infants because of this lung immaturity (94, 95) a continuous 
work was done to prevent such fatal condition. Clinically, GCs has been used to prevent 
neonatal respiratory distress syndrome successfully (96). Thereafter, many studies found 
that maternal treatment of GCs will significantly decrease neonatal death due to reduction 
of intraventricular haemorrhage and necrotising enterocolitis beside reduction in RDS (97, 
98). However, randomized controlled trials shown that no differences in the effectiveness of 
both dexamethasone and betamethasone in reducing the rate of respiratory distress 
syndrome, need for vasopressor therapy, necrotizing enterocolitis, retinopathy of 
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prematurity, patent ductus arteriosus, neonatal sepsis, and neonatal mortality but reduction 
in the frequency of intraventricular haemorrhage was more with dexamethasone compared 
to betamethasone (99). 
When synthetic GCs administered during pregnancy they can cross placenta freely since 
they are not a good substrates to 11 β-HSD 2 (88) and is not bound by CBP (100). Although, 
the mechanism by which GCs enhance fetal lung maturity is not well established, the 
administration of antenatal GCs in threatened preterm labour was widely recommended by 
many institutes. For instance, the National Institutes of Health (NIH) published a Consensus 
Development Conference Statement in 1994 on the use of antenatal GCs (101) and in 2002, 
the American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice 
(ACOG) supported the conclusions of the NIH consensus conference (102), whereas, the 
Royal College of Obstetricians and Gynecologists (RCOG) published guideline in 1996 (103) 
about antenatal GCs use in preterm labour which then up dated in 1999 and further in 2004. 
Recently, there are many evidences that GCs induce fetal lung maturity at both transcriptional 
and post transcriptional levels (104-106). Pulmonary surfactant is a complex lipoprotein which 
main action is to reduce surface tension in the alveoli, and subsequently prevent alveolar 
collapse upon expiration (107). There are four major types of surfactant proteins (SP) A, B, C 
and D (108). GCs act mainly by increasing the surfactant protein-B (SP-B) mRNA expression at 
transcription level and its stability at post transcription level (109). Treatment consists of two 
doses of 12 mg of betamethasone given intramuscularly 24 hours apart or four doses of 6 mg 
of dexamethasone given intramuscularly 12 hours apart. Optimal benefit begins 24 hours after 
initiation of therapy and lasts 7 days (101). It has been recently established the use of repeated 
GCs courses every 14 days for those who still not delivered after the first course. Studies on 
animal models and also on human showed no additional benefits from repeated courses 
compared with single GCs course (110-112) and even can be harmful (113-116). 
In fact, multiple courses of antenatal GCs have been found to be associated with reduction 
in ponderal measurements including birth weight, height (116-120) and birth head 
circumference (117, 119, 121) and higher infant blood pressure and myocardial wall 
thickness (122, 123) also with maternal infection such as chorioamnionitis and endometritis 
(116, 121, 124). Rodríguez-Pinilla also reported that antenatal exposure to single steroid 
course is able to produce similar effects of multiple courses on birth weight and height but 
not head circumference (117). 
With regard to fetal bone metabolism, there were few studies addressing this subject. 
However, the available data do suggest that both single as well as multiple antenatal steroid 
courses have no detrimental effects on fetal bone metabolism as evidenced by umbilical cord 
serum levels of carboxy-terminal propeptide of type I procollagen, a marker for bone 
formation, and cross-linked carboxy-terminal telopeptide of type I procollagen, a marker of 
bone resorption (125-127). 
The impact of maternal GCs administration antenataly on neonatal hypothalamic-pituitary- 
adrenal (HPA) axis has been examined extensively but data are controversy. Sandesh Kiran 
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and coworkers found that multiple courses of antenatal dexamethasone causing a significant 
decrease in RDS without adrenal suppression, decreased growth or impaired neuro-
development (128). However, Schäffer and colleagues found that single course of antenatal 
GCs can lead to absence of stress-induced plasma cortisone and cortisol elevation in 
neonates at 4 days of life (129). On the other hand, Davis reported that antenatal GCs 
administration in threatened preterm labour was associated with higher pain-induced 
plasma cortisol elevation despite no difference in baseline levels than non-treated matched 
infants at 24 hr after birth (81). Others have assessed the impact of antenatal corticosteroid 
courses on HPA axis by measuring neonatal 17-OHP in filter-paper blood spots collected 
between 72 and 96 hr after birth, which usually used for screening the neonates for CAH 
(Section 1.2.1) (130). These studies revealed a significant reduction of blood 17-OHP in those 
received multiple courses compared to non-treated matched neonates (130). This fact raise 
the suspicion in the effectiveness of this screening test in this particular group of neonates as 
prenatal steroid-induced reduction in 17-OHP could be interpreted falsely as negative test in 
affected newborns. Ng et al found that at postnatal day 7 and 14 neonatal plasma ACTH 
and cortisone levels measured after human corticotrophin releasing hormone (hCRH) 
stimulation test was mildly lower in those exposed to multiple dexamethasone injections 
antenataly than none treated neonates. Interestingly, there was a negative correlation 
between plasma cortisone and the number of dexamethasone injections antenataly (131). 
These finding strongly indicate that antenatal steroid therapy, multiple courses in particular, 
has impact, which could be transient, on HPA axis harmony and neonatal observation 
during the first few days is warranted. Animal model of prenatal betamethasone using 
guinea pigs reported same finding that ACTH and plasma cortisol both suppressed by 
prenatal betamethasone treatment. This was assosiated with significant reduction in 
hippocampal mineralococrticoids receptor mRNA and protein expression especially in male 
offspring with no much difference among GR mRNA and protein expression (132).  
It has been found that multiple prenatal steroid courses are not associated with a deleterious 
effect on auditory neural maturation when assessed at 24 hr after birth (133). However, the 
use of multiple dexamethasone but not betamethasone are associated with persistent 
increases in brain parenchymal echogenicity in preterm infants (134) as well as cystic 
leukomalacia and neurodevelopmental delay at 2 years of age (135). Animal models of 
prenatal steroid therapy presented some evidence regarding possible mechanism by which 
antenatal glucocorticoids prevent intraventricular haemorrhage in preterm infants. In mice, 
prenatal steroid therapy can induce choroid plexus capillary stability and maturation by 
increasing basement membrane thickness and integrity with subsequent reduction in both 
peri and intraventricular haemorrhage (136). The frequency and severity of periventricular 
and intraventricular haemorrhage were even less if vitamin K injection administered 
antenataly along with steroid course (137). 
More recent data comparing the efficacy of single steroid course with multiple courses 
stated that there were no significant differences in the frequency of respiratory distress 
syndrome, intraventricular hemorrhage, necrotizing enterocolitis, sepsis and neonatal 
mortality in neonates receiving either single betamethasone course or multiple courses (138). 
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According to the same study, the use of multiple courses is not superior to single course. 
Similar beneficial effect was noted from the use of single and multiple antenatal steroid 
courses in decreasing the need for postnatal blood pressure support in extreme preterm 
infants born between 24 to 28 weeks of age (139).  
On the same bases, the ACOG Committee on Obstetric Practice (2011) has published its 
opinion regarding the use of multiple courses. The committee recommended the use of 
single corticosteroids course to all pregnant women at risk of preterm delivery at 24 to 34 
weeks gestation. Another single rescue course of antenatal corticosteroids may be 
considered if the initial steroid course was given more than 2 weeks earlier (140).  
2.2.2. Long term effects of prenatal GCs overexposure 
There are accumulating evidence about solid role played by fetal overexposure to both 
endogenous or synthetic GCs and the risk of developing metabolic and cardiovascular 
disease in adulthood (141, 142). This remote response to an intrauterine insult has been 
termed (fetal programming of adult disease). 
3. Fetal programming of adult disease 
Programming refers to physiological, metabolic, or behavioral adaptation resulting from 
exposure to or lack of hormones, nutrients, stress, and other agents at critical period during 
embryonic and fetal development. These insults may encode the function of organs and 
systems and manifested later as elevated risk for disease in adult life (143, 144). The concept 
of programming was emerged from many epidemiological studies. For instant, follow up 
study of a cohort of men who were born during Duch famine in 1944-45 found that 
exposure to undernutrition during the first half of pregnancy were significantly associated 
with obesity at adulthood (145). subsequent studies have linked the low birth weight with 
developing of hypertension, ischaemic heart disease, glucose intolerance, insulin resistance, 
type 2 diabetes, hyperlipidaemia, hypercortisolaemia, obesity, obstructive pulmonary 
disease, renal failure and reproductive disorders in the adult (146). 
The factors that can programme disease risk in later life are multiple but interact together 
and include undernutrition (147), stress(148) and endocrine disturbances (149). It has been 
found that maternal undernutrition leads to decreased placental and fetal birth weight 
associated with elevated maternal plasma GCs and reduced placental expression of 11 β-
Hydroxysteroid Dehydrogenase-2 and subsequently fetal over exposure to maternal 
corticosterone in rat (150). Maternal low protein diet, for instance, programmed the 
development of hypertension (151, 152), glucose intolerance (153, 154) and even feeding 
behavioral abnormalities (155). In human, fetal over exposure to endogenous maternal GCs, 
such as in maternal psychological stress, programmed the development of metabolic 
syndrome with higher BMI and body fat percentage, insulin resistance, and atherogenic 
lipid profile in the offspring at adult life (156). Moreover, adult offspring exposed to 
prenatal maternal stress, and hence high endogenous GCs, have altered T-helper 1 and 2 
balance and abnormal cytokines and ultimately become more prone to develop autoimmune 
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disorders and asthma (157). Similarly, there was impaired cognitive performance as well as 
memory in the offspring who exposed to maternal stress and higher endogenous GCs. This 
disturbances in mental function was associated with altered HPA axis in later life where 
ACTH was increased and plasma cortisol level was decreased (158). 
Interestingly, the same programming effect was observed using synthetic GCs such as 
dexamethasone, which is poor substrate to 11 β-Hydroxysteroid Dehydrogenase-2 (142, 
159). Prenatal exposure to synthetic GCs resulted in anxiety and depressive-like behavior in 
adult offspring. There was altered brain structure with significant increase in volume of the 
bed nucleus of the stria terminalis and on the other hand decrease amygdala volume due to 
dendritic atrophy. Dopamin was reduced and dopamin receptor 2 was up regulated in this 
area (160, 161). 
Dexamethasone exposure during late gestation is also able to alter the hepatic and adipose 
tissue activity and mRNA expression of β-HSD 1 in marmoset monkey with subsequent 
development of obesity and overt metabolic syndrome (162). It is clear from these data that 
both fetal exposure to undernutrition, as stress event that lead to fetal over exposure to 
endogenous maternal GCs, as well as overexposure to synthetic GCs, which are poor 
substrates to placental 11 β-HSD 2, share common mechanistic pathway in the 
programming of metabolic syndrome in the offspring at adult life.  
3.1. Proposed mechanism of fetal programming of adult disease 
The concept of the programming has its roots since 50 years ago (163) and proven by both 
animal (152, 164) and human studies (119, 149), however, the mechanism that events during 
intrauterine life are carried in the memory of every molecule, gene, cell, tissue and systems` 
organs of the body still not completely revealed. Many hypotheses have been proposed with 
their inherited power and weakness. These include epigenetic modifications of DNA, 
altered gene expression and regulation, disruption of organ structure by variation in cell 
number and differentiation and apoptotic remodeling (165, 166). “Hormonal imprinting” 
where exposure to abnormal levels of a particular hormone during specific window of tissue 
plasticity is able to exert lifelong abnormal metabolism is another proposed mechanism 
(167). 
3.1.1. Tissue remodeling 
In maternal undernutrition model, programming was found to be associated with decreased 
organ size and total cell mass. Programming of diabetes, in this model, was accompanied by 
altered pancreatic structure, with predominantly a decrease in β-cell mass (153) due, 
primarily, to decreased proliferation and increased apoptosis (168). In this model, last week 
of rat pregnancy was identified as the critical window of programming. Similarly, 
programming of hypertension was linked to decreased number of nephrons and impaired 
renal electrolytes and fluid balance (169). GCs, both synthetic one and endogenous, are 
mediating their programming effects through similar mechanism. As mentioned previously 
that the observed psychological, behavioral and neuromuscular disturbances were all 
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associated with decreased volume of brain area responsible on that particular function. 
Moreover, dexamethasone prenatally caused marked reduction in thymus (170). Therefore, 
antenatal exposure to glucocorticoids above the physiological limit will perturb the growth 
and ultimate size of the developing fetal organs and eventually their functional capacity 
which then manifested as disease in adult life.  
3.1.2. Epigenetic DNA modification 
Epigenetic phenomenon refers to altered heritable genomic function without change in 
DNA sequence (171). Epigenetic modification involves mainly DNA methylation, histone 
modification, and miRNA effects (172). DNA methylation has been well explored. In this 
case there is methylation of cytosine residues within CpG dinucleotides. When this 
abnormal methylation of CpG islands occur in the promoter region of genes it will result in 
silencing of genetic information and subsequently to altered biological function (171). 
Methylation status is a dynamic status and changes are observed since fertilization where 
both maternal and paternal genomes undergo extensive demethylation followed by 
selective methylation just prior to implantation (173). This alteration in methylation status 
has been suggested to play role in cell differentiation and organ development (174). DNA 
methylation blocks the binding of transcription factors to the promoter of the target gene 
(Figure 5) and hence prevent gene expression or it promote the binding of the methyl CpG 
binding protein (MeCP2) which recruits other protein complexes to bind to DNA resulting 
in a closed chromatin structure and transcriptional silencing (174). 
 
Figure 5. Epigenetic modification of GR promoter by CpG altered methylation. 
Maternal low protein diet during pregnancy as experimental model of programming of 
metabolic syndrome like phenotype has been found to be associated with altered DNA 
methylation in key genes. For instance, maternal low protein diet resulted in GR over 
expression and 11 β-HSD 2 decreased expressions in liver, lung, kidney and brain of the 
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offspring (175). GCs induce the hepatic expression and activity of phosphoenolpyruvate 
carboxykinase (PEPCK) the key enzyme responsible for gluconeogenesis and subsequently 
produce insulin resistance in this model (176). Interestingly, these changes in expression of 
target genes were associated with altered methylation status in their promoter area. Namely, 
GR promoter was found to be hypomethylated in liver tissue of 5 weeks old offspring (177). 
Some preliminary evidence suggest that hypomethylation of GR occur during early 
embryogenesis even before cell line differentiation, this was because of finding that GR 
hypomethylation found in all examined tissue of the offspring in this model (174). GR 
promoter hypomethylation was associated with histone modification, due to decreased 
acetylation, in way facilitating transcription (178). Supplementation of maternal low protein 
diet with glycine or folic acid prevented the development of metabolic syndrome like 
phenotype as well as GR promoter hypomethylation. Similarly, perinatal stress exposure 
resulted in altered stress response in the offspring which found to be accompanied with GR 
promoter hypermethylation at specific CpG dinucleotides in the hippocampus of the 
offspring. These changes were reversed in adult brain with intra-cranial histone deacetylase 
inhibitor administration (179). Similarly, in human fetal exposure to maternal stress during 
second and third trimesters was associated with increased methylation in specific CpG 
sequence in axon 1F of the GR gene analyzed in cord blood mononuclear cells and at 3 
months of offspring age there was significant association between higher CpG methylation 
in GR gene and higher plasma cortisol response to stress (180). These epigenetic DNA 
modification seen in antenatal malnutrition or dexamethasone exposure are transmitted to 
the second generation (181), however, in human it needs to be further explored. It has been 
suggested that GCs exposure, either endogenous as in maternal psychological stress or in 
food deprivation or due to antenatal synthetic GCs administration, lead to altered DNA 
methylation via reduce folic acid availability (182). N5- methyltetrahydrofolate is folic acid 
derivative and it is considered one of the important methyl donors, therefore, any constrain 
on folic acid availability will affect methyl donors availability as well. 
All these valuable data gave strong evidence that intrauterine life environment has crucial 
role in human health during adulthood and that the unfavorable conditions will act on the 
basic unit in the body, that is DNA. Therefore, altered DNA function via epigenetic 
modification will constrain the functional capacity of key organs when needed to work with 
their full capacity at adult life and ultimately expressed as disease. The understanding of the 
mechanism of disease can open the door for discovering early markers for the risk of 
developing disease and importantly more targeted therapeutic strategies. 
3.1.3. Glucocorticoids over exposure 
Most of animal models of disease programming and human studies including 
epidemiological data indicated that glucocorticoids have crucial role in the development of 
cardio-metabolic and neouro-psychological disease at adulthood. This deleterious effect of 
glucocorticoids can be exerted directly up on maternal administration of synthetic 
glucocorticoids and by stress induced endogenous maternal glucocorticoids hypersecretion 
or indirectly through other types of stress such as food restriction. The development of low 
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birth weight, hypertension, glucose intolerance and insulin resistance in offspring of rat 
dams fed low protein diet during pregnancy were linked to decreased placental 11 β-HSD 2 
expression and activity which resulted in high influx of maternal glucocorticoids to fetal 
compartment in addition to increased sensitivity of key metabolic organs such as liver, 
kidney and adipose tissue to glucocorticoids secondary to increased GR expression in these 
organs (175, 183). The development of metabolic syndrome like phenotype in this animal 
model has been replicated in human offspring who were exposed to prenatal synthetic 
glucocorticoids due to threatened preterm delivery to induce lung maturity and also in 
human offspring who were exposed to high maternal glucocorticoids secondary to maternal 
stress during pregnancy. Therefore, fetal glucocorticoids over exposure is the main 
programming pathway despite the variation in the prenatal insult. This hypothesis has 
many supporting evidence from low protein diet model and other human studies. In rodent, 
treatment of pregnant dams with placental 11 β-HSD 2 inhibitor, carbenoxolone, resulted in 
low birth weight and hypertension at adulthood (141). Hypertension in low protein model 
also was glucocorticoid dependent as maternal adrenalectomy significantly reduced the 
blood pressure to control levels and corticosterone replacement restored the hypertensive 
state seen these exposed offspring (151). In human, the placental 11 β-HSD 2 activity 
correlated with birth weight (184) and reduced in pre-eclampsia (185) and in intrauterine 
growth restricted fetuses (186). Moreover, 11 β-HSD 2 gene mutation constantly resulted in 
lower fetal birth weight compared to normal human fetus (187). High maternal GCs 
associated with decreased placental 11 β-HSD 2, elevated fetal plasma GCs, lower hepatic 11 
β-HSD 2 protein expression and enzyme activity which cause over expression and activity 
of key hepatic gluconeogenesis enzyme, phosphoenolpyruvate kinase (PEPCK), which is 
linked to insulin resistance and glucose intolerance. In the kidney, the main role of 11 β-
HSD 2 is to prevent GCs occupying and activating mineralocorticoid receptor (MR) (188), 
see figure 6.  
GCs-exposed offspring has decreased 11 β-HSD 2 expression and increased GR expression 
as well as GR promoter hypomethylation in kidney (189). Cortisol will then exert 
mineralocorticoid activity through MR binding in kidney and resulted in sodium and water 
retention, hypokalaemia, low plasma renin and aldosterone concentrations, and eventually 
hypertension in adult life (190). In brain the observed cognitive deficit, altered memory and 
psychological disturbances in GCs exposed offspring was associated with decreased GR 
expression in hippocampus (191), which could block the negative feedback regulation of 
HPA axis by plasma cortisol and hence resulted in abnormal regulation of this crucial 
nuerohormonal axis. GCs induce the expression of key lipogenic transcription factor, Sterol 
regulatory element binding protein-1c (SREBP-1c) in liver (192). SREBP-1c transgenic mice, 
with mRNA and protein over expression of this nuclear factor, developed 
hyperinsulinaemia, hyperglycaemia, and hepatic steatosis (193, 194). 
Interestingly, the metabolic syndrome like phenotype seen in low-protein diet exposed 
offspring was associated with abnormal expression of SREBP-1c. SREBP-1c mRNA and 
protein expression were both suppressed from birth until age 9 months in the rat offspring. 
At 18 months, however, marked over expression seen specially in hepatic tissue with 
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development of non-alcoholic fatty liver, hypercholestreamia, hpertriglycerideamia, 
hyperglycemia and insulin resistance (147). 
 
Figure 6. Glucocorticoids central role in the programming of the adult disease. Prenatal exposure to 
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4. Conclusions 
The understanding of pathogenesis of adult cardio-metabolic and psycho-cognitive 
disorders is now advanced beyond the idea that such diseases are result of current 
behavioral and environmental factors. It is well established that adult health originated from 
wellbeing during fetal life or even at gametes stage. Grandparents’ environmental 
challenges can have impact on human health many generations later. In fact, factors which 
operate at early life will increase the individual`s susceptibility and vulnerability to adverse 
environmental events in later life. It is obvious now that different early life environmental 
events share common programming pathway. The mechanism of programming started to 
be revealed which include epigenetic DNA modification and promoter methylation status 
resulting in altered gene expression as well as glucocorticoids over exposure as a primary 
mechanism where as tissue remodeling and decreased organ and body size as a secondary 
mechanism. Glucocrticoids over exposure is the main triggering stimulus in this 
programming, therefore the widely clinical use of prenatal glucocorticoids such as 
betamethasone and dexamethasone to induce lung maturity in preterm fetus need to be 
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carefully evaluated since they access fetal compartment very easily. Introduction of multiple 
courses of glucocorticoids as a routine should be discouraged and instead it should be 
restricted to wisely selected cases. The maximum number of safest courses and lowest 
therapeutic dose of each subsequent course should be standardized. However, prenatal 
glucocorticoids have provided the suitable model to study the effects of direct maternal 
administration of this programming hormone in human candidates. Notwithstanding, these 
studies still in their neonatal stage and extensive research in this particular area is 
warranted. The identification of how early life unfavorable environment still able to express 
pathogenesis at adulthood is crucial to set up pre-disease markers which can be applied 
clinically in health screening even before the disease itself develops. This will lead to early 
behavioral and life style interventions which may postponed the onset of disease for many 
years or even freeze the pathogenesis at its pre-disease stage. Obviously this will lead to 
decrease financial burden on the health authorities and will markedly cuts the expenses of 
medical and surgical treatment of the resulted complications.  
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1. Introduction 
Systemic lupus erythematosus (SLE), which is an inflammatory disease of unknown cause, 
is a representative autoimmune disease. Although SLE has multisystem organ involvement 
with a predilection for females, the disease varies from mild to severe and/or from active to 
inactive. The severity and activity of the disease affect SLE prognosis [1]. 
Glucocorticosteroids (steroids) have anti-inflammatory and immunosuppressive effects, 
although the biological effects of steroids are multiple. The anti-inflammatory effect of 
steroids is powerful and acts rapidly, and the immunosuppressive effect after 
administration of large doses of steroids is also strong. Therefore, steroids play a major and 
essential role in the treatment and management of SLE patients, especially those having 
severe and active SLE. However, the effectiveness and usefulness of steroids are limited 
because of their severe side effects, unresponsiveness and resistance to steroids. In these 
situations, additional therapies such as immunosuppressive agents or plasmapheresis, etc. 
are usually used in conjunction with steroids. 
This paper will present clinical data related to steroid therapy from 1,125 patients with SLE 
who were examined and treated in Juntendo University Hospital between 1955 and 2002. It 
will show the benefits and risks of treatment with steroids and/or combined therapy with 
steroids and immunosuppressants. 
2. Clinical presentation of 1,125 patients with SLE 
2.1. Clinical findings  
One thousand one hundred and twenty-five SLE patients fulfilling four or more of the 
revised ACR (American College of Rheumatology) criteria [2] were examined and treated at 
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the Department of Internal Medicine and Rheumatology in Juntendo University School of 
Medicine between 1955 and 2002. In all patients, the diagnosis and treatment procedures 
were conducted during a period when the use of steroids and immunosuppressive agents 
was common. Computerized analysis of clinical manifestations, laboratory and 
immunological findings, treatments, complications, causes of death and prognosis was 
conducted. 
The distribution of age at diagnosis and the difference in gender, showing that mean age at 
diagnosis was 27.1 years old and the male to female ratio was 1:9. In children and adults 
over the age of 50, the incidence of SLE demonstrated only a slight female predominance, 
however, for those in their twenties, thirties and forties, close to 90% of patients were 
women. The frequencies of major clinical manifestations and laboratory findings from 
observations together with the data from other investigators [3-6] are shown in Table 1.  
Table 1. Cumulative percentage incidence of clinical and laboratory manifestations in SLE 
2.2. Treatment according to disease severity  
Clinical subsets of SLE were divided into three groups according to disease severity that 
related to prognosis [7]. They were severe, moderate and mild diseases. Severe disease 
included organ-threatening conditions: lupus nephritis; rapidly progressive 
glomerulonephritis (RPGN), diffuse proliferative glomerulonephritis (DPGN), nephrotic 
syndrome, neuropsychiatric lupus (NPLE); acute confusional state or organ brain syndrome, 
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while pulmonary manifestations included acute lupus pneumonitis, alveolar hemorrhage, 
etc. Moderate disease: lupus nephritis without renal failure, pleuritis, pericarditis, 
meningitis, hemolytic anemia, thrombocytopenic purpura, etc. Mild disease: 
arthralgia/arthritis, myopathy, skin rash, etc. 
 
PSL ≦39mg/day was used for patients with mild or moderate diseases. 
PSL 40-59mg/day was used for patients with moderate or severe diseases. 
PSL ≧60mg/day was used for patients with severe diseases. Pulse therapy was used for patients with severe diseases 
followed by large doses of steroids. 
Table 2. Treatments of 1125 SLE patients 
Treatments including steroids and immunosuppressive agents are shown in Table 2. 
Steroids were a mainstay of treatment for SLE. Although there are several kinds of steroids, 
prednisolone (PSL) is commonly used to treat SLE. The initial dose of steroids was usually 
determined according to the severity and activity of the disease. The above severe diseases 
required large doses of steroids usually of 1 mg/kg/day of PSL or more. Sometimes steroid 
pulse therapy (methylprednisolone 0.5-1g/day, intravenously administration, for 3days) was 
used followed by large doses of steroids. The above moderate to mild diseases usually 
required 0.5-1mg/kg/day and less than 0.5mg/kg/day of PSL, respectively. When a 
satisfactory response was achieved, the daily dose was reduced by 5 to 10% over 2 or 3 
weeks until reaching a maintenance dose of 0.2 to 0.3mg/kg/day. 
Steroids have sometimes little or no effect because of impaired bioavailability due to 
reduced steroid absorption, increased steroid metabolism, induction of activating protein 
1(AP-1) which is mutually antagonistic with steroid receptors for trans-activation effects [8], 
and insensitive steroid-mediated apoptosis of T cells [9], etc. Furthermore, steroids 
characteristically have a high risk of serious side effects such as infection, gastric ulcer, 
diabetes mellitus, osteoporosis, etc. Therefore, the effectiveness and usefulness of steroids 
were limited because of severe side effects, unresponsiveness and resistance to steroids. In 
Nonsteroidal anti-inflammatory drugs
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these situations, immunosuppressive agents such as cyclophosphamide, azathioprine, 
mizoribine, tacrolimus and/or plasmapheresis or other innovative therapies were usually 
used in conjunction with steroids. Recently, belimumab (anti-BLyS antibody), the first 
targeted biological drug, was approved for treatment of SLE by the FDA [10]. Targeted 
biological and small-molecule therapies in SLE are going to begin to take the place of 
steroids that have been used as the major drug in SLE for more than 50 years. 
2.3. Prognosis and causes of death 
In this paper, the survival rate was 93% at 5years, 89% at 10years and 69% at 20years after 
diagnosis. One hundred and fifty-one out of 1,125 patients (13%) died. The causes of death 
were renal failure (30%), cerebrovascular diseases (23%), infection (19%), and others. 
Infections which led to causes of death included sepsis or bacteremia due to E. coli, 
methicillin resistant Staphylococcus aureus (MRSA), candidiasis, asprgilosis, Klebsiella, 
Pseudomonas, etc., and tuberculosis, pneumocyctis carini pneumonia, Cryptococcus 
meningitis, listeria meningitis, cytomegalovirus infection, etc. In the last 2 or 3 decades it has 
been noted that the prognosis of SLE has improved [11-13]. Changes in the mortality rate in 
accordance with the cause of death in SLE patients were also observed, showing a 
significant reduction in death due to renal failure.  
3. Steroid therapy in principal organ involvement in SLE 
3.1. Lupus nephritis (LN) 
3.1.1. Clinical analysis of LN 
LN is one of the diseases influencing the prognosis of SLE. The diseases of LN vary from 
mild to severe and from active to inactive. The clinical pictures of LN and the types of the 
World Health Organization (WHO) classification according to histopathological findings 
[14] in this study are shown in Table 3.  
Persistent proteinuria of more than 0.2g/day and less than 3.5g/day was observed in 
approximately 37% of cases and profuse proteinuria of more than 3.5g per day was 
observed in approximately 17% of cases. Patients without proteinuria accounted for 16%. 
Abnormal urinary sediments including erythrocytes, leukocytes and casts were observed 
frequently. An increasing serum creatinine level was observed in 41% of cases. The WHO 
classification according to histopahological findings of LN by renal biopsy was used in this 
study, although the classification of LN by the International Nephrology/Renal Pathology 
Society (ISN/RPS) was proposed in 2003[15]. Diffuse proliferative glomerulonephritis 
(DPGN) of Type IV, which has a poor prognosis, could be seen in 55 of 216 cases (25%), 
which underwent renal biopsy. Membranous glomerulonephritis (MGN) of Type V 
characteristic of nephrotic syndrome, was observed in 18% of cases. Types I and II, which 
are thought to have better prognosis, were observed in 23% and 16% of cases, respectively. 
Advanced Type VI, which indicates end stage GN, could be seen in 12% of cases.  
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3.1.2. Treatment of LN 
The available therapeutic procedures include steroids, immunosuppressive agents, 
plasmapheresis, anticoagulants and hemodialysis, etc. Steroids were the first choice for 
treatment of LN. However, doses of steroids were determined according to urinary findings, 
renal function and renal histopathological findings evaluating the activity and severity of 
LN. The patients with active and /or severe LN, including persistent or profuse proteinuria, 
renal dysfunction, DPGN of type IV, rapidly progressive glomerulonephritis (RPGN) or 
MGN of Type V in conjunction with low serum complement levels and high titers of anti-
dsDNA antibodies, were initially treated with large doses of steroids (PSL 1-1.5mg/kg/day) 
as induction therapy for remission. Steroid pulse therapy was often administered at first. It 
led to more rapid recovery which might be result of a rapid nongenomic physicochemical 
effect. The patients with intermittent proteinuria, abnormal urine sediments, and Type II or 
III, were initially treated with PSL less than 0.5-1mg/kg/day. After PSL administration for 3-
6 weeks, the dosage of PSL was then reduced by nearly 10% every 2–3 weeks according to 
the improvement in proteinuria, urinary sediments, abnormal renal function, low serum 
complement levels and high titers of anti-dsDNA antibodies. If PSL had no or incomplete 
response, the dosage was increased by 20% or steroid pulse therapy was conducted again. In 
the patients with DPGN or RPGN, intravenous pulse therapy of cyclophosphamide (IVCY) 
(500-750mg, monthly for 3 to 6 months), as immunosuppressive agent, was used. 
Alternative induction therapies included combined therapies with steroids and 
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mizoribine, and cyclosporine, etc. If an incomplete response after 2 months treatment with 






























B. Histopathological findings (WHO classification) 
I. Minimal change (MC) or Normal                       
II. Mesagial alteration
III. Focal segmental glomerulonephritis (FGN)
IV. Diffuse proliferative glomerulonephritis (DPGN)
V. Membranous glomerulonephritis (MGN)
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PSL alone was also observed, immunosuppressant agents were administered in addition to 
PSL. If the patients had high titers of anti-dsDNA antibodies and/or immune complexes, 
plasmapheresis was conducted in conjunction with the above steroid and 
immunosuppressant agent treatment. In patients who achieved remission showing less than 
0.5g/day of proteinuria, inactive urine sediment, normal complement levels and /or 
quiescent extrarenal lupus activity, they continued maintenance treatment with a 
maintenance dosage of steroids of PSL 5–15mg/day. Thereafter, the PSL dosage was tapered 
to discontinuance in an extremely gradual manner.  
3.1.3. Outcome and prognosis of LN 
During the past half century, the prognosis of SLE has significantly improved. One of the 
major factors in this improvement is the significant reduction in renal death. This is 
assumed to be partially due to early diagnosis and early treatment with the development of 
diagnostic procedures, as well as the development of treatments including the 
implementation of hemodialysis [1,11-13]. However, the remission rate of lupus nephritis 
was not so high.  
 
Figure 1. Remission rate of lupus nephritis according the WHO classification type and degree of 
proteinuria 
Figure 1 shows the remission rate after onset according to the WHO classification type and 
degree of proteinuria. The remission rates of patients with Type IV (DPGN) and profuse 
peroteiniria or nephrotic syndrome tended to decrease during the course of the disease, 
while the remission rates of patients with Type II and persistent proteinuria tended to 
increase. Patients with Type V (MGN) had a low remission rate through out the course of 
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the disease, but no decrease in the remission rate was observed until later on. Furthermore, 
in the outcome of 32 patients who were treated over the long-term for over 20 years, the 
complete remission rate was 27%, the incomplete remission rate was 37.8%, and the 
worsening rate was 21.6 %. As for the treatments used, those that contributed to remission 
could not be specified. This fact suggests that the underlying disease types had a greater 
influence on the remission rate than the treatment method.  
3.2. Neuropsychiatric manifestations of SLE (NPLE) 
3.2.1. Clinical analysis of NPLE 
The frequencies of various neuropsychiatric manifestations of SLE (NPLE) have been 
reported to vary from 28 to 59%. In our study, NPLE could be observed in 47.6% of 1,125 
cases as shown in Table 4.  
 
Table 4. Frequencies of neuropsychiatric manifestations (NPLE) in 1125 lupus patients 
The American College of Rheumatology (ACR) proposed new criteria for the classification 
of neuropsychiatric syndrome of systemic lupus erythematosus (NPSLE) in 1999 [16]. NPLE 
is divided into psychiatric and neurological manifestations. The frequency of psychiatric 
manifestations was higher than that of neurological manifestations. The former included 
acute confusional state or organ brain syndrome, cognitive dysfunction, anxiety disorders 
and psychosis, etc., while the latter included seizure, cerebrovascular disease, myelopathy, 
aseptic meningitis, headache, and peripheral neuropathy, etc. 
Although no single pathogenetic process could explain all these manifestations, it was 
assumed that other potential causes of these manifestations, such as side effects from 
treatment, complications including infections, etc., had been excluded except for causes due 
to lupus itself. Many NPLE cases were considered to be caused by lupus itself, excluding 
obvious causes such as antiphospholipid antibody syndrome (APS), necrotizing angiitis, 
and complications. 
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NPLE is one of the diseases that influence the prognosis of SLE as well as LN. Especially, 
patients with acute confusional state or organ brain syndrome (OBS), cognitive dysfunction, 
recurrent seizure, and cerebrovascular disease, etc., had poor prognosis. Acute OBS exhibits 
characteristic malfunctions such as consciousness disorders (i.e. delirium), disorientation, 
memory disorders, and cognitive dysfunction. Acute OBS showed an 85% correlation with 
SLE activity and exacerbation, which was greater than that of the psychiatric illness group 
(57%) and the psychosyndrome group (23%) [17]. 
Although acute OBS was correlated with active SLE lesions, correlations with high titers of 
anti-dsDNA antibodies and low complement levels, which were seen in active LN, were not 
necessarily observed. Serologically, acute OBS correlated with the serum anti-liposomal P 
antibody, interferon α and IL-6 in cerebrospinal fluid (CSF) [18-19]. 
On the other hand, acute neurologic syndrome has been reported to correlate with the anti-
asialo GM1 antibody, anti-liposomal P antibody, anti-lymphocyte antibody, and anti-
neurocyte antibody, as well as the anti-PCNA antibody and anti-Sm antibody [7,20]. 
Psychiatric symptoms often required differentiation from steroidal psychiatric symptoms. 
Differentiation from secondary psychiatric symptoms due to uremia and/or infection was 
also important. Although quite a number of cases were difficult to determine, the following 
information might have been helpful:  
a. The actual incidence of steroid-induced psychosis is small, probably about 5%, which is 
less than that of lupus-induced psychosis [21]. 
b. The psychiatric side effects of steroids include, most commonly, mild to moderate 
mood changes such euphoria, sleeplessness, or depression rather than unconsciousness 
disorders, although there are also perceptual changes, hallucinations, anxiety, insomnia 
and confusion.  
c. Steroid-induced psychosis appears half a month to one month after administration of 
steroids. It has been reported that the incidence of steroid-induced psychosis increases 
when over 40mg/day of PSL is administered [22].  
d. Although lupus psychosis may not always be improved by increasing of the dosage 
of PSL, deterioration of lupus psychosis after increasing the dosage of PSL is rare. 
e. High levels of IgG index and IL-6 in CSF can be seen in lupus psychosis [23]. 
The evaluation of NPLE should always include an assessment of whether SLE is active or not. 
In addition, patients with both focal and diffuse syndromes should have various examinations 
including CSF, electroencephalogram (EEG), and an imaging studies (such as computed 
tomography (CT) and magnetic resonance imaging (MRI)), cerebral blood flow by angiography 
or single photon emission computerized tomography (SPECT), etc. The more serious the NPLE, 
the more aggressive immunosuppressive therapy, including steroids, is needed. 
3.2.2. Treatment of NPLE 
If NPLE was active and there was severe major organ involvement, steroid therapy was 
indicated. In particular, patients with an acute confusional state or organic brain syndrome, 
 
Glucocorticoid Therapy in Systemic Lupus Erythematosus – Clinical Analysis of 1,125 Patients with SLE 489 
and recurrent convulsive seizures were treated with high steroid doses (PSL l–2 mg/kg/day) in 
conjunction with steroid pulse therapy. However, when improvement could not be seen 
within 48 hours after treatment, 250 to 500mg of hydrocortone was administered every 12 
hours. If improvement could not be seen after treatment of steroids alone, IVCP pulse therapy 
or oral administration of CP in conjunction with steroids and/or plasmapheresis was given. 
When signs of clinical manifestations were stable for more than 6 weeks and acute phase 
reactants or tests of organ function were improved or stable for 6 weeks, the dose of PSL 
was reduced by approximately 10 to 20% every two weeks. When the dose of PSL reached 
about 15mg/day, it was slowly tapered and reduced by 1mg every week.  
When the patients showed panic or marked agitation and their hallucinations and delusions 
were threatening, several antipsychotic drugs in conjunction with steroids were also used.  
3.2.3. Outcome and prognosis of NPLE 
Almost all patients with NPLE improved after immunosuppressive therapies including 
steroids, immunosuppressive drugs and /or plasmapheresis.  
 
 
Figure 2. The clinical course of SLE patient (46 years old, female) with organic brain syndrome (OBS) 
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Figure 2 shows the clinical course of an SLE patient with OBS who was a 46-year old female. 
She was diagnosed as SLE with malar rash, eruption, leucopenia, thrombocytopenia, 
proteinuria and positive anti-nuclear antibodies, etc. in March 1997. In April 1997, she had 
recurrent unconsciousness with delirium, disturbance of articulation with high fever and a 
worsening malar rash. Although anti-DNA antibodies and low complemetemia could not be 
seen, she was diagnosed as OBS or acute confusional state and treatment with steroid pulse 
therapy followed by a PSL dose of 80mg/day. Plasmapheresis was also conducted to remove 
anti-lymphocyte antibodies. Although mood disorder and depression were observed in 
August, 1997, her disease improved without increasing doses of steroids or additional 
treatment with immunosuppressive agents. 
As for prognosis of lupus patients with NPLE according to the different treatment, patients 
treated with combined therapy of steroid pulse therapy and other therapies was 
significantly more favorable than those treated with steroids alone (PSL>40mg/day) and 
those treated with combined therapy of immunosuppressive agents and steroids. 
3.3. Pulmonary manifestations 
3.3.1. Pleuritis 
Pleuritis is by far the most common pulmonary manifestation, occurring at some time in the 
course in 40 to 50% of lupus patients. However, the frequency of pleuritis in Japanese SLE 
patiens was lower than that in European countries and the United States. The frequency of 
pleuritis was 11% in this study. . Clinically, fever, chest pain, cough, dyspnea etc. could be 
seen in patients with pleuritis. On chest X-rays, slight to moderate pleural effusion caused 
by pleural inflammation could be observed bilaterally in approximately half of cases.  
Pleuritis mostly improved after administration of PSL (20-40mg/day). However, in cases 
with a large amount of pleural effusion , thoracic drainage was needed.  
3.3.2. Interstitial pneumonitis 
Lupus pneumonitis is classified as acute lupus pneumonitis and chronic interstitial 
pneumonitis/pulmonary fibrosis. Acute lupus pneumonitis was relatively rare with an 
occurrence of 0.5–11.7% [24-25]. It was observed in 6 of 1,125 patients (0.5%) in this study. 
As clinical symptoms, fever, chest pain, dry cough, severe dyspnea, and occasional 
hemoptysis were noted. Bibasilar Velcro rales were noted in all instances. The majority of 
patients were hypoxic, requiring supplemental oxygen or intubation for assisted ventilation. 
Acute lupus pneumonitis was diagnosed by several examinations including X-ray, CT scan, 
KL-6 and/or SP-D as biomarkers, and various kinds of infectious examination to exclude 
infectious diseases.  
All 6 patients with acute lupus pneumonitis were treated with steroid pulse therapy 
following 1-2mg/kg/day of PSL. Half of the patients drastically improved, but the remaining 
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3 patients died of pulmonary hemorrhage despite combined therapy with steroid and 
immunosuppressant agents and /or plasmapheresis. 
Chronic interstitial pneumonitis in SLE is also rare, showing a low frequency of 3-5%. Six 
patients with chronic interstitial pneumonitis were observed in this study and they were 
treated with maintenance therapies including low doses of steroids and/or 
immunosuppressant agents. In one patient, chronic interstitial pneumonitis deteriorated to 
acute interstitial pneumonitis during the course of the disease and a large dose of steroids 
was needed 
3.3.3. Alveolar hemorrhage 
Alveolar hemorrhage in SLE is relatively rare, and it has been reported to occur in 1.4–1.7% 
of SLE patients in Europe and the United States [26].  
It is a serious complication and results in poor prognosis. It was observed in 8 out of 1,125 
patients (0.7%) in this study.  
SLE patients with alveolar hemorrhage had hemoptysis and hypoxemia and rapid 
progression of anemia in conjunction with active LN and/or NSLE disease.  
All patients with alveolar hemorrhage were treated with steroid pulse therapy following large 
doses of PSL, but it was also necessary to concomitantly use other immunosuppressive 
tharapies such as cyclophosphamide including IVCY, and plasmapheresis. Unfortunately, all 
of the patients with alveolar hemorrhage died, comfirming that the prognosis was very poor. 
3.4. Cardiac manifestations 
3.4.1. Pericarditis 
The most common cardiac abnormality was pericarditis, which occured in 8-25% [27], but it 
was relatively rare in Japan, with a frequency of 7% (47 out of 1,125cases) in this study. 
Pericarditis is often one of the first manifestations. Most of the cases with pericarditis 
improved with administration of PSL 0.5–1 mg/day, but cases with cardiac tamponade, 
which was rare in this study, needed large doses of PSL over 1mg/day and/or steroid pulse 
therapy. 
3.4.2. Myocarditis 
Myocarditis was rarely observed in 2% in this study. In cases with myocarditis, positive 
CRP, elevated CK, IgG class anti-dsDNA antibodies, hematuria, etc., in conjunction with 
tachycardia, cardiac enlargement, congestive heart failure could often be observed. A 
myocardial biopsy was performed in order to confirm the diagnosis in one patient. The 
patients with myocarditis associated with congestive heart failure were treated with large-
dose administration of steroids (PSL l–1.5 mg/kg/day, divided into 3~4 dosages). All of the 
patients with myocarditis improved after steroid therapy. 
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3.4.3. Myocardial infarction and coronary artery disease 
Coronary artery disease due to arteriosclerotic changes is more common in SLE patients. 
Death from myocardial infarction late in the course of the disease is one of the most frequent 
causes of death after 10 to 30 years of SLE [28]. Eleven lupus patients with myocardial 
infarction could be seen in this study. The average age at diagnosis of SLE was 37 years old 
(26–63 years old), and the average age at development of myocardial infarction was 51 years 
old (41–66 years old) in these patients. There were two death cases, including one case of 
death from cardiac rupture. 
Several risk factors that cause myocardial infarction due to atherosclerosis in SLE are 
considered. They are renal involvement, hypertension, hyperlipidemia, long-term 
administration of steroids, diabetes mellitus, anti-phospholipid syndrome, smoking, etc. In 
this study, 4 patients had hypertension, hyperlipemia and diabetes mellitus as risk factors. 
Furthermore, positive antiphospholipid antibodies were observed in 5 cases. Death from 
myocardial infarction due to inflammation of the coronary arteries has been reported in SLE 
patients dying early in the course of their disease, but this is a rare event [28].  
Regarding the treatment in this study, conservative medical management without large 
doses of steroids was used in most cases. PTCA and AC bypass procedures were also 
occasionally conducted. 
3.5. Intestinal vasculitis 
Acute abdomen caused by intestinal vasculitis is often observed. Occasionally, surgery is 
needed. According to a report by Zizic, et al. [29], acute abdomen was observed in 15 of 140 
cases, and caused death in 53% of cases. Vasculitis was observed in 9 of 11 cases with 
abdominal surgery, and intestinal perforation was observed in 6 cases. In this study, 4 
patients had intestinal vasculitis and 3 died of intestinal perforation. Intestinal bleeding and 
peritoneal bleeding due to vasculitis were often observed. In cases with mesenteric arteritis, 
acute abdomen with severe abdominal pain in conjunction with nausea/vomiting, diarrhea, 
ascites, gastrointestinal bleeding, and fever, etc., were observed. Those symptoms may be 
masked by steroids or immunosuppressive drugs used for treatment, thus resulting in a 
delayed diagnosis. 
Patients with intestinal vasculitis and/or mesenteric arteritis were treated with large dose 
steroids including steroid pulse therapy.  
When a rapid improvement was not obtained, intermittent IVCY therapy was 
simultaneously used. In cases associated with bowel infarction or perforation, treatment for 
infection was also needed.  
3.6. Hematologic manifestations 
Hematologic manifestations in SLE include normochromic-normocytic anemia caused by 
chronic inflammation, autoimmune hemolytic anemia (AIHA), iron-deficiency anemia, 
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leukocytopenia, lymphocytopenia, thrombocytopenia, thrombocytopenic purpura (TP), 
thrombotic thrombocytopenic purpura (TTP), and antiphosphlipid syndrome (APS), etc. 
The diseases, which needed high doses of steroids were AIHA, TP, and TTP. 
3.6.1. AIHA 
AIHA was observed in 11% of patients in this study. AIHA is rare in Japanese SLE patients 
in comparison to those in Europe and the United States. Steroids were the mainstay of the 
treatment for AIHA and a response was achieved in about 75% of patients. PSL was given 
initially at a dose of 1.0 to1.5mg/kg and continued at that level for at least 4 to 6 weeks. 
Following a satisfactory response, the dose was reduced gradually by 10% every week. The 
reticlocyte count was a reliable indicator of both responsiveness to treatment and relapse. In 
cases of severe fulminant hemolysis, steroid pulse therapy was conducted. Patients with 
AIHA who failed to respond to steroids were treated with immunosuppressant agents 
and/or splenectomy. Plasmapheresis, high-dose intravenous gammagloburin therapy (IVIg), 
and danazole were also used for some refractory cases. 
3.6.2. TP 
Thrombocytopenia lower than 150,000 was observed in 34% of cases in this study. However, 
thrombocytopenia lower than 50,000 was relatively rare, and it occured in approximately 
10% of cases. Thrombocytopenia in SLE is usually due to antiplatelet autoantibodies 
(platelet associate-IgG; PA-IgG, platelet binding-IgG; PB-IgG). In some cases, 
thrombocytopenia was associated with antiphospholipid antibodies. In rare case, so-called 
Evans syndrome, in which AIHA and TP coexist, was observed. Some cases did not tend to 
bleed until platelet counts were less than 20,000/ul. Patients with thrombocytopenia less 
than 20,000 were treated with large doses of steroids. The initial dose of PSL was usually 1-
2mg /kg/day. After an increase in platelet count occurred in response to steroids, the dose 
was gradually reduced after 4 weeks. If thrombocytopenia did not respond to steroids with 
bleeding from the major organs such as gastrointestinal tract, kidney, bladder, other 
mucosal surface, steroid pulse therapy was used. IVIg was useful to achieve a temporary 
improvement in thrombocytopenia in surgical operations such as splenectomy, which was 
often conducted in steroid resistant cases. .In steroid resistant cases, immunosuppressive 
drugs such as azathioprine, cyclophosphamide, and cyclosporine, danazol, and vincristine, 
etc., were also used.  
3.6.3. TTP 
TTP usually consists of a pentad of TP, microangiopathic hemolytic anemia, fever, renal 
failure, and neurologic manifestations. TTP has been reported in association with various 
other diseases, including SLE, most of which are characterized by some degree of vasculitis 
of the small vessels and circulating immune complexes [30]. The main cause of acquired TTP 
including SLE is assumed to be an autoantibody that is an inhibitor (IgG inhibitor) of von 
Willebrand factor cleaving protease [31]. It has been clarified that congenital TTP is caused 
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by a mutation in the ADAMTS-13 gene of cleaving protease. TTP must be differentiated 
from DIC or catastrophic antiphospholipid syndrome, but coexistence of both are often 
observed.  
Regarding treatment, plasmapheresis using fresh frozen plasma, and transfusion therapy of 
normal plasma are used. In addition, large-doses of steroids including steroid pulse therapy, 
immunosuppressive drugs, IVIg therapy, and anti-platelet drugs, etc. are simultaneously 
used. 
3.7. Pregnancy and birth 
When an SLE patient wished to conceive and give birth, a medical determination as to 
whether pregnancy would be possible was considered. Basically, there were presumed to be 
almost no problems in pregnancy when the patient was in remission with a maintenance 
dosage of steroids, and when serious organ failure was not observed. Moreover, even if the 
patient had active disease, pregnancy was allowed after the disease improved with 
treatment.  
3.7.1. Treatment and management during pregnancy  
It was important for the physician and the gynecologist to be in close communication for the 
treatment and management during pregnancy. Usually, it was unnecessary to change the 
maintenance dose of the steroid during pregnancy. When mild deterioration was observed 
in the early stage of pregnancy, an increased steroid dosage was attempted according to the 
clinical manifestations. If the clinical manifestations required administration of a large-dose 
of steroids, considering the risks to the mother and the effect of the steroids on the fetus, an 
artificial abortion was performed at an early stage. Although the level of serum cortisol in 
the fetus decreases during the steroid administration, cortisol secretion and response to 
ACTH are believed to remain normal [32]. If a mother is treated with prednisolone or 
hydrocortisone, these steroids are assumed to have a minimal effect on the fetus because 
they are inactivated by 11-β-dehydrogenase in the placenta. However, the use of 
dexamethasone and betamethasone is avoided because these steroids are difficult for the 
enzyme to inactivate and were assumed to have an adverse effect on the fetus. 
3.7.2. Treatment and management during and after deliverly 
3.7.2.1. Prevention of exacerbation 
The mother was hospitalized prior to the expected delivery date for management of the 
mother and fetus. If pregnancy remained steady, and SLE activity was not observed, the 
dose of steroids was increased immediately after delivery to prevent any exacerbation of 
SLE. The dose of steroids was usually increased to two or three times the pre-delivery dose. 
The dose was reduced by 10% every 4 to 7 days while confirming no exacerbation, and 
continually observed until eventually reducing it to the dosage at the time of delivery. If an 
exacerbation of SLE such as active LN or serositis was observed in the late stage of 
 
Glucocorticoid Therapy in Systemic Lupus Erythematosus – Clinical Analysis of 1,125 Patients with SLE 495 
pregnancy, the delivery of the fetus was attempted as early as possible in order to start 
treatment of the mother’s clinical manifestations. 
3.7.2.2. Breast-feeding  
Because the amount of steroids was increased upon delivery, breast-feeding was prohibited 
until the dose was reduced to less than 20 mg of PSL, considering the rate of transfer of 
steroids (0.1–0.3%/day) to the mother’s milk [33]. 
3.8. Adverse effects and complications due to steroid treatment 
Side effects of prolonged treatment with oral steroids are well known. Changes in the 
physical appearance could usually be seen. They were acne, hirsutism, moon face, buffalo 
hump, obesity, and abdominal striae, etc. Although reversible with a discontinuation or 
reduction in dose, hypertension, peptic ulcer, diabetes mellitus, pancreatitis, osteoporosis, 
psychosis, etc. were also induced. Thinning of the skin, cataracts, glaucoma, osteoporosis, 
and osteonecrosis could be observed as irreversible side effects.  
Infections were major complications in SLE and one of the major causes of death. 
Susceptibility to infection, particularly bacterial infection, was increased with steroid use. 
Staples et al. found that the infection rate in hospitalized patients increased from 0.43 to 1.63 
per 100 hospital days with an increase in steroid dose from zero to more than 50mg/day [34]. 
Although infection rarely occurs with a small dose of PSL (2–10 mg/day), the SLE patients 
treated with PSL of more than 20mg/day have a higher risk of infection due to the higher 
dose of PSL, especially after 14 days of administration. PSL was also noted to be a major risk 
factor for the development of opportunistic infection, with the most common organisms 
including Salmonella, Candida, Strongyloides, and Aspergillus.sp according to a case 
controlled study of 797 SLE patients [35]. 
It has been noted that systemic administration of steroids could be linked to the higher 
occurrence of vascular diseases such as coronary artery disease, stroke, peripheral vascular 
disease than the expected occurrence in SLE. However, it is unclear whether this reflects 
pro-atherogenic effects of the underlying disease process or adverse metabolic effects 
associated with steroid use [36]. Recently, the number of patients with complications such as 
myocardial infarction/angina pectoris, cerebral infarction, diabetes mellitus, hypertension, 
and aseptic bone necrosis, has tended to increase over a long-term observation period due to 
a favorable SLE prognosis.  
Table 5 shows the frequencies of these complications at the time of occurence in 97 SLE 
patients who had been observed for over 20 years. The number of patients with myocardial 
infarction/angina pectoris, diabetes, cerebral infarction increased from the ninth year of the 
observation period. Hypertension and aseptic osteonecrosis were seen from the onset of 
SLE. Most of the above complications were thought to be due to treatment including 
steroids, as well as aging. It was also noted that GC-associated damage accumulated over 
time to constitute most of the damage at 15 years, although disease –activity related damage 
occurred early [37]. 
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pregnancy, the delivery of the fetus was attempted as early as possible in order to start 
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It has been noted that systemic administration of steroids could be linked to the higher 
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disease than the expected occurrence in SLE. However, it is unclear whether this reflects 
pro-atherogenic effects of the underlying disease process or adverse metabolic effects 
associated with steroid use [36]. Recently, the number of patients with complications such as 
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and aseptic bone necrosis, has tended to increase over a long-term observation period due to 
a favorable SLE prognosis.  
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patients who had been observed for over 20 years. The number of patients with myocardial 
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Table 5. Frequencies of complications related to vascular diseases according to the year (s) of the 
occurrence in 97 SLE patients who had been observed for over 20 years 
Steroid use contributes significantly to risk of osteoporosis in women with SLE. Ramsey-
Goldman et al. surveyed the frequency of fractures and associated risk factores in702 
women with SLE who had been followed for 5951 person-years and found that fractures 
occurred in 12.3% of patients, an almost fivefold increase compared with a background 
population [38]. Older age at diagnosis and longer duration of steroid use were 
important valuables. Sinigaglia, et al. reported that osteoporosis in 22.6% of 84 
premenopousal patients with SLE according to bone mineral density (BMD) was 
observed, and both disease duration and glucocorticoids were associated risks [39]. 
Steroid–induced osteoporosis leading to fracture, particularly vertebral collapse, was a 
major problem.  
Aseptic osteonecrosis (AON) was observed in approximately 10% of SLE, with the 
femoral head being a common site. It also appeared in the femoral condyle, caput 
humeri, proximal end and distal end of the tibia, etc.. It has been suggested that 
increased doses of steroids (especially in the first year of treatment) and the duration of 
steroid therapy are correlated with a grater risk of AON in SLE patients [40]. In a 
prospective survey of SLE patients with administration of high-dose steroids (more than 
30 mg/day of PSL for more than one month), AON occurred in 15% (9/62 patients) and 
the average period from the administration of a large dose of steroids to onset of AON 
was 640 days [41].  
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4. Conclusion 
In this paper, steroid therapy for SLE based on the clinical analysis of 1,125 cases, especially 
for principal organ involvement that required large doses of steroids, was evaluated. 
Although there is no doubt that steroids contribute to a significant improvement in the 
prognosis in SLE, the effectiveness and usefulness of steroids are limited because of severe 
side effects, unresponsiveness and resistance to steroids. 
Now, new biological agents that target B cells, T-B cell interaction, co-stimulatory pathways, 
intracellular molecules, etc. are being developed and are going to begin to revolutionize 
nonspecific therapy to a more specific pathophysiological tharapy in SLE.  
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1. Introduction 
1.1. Pathophysiology of asthma and acute asthma exacerbations: Brief overview 
Asthma is a chronic respiratory disease that is prevalent worldwide. It is considered as a 
major cause of morbidity and a main contributor to the high health care expenditure 
especially in developed countries (Subbarao et al, 2009). There are two major pathological 
features in asthmatics’ airways, inflammation and hyperresponsiveness. These features are 
interrelated but not totally dependent on each other. Airway inflammatory changes include 
increased airway mucus secretions, airway wall edema, inflammatory cellular infiltrates, 
epithelial cell damage, smooth muscle hypertrophy, and submucosal fibrosis (Bergeron et al, 
2009).  The cellular infiltrates are mainly composed of eosinophils, neutrophils, mast cells, 
lymphocytes, basophils and macrophages. The ratio of these cells may widely vary between 
patients pointing to asthma heterogeneity (Holgate, 2008). Overall, asthma can be divided 
into eosinophilic, neutrophilic, and pauci-granulocytic phenotypes. The eosinophilic 
phenotype is characterized by predominant eosinophilic infiltration of the airways. Patients 
tend to be allergic, have asthma triggered by exposure to allergens and tend to respond well 
to glucocorticoids. The neutrophilic phenotype is characterized by predominant neutrophil 
infiltration of the airways. Patients tend to have severe, more aggressive, poorly controlled 
asthma, or acute asthma triggered by viral infection. They usually do not respond to 
glucocorticoids as good as the eosinophilic type. In the pauci-granulocytic phenotype 
neutrophils and eosinophils are almost absent (Holgate, 2008). 
Triggers of acute asthma exacerbation include allergens like pollens, animal dander, dust 
mites and mold; viral respiratory tract infections; irritants like smoke and dust; cold air and 
exercise. When pollens, for instance, are inhaled by an allergic individual, the allergenic 
protein is taken up by antigen presenting cells (dendritic cells) in the airway. It is then 
presented to naïve T-helper (Th) cells that develop into Th2 cell phenotype. These cells 
respond by secreting Th2 cytokines like IL-4 and IL-13 that cause allergen specific B-cells to 
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switch from IgM producing to IgE producing cells. These cytokines could also contribute to 
epithelial cell damage, increased mucus secretion and airway hyperresponsiveness. Th2 
cells also secrete IL-5 that stimulates eosinophil development, release from the bone marrow 
and their recruitment to the site of inflammation. IgE antibodies bind to their receptors on 
the surface of mast cells. Cross linking of adjacent IgE molecules leads to degranulation and 
release of mediators like histamine and tryptase that are key to features of immediate 
hypersensitivity reaction. Activation of mast cells and eosinophils will also stimulate the 
synthesis and release of lipid derived mediators like prostaglandins and cysteinyl 
leukotrienes that are very potent bronchoconstrictors. Moreover, activation of eosinophils 
leads to the release of mediators like eosinophil cataionic protein and major basic protein, 
which can cause airway epithelial cell damage and submucosal fibrosis. New evidence 
suggests that Th1 cells contribute to chronic changes in the airways including epithelial cells 
damage and smooth muscle cells activation. Regulatory T cells (Treg) inhibit Th2 cells by 
secreting IL-10 and tansforming growth factor  (TGF). Also, antigen specific Th17 cells 
were found to play an important role in neutrophilic airway inflammation and the process 
of airway remodeling (fixed changes to the airway) through the secretion of IL-17A and IL-
17F (figure 1). This is a very quick overview, but many other changes take place during this 
process that are beyond the scope of this chapter. 
 
Figure 1. Major immunopahtologic processes that take place in the bronchial airways of patients with 
asthma. Please see the text for detailed description.  FcRI, high-affinity receptor for IgE; IFN, 
interferon-; TCR, T-cell receptor; TNF, tumour-necrosis factor. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Immunology. Stephen T. Holgate and Riccardo Polosa. 
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The most common cause of acute asthma exacerbation in both adults and children, but more 
in children, is viral respiratory tract infections. Viruses may be responsible for up to 80% of 
wheezing episodes in children and 50-75% of episodes in adults (Jackson et al, 2011b). Many 
viruses can cause exacerbation of asthma symptoms, the most important and most common 
is rhinovirus (Khetsuriani et al, 2007). Respiratory syncycial virus and influenza virus also 
cause significant proportion of exacerbations. The pathology of virally induced asthma 
exacerbation is more related to the airway epithelial cells which, in response to infection 
secret chemokines like IL-8 and CCL-5 that can attract inflammatory cells including 
neutrophils and lymphocytes and augment allergic inflammation (Gern & Busse, 2002). This 
finding is supported by epidemiological observations that allergen sensitization and 
respiratory viral infections can synergize to cause asthma exacerbation (Green et al, 2002). 
Children who are atopic are more likely to have virally induced wheezing and respiratory 
distress than non-atopic children (Jackson et al, 2011a). 
1.2. Treatment of acute asthma exacerbation: general overview 
Acute asthma exacerbations are defined as “episodes of progressive increase in shortness of 
breath, cough, wheezing, or chest tightness, or some combination of these symptoms” 
(EPR3, 2007; GINA, 2011). Most recently an expert group formed by the NIH agreed to 
define acute asthma as “a worsening of asthma requiring the use of systemic corticosteroids 
to prevent a serious outcome” (Fuhlbrigge et al, 2012). Acute exacerbation of asthma 
symptoms is a common complication of the disease. The frequency in which exacerbations 
happen vary widely depending on the severity of disease (Moore et al, 2007), the degree of 
control with prophylactic medications (Peters et al, 2007), and exposure to triggers. In a 
multicenter study from the US (Pollack et al, 2002) the admission rate of all comers to the ER 
with acute asthma was 23%. On the other hand, a European study showed that only about 
7% of all patients with acute asthma exacerbation required hospitalization (Rabe et al, 2000). 
We have a similar experience in Saudi Arabia where about 8% of all asthmatics with acute 
exacerbation are hospitalized, but if we look at only the severe group the rate goes up to 
40% (unpublished data). These epidemiological data underscores the importance of effective 
treatment of asthma exacerbations and their prevention. 
Patients with acute asthma exacerbation usually present with increasing cough, and 
dyspnea. On examination patients may have increased respiratory rate, retractions 
(accessory respiratory muscle use), wheezing, oxygen desaturation on pulse oxymetry and, 
in more severe cases, inability to speak, silent chest, with reduced respiratory lung volumes, 
cyanosis and change in mental status. Asthma exacerbations can be classified as mild, 
moderate, or severe based on the level of severity of the signs and symptoms as illustrated 
in Table 1. (Adams et al, 2011) 
Different asthma scoring systems have been developed to assess the severity of asthma 
exacerbations more objectively, which is more useful for research purposes. An example is 
shown in table 2. (Qureshi et al, 1998). This scoring system is becoming more widely used 
because of its high reliability and objectivity. 
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secret chemokines like IL-8 and CCL-5 that can attract inflammatory cells including 
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in more severe cases, inability to speak, silent chest, with reduced respiratory lung volumes, 
cyanosis and change in mental status. Asthma exacerbations can be classified as mild, 
moderate, or severe based on the level of severity of the signs and symptoms as illustrated 
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because of its high reliability and objectivity. 
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Severity Mild Moderate Severe 
PEFR*  70% 40-69% <40% 
Speech Sentences Phrases Words 
Mental Status Anxious Agitated Distressed 
Accessory muscle use No Sometimes Commonly 
Oxygen saturation  95% 90-95% <90% 
Table 1. General classification of asthma severity. * PEFR: Peak Expiratory Flow Rate 
Other frequently used scoring systems in the literature include; the Pulmonary Index Score 
(Scarfone et al, 1993) (table 3), and to a lesser degree the Preschool Respiratory Assessment 
Measure (PRAM)  (Ducharme et al, 2008)(table 4), and the Pediatrics Asthma Severity Score 




1 point 2 points 3 points 
Respiratory rate 
(breaths/min) 
   
2-3 years  34 35 - 39  40 
4-5 years  30 31 - 35  36 
6-12 years  26 27 - 30  31 
>12 years  23 24 - 27  28 
Oxygen 
saturation (%) 
> 95 with room air 90 - 95 with room air <90 with room air or 
supplemental oxygen 
Auscultation 
Normal breathing or 
end-expiratory 
wheezing 
Expiratory wheezing Inspiratory and expiratory 
wheezing, diminished 
breath sounds, or both 
Retractions 
None or intercostal Intercostal and 
substernal 
Intercostal, substernal, and 
supraclavicular 
Dyspnea 
Speaks in sentences 
or coos and babbles 
Speaks in partial 
sentences or utters 
short cries 
Speaks in single words or 
short phrases or grunts 
Table 2. Asthma severity score (Qureshi et al). Score interpretation: Mild asthma 5-7, Moderate 8-11, 
Severe 12-15 
In patients with mild asthma exacerbation, inhaled 2-agonists like albuterol (salbutamol) is 
usually sufficient to resolve symptoms. The dose can be repeated 3 times every 15-20 
minutes. Levalbuterol, the (R)-enantiomer of albuterol is the effective form of the drug, but 
clinical trials did not show any advantage of using it over albuterol in terms of efficacy or 
side effects (Kelly, 2007). Most patients with mild asthma exacerbation will not require 
systemic glucocoricoids. However, it is recommended that patients who take them regularly 
or patients who fail initial treatment with albuterol should be given systemic 
glucocorticoids. 
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chest with minimal 
air entry 
O2 saturation 95% 92%-94% <92%  
Table 4. The Preschool Respiratory Assessment Measure (PRAM). *If asymmetric findings between 
right and left lungs, the most severe side is rated. 
Current guidelines recommend that patients with mild-moderate or moderate exacerbation 
should receive 3 doses of inhaled or nebulized 2-agonist every 15-20 minutes in the first 
hour (Camargo et al, 2003). Additional doses may be repeated in the next 2-3 hours every 
30-60 minutes. All those patients should be treated with systemic glucocorticoids at a dose 
of 2mg/kg or a maximum dose of 80 mg early in the course of management as it takes at 
least 4 hours to start working (Rowe et al, 2004). Doses more than 80 mg will not confer any 
additional benefit. Systemic glucocorticoids were found to speed resolution of symptoms, 
decrease the rate of admission and decrease the rate of relapse if administered for 3-5 days 
after the acute exacerbation. More detailed discussion about the use of systemic 
glucocoricoids in the treatment of acute asthma can be found below in section 2.1. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 504 
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PEFR*  70% 40-69% <40% 
Speech Sentences Phrases Words 
Mental Status Anxious Agitated Distressed 
Accessory muscle use No Sometimes Commonly 
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Measure (PRAM)  (Ducharme et al, 2008)(table 4), and the Pediatrics Asthma Severity Score 
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short cries 
Speaks in single words or 
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Table 2. Asthma severity score (Qureshi et al). Score interpretation: Mild asthma 5-7, Moderate 8-11, 
Severe 12-15 
In patients with mild asthma exacerbation, inhaled 2-agonists like albuterol (salbutamol) is 
usually sufficient to resolve symptoms. The dose can be repeated 3 times every 15-20 
minutes. Levalbuterol, the (R)-enantiomer of albuterol is the effective form of the drug, but 
clinical trials did not show any advantage of using it over albuterol in terms of efficacy or 
side effects (Kelly, 2007). Most patients with mild asthma exacerbation will not require 
systemic glucocoricoids. However, it is recommended that patients who take them regularly 
or patients who fail initial treatment with albuterol should be given systemic 
glucocorticoids. 
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Current guidelines recommend that patients with mild-moderate or moderate exacerbation 
should receive 3 doses of inhaled or nebulized 2-agonist every 15-20 minutes in the first 
hour (Camargo et al, 2003). Additional doses may be repeated in the next 2-3 hours every 
30-60 minutes. All those patients should be treated with systemic glucocorticoids at a dose 
of 2mg/kg or a maximum dose of 80 mg early in the course of management as it takes at 
least 4 hours to start working (Rowe et al, 2004). Doses more than 80 mg will not confer any 
additional benefit. Systemic glucocorticoids were found to speed resolution of symptoms, 
decrease the rate of admission and decrease the rate of relapse if administered for 3-5 days 
after the acute exacerbation. More detailed discussion about the use of systemic 
glucocoricoids in the treatment of acute asthma can be found below in section 2.1. 
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above normal for 
age 
Absent Present  
Mental status 
Observation of 
the child’s state 
of alertness 
Normal Depressed  
Table 5. The Pediatrics Asthma Severity Score (PASS) 
Patients with severe asthma exacerbation should obviously be treated more aggressively. 
High dose inhaled (8-12 puffs) or nebulized 2-agonist should be given every 15-20 minutes 
at least in the first hour, which could be repeated for up to 4 hours then as required. The 
data are conflicting whether continuous nebulization using 2-agonist is superior to 
intermittent nebulaization or not (Camargo et al, 2003; Rodrigo & Rodrigo, 2002). 
Practically, continuous high dose nebulization could be used for the first hour and then 
intermittent nebulization thereafter as required. Ipratropium bromide has been shown to 
decrease the rate of hospitalization and shorten the stay in the emergency room in patients 
with severe or moderate to severe asthma exacerbation in many clinical trials (Qureshi et al, 
1998; Rodrigo & Castro-Rodriguez, 2005; Zorc et al, 1999). Therefore, it is recommended to 
add it to each treatment of 2-agonist at least in the first hour of therapy. Its use in patients 
after admission to the hospital was not shown to make a difference. Systemic steroids 
should be used as mentioned in patients with moderate exacerbation. Other treatment 
modalities may be considered like magnesium sulfate and helium oxygen (heliox) therapy 
in the more severe and non-responsive patients. Subcutaneous or intravenous 2-agonists 
(Travers et al, 2002), intravenous aminophylline (Parameswaran et al, 2000), intravenous 
montelukast (Camargo et al, 2010; Morris et al, 2010), or oral montelukast added to standard 
therapy in the ER (Todi et al, 2010) were not shown to be helpful in the treatment of patients 
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with severe asthma exacerbation and therefore are not recommended. Moreover, oral 
montelukast given to patients post discharge for 5 days was also shown not to be helpful 
(Schuh et al, 2009). 
2-agonists can be delivered via a nebulizer or by metered dose inhaled (MDI) with a 
holding chamber. An MDI dose of 4-8 puffs depending on age is equivalent to a nebulized 
dose of 2.5-5 mg of albuterol (Cates et al, 2006). Nebulizer is preferable in cases of severe 
symptoms when patients are unable to use the MDI effectively or if other nebulized 
medications are needed to be mixed with albuterol at the same time or if the patient is 
requiring oxygen supplementation. Oxygen therapy should be given to maintain saturation 
 90% in adults and 95% in pregnant women or children. 
Patients who maintain normal oxygen saturation, have no or minimal wheezing on chest 
auscultation, and have no or mild intercostal retractions can be discharged home after 1 
hour of assessment on no additional medications in the emergency room. However, these 
patients should have a step up in their maintenance medications to prevent relapse. Patients 
who fail to achieve improvement after 4 hours of treatment should be admitted to the 
hospital for further aggressive therapy. 
1.3. Introduction and evolution of glucocorticoids in the management of asthma: 
Historical background 
Shortly after the discovery of the structure of adrenal steroid hormones, Hench and his 
colleagues examined using cortisone to treat arthritis in 1949. The effect was remarkable and 
that work won the Nobel Prize the next year. It also started a series of trials of 
corticosteroids in various inflammatory conditions. The first use of corticosteroid to treat 
acute asthma exacerbation occured in 1956 (Subcommittee on clinical trials in asthma, 1956). 
Development of corticosteroids that have less mineralocorticoid activity, like prednisone, 
and later those that have no mineralocorticoid activity, like dexamethasone, made 
glucocorticoids more attractive therapies to use in asthma. In 1972, Clerk et. al. showed for 
the first time that inhaled beclomethasone was effective in the management of asthma with 
less adverse effects than systemic steroids (Clark, 1972). Numerous reports came afterwards 
describing the efficacy of oral prednisone and prednisolone, intravenous 
methylprednisolone and inhaled glucocorticoids (IGC) like triamcinolone, budesonide, and 
fluticasone in the management of asthma. Table 3 shows some common systemic 
glucocorticoids and their relative potency. 
 






Hydrocortisone 1 1 8-12 
Prednisone/Prednisolone 4 0.8 12-36 
Methylprednisolone 5 0.5 12-36 
Dexamethasone 25 0 36-72 
Table 6. Common types of systemic glucocorticoids and their relative properties  
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add it to each treatment of 2-agonist at least in the first hour of therapy. Its use in patients 
after admission to the hospital was not shown to make a difference. Systemic steroids 
should be used as mentioned in patients with moderate exacerbation. Other treatment 
modalities may be considered like magnesium sulfate and helium oxygen (heliox) therapy 
in the more severe and non-responsive patients. Subcutaneous or intravenous 2-agonists 
(Travers et al, 2002), intravenous aminophylline (Parameswaran et al, 2000), intravenous 
montelukast (Camargo et al, 2010; Morris et al, 2010), or oral montelukast added to standard 
therapy in the ER (Todi et al, 2010) were not shown to be helpful in the treatment of patients 
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with severe asthma exacerbation and therefore are not recommended. Moreover, oral 
montelukast given to patients post discharge for 5 days was also shown not to be helpful 
(Schuh et al, 2009). 
2-agonists can be delivered via a nebulizer or by metered dose inhaled (MDI) with a 
holding chamber. An MDI dose of 4-8 puffs depending on age is equivalent to a nebulized 
dose of 2.5-5 mg of albuterol (Cates et al, 2006). Nebulizer is preferable in cases of severe 
symptoms when patients are unable to use the MDI effectively or if other nebulized 
medications are needed to be mixed with albuterol at the same time or if the patient is 
requiring oxygen supplementation. Oxygen therapy should be given to maintain saturation 
 90% in adults and 95% in pregnant women or children. 
Patients who maintain normal oxygen saturation, have no or minimal wheezing on chest 
auscultation, and have no or mild intercostal retractions can be discharged home after 1 
hour of assessment on no additional medications in the emergency room. However, these 
patients should have a step up in their maintenance medications to prevent relapse. Patients 
who fail to achieve improvement after 4 hours of treatment should be admitted to the 
hospital for further aggressive therapy. 
1.3. Introduction and evolution of glucocorticoids in the management of asthma: 
Historical background 
Shortly after the discovery of the structure of adrenal steroid hormones, Hench and his 
colleagues examined using cortisone to treat arthritis in 1949. The effect was remarkable and 
that work won the Nobel Prize the next year. It also started a series of trials of 
corticosteroids in various inflammatory conditions. The first use of corticosteroid to treat 
acute asthma exacerbation occured in 1956 (Subcommittee on clinical trials in asthma, 1956). 
Development of corticosteroids that have less mineralocorticoid activity, like prednisone, 
and later those that have no mineralocorticoid activity, like dexamethasone, made 
glucocorticoids more attractive therapies to use in asthma. In 1972, Clerk et. al. showed for 
the first time that inhaled beclomethasone was effective in the management of asthma with 
less adverse effects than systemic steroids (Clark, 1972). Numerous reports came afterwards 
describing the efficacy of oral prednisone and prednisolone, intravenous 
methylprednisolone and inhaled glucocorticoids (IGC) like triamcinolone, budesonide, and 
fluticasone in the management of asthma. Table 3 shows some common systemic 
glucocorticoids and their relative potency. 
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1.4. Adverse effects of glucocorticoids 
There are many adverse effects that may result from the use of oral or IGC in the treatment 
of asthma especially in high doses. I will summarize here the most pertinent ones. 
a. Suppression of the hypothalamic-pituitary-adrenal axis. Soon after the commencement 
of high dose oral glucocorticoids adrenal suppression may be noticeable. It also occurs 
with longer use of lower doses. IGC can also be systemically absorbed in their active 
form through particle deposition in the orophaynx or the lungs (particles deposited in 
the stomach usually undergo first pass hepatic metabolism where they are deactivated). 
High doses of IGC, more than 400 mcg of becloemthasone and 200 mcg of fluticasone or 
budesonide per day, could cause systemic adverse effects especially in children 
(Gulliver & Eid, 2005). Patients who undergo a stressful situation like major surgery 
should receive systemic steroid coverage to avoid symptoms of adrenal crises. These 
symptoms include lethargy, vomiting, change in mental status, and electrolyte 
disturbances. The hypothalamic-pituitary-adrenal axis can be evaluated by measuring 
early morning cortisol level. 
b. Osteoporosis. A common and serious complication of prolonged oral or high dose IGC 
therapy. Patients on such treatment, especially women and those with limited physical 
activity or who are taking medications that increase vitamine D metabolism in the liver, 
should undergo bone densitometry evaluation because this complication cannot be 
detected clinically. In one specialized center in the US, 40% of adolescent females 
admitted with severe asthma had osteopenia (Covar et al, 2000).  
c. Growth suppression. Glucocorticiods have been consistently shown to suppress growth 
in children. This seems to be independent from the growth suppression caused by the 
disease itself (Covar et al, 2000). The degree of growth suppression may reach 1 cm 
especially in the first year after starting IGC treatment. However, children eventually 
reach their expected height as adults (Agertoft & Pedersen, 2000; Sharek & Bergman, 
2000).  
d. Ophthalmologic adverse effects. Long-term administration of oral glucocorticoids or 
high doses IGC can lead to the development of posterior capsular cataract (Cumming et 
al, 1997). Some patients may need lens replacement surgery. Another ophthalmic 
complication is glaucoma that also may result from prolonged therapy with high dose 
IGC (Garbe et al, 1997). However, short-term treatment for less than 2 years or the use 
of moderate doses of IGC was found to be safe (Li et al, 1999; Pelkonen et al, 2008). 
e. Local adverse effects: Chronic use of IGC can be associated with the development of 
oral thrush (candidiasis), which could be minimized by washing the mouth with 
water after the inhalation. It may also be associated with hoarseness of voice and 
dysphonia due probably to laryngeal edema. These effects can be managed by 
changing the mode of inhalation (e.g: from dry powder inhaler to MDI) and the use of 
a holding chamber. 
f. Other adverse effects: These include immune suppression, metabolic changes like 
hyperglycemia, acne, hirsutism, skin thinning, delayed wound healing, myopathy, 
psychosis or mood changes. 
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2. Clinical evidence of the effect of glucocorticoids in acute asthma 
2.1. Systemic glucocorticoids 
Systemic glucocorticoids given early in the course of treatment of acute asthma 
exacerbations in the emergency room were overall shown to be effective and are 
recommended by different asthma guidelines like GINA and EPR3. Littenberg et al. initially 
showed that they decrease hospital admission rate (Littenberg & Gluck, 1986). Five 
subsequent studies had, however, conflicting results. Rodrigo & Rodrigo reviewed all these 
six studies and concluded that there was no improvement in hospital admission rate or lung 
function (Rodrigo & Rodrigo, 1999). They, however, reported a trend of improvement in 
lung function only with medium or high doses systemic glucocorticoids. So data in terms of 
lung function are more encouraging (Fanta et al, 1983; Lin et al, 1999). In terms of effect on 
exacerbation relapse after discharge from the emergency room, most studies showed less 
relapse with systemic glucocorticoids (Schneider et al, 1988; Subcommittee on clinical trials 
in asthma, 1956) although others did not (Rodrigo & Rodrigo, 1994). One important issue 
with all these studies is the low number of patients recruited. Almost all had subject number 
less than 100 per study and all were performed in adults. On the other hand, Krishnan et al 
recently reviewed 9 published studies in the use of systemic glucocorticoids in acute asthma 
in adults and concluded “systemic corticosteroids provide clinically meaningful benefits in 
patients presenting with acute asthma” (Krishnan et al, 2009). In children, more limited data 
showed benefit of systemic steroids used early in the emergency room with decreased rate 
of admission (Scarfone et al, 1993). A Cochrane database review by Rowe et al showed 
decrease rate of admission in patients with acute asthma with the use of systemic 
glucocorticoids in adults and children especially those with severe asthma and those not 
currently receiving steroids (Rowe et al, 2001). 
There is no significant difference in efficacy of systemic glucocorticoids at doses above 60-80 
mg/d or 2 mg/kg/d in regards to pulmonary function, rate of admission, or length of stay in 
the hospital. For example, Marquette et al compared 1 mg/kg/d to 6 mg/kg/d 
methylprednisolone in 47 adults hospitalized with severe acute asthma and found no 
benefit of the high dose over the low dose (Marquette et al, 1995). Manser et al performed a 
systematic review of randomized controlled studies of patients with acute severe asthma 
comparing different doses of glucocorticoids with a minimum follow up of 24 hours. They 
divided the different doses used in the trials included into 3 groups as equivalent dose of 
methylprednisolone in 24 hours; low dose (≤80 mg), medium dose (>80 mg and ≤360 mg), 
and high dose (>360 mg). Nine trials were included with a total of 344 adults. They found no 
difference between the different doses (Manser et al, 2001).   
Studies also showed no difference in efficacy between oral or intravenous administration or 
in their onset on action. Fifty-two adults with severe acute asthma were treated with either 
IV hydrocortisone or PO prednisolone. There was no difference in their peak flow 
measurements 24 hours after admission (Harrison et al, 1986). Ratto et al compared four 
different doses of methylprednisolone; 160 or 320 mg given orally, or 500 or 1000 mg given 
IV in four divided doses in adults with acute asthma and found no difference in their FEV1, 
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1.4. Adverse effects of glucocorticoids 
There are many adverse effects that may result from the use of oral or IGC in the treatment 
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form through particle deposition in the orophaynx or the lungs (particles deposited in 
the stomach usually undergo first pass hepatic metabolism where they are deactivated). 
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(Gulliver & Eid, 2005). Patients who undergo a stressful situation like major surgery 
should receive systemic steroid coverage to avoid symptoms of adrenal crises. These 
symptoms include lethargy, vomiting, change in mental status, and electrolyte 
disturbances. The hypothalamic-pituitary-adrenal axis can be evaluated by measuring 
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b. Osteoporosis. A common and serious complication of prolonged oral or high dose IGC 
therapy. Patients on such treatment, especially women and those with limited physical 
activity or who are taking medications that increase vitamine D metabolism in the liver, 
should undergo bone densitometry evaluation because this complication cannot be 
detected clinically. In one specialized center in the US, 40% of adolescent females 
admitted with severe asthma had osteopenia (Covar et al, 2000).  
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in children. This seems to be independent from the growth suppression caused by the 
disease itself (Covar et al, 2000). The degree of growth suppression may reach 1 cm 
especially in the first year after starting IGC treatment. However, children eventually 
reach their expected height as adults (Agertoft & Pedersen, 2000; Sharek & Bergman, 
2000).  
d. Ophthalmologic adverse effects. Long-term administration of oral glucocorticoids or 
high doses IGC can lead to the development of posterior capsular cataract (Cumming et 
al, 1997). Some patients may need lens replacement surgery. Another ophthalmic 
complication is glaucoma that also may result from prolonged therapy with high dose 
IGC (Garbe et al, 1997). However, short-term treatment for less than 2 years or the use 
of moderate doses of IGC was found to be safe (Li et al, 1999; Pelkonen et al, 2008). 
e. Local adverse effects: Chronic use of IGC can be associated with the development of 
oral thrush (candidiasis), which could be minimized by washing the mouth with 
water after the inhalation. It may also be associated with hoarseness of voice and 
dysphonia due probably to laryngeal edema. These effects can be managed by 
changing the mode of inhalation (e.g: from dry powder inhaler to MDI) and the use of 
a holding chamber. 
f. Other adverse effects: These include immune suppression, metabolic changes like 
hyperglycemia, acne, hirsutism, skin thinning, delayed wound healing, myopathy, 
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2. Clinical evidence of the effect of glucocorticoids in acute asthma 
2.1. Systemic glucocorticoids 
Systemic glucocorticoids given early in the course of treatment of acute asthma 
exacerbations in the emergency room were overall shown to be effective and are 
recommended by different asthma guidelines like GINA and EPR3. Littenberg et al. initially 
showed that they decrease hospital admission rate (Littenberg & Gluck, 1986). Five 
subsequent studies had, however, conflicting results. Rodrigo & Rodrigo reviewed all these 
six studies and concluded that there was no improvement in hospital admission rate or lung 
function (Rodrigo & Rodrigo, 1999). They, however, reported a trend of improvement in 
lung function only with medium or high doses systemic glucocorticoids. So data in terms of 
lung function are more encouraging (Fanta et al, 1983; Lin et al, 1999). In terms of effect on 
exacerbation relapse after discharge from the emergency room, most studies showed less 
relapse with systemic glucocorticoids (Schneider et al, 1988; Subcommittee on clinical trials 
in asthma, 1956) although others did not (Rodrigo & Rodrigo, 1994). One important issue 
with all these studies is the low number of patients recruited. Almost all had subject number 
less than 100 per study and all were performed in adults. On the other hand, Krishnan et al 
recently reviewed 9 published studies in the use of systemic glucocorticoids in acute asthma 
in adults and concluded “systemic corticosteroids provide clinically meaningful benefits in 
patients presenting with acute asthma” (Krishnan et al, 2009). In children, more limited data 
showed benefit of systemic steroids used early in the emergency room with decreased rate 
of admission (Scarfone et al, 1993). A Cochrane database review by Rowe et al showed 
decrease rate of admission in patients with acute asthma with the use of systemic 
glucocorticoids in adults and children especially those with severe asthma and those not 
currently receiving steroids (Rowe et al, 2001). 
There is no significant difference in efficacy of systemic glucocorticoids at doses above 60-80 
mg/d or 2 mg/kg/d in regards to pulmonary function, rate of admission, or length of stay in 
the hospital. For example, Marquette et al compared 1 mg/kg/d to 6 mg/kg/d 
methylprednisolone in 47 adults hospitalized with severe acute asthma and found no 
benefit of the high dose over the low dose (Marquette et al, 1995). Manser et al performed a 
systematic review of randomized controlled studies of patients with acute severe asthma 
comparing different doses of glucocorticoids with a minimum follow up of 24 hours. They 
divided the different doses used in the trials included into 3 groups as equivalent dose of 
methylprednisolone in 24 hours; low dose (≤80 mg), medium dose (>80 mg and ≤360 mg), 
and high dose (>360 mg). Nine trials were included with a total of 344 adults. They found no 
difference between the different doses (Manser et al, 2001).   
Studies also showed no difference in efficacy between oral or intravenous administration or 
in their onset on action. Fifty-two adults with severe acute asthma were treated with either 
IV hydrocortisone or PO prednisolone. There was no difference in their peak flow 
measurements 24 hours after admission (Harrison et al, 1986). Ratto et al compared four 
different doses of methylprednisolone; 160 or 320 mg given orally, or 500 or 1000 mg given 
IV in four divided doses in adults with acute asthma and found no difference in their FEV1, 
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days of hospitalization (Ratto et al, 1988). In children oral prednisolone was found 
equivalent to IV methylprednisolone in regards to patients’ length of hospital stay (Becker et 
al, 1999). In addition, oral treatment was cost saving.  GINA and the EPR3 guidelines prefer 
oral administration because it is less invasive except in patients with absorption problems or 
those who are not able to take orally due to the severity of their respiratory distress or 
because they are vomiting. 
Prescribing oral glucocorticoids for the treatment of acute asthma exacerbations for longer 
than 5 days was not found to provide any additional benefit (Hasegawa et al, 2000; Jones et 
al, 2002). In children, a single dose of dexamethasone 0.6 mg/kg (max. 18 mg) was found to 
be equivalent to prednisolone 2 mg/kg/d in two divided doses for 5 days in terms of 
symptoms resolution (Altamimi et al, 2006). There is also no benefit from using a dose taper 
over fixed-dose regimen (Krishnan et al, 2009). Because of poor compliance on oral 
prednisone after discharge from the emergency, intramuscular injection of 
methylprednisolone was studied as an alternative but was not found superior, plus there 
was an evidence of injection-site adverse reaction (see last reference). 
2.2. Inhaled glucocorticoids 
IGC were studied in the treatment of acute asthma in 4 contexts: as compared to placebo, as 
compared to systemic glucocorticoids, as add on therapy to systemic steroids for up to few 
weeks after discharge from the ER, or as add on therapy to systemic steroids in the ER only. 
In the first context, a review that looked at 8 randomized and blinded studies comparing the 
efficacy of IGC to placebo in acute asthma exacerbation suggested that IGC are superior to 
placebo especially when given at high doses (> 1mg of budesonide or fluticasone) and to 
patients with severe exacerbations (Rodrigo, 2006). It is important to note that those 
studies were quite heterogeneous in terms of the severity of asthma in recruited patients, 
the dose and frequency of IGC administered, and in the outcome measures that included 
clinical symptoms, pulmonary function, oxygen saturation, admission rate, or relapse 
rate. A recent study found that preemptive use of high dose fluticasone (750 mcg BID) at 
the onset of an upper respiratory tract infection in children with recurrent virus induced 
wheezing and continuing it for 10 days, reduced the use of rescue oral glucocorticoids 
(Ducharme et al, 2009). 
When IGCs were compared with systemic glucocorticoids in randomized and blinded 
studies the data were more controversial. Some studies reported superiority of systemic 
steroids in reducing admission rate (Schuh et al, 2000), some reported equal efficacy in 
relation to admission rate as well (Lee-Wong et al, 2002; Levy et al, 1996; Scarfone et al, 
1995), and some reported clear superiority of IGC (Devidayal et al, 1999; Rodrigo, 2005). A 
study compared high dose fluticasone in the ER and for 5 days post discharge to systemic 
glucocorticoids in the same period in patients with mild to moderate asthma found that oral 
steroids lead to faster improvement in FEV1 at 4 hours in the ER and less relapse rate at 48 
hours post discharge (Schuh et al, 2006). One recent study showed that in patients who were 
given systemic glucocorticoids plus IGC post discharge from the ER, stopping the systemic 
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glucocorticoids after 1 week resulted in rebound in the level of exhaled NO 2 weeks post 
discharge despite continuing IGC with no effect on the use of rescue medications or on FEV1 
(Khoo & Lim, 2009). GINA guideline state that “IGC are effective as part of therapy for 
asthma exacerbations….and can be as effective as oral glucocorticoids at preventing 
relapses”(GINA, 2011), while the EPR3 guidelines state that “high doses of IGC may be 
considered in the ER, although current evidence is insufficient to permit conclusions about 
using IGC rather than oral systemic corticosteroids in the ER”(EPR3, 2007). 
When IGC were used as add on therapy to systemic glucocorticoids in the ER and continued 
after discharge for few weeks, Rowe et al found decrease in relapse rate when 1600 mcg/d 
budesonide for 21 days was added to a course of 50 mg/d prednisone for 7 days as 
compared to placebo (Rowe et al, 1999). On the other hand, Brenner et al found no 
difference in the peak expiratory flow rate between high dose flunisolide used for 24 days 
added to prednisone 40 mg/d for 5 days as compared to placebo (Brenner et al, 2000). A 
systematic review of ten trials concluded no benefit of adding inhaled to systemic 
glucocorticoids in reducing the relapse rate of acute asthma (Edmonds et al, 2000). 
There are few randomized and blinded studies examining only the short-term effect of IGC 
in the ER as add on therapy to systemic glucocorticoids plus other standard acute asthma 
therapy. One study looked at the addition of high dose beclomethasone versus placebo to 
methylprednisolone in 60 adults and found no difference in FEV1 or symptoms between the 
two groups (Guttman et al, 1997). One study looked at the addition of budesonide 
nebulizations to methylprednisolone in a population of 26 children with moderate asthma 
(Nuhoglu et al, 2005) and found no difference in the primary outcome of pulmonary index 
score but there was an improvement in the PEFR in the budesonide group compared to 
placebo. However, the patient number included is very small and PEFR is generally not 
reliable in young children. The two other randomized and blinded studies that were larger 
and more rigorous examined the effect of adding 2 mg of budesonide nebulization to 
prednisone in children with moderate to severe asthma (Sung et al, 1998; Upham et al, 2011). 
In the study by Sung et al, 44 children with moderate to severe asthma were included. Both 
groups had no difference in the pulmonary index score. In the Upham et al study, 180 
children with moderate to severe asthma were included.  There was no difference in the 
asthma score (adopted form (Qureshi et al, 1998)) at 2 hours after intervention or in the 
admission rate or time to discharge from the ER between the two groups. Collectively, all 
these studies, although small in subjects number, indicate that the addition of IGC to 
systemic steroid is not helpful in patients with moderate to severe acute asthma. We are 
conducting a larger study that will hopefully shed more light on that question, the results of 
which should be available quite soon. 
3. A brief overview of the use of glucocorticoids in asthma prophylaxis 
3.1. Inhaled glucocorticoids 
IGCs are the main stay of asthma management. They were shown to very consistently 
change many of the pathologic inflammatory features of asthma in the lung airways. They 
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days of hospitalization (Ratto et al, 1988). In children oral prednisolone was found 
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those who are not able to take orally due to the severity of their respiratory distress or 
because they are vomiting. 
Prescribing oral glucocorticoids for the treatment of acute asthma exacerbations for longer 
than 5 days was not found to provide any additional benefit (Hasegawa et al, 2000; Jones et 
al, 2002). In children, a single dose of dexamethasone 0.6 mg/kg (max. 18 mg) was found to 
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systematic review of ten trials concluded no benefit of adding inhaled to systemic 
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score but there was an improvement in the PEFR in the budesonide group compared to 
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asthma score (adopted form (Qureshi et al, 1998)) at 2 hours after intervention or in the 
admission rate or time to discharge from the ER between the two groups. Collectively, all 
these studies, although small in subjects number, indicate that the addition of IGC to 
systemic steroid is not helpful in patients with moderate to severe acute asthma. We are 
conducting a larger study that will hopefully shed more light on that question, the results of 
which should be available quite soon. 
3. A brief overview of the use of glucocorticoids in asthma prophylaxis 
3.1. Inhaled glucocorticoids 
IGCs are the main stay of asthma management. They were shown to very consistently 
change many of the pathologic inflammatory features of asthma in the lung airways. They 
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lead to decrease cellular infiltrates including T-lymphocytes, mast cells, eosinophils, and 
macrophages. Also, epithelial damage, goblet cell hyperplasia, and vascular blood flow 
significantly decreases with IGC therapy (Fanta, 2009).  Consistent with the histological 
changes, clinical changes are observed. Compliant use of IGC is associated with decreased 
airway hyperresponsiveness and improved asthma symptomatology (CAMP, 2000; 
Haahtela et al, 1991). Most patients will also have improved lung function demonstrated by 
increased FEV1. In addition, the risk of patients’ hospitalization from asthma exacerbations 
is decreased by up to 50% (Donahue et al, 1997). Moreover, the risk of death from asthma is 
decreased, an effect that is dependent on the patients’ compliance on IGC and the duration 
of their use (Suissa et al, 2000).  
It is important here to note several points. First, the local anti-inflammatory effect of IGC 
usually plateaus after reaching low to moderate dosages, except probably for the most 
severe patients. However, the other systemic effects of IGC increase steeply after exceeding 
the low to moderate dose (Szefler et al, 2005). Therefore, efforts should be made to maintain 
patients on the lowest possible dose of IGC and, in cases of inappropriate response, long 
acting beta-agonists (LABA) or leukotriene receptor antagonists (LTRA) or both should be 
added before doubling the dose of IGC (Fanta, 2009).  Second, there is great heterogeneity 
among asthmatics in their response to IGC. This variability can be attributed to several 
factors, most importantly are genetic variations between individuals (Lima et al, 2009). 
Third, multiple studies have shown that IGC therapy over the years do not change the 
natural history of the disease or prevent decline in lung function. They may have little effect 
on some features of remodeling but not all of them. Also, IGC, even when used in high risk 
infants who are very likely to develop asthma, were not able to prevent its development 
(Murray, 2008). 
3.2. Systemic glucocorticoids 
Systemic glucocorticoids are only occasionally used for long-term asthma control. There use 
is limited to the most severe patients who are difficult to control using other common 
modalities (EPR3, 2007). This is due to their side effects that can be very serious as stated 
above. The side effects are dose and duration dependent. Prolonged low dose therapy (<7.5 
mg prednisone-equivalent in adults/day) is usually associated with mild adverse effects. 
Moderate doses (7.5 mg – 30 mg/day) are usually associated with significant adverse effects, 
and high doses (30 mg – 100 mg) may be associated with serious adverse effects (Stahn & 
Buttgereit, 2008). 
4. Mechanism of action of glucocorticoids in asthma 
Discussion of the mechanism of action of glucocorticoids in asthma is beyond the scope of 
this chapter and was recently reviewed (Alangari, 2010). Glucocorticoids act either by 
altering the rate of transcription of certain genes at the DNA level or through non-genomic 
pathways. Some of these effects could lead to the desirable anti-inflammatory action and 
some may result in adverse reactions. 
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4.1. Genomic action 
The main mechanism whereby glucocorticoids deliver their anti-inflammatory action 
involves genomic action. This mechanism entails binding of glucocorticoids to their 
cytoplasmic receptors forming complexes that then translocate to the nucleus, where they 
either homo-dimerize then bind to their glucocorticoid response elements (GRE) in the 
DNA, or bind to different transcription factors (protein-protein interaction) as monomers 
(Ito et al, 2006; Lowenberg et al, 2008).  Because of this, the genomic action of glucocorticoids 
takes at least 4 hours to start showing an effect and the duration of action is also prolonged 
and may exceed 24 hours.  
 
Figure 2. The genomic effect of glucocorticoids is in the form of transactivation or transrepression. In 
transactivation, the transcription of genes encoding certain anti-inflammatory or regulatory proteins is 
upregulated, while in transrepression the transcription of certain genes encoding proinflammatory 
proteins is up regulated. Abbreviations: AP1, activator protein 1; cGCR, cytosolic glucocorticoid 
receptor; COX-2, cyclooxygenase 2; GRE, glucocorticoid response element; IkB, inhibitor of NFkB; IFNγ 
interferon IL, interleukin; NF-AT, nuclear factor of activated T cells; NFkB, nuclear factor kB; STAT5, 
signal transducer and activator of transcription 5; TF, transcription factor; TNF, tumor necrosis factor; 
VEGF, vascular endothelial growth factor. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Rheumatology. Cindy Stahn and Frank Buttgereit. Vol. 4(10):Page 529, copyright 2008. 
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Third, multiple studies have shown that IGC therapy over the years do not change the 
natural history of the disease or prevent decline in lung function. They may have little effect 
on some features of remodeling but not all of them. Also, IGC, even when used in high risk 
infants who are very likely to develop asthma, were not able to prevent its development 
(Murray, 2008). 
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Systemic glucocorticoids are only occasionally used for long-term asthma control. There use 
is limited to the most severe patients who are difficult to control using other common 
modalities (EPR3, 2007). This is due to their side effects that can be very serious as stated 
above. The side effects are dose and duration dependent. Prolonged low dose therapy (<7.5 
mg prednisone-equivalent in adults/day) is usually associated with mild adverse effects. 
Moderate doses (7.5 mg – 30 mg/day) are usually associated with significant adverse effects, 
and high doses (30 mg – 100 mg) may be associated with serious adverse effects (Stahn & 
Buttgereit, 2008). 
4. Mechanism of action of glucocorticoids in asthma 
Discussion of the mechanism of action of glucocorticoids in asthma is beyond the scope of 
this chapter and was recently reviewed (Alangari, 2010). Glucocorticoids act either by 
altering the rate of transcription of certain genes at the DNA level or through non-genomic 
pathways. Some of these effects could lead to the desirable anti-inflammatory action and 
some may result in adverse reactions. 
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Binding of glucocorticoid receptors to their GRE activates the transcription of certain genes 
encoding anti-inflammatory proteins, like IL-10 and IkB, and regulatory proteins. This 
process is called transactivation (figure 2). Some of the glucocorticoids adverse effects like 
glaucoma and hyperglycemia are mediated through this pathway (Schacke et al, 2002). On 
the other hand, binding of glucocorticoid receptors to pro-inflammatory transcription 
factors like nuclear factor kappa B (NFkB) or activator protein 1 (AP-1), or their competition 
for nuclear coactivators; down regulates the transcription of certain genes encoding pro-
inflammatory proteins like IL-1, IL-2, IL-6, and TNF. This process is called transrepression 
(De Bosscher et al, 2003) (figure 2). Most of the desired genomic actions of glucocorticoids in 
asthma are mediated through this pathway. 
4.2. Non-genomic action 
Non-genomic action of glucocorticoids includes all actions that do not directly alter gene 
expression and are not blunted by inhibitors of gene transcription (Losel & Wehling, 2003).  
This mode of action is characterized by its rapid onset (seconds to minutes) and short 
duration (60-90 min). These actions are dose dependent (Wanner et al, 2004). There are four 
types of non-genomic action of glucocorticoids (Alangari, 2010). Firstly, acting through the 
inhibition of the extraneuronal monoamine transporter-mediated uptake of norepinephrine. 
Asthmatic patients have increased blood flow in their airways (Kumar et al, 1998). IGC were 
shown to decrease blood flow in the airways within few minutes. This effect will last for 90 
minutes only and therefore, cannot be explained by the genomic action (Kumar et al, 2000; 
Mendes et al, 2003). The proposed mechanism is that IGCs by a topical effect can block the 
extraneuronal monoamine transporter on the membrane of vascular endothelial cells, 
preventing their uptake of norepinephrine and thus making it more available in the synaptic 
cleft (Horvath & Wanner, 2006). Secondly, in high doses, glucocorticoids can induce 
physiochemical changes in the cell membrane by directly incorporating into the membrane. 
This can result in immune cell suppression (Buttgereit & Scheffold, 2002). Thirdly, 
glucocorticoids may interact with membrane bound GRs on mononuclear cells. These 
receptors are variants of cytosolic GRs and can mediate inhibition of Lck/Fyn kinases down 
stream form the T-cell receptor leading to immune suppression (Lowenberg et al, 2005; 
Lowenberg et al, 2007). Lastly, few in vitro studies showed that some protein components 
associated with GRs complex, which are released upon GR ligation can inactivate cytosolic 
phospholipase 2 and therefore inhibit the production of arachidonic acid and downstream 
components like prostaglandins and leukotriens (Croxtall et al, 2000; Croxtall et al, 2002). 
However this action was not shown to be of clinical significance. 
5. Future directions and recommendations 
We have seen through this chapter that glucocorticoids play an extremely important role in 
the current prophylactic treatment of patients with persistent asthma, in the treatment of 
acute asthma exacerbations post discharge from the ER and possibly in the acute 
management in the ER. The introduction of IGC has revolutionized the way we manage 
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asthma and it seems that those medications will stay with us for a long while.  Further 
research is greatly needed to shed more light on the use of IGC in the ER in patients coming 
with acute asthma exacerbation and on the safety of dispensing oral glucocorticoids for 
home use in case of asthma exacerbation. Training physicians to follow asthma management 
guidelines as well as education of patients and their families cannot be over emphasized and 
will save a lot of money.  
Our improved understanding of the tertiary structure of glucocorticoids and their receptors 
and their mechanisms of action has led to the discovery and development of selective 
glucocorticoid receptor modulators (SGRM). Those are new agents that have the 
transrepression but little or no transactivation properties of glucocorticoids, which means 
that those compounds could deliver the desired anti-inflammatory action of glucocorticoids 
while avoiding most of their adverse effects (De Bosscher et al, 2010). Still under 
investigation, those agents could hold a lot of promise in the future. Moreover, it was 
recently shown that simultaneous activation of GRα and peroxisome proliferator-activated 
receptor alpha (PPARα), which are cytosolic receptors with many immunomodulatory 
functions and multiple natural ligands, can block the GRE mediated transactivating effects 
of glucocorticoids while potentiating their anti-inflammatory effects in mice (Bougarne et al, 
2009). If this holds true in humans, combination therapy of a glucocorticoid and a PPARα 
agonist could be very promising. 
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1. Introduction 
The nasal mucosa is known to be the first important barrier against inhalants of the 
respiratory tract. In contrast to initial opinion, this tissue actively interacts with external 
factors, producing a wide combination of mediators in response to aggressor agents [1]. In 
this respect, it is easy to understand why the nasal mucosa is predisposed to the 
development of several chronic inflammatory diseases, with rhinitis and rhinosinusitis 
being the most common disorders.  
According to the ARIA guideline [2], the prevalence of allergic rhinitis has increased in the 
last years and has been found to be around 25% in Europe [3]. The prevalence of symptoms 
related to chronic rhinosinusitis is about 15% in the USA, being the second most prevalent 
chronic condition in the American population [4]. 
The most common and studied cause of chronic rhinitis is allergic rhinitis (AR) [2]. AR is a 
nasal inflammatory disease in which the allergen induces IgE-mediated inflammation. The 
mediators released by the nasal mucosa will finally lead to intense inflammatory cell 
recruitment (predominantly eosinophils) [5], epithelial metaplasia (more pronounced in 
perennial AR) [6], and noticeable stromal edema, especially due to the action of matrix 
metalloproteinases [7]. This response to allergens will finally induce the classical symptoms 
of AR, such as sneezing, itching, nasal discharge and nasal obstruction. These symptoms 
considerably impair the quality of life, affecting sleep quality, concentration during 
work/school, and other daily activities [2]. 
Chronic rhinosinusitis can be subdivided into two forms: chronic rhinosinusitis without 
nasal polyps (CRSsNP) and with nasal polyps (CRSwNP). These two entities are almost 
clinically identical, and it is very difficult to differentiate them based only on nasal 
symptoms [8]. Both forms present variable degrees of facial pain, decreased sense of smell, 
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nasal discharge and nasal congestion. Clinically, the differentiation of these two entities is 
made by the detection of nasal polyps by nasal endoscopy. However, the major differences 
between CRSsNP and CRSwNP concern histology and molecular biomarkers [9]. CRSsNP is 
characterized by neutrophil recruitment, light edema, increased remodelling [9] and a Th1-
subset profile. In contrast, CRSwNP is characterized by an eosinophil recruitment, intense 
oedema, loose connective tissue and a Th1/Th2 mixed –subset profile, but with remarkable 
Th2 polarization [8-10].  
2. Cellular and molecular knowledge in nasal inflammatory diseases 
2.1. Allergic Rhinitis 
The development of signs and symptoms that characterize allergic rhinitis (AR) depends on 
three events: sensitization to an allergen, degranulation of inflammatory mediators after re-
exposure to the allergen (early phase) and infiltration of inflammatory cells into the tissue 
(late phase). 
The respiratory nasal mucosa is continuously exposed to several particles that are deposited 
on the mucous blanket that covers the respiratory epithelium. These antigens are processed 
by antigen-presenting cells (APCs) such as Langerhans cells, that are later presented to a 
naïve lymphocyte through a major histocompatibility complex (MHC) class II molecule [11]. 
For reasons not completely elucidated, naïve lymphocytes (Th0) differentiate into Th2 
lymphocytes and produce and release a pool of cytokines characteristic of the Th2 response 
pattern (IL-3, IL-4, IL-5, IL-9, IL-10, IL-13, GM-CSF). Moreover, the differentiated Th2 
lymphocytes stimulate the production of specific IgE by plasmocytes through IL-3 and IL-4, 
and inhibit the differentiation of Th0 lymphocytes into Th1, as well as its messenger 
molecules. This selective environment polarized to a Th2 response is typically seen in 
allergic mechanisms, such as AR, asthma and atopic dermatitis, and in helminthic infections. 
B cells that recognize the processed antigen and receive appropriate contact signals (CD40-
CD40) and molecular stimuli (IL-4, IL-6, IL-10, IL-13) start to produce specific IgE. In the 
presence of continuous antigen stimulation, B-cells switch from the production of a low-
affinity IgE molecule to the production of a high-affinity one [11]. 
Once high-affinity IgE circulates in the plasma and interstitial fluid, it binds to the Fc 
receptors. These receptors are present on the surface of mast cells and basophils, and are 
responsible for activating these cells when exposed to the binomial antibody-pathogen. 
After mast cells leave the post-capillary venules, they are able to reside in the stroma of the 
nasal submucosa and intraepithelially, probably by the production of several proteases. 
Resident mast cells are also able to produce some cytokines related to Th2 polarization (IL-4, 
IL-5), which in turn can cause an increased cell proliferation and survival time. In allergic 
mucosa, for instance, mast cells proliferate at a higher rate compared to a non-allergic 
environment, probably by the effect of Th2 cytokines [12, 13]. 
In a second phase, after sensitization and priming of resident mast cells with IgE, the 
respiratory mucosa becomes susceptible to a new exposure. When the specific inspired 
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allergen binds to the complex IgE-mediator cell, massive degranulation of allergic molecules 
(either already existent and newly synthetized) are released in the extracellular 
compartment. Histamine is the main molecule released and involved in the early phase of 
symptoms of AR, but other mediators such as leukotriene, bradykinin, prostaglandins, 
platelet activating factor, and even some proteases (tryptase and chymase) and cytokines 
(TNF-α, IL-4, IL-5) also have a role in the development of allergic symptoms [14]. These 
mediators lead to the classical early symptoms of sneezing, itching, rhinorrhea, and nasal 
congestion that occur within a few minutes after allergen exposure (5-30 minutes). These 
symptoms are the consequence of direct actions of these mediators on different resident cells 
[15]. Glands are stimulated by leukotrienes and chymases to produce and release mucous 
secretions. Endothelial cells of post-capillary venules are affected by histamine, bradykinin, 
platelet activating factor and leukotrienes, inducing vasodilatation, increased vascular 
permeability and cell adhesion. Peripheral sensory endings are stimulated by histamine type 
1 receptors on nociceptive type C fibers that generate an uncomfortable sensation of pain 
and pressure, sneezing and itching [16]. As the nasal mucosa is constantly assaulted by 
physical and chemical agents, the disruption of some areas facilitates the exposure of 
allergens to allergic mediator cells. 
After the IgE-mediated inflammatory burst triggered by the allergen, some individuals 
present total clearance of mediators and have complete resolution of symptoms after some 
minutes. However, a significant percentage (60-70%) of the allergic population develops the 
late AR response due to the recruitment of inflammatory cells into the nasal mucosa. The 
increased vascular permeability added to the expression of adhesion molecules (ICAM-1) 
and production of chemokines, recruits a variety of inflammatory cells that include 
eosinophils and basophils and, to a lesser extent, neutrophils and other leukocytes. 
The late phase typically occurs 4-6 hours after the allergen contact and is clinically 
represented by the nasal obstruction and congestion caused by mucosal edema. Toxic 
products of eosinophils, such as eosinophil cationic protein (ECP), major basic protein 
(MBP), eosinophil-derived neurotoxin and eosinophil peroxidase, are evident during the 
late phase and are proportional to the eosinophil recruitment. These highly charged proteins 
bind to proteoglycans and hyaluronic acid and cause cell damage and epithelial detachment. 
Other important inflammatory mediators involved in the late phase are leukotrienes, 
histamine, and cytokines of the Th2 response (IL-5, IL-6, GM-CSF) [17, 18]. Interestingly, the 
recruited eosinophils are able to promote an auto-positive feedback to prolong their survival 
and recruitment into the tissue, which ultimately leads to an independent eosinophilic 
inflammation (Figure 1). IL-3, IL-5, and GM-CSF are Th2 cytokines that reduce apoptosis 
and prolong eosinophil cell survival. Besides, IL-5, eotaxin and RANTES produced by 
eosinophils and other infiltrated cells recruit even more eosinophils to the inflammatory site, 
explaining the reason why a chronic allergic inflammation can be seen even when the 
allergen is not present [19].  
Lymphocytes are another group of cells that may play an important role in the late phase of 
AR. Memory T cells, T-cytotoxic and B cells have been demonstrated to be increased in AR 
compared to other forms of non-allergic rhinitis and to controls [20].  
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platelet activating factor, and even some proteases (tryptase and chymase) and cytokines 
(TNF-α, IL-4, IL-5) also have a role in the development of allergic symptoms [14]. These 
mediators lead to the classical early symptoms of sneezing, itching, rhinorrhea, and nasal 
congestion that occur within a few minutes after allergen exposure (5-30 minutes). These 
symptoms are the consequence of direct actions of these mediators on different resident cells 
[15]. Glands are stimulated by leukotrienes and chymases to produce and release mucous 
secretions. Endothelial cells of post-capillary venules are affected by histamine, bradykinin, 
platelet activating factor and leukotrienes, inducing vasodilatation, increased vascular 
permeability and cell adhesion. Peripheral sensory endings are stimulated by histamine type 
1 receptors on nociceptive type C fibers that generate an uncomfortable sensation of pain 
and pressure, sneezing and itching [16]. As the nasal mucosa is constantly assaulted by 
physical and chemical agents, the disruption of some areas facilitates the exposure of 
allergens to allergic mediator cells. 
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minutes. However, a significant percentage (60-70%) of the allergic population develops the 
late AR response due to the recruitment of inflammatory cells into the nasal mucosa. The 
increased vascular permeability added to the expression of adhesion molecules (ICAM-1) 
and production of chemokines, recruits a variety of inflammatory cells that include 
eosinophils and basophils and, to a lesser extent, neutrophils and other leukocytes. 
The late phase typically occurs 4-6 hours after the allergen contact and is clinically 
represented by the nasal obstruction and congestion caused by mucosal edema. Toxic 
products of eosinophils, such as eosinophil cationic protein (ECP), major basic protein 
(MBP), eosinophil-derived neurotoxin and eosinophil peroxidase, are evident during the 
late phase and are proportional to the eosinophil recruitment. These highly charged proteins 
bind to proteoglycans and hyaluronic acid and cause cell damage and epithelial detachment. 
Other important inflammatory mediators involved in the late phase are leukotrienes, 
histamine, and cytokines of the Th2 response (IL-5, IL-6, GM-CSF) [17, 18]. Interestingly, the 
recruited eosinophils are able to promote an auto-positive feedback to prolong their survival 
and recruitment into the tissue, which ultimately leads to an independent eosinophilic 
inflammation (Figure 1). IL-3, IL-5, and GM-CSF are Th2 cytokines that reduce apoptosis 
and prolong eosinophil cell survival. Besides, IL-5, eotaxin and RANTES produced by 
eosinophils and other infiltrated cells recruit even more eosinophils to the inflammatory site, 
explaining the reason why a chronic allergic inflammation can be seen even when the 
allergen is not present [19].  
Lymphocytes are another group of cells that may play an important role in the late phase of 
AR. Memory T cells, T-cytotoxic and B cells have been demonstrated to be increased in AR 
compared to other forms of non-allergic rhinitis and to controls [20].  
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Figure legend: Ag: antigen; APC: antigen presenting cell; TSLP: thymic stromal lymphopoietin; TLR: toll-like receptor; 
IL: interleukin; TNF: tumor necrosis factor; TF: transcriptor factor; Ig: immunoglobulin; GM-CSF: granulocyte 
macrophage colony-stimulating factor; LT: leukotriene; PG: prostaglandin; ECP: eosinophil cationic protein; MBP: 
major basic protein; PAF: platelet activating factor 
Figure 1. Cellular and molecular events involved in the early and late phase response of AR. Initially, 
the antigen invades the cell, and either binds to the APC (antigen presenting cell) or activates innate 
immune response through TSLP or TLR-4. These mechanisms together will activate adaptative immune 
response, and T cells are triggered to Th2 response, producing cytokines as IL-4, IL-5 and IL-13. These 
cytokines will induce epithelial cells to produce rhinorrhea and will recruit inflammatory cells (as 
eosinophils) to nasal mucosa. Eosinophils will produce several cytokines that will lead to nasal 
obstruction. B cells are activated and produce IgE, which, among the antigen itself, will induce the mast 
cell to secrete histamine, leukotrienes and prostaglandins, among others, finally leading to the 
symptoms of sneezing and itching. 
Resident cells may also participate in the late phase and development of chronic allergic 
inflammation. Nasal epithelial cells express an increased number of pro-inflammatory 
cytokines such as IL-1α, IL-1β, IL-6, IL-8 and GM-CSF in allergic patients [21, 22]. Also, 
epithelial cells are the main source of thymic stromal lymphopoietin (TSLP) on the nasal 
mucosa, an important cytokine that drives T cells to produce Th2 cytokines [23] and is 
increased in AR patients compared to controls [24]. Submucosal glands located in the lamina 
propria are substantially increased in allergic patients (25%) compared to non-allergic 
individuals (15%), consistent with the chronic state of increased production of nasal 
secretions [25] 
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In summary, the cellular and molecular mechanisms of AR involve B cell production of IgE 
and mast cell/basophil priming, activation of resident cells, recruitment of inflammatory 
cells and, in some circumstances, induction of a persistent inflammatory reaction 
maintained by a positive feedback.  
2.2. Chronic Rhinosinusitis (CRS) 
Chronic Rhinosinusitis (CRS) is clinically defined as the persistence of signs and symptoms  
such as nasal obstruction, nasal congestion, rhinorrhea, facial pain, cough, and loss of smell 
for more than 12 weeks, confirmed by nasal endoscopy or computed tomography. It is 
related to an inflammatory process of the mucoperiosteal pavement of the sinonasal cavity, 
whose etiology can be clearly defined in a few subgroups of patients, involving mechanical 
obstruction, immunodeficiency, cystic fibrosis, and ciliary dyskinesia. However, in the 
majority of cases, the etiology of CRS cannot be determined. Some investigators have raised 
different hypotheses for the pathogenesis of CRS such as disruption of the epithelial barrier, 
allergy, exposure to pollutants, maintenance of mucosal inflammation due to underlying 
osteitis, persistence of bacterial biofilms, and overreaction to staphylococcal superantigens or 
fungus. It is interesting to note that individually these theories do not apply to all patients but 
may explain the pathogenicity in some cases. Despite the unrevealed etiopathogenesis, recent 
advances have been made in the elucidation of the cellular and molecular events involved in 
different situations of CRS. Based on molecular phenotyping studies, the classification of CRS 
into two different clinical subsets has been currently accepted: CRS without nasal polyps (CRS 
sine NP, CRSsNP) and CRS with nasal polyps (CRSwNP) [8, 26]. Clinically, the symptoms of 
both types are very similar to each other, with slight differences in the severity of nasal 
congestion, nasal obstruction, rhinorrhea, postnasal drip, change in the sense of smell, cough, 
and facial pain. In terms of physical examination, they differ by the presence or absence of 
nasal polyps extruding from the middle meatus of the nasal cavity. This simple difference 
noted by nasal endoscopy involves profound differences in cellular and molecular aspects that 
might be related to the prognosis and treatment of these two subsets of CRS. 
Histologically, both forms of CRS are marked by niches of denuded respiratory epithelium 
with associated metaplasia, basal membrane thickening, and goblet cell hyperplasia. The 
histology of submucosal stroma demonstrates clear differences between CRSwNP and 
CRSsNP. In CRSwNP, the submucosal stroma usually is found with robust edema and low 
cellularity, in contrast to CRSsNP that characteristically involves more pronounced fibrosis 
and less edema [9]. 
In CRSwNP, eosinophilic infiltration is the hallmark of chronic inflammation. For reasons 
not fully elucidated, there is an increased expression of pro-inflammatory cytokines (IL-1β) 
mediated by transcription factors. These cytokines mediate the recruitment of inflammatory 
cells (eosinophils, lymphocytes, neutrophils, mast cells) through the up-regulation and 
expression of adhesion molecules (ICAM-1, VCAM-1) and chemokines (IL-8, eotaxin, and 
RANTES). In CRSwNP, the striking influx of inflammatory cells, especially eosinophils, into 
the stroma, leads to a positive feedback recruitment similar to allergic rhinitis [27]. In the 
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In summary, the cellular and molecular mechanisms of AR involve B cell production of IgE 
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maintained by a positive feedback.  
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whose etiology can be clearly defined in a few subgroups of patients, involving mechanical 
obstruction, immunodeficiency, cystic fibrosis, and ciliary dyskinesia. However, in the 
majority of cases, the etiology of CRS cannot be determined. Some investigators have raised 
different hypotheses for the pathogenesis of CRS such as disruption of the epithelial barrier, 
allergy, exposure to pollutants, maintenance of mucosal inflammation due to underlying 
osteitis, persistence of bacterial biofilms, and overreaction to staphylococcal superantigens or 
fungus. It is interesting to note that individually these theories do not apply to all patients but 
may explain the pathogenicity in some cases. Despite the unrevealed etiopathogenesis, recent 
advances have been made in the elucidation of the cellular and molecular events involved in 
different situations of CRS. Based on molecular phenotyping studies, the classification of CRS 
into two different clinical subsets has been currently accepted: CRS without nasal polyps (CRS 
sine NP, CRSsNP) and CRS with nasal polyps (CRSwNP) [8, 26]. Clinically, the symptoms of 
both types are very similar to each other, with slight differences in the severity of nasal 
congestion, nasal obstruction, rhinorrhea, postnasal drip, change in the sense of smell, cough, 
and facial pain. In terms of physical examination, they differ by the presence or absence of 
nasal polyps extruding from the middle meatus of the nasal cavity. This simple difference 
noted by nasal endoscopy involves profound differences in cellular and molecular aspects that 
might be related to the prognosis and treatment of these two subsets of CRS. 
Histologically, both forms of CRS are marked by niches of denuded respiratory epithelium 
with associated metaplasia, basal membrane thickening, and goblet cell hyperplasia. The 
histology of submucosal stroma demonstrates clear differences between CRSwNP and 
CRSsNP. In CRSwNP, the submucosal stroma usually is found with robust edema and low 
cellularity, in contrast to CRSsNP that characteristically involves more pronounced fibrosis 
and less edema [9]. 
In CRSwNP, eosinophilic infiltration is the hallmark of chronic inflammation. For reasons 
not fully elucidated, there is an increased expression of pro-inflammatory cytokines (IL-1β) 
mediated by transcription factors. These cytokines mediate the recruitment of inflammatory 
cells (eosinophils, lymphocytes, neutrophils, mast cells) through the up-regulation and 
expression of adhesion molecules (ICAM-1, VCAM-1) and chemokines (IL-8, eotaxin, and 
RANTES). In CRSwNP, the striking influx of inflammatory cells, especially eosinophils, into 
the stroma, leads to a positive feedback recruitment similar to allergic rhinitis [27]. In the 
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Caucasian CRS population, nasal polyps are remarkably characterized by a mixed 
expression of Th1 (INF-γ, IL-8) and Th2 cytokines, with an imbalance favoring the Th2 
response. Th2 cytokines (IL-3, IL-5, GM-CSF) are produced by eosinophils and Th2 cells and 
increase eosinophil recruitment and survival, creating an autonomous inflammatory cycle 
even after the removal of the initial trigger. (Figure 2) 
 
Figure legend: NF-κB: nuclear factor- κB; STAT: signal transducers and activators of tranascription; NFAT: nuclear 
factor of activated T-cells; AP: activator protein; IL: interleukin; FGF: fibroblast growth factor; TGF: transforming 
growth factor; Treg: regulatory T cell;  GM-CSF: granulocyte-macrophage colony-stimulating factor; ECP: eosinophil 
cationic protein; LT: leukotriene; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of metalloproteinase; 
RANTES: regulated on activation, normal T cell expressed and secreted; ICAM: intercellular adhesion molecule; 
VCAM: vascular cell adhesion molecule; Th: T helper cell 
Figure 2. Cellular and molecular events involved in the pathogenesis of CRSwNP. 
Despite the similarities to allergic rhinitis and contrary to some speculations raised in the 
first studies, the eosinophilic infiltration and activation found in CRSwNP is not dependent 
on allergic mechanisms mediated by IgE [28, 29]. In the Chinese population, however, 
CRSwNP has been characterized by a different Th pattern of inflammation. A mixed 
Th1/Th17 has been found instead of the Th1/Th2 pattern, with a significantly lower GATA-3 
(Th2 specific) expression and higher IL-17 levels in the polyp tissue. The Th17 response 
drives a more neutrophilic infiltration rather than an eosinophilic recruitment [30]. 
Another important feature of CRSwNP is the impaired regulatory modulation promoted by 
Treg cells, which balances the T helper cell response. Low levels of Treg cell biomarkers 
(transforming growth factor-β1 -TGF-β1- and forkhead box protein P3 -FOXP3) together 
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with high expression of T-bet (Th1) and GATA-3 (Th2) demonstrate the deficiency of Treg 
control in CRSwNP patients [31].  
In terms of molecular markers, among Caucasians, IL-5 is the most important cytokine 
found in CRSwNP. IL-5 is related to eosinophil infiltration and activation, and is 
significantly related to recurrence of nasal polyps after surgical removal [32]. Activated 
eosinophils also release several inflammatory mediators, such as leukotrienes, and other 
toxic products (Eosinophil Cationic Protein – ECP, Major Basic Protein – MBP, neurotoxin 
eosinophil protein). Besides the damage induced by infiltrated inflammatory cells, resident 
fibroblasts also play a role in the structural modification of the stroma. Stimulated by 
fibroblast growth factor (FGF) and TGF-β, fibroblasts are recruited, proliferate, and express 
matrix metalloproteinases (MMP), which degrade extracellular proteins (collagen, laminin, 
fibronectin, elastin) and favor tissue edema and albumin deposition. Other cells such as 
eosinophils and neutrophils are also able to produce MMP and may play a role in tissue 
remodeling [33]. Furthermore, fibroblasts suppress the expression of tissue inhibitors of 
metalloproteinases (TIMP) which increase the activity of MMP. Taken together, these 
features explain the main histopathological and molecular findings in CRSwNP, i.e., 
eosinophilic infiltration, tissue edema, and Th2 skewing polarization. 
On the other hand, CRSsNP present some different features compared to CRSwNP. 
Although mixed inflammatory cells are found in CRSsNP, neutrophils are the predominant 
cells in this subset of CRS and,  together with Th1 cells. seem to play the main cellular role in 
the pathogenesis of the disease. Neutrophil markers of activation such as myeloperoxidase 
and IL-8 are found in high levels in CRSsNP compared to controls and CRSwNP. Besides, 
the levels of Th1 cytokines (INF-γ, IL-8) found in CRSsNP are unbalanced with Th2 
cytokines, revealing Th1 polarization. In contrast to CRSwNP, FOXP3 and TGF-β are not 
decreased in CRSsNP, demonstrating that Treg function is not altered in CRSsNP [31]. The 
up-regulated TGF- β signaling pathways are believed to be an important marker that reflects 
the fibrosis/albumin deposition remarkably seen in CRSsNP. (Figure 3) 
In conclusion, in contrast to CRSwNP, the cellular and molecular findings in CRSsNP are 
characterized by neutrophilic infiltration, tissue fibrosis, and Th1 skewing polarization. 
3. Glucocorticoid action on nasal mucosa 
Glucocorticoid (GC) has a broad anti-inflammatory effect, regulating both innate and 
adaptive immune responses in a wide variety of cells, such as epithelial cells, fibroblasts, 
eosinophils and T cells [1, 12, 34]. This is the main reason why GC is considered to be the 
medication of choice to treat chronic rhinitis [2] and rhinosinusitis [8].  
This wide anti-inflammatory effect of GC is explained by several events induced by it, from 
the signaling event to post-translational mechanisms. Basically, GC is a lipophilic compound 
which diffuses though the membrane and binds to its cytoplasmic receptor, called 
glucocorticoid receptor  (GR) [35]. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 528 
Caucasian CRS population, nasal polyps are remarkably characterized by a mixed 
expression of Th1 (INF-γ, IL-8) and Th2 cytokines, with an imbalance favoring the Th2 
response. Th2 cytokines (IL-3, IL-5, GM-CSF) are produced by eosinophils and Th2 cells and 
increase eosinophil recruitment and survival, creating an autonomous inflammatory cycle 
even after the removal of the initial trigger. (Figure 2) 
 
Figure legend: NF-κB: nuclear factor- κB; STAT: signal transducers and activators of tranascription; NFAT: nuclear 
factor of activated T-cells; AP: activator protein; IL: interleukin; FGF: fibroblast growth factor; TGF: transforming 
growth factor; Treg: regulatory T cell;  GM-CSF: granulocyte-macrophage colony-stimulating factor; ECP: eosinophil 
cationic protein; LT: leukotriene; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of metalloproteinase; 
RANTES: regulated on activation, normal T cell expressed and secreted; ICAM: intercellular adhesion molecule; 
VCAM: vascular cell adhesion molecule; Th: T helper cell 
Figure 2. Cellular and molecular events involved in the pathogenesis of CRSwNP. 
Despite the similarities to allergic rhinitis and contrary to some speculations raised in the 
first studies, the eosinophilic infiltration and activation found in CRSwNP is not dependent 
on allergic mechanisms mediated by IgE [28, 29]. In the Chinese population, however, 
CRSwNP has been characterized by a different Th pattern of inflammation. A mixed 
Th1/Th17 has been found instead of the Th1/Th2 pattern, with a significantly lower GATA-3 
(Th2 specific) expression and higher IL-17 levels in the polyp tissue. The Th17 response 
drives a more neutrophilic infiltration rather than an eosinophilic recruitment [30]. 
Another important feature of CRSwNP is the impaired regulatory modulation promoted by 
Treg cells, which balances the T helper cell response. Low levels of Treg cell biomarkers 
(transforming growth factor-β1 -TGF-β1- and forkhead box protein P3 -FOXP3) together 
 
Glucocorticoid Resistance in the Upper Respiratory Airways 529 
with high expression of T-bet (Th1) and GATA-3 (Th2) demonstrate the deficiency of Treg 
control in CRSwNP patients [31].  
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eosinophil protein). Besides the damage induced by infiltrated inflammatory cells, resident 
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fibronectin, elastin) and favor tissue edema and albumin deposition. Other cells such as 
eosinophils and neutrophils are also able to produce MMP and may play a role in tissue 
remodeling [33]. Furthermore, fibroblasts suppress the expression of tissue inhibitors of 
metalloproteinases (TIMP) which increase the activity of MMP. Taken together, these 
features explain the main histopathological and molecular findings in CRSwNP, i.e., 
eosinophilic infiltration, tissue edema, and Th2 skewing polarization. 
On the other hand, CRSsNP present some different features compared to CRSwNP. 
Although mixed inflammatory cells are found in CRSsNP, neutrophils are the predominant 
cells in this subset of CRS and,  together with Th1 cells. seem to play the main cellular role in 
the pathogenesis of the disease. Neutrophil markers of activation such as myeloperoxidase 
and IL-8 are found in high levels in CRSsNP compared to controls and CRSwNP. Besides, 
the levels of Th1 cytokines (INF-γ, IL-8) found in CRSsNP are unbalanced with Th2 
cytokines, revealing Th1 polarization. In contrast to CRSwNP, FOXP3 and TGF-β are not 
decreased in CRSsNP, demonstrating that Treg function is not altered in CRSsNP [31]. The 
up-regulated TGF- β signaling pathways are believed to be an important marker that reflects 
the fibrosis/albumin deposition remarkably seen in CRSsNP. (Figure 3) 
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Glucocorticoid (GC) has a broad anti-inflammatory effect, regulating both innate and 
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Figure legend: Treg: regulatory T cell; IL: interleukin; INF: interferon; TNF: tumor necrosis factor; Th: T helper cell; 
TGF: transforming growth factor; TIMP: tissue inhibitor of metalloproteinase; MMP: metalloproteinase 
Figure 3. Cellular and molecular events involved in the pathogenesis of CRSsNP. 
GR belongs to a large superfamily of steroid receptors. When inactivated, this receptor stays 
in the cytosol bound to heat shock proteins (hsp) [36]. When GC binds to GR, 
phosphorylation occurs to this receptor, which dissociates GR from hsp. The dimer GC-GR 
is able to translocate into the nucleus and then act as a transcription factor. In this respect, 
the GC-GR dimer can bind directly to a specific palindromic DNA consensus sequence, 
called glucocorticoid response elements (GREs), and consequently induces or inhibits (in 
case of nGREs) the transcription of several genes [35]. Nevertheless, it is recognized that the 
main anti-inflammatory action of GC at the transcriptional level is mediated by a direct 
interaction of GC-GR with other transcription factors (TF), inhibiting their action. This 
inhibition, called “DNA-independent transrepression” affects several pro-inflammatory TF, 
the most important ones being activator protein-1 (AP-1) and nuclear fator-κB (NF-κB) [1, 
35-39] (Figure 4). This connection inhibits gene transcription by direct binding to DNA or by 
inducing histone deacetylation. Although the non-genomic effect of GC is widely known in 
the literature [2, 17], there is no report on its effect on chronic upper respiratory diseases, 
and only few studies have reported controversial results regarding asthma [40, 41]. 
The final effect of GC on nasal diseases is the inhibition of pro-inflammatory cytokines (IL-
1β, TNF-α, GM-CSF, IL-3, IL-5, IL-6), chemokines (IL-8, RANTES, eotaxin) and adhesion 
molecules (VCAM-1, ICAM-1) [1, 13, 42]. Glucocorticoids also have a favorable effect on 
tissue remodeling (reducing MMP expression) [43, 44], reduce mucin production [45], 
increase cell apoptosis [46, 47], and decrease mast cell recruitment and activation [48]. 
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Finally, glucocorticoids inhibit the expression of some cytokine receptors, among them IL-2 
and IL-4 receptors. 
Due to its holistic action, GC is considered to be the best medication for the treatment of 
chronic inflammatory diseases of the upper respiratory airways. 
 
Figure 4. GC mode of action: binding to its cytoplasmic GR, and then translocating into the nucleus. 
GC: glucocorticoid; GR: glucocorticoid receptor; hsp: heat shock protein; GRE: glucocorticoid response 
element; NF-κB: nuclear factor κB; AP-1: activator protein-1 
4. GR splicing 
The GR gene is located in chromosome 5 and is composed of 9 exons. Alternative splicing in 
the ninth exon (hormone-binding domain) gives raise to several alternative GRs, GRα and 
GRβ being the most common [35-39]. 
GRα is the predominant GR isoform. It is transcriptionally active and, when ligated to GC, it 
can translocate into the nucleus, induce expression by binding to GRE, or repress expression 
by either binding to nGRE or by interacting with AP-1 and NF-κB [1, 35, 36]. 
For instance, GRβ is expressed at much lower rates than GRα. It cannot bind to GC, and 
although it can bind to GRE, nGRE, AP-1 and NF-κB, it does not activate their 
transcriptional action. Some authors have shown that, when overexpressed, GRβ inhibits the 
effect of GRα on both transactivation and on AP-1 and NF-κB repression [49-51]. GRβ is 
thus considered to be the dominant negative of GRα; instead, a recent study has shown that 
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Glucocorticoids – New Recognition of Our Familiar Friend 532 
a glucocorticoid antagonist, named RU-486, has the ability to bind to GRβ, regulating gene 
expression even in the absence of GRα [52]. 
There is no previous study regarding the influence of GRγ on nasal mucosa. 
5. Resistance to GC 
Although GC is the medication of choice in chronic upper respiratory diseases in general, 
the rate of CG therapy failure in CRSwNP is reported to be between 60 and 80% [8]. 
Although there is no report on GC resistance in chronic rhinitis, resistance is believed to be 
identical to that occurring in CRSwNP. The main reasons for GC failure are: limited action 
of topical GC in extensive diseases [53], poor compliance with treatment [54] , and 
cellular/molecular resistance to GC [36, 55]. Among cellular and molecular mechanisms of 
GC resistance, the main lines investigated are GRα- GRβ interaction and TF influence. 
One of the most studied mechanisms is the GRα-GRβ imbalance. Although GRβ is able to 
interact directly with GRα within the nucleus, it has a low capacity to bind to GC. This is 
why GRβ is considered to be an endogenous inhibitor of GRα [36, 56]. GRα-GRβ imbalance 
has been reported to increase cell resistance in chronic immune-mediated diseases, among 
those affecting the upper [37, 57] and lower airways [58, 59]. 
Increased expression of GRβ has been widely reported in the literature on inflammatory 
respiratory diseases such as CRSwNP and asthma, when compared to control mucosa [36, 
55, 60, 61]. This has led to the hypothesis that increased GRβ expression could impair the 
action of GC. Decreased expression of GRα has also been recently reported in CRswNP with 
the use of a more reliable quantitative method of analysis [56, 62, 63]. More important than 
the expression of each individual isoform, GRα-GRβ imbalance might be the most relevant 
determinant of GC resistance. It is important to mention that some studies have 
demonstrated that CG therapy in CRSwNP does not change GR isoform expression or the 
GRα-GRβ relation [56, 63, 64]. 
Higher expression of TF could also lead to GC resistance, because TF (mainly AP-1 and NF-
κB) repress the binding of the translocated GC-GR complex to GRE. This mechanism of GC 
resistance has been reported in several inflammatory diseases, such as inflammatory bowel 
diseases. Nevertheless, this mechanism has been poorly reported in respiratory diseases. 
AP-1 is a dimer predominantly consisting of c-Fos/c-Jun heterodimers. As is the case for 
most TF, they are located in the cytoplasm and, when activated, translocate into the nucleus 
and induce the expression of several pro-inflammatory genes which regulate cell 
inflammation, proliferation, differentiation and apoptosis [65]. Conflicting results have been 
reported regarding the presence of AP-1 in CRSwNP. c-Fos expression has been studied in 
two reports because it is more important regarding the transcriptional action. One study [66] 
has reported an increased presence of c-Fos in patients with CRSwNP than in control 
mucosa using qualitative PCR, while the other [56] has observed a similar expression in the 
two groups using quantitative RT-PCR. The latter study also did not observe any influence 
of c-Fos expression on the outcome of GC treatment. 
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NF-κB is also a heterodimer, mainly consisting of p50 and p65 isoforms. When activated, 
NF-κB translocates into the nucleus, and p65 directly binds to DNA, inducing gene 
expression of pro-inflammatory and anti-apoptotic genes [37, 65]. NF-κB is considered 
pivotal to the regulation of immune and inflammatory genes, and its absence is 
incompatible with life. It is important to mention that the most important pro-inflammatory 
cytokines (IL-1β and TNF-α), whose expression is considerably influenced by NF-κB, also 
activate NF-κB translocation, inducing perpetuation of the inflammatory process. 
Two studies have reported increased expression of both isoforms (p50 and p65) of NF-κB in 
patients with CRSwNP when compared to control nasal mucosa [56, 67]. Also, a high 
expression of p65 was related to a poor clinical outcome in response to medical treatment in 
CRSwNP patients [56]. This finding suggests that NF-κB may also have a pivotal effect on 
GC resistance. 
6. Conclusions 
Chronic inflammatory nasal diseases are highly prevalent in the population, and therefore 
nasal TGC has been widely prescribed by physicians. Considering that a high percentage of 
these patients only partially benefit from TGC, or do not respond to TCG treatment at all, 
the understanding of possible mechanisms of GC resistance is essential for future 
treatments. 
Today, it has been accepted that cellular and molecular mechanisms of resistance do exist 
in nasal mucosa. Future investigations are still required to recognize affected individuals 
and how this would influence medical treatment. This will be essential to develop new 
drugs that would replace or act synergistically with CG, in order to improve the clinical 
outcome. 
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1. Introduction 
Corticosteroids are group of hormones with similar chemical formulas which are secreted 
by adrenal cortex. The very slight differences in molecular structure of various 
corticosteroids give them very different functions. The hormonal steroids are classified 
according to their biologic effects as glucocorticoids, which mainly affect intermediary 
metabolism and the immune system, and mineralocorticoids , which have principally a salt-
retaining activity. Of large number of steroids released into the circulation by adrenal cortex, 
two are of greater importance – aldosterone, which is a mineralocorticoid, and cortisol, 
which is a glucocorticoid. 
Mineralocorticoids promote sodium and water retention, and potassium loss by kidney, but 
have no anti-inflammatory or anti-allergic effect. 
Cortisol, also known as hydrocortisone, is the major glucocorticoid in humans. It is 
synthesized by the cells of the zona fasciculata and zona reticularis of adrenal cortex; its 
secretion is regulated by the adrenocorticotropic hormone (ACTH) from anterior pituitary 
gland. Cortisol has a wide range of physiologic actions such as influencing carbohydrate, 
protein, and fat metabolism; regulation of blood pressure and cardiovascular function; and 
affecting immune system. 
Corticosteroid drugs are the synthetic analogs of cortisol hormone. They bind to specific 
intracellular receptors upon entering target tissues, and mimic the effects of the naturally 
occurring hormones; the main differences are the relative glucocorticoid versus 
mineralocorticoid potency and the long half-life that the synthetic analogs have. The 
relative potencies and duration of action of representative corticosteroids are presented in 
Table 1. 
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Compound Glucocorticoid potency 
Mineralocorticoid 
potency Duration of action 
Cortisol 1 1 short 
Cortisone 0.8 0.8 short 
Fludrocortisone 10 125 Intermediate 
Prednisone 4 0.8 Intermediate 
Prednisolone 4 0.8 Intermediate 
Methylprednisolone 5 0.5 Intermediate 
Triamcinolone 5 0 Intermediate 
Betamethasone 25 0 Long 
Dexamethasone 25 0 Long 
Short: 8-12 hours biologic half-life; Intermediate: 12-36 hours biologic half-life; Long: 36-72 hours biologic half-life. 
Adapted and modified from [1]  
Table 1. Relative potencies and equivalent doses of representative corticosteroids 
Glucocorticoids are used, either singly or in combination with other drugs, in the treatment 
of a wide variety of medical disorders. Some therapeutic indications for these drugs are as 
follows: 
 Musculoskeletal and connective tissue diseases (rheumatoid arthritis, polymyositis, 
systemic lupus erythematosus, and vasculitis) 
 Respiratory diseases (sarcoidosis and chronic bronchitis) 
 Gastrointestinal diseases (ulcerative colitis and crohn's disease) 
 Allergic disorders (asthma, hay fever, and allergic rhinitis) 
 Skin conditions (pemphigus, eczema, and dermatitis) 
 Eye diseases (conjunctivitis, uveitis, and optic neuritis) 
 Oral and maxillofacial diseases (lichen planus, keloid formation, and Bell's palsy) 
Although corticosteroids are widely used for treatment of diseases and conditions affecting 
oral and maxillofacial region, the scientific literature on this topic is limited and scattered 
throughout numerous journals and books. By gathering this scattered information, this 
chapter presents a concise review of various uses of corticosteroid drugs in the treatment of 
diseases affecting oral and maxillofacial region, and the role they have in reducing post-
operative morbidities such as pain, edema and trismus after various maxillofacial surgical 
procedures. The relation between maternal corticosteroid use and congenital maxillofacial 
deformities are explained. Also discussed is the perioperative management of patients 
receiving long-term therapeutic doses of corticosteroids. 
2. Uses of corticosteroids in the treatment of oral and maxillofacial 
diseases 
Corticosteroids are widely used in the treatment of diseases, disorders and conditions 
affecting the oral and maxillofacial area and the adjacent and associated structures. The 
diseases of the oral and maxillofacial region may be either local or the manifestation of a 
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systemic problem. Corticosteroids have their widest application in the management of acute 
and chronic conditions which have an allergic, immunologic, or inflammatory basis. 
Therefore, a group of corticosteroids which have predominantly a glucocorticoid activity 
and little or no mineralocorticoid action such as betamethasone, dexamethasone, 
triamcinolone, and prednisolone are used. 
The following are the main therapeutic indications for glucocorticoids in oral and 
maxillofacial diseases. 
2.1. Temporomandibular disorders (TMDs) 
TMDs are clinical problems involving the temporomandibular joints (TMJs), the masticatory 
muscles, or both. TMDs affect a significant number of individuals, and are the most common 
musculoskeletal disorders that cause orofacial pain. [2] Trauma to the joint structures, 
especially microtrauma, accounts for the majority of patients who develop TMJ problems. 
However, a small number of joint diseases are caused by nontraumatic etiologic factors 
including benign and malignant neoplasms (osteoma, chondroma, and synovial sarcoma), 
congenital or developmental anomalies (condylar agenesis and heperplasia), arthritides 
(rheumatoid arthritis), and systemic diseases. The most common signs and symptoms of 
TMDs are pain, altered mandibular movements, and the elicitation of joint noise.  
Treatment of TMDs varies according to their etiologic basis. Conservative managements 
(splint therapy, thermal application, pharmacotherapy, and physiotherapy), surgical 
treatments, or a combination of them may be required. A variety of medications have been 
used to relieve pain, inflammation, muscle spasm and other signs and symptoms associated 
with TMDs. They include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, 
analgesics, and muscle relaxants. 
Various glucocorticoids are used in the treatment of TMDs (Table 2). These drugs have 
dramatic effects on pain, hypomobility, and inflammation associated with acute TMJ 
problems. Oral corticosteroids are used mainly for treatment of acute TMJ discomforts or for 
diagnostic purposes. They should be used in a short term basis (tapering dose lasting 5 to 7 
days), and repeated as infrequently as possible. Long term use of corticosteroids for the 
treatment of TMDs is contraindicated; it can result in a cushing's- like disease process, acute 
adrenal crisis, hypertension, electrolyte abnormalities, diabetes, and formation of 
osteoporosis including the TMJ. [2] 
 
Drug Alternative name Usual dose
Hydrocortisone Hydrocortone 20-240 mg/day 
Prednisone Deltasone, Orasone 5-60 mg/day 
Prednisolone Delta-Cortef 5-60 mg/day 
Dexamethasone Decadron 0.75-9.0 mg/day 
Betamethasone Celestone 0.6-7.2 mg/day 
Adapted and modified from [2] 
Table 2. Oral corticosteroids used in TMDs 
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Intracapsular injection of glucocortcoids has been reported to decrease pain in patients with 
both pain and limited mouth opening secondary to inflammatory disorders of the joint, such 
as arthritis and capsulitis. [3-5] 
A number of mechanisms have been described for the anti-inflammatory actions of 
glucocorticoids. These drugs inhibit inflammatory mediator release from many cell types 
involved in inflammation such as macrophages, T-lymphocytes, mast cells, dendritic cells, 
and neutrophilic leukocytes. Glucocorticoids also reduce prostaglandin production by 
blocking the phospholipase A2 enzyme.  
The most striking effect of glucocorticoids is to inhibit the expression of multiple 
inflammatory genes encoding cytokines, chemokines, inflammatory enzymes, receptors and 
adhesion molecules. [6] Changes in gene transcription are regulated by proinflammatory 
transcription factors, such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1). These 
proinflammatory transcription factors switch on inflammatory genes via a process involving 
recruitment of transcriptional coactivator proteins and changes in chromatin modifications 
such as histone acetylation. Glucocorticoids exert their anti-inflammatory effect on 
responsive cells by binding and activating a cytoplasmic glucocorticoid receptor. The 
interaction between the activated glucocorticoid receptor and proinflammatory transcription 
factors may result in deacetylation of histones and repression of inflammatory genes. [7]  
In chronic inflammatory disorders of TMJ, macrophages, T-lymphocytes, and other cell 
types involved in inflammation release many cytokines and chemokines which will induce 
expression of adhesion molecules, release of variable enzymes from fibroblasts and 
osteoclasts and result in bone erosion. IL-8, which is a chemokine, is known to cause the 
infiltration of neutrophils into synovial fluid and promote joint inflammation. It was 
detected in 80% of the synovial tissue specimens taken from the TMJs with internal 
derangement. Similarly, IL-11 has been involved in the pathogenesis of osteoarthritis and 
rheumatoid arthritis. It has been found in synovial fluids of diseased temporomandibular 
joint and other joints. [8]  
Cytokines participate in various inflammatory processes and induce protease synthesis; 
their effects can be either synergic or inhibitory. In synovial joints, IL-1 α, IL-1 β and TNF-α 
induce synovitis and promote the production of proteinases resulting in degradation of 
cartilage, while IL-1ra works to block IL-1α and IL-1 β from binding to other cell receptors 
and has many beneficial effects on inflammatory diseases. [9] In a study by Nordahl et al. it 
was found that the local production of tumor necrosis factor-alpha (TNF-α) occured in the 
TMJ synovium of patients with chronic inflammatory connective tissue disease, and the 
severity of pain and tenderness of the TMJ was related to the level of TNF-α. [10] In a study 
by Frediksson et al., it was shown that the presence of TNF-α in the synovial fluid of TMJ 
predicted a positive treatment response to intra-articular glucocorticoid injection in patients 
with chronic TMJ inflammatory disorders. [11]  
Long-term complications associated with intra-articular glucocorticoid injection cannot be 
determined from the limited investigations done to date and thus remained unclear. 
Wenneberg et al. in a study evaluating the long-term prognosis of intra-articular 
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glucocorticoid injections for TMJ arthritis observed that this treatment modality was helpful, 
and there were no radiographically demonstrable side effects of the treatment. [12] In 
contrast, Haddad IK showed that intra-articular injections of corticosteroids (triamcinolone 
acetonide) cause damage to fibrous layer, cartilage, and bone of TMJ. [13] 
Juvenile idiopathic arthritis (JIA) is a chronic rheumatologic disease of children which may 
involve TMJ region, and cause significant craniofacial growth disturbances. The treatment of 
TMJ arthritis is controversial. It has been shown that glucocorticoid injection of the TMJ 
reduces pain and inflammation, and improves the function of TMJ in children with JIA. [14] 
Other studies also confirmed that corticosteroid injection of the TMJ can be safely performed 
in children with JIA, and is effective. [15-18] Few studies have evaluated TMJ corticosteroid 
injection in JIA. In these studies the volume of corticosteroid injected was chosen 
empirically. Treatment protocols such as injection of 1 cc (40 mg) of triamcinolone acetonide, 
1 cc (20 mg) of triamcinolone hexacetonidein, and 0.5 to 1 cc of the diluted (with 1% 
lidocaine HCL) triamcinolone hexacetonidein into each of the involved TMJs, all have been 
used in previous studies. [14-16] The peak effect occurs after approximately 6 weeks of 
treatment, and the expected duration is 6-17 months. The children may receive a second 
injection approximately 6 months after the first. [16] 
Side effects of intra-articular steroid injection in children include immediate reactions, such 
as pain and headache, or delayed side effects, such as joint infection and loss of 
subcutaneous fat. [16] Because the mandibular endochondral growth zone is located at the 
head of condyle (at the site of corticosteroid injection), the concern is whether intra-articular 
corticosteroid injection per se may cause growth retardation.  Stoustrup et al., in an animal 
study demonstrated that intra-articular glucocorticoid injection may result in even more 
pronounced mandibular growth reduction than that caused by the arthritis alone. [19] 
Schindler et al. reported a case of severe temporomandibular dysfunction and joint 
destruction after intra-articular injection of triamcinolone, and El-Hakim et al. showed TMJ 
resorption with active osteoclastic activity after intra-articular injection of a single dose of 
dexamethasone in rats. [20,21] 
intra-articular corticosteroid injection has been used to improve mouth opening in patients 
with anterior disk displacement without reduction (ADDWOR), i.e., closed lock. [22] 
2.2. Oral ulcerative and vesiculobullous lesions 
Corticosteroids are successfully used for the treatment of several ulcerative and 
vesiculobullous lesions involving the oral cavity and perioral areas including recurrent 
aphthous stomatitis (RAS), Behcet's syndrome, pemphigus vulgaris, bullous pemphigoid, 
mucous membrane pemphigoid, erythema multiforme and Stevens-Johnson syndrome 
(Tables 3-5). [23] 
Recurrent aphthous stomatitis: These superficial painful ulcers occur commonly in the oral 
cavity. Minor form of the disease has 1 to 5 ulcers at one episode. The ulcers which are 
under 1 cm in diameter persist 8 to 14 days, and heal spontaneously without sequelae. The 
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Intracapsular injection of glucocortcoids has been reported to decrease pain in patients with 
both pain and limited mouth opening secondary to inflammatory disorders of the joint, such 
as arthritis and capsulitis. [3-5] 
A number of mechanisms have been described for the anti-inflammatory actions of 
glucocorticoids. These drugs inhibit inflammatory mediator release from many cell types 
involved in inflammation such as macrophages, T-lymphocytes, mast cells, dendritic cells, 
and neutrophilic leukocytes. Glucocorticoids also reduce prostaglandin production by 
blocking the phospholipase A2 enzyme.  
The most striking effect of glucocorticoids is to inhibit the expression of multiple 
inflammatory genes encoding cytokines, chemokines, inflammatory enzymes, receptors and 
adhesion molecules. [6] Changes in gene transcription are regulated by proinflammatory 
transcription factors, such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1). These 
proinflammatory transcription factors switch on inflammatory genes via a process involving 
recruitment of transcriptional coactivator proteins and changes in chromatin modifications 
such as histone acetylation. Glucocorticoids exert their anti-inflammatory effect on 
responsive cells by binding and activating a cytoplasmic glucocorticoid receptor. The 
interaction between the activated glucocorticoid receptor and proinflammatory transcription 
factors may result in deacetylation of histones and repression of inflammatory genes. [7]  
In chronic inflammatory disorders of TMJ, macrophages, T-lymphocytes, and other cell 
types involved in inflammation release many cytokines and chemokines which will induce 
expression of adhesion molecules, release of variable enzymes from fibroblasts and 
osteoclasts and result in bone erosion. IL-8, which is a chemokine, is known to cause the 
infiltration of neutrophils into synovial fluid and promote joint inflammation. It was 
detected in 80% of the synovial tissue specimens taken from the TMJs with internal 
derangement. Similarly, IL-11 has been involved in the pathogenesis of osteoarthritis and 
rheumatoid arthritis. It has been found in synovial fluids of diseased temporomandibular 
joint and other joints. [8]  
Cytokines participate in various inflammatory processes and induce protease synthesis; 
their effects can be either synergic or inhibitory. In synovial joints, IL-1 α, IL-1 β and TNF-α 
induce synovitis and promote the production of proteinases resulting in degradation of 
cartilage, while IL-1ra works to block IL-1α and IL-1 β from binding to other cell receptors 
and has many beneficial effects on inflammatory diseases. [9] In a study by Nordahl et al. it 
was found that the local production of tumor necrosis factor-alpha (TNF-α) occured in the 
TMJ synovium of patients with chronic inflammatory connective tissue disease, and the 
severity of pain and tenderness of the TMJ was related to the level of TNF-α. [10] In a study 
by Frediksson et al., it was shown that the presence of TNF-α in the synovial fluid of TMJ 
predicted a positive treatment response to intra-articular glucocorticoid injection in patients 
with chronic TMJ inflammatory disorders. [11]  
Long-term complications associated with intra-articular glucocorticoid injection cannot be 
determined from the limited investigations done to date and thus remained unclear. 
Wenneberg et al. in a study evaluating the long-term prognosis of intra-articular 
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glucocorticoid injections for TMJ arthritis observed that this treatment modality was helpful, 
and there were no radiographically demonstrable side effects of the treatment. [12] In 
contrast, Haddad IK showed that intra-articular injections of corticosteroids (triamcinolone 
acetonide) cause damage to fibrous layer, cartilage, and bone of TMJ. [13] 
Juvenile idiopathic arthritis (JIA) is a chronic rheumatologic disease of children which may 
involve TMJ region, and cause significant craniofacial growth disturbances. The treatment of 
TMJ arthritis is controversial. It has been shown that glucocorticoid injection of the TMJ 
reduces pain and inflammation, and improves the function of TMJ in children with JIA. [14] 
Other studies also confirmed that corticosteroid injection of the TMJ can be safely performed 
in children with JIA, and is effective. [15-18] Few studies have evaluated TMJ corticosteroid 
injection in JIA. In these studies the volume of corticosteroid injected was chosen 
empirically. Treatment protocols such as injection of 1 cc (40 mg) of triamcinolone acetonide, 
1 cc (20 mg) of triamcinolone hexacetonidein, and 0.5 to 1 cc of the diluted (with 1% 
lidocaine HCL) triamcinolone hexacetonidein into each of the involved TMJs, all have been 
used in previous studies. [14-16] The peak effect occurs after approximately 6 weeks of 
treatment, and the expected duration is 6-17 months. The children may receive a second 
injection approximately 6 months after the first. [16] 
Side effects of intra-articular steroid injection in children include immediate reactions, such 
as pain and headache, or delayed side effects, such as joint infection and loss of 
subcutaneous fat. [16] Because the mandibular endochondral growth zone is located at the 
head of condyle (at the site of corticosteroid injection), the concern is whether intra-articular 
corticosteroid injection per se may cause growth retardation.  Stoustrup et al., in an animal 
study demonstrated that intra-articular glucocorticoid injection may result in even more 
pronounced mandibular growth reduction than that caused by the arthritis alone. [19] 
Schindler et al. reported a case of severe temporomandibular dysfunction and joint 
destruction after intra-articular injection of triamcinolone, and El-Hakim et al. showed TMJ 
resorption with active osteoclastic activity after intra-articular injection of a single dose of 
dexamethasone in rats. [20,21] 
intra-articular corticosteroid injection has been used to improve mouth opening in patients 
with anterior disk displacement without reduction (ADDWOR), i.e., closed lock. [22] 
2.2. Oral ulcerative and vesiculobullous lesions 
Corticosteroids are successfully used for the treatment of several ulcerative and 
vesiculobullous lesions involving the oral cavity and perioral areas including recurrent 
aphthous stomatitis (RAS), Behcet's syndrome, pemphigus vulgaris, bullous pemphigoid, 
mucous membrane pemphigoid, erythema multiforme and Stevens-Johnson syndrome 
(Tables 3-5). [23] 
Recurrent aphthous stomatitis: These superficial painful ulcers occur commonly in the oral 
cavity. Minor form of the disease has 1 to 5 ulcers at one episode. The ulcers which are 
under 1 cm in diameter persist 8 to 14 days, and heal spontaneously without sequelae. The 
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major aphthous ulcers are larger than 1 cm, and persist for weeks to months. Corticosteroids 
either alone or in combination with other drugs have been used for treatment of these 
lesions. [24-28] Topical steroids, such as triamcinolone acetonide and prednisolone (2 
times/day), are formulated as oral pastes. Therapeutic benefit can be derived from a 
mouthwash containing betamethasone. It should be noted that the long-term use of topical 
steroids may predispose patient to developing oral candidiasis. [28] 
Topical and injectable (intralesional) corticosteroids are useful for large and painful lesions. 
Systemic administration of corticosteroids is reserved for severe cases to prevent lesion 
formation or to reduce the number of lesions. Systemic corticosteroids should be prescribed 
in short courses, and only for severe outbreaks or cases that don't respond to topical or 
injectable corticosteroids. [23] 
Behcet's syndrome: The treatment of oral lesions of Behcet's syndrome is similar to the 
treatment of severe or major RAS. [23] 
Pemphigus vulgaris: Pemphigus vulgaris is a severe, potentially life-threatening 
vesiculobullous disease that may affect skin and mucous membranes. Oral cavity is 
involved in nearly 80% of patients. In the past, corticosteroid therapy was the treatment of 
choice but later, combination therapy involving the use of systemic corticosteroids with 
immunosuppressive agents was introduced, in an attempt to achieve disease control with 
lower doses of steroids. [29-31] 
The principal treatment of pemphigus vulgaris is systemic administration of corticosteroids 
at doses of 1 to 2 mg/kg/day. Maintenance of remission may be achieved with topical 
corticosteroids, allowing reduction of systemic drugs. Isolated lesions can be treated with 
injectable corticosteroids. [23] 
Bullous and mucous membrane pemphigoid: The choice of drugs used for the treatment of 
pemphigoid is based upon the sites of involvement, clinical severity, and disease 
progression. For more severe disease, or with rapid progression, systemic corticosteroids are 
the agents of choice for initial treatment, combined with steroid-sparing agents for long-
term maintenance. [32] Topical and injectable corticosteroids are useful for treatment of mild 
or localized oral lesions. [23] 
Erythema multiforme (EM) and Stevens-Johnson syndrome (SJS): It has been shown that 
corticosteroids have a favorable influence on the outcome of EM and SJS, if 
administered in high doses, over a short period of time, early in the course of the 
disease, and with proper tapering of medication. [33-37] However, the dosing and route 
of administration that provides the most benefit for EMM and SJS patients is in 
question. Treatment protocols such as early therapy with systemic prednisone (0.5 to 
1.0mg/kg/day) or pulse methylprednisolone (1mg/kg/day for 3 days), intravenous 
pulsed dose methylprednisolone (3 consecutive daily infusions of 20–30mg/kg to a 
maximum of 500mg given over 2 to 3 hours), and dexamethasone pulse therapy 
(1.5mg/kg IV over 30 to 60 minutes on 3 consecutive days), all have been shown to be 
effective. [33-35,37-39] 
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Drug Triamcinolone (10 mg/ml)          Dexamethasone (4 mg/ml) 
Indications Severe recurrent aphthous stomatitis,
 major aphthous stomatitis, erosive lichen planus 
Usual dosage Inject 0.1 cc/cm lesion
Contraindications Hypersensitivity to corticosteroids, systemic fungal infection, live vaccines, active tuberculosis
Common side effects Candidiasis, hyperglycemia
Unusual side effects Peptic ulceration with perforation, osteoporosis, impaired wound healing, mucosal atrophy
Adapted and modified from [23]. 
Table 3. Injectable (intralesional) corticosteroids used for treatment of oral lesions 
 
Drug Beclomethasone Betamethasone Clobetasol Halobetasol Fluocinonide 
Indications Severe recurrent aphthous stomatitis, 
Behcet's syndrome, pemphigus vulgaris, pemphigoid 




cream or gel, 











Usual dosage 50-100 µg 
sprayed onto oral
lesion 
0.1% cream or 
0.05% gel 
applied thinly 
bid; 0.5 mg 2-4 
times daily as 
mouth wash
0.05% cream 










Common side effects Oral candidiasis
Unusual side effects Adrenal suppression if doses exceeded
Adapted and modified from [23]. 
Table 4. Topical corticosteroids used for treatment of oral lesions 
 
Drug Prednisone (tablets)
Indications Severe recurrent aphthous stomatitis, Behcet's syndrome, pemphigus 
vulgaris, pemphigoid, erythema multiforme
Usual dosage 1. 30-40 mg daily after breakfast for 4-5 days 
2. 1-2 mg/kg/day after breakfast until disease controlled  
3. 1-2 mg/kg/day, then maintenance of 2.5-15 mg daily  
4. 20-40 mg daily for 7-10 days at onset of lesions or until lesions resolve  
5. 60 mg daily for 2 days, 50 mg daily for 2 days, 40 mg daily for 2 days, 
30 mg daily for 2 days, 20 mg daily for 2 days, 10 mg daily for 2 days 
Contraindications Hypersensitivity to corticosteroids, systemic infection (unless specific 
antimicrobial therapy given), peptic disease (unless proton pump 
inhibitor given), live vaccines
Common side effects Dyspepsia, candidiasis, myopathy, osteoporosis, adrenal suppression,  
Cushing's syndrome, euphoria, depression
Unusual side effects Peptic ulceration with perforation, Cushingoid side effects increasingly 
likely with doses above 7.5 mg daily
Adapted and modified from [23]. 
Table 5. Systemic corticosteroids used for treatment of oral lesions 
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major aphthous ulcers are larger than 1 cm, and persist for weeks to months. Corticosteroids 
either alone or in combination with other drugs have been used for treatment of these 
lesions. [24-28] Topical steroids, such as triamcinolone acetonide and prednisolone (2 
times/day), are formulated as oral pastes. Therapeutic benefit can be derived from a 
mouthwash containing betamethasone. It should be noted that the long-term use of topical 
steroids may predispose patient to developing oral candidiasis. [28] 
Topical and injectable (intralesional) corticosteroids are useful for large and painful lesions. 
Systemic administration of corticosteroids is reserved for severe cases to prevent lesion 
formation or to reduce the number of lesions. Systemic corticosteroids should be prescribed 
in short courses, and only for severe outbreaks or cases that don't respond to topical or 
injectable corticosteroids. [23] 
Behcet's syndrome: The treatment of oral lesions of Behcet's syndrome is similar to the 
treatment of severe or major RAS. [23] 
Pemphigus vulgaris: Pemphigus vulgaris is a severe, potentially life-threatening 
vesiculobullous disease that may affect skin and mucous membranes. Oral cavity is 
involved in nearly 80% of patients. In the past, corticosteroid therapy was the treatment of 
choice but later, combination therapy involving the use of systemic corticosteroids with 
immunosuppressive agents was introduced, in an attempt to achieve disease control with 
lower doses of steroids. [29-31] 
The principal treatment of pemphigus vulgaris is systemic administration of corticosteroids 
at doses of 1 to 2 mg/kg/day. Maintenance of remission may be achieved with topical 
corticosteroids, allowing reduction of systemic drugs. Isolated lesions can be treated with 
injectable corticosteroids. [23] 
Bullous and mucous membrane pemphigoid: The choice of drugs used for the treatment of 
pemphigoid is based upon the sites of involvement, clinical severity, and disease 
progression. For more severe disease, or with rapid progression, systemic corticosteroids are 
the agents of choice for initial treatment, combined with steroid-sparing agents for long-
term maintenance. [32] Topical and injectable corticosteroids are useful for treatment of mild 
or localized oral lesions. [23] 
Erythema multiforme (EM) and Stevens-Johnson syndrome (SJS): It has been shown that 
corticosteroids have a favorable influence on the outcome of EM and SJS, if 
administered in high doses, over a short period of time, early in the course of the 
disease, and with proper tapering of medication. [33-37] However, the dosing and route 
of administration that provides the most benefit for EMM and SJS patients is in 
question. Treatment protocols such as early therapy with systemic prednisone (0.5 to 
1.0mg/kg/day) or pulse methylprednisolone (1mg/kg/day for 3 days), intravenous 
pulsed dose methylprednisolone (3 consecutive daily infusions of 20–30mg/kg to a 
maximum of 500mg given over 2 to 3 hours), and dexamethasone pulse therapy 
(1.5mg/kg IV over 30 to 60 minutes on 3 consecutive days), all have been shown to be 
effective. [33-35,37-39] 
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2.3. Keloid and hypertrophic scars 
Keloid and hypertrophic scar (HS) represent pathologic overhealing conditions which are 
caused by excessive production of fibrous tissue following healing of skin injuries. Keloid 
produces significantly more collagen than HS. Their exact cause is unknown but 
inflammation, tension, and genetic background are mentioned as contributing factors. 
Keloid and HS have different clinical features. Keloids extend beyond the confines of the 
original wound, develop months after injury, and rarely regress. HS is a raised scar that 
remains confined to the area of the injury, usually form within weeks, and may regress 
without intervention. 
Various treatment modalities have been used for prevention and treatment of keloid and 
HSs such as pressure therapy, silicone gel sheeting, topical flavonoids, corticosteroid 
therapy, radiotherapy, and surgery. 
Topical and intralesional glucocorticoids are frequently used to treat existing keloid and HS 
or, prophylactically, to prevent their formation or recurrence after surgical removal. Topical 
administration of steroids doesn't appear to be as efficacious as intralesional injection of the 
drug. Intralesional steroid injection, either on its own or in combination with other 
treatment modalities is the most common treatment used for keloid and HSs. 
Glucocorticoids have a multiplicity of effects on scars including suppressive effects on the 
inflammatory process in the wound, diminishing collagen and glycosaminoglycan 
synthesis, inhibition of fibroblast growth, and enhancing collagen and fibroblast 
degeneration. [40,41] Triamcinolone acetonide is the most commonly used steroid for the 
treatment of HS and keloid. It is used in a concentration of 10-20 mg/ml, though it can be 
given at a dose of 40 mg/ml for a tough bulky lesion; the concentration depends upon the 
size and site of the lesion and age of the individual. [42] Side effects of steroid injection 
include hypopigmentation, dermal atrophy, telangiectasia, and cushingoid effects from 
systemic absorption. [41] Cushing's syndrome secondary to injection of triamcinolone 
acetonide for the treatment of keloids have been reported by several investigators. [43,44]  
2.4. Central giant cell granuloma 
Central giant cell granuloma of the jaws is a benign tumor which occurs most often in 
children and young adults. This tumor is made up of loose fibrous connective tissue stroma 
with many interspersed proliferating fibroblasts, aggregations of multinucleated giant cells, 
and foci of hemorrhage. 
Various surgical and nonsurgical treatments have been advocated for this lesion. One of the 
nonsurgical treatments proposed is intralesional corticosteroid injections. Intralesional 
injection of triamcinolone acetonide has been shown to induce partial and in some cases 
complete resolution of central giant cell granuloma. However, there is no reasonably strong 
consensus in the literature regarding optimal dosage and duration of treatment that 
provides the most benefit. The mechanism of action of corticosteroids in the treatment of 
central giant cell granuloma is unknown. A rationale for its use has been the histologic 
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resemblance of central giant cell granuloma to sarcoid. Because corticosteroids have been 
effective in the treatment of sarcoid, it was thought that they may have a similar therapeutic 
effect on central giant cell granuloma. In addition, corticosteroids may act by suppressing 
any angiogenic component of the lesion. [45] 
2.5. Bell's palsy  
Bell's palsy is an idiopathic inflammation of the facial nerve (the seventh of twelve paired 
cranial nerves) which occurs almost always on one side only. It is characterized by facial 
muscle weakness, hyperacusis, decreased tearing, and loss of taste on the anterior two thirds 
of the tongue. Because Bell's palsy results from inflammation and edema of the facial nerve, 
corticosteroids constitute the standard medicine in the treatment of this condition. [46-48] 
For adults, prednisolone at doses of 1 mg/kg/day for 7 to 10 days, taken in divided doses in 
the morning and evening, is suggested.  
2.6. Management of post-operative morbidities associated with maxillofacial 
surgeries 
Facial pain, edema, ecchymosis and limitation of mouth opening are the expected sequelae 
of oral and maxillofacial surgeries. These post-operative complications affect the ability of 
patient to interrelate and to return to the daily life and activities, and deteriorate the quality 
of life of patient. [49,50] 
Many modalities are used to abate sequelae in the oral and maxillofacial surgery including 
use of ice pack, pressure dressing, surgical drain, and drugs.  
Corticosteroids are commonly used to control post-operative morbidities and to provide 
comfort for patients. However, there are no definite protocols relative to molecules, doses, 
schedules, and routes of administration. [51] The most commonly administered types of 
corticosteroids are betamethasone, dexamethasone, and methylprednisolone, administered 
intravenously, orally or by injection into the masseter muscle. The morbidity-management 
protocol also varies depending upon the type of surgery being performed. 
To decrease post-rhinoplasty edema, the administration of corticosteroids has been 
advocated for many years. In a study by Gurlek et al., it was shown that high dose 
methylprednisolone was effective in preventing and reducing both the periorbital 
ecchymosis and edema in open rhinoplasty. [52] In the same line, Kargi et al., and Kara and 
Gokalan showed that the perioperative use of corticosteroids reduced edema and 
ecchymosis associated with rhinoplasty surgery. [53,54] In contrast, Hoffmann et al. did not 
observe any increase either in the edema or the ecchymosis after rhinoplasty surgery. [55]  
Regarding orthognathic surgery, several investigations demonstrated that perioperative 
corticosteroid administration significantly reduced post-operative inflammation and edema. 
[56-59] In contrast, Munro et al. did not observe any significant decrease in postoperative 
edema even with the highest doses and the longest durations of corticosteroid treatment. (56) 
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2.3. Keloid and hypertrophic scars 
Keloid and hypertrophic scar (HS) represent pathologic overhealing conditions which are 
caused by excessive production of fibrous tissue following healing of skin injuries. Keloid 
produces significantly more collagen than HS. Their exact cause is unknown but 
inflammation, tension, and genetic background are mentioned as contributing factors. 
Keloid and HS have different clinical features. Keloids extend beyond the confines of the 
original wound, develop months after injury, and rarely regress. HS is a raised scar that 
remains confined to the area of the injury, usually form within weeks, and may regress 
without intervention. 
Various treatment modalities have been used for prevention and treatment of keloid and 
HSs such as pressure therapy, silicone gel sheeting, topical flavonoids, corticosteroid 
therapy, radiotherapy, and surgery. 
Topical and intralesional glucocorticoids are frequently used to treat existing keloid and HS 
or, prophylactically, to prevent their formation or recurrence after surgical removal. Topical 
administration of steroids doesn't appear to be as efficacious as intralesional injection of the 
drug. Intralesional steroid injection, either on its own or in combination with other 
treatment modalities is the most common treatment used for keloid and HSs. 
Glucocorticoids have a multiplicity of effects on scars including suppressive effects on the 
inflammatory process in the wound, diminishing collagen and glycosaminoglycan 
synthesis, inhibition of fibroblast growth, and enhancing collagen and fibroblast 
degeneration. [40,41] Triamcinolone acetonide is the most commonly used steroid for the 
treatment of HS and keloid. It is used in a concentration of 10-20 mg/ml, though it can be 
given at a dose of 40 mg/ml for a tough bulky lesion; the concentration depends upon the 
size and site of the lesion and age of the individual. [42] Side effects of steroid injection 
include hypopigmentation, dermal atrophy, telangiectasia, and cushingoid effects from 
systemic absorption. [41] Cushing's syndrome secondary to injection of triamcinolone 
acetonide for the treatment of keloids have been reported by several investigators. [43,44]  
2.4. Central giant cell granuloma 
Central giant cell granuloma of the jaws is a benign tumor which occurs most often in 
children and young adults. This tumor is made up of loose fibrous connective tissue stroma 
with many interspersed proliferating fibroblasts, aggregations of multinucleated giant cells, 
and foci of hemorrhage. 
Various surgical and nonsurgical treatments have been advocated for this lesion. One of the 
nonsurgical treatments proposed is intralesional corticosteroid injections. Intralesional 
injection of triamcinolone acetonide has been shown to induce partial and in some cases 
complete resolution of central giant cell granuloma. However, there is no reasonably strong 
consensus in the literature regarding optimal dosage and duration of treatment that 
provides the most benefit. The mechanism of action of corticosteroids in the treatment of 
central giant cell granuloma is unknown. A rationale for its use has been the histologic 
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resemblance of central giant cell granuloma to sarcoid. Because corticosteroids have been 
effective in the treatment of sarcoid, it was thought that they may have a similar therapeutic 
effect on central giant cell granuloma. In addition, corticosteroids may act by suppressing 
any angiogenic component of the lesion. [45] 
2.5. Bell's palsy  
Bell's palsy is an idiopathic inflammation of the facial nerve (the seventh of twelve paired 
cranial nerves) which occurs almost always on one side only. It is characterized by facial 
muscle weakness, hyperacusis, decreased tearing, and loss of taste on the anterior two thirds 
of the tongue. Because Bell's palsy results from inflammation and edema of the facial nerve, 
corticosteroids constitute the standard medicine in the treatment of this condition. [46-48] 
For adults, prednisolone at doses of 1 mg/kg/day for 7 to 10 days, taken in divided doses in 
the morning and evening, is suggested.  
2.6. Management of post-operative morbidities associated with maxillofacial 
surgeries 
Facial pain, edema, ecchymosis and limitation of mouth opening are the expected sequelae 
of oral and maxillofacial surgeries. These post-operative complications affect the ability of 
patient to interrelate and to return to the daily life and activities, and deteriorate the quality 
of life of patient. [49,50] 
Many modalities are used to abate sequelae in the oral and maxillofacial surgery including 
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The effects of corticosteroids on post-operative edema after oral surgery have been widely 
investigated in the literature. Many prior studies demonstrated a significant decrease in 
post-operative edema after administration of corticosteroids. [60-63] In a study by Zandi, it 
was shown that steroids not only reduced the facial swelling, but also the severity of pain 
after surgery. [60] Similarly, several studies reported that corticosteroids significantly 
decreased post-operative edema and pain, indicating a strong correlation between edema 
and pain decreases. [62-64] 
Even though the effects of corticosteroids on post-operative morbidities after various oral 
and maxillofacial surgeries have been widely investigated in the literature, methodological 
differences, variation in agents, doses, and routes of administration of the drugs have 
compromised the scientific conclusions. 
2.7. Other uses of corticosteroids in oral and maxillofacial surgery 
In addition to the aforementioned indications, corticosteroids are successfully used in the 
management of acute trigeminal nerve injuries, traumatic facial nerve paralysis, chronic 
facial pain, and allergic diseases involving maxillofacial area. 
3. Corticosteroids contraindications  
In prescribing corticosteroids, physicians must be aware that some patients are poor 
candidates for systemic, locally injected, or topical corticosteroid therapy.      
Systemic corticosteroids must be used with the greatest of caution in patients with 
uncontrolled hypertension, diabetes, active peptic ulcer, heart diseases, infections, 
psychiatric disorders, osteoporosis, cataract, glaucoma, tuberculosis, mycobacterial diseases, 
herpes simplex infection, pregnancy, varicella zoster infection, immune deficiency, 
underactive thyroid, and mental disorders. 
Injectable corticosteroid use is contraindicated in patients with hypersensitivity to 
corticosteroids, infections, and active tuberculosis.  
Use of topical corticosteroids is absolutely contraindicated in the treatment of primary 
bacterial infections such as impetigo, furuncles, carbuncles, erysipelas, cellulitis, 
lymphangitis, and erythrasma. Topical corticosteroids are also contraindicated in patients 
with a history of hypersensitivity to any of the components of the preparation. Currently, 
little is known about the safety of topical corticosteroids in pregnancy. Although it has been 
reported that there is an association between very potent topical corticosteroids and 
congenital abnormalities including low birth weight and orofacial clefts, use of these drugs 
in pregnancy is not recommended unless the potential benefit justifies the potential risks to 
fetus. [65] 
Ophthalmic use of topical corticosteroids is contraindicated in most viral, bacterial, and 
fungal diseases of ocular structures. 
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4. Corticosteroids side effects 
Although corticosteroids have great potential in the treatment of various diseases and 
conditions affecting oral and maxillofacial region, they also carry the risk of many side 
effects. Therefore, benefits from corticosteroids should always be weighed against their 
potential risks. Side effects of corticosteroids vary depending on the type and dose of the 
medication, rout of administration, and length of treatment. Significant adverse effects are 
most likely to occur in patients using oral corticosteroids for a long period of time. These 
may include weight gain, impaired growth, adrenal insufficiency, electrolyte abnormalities, 
increased susceptibility to infection, myopathy, osteoporosis, osteonecrosis, cataract, 
glaucoma, psychological problems, fractures, hypertension, insomnia, moon face, diabetes, 
and peptic ulcer. [1,66]  
Topical glucocorticoids may cause adverse effects such as skin atrophy, 
hypopigmentation, subcutaneous fat wasting, telangectasia, contact dermatitis, oral 
thrush, and cushingoid effects from systemic absorption. [28,41] Application of topical 
corticosteroids on eyelids has been reported to cause glaucoma. Adrenal suppression, 
growth retardation in children, and cushing's syndrome are rare adverse effects of long 
term topical corticosteroid use.  
Intralesional glucocorticoids may cause sterile abscess, skin atrophy, hypopigmentation, 
panniculitis, and skin necrosis. 
Although the frequency of side effects of inhaled corticosteroids is lower than systemic 
corticosteroids, high doses of inhaled corticosteroids have the potential to produce various 
local and systemic side effects. Systemic side effects associated with inhaled corticosteroids  
include osteoporosis, retarded growth in children, cataracts, glaucoma, and skin thinning. 
Inhaled corticosteroids may cause local side effects including oropharyngeal candidiasis, 
dysphonia, reflex cough, bronchospasm, and pharyngitis. [67] 
5. Perioperative management of patients with adrenal insufficiency 
Insufficient adrenocortical function is a rare disorder resulting from endogenous deficiency 
(primary) or from the administration of exogenous corticosteroids (secondary). Adrenal 
suppression should be suspected in those patients receiving the equivalent of 20 mg of 
prednisone daily for one week or the equivalent of 7.5 mg of prednisone daily for one 
month within the past year. [2] In adrenal suppression the body is not able to appropriately 
manage the challenge of stresses such as medical illness, surgery, and trauma. This may 
precipitate an adrenal crisis, signaled by the onset of fever, restlessness, flank and 
abdominal pain, vomiting, lethargy, hypotension, or coma.  
Any patient suspected of having adrenal insufficiency should be evaluated with an ACTH 
(cortrosyn) stimulation test or be given supplemental corticosteroids empirically 
perioperatively. Cortrosyn stimulation test measures how well the adrenal glands respond 
to a synthetic ACTH administered to the patient. 
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The currently recommended corticosteroid coverage for various surgical procedures is 
based on the magnitude of stress and the known glucocorticoid production rate associated 
with it, and includes the following: [2,68] 
 Minor surgical stress such as tooth extraction, biopsy, periodontal surgery, genioplasty, 
etc: 25 mg of hydrocortisone equivalent, the day of surgery 
 Moderate surgical stress such as panfacial fractures, two jaw surgery, etc: 50-75 mg of 
hydrocortisone equivalent for 1 to 2 days. 
 Major surgical stress such as extensive head and neck resection and reconstruction, etc: 
100-150 mg of hydrocortisone equivalent for 2 to 3 days. 
In the case of postoperative complications such as fever and pain, it is recommended that 
the corticosteroid administration be continued consistent with the post-operative stress 
response. [68] 
6. Maternal corticosteroid use and the risk of orofacial clefts in infants  
Orofacial clefts are the most common congenital deformity affecting maxillofacial area. The 
etiology of facial clefting is complex and has been extensively investigated. There are both 
major and minor genetic influences involved, with variable interactions from environmental 
factors. [69] Several environmental factors such as maternal drug intake, trauma, smoking, 
and exposure to x-rays during the pregnancy period have been suggested to increase the 
chance of cleft development in infants. [70]  
Pregnant women often use topical, inhaled, or systemic corticosteroid drugs for a variety of 
inflammatory and allergic conditions. Several investigations have reported that the use of 
corticosteroids during early pregnancy is associated with a 3- to 6-fold increased risk of 
orofacial clefts. [71-75] Although systemic corticosteroids are associated with a higher risk of 
orofacial clefts than topical corticosteroids, the latter is not without risk. It has been shown 
that application of hydrocortisone cream on eczematous skin is associated with significant 
increase in the level of plasma cortisol. [76] In a study by Edwards et al., a significant 
association between topical corticosteroids and orofacial cleft was observed. [77] 
Epidemiologic data have shown that low-to-moderate doses of inhaled corticosteroids taken 
during the first trimester of pregnancy are safe but raise concerns about high doses. [78]  
The mechanism of cleft palate production by corticosteroids is uncertain; it is a complicated 
interference in a complex developmental program involving many genetic and biochemical 
processes. Glucocorticoids may cause cleft palate deformity by delaying palatal shelf elevation. 
[79] Corticosteroids can reduce the collagen content of connective tissue by inhibiting collagen 
synthesis, which could disrupt cell-cell interaction and tissue-tissue interactions. [71] 
7. Conclusion 
Glucocorticoids are used, either singly or in combination with other drugs, for the treatment 
of various diseases affecting oral and maxillofacial area. They are also frequently used to 
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minimize expected post-operative morbidities such as pain and edema after oral and 
maxillofacial surgeries. Because of anti-inflammatory and anti-allergic actions of 
glucocorticoids, they have their widest application in the management of acute and chronic 
conditions which have allergic, immunologic, or inflammatory basis. However, 
corticosteroids carry the risk of potential side effects which are sometimes severe and life 
threatening. Therefore, benefits from corticosteroids should always be weighed against their 
potential risks in each patient. 
Prescribing the minimal dose and the least potent type of corticosteroids necessary to 
produce a given therapeutic effect, simultaneous use of non-steroidal agents to reduce the 
dose of corticosteroids, and prescribing corticosteroids for a short period of time or 
sporadically are some strategies to minimize corticosteroids adverse effects.  
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1. Introduction 
In 1948, the US rheumatologist Philip Hench and his associates at the Mayo Clinic first 
administered hydrocortisone to a patient with rheumatoid arthritis and discovered its 
clinical benefits [1]. Two years later, Hench, together with biochemists Edward Kendall and 
Tadeus Reichstein, shared the Nobel Prize in Medicine. Today, glucocorticoids are among 
the most frequently prescribed class of anti-inflammatory medications [2]. They are part of 
the standard treatment for a wide range of disorders which feature inflammation and/or 
immune activation, such as asthma, chronic obstructive pulmonary disease, hypersensitivity 
reactions, autoimmune diseases, and in organ transplantation. However, even early on, the 
euphoria generated by the discovery of corticosteroids was rapidly tempered by the 
realization that clinicians were, in a sense, engaging in a Faustian pact between its 
impressive anti-inflammatory benefits and its potentially devastating Cushingoid side 
effects [3, 4]. 
From a cardiovascular standpoint, the propensity of glucocorticoids to produce 
hyperglycemia, hypertension, dyslipidemia, and central obesity has long produced concern 
regarding possible adverse cardiovascular events [5]. Glucocorticoids administration 
increases blood pressure in a dose dependent fashion. The mechanisms of glucocorticoids-
mediated hypertension are incompletely understood but appear to be principally related to 
increased peripheral vascular resistance rather than to mineralocorticoid receptor mediated 
effects of increased sodium retention and plasma volume expansion [6].  Dyslipidemia in 
the context of long term glucocorticoids use is characterized by increased total cholesterol, 
low density lipoprotein cholesterol, and triglycerides. Corticosteroid treatment increases the 
risk of glucose intolerance in patients without known diabetes and is associated with 
deterioration of glycaemic control in diabetic patients [7]. Glucocorticoids treatment 
therefore contributes to the exacerbation of a cluster of cardiovascular risk factors that are 
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clinical benefits [1]. Two years later, Hench, together with biochemists Edward Kendall and 
Tadeus Reichstein, shared the Nobel Prize in Medicine. Today, glucocorticoids are among 
the most frequently prescribed class of anti-inflammatory medications [2]. They are part of 
the standard treatment for a wide range of disorders which feature inflammation and/or 
immune activation, such as asthma, chronic obstructive pulmonary disease, hypersensitivity 
reactions, autoimmune diseases, and in organ transplantation. However, even early on, the 
euphoria generated by the discovery of corticosteroids was rapidly tempered by the 
realization that clinicians were, in a sense, engaging in a Faustian pact between its 
impressive anti-inflammatory benefits and its potentially devastating Cushingoid side 
effects [3, 4]. 
From a cardiovascular standpoint, the propensity of glucocorticoids to produce 
hyperglycemia, hypertension, dyslipidemia, and central obesity has long produced concern 
regarding possible adverse cardiovascular events [5]. Glucocorticoids administration 
increases blood pressure in a dose dependent fashion. The mechanisms of glucocorticoids-
mediated hypertension are incompletely understood but appear to be principally related to 
increased peripheral vascular resistance rather than to mineralocorticoid receptor mediated 
effects of increased sodium retention and plasma volume expansion [6].  Dyslipidemia in 
the context of long term glucocorticoids use is characterized by increased total cholesterol, 
low density lipoprotein cholesterol, and triglycerides. Corticosteroid treatment increases the 
risk of glucose intolerance in patients without known diabetes and is associated with 
deterioration of glycaemic control in diabetic patients [7]. Glucocorticoids treatment 
therefore contributes to the exacerbation of a cluster of cardiovascular risk factors that are 
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central to the metabolic syndrome. However, as inflammation plays a central role in the 
pathogenesis of atherosclerosis [8], it is also possible that glucocorticoids may exert some 
anti-atherosclerotic effects.  
There was a significant association between ever use of oral glucocorticoids and any 
cardiovascular or cerebrovascular outcome. The association was stronger for current use of 
oral glucocorticoids than for recent or past use. Among current users, the highest odds 
ratios were observed in the group with the highest average daily dose, although the dose–
response relation was not continuous. Current use was associated with an increased risk of 
heart failure, which was consistent between patients with rheumatoid arthritis, patients with 
chronic obstructive pulmonary disease, and patients without either of the two conditions. 
Also, current use was associated with a smaller increased risk of ischaemic heart disease [9]. 
RA population has an increased cardio -vascular mortality and premature death rate, but 
why does these patients have a higher incidence of atherosclerosis? There are several factors 
which are known risks in the development of atherosclerosis. Steroids may play a role in the 
increased mortality from vascular disease. Some reports have suggested that prolonged 
treatment with steroids accelerates the development of atherosclerosis. Steroids have 
atherogenic properties that are known to enhance the development of atherosclerosis and 
they induce vascular injury. In addition, they produce a state of hypercoagulability. In 
Moreland and O’Dell study, they found an increased atherosclerotic burden in the patients 
who were on long-term steroids. This suggests that steroid treatment may be a contributor 
to the higher rate of atherosclerosis seen in them [10]. Del Rincón et al. studied the carotid 
and lower-limb arteries in a sample of RA patients, and found that the extent of cumulative 
glucocorticoids dose was significantly associated with arterial incompressibility. This 
association displayed a gradient in which the proportion of incompressible arteries 
increased with higher glucocorticoids exposure. This pattern was independent of age at RA 
onset, sex, disease duration, CV risk factors, and manifestations of RA [11]. 
2. Historical background 
Calcification of the arterial atheroma occurs in the coronary tree as it does in the remainder 
of the arterial tree. Such calcified coronary arteries are occasionally noted on routine chest 
radiographs but are difficult to distinguish from normal mediastinal structures and are 
confused with calcification in the chest wall, lungs, or other intracardiac structures [12]. 
Calcification of the coronary arteries is a common autopsy finding and is generally present 
in 80 to 90% of post-mortem studies. Despite this common pathologic finding, description of 
coronary calcification was rare until the work of Lenk [13] in 1927, who noted calcification of 
the left coronary artery on a posteroanterior chest radiograph in a 61-year-old male with left 
ventricular aneurysm. In 1964 Beadenkopf et al. [14] reported their findings in 904 
consecutive autopsies; their results indicated that as the number of coronary arteries with 
calcification increased, coronary artery wall thickness increased. Tampas and Soule [15] in 
1965 using radiographs in 1097 patients over the age of 40 found an incidence of 15% 
coronary calcification with a male to female ratio of 3 to 2 that was associated with 
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increasing age.  They suggested that coronary calcification might be an alarm signal of 
potential ischemic heart disease. Currently, it is generally recognized that the incidence of 
Coronary artery disease (CAD) was greater in patients with coronary calcification and 
atherosclerosis than in those without calcification [16].  
3. Value of assessment of preclinical atherosclerosis 
The presence of preclinical atherosclerosis increases global cardiovascular risk; therefore, it 
can be considered an emerging determinant in assessing such a risk. Single or multiple risk 
factors increase cardiovascular risk in an exponential manner, meanwhile the presence of 
one or more risk factors for atherosclerosis is associated with the development of 
cardiovascular disease. A specific issue is defined as risk factor when it is possible, on the basis of a 
strong statistical association, to relate it to the incidence of new cases of disease and if it is clinically 
demonstrated that new disease cases can be reduced by correcting the same risk factor.  
Atherosclerosis is defined as a progressive structural remodeling of a vessel wall towards 
definitive plaque formation and possible related complications. According to new data, the 
disease begins as an endothelium functional disorder [dysfunction] inducing loss of 
vascular homeostasis and related functional reserve that initially can become clinically 
evident only in conditions in which there is a need to increase tissue metabolic requirements 
(as for instance effort Angina, transient Ischemic Attack, intermittent Claudication) while, 
after more time, they can become symptomatic at rest because even basal perfusion [blood 
flow] is impaired (acute coronary syndrome, stroke, critical leg ischemia, and even 
cardiovascular death) [12].  
Coronary atherosclerosis is the leading cause of death in industrialized western countries. In 
up to 50% of its victims the first manifestation of CAD is sudden death or acute myocardial 
infarction. The cost of lost human value and approximate dollars spent ($90 billion 
annually) due to coronary artery disease in the western society is of great concern and is the 
reason for increased efforts for its prevention and its consequences as well. The detection of 
CAD in its asymptomatic stage is highly desirable because it is an increasingly treatable 
disease, but till now it has been hindered by the lack of sensitive and specific tests [13]. 
4. Methodology of assessment 
4.1. Clinical background and limitations 
In evaluating atherosclerosis the following demographic and clinical data are needed; sex, 
age, cigarette smoking, alcohol consumption, physical activity and life style, socioeconomic 
status, previous diseases, family history, BMI, WHR [waist to hip ratio] and blood pressure 
assessments in the standard way.  
Chronic subclinical inflammation is thought to be part of the metabolic syndrome [MetSyn]. 
The latter is characterized by a clustering of atherosclerotic CVD risk factors. The WHO 
definition of MetSyn [14] requires the presence of insulin resistance plus 2 other of central 
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central to the metabolic syndrome. However, as inflammation plays a central role in the 
pathogenesis of atherosclerosis [8], it is also possible that glucocorticoids may exert some 
anti-atherosclerotic effects.  
There was a significant association between ever use of oral glucocorticoids and any 
cardiovascular or cerebrovascular outcome. The association was stronger for current use of 
oral glucocorticoids than for recent or past use. Among current users, the highest odds 
ratios were observed in the group with the highest average daily dose, although the dose–
response relation was not continuous. Current use was associated with an increased risk of 
heart failure, which was consistent between patients with rheumatoid arthritis, patients with 
chronic obstructive pulmonary disease, and patients without either of the two conditions. 
Also, current use was associated with a smaller increased risk of ischaemic heart disease [9]. 
RA population has an increased cardio -vascular mortality and premature death rate, but 
why does these patients have a higher incidence of atherosclerosis? There are several factors 
which are known risks in the development of atherosclerosis. Steroids may play a role in the 
increased mortality from vascular disease. Some reports have suggested that prolonged 
treatment with steroids accelerates the development of atherosclerosis. Steroids have 
atherogenic properties that are known to enhance the development of atherosclerosis and 
they induce vascular injury. In addition, they produce a state of hypercoagulability. In 
Moreland and O’Dell study, they found an increased atherosclerotic burden in the patients 
who were on long-term steroids. This suggests that steroid treatment may be a contributor 
to the higher rate of atherosclerosis seen in them [10]. Del Rincón et al. studied the carotid 
and lower-limb arteries in a sample of RA patients, and found that the extent of cumulative 
glucocorticoids dose was significantly associated with arterial incompressibility. This 
association displayed a gradient in which the proportion of incompressible arteries 
increased with higher glucocorticoids exposure. This pattern was independent of age at RA 
onset, sex, disease duration, CV risk factors, and manifestations of RA [11]. 
2. Historical background 
Calcification of the arterial atheroma occurs in the coronary tree as it does in the remainder 
of the arterial tree. Such calcified coronary arteries are occasionally noted on routine chest 
radiographs but are difficult to distinguish from normal mediastinal structures and are 
confused with calcification in the chest wall, lungs, or other intracardiac structures [12]. 
Calcification of the coronary arteries is a common autopsy finding and is generally present 
in 80 to 90% of post-mortem studies. Despite this common pathologic finding, description of 
coronary calcification was rare until the work of Lenk [13] in 1927, who noted calcification of 
the left coronary artery on a posteroanterior chest radiograph in a 61-year-old male with left 
ventricular aneurysm. In 1964 Beadenkopf et al. [14] reported their findings in 904 
consecutive autopsies; their results indicated that as the number of coronary arteries with 
calcification increased, coronary artery wall thickness increased. Tampas and Soule [15] in 
1965 using radiographs in 1097 patients over the age of 40 found an incidence of 15% 
coronary calcification with a male to female ratio of 3 to 2 that was associated with 
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increasing age.  They suggested that coronary calcification might be an alarm signal of 
potential ischemic heart disease. Currently, it is generally recognized that the incidence of 
Coronary artery disease (CAD) was greater in patients with coronary calcification and 
atherosclerosis than in those without calcification [16].  
3. Value of assessment of preclinical atherosclerosis 
The presence of preclinical atherosclerosis increases global cardiovascular risk; therefore, it 
can be considered an emerging determinant in assessing such a risk. Single or multiple risk 
factors increase cardiovascular risk in an exponential manner, meanwhile the presence of 
one or more risk factors for atherosclerosis is associated with the development of 
cardiovascular disease. A specific issue is defined as risk factor when it is possible, on the basis of a 
strong statistical association, to relate it to the incidence of new cases of disease and if it is clinically 
demonstrated that new disease cases can be reduced by correcting the same risk factor.  
Atherosclerosis is defined as a progressive structural remodeling of a vessel wall towards 
definitive plaque formation and possible related complications. According to new data, the 
disease begins as an endothelium functional disorder [dysfunction] inducing loss of 
vascular homeostasis and related functional reserve that initially can become clinically 
evident only in conditions in which there is a need to increase tissue metabolic requirements 
(as for instance effort Angina, transient Ischemic Attack, intermittent Claudication) while, 
after more time, they can become symptomatic at rest because even basal perfusion [blood 
flow] is impaired (acute coronary syndrome, stroke, critical leg ischemia, and even 
cardiovascular death) [12].  
Coronary atherosclerosis is the leading cause of death in industrialized western countries. In 
up to 50% of its victims the first manifestation of CAD is sudden death or acute myocardial 
infarction. The cost of lost human value and approximate dollars spent ($90 billion 
annually) due to coronary artery disease in the western society is of great concern and is the 
reason for increased efforts for its prevention and its consequences as well. The detection of 
CAD in its asymptomatic stage is highly desirable because it is an increasingly treatable 
disease, but till now it has been hindered by the lack of sensitive and specific tests [13]. 
4. Methodology of assessment 
4.1. Clinical background and limitations 
In evaluating atherosclerosis the following demographic and clinical data are needed; sex, 
age, cigarette smoking, alcohol consumption, physical activity and life style, socioeconomic 
status, previous diseases, family history, BMI, WHR [waist to hip ratio] and blood pressure 
assessments in the standard way.  
Chronic subclinical inflammation is thought to be part of the metabolic syndrome [MetSyn]. 
The latter is characterized by a clustering of atherosclerotic CVD risk factors. The WHO 
definition of MetSyn [14] requires the presence of insulin resistance plus 2 other of central 
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obesity, hypertension, or dyslipidemia. Insulin resistance is thought to be the most 
prominent pathophysiological process underlying MetSyn. Recent studies of coronary artery 
calcification (CAC) in asymptomatic samples have shown an association of MetSyn and 
insulin resistance with the burden of coronary atherosclerosis [13]. Lakka et al. [15] found a 2- 
to 4-fold increased risk of cardiovascular death with MetSyn in a sample of 1209 Finnish men 
free from diabetes and CVD at baseline. MetSyn predicted atherosclerosis progression and 
CVD events in 888 subjects in the Bruneck study, whereas most individual components of the 
syndrome were not significantly associated with CVD out-comes [16] supporting the concept 
that MetSyn provides information that is “more than the sum of its parts.”[17].  
4.2. Laboratory methods 
In more than 15 large prospective studies, C-reactive protein (CRP) has emerged as an 
independent predictor of an incident cardiovascular event in initially healthy subjects and 
outcome after acute coronary syndrome [18]. More importantly, its high levels have been 
demonstrated to be an even stronger predictor of cardiovascular events than LDL 
cholesterol levels. CRP represents only one of several new inammatory biomarkers to be 
associated, independent of lipid prole, with future cardiovascular events. Among these, 
serum amyloid A (SAA), soluble vascular cell adhesion molecule-1 (VCAM-1), soluble 
intercellular adhesion molecule 1 (ICAM-1), lipoprotein associated phospholipase A2 (Lp-
PLA2), homocysteine and monocyte chemoattractant protein-1 (MCP-1) are the best 
characterized. Interestingly, from the most recent epidemiological trials, evidence has 
consistently emerged that these biomarkers are independent from cholesterol levels, but also 
unrelated to each other. For instance, in healthy middle-aged men, CRP levels were found to 
correlate only marginally to Lp-PLA2 and MCP-1. The direct evidence that inammatory 
biomarkers contribute to atherogenesis would be validated from the utilization of novel 
specic inhibitors for each of the soluble molecules which should prevent atherogenesis and 
coronary artery disease [18]. 
4.3. Sonographic modalities 
Atherosclerosis is a chronic inflammatory disorder that often progresses silently for decades 
before becoming clinically evident. In this section we will preview sonographic noninvasive 
imaging of the vascular changes that occur in the atherosclerosis disease process including 
assessment of its inflammatory component. Because inflammation participates in plaque 
initiation and progression, a method capable of imaging the extent of vascular inflammation 
could potentially provide powerful predictive information on both early disease presence 
and future risk for disease progression.  
4.3.1. Intima-Media Thickness (IMT) or Asymptomatic Carotid Plaque (ACP) 
Echocolordoppler scanning evaluation of the carotid wall is a non invasive, low cost, and 
highly reproducible procedure even if, like most parts of the echographic analysis, it is 
strongly operator dependent. The Doppler mode permits the visualization of vessels and an 
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evaluation of flow disturbance that helps to quantify stenosis severity. It measures the IMT 
and size and number of atheromatous plaques.  According to the European Society of 
Cardiology; 2007-Guidelines on the Management of arterial Hypertension, normal IMT is 
the distance between the media-adventitia and the intima-media interfaces and is 
interpreted as follows: 
 under 0,9 mm of the entire vascular wall;  normal  
 between 0.9 and 1.5 mm is an increased IMT,  
 While all conditions in which it is greater than 1.5 mm can be considered an ACP.  
Increased IMT (or ACP) is related to the presence, number, intensity and duration of 
atherosclerosis risk factors as well as endothelial dysfunction [24, 25]. Also, IMT is a potent 
and independent predictor of future cerebro- and cardiovascular events, as proven by 
several studies (Finnish, American Rotterdam groups) [17].  
4.3.2. Ankle Brachial Pressure Index (ABI) 
Normally, ankle systolic arterial pressure (posterior or anterior tibial artery) is just a little 
higher than brachial pressure measurements so that their ratio always is always > 1.0. This 
parameter is called the Ankle-Brachial pressure Index (ABI) and can reflect altered pressure 
values. It is reduced < 0.90 if atherosclerosis induced arterial system impairment is present; 
hence the patient is considered to have an asymptomatic peripheral artery disease. It is a 
simple, non-expensive procedure and can also be practiced by general practitioners [17]. 
Several population trials evidenced an important correlation between decreased ABI, 
carotid or coronary atherosclerosis and future cardiac or cerebrovascular events (27). 
4.3.3. Endothelial function evaluation 
A new, non-invasive technique was introduced to evaluate brachial artery flow-mediated 
dilatation (FMD). The evaluation through a sonographic assessment of brachial artery in 
basal condition and after 5 minutes of occlusion using pneumonic cuff (250 mm Hg) 
determined a reactive hyperemia and therefore, FMD. A low FMD is a marker of multifocal 
atherosclerosis and severity of the disease where the progressive reduction of FMD is 
associated with more extensive coronary tree involvement and future cardiovascular events 
[28, 29].  
4.3.4. Targeted Ultrasound Detection of Vascular Cell Adhesion Molecule-1 (VCAM-1) 
VCAM-1 is expressed by activated endothelial cells and participates in leukocyte rolling and 
adhesion primarily by interacting with its counterligand VLA-4 (α4 β1) on monocytes and 
lymphocytes. VCAM-1 expression on the vessel endothelial surface or the underlying vasa 
vasorum plays an important role in atherosclerotic plaque development by monocyte and T-
lymphocyte recruitment. It is an ideal target for molecular imaging because there is little 
constitutive expression and its upregulation occurs at the earliest stages of atherogenesis. It 
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obesity, hypertension, or dyslipidemia. Insulin resistance is thought to be the most 
prominent pathophysiological process underlying MetSyn. Recent studies of coronary artery 
calcification (CAC) in asymptomatic samples have shown an association of MetSyn and 
insulin resistance with the burden of coronary atherosclerosis [13]. Lakka et al. [15] found a 2- 
to 4-fold increased risk of cardiovascular death with MetSyn in a sample of 1209 Finnish men 
free from diabetes and CVD at baseline. MetSyn predicted atherosclerosis progression and 
CVD events in 888 subjects in the Bruneck study, whereas most individual components of the 
syndrome were not significantly associated with CVD out-comes [16] supporting the concept 
that MetSyn provides information that is “more than the sum of its parts.”[17].  
4.2. Laboratory methods 
In more than 15 large prospective studies, C-reactive protein (CRP) has emerged as an 
independent predictor of an incident cardiovascular event in initially healthy subjects and 
outcome after acute coronary syndrome [18]. More importantly, its high levels have been 
demonstrated to be an even stronger predictor of cardiovascular events than LDL 
cholesterol levels. CRP represents only one of several new inammatory biomarkers to be 
associated, independent of lipid prole, with future cardiovascular events. Among these, 
serum amyloid A (SAA), soluble vascular cell adhesion molecule-1 (VCAM-1), soluble 
intercellular adhesion molecule 1 (ICAM-1), lipoprotein associated phospholipase A2 (Lp-
PLA2), homocysteine and monocyte chemoattractant protein-1 (MCP-1) are the best 
characterized. Interestingly, from the most recent epidemiological trials, evidence has 
consistently emerged that these biomarkers are independent from cholesterol levels, but also 
unrelated to each other. For instance, in healthy middle-aged men, CRP levels were found to 
correlate only marginally to Lp-PLA2 and MCP-1. The direct evidence that inammatory 
biomarkers contribute to atherogenesis would be validated from the utilization of novel 
specic inhibitors for each of the soluble molecules which should prevent atherogenesis and 
coronary artery disease [18]. 
4.3. Sonographic modalities 
Atherosclerosis is a chronic inflammatory disorder that often progresses silently for decades 
before becoming clinically evident. In this section we will preview sonographic noninvasive 
imaging of the vascular changes that occur in the atherosclerosis disease process including 
assessment of its inflammatory component. Because inflammation participates in plaque 
initiation and progression, a method capable of imaging the extent of vascular inflammation 
could potentially provide powerful predictive information on both early disease presence 
and future risk for disease progression.  
4.3.1. Intima-Media Thickness (IMT) or Asymptomatic Carotid Plaque (ACP) 
Echocolordoppler scanning evaluation of the carotid wall is a non invasive, low cost, and 
highly reproducible procedure even if, like most parts of the echographic analysis, it is 
strongly operator dependent. The Doppler mode permits the visualization of vessels and an 
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evaluation of flow disturbance that helps to quantify stenosis severity. It measures the IMT 
and size and number of atheromatous plaques.  According to the European Society of 
Cardiology; 2007-Guidelines on the Management of arterial Hypertension, normal IMT is 
the distance between the media-adventitia and the intima-media interfaces and is 
interpreted as follows: 
 under 0,9 mm of the entire vascular wall;  normal  
 between 0.9 and 1.5 mm is an increased IMT,  
 While all conditions in which it is greater than 1.5 mm can be considered an ACP.  
Increased IMT (or ACP) is related to the presence, number, intensity and duration of 
atherosclerosis risk factors as well as endothelial dysfunction [24, 25]. Also, IMT is a potent 
and independent predictor of future cerebro- and cardiovascular events, as proven by 
several studies (Finnish, American Rotterdam groups) [17].  
4.3.2. Ankle Brachial Pressure Index (ABI) 
Normally, ankle systolic arterial pressure (posterior or anterior tibial artery) is just a little 
higher than brachial pressure measurements so that their ratio always is always > 1.0. This 
parameter is called the Ankle-Brachial pressure Index (ABI) and can reflect altered pressure 
values. It is reduced < 0.90 if atherosclerosis induced arterial system impairment is present; 
hence the patient is considered to have an asymptomatic peripheral artery disease. It is a 
simple, non-expensive procedure and can also be practiced by general practitioners [17]. 
Several population trials evidenced an important correlation between decreased ABI, 
carotid or coronary atherosclerosis and future cardiac or cerebrovascular events (27). 
4.3.3. Endothelial function evaluation 
A new, non-invasive technique was introduced to evaluate brachial artery flow-mediated 
dilatation (FMD). The evaluation through a sonographic assessment of brachial artery in 
basal condition and after 5 minutes of occlusion using pneumonic cuff (250 mm Hg) 
determined a reactive hyperemia and therefore, FMD. A low FMD is a marker of multifocal 
atherosclerosis and severity of the disease where the progressive reduction of FMD is 
associated with more extensive coronary tree involvement and future cardiovascular events 
[28, 29].  
4.3.4. Targeted Ultrasound Detection of Vascular Cell Adhesion Molecule-1 (VCAM-1) 
VCAM-1 is expressed by activated endothelial cells and participates in leukocyte rolling and 
adhesion primarily by interacting with its counterligand VLA-4 (α4 β1) on monocytes and 
lymphocytes. VCAM-1 expression on the vessel endothelial surface or the underlying vasa 
vasorum plays an important role in atherosclerotic plaque development by monocyte and T-
lymphocyte recruitment. It is an ideal target for molecular imaging because there is little 
constitutive expression and its upregulation occurs at the earliest stages of atherogenesis. It 
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was hypothesized that molecular imaging with targeted contrast enhanced ultrasound [CEU] 
could be used to evaluate the degree of vascular inflammation in atherosclerosis. CEU have 
multiple practical considerations; low cost, short duration [10 Minutes], good sensitivity and 
balance between spatial resolution and sensitivity for targeted contrast agent detection. It 
can potentially be useful in the early diagnosis of atherosclerosis and in monitoring the 
efficacy of therapeutic interventions. 
4.4. Radiological modalities 
4.4.1. Fluoroscopy  
The detection of coronary calcification on chest films is not easy and the accuracy is only 
42% compared with fluoroscopy, which itself is not sensitive. Fluoroscopy has frequently 
been used to detect calcification in the coronary arteries [31]. Data from the Duke registry of 
800 patients by Margolis et al. [32] showed that patients with fluoroscopic evidence of 
calcium in the coronary arterial tree had a remarkably high prevalence of significant disease 
(94%). Only 6% of patients with coronary calcification had normal coronary angiograms. 
Among those without demonstrable calcification, 87% survived for more than 5 years 
compared to 58% with coronary calcification. Hence the latter implies a greater risk of future 
cardiac events. Fluoroscopy is widely available but it has several disadvantages [18]: 
1. Although it can detect moderate to large calcifications; its ability to identify small 
calcifications is low. 
2. Fluoroscopic detection of calcification is dependent on the skill and experience of the 
operator as well as the number of views studied.  
3. Other important factors include variability of the equipment, patient’s body habitus, 
and calcifications in other structures such as valves and vertebrae and overlying 
anatomic structures.  
4. Finally with fluoroscopy, quantification of calcium is not possible and film 
documentation is not commonly obtained. 
4.4.2. Computed tomography (CT)  
Conventional CT is extremely sensitive in detecting vascular calcification. CT showed 50% 
more calcified vessels than did fluoroscopy. Its limitations are slow scan times resulting in 
motion artifacts, breathing misregistration, and inability to quantify amount of plaque. 
Helical CT has considerably faster scan times than conventional CT and overlapping sections 
improves calcium detection. Double-helix CT scanners  appear to be more sensitive and now 
termed electron beam (EBCT) to distinguish them from conventional CT scanners. 
Only EBCT can quantitate the amount or volume of calcium. The absence of calcific deposits 
on an EBCT scan implies the absence of significant angiographic coronary narrowing; 
however, it does not imply the absence of atherosclerosis, including unstable plaque. One of 
the most appealing features of EBCT is the potential to detect progression or regression of 
 
Assessment of Glucocorticoids Induced Preclinical Atherosclerosis 563 
coronary atherosclerotic disease non-invasively and quantification with the use of calcium-
volume score. Although the ACC/AHA [American College of Cardiology (ACC) and the 
American Heart Association (AHA)] guidelines affirm the strong negative predictive value of 
a normal EBCT they are not supportive for its widespread use in asymptomatic patients [18]. 
4.4.3. Magnetic Resonance Imaging [MRI] 
Imaging techniques are needed that allow earlier and more rened diagnosis, guide targeted 
treatment in individual patients and monitor response to that treatment. MRI is well-suited 
to these tasks as it can provide anatomical, structural, and functional data of the arterial 
wall. Its capabilities are further enhanced by the use of a range of increasingly sophisticated 
contrast agents that target specic molecules, cells, and biological processes. Currently, it is 
considered to identify biologically relevant targets involved in the pathogenesis of 
atherosclerosis along its different stages [33]. 
For assessment of lesions that encroach on the vessel lumen inducing ischemia as in angina; 
angiography provides excellent resolution for the affected vascular territory with possible 
therapeutic intervention. However, atherosclerosis commonly develops within the walls of 
arteries without impinging on the vessel lumen; even established disease can be concealed 
from lumenographic methods. Unfortunately, even these non-stenotic lesions can rupture or 
erode precipitating intra-arterial thrombosis and acute ischemic events.  
Distinct from alternative imaging modalities, MRI can provide data on a large range of 
vascular parameters that includes measures of vascular physiology (compliance, pulse wave 
velocity, and ow-mediated vasodilatation), cellular imaging, molecular imaging [adhesion 
molecule expression (VCAM-1), brin and platelets targeting] and functional anatomical 
data such as wall sheer stresses and density of neovascularization [33]. 
4.5. Radionuclide evaluation 
4.5.1. Tc-99m sestamibi lower extremity muscle scan 
Amin et al. [34] stated that Tc-99m sestamibi lower extremity muscle scan is a technique that 
can be effectively used to diagnose preclinical atherosclerosis in rheumatoid arthritis disease 
by measuring the so called perfusion reserve [PR]. They reported that it has a place as a 
screening tool considering the fact; whenever the diagnosis, the better it is the result, 
however, it could be used for detecting preclinical atherosclerosis even in apparently 
healthy subjects. 
4.5.2. Technique 
Prior to the administration of Tc-99m sestamibi for measurement of PR in lower limbs, each 
subject moved her right foot to produce maximal dorsal and plantar exion 30–40 times in 
the sitting position (exercising side). 185 mBq of Tc-99m sestamibi was injected through 
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was hypothesized that molecular imaging with targeted contrast enhanced ultrasound [CEU] 
could be used to evaluate the degree of vascular inflammation in atherosclerosis. CEU have 
multiple practical considerations; low cost, short duration [10 Minutes], good sensitivity and 
balance between spatial resolution and sensitivity for targeted contrast agent detection. It 
can potentially be useful in the early diagnosis of atherosclerosis and in monitoring the 
efficacy of therapeutic interventions. 
4.4. Radiological modalities 
4.4.1. Fluoroscopy  
The detection of coronary calcification on chest films is not easy and the accuracy is only 
42% compared with fluoroscopy, which itself is not sensitive. Fluoroscopy has frequently 
been used to detect calcification in the coronary arteries [31]. Data from the Duke registry of 
800 patients by Margolis et al. [32] showed that patients with fluoroscopic evidence of 
calcium in the coronary arterial tree had a remarkably high prevalence of significant disease 
(94%). Only 6% of patients with coronary calcification had normal coronary angiograms. 
Among those without demonstrable calcification, 87% survived for more than 5 years 
compared to 58% with coronary calcification. Hence the latter implies a greater risk of future 
cardiac events. Fluoroscopy is widely available but it has several disadvantages [18]: 
1. Although it can detect moderate to large calcifications; its ability to identify small 
calcifications is low. 
2. Fluoroscopic detection of calcification is dependent on the skill and experience of the 
operator as well as the number of views studied.  
3. Other important factors include variability of the equipment, patient’s body habitus, 
and calcifications in other structures such as valves and vertebrae and overlying 
anatomic structures.  
4. Finally with fluoroscopy, quantification of calcium is not possible and film 
documentation is not commonly obtained. 
4.4.2. Computed tomography (CT)  
Conventional CT is extremely sensitive in detecting vascular calcification. CT showed 50% 
more calcified vessels than did fluoroscopy. Its limitations are slow scan times resulting in 
motion artifacts, breathing misregistration, and inability to quantify amount of plaque. 
Helical CT has considerably faster scan times than conventional CT and overlapping sections 
improves calcium detection. Double-helix CT scanners  appear to be more sensitive and now 
termed electron beam (EBCT) to distinguish them from conventional CT scanners. 
Only EBCT can quantitate the amount or volume of calcium. The absence of calcific deposits 
on an EBCT scan implies the absence of significant angiographic coronary narrowing; 
however, it does not imply the absence of atherosclerosis, including unstable plaque. One of 
the most appealing features of EBCT is the potential to detect progression or regression of 
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coronary atherosclerotic disease non-invasively and quantification with the use of calcium-
volume score. Although the ACC/AHA [American College of Cardiology (ACC) and the 
American Heart Association (AHA)] guidelines affirm the strong negative predictive value of 
a normal EBCT they are not supportive for its widespread use in asymptomatic patients [18]. 
4.4.3. Magnetic Resonance Imaging [MRI] 
Imaging techniques are needed that allow earlier and more rened diagnosis, guide targeted 
treatment in individual patients and monitor response to that treatment. MRI is well-suited 
to these tasks as it can provide anatomical, structural, and functional data of the arterial 
wall. Its capabilities are further enhanced by the use of a range of increasingly sophisticated 
contrast agents that target specic molecules, cells, and biological processes. Currently, it is 
considered to identify biologically relevant targets involved in the pathogenesis of 
atherosclerosis along its different stages [33]. 
For assessment of lesions that encroach on the vessel lumen inducing ischemia as in angina; 
angiography provides excellent resolution for the affected vascular territory with possible 
therapeutic intervention. However, atherosclerosis commonly develops within the walls of 
arteries without impinging on the vessel lumen; even established disease can be concealed 
from lumenographic methods. Unfortunately, even these non-stenotic lesions can rupture or 
erode precipitating intra-arterial thrombosis and acute ischemic events.  
Distinct from alternative imaging modalities, MRI can provide data on a large range of 
vascular parameters that includes measures of vascular physiology (compliance, pulse wave 
velocity, and ow-mediated vasodilatation), cellular imaging, molecular imaging [adhesion 
molecule expression (VCAM-1), brin and platelets targeting] and functional anatomical 
data such as wall sheer stresses and density of neovascularization [33]. 
4.5. Radionuclide evaluation 
4.5.1. Tc-99m sestamibi lower extremity muscle scan 
Amin et al. [34] stated that Tc-99m sestamibi lower extremity muscle scan is a technique that 
can be effectively used to diagnose preclinical atherosclerosis in rheumatoid arthritis disease 
by measuring the so called perfusion reserve [PR]. They reported that it has a place as a 
screening tool considering the fact; whenever the diagnosis, the better it is the result, 
however, it could be used for detecting preclinical atherosclerosis even in apparently 
healthy subjects. 
4.5.2. Technique 
Prior to the administration of Tc-99m sestamibi for measurement of PR in lower limbs, each 
subject moved her right foot to produce maximal dorsal and plantar exion 30–40 times in 
the sitting position (exercising side). 185 mBq of Tc-99m sestamibi was injected through 
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intravenous line at least 10 sec before exercise termination. Posterior images of each calf 
were obtained 10 min post-injection. The processing phase was carried out by drawing 
symmetrical and equal regions of interest (ROI) over both exercising and resting calves. The 
total counts (Cts) in each (ROI) were obtained through a closed program inherent to the 
computer system [figure 1]. The percentage of increase of Cts in the exercising right calf was 
calculated, and the percentile increase obtained was considered as the perfusion reserve 
using the following formula [normal PR is approx. 50%]: 
 
Figure 1. Tc-99m sestamibi muscle scans of an RA patient (PR 29.4%) [Left panel] and a control subject 
(PR 85%) [Right panel] 
4.5.3. Myocardial sestaMIBI Gated-SPECT 
Also, in our center a study was designed to evaluate usefulness of Dipyridamole 
pharmacological stress test in conjunction with Tc-99m sestamibi Gated-SPECT to screen the 
prevalence of subclinical coronary vascular dysfunction [SCED] in asymptomatic Egyptian 
Behçet’s disease patients and to identify those at higher risk for the presence of such 
abnormalities as a predictor for preclinical atherosclerosis [data are not published yet]. 
Dipyridamole is an indirect coronary vasodilator that works by increasing intravascular 
adenosine through inhibition of phosphodiesterase that prohibits reuptake of endogenously 
produced adenosine into endothelial and red blood cells leading to arteriolar vasodilatation. 
This increases coronary arterial flow to approximately three times resting values in healthy 
endothelial state, however it is attenuated in diseased coronary arteries that cannot further 
dilate in response to adenosine. So, Dipyridamole infusion produces relative flow 
heterogeneity throughout coronary arteries, resulting in relatively more coronary blood 
flow in healthy arteries compared with the diseased-arteries inducing ischemia via a 
“coronary steal phenomenon” with subsequent perfusion defects ± abnormal left ventricular 
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wall motion during radionuclide imaging. Hence, we used Dipyridamole stress in 
conjunction with Tc-99m sestamibi Gated-SPECT as a screening tool for SCED [Figure 2 and 
3].  
 
Figure 2. A 35-year-old male with stress induced reduced flow in LAD [anterior wall] and RCA 
vascular territories [inferior wall] with Complete recovery in the rest phase Coronary angiography was 
normal; [Stress; Upper row and Rest; Lower row- Short axis slices] 
 
Figure 3. A 33-year-old negative Case for SCED [Stress; Upper row and Rest; Lower row-Short axis 
slices] 
5. Special consideration  
5.1. Premature lower limb atherosclerosis  
Symptomatic lower extremity arterial occlusive disease in young adults is presumably rare 
provided that atherosclerosis is a natural consequence of ageing process. Several factors 
contribute to the “neglect” of premature lower extremity atherosclerosis (PLEA) among 
young population in clinical practice; including low public health awareness of this 
pathology, absence of large-scale epidemiologic studies, and overall low index of suspicion 
for vascular etiology of effort-induced lower extremity symptoms. A number of small 
clinical studies published in the last decade have strongly suggested that PLEA is the major 
cause for peripheral arterial disease (PAD) in young patients [35]. 
Levy report in 2002 identified 3 major clinical presentations of PLEA; the majority of 
patients had typical symptoms of effort-induced claudication, frequently misdiagnosed and 
attributed to arthritides, muscle spasms, and trauma. Approximately 20-25% present with 
“blue toe syndrome” caused by atheromatous embolization, most frequently originating 
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from a segmental aortoiliac atherosclerotic lesion. The rest of patients presents with rapidly 
progressive symptoms of limb-threatening ischemia secondary to atherothrombosis. Also, 
they observed that many younger patients with isolated aortoiliac atherosclerotic disease 
had prolonged lower back pain on ambulation involving the spinal muscles who have been 
treated for several years for chronic low back pain by orthopedic surgeons, or 
neurosurgeons and some of them even had “unsuccessful” laminectomies before the 
diagnosis of PAD. In PLEA patients, clinical atherosclerotic disease was present in more 
than one anatomic location in approximately 60% including the coronary tree. Noninvasive 
studies are a mainstay of the PLEA diagnosis including ABI measurement and standardized 
lower extremity treadmill testing that has been developed to assess hyperemic blood flow 
response to exercise with repeat ABIs compared to the resting ABI with pulse-wave 
recordings. Also, Tc-99m sestamibi lower extremity muscle scan is suggested as a diagnostic 
test in PLEA patients [35]. 
6. Summary and conclusions 
In summary, improved understanding of atherogenesis allowed the identication of a large 
number of molecules and processes. This will provide functional insights to aid diagnosis 
and to guide treatment with the introduction of new molecular imaging approaches that 
hold much promise for translation to the clinical practice. In fact, inflammatory biomarkers 
and imaging will combine structural and functional information to provide a 
comprehensive evaluation of vascular status at an early stage; hoping to be reversible. 
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1. Introduction 
Asthma is a common chronic inflammatory disease of the respiratory tract characterized by 
episodic exacerbations with a heterogeneous population distribution. The prevalence of 
asthma has increased substantially over the past 5 decades throughout the globe, yet the 
reasons for this increase remain unknown. The disease represents a substantial burden, not 
only in terms of morbidity, mortality and reduced quality of life of patients, but also 
imposing a huge cost on the healthcare facilities in all countries.  
2. Burden of asthma  
Approximately 300 million people worldwide currently have asthma, and its prevalence 
increases by 50% every decade, seeing a rise to 400 million by year 2025 (Braman, 2006; 
Masoli et al., 2004) The increasing number of hospital admissions for asthma, which are 
most pronounced in young children, reflect an increase in severe asthma, poor disease 
management, and poverty. Worldwide, approximately 180,000 deaths annually are 
attributable to asthma. Most asthma deaths occur in those >45 years old and are largely 
preventable, frequently being related to inadequate long-term medical care or delays in 
obtaining medical help during the attack.  
The financial burden on patients with asthma in different western countries ranges from 
$300 to $1,300 per patient per year, disproportionately affecting those with the most severe 
disease. It is the most common chronic disorder in children and adolescents, with more than 
3 million asthma attacks occurring in more than 5% of all children each year. 
Asthma is a cause of concern due to under diagnosis, under investigated, under control and 
non-adherence to treatment (Barreto, 2006, National Institutes of Health, Bethesda, 2006, 
Woolcock, 1989, Bassam, 2012). A recent report from WHO suggests that 50% of patients 
from developed world with chronic diseases do not take their medications as recommended. 
In developing countries, the situation may be even worse when considering together all the 
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1. Introduction 
Asthma is a common chronic inflammatory disease of the respiratory tract characterized by 
episodic exacerbations with a heterogeneous population distribution. The prevalence of 
asthma has increased substantially over the past 5 decades throughout the globe, yet the 
reasons for this increase remain unknown. The disease represents a substantial burden, not 
only in terms of morbidity, mortality and reduced quality of life of patients, but also 
imposing a huge cost on the healthcare facilities in all countries.  
2. Burden of asthma  
Approximately 300 million people worldwide currently have asthma, and its prevalence 
increases by 50% every decade, seeing a rise to 400 million by year 2025 (Braman, 2006; 
Masoli et al., 2004) The increasing number of hospital admissions for asthma, which are 
most pronounced in young children, reflect an increase in severe asthma, poor disease 
management, and poverty. Worldwide, approximately 180,000 deaths annually are 
attributable to asthma. Most asthma deaths occur in those >45 years old and are largely 
preventable, frequently being related to inadequate long-term medical care or delays in 
obtaining medical help during the attack.  
The financial burden on patients with asthma in different western countries ranges from 
$300 to $1,300 per patient per year, disproportionately affecting those with the most severe 
disease. It is the most common chronic disorder in children and adolescents, with more than 
3 million asthma attacks occurring in more than 5% of all children each year. 
Asthma is a cause of concern due to under diagnosis, under investigated, under control and 
non-adherence to treatment (Barreto, 2006, National Institutes of Health, Bethesda, 2006, 
Woolcock, 1989, Bassam, 2012). A recent report from WHO suggests that 50% of patients 
from developed world with chronic diseases do not take their medications as recommended. 
In developing countries, the situation may be even worse when considering together all the 
 The Author(s). Lice see InTech. This c apter i  distributed under the terms of th  Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
 
Glucocorticoids – New Recognition of Our Familiar Friend 570 
issues related with poor access to health care, lack of appropriate diagnosis, and limited 
access to medicines. Poor adherence seriously threatens any effort to tackle such chronic 
illness (WHO, 2003, Horne, 2003). 
Steroids V/S No Steroids in asthma: If ever there was a magic potion that should resolve 
the symptoms of an affliction, it is the use of glucocorticoids in asthma. Since their first 
clinical application, there has been uniform agreement that the anti-inflammatory activities 
of the corticosteroids make them ideal agents to stabilize asthma during all stages of asthma 
symptomatology ranging from chronic persistent phase to acute severe life threatening 
exacerbations. 
Pathophysiology of asthma: Asthmatic inflammatory process results from inappropriate 
immune responses to common environmental antigens in a genetically susceptible 
individual (Wills-Karp 1999). These inappropriate immune responses are orchestrated by a 
subset of CD4+ T helper cells termed T helper 2 (Th2) cells. 
Cytokines play a pivotal role in the development of asthma by regulating the expansion of 
Th2 cells and by mediating many of the Th2 effector functions that underlie the pathogenic 
events of an asthmatic response. Much effort has recently been placed in elucidating the 
pathways used by cytokines to mediate their actions. These studies have revealed that 
cytokine-mediated signals are primarily transduced by the Janus Kinase- Signal Transducer 
and Activator of Transcription (JAK-STAT) signaling cascade (Darnell, 1997). Recent 
advances have shown the important roles of JAK-STAT signaling pathway in the 
pathogenesis of asthma. 
3. JAK-STAT signaling in Th1 and Th2 differentiation: 
The two major subsets of CD4+ T helper cells, Th1 and Th2, secrete mutually distinct 
profiles of cytokines and thereby coordinate different classes of immune response. The 
cytokines IL-12 and IL-4 direct the differentiation of Th1 and Th2 cells, respectively, from 
naive T helper cells. Th1 cells secrete IL-2, IFN-γ, and TNF-β, whereas Th2 cells produce IL-
4, IL-5, IL-6, IL-10, and IL-13.  
Th1 cells are critically involved in the generation of delayed-type hypersensitivity 
responses, whereas Th2 cells can direct B cells to mount strong humoral responses. 
Polarization of immune response toward a Th2 phenotype and when directed against an 
otherwise innocuous environmental antigen result in the pathogenesis of allergic diseases 
like asthma. 
The Th2 cytokines (IL-4, IL-5, and IL-13) control all the major components that characterize 
an inflammatory asthmatic response, including IgE isotype switching, mucus production, 
and the recruitment and activation of eosinophils and have been corroborated by studies in 
humans. The population of Th2 cells is notably expanded in the airways of asthmatic 
subjects, and presence of these cells correlates with airway hyper responsiveness (AHR) and 
airway eosinophilia (Rengarajan et al., 2000, Murphy et al., 2000). 
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IL-4 and IL-12 activate the Jak-Stat signaling cascade discussed elsewhere in this Perspective 
series. In this signaling pathway, binding of a cytokine to its receptor leads to the activation 
of members of the JAK family of receptor associated kinases. These kinases subsequently 
activate, via tyrosine phosphorylation, preexistent cytoplasmic factors termed Stats (signal 
transducer and activator of transcription). Tyrosine phosphorylation allows the Stat proteins 
to dimerize and translocate to the nucleus, where they mediate changes in gene expression 
by binding specific DNA elements. Although both IL-4 and IL-12 follow this basic signaling 
framework, the two cytokines differ in the specific Jak and Stat components that they 
activate (Wurster, A.L. et al 2000). IL-4 stimulates Jak1 and Jak3 to activate Stat6. In contrast, 
interaction of IL-12 with its receptor leads to the activation of Jak2 and Tyk2 and the 
subsequent phosphorylation of Stat4. Activation of Stat6 and Stat4 are thus critical events in 
the signaling cascades of IL-4 and IL-12, respectively. 
Mechanism of Action of steroids: Glucocorticoids (GC’s) are potent anti-inflammatory agents 
and are useful in the treatment of both allergic and idiosyncratic asthma. Although the 
mechanisms of corticosteroid action in asthma are poorly understood, several possible sites of 
action have been proposed which help reverse the pathologic process of bronchial asthma. 
Glucocorticoid receptors (GRs) are specific cytoplasmic transcription factors that mediate 
the biological actions of corticosteroids (Beato M et al 1995). On ligand binding, GR 
translocates into the nucleus and binds to DNA at glucocorticoid response elements (GREs) 
in the promoter region of corticosteroid-responsive genes that induce transcription (Barnes 
PJ & Adcock IM 1998). GR activation may also influence antiinflammatory events by 
nongenomic pathways, forming inhibitory interactions within the nucleus with 
proinflammatory DNA-binding transcription factors, such as activator protein (AP)-1 or 
nuclear factor (NF)–_B, or by recruitment of co-repressors, and thereby repressing the 
actions of these important inflammatory proteins (Karin M. 1998, Ito K et al. 2000). GR 
nuclear translocation is, therefore, essential and necessary for corticosteroid action. 
It has been well investigated that the novel mechanism of GC action is by blocking cytokine 
signaling via the JAK-STAT signaling pathway. Dexamethasone inhibited IL-2-induced 
DNA binding, tyrosine phosphorylation, and nuclear translocation of Stat5 in primary T 
cells. Inhibition of Stat5 correlated with inhibition of expression of IL-2-inducible genes and 
T cell proliferation. The mechanism of inhibition involved suppression of IL-2 receptor and 
Jak3 expression. Signaling by IL-4, IL-7, and IL-15, which use IL-2 receptor components, also 
was inhibited, indicating a block in T cell responses similar to that seen in immunodeficient 
patients lacking the IL-2 receptor gamma chain or Jak3. 
IL-2 signaling also was blocked in patients after treatment with GC’s, suggesting that 
inhibition of cytokine signaling contributes to the clinical efficacy of GC’s. Hence inhibition 
of both cytokine production and Jak- stat signaling contribute to their therapeutic potency 
(Bianchi, 2000). 
Corticosteroids enhance the beta-adrenergic response to relieve the muscle spasm. They also 
act by reversing the mucosal edema, decreasing vascular permeability by vasoconstriction, 
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issues related with poor access to health care, lack of appropriate diagnosis, and limited 
access to medicines. Poor adherence seriously threatens any effort to tackle such chronic 
illness (WHO, 2003, Horne, 2003). 
Steroids V/S No Steroids in asthma: If ever there was a magic potion that should resolve 
the symptoms of an affliction, it is the use of glucocorticoids in asthma. Since their first 
clinical application, there has been uniform agreement that the anti-inflammatory activities 
of the corticosteroids make them ideal agents to stabilize asthma during all stages of asthma 
symptomatology ranging from chronic persistent phase to acute severe life threatening 
exacerbations. 
Pathophysiology of asthma: Asthmatic inflammatory process results from inappropriate 
immune responses to common environmental antigens in a genetically susceptible 
individual (Wills-Karp 1999). These inappropriate immune responses are orchestrated by a 
subset of CD4+ T helper cells termed T helper 2 (Th2) cells. 
Cytokines play a pivotal role in the development of asthma by regulating the expansion of 
Th2 cells and by mediating many of the Th2 effector functions that underlie the pathogenic 
events of an asthmatic response. Much effort has recently been placed in elucidating the 
pathways used by cytokines to mediate their actions. These studies have revealed that 
cytokine-mediated signals are primarily transduced by the Janus Kinase- Signal Transducer 
and Activator of Transcription (JAK-STAT) signaling cascade (Darnell, 1997). Recent 
advances have shown the important roles of JAK-STAT signaling pathway in the 
pathogenesis of asthma. 
3. JAK-STAT signaling in Th1 and Th2 differentiation: 
The two major subsets of CD4+ T helper cells, Th1 and Th2, secrete mutually distinct 
profiles of cytokines and thereby coordinate different classes of immune response. The 
cytokines IL-12 and IL-4 direct the differentiation of Th1 and Th2 cells, respectively, from 
naive T helper cells. Th1 cells secrete IL-2, IFN-γ, and TNF-β, whereas Th2 cells produce IL-
4, IL-5, IL-6, IL-10, and IL-13.  
Th1 cells are critically involved in the generation of delayed-type hypersensitivity 
responses, whereas Th2 cells can direct B cells to mount strong humoral responses. 
Polarization of immune response toward a Th2 phenotype and when directed against an 
otherwise innocuous environmental antigen result in the pathogenesis of allergic diseases 
like asthma. 
The Th2 cytokines (IL-4, IL-5, and IL-13) control all the major components that characterize 
an inflammatory asthmatic response, including IgE isotype switching, mucus production, 
and the recruitment and activation of eosinophils and have been corroborated by studies in 
humans. The population of Th2 cells is notably expanded in the airways of asthmatic 
subjects, and presence of these cells correlates with airway hyper responsiveness (AHR) and 
airway eosinophilia (Rengarajan et al., 2000, Murphy et al., 2000). 
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IL-4 and IL-12 activate the Jak-Stat signaling cascade discussed elsewhere in this Perspective 
series. In this signaling pathway, binding of a cytokine to its receptor leads to the activation 
of members of the JAK family of receptor associated kinases. These kinases subsequently 
activate, via tyrosine phosphorylation, preexistent cytoplasmic factors termed Stats (signal 
transducer and activator of transcription). Tyrosine phosphorylation allows the Stat proteins 
to dimerize and translocate to the nucleus, where they mediate changes in gene expression 
by binding specific DNA elements. Although both IL-4 and IL-12 follow this basic signaling 
framework, the two cytokines differ in the specific Jak and Stat components that they 
activate (Wurster, A.L. et al 2000). IL-4 stimulates Jak1 and Jak3 to activate Stat6. In contrast, 
interaction of IL-12 with its receptor leads to the activation of Jak2 and Tyk2 and the 
subsequent phosphorylation of Stat4. Activation of Stat6 and Stat4 are thus critical events in 
the signaling cascades of IL-4 and IL-12, respectively. 
Mechanism of Action of steroids: Glucocorticoids (GC’s) are potent anti-inflammatory agents 
and are useful in the treatment of both allergic and idiosyncratic asthma. Although the 
mechanisms of corticosteroid action in asthma are poorly understood, several possible sites of 
action have been proposed which help reverse the pathologic process of bronchial asthma. 
Glucocorticoid receptors (GRs) are specific cytoplasmic transcription factors that mediate 
the biological actions of corticosteroids (Beato M et al 1995). On ligand binding, GR 
translocates into the nucleus and binds to DNA at glucocorticoid response elements (GREs) 
in the promoter region of corticosteroid-responsive genes that induce transcription (Barnes 
PJ & Adcock IM 1998). GR activation may also influence antiinflammatory events by 
nongenomic pathways, forming inhibitory interactions within the nucleus with 
proinflammatory DNA-binding transcription factors, such as activator protein (AP)-1 or 
nuclear factor (NF)–_B, or by recruitment of co-repressors, and thereby repressing the 
actions of these important inflammatory proteins (Karin M. 1998, Ito K et al. 2000). GR 
nuclear translocation is, therefore, essential and necessary for corticosteroid action. 
It has been well investigated that the novel mechanism of GC action is by blocking cytokine 
signaling via the JAK-STAT signaling pathway. Dexamethasone inhibited IL-2-induced 
DNA binding, tyrosine phosphorylation, and nuclear translocation of Stat5 in primary T 
cells. Inhibition of Stat5 correlated with inhibition of expression of IL-2-inducible genes and 
T cell proliferation. The mechanism of inhibition involved suppression of IL-2 receptor and 
Jak3 expression. Signaling by IL-4, IL-7, and IL-15, which use IL-2 receptor components, also 
was inhibited, indicating a block in T cell responses similar to that seen in immunodeficient 
patients lacking the IL-2 receptor gamma chain or Jak3. 
IL-2 signaling also was blocked in patients after treatment with GC’s, suggesting that 
inhibition of cytokine signaling contributes to the clinical efficacy of GC’s. Hence inhibition 
of both cytokine production and Jak- stat signaling contribute to their therapeutic potency 
(Bianchi, 2000). 
Corticosteroids enhance the beta-adrenergic response to relieve the muscle spasm. They also 
act by reversing the mucosal edema, decreasing vascular permeability by vasoconstriction, 
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and inhibiting the release of Leukotrienes (LT) LT-C4 and LT-D4. Corticosteroids reduce the 
mucus secretion by inhibiting the release of secretagogue from macrophages. 
Corticosteroids inhibit the late phase reaction by inhibiting the inflammatory response and 
interfering with chemotaxis due to the inhibition of LT-B4 release. The eosinopenic effect of 
corticosteroids may help to prevent the cytotoxic effect of the major basic protein and other 
inflammatory mediators released from eosinophils. Corticosteroids have no effect on the 
immediate hypersensitivity reaction and have no direct role in bronchial reactivity. By 
blocking the late reaction, they prevent the increased airway reactivity observed with late 
bronchial reactions, all of which aid in the resolution of bronchospasm in asthmatic patients 
(Figure 1) 
 
Figure 1. Mechanism of Action of Corticosteroids in asthma 
Mode of Delivery: All levels of persistent asthma require daily anti-inflammatory treatment 
(with additional doses of oral or intravenous steroid based on the severity of symptoms). 
Inhaled corticosteroids (ICS’s) are the safest and most effective anti-inflammatory treatment 
for patients with persistent asthma of all severity having a significant positive impact on 
outcomes. Although steroids may be given orally or systemically, and numerous non-
steroidal medications are available for treating persistent asthma, ICS’s are the treatment of 
choice considering their risk-benefit and cost-effectiveness ratio. Even when ICS’s are given 
daily over prolong period of time, they have less toxicity than oral or systemic steroids 
administered only occasionally. A wide range of ICS’s are available & the choice depends 
upon the availability, cost, physician and patient’s preference, however it is important to use 
the equipotent doses of various ICS’s while switching over the ICS’s for control of asthma 
(Table-1) 
In cases of acute severe asthma or patients requiring maintenance therapy with steroids for 
chronic persistent asthma intravenous or oral routes are to be preferred, it’s important to 
know the equipotent doses of various type of steroid while starting or switching from one 
form to another or from one steroids to another in order to get the equivalent response and 
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to avoid worsening of symptoms (if underdosing done) or side effects (if overdosing done). 




Low Daily dose 
(µgm) 
 Medicum Daily dose 
(µgm) 




200-500 500-1000 1000-2000 
Budesonide 200-400 400-800 800-1600 
Ciclesonide 80-160 10-320 320-1280 
Flunisolide 500-1000 1000-2000 >2000 
Fluticasone Propionate 100-250 250-500 500-1000 
Mometasone Furoate 200 400 800 
Triamcinolone acetonide 400-1000 1000-2000 >2000 
Table 1. Estimated Equipotent daily doses of all formulations of ICS in adults 
 
Glucocorticoid Approximate Equivalent dose (mg) Half-life(Biologic) hours 
Short-Acting 
Cortisone 25 8-12 
Hydrocortisone 20 8-12 
Intermediate-Acting 
Methylprednisolone 4 18-36 
Prednisolone/ Prednisone 5 18-36 
Triamcinolone 4 18-36 
Long-Acting 
Betamethasone 0.6 - 0.75 36-54 
Dexamethasone 0.75 36-54 
Table 2. Estimated Equipotent daily doses of all formulations of glucocorticoids in adults 
Steroids in Children: ICS are the first-line therapy for persistent asthma in children. Major 
safety concerns of long-term ICS therapy in children include suppression of adrenal 
function and impaired growth and bone development. Dosage, type of inhaler device used, 
patient technique, and characteristics of the individual drug influence systemic effects of 
ICS’s. Systemic side effects can occur when continuous high-dose treatment is required for 
severe asthma or when prescribed dosage is excessive and compliance is unusually good. 
It is very important to know that uncontrolled or severe asthma adversely affects growth 
and final adult height in children & no long-term controlled studies have reported any 
statistically or clinically significant adverse effects on growth of 100-200 µg/ day of ICS’s 
however it may be seen with all ICS’s when a high dose is administered for prolonged 
periods (dose dependent effect). Different age groups seem to differ in their susceptibility to 
the growth-retarding effects of ICS’s, children aged 4 to 10 are more susceptible than 
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inflammatory mediators released from eosinophils. Corticosteroids have no effect on the 
immediate hypersensitivity reaction and have no direct role in bronchial reactivity. By 
blocking the late reaction, they prevent the increased airway reactivity observed with late 
bronchial reactions, all of which aid in the resolution of bronchospasm in asthmatic patients 
(Figure 1) 
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outcomes. Although steroids may be given orally or systemically, and numerous non-
steroidal medications are available for treating persistent asthma, ICS’s are the treatment of 
choice considering their risk-benefit and cost-effectiveness ratio. Even when ICS’s are given 
daily over prolong period of time, they have less toxicity than oral or systemic steroids 
administered only occasionally. A wide range of ICS’s are available & the choice depends 
upon the availability, cost, physician and patient’s preference, however it is important to use 
the equipotent doses of various ICS’s while switching over the ICS’s for control of asthma 
(Table-1) 
In cases of acute severe asthma or patients requiring maintenance therapy with steroids for 
chronic persistent asthma intravenous or oral routes are to be preferred, it’s important to 
know the equipotent doses of various type of steroid while starting or switching from one 
form to another or from one steroids to another in order to get the equivalent response and 
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to avoid worsening of symptoms (if underdosing done) or side effects (if overdosing done). 
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Hydrocortisone 20 8-12 
Intermediate-Acting 
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Triamcinolone 4 18-36 
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Betamethasone 0.6 - 0.75 36-54 
Dexamethasone 0.75 36-54 
Table 2. Estimated Equipotent daily doses of all formulations of glucocorticoids in adults 
Steroids in Children: ICS are the first-line therapy for persistent asthma in children. Major 
safety concerns of long-term ICS therapy in children include suppression of adrenal 
function and impaired growth and bone development. Dosage, type of inhaler device used, 
patient technique, and characteristics of the individual drug influence systemic effects of 
ICS’s. Systemic side effects can occur when continuous high-dose treatment is required for 
severe asthma or when prescribed dosage is excessive and compliance is unusually good. 
It is very important to know that uncontrolled or severe asthma adversely affects growth 
and final adult height in children & no long-term controlled studies have reported any 
statistically or clinically significant adverse effects on growth of 100-200 µg/ day of ICS’s 
however it may be seen with all ICS’s when a high dose is administered for prolonged 
periods (dose dependent effect). Different age groups seem to differ in their susceptibility to 
the growth-retarding effects of ICS’s, children aged 4 to 10 are more susceptible than 
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adolescents, however Children with asthma treated with ICS’s attain normal adult height 
(predicted from family members) but at a later age( Pedersen, 2001, Agertoft & Pedersen, 
2000,. Sharek, & Bergman 2000). No studies have reported any statistically significant 
increase in risk of fracture in children taking ICS’s. 
Oral or systemic steroids increases the risk of fracture in children with a 32 % increase in 4 
courses ever, however ICS’s are safe in this regard. Controlled longitudinal studies of 2-5 yrs 
duration and several cross sectional studies found no adverse effect of ICS on bone mineral 
density (Agertoft & Pedersen , 1998, Hopp et al., 1995). 
Suppression of Hypothalamic-pituitary-adrenal (HPA) axis: Though differences exist 
between the various ICS’s and inhaler devices, treatment with ICS’s doses of less than 200 
µg budesonide or equivalent daily is normally not associated with any significant 
suppression of the HPA axis in children. At higher doses, small changes in HPA axis 
function can be detected with sensitive methods. The clinical relevance of these findings is 
not known, since there have not been reports of adrenal crisis in clinical trials of ICS’s in 
children. However, adrenal crisis has been reported in children treated with excessively 
high doses of ICS’s (Roux et al., 2003). 
Recent studies confirm that benefits of ICS, properly prescribed and used, clearly outweigh not 
only their potential adverse effects but also the risks associated with poorly controlled asthma. 
Benefits of oral corticosteroids for asthma include reduction in mucus production, chest 
tightness, coughing, and wheezing. Other non-asthma related conditions, such as sinus 
conditions and psoriasis, may also improve due to the anti-inflammatory properties of oral 
steroids.  
Side effects of steroids: Side effects of short-term oral steroids include fluid retention, 
stomach upset, excessive hunger, and blurred vision. Difficulty concentrating, insomnia, 
and mood changes can also occur as a result of taking oral corticosteroids. The systemic 
side-effects of long-term treatment with high doses of ICS’s may include cataracts, 
osteoporosis, easy bruising, and hair loss, Weight gain, an increase in facial hair in women, 
and muscle weakness. Long term use of oral corticosteroids may also increase the risk of 
diabetes, high blood pressure, and certain infections. Systemic effects of inhaled 
glucocorticosteroids are not a problem in adults at doses of ≤ 400 mg budesonide or 
equivalent daily. 
Factors affecting response of ICS’s: Three most important factors that appear to have 
significant impact on the effectiveness of inhaled corticosteroid (ICS) treatment are:  
1.) Patient compliance with inhaled anti-asthma therapy: The term “Compliance” is 
defined as the extent to which a patient’s behavior matches the prescriber’s advice but 
recently it has mostly been superseded by the term adherence, a similar concept but having 
fewer negative connotations from physician/patient relationship point of view (Haynes, 
1979). Adherence is defined as the extent to which the patient’s behavior matches agreed 
recommendations from the prescriber. 
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The issue of noncompliance is complicated by different patterns of noncompliance and a 
variety of measurements of noncompliance. Cochrane GM 1996 identified several patterns 
of noncompliance, including taking only half of the medications at the prescribed times, 
taking the medication regularly for a period and stopping, and skipping prescribed doses. 
Compliance with preventive therapy such as ICSs whose effect is seen over a period of 
weeks may be less than compliance with drugs that relieve asthma symptoms more rapidly. 
Patient adherence to medication is influenced by a number of factors relating to how the 
individual judges the necessity of their treatment relative to their concerns. These factors can 
be categorized as follows:  
1.  Treatment factors: 
 Dosing schedule too frequent  
 cost / non-availability of medicine 
 Complexity or inconvenience of treatment regimen 
 Need to use proper inhaler technique 
 Discomfort of drug administration (eg, bad taste, dry throat, hoarseness, fungal 
infections) 
 Physician’s Inertia / Attitude/ lack of communication 
 Proper education about the disease not given by physician  
2. Behavioral factors 
 Belief that medication is not really needed ( esp. Controller medicine (ICS) 
 Belief that medication would not work 
 Poor perception of the impact of the disease (symptoms, experience, expectations & 
interpretation of illness ) 
 Fear of adverse effects or dependence/ negative orientation to medicines 
 Steroid phobia 
 Forgetting to take medication 
 Volitional non-adherence: voluntarily not taking medication 
 Non-volitional non-adherence: from failure to take medication properly (e.g. ICS± 
LABA) 
3.  Contextual issues: Past experiences, Cultural issues/ Social beliefs/ Poor pt /View of 
others/ Practical difficulties 
It is important to keep the medication regimen as simple as possible, prioritize 
recommendations, educate the patient regarding disease management, and individualized 
the dosing and schedule of ICS as per patient’s requirment. 
2.) Inhalation technique. The effectiveness of inhaler therapy depends not only on 
compliance, but also on the inhaler technique. Various types of inhaler devices are available 
including trubohaler, discus etc however they can be broadly categorized based on the form 
of drugs used as dry powder inhalers (DPI) and Metered Dose inhalers (MDI). Although 
both types of inhalers are equally effective but While prescribing ICS to patient due 
consideration should be given to the age of the patient, comorbid conditions, coordination 
between the hands & mouth & the educational level of patient, otherwise the inhaled ICS 
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adolescents, however Children with asthma treated with ICS’s attain normal adult height 
(predicted from family members) but at a later age( Pedersen, 2001, Agertoft & Pedersen, 
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increase in risk of fracture in children taking ICS’s. 
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density (Agertoft & Pedersen , 1998, Hopp et al., 1995). 
Suppression of Hypothalamic-pituitary-adrenal (HPA) axis: Though differences exist 
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children. However, adrenal crisis has been reported in children treated with excessively 
high doses of ICS’s (Roux et al., 2003). 
Recent studies confirm that benefits of ICS, properly prescribed and used, clearly outweigh not 
only their potential adverse effects but also the risks associated with poorly controlled asthma. 
Benefits of oral corticosteroids for asthma include reduction in mucus production, chest 
tightness, coughing, and wheezing. Other non-asthma related conditions, such as sinus 
conditions and psoriasis, may also improve due to the anti-inflammatory properties of oral 
steroids.  
Side effects of steroids: Side effects of short-term oral steroids include fluid retention, 
stomach upset, excessive hunger, and blurred vision. Difficulty concentrating, insomnia, 
and mood changes can also occur as a result of taking oral corticosteroids. The systemic 
side-effects of long-term treatment with high doses of ICS’s may include cataracts, 
osteoporosis, easy bruising, and hair loss, Weight gain, an increase in facial hair in women, 
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equivalent daily. 
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defined as the extent to which a patient’s behavior matches the prescriber’s advice but 
recently it has mostly been superseded by the term adherence, a similar concept but having 
fewer negative connotations from physician/patient relationship point of view (Haynes, 
1979). Adherence is defined as the extent to which the patient’s behavior matches agreed 
recommendations from the prescriber. 
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The issue of noncompliance is complicated by different patterns of noncompliance and a 
variety of measurements of noncompliance. Cochrane GM 1996 identified several patterns 
of noncompliance, including taking only half of the medications at the prescribed times, 
taking the medication regularly for a period and stopping, and skipping prescribed doses. 
Compliance with preventive therapy such as ICSs whose effect is seen over a period of 
weeks may be less than compliance with drugs that relieve asthma symptoms more rapidly. 
Patient adherence to medication is influenced by a number of factors relating to how the 
individual judges the necessity of their treatment relative to their concerns. These factors can 
be categorized as follows:  
1.  Treatment factors: 
 Dosing schedule too frequent  
 cost / non-availability of medicine 
 Complexity or inconvenience of treatment regimen 
 Need to use proper inhaler technique 
 Discomfort of drug administration (eg, bad taste, dry throat, hoarseness, fungal 
infections) 
 Physician’s Inertia / Attitude/ lack of communication 
 Proper education about the disease not given by physician  
2. Behavioral factors 
 Belief that medication is not really needed ( esp. Controller medicine (ICS) 
 Belief that medication would not work 
 Poor perception of the impact of the disease (symptoms, experience, expectations & 
interpretation of illness ) 
 Fear of adverse effects or dependence/ negative orientation to medicines 
 Steroid phobia 
 Forgetting to take medication 
 Volitional non-adherence: voluntarily not taking medication 
 Non-volitional non-adherence: from failure to take medication properly (e.g. ICS± 
LABA) 
3.  Contextual issues: Past experiences, Cultural issues/ Social beliefs/ Poor pt /View of 
others/ Practical difficulties 
It is important to keep the medication regimen as simple as possible, prioritize 
recommendations, educate the patient regarding disease management, and individualized 
the dosing and schedule of ICS as per patient’s requirment. 
2.) Inhalation technique. The effectiveness of inhaler therapy depends not only on 
compliance, but also on the inhaler technique. Various types of inhaler devices are available 
including trubohaler, discus etc however they can be broadly categorized based on the form 
of drugs used as dry powder inhalers (DPI) and Metered Dose inhalers (MDI). Although 
both types of inhalers are equally effective but While prescribing ICS to patient due 
consideration should be given to the age of the patient, comorbid conditions, coordination 
between the hands & mouth & the educational level of patient, otherwise the inhaled ICS 
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will get deposited in the oropharynx & produce local side effects(such as change in voice, 
Oropharyngeal candidiasis). Use of Spacer with MDI can largely reduce the deposition of 
the ICS in throat & hence avoid local side effects of the steroids. 
3.) Impact of inhalation technique and device on drug deposition in the lungs: For ICSs, 
the efficacy depends on the topical activity of the drug that reaches the target area, whereas 
the adverse events depend both on oral deposition and systemic activity. Systemic activity 
of the drug depends on the amount of the drug absorbed either through the GI tract or 
through the lungs, as well as on the first-pass metabolism for drug absorbed through the GI 
tract. 
The amount of drug delivered to the lungs depends on the inhalation technique,(Dolovich, 
1981, Jackson & Lipworth , 1995) as well as on the type of inhaler used and the fine particle 
size (respirable particle diameter between 1- 4 µm) of the drug. Table -3 shows the 
Estimates of the Lung to Systemic Bioavailability Ratios for different types of ICS’s. 
 
Product 
% Dose Deposited in
the Lungs 
% Dose Reaching the 
Systemic 
Circulation after 




BDP via CFC 
propellant 
5.5  14.7  0.27 
BDP (non-CFC 
propellant) 
56.1  5.5  0.92 
Budesonide via MDI  15  7.7 0.66 
Budesonide via DPI  30 5.3 0.85 
BDP-beclomethasone dipropionate. CFC-chlorofluorocarbon. MDI-metered-dose inhaler, DPI- dry powder inhaler. 
Table 3. Estimates of the Lung to Systemic Bioavailability Ratios for Inhaled Corticosteroids 
Recent Recommendations about the delivery device for ICS from American College of Chest 
Physicians/American College of Asthma, Allergy, and Immunology states that: 
1. For the treatment of asthma in the outpatient setting, both the MDI with a 
spacer/holding chamber and the DPI are appropriate devices for the delivery of ICS’s. 
2. For outpatient asthma therapy, the selection of an appropriate aerosol delivery device 
for ICS’s includes the patient’s ability to use the device correctly, the preferences of the 
patient for the device, the availability of the drug/device combination, the compatibility 
between the drug and delivery device, the lack of time or skills to properly instruct the 
patient in the use of the device or monitor the appropriate use, the cost of therapy, and 
the potential for reimbursement( Dolovich, 2005). Table -4 summarizes the advantages 
& disadvantages of all the devices available for the delivery of ICS’s 
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Patient coordination not required 
Effective with tidal breathing 
High dose possible 
Dose modification possible 
Can be used with supplemental 
oxygen 
Can deliver combination therapies 
if compatible 
Lack of portability
Pressurized gas source required 
Lengthy treatment time 
Device cleaning required 
Contamination possible 
Not all medication available in solution 
form 
Does not aerosolize suspensions well 
Device preparation required 
Performance variability 
Expensive when compressor added 
Ultrasonic 
nebulizer 
Patient coordination not required 
High dose possible 
Dose modification possible 
Small dead volume 
small and portable 
Faster delivery than jet nebulizer 
No drug loss during exhalation 
(breath actuated devices) 
Expensive
Need for electric power source  
Contamination possible 
Not all medication available  
Device preparation required before 
treatment 
Does not nebulize suspensions well 
Possible drug degradation airway 
irritation with some drugs
Pressurized 
MDI 





Treatment time is short 
No drug preparation required 
No contamination of contents 
Dose-dose reproducibility high 
Some can be used with breath 
actuated mouthpiece
Coordination of breathing and device 
actuation needed 
High pharyngeal deposition 
Upper limit to unit dose content 
Remaining doses difficult to determine 
Potential for abuse 









Reduces need for coordination 
Reduces pharyngeal deposition 
Inhalation can be more complex for 
some patients 
Can reduce dose available if not used 
properly 
More expensive/Less portable Integral 
actuator devices may alter aerosol 








Less coordination required 
No Propellant required 
Small and portable 
Short treatment time 
Dose counters
Requires moderate to high inspiratory 
flow 
Can result in high pharyngeal 
deposition 
Not all medications available 
CFC-Cloro-fluor-Carbon, HFA- hydro-fluoro-alkane, MDI- Metered dose inhaler, DPI- Dry Powder inhaler 
Table 4. Advantages and Disadvantages of Aerosol-Generating Device or System 
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In short, effective asthma treatment requires a combination of pharmacology and 
psychology. Effective prescribing needs to take account of patients’ beliefs, expectations, 
and adherence behavior. 
Goal of Asthma Management: According to Global Initiative for Asthma (GINA 2010) 
Guidelines issued by the National Heart Lung & Blood institute, the goals for successful 
management of asthma are to: 
 Achieve and maintain control of symptoms 
 Maintain normal activity level including exercise 
 Maintain pulmonary functions as close to normal as possible 
 Prevent asthma exacerbations 
 Avoid side effects from asthma medications 
 Avoid asthma mortality 
Therefore, for successful management of asthma and optimum control of asthma , patients 
should always be assessed to know their status of asthma control , Following classification 
of asthma by level of control is more relevant and useful (Figure 2). 
 
 
 Adopted from Global Initiative for Asthma (GINA 2010) Guidelines 
* Any exacerbation should prompt review of maintenance treatment to ensure that it is adequate. 
† By denition, an exacerbation in any week makes that an uncontrolled asthma week. 
‡ Lung function testing is not reliable for children 5 years and younger. 
Figure 2. Classification of asthma by level of control 
To reach this goal, four interrelated components of therapy are required:  
Component 1: Develop patient/doctor partnership: In order to help in the effective 
management of asthma so that the asthmatic patient can learn how to: avoid risk factors, 
take medications correctly, understand the difference between “controller” and “reliever” 
medications, monitor their status using symptoms and, if relevant Peak expiratory Flow 
(PEF) recognize signs that asthma is worsening and take action, seek medical help as 
appropriate. 
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Component 2: Identify and Reduce Exposure to Risk Factors: To improve control of 
asthma and reduce medication needs, despite physical activity is a common cause of 
asthma symptoms however patients should not avoid exercise. Common strategies for 
avoiding allergens and pollutants include the followings; Stay away from tobacco smoke, 
patients and parents should not smoke, avoid drugs, foods, and additives if they are 
known to cause symptoms, reduce or, preferably, avoid exposure to occupational 
sensitizers. 
Component 3: Assess, Treat, and Monitor Asthma: Each patient is assigned to one of 
five treatment “steps” based on the frequency and severity of symptoms, PFT values and 
the exacerbations. At each treatment step, asthma education, environmental control & 
vaccination are important component of asthma control. Rescue medication should be 
provided for quick relief of symptoms as needed. As the severity of disease increases, 
from Steps 2- 5, patients should be given one or more regular controller medications (ICS 
) in order to keep asthma under control & to avoid the morbidity & mortality related 
with asthma and to prevent the long term consequences of the disease. Regular use of 
ICS has demonstrated high efficiency in reducing asthma symptoms, reducing frequency 
& severity of exacerbations, reducing mortality, improving quality of life, improving 
lung function, decreasing airway hyper-responsiveness & controlling airway 
inflammation. 
Component 4: Managing asthma exacerbations: Exacerbations of asthma are characterized 
by episodes of progressive increase in shortness of breath, cough, wheezing or chest 
tightness, or some combination of these symptoms. Mamgement of asthma exacerbation 
requires close objective monitoring (both clinical and using PEF), repetitive administration 
of rapid-acting inhaled bronchodilators, early introduction of systemic glucocorticosteroids 
and oxygen supplementation. It is very important to use systemic steroids early in case of 
exacerbation in order to control the underlying inflammation earliest possible. GINA 
guidelines have simplified the recognition of severity of acute exacerbation of asthma and 
management in acute care setting base on the severity of symptoms & response to treatment 
(For details: www.ginasthma.org)  
Stepwise approach for asthma Management: GINA guidelines have simplified the 
management of asthma at all stages in stepwise manner starting from rescue medicines to 
regular controller medicine. (Figure 3)  
4. Glucocorticoid resistance 
Although glucocorticoids are highly effective in the control of chronic inflammation or 
immune dysregulation occurring in asthma pts however a small proportion of patients 
displays persistent immune activation and airway inflammation and fail to respond despite 
high doses of oral corticosteroids imposing a big challenge for the physicians. (Barnes, 1995, 
1995, Sze¯er, 1997). This group of patients has been classified as “steroid-resistant”  
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vaccination are important component of asthma control. Rescue medication should be 
provided for quick relief of symptoms as needed. As the severity of disease increases, 
from Steps 2- 5, patients should be given one or more regular controller medications (ICS 
) in order to keep asthma under control & to avoid the morbidity & mortality related 
with asthma and to prevent the long term consequences of the disease. Regular use of 
ICS has demonstrated high efficiency in reducing asthma symptoms, reducing frequency 
& severity of exacerbations, reducing mortality, improving quality of life, improving 
lung function, decreasing airway hyper-responsiveness & controlling airway 
inflammation. 
Component 4: Managing asthma exacerbations: Exacerbations of asthma are characterized 
by episodes of progressive increase in shortness of breath, cough, wheezing or chest 
tightness, or some combination of these symptoms. Mamgement of asthma exacerbation 
requires close objective monitoring (both clinical and using PEF), repetitive administration 
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and oxygen supplementation. It is very important to use systemic steroids early in case of 
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Although glucocorticoids are highly effective in the control of chronic inflammation or 
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high doses of oral corticosteroids imposing a big challenge for the physicians. (Barnes, 1995, 
1995, Sze¯er, 1997). This group of patients has been classified as “steroid-resistant”  
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Adopted from Global Initiative for Asthma (GINA 2010) Guidelines 
Figure 3. Stepwise approach for asthma Management 
Steroid resistant asthma: American Thoracic Society (ATS) defined Steroid resistant 
patients as characterized by a pre-bronchodilator Force expiratory volume in 1 sec (FEV1) of 
less than 70% predicted with a maintained bronchodilator response. Steroid resistance is 
defined by administering a course of oral prednisone e.g. 40 mg/d (divided doses) for 7 days 
or preferably 2 wk, and observing the effect on morning pre-bronchodilator FEV1 (Lee, 
1996). If the FEV1 fails to increase by 15% (and 200 ml), the patient is considered steroid 
resistant (Sally et al., 2000). These patients show the typical diurnal variability in peak 
expiratory flow and bronchodilatation with inhaled B-2 agonists. This type of trial can also 
assess the possibility of poor adherence to the maintenance regimen.  
Patients with steroid resistance can be grouped into two broad categories, 
Type 1 steroid resistance: is either immune-mediated or acquired as the result of 
environmental triggers or lifestyle. Clinically, such patients will develop steroid side effects, 
including adrenal gland suppression, osteoporosis, and cushingoid features from 
pharmacologic doses of systemic steroids. This is because there is only one (glucocorticoid 
resistant) GR gene and these patients have steroid resistance only at the level of their 
immune/inflammatory cells (i.e., T cells). The rest of the tissues in their body remain 
sensitive to the deleterious effects of systemic steroids.  
Type 2 steroid resistances: is rare but involves a generalized primary cortisol resistance that 
affects all tissues and is likely associated with a mutation in the GR gene or genes that 
modulate GR function. This form is not associated with the development of steroid’s side 
effects or suppression of morning cortisol levels (Table 5). It is analogous to genetically 
inherited familial cortisol resistance. When patients present with a history of no side effects 
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after high doses of prednisone, it is critical to confirm that they are taking the oral prednisone 
by checking their morning serum cortisol after a course of therapy under strict supervision. 
Such individuals need alternative approaches to control their pulmonary inflammation. 
 
Features Type 1 steroid resistances Type 2 steroid resistances 
AM cortisol levels Suppressed No 
Cushingoid side effects Yes  No 
Cause 
Cytokine induced(May be 
genetic), Allergy, Microbes 
Genetic 
GCR ligand and DNA 
binding affinity 
Reduced Normal 
GCR numbers Normal or High Low 
Reversibility of GCR defect Yes No 
Table 5. Summarizes difference in both Types of steroid resistance 
It is imperative to exclude confounding factors when trying to make the diagnosis of 
steroid-resistant asthma in a patient. These factors include non-adherence with asthma 
medication, inadequate inhalation technique, incorrect diagnosis, unrecognized concomitant 
diagnoses, and ongoing exposure to environmental allergens, abnormal corticosteroid 
pharmacokinetics, and psychosocial disturbances. Low dose methotrexate, cyclosporine, 
Intravenous immunoglobulin, leukotriene antagonists, such as zafirlukast and montelukast 
and Nedocromil sodium has been used in steroid resistant patients with varying success 
rates and with associated side effects. 
5. Clinical features of glucocorticoid-resistant asthma 
Glucocorticoid resistance in asthma was first described in six patients with asthma who did 
not respond clinically to high doses of systemic glucocorticoids and in whom there was also 
a reduced eosinopenic response (Schwartz et al .,1968). Larger groups of patients with 
chronic asthma who were glucocorticoid resistant were subsequently identified (Carmichael 
et al ., 1981). These patients were not Addisonian and did not suffer from the abnormalities 
in sex hormones described in familial glucocorticoid resistance (see below). Plasma cortisol 
and adrenal suppression in response to exogenous cortisol is normal (Lane et al., 1996). 
Complete glucocorticoid resistance in asthma is very rare, but reduced responsiveness is 
more common, so that oral glucocorticoids are needed to control asthma adequately 
(steroid-dependent asthma). 
Mechanisms of glucocorticoid resistance: There may be several mechanisms for resistance 
to the effects of glucocorticoids. Although a family history of asthma is more common in 
patients with GCR than GCS asthma, little is known about its inheritance. It is possible that 
a certain proportion of the population has glucocorticoid resistance which only becomes 
manifest when they develop a severe immunological or immune disease that requires 
glucocorticoid therapy. Resistance to the inflammatory and immune effects of 
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Mechanisms of glucocorticoid resistance: There may be several mechanisms for resistance 
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glucocorticoids should be distinguished from the rare familial glucocorticoid resistance, 
where there is an abnormality of glucocorticoid binding to GR. 
Glucocorticoid resistance may be primary (inherited or acquired of unknown cause) or 
secondary due to reduced glucocorticoid responsiveness (glucocorticoids themselves, 
cytokines, b-adrenergic agonists).  
Primary glucocorticoid resistance: There are several possible mechanisms for a reduced 
anti-inflammatory response to glucocorticoids.  
a. Pharmacokinetic abnormalities. 
b. Antibodies to lipocortin-1. 
c. Cellular abnormalities. 
d. Abnormality in GR function. 
e. Interaction between GR and transcription factors. 
Secondary glucocorticoid resistance: various probable mechanisms include: 
a. Down-regulation of GR. 
b. Effects of cytokines. 
c. Effect of B2 agonists. 
6. Factors contributing to corticosteroid resistance 
A variety of factors known to contribute to immune activation and pulmonary disease have 
been found to alter corticosteroid responsiveness (Table 6). 
 






Low vitamin D level 
Table 6. Factors Contributing to Corticosteroid Insensitivity 
6.1. Allergen exposure 
Allergen exposure in vivo reduces GR binding affinity in PBMCs from atopic asthmatics. In 
vitro treatment with cat allergen of peripheral blood mononuclear cell (PBMC) from cat-
allergic asthmatics was also observed to reduce GR binding affinity and T-cell proliferation 
induced by allergens compared with control antigens. The induction of these GR binding 
abnormalities was found to be IL-2 and IL-4 dependent. 
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6.2. Infection 
Infection is a common trigger for pulmonary disease. An analysis of the T-cell repertoire in 
patients whose asthma was poorly controlled (FEV1 <75% predicted despite use of high-dose 
corticosteroids) revealed that their T cells were activated by a microbial superantigen. To 
determine whether microbial super antigens could alter corticosteroid sensitivity, the 
capacity of corticosteroids to inhibit the activation of T cells from normal subjects with super 
antigens as compared with the mitogen, phytohemagglutinin, was studied. While 
corticosteroids caused a 99% inhibition of phytohemagglutinin-induced PBMC proliferation, 
there was only 19% inhibition of super antigen-induced T-cell proliferation. The mechanism 
by which super antigens induce corticosteroid resistance of human T cells is via activation of 
the Mitogen-Activated protein Kinase Kinase/Extracellular signal-Regulated Kinase (MEKK-
ERK ) pathway (Li et al., 2004, Goleva et al., 2004). Viruses can also alter response in 
corticosteroids. In particular, rhinovirus has been reported to reduce GR nuclear 
translocation and thereby reduce corticosteroid response. 
6.3. Neutrophilia 
The nature of the inflammatory infiltrate will also determine whether the particular 
pulmonary disease being treated is likely to resolve with corticosteroid therapy. Pulmonary 
diseases associated with infiltration of neutrophils are likely to be Steroid resistant. To 
determine the potential mechanism of corticosteroid resistance in neutrophils, Strickland et 
al.,2001 examined relative amounts of GRα and GRβ in freshly isolated neutrophils and 
observed increased GRβ, but not GRα, protein and mRNA expression in neutrophils at 
baseline and after IL-8 exposure (Strickland et al. 2001). High constitutive expression of GR-
β by neutrophils may provide a mechanism by which these cells escape corticosteroid-
induced cell death.  
6.4. Other factors contributing to steroid resistance 
Other factors contributing to steroid resistance include smoking, stress, obesity, ethnicity, 
and vitamin D deficiency. In smokers, oxidative stress results in reduced levels of histone 
deacetylase-2 (Barnes, Adcock, 2009). Stress may induce steroid resistance via multiple 
mechanisms, including the chronic elevation of the stress hormone, cortisol, which 
downregulates expression of the GR (Haczku , Panettieri, 2010). The association of steroid 
resistance with obesity may be related to the systemic inflammation found in this condition, 
leading to chronic elevation of TNF and mitogen-activated protein kinase (MAPK) 
activation that causes GR dysfunction (Sutherland et al., 2008) Black patients with asthma 
have also been found to have reduced steroid responsiveness compared with white 
asthmatics (Federico, 2005), although the reason for this is not known, but it could be due to 
a combination of genetic and environmental factors. 
Several recent studies on asthmatics have now shown that low vitamin D levels are 
associated with increased corticosteroid requirements, and there is a potential role for 
vitamin D in the enhancement of corticosteroid response (Sutherland et al., 2010) 
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glucocorticoids should be distinguished from the rare familial glucocorticoid resistance, 
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secondary due to reduced glucocorticoid responsiveness (glucocorticoids themselves, 
cytokines, b-adrenergic agonists).  
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c. Cellular abnormalities. 
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e. Interaction between GR and transcription factors. 
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a. Down-regulation of GR. 
b. Effects of cytokines. 
c. Effect of B2 agonists. 
6. Factors contributing to corticosteroid resistance 
A variety of factors known to contribute to immune activation and pulmonary disease have 
been found to alter corticosteroid responsiveness (Table 6). 
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7. Management of corticosteroid resistance 
The management of steroid resistant (SR) asthma poses a significant challenge to the 
clinician. Identification of the SR patient early in the course of illness is important to prevent 
tissue remodeling and irreversible changes in lung pathology. Definitions of clinical 
response to steroid therapy will be dictated by the pulmonary disease being treated and 
time frame for improvement of clinical disease before unacceptable steroid side effects 
occur. In the case of asthma, clinical studies have suggested that favorable response to 
inhaled steroids is associated with high levels of exhaled nitric oxide, high bronchodilator 
response, and a low FEV1/FVC ratio prior to treatment (Barnes,2008) 
A systematic, stepwise approach is important for a successful outcome (Leung and Bloom, 
2003). Table 7 lists factors to be considered in the evaluation of patients with a history of 
steroid resistance.  
 
Correct diagnosis 




Drug interactions causing enhanced metabolism of steroids 
Alternative anti-inflammatory therapies 
Table 7. Considerations in Treating Steroid Resistance 
Step 1. Complete Evaluation including history, physical examination, pulmonary function 
testing, and appropriate laboratory tests to confirm the diagnosis and rule out 
concomitant medical disorders such as vocal cord dysfunction, Gastroesophageal 
reflux/aspiration, chronic rhinosinusitis, allergic bronchopulmonary aspergillosis, heart 
failure, COPD & broncholitis etc.(Figure 4) 
Step 2. Try to find out psychological & social factors including adherence to therapy and 
take corrective measures for them.  
Step 3. Observe the inhalational technique of patient, reeducate, reinforce about the proper 
technique especially in patients requiring high doses of ICS for severe persistent 
asthma. Spacer devices should be used to maximize ICS dose delivery and reduce 
adverse effects. 
Step 4. Strict environmental control at home, in school, and at work including finding the 
source of allergens & eliminating the same because persistent allergen exposure will 
increase the symptoms of asthma & reduces steroid responsiveness. 
Step 5. Search for concomitant bacterial/ mycobacterial/ fungal infection of the 
tracheobronchial tree especially in patients taking high doses of ICS or chronic oral 
steroids. Chronic colonization with Mycoplasma pneumoniae or Chlamydia pneumoniae, 
can trigger airway inflammation in chronic asthmatics and thus poor responsiveness to 
steroids. 
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Figure 4. Flow diagram to manage steroid resistant asthma 
Step 6. Search for factors affecting lifestyle and steroid responsiveness. Patients with 
Vitamin D deficiency have increased steroid requirements. Other cofactors, including 
obesity, smoking, no or little exposure to sunlight and pigmented skin are well known 
to lower vitamin D levels.  
Step 7. Combination therapy can be used to maximize clinical response. Inhaled long-
acting β2-agonists (LABA) have been found to enhance Glucocorticoid receptor (GR) 
nuclear translocation and reduced corticosteroid requirements. Consider addition of 
other steroid-sparing drugs such as leukotriene modifiers, anticholinergic drugs, 
nidocromil sodium( Marin, 1996) and theophylline.  
Step 8. In very difficult case, studies to identify systemic steroid pharmacokinetics and 
receptors to assess the basis for corticosteroid resistance to determine whether there is 
incomplete corticosteroid absorption, failure to convert corticosteroids to an active 
form, or rapid elimination of steroids (frequently as a result of interactions with other 
medications). Patients with poor absorption of prednisone usually respond well to oral 
liquid steroid preparations. In patients with rapid corticosteroid elimination, a split 
dosing regimen (morning & afternoon) is suggested. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 584 
7. Management of corticosteroid resistance 
The management of steroid resistant (SR) asthma poses a significant challenge to the 
clinician. Identification of the SR patient early in the course of illness is important to prevent 
tissue remodeling and irreversible changes in lung pathology. Definitions of clinical 
response to steroid therapy will be dictated by the pulmonary disease being treated and 
time frame for improvement of clinical disease before unacceptable steroid side effects 
occur. In the case of asthma, clinical studies have suggested that favorable response to 
inhaled steroids is associated with high levels of exhaled nitric oxide, high bronchodilator 
response, and a low FEV1/FVC ratio prior to treatment (Barnes,2008) 
A systematic, stepwise approach is important for a successful outcome (Leung and Bloom, 
2003). Table 7 lists factors to be considered in the evaluation of patients with a history of 
steroid resistance.  
 
Correct diagnosis 




Drug interactions causing enhanced metabolism of steroids 
Alternative anti-inflammatory therapies 
Table 7. Considerations in Treating Steroid Resistance 
Step 1. Complete Evaluation including history, physical examination, pulmonary function 
testing, and appropriate laboratory tests to confirm the diagnosis and rule out 
concomitant medical disorders such as vocal cord dysfunction, Gastroesophageal 
reflux/aspiration, chronic rhinosinusitis, allergic bronchopulmonary aspergillosis, heart 
failure, COPD & broncholitis etc.(Figure 4) 
Step 2. Try to find out psychological & social factors including adherence to therapy and 
take corrective measures for them.  
Step 3. Observe the inhalational technique of patient, reeducate, reinforce about the proper 
technique especially in patients requiring high doses of ICS for severe persistent 
asthma. Spacer devices should be used to maximize ICS dose delivery and reduce 
adverse effects. 
Step 4. Strict environmental control at home, in school, and at work including finding the 
source of allergens & eliminating the same because persistent allergen exposure will 
increase the symptoms of asthma & reduces steroid responsiveness. 
Step 5. Search for concomitant bacterial/ mycobacterial/ fungal infection of the 
tracheobronchial tree especially in patients taking high doses of ICS or chronic oral 
steroids. Chronic colonization with Mycoplasma pneumoniae or Chlamydia pneumoniae, 
can trigger airway inflammation in chronic asthmatics and thus poor responsiveness to 
steroids. 
 
Steroids in Asthma: Friend or Foe 585 
 
Figure 4. Flow diagram to manage steroid resistant asthma 
Step 6. Search for factors affecting lifestyle and steroid responsiveness. Patients with 
Vitamin D deficiency have increased steroid requirements. Other cofactors, including 
obesity, smoking, no or little exposure to sunlight and pigmented skin are well known 
to lower vitamin D levels.  
Step 7. Combination therapy can be used to maximize clinical response. Inhaled long-
acting β2-agonists (LABA) have been found to enhance Glucocorticoid receptor (GR) 
nuclear translocation and reduced corticosteroid requirements. Consider addition of 
other steroid-sparing drugs such as leukotriene modifiers, anticholinergic drugs, 
nidocromil sodium( Marin, 1996) and theophylline.  
Step 8. In very difficult case, studies to identify systemic steroid pharmacokinetics and 
receptors to assess the basis for corticosteroid resistance to determine whether there is 
incomplete corticosteroid absorption, failure to convert corticosteroids to an active 
form, or rapid elimination of steroids (frequently as a result of interactions with other 
medications). Patients with poor absorption of prednisone usually respond well to oral 
liquid steroid preparations. In patients with rapid corticosteroid elimination, a split 
dosing regimen (morning & afternoon) is suggested. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 586 
Step 9. Consider Steroid sparing anti-inflammatory therapies that would enhance 
corticosteroid action including cyclosporine (Alexander et al., 1992), IV 
Immunoglobulin (Mazer , 1991), methotrexate (Mullarkey et al. 1998, Erzurum et al., 
1991), mycophenolate mofetil, azathioprine, Macrolides, trolendamycin and gold, 
depending on the severity of asthma and the potential of significant side effects. 
Omalizumab (recombinant anti IgE antibody) is useful in patients with primarily 
allergic asthma & with severe persistent allergic rhinitis.  
Further Studies are needed to determine whether cytokine antagonism—TNF-α, IL-2, IL-4, 
or IL-13—could restore steroid responsiveness because such cytokines have been found to 
induce steroid resistance. Vitamin D has recently been demonstrated to induce IL-10-
producing regulatory T cells (Xystrakis et al., 2006) and enhance steroid action, and may 
therefore be steroid sparing( Zhang et al., 2010) 
8. Novel steroids 
Steroids, either systemic or inhaled, are exquisitely active and effective in asthma, but their 
mechanism of action is broad, and concern for toxicity—even with topical steroids—has 
limited their wider use. A variety of approaches are being pursued to maximize local 
activity within the airways and at the same time to minimize systemic absorption and 
toxicity. One approach is development of on-site-activated steroids such as ciclesonide, 
which is a nonhalogenated ICS prodrug that requires endogenous cleavage by esterases for 
activity. Soft steroids are also being developed; these have improved local, topical selectivity 
and have much less steroid effect outside the target area. They may be inactivated by 
esterases or other enzymes (for example a lactone–glucocorticosteroid conjugate).  
Dissociated glucocorticoids: The recognition that most of the anti-inflammatory effects of 
glucocorticoids are mediated by repression of transcription factors (transrepression), 
whereas the endocrine and metabolic effects of steroids are likely to be mediated via 
glucocorticoid response element binding (transactivation) has led to a search for novel 
corticosteroids that selectively transrepress, thus reducing the potential risk of systemic side 
effects. These dissociated steroids which favor monomeric glucocorticoid receptor 
complexes (i.e., they produce transrepression) and avoid dimerization or transactivation, 
which is undesirable in asthma would make the treatment of asthma more effective without 
the current fear of steroid’s side effects. Agents from each of these categories are undergoing 
clinical trials.  
Steroid sparing : The combination of long acting beta agonist (LABA) with inhaled 
corticosteroid (ICS) is used frequently in asthma and a benefit from adding LABA to ICS has 
been described. One review compared reduced dose (mean 60% reduction in inhaled 
steroid) ICS/LABA combination to either a fixed moderate/high dose ICS or a 
reduced/tapering ICS dose. In adults with asthma, who use moderate to high maintenance 
doses of ICS, the addition of LABA has an ICS-sparing effect. LABA permit a reduction of 
37% (253 mcg BDP) in subjects on minimum maintenance ICS and up to 60% (300 mcg FP) in 
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subjects on maintenance ICS without deterioration in asthma control. They are most 
effective when combined with ICS, and this combination therapy is the preferred treatment 
when a medium dose of ICS alone fails to achieve control of asthma (Gibson, 2005). The 
addition of a LABA to a daily regimen of ICS improves symptom scores, decreases 
nocturnal symptoms, improves lung function, decreases the use of relief medication, 
reduces the number of exacerbations and achieves clinical control of asthma in more 
patients, more rapidly, and at a lower dose of ICS, than ICS given alone(Greening,1994, 
Pauwel, 1997). 
Certain case reports have documented tiotropium as a useful steroid sparing agent however 
future clinical trials are warranted that explore the use of tiotropium as a potential ‘steroid-
sparing agent’ in severe refractory asthma (Kapoor, 2009). 
9. Immunomodulator therapy as steroid sparing 
Methotrexate: Methotrexate may have a small steroid sparing effect in adults with asthma 
who are dependent on oral corticosteroids. However, the overall reduction in daily steroid 
use is probably not large enough to reduce steroid-induced adverse effects. This small 
potential to reduce the impact of steroid side-effects is probably insufficient to offset the 
adverse effects of methotrexate (Davies, 1998) 
Azathioprine : Currently there is a clear lack of evidence to support the use of azathioprine 
in the treatment of chronic asthma as a steroid sparing-agent. Large, long-term studies with 
pre-defined steroid reducing protocols are required before recommendations for clinical 
practice can be made (Dean, 2004) 
Cyclosporine: The improvement in asthma with cyclosporin are small and of questionable 
clinical significance. Given the side effects of cyclosporin, the evidence available does not 
recommend routine use of this drug in the treatment of oral corticosteroid dependent 
asthma (Evans, 2001) 
Chloroquine : There is insufficient evidence to support the use of chloroquine as an oral 
steroid-sparing agent in chronic asthma. Further trials should optimise oral steroid dosage 
before addition of the steroid-sparing agent (Dewey, 2003) 
Troleandomycin : There is insufficient evidence to support the use of troleandomycin in the 
treatment of steroid dependent asthma.( Evans ,2001) 
Gold: Gold has limited clinically significanct benefits as steroid sparing agent & given the 
side effects of gold and necessity for monitoring the use of gold as a steroid sparing agent in 
asthma cannot be recommended.(Evans , 2001) 
10. Conclusion 
Inhaled Corticosteroids are the most effective first line of therapeutic intervention to control 
the primary immunologic mechanism of the disease and to avoid the devastating 
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subjects on maintenance ICS without deterioration in asthma control. They are most 
effective when combined with ICS, and this combination therapy is the preferred treatment 
when a medium dose of ICS alone fails to achieve control of asthma (Gibson, 2005). The 
addition of a LABA to a daily regimen of ICS improves symptom scores, decreases 
nocturnal symptoms, improves lung function, decreases the use of relief medication, 
reduces the number of exacerbations and achieves clinical control of asthma in more 
patients, more rapidly, and at a lower dose of ICS, than ICS given alone(Greening,1994, 
Pauwel, 1997). 
Certain case reports have documented tiotropium as a useful steroid sparing agent however 
future clinical trials are warranted that explore the use of tiotropium as a potential ‘steroid-
sparing agent’ in severe refractory asthma (Kapoor, 2009). 
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use is probably not large enough to reduce steroid-induced adverse effects. This small 
potential to reduce the impact of steroid side-effects is probably insufficient to offset the 
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in the treatment of chronic asthma as a steroid sparing-agent. Large, long-term studies with 
pre-defined steroid reducing protocols are required before recommendations for clinical 
practice can be made (Dean, 2004) 
Cyclosporine: The improvement in asthma with cyclosporin are small and of questionable 
clinical significance. Given the side effects of cyclosporin, the evidence available does not 
recommend routine use of this drug in the treatment of oral corticosteroid dependent 
asthma (Evans, 2001) 
Chloroquine : There is insufficient evidence to support the use of chloroquine as an oral 
steroid-sparing agent in chronic asthma. Further trials should optimise oral steroid dosage 
before addition of the steroid-sparing agent (Dewey, 2003) 
Troleandomycin : There is insufficient evidence to support the use of troleandomycin in the 
treatment of steroid dependent asthma.( Evans ,2001) 
Gold: Gold has limited clinically significanct benefits as steroid sparing agent & given the 
side effects of gold and necessity for monitoring the use of gold as a steroid sparing agent in 
asthma cannot be recommended.(Evans , 2001) 
10. Conclusion 
Inhaled Corticosteroids are the most effective first line of therapeutic intervention to control 
the primary immunologic mechanism of the disease and to avoid the devastating 
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consequences of this disease with resultant cost- effectiveness and risk benefits analysis 
leading to best control of asthma. As far as steroids are concerned, there is over fear of its 
side effects in the patients as well as physicians which has to be removed. It should be make 
clear that steroids are friends of asthma pts if optimally used but if overused it may turned 
out to be foe, hence emphasis should be given on the optimized and appropriate use of 
steroids based on the asthma severity, Hence physicians should try to use the both edges of 
this “double edged sword” for the benefit of patients. 
In addition to pharmacological intervention, emphasis should always be given on the 
patient’s education about asthma including its pathogenesis, medications, inhalation 
technique and strict environmental control on every visit of the patient. Definitively the 
safety issues of the use of 
Steroids in asthma has to be taken in to consideration in order to address the instructions of 
Hippocrates, “first do no harm” in relation to the steroids, however steroids continue to be 
the most potent and the most effective controller medication for asthma, and their use in the 
appropriate clinical setting remains invaluable for the control & management of asthma in 
clinical practice. 
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consequences of this disease with resultant cost- effectiveness and risk benefits analysis 
leading to best control of asthma. As far as steroids are concerned, there is over fear of its 
side effects in the patients as well as physicians which has to be removed. It should be make 
clear that steroids are friends of asthma pts if optimally used but if overused it may turned 
out to be foe, hence emphasis should be given on the optimized and appropriate use of 
steroids based on the asthma severity, Hence physicians should try to use the both edges of 
this “double edged sword” for the benefit of patients. 
In addition to pharmacological intervention, emphasis should always be given on the 
patient’s education about asthma including its pathogenesis, medications, inhalation 
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1. Introduction 
Currently, corticosteroids are the most widely used class of anti-inflammatory drugs. The 
introduction of topical hydrocortisone in the early 1950s provided great advantages over 
previously available therapies and initiated a new era for dermatological therapy. Their 
clinical effectiveness in the treatment of dermatological disorders is related to their 
vasoconstrictive, anti-inflammatory, immunosuppressive and anti-proliferative effects. 
Despite their benefit in the therapy of inflammatory diseases, topical corticosteroids (TC) are 
associated number of side effects that limit their use. Most TC are absorbed in quantities that 
can produce both systemic and topical side effects [1-2]. Table 1 shows the currently used 
TC in various dermatological disorders according to the British classification system [3]. In 
general, mild and moderate TC are used for long-term treatments while the potent and very 
potent products especially preferred for shorter regimes. 
Over the years, research has focused on strategies to optimize the potency of steroids while 
minimizing adverse effects due to drug absorption across the skin. In other words, research 
focus no longer been on the synthesis of more potent derivatives but on safer one. Several 
attempts have been made to increase the safety of TC treatment, including new application 
schedules, special vehicles and new synthesized agents [4]. However, “ideal” TC have not 
yet been synthesized. They should be able to permeate the stratum corneum (SC) and reach 
adequate concentrations in the epidermis without reaching high systemic concentrations.   
One of the approaches to reduce the adverse effects of TC is to enhance their permeability so 
as to reduce the topically applied dose [5]. Several approaches have been attempted, such as 
iontophoresis, electroporation or the application of eutectic mixtures [6,7]. However, the use 
of chemical penetration enhancers is the most widely used approach to increase skin 
delivery [8]. 
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POTENCY DOSE % (w/w) TC 
Mild 
 Hydrocortisone 






0.0025 Fluocinolone acetonide 
0.75 Fluocortyn butyl ester 
0.5 Prednisolone 
Moderate 
0.05 Clobetasone butyrate 
0.02 Triamcinolone acetonide 





0.1 Betamethasone valerate 
0.025 Fluocinolone acetonide 




0.1 Diflucortolone valerate 
Very potent 
0.1 Halcinonide 
0.05 Clobetasol propionate 
Table 1. The currently used TC in various dermatological disorders [3] 
TC are formulated in a variety of conventional vehicles, including ointments, creams, lotions 
and gels. In addition to conventional formulations several innovative systems such as 
nanoparticles, liposomes, microemulsions, foams and patches have been evaluated for 
different dermatological conditions. Colloidal drug carrier systems, such as liposomes and 
nanoparticles, could target TC to the viable epidermis, where the inflammatory reactions 
take place. In particular, liposomal preparations showed a strong affinity for the SC. Patents 
filed on topical nanoparticulate formulations also claimed the importance of colloidal drug 
carrier systems for this type of applications [9-12]. 
This chapter will review major innovations and advances in TC formulations based on the 
published articles and patent applications. The main factors influencing the effectiveness 
and bioavailability of TC will be also briefly discussed before emphasizing formulation 
alternatives. 
2. Skin structure 
The skin, in Latin called cutis, is considered the largest organ of the body, accounting more 
than 10% of the body mass and having an average surface of approximately 2 m2. The 
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thickness of the skin is highly variable (average thickness of 1.5 mm), depending of several 
factors as the anatomic location, age and sex. The functions of the skin have been classified 
as protective, homeostatic, or sensorial. To maintain its characteristics, this organ is in a 
continual renewing process [13].  
Anatomically, the skin consists on 3 basic layers: epidermis, dermis and subcutaneous 
tissues. Depending on the region considered, the epidermis is made of 4-5 sublayers that, 
from bottom to top, are: stratum basale, stratum spinosum, stratum granulosum, stratum 
lucidum (present only in palm and soles) and SC or horny layer. In addition to these 
structures, there are also several associated appendages: hair follicles, sweat glands, 
apocrine glands, and nails [14]. 
The most important skin function is permeability barrier function. The outermost layer of 
the epidermis, the SC, with its peculiar structure, plays an important role in permeability 
barrier function [15]. Due to its barrier properties, the skin membrane is equally capable at 
limiting the molecular transport from and into the body. Overcoming this barrier function 
will be the purpose of skin drug delivery. 
3. Clinical limitations and side effects of TC 
TC are successfully used in the treatment of several common cutaneous diseases but their 
major limitation is still their side effect potential. The most common side-effects occur 
locally in the areas of skin treated with the steroid. Probably the most well known is 
thinning of the skin (atrophy), which sometimes results in permanent stretch marks (striae). 
Fine blood vessels may swell and become prominent under the skin surface (telangiectasia), 
again a permanent change. In addition, there may be a temporary loss of pigment in the 
areas of skin treated; this may be more noticeable in dark-skinned people. Sometimes the 
skin may become allergic to the steroid, making the eczema appear to get worse. The skin 
may also bruise more easily and become more susceptible to infection.  
The occurrence and severity of the side effects are depend on the duration of use, dosage, 
dosing regime and spesific drug used, along with individual patient variability. However, 
the highest risk factor seems to be prolonged use [16-18]. The concentration of corticosteroid 
in systemic circulation and risk of sytemic side effects are increased by prolonged therapy 
with TC. Systemic side-effects of TC, such as pituitary–adrenal axis suppression, should be 
taken into account when treating children. Children have a higher ratio of total body surface 
area to body weight (about 2.5- to 3-fold that of adults) and adrenal suppression may cause 
growth retardation.  
The principle systemic side effects associated with TC are bodyweight gain, Cushing’s 
syndrome, electrolyte imbalance, hypertension, diabetes mellitus, pseudoprimary 
aldosteronisim, growth retardation, osteoporosis peptic ulser and gastritis. In addition, TC 
are mostly capable of causing local side effects. One particularly important local side effect 
is epidermal thinning or atrophy [19]. This effect is characterized with the reduction in cell 
size and number of cell layers in epidermis. Other local side effects related to TC treatment 
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are steroid acne, rosacea, perioral dermatitis, corticoid acne, allergic contact dermatitis, 
hypopigmentation, glaucoma, cataracts, worsening of cutaneous infections and 
hypertrichosis [2]. Table 2 represents the possible local and systemic side effects of TC which 
are organized in subsections for tissue-organ level. 
 
TISSUE - ORGAN SIDE EFFECTS
Cardiovascular system Hypertension 
Endocrin system Adrenal insufficiency, Cushing’s syndrome, diabetes 
mellitus, bodyweight gain, pseudoprimary aldosteronism 
Eye Glaucoma, cataract
Immune system Increased risk of infection, re-activation of latent viruses 
Gastrointestinal Peptic ulser, gastritis 
Central nervous system Behavioural changes, loss of memory/cognition 
Skeleton and muscle Growth retardation, osteoporosis
Skin Atrophy, striae, allergic contact dermatitis, delayed 
wound healing, steroid acne, perioral dermatitis, rosacea,  
erythema, teleangiectasia, hypertrichosis, 
hypopigmentation 
Table 2. The possible local and systemic side effects of TC 
4. Classification of TC 
TC are classified in two different ways by American and British National Formulary 
classification systems [20-21]. The American classification system includes seven potency 
groups while the British National Formulary contains four groups. In the former system, the 
potency of a product is defined by the corticosteroid, its concentration and the nature of the 
vehicle. On the other hand, The British classification system is irrespective of the topical 
vehicle used. According to the American classification sytem, it is important to note that the 
greater in potency for TC result in the greater therapeutic efficacy and side effects. 
Therefore, low-potency formulations should be used for long term treatments by physicians 
while the more potent products should be chosen for short periods and sites such as palms 
and soles, where low potency TC are ineffective [1,2]. 
5. Formulations of TC 
It is well known that, besides the active molecule, the potency of each topical formulation 
can be influenced by vehicle characteristics. Vehicles should allow adequate release of the 
active compound, spread easily and be aesthetically pleasant [21]. Some important rules 
should be considered when choosing a vehicle; the solubility, release rate and stability of the 
therapeutic agent in the vehicle, the ability of the vehicle to hydrate the SC, the physical and 
chemical interactions of the vehicle with the skin and active molecule and also the phase, 
localization and extent of disease [22].  
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TC are formulated in a variety of conventional vehicles, including ointments, creams, lotions 
and gels. As mentioned previously, the character of the vehicle system defines the potency 
of topical preparations and its selection is crucial for product performance. 
Ointments are semi-solid preparations intended for application to skin or mucous 
membranes. There are four types of ointment bases; hydrocarbon bases, absorption bases, 
emulsion bases and water-soluble bases. The potential of the absorption is affected by choice 
of the bases. Hence, appropriate selection of the base is important for the efficacy of the 
dermal therapy [23].  
Ointment formulations are generally more effective than creams containing the same drug 
and they are especially preferred for infiltrated, lichenified lesions. In a comparative study, 
the absorption of clobetasol propionate from ointment and cream formulations was 
evaluated and it was reported that a greater amount of clobetasol propionate was absorbed 
from the ointment [24]. Ointments including well-known and new synthesized TC were 
formulated and they were still first-option for treatment of dermatological diseases. 
However, the greasy nature and hardness of the removal from the skin due to their lack of 
water-washability is their disadvantages. 
Mobile dispersions intended for topical application are generally described as lotions and 
semi-solid systems as creams. Although, creams are usually emulsions of the oil-in-water 
type (aqueous creams) or water-in-oil type (oily creams), lotions are mostly oil-in-water 
emulsions [25]. Regarding to the phase of disease, lotions and creams are generally 
recommended in acute and subacute dermatoses. Good compliance is obtained by 
prescribing creams and lotions which are easily applied by patients rather than ointments in 
case of large extensional dermatoses. Sequeira et al. [26] filed a patent application which 
provided a corticosteroid lotion formulation exhibiting high vasoconstrictor and excellent 
anti-inflammatory activities in steroid responsive dermatoses. The addition of propylene 
glycol to a hydro-alcoholic lotion base exhibited and significantly higher vasoconstrictor 
activity than the corresponding lotion without propylene glycol. 
Gels are semi-solid systems with dispersions of small or large molecules in an aqueose 
vehicle with a gelling agent. The gel formulations are suitable for topical delivery of drugs 
for treatment of diseases due to lack of irritating components. Pharmaceutical gel 
formulations for topical drug delivery include drug and gelling agent [27]. Gels based on 
carbopol, cellulose derivatives and chitosan are commonly used in the pharmaceutical and 
cosmetic industries [28, 29].  
Recently, new hydrogel formulation intended for cosmetic use was introduced as a novel 
formulation of steroids for the treatment of atopic dermatitis. The formulation was prepared 
with carbopol-based polymer that contained 0.05% (w/w) of micronized desonide which is a 
well-known synthetic corticosteroid. This formulation was easily applied for atopic 
dermatitis patients aged 3 months. A wide variety of studies have been performed to 
validate the safety and efficacy of this product and these studies supported very favourable 
safety, tolerability and efficacy profile [30, 31]. 
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Senyigit et al. [32] investigated the effect of vehicles (chitosan and sodium-deoxycholate 
gel) on the skin accumulation and permeation of two topical corticosteroids: clobetasol 
propionate and mometasone furoate. Commercial cream formulations containing the 
same amount of drug were also used for comparison. It was reported that sodium-
deoxycholate gel formulation dramatically improved the amount of drug in the skin 
although chitosan gel produced the same skin accumulation as commercial creams for 
both active agents. In addition, all of these gel formulations did not induce the 
permeation.  
For conventional formulations it can be stated that the effectiveness of the active agent is 
directly related to the composition of the formulation. In general, the potency of the 
corticosteroids in the formulations could be listed in order such as; ointments> gels> 
creams> lotions. This generalization was supported with a patent filed by McCadden [33]. 
The brief summary about conventional TC formulations including pharmaceutical 
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The activity of a TC formulation can be enhanced by adding a chemical penetration 
enhancer which may result in an increase of drug delivery into skin. Chemical penetration 
enhancers have been reviewed by several researchers and the authors underline the 
difficulty to select rationally a penetration enhancer for a specific permeant [34-36]. Recent 
studies showed that terpenes appear to be promising penetration enhancers for 
pharmaceutical formulations with favourable properties such as low cutaneous irritancy 
and possess good toxicological profile [32, 37]. 
Recently, it has been a great interest in developing new drug carriers for TC that may 
contribute to reduction of side effects. Therefore, in addition to previously mentioned 
conventional formulations several innovative systems such as nanoparticles, liposomes, 
microemulsions, foams and patches have been developed for TC.  
Liposomes, microemulsions, solid lipid and polymeric nanoparticles have been proposed to 
increase percutaneous absorption of therapeutic agents while mitigating the damage to the 
skin barrier function [38,39]. Besides, the drug targeting to the skin or even to its 
substructures could be realized by micro- and nanoparticulate systems [40,41]. These drug 
carrier systems could target glucocorticoids to the viable epidermis, where the inflammatory 
reactions take place [9]. In particular, liposomal preparations showed strong affinity for the 
SC [42].  
The loading of therapeutic agents into nanoparticles and administration to the skin using a 
simple vehicle offer many advantages over other traditional topical formulations, including 
enhanced formulation aesthetics, protection of unstable active agents against degredation, 
targeting of active agents to the skin layers and prolonged active agent release [43]. As a 
consequence of their proposed advantages in dermal/transdermal formulations two most 
common types of particles have been produced: Lipid nanoparticles and polymeric 
nanoparticles. The uses of lipid and polymeric nanoparticles for pharmaceutical 
formulations applied to skin have been reviewed by several authors [40, 44-46]. Most of the 
data reported on TC was obtained using lipid nanoparticles of differing lipid compositions. 
The inclusion of prednicarbate into solid lipid nanoparticles (SLN) of various composition 
appeared to increase the penetration of the drug into human skin by 30% as compared to 
cream, permeation of reconstructed epidermis increased even 3-fold [47]. In a subsequent 
report SLN were shown to induce prednicarbate targeting in the epidermal layer in excised 
human skin and reconstructed epidermis [9]. Epidermal targeting was evidenced also for 
prednisolone, the diester prednicarbate and the monoester betamethasone 17-valerate 
included in solid lipid nanoparticles [48]. The authors hypothesized specific interactions of 
the drug-carrier complex and the skin surface, possible by the lipid nature and nanosize of 
the carrier. On the other hand, using the appropriate lipid combination, the skin retention of 
betamethasone 17 valerate was increased when SLN was used as a vehicle compared to a 
conventional formulations [49], both using intact skin as well as barrier impaired [50]. 
Clobetasol propionate was included in SLN as well [51]. SLN containing cream registered 
significant improvement in therapeutic response (1.9 fold inflammation, 1.2 fold itching) in 
terms of percent reduction in degree of inflammation and itching against marketed cream.  
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de Vringer disclosed a stable aqueous suspension of SLNs, comprising at least one lipid and 
preferably also at least one emulsifier for topical application to the body. According to this 
invention steroidal anti-inflammatory compound such as hydrocortisone, hydrocortisone-
17α-butyrate, budesonide or TA, anti-proliferatives, anti-psoriatics, anti-eczema agents and 
dithranol could be succesfully incorporated into the suspension of SLNs. It was stated that a 
combination of two or more topically effective medicaments could also be used [52]. 
Senyigit et al. [53] prepared lecithin/chitosan nanoparticles containing clobetasol propionate 
and found a preferential retention in the epidermis while no permeation across the skin was 
observed. In vivo studies including transepidermal water loss measurements, anti-
inflammatory effect and histological evaluation of the formulations on wistar albino rats 
were also performed and the results were promising (Data not published). 
Liposomes are lipid vesicles prepared with phospholipids which have been shown to 
facilitate transport of drugs into and across skin [54]. Recently, many reports have been 
published on percutaneous enhancing property of liposomes for both hydrophilic and 
lipophilic compounds [55]. Liposomes do not only enhance the drug penetration into the 
skin by showing slow release, but also decrease the clearence of drug by minimizing its 
absorption into the systemic circulation [56]. Hence, the liposomes can improve the 
therapeutic effectiveness of TC while reducing systemic side effects. However, many 
stability problems are reported for liposomes.  
Mezei et al. [57, 58] applied triamcinolone acetonide (TA) in liposomes and compared it 
with TA in Dermabase®. In this study, four- to five fold higher TA concentrations in the 
epidermis and dermis, with lower systemic drug levels were observed when the drug was 
delivered from liposomal lotion in comparison with conventional formulations of the same 
drug concentration.  
Lasch and Wohlrab [59, 60] studied the skin distribution of cortisol and hydrocortison after 
application in a cream and liposomes. As a result, improved concentration-time profile was 
observed in skin layers by liposomes for both drugs.  
Korting et al. [61] compared the efficacy of betamethasone dipropionate encapsulated in 
liposomes and cream. The liposomes were prepared with egg lecithine and incorporated in 
a polyacrylate gel. The in vivo studies were carried out in patients with atopic eczema and 
psoriasis vulgaris. It was concluded that, betamethasone encapsulated in liposomes 
improved the antiinflammatory action, but not the antiproliferative effect.  
Fresta et al. [62] prepared skin-lipid liposome formulations of different corticosteroids 
(hydrocortisone, betamethasone valerate and TA). They indicated that skin lipid liposomes 
showed a 6 and 1.3 fold higher blanching effect than control formulations of ointment and 
the phospholipid-based liposomes, respectively. Skin-lipid liposomes also produced a 
reduction in drug levels in the blood and urine. Consequently, this liposome formulation 
was proposed for improving the pharmacological effectiveness and reducing the systemic 
absorption of TC. 
In order to overcome the stability problem of liposomes, new attempts have been maden 
and new drug carrier systems have been developed by adding some functional chemicals 
into the liposome structure. These systems are niosomes, transfersomes and ethosomes. 
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Niosomes, non-ionic surfactant vesicules, are widely studied as an alternative to liposomes 
for topical and transdermal drug delivery. Niosomes alleviate the disadvantages associated 
with liposomes, such as chemical instability, variable purity of phospholipids and high cost. 
In addition, they have the potential for controlled and targeted drug delivery to the skin [63-
65]. Deformable liposomes (Transfersomes®) are the first generation of elastic vesicles 
introduced by Cevc [66]. They consist of phospholipids and an edge activator. An edge 
activator is often a single chain surfactant that destabilizes lipid bilayers of the vesicles and 
increases deformability of the bilayers [67-68].  
Cevc et al. [69] investigated the regio-specificity potential of transfersomes which included 
different corticosteroids (hydrocortisone, dexamethasone and TA). They demonstrated that 
transfersomes ameliorate the targetability of all tested corticosteroids into the viable skin. 
They also suggested that the introduction of transfersomal corticosteroids creates new 
opportunities for the well controlled topical medication.  
In another study performed by Fesq et al. [70], the efficacy of transfersomes was compared 
with commercially available cream and ointment formulations of TA in humans. According 
to the results of this study, 10-fold lower dose of TA in transfersome was found 
bioequivalent to conventional formulations as measured by erythema suppression. 
Ultrasonic measurements also revealed significantly reduced atrophogenic potential of 
transfersomes in comparison to commercial formulations.  
Ethosome is another novel lipid carrier showing enhanced skin delivery and recently 
developed by Touitou. The ethosomal system is composed of phospholipid, ethanol and 
water. The use of high ethanol content was decribed for ethosomes although liposomal 
formulations containing up to 10% ethanol [71, 72]. 
Microemulsions are thermodynamically stable, transparent, isotropic, low-viscosity 
colloidal dispersions consisting of microdomains of oil and/or water stabilized by an 
interfacial film of alternating surfactant and cosurfactant molecules [73]. Microemulsions are 
effective formulations for the dermal and transdermal delivery of particularly lipophilic 
compounds like TC because of their solubilizing properties and also their components may 
act as penetration enhancers [74, 75].  
Wiedersberg et al. [76] studied the dermato-pharmacokinetic properties of betamethasone 
valerate from two different formulations either in the reference vehicle consisting of 
medium chain triglycerides or in the microemulsion. The results showed that 
microemulsion significantly increased the extent of drug delivery into the SC. 
In another study, the penetration behaviour of hydrocortisone from the microemulsion 
system and a commercialy available cream formulation containing the same amount of 
hydrocortisone (0.5%) was investigated. Ex vivo penetration studies on human breast skin 
were carried out and the drug contents in the different skin layers were measured. With 
regard to the cream, the results showed that, a higher percentage of hydrocortisone was 
found in the epidermis and dermis. This result pointed out the skin targeting effect achieved 
by microemulsion formulation [77, 78]. 
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Table 4. The summary about innovative TC formulations 
Patches are other innovative drug delivery systems intended for skin application in view of 
achieving local or systemic effect. The patch provides the administration of effective and 
known drug amount to the skin [79]. 
The occlusive effect of Actiderm® (hydrocolloid dermatological patch) has been studied on 
the percutaneous penetration of several drugs including corticosteroids. It was found to be 
effective in controlling and sustaining the localized delivery of the steroid into the skin and 
enhancing the healing of dermatological disorders [80, 81].  
Ladenheim et al. [82] investigated the effect of occlusion on in vitro TA penetration using 
hydrocolloid containing patches by measuring transepidermal water loss. They found that 
the diffusion rate of TA was increased 3-4 fold when applied occluded patch in comparison 
with unoccluded. Same research group was also evaluated the occlusive properties of a 
range of hydrocolloid patches containing TA on the drug penetration in vivo using visual 
assessment and the graded multiple-measuremet procedure. They concluded that these 
patch formulations showed great potential for localized prolonged delivery of drugs to the 
skin, which would be desirable for the topical use of other corticosteroids [83]. 
 







Nanoparticles Solid lipid 
nanoparticles include 
solid or the mixture of 








aesthetics, protection of 
unstable active agents 
against degredation, 
targeting of active 
agents to the skin layers 







and in vivo 
toxicity issues 
are need to be 
clarified 




slow release and  
decrease the clearence of 
drug by minimizing its 









liposomes, such as 
chemical instability, 
variable purity of 
phospholipids and high 
cost. 
 
Controlled and targeted 
drug delivery to the 
skin. 
Less effective 
drug delivery in 
comparison to 
liposomes 
Transfersomes Consist of 
phospholipids and an 
edge activator 
Improved therapeutic 
risk-benefit ratio,due to 
better targeting and 
longer drug presence in 
the skin 
- 









of action is not 
clear 
 











microdomains of oil 
and/or water stabilized 




Ease of manufacturing 




for the dermal and 




Patches Drug delivery systems 




effective and known 
drug amount to the skin 
and the occlusive effect 
Skin irritation 
Foams Incorporate active 
agents, solvents, co-
solvents, surfactants 
and propellants in a 
sealed canister under 
pressure 
More convenient topical 




comparision to other 
topical dosage forms 
- 
Table 4. The summary about innovative TC formulations 
Patches are other innovative drug delivery systems intended for skin application in view of 
achieving local or systemic effect. The patch provides the administration of effective and 
known drug amount to the skin [79]. 
The occlusive effect of Actiderm® (hydrocolloid dermatological patch) has been studied on 
the percutaneous penetration of several drugs including corticosteroids. It was found to be 
effective in controlling and sustaining the localized delivery of the steroid into the skin and 
enhancing the healing of dermatological disorders [80, 81].  
Ladenheim et al. [82] investigated the effect of occlusion on in vitro TA penetration using 
hydrocolloid containing patches by measuring transepidermal water loss. They found that 
the diffusion rate of TA was increased 3-4 fold when applied occluded patch in comparison 
with unoccluded. Same research group was also evaluated the occlusive properties of a 
range of hydrocolloid patches containing TA on the drug penetration in vivo using visual 
assessment and the graded multiple-measuremet procedure. They concluded that these 
patch formulations showed great potential for localized prolonged delivery of drugs to the 
skin, which would be desirable for the topical use of other corticosteroids [83]. 
 
Glucocorticoids – New Recognition of Our Familiar Friend 606 
More recently, novel foam formulations of TC have been developed and proposed as 
alternative therapy to conventional formulations. They offer more convenient topical drug 
delivery with easy application and spreadability characteristics in comparision to other 
topical dosage forms [84, 85]. 
A novel foam formulation with enhanced BMV bioavailability has been shown to be 
superior in efficacy when compared with a lotion in the treatment of disease, without an 
concomitant increase in toxicity [86]. Another study has been performed comparing the 
ability of a foam formulation to release the active ingredient (betamethasone benzoate) with 
ointment, gel, and cream formulations. It was found that the release of betamethasone 
benzoate from the foam formulation better than the release from the cream [87]. 
The thermolabile and low-residue foam formulations of corticosteroids (betamethasone 
valerate and clobetasol propionate) are available in USA market. These foam formulations 
are associated with better patient compliance and improvements in quality of life [88, 89]. 
Table 4 summarizes the new drug carrier formulations of TC. 
6. Conclusion 
Current therapy of dermatological disorders with conventional dosage forms including 
TC is insufficient due to the low absorption rate and the risk of side effects. Therefore, it is 
necessary to synthesize the new topical corticosteroid molecules with adequate anti-
inflammatory activity and minimal side effects. Fluticasone propionate, mometasone 
furoate and prednicarbate are very promising molecules showed lower side effects and 
better tolerability as a member of new generation TC. Also, improved dermal absorption 
of established TC may be obtained by new designed vehicle system as an alternative to 
conventional formulation. Recently, lipid and polymeric based carriers such as liposomes, 
niosomes, transfersomes, ethosomes, microemulsions and nanoparticles have been 
studied intensively and the potential of these carrier systems have also been described. 
Another alternative approach for TC treatment is a combined therapy which is more 
effective than in case of drug alone. The combined use of TC and synthetic vitamin D 
analogues such as calcipotriol would be promising for the treatment of inflammatory skin 
diseases. I 
In conclusion, due to the difficulty of synthesizing new steroid molecules, developing the 
novel alternative drug carrier systems which improve the risk-benefit ratio of TC would 
be more beneficial in topical corticosteroid treatment. Besides, more in vivo study is 
required to validate the ability of new formulations in enhancing topical delivery of 
corticosteroids. 
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1. Introduction 
Steroids play a vital role in human physiology and medicine. Glucocorticoids have 
dominated the class of anti-inflammatory agents quite successfully over other drugs since 
their introduction to dermatology more than fifty years ago. Later they have been developed 
both as topical and systemic anti-inflammatory agents. From studies it has been found that 
glucocorticoids normally release their anti-inflammatory effects mainly through the 
modulation of the cytosolic glucocorticoid receptor (GR) at the genomic level [1, 2]. The 
activated glucocorticoid-GR complex formed via binding of glucocorticoid with the GR in 
the cytoplasm, migrates to the nucleus, where it upregulates the expression of anti-
inflammatory proteins and repress the expression of pro-inflammatory proteins. In some 
recent work, it has been reported that the activated glucocorticoid-GR complex has also 
been found to initiate nongenomic effects like inhibition of vasodilation, vascular 
permeability and migration of leukocytes [1, 3]. Glucocorticoids also mediate anti-
inflammatory activity through membrane-bound GR-mediated nongenomic effects and also 
through direct non specific interaction with cellular membranes [3, 4]. Since GR is involved 
in a plethora of signalling pathways, more than 5000 genes are expressed or suppressed 
following glucocorticoid exposure [4, 5]. Therefore long term use or high dosages of 
glucocorticoids could result in adverse drug reactions (ADRs) like increased Intraocular 
Pressure (IOP) [6, 7] in ocular therapeutics. Glucocorticoids- induced ocular hypertension is 
of great concern in ophthalmic therapeutics as it can lead to secondary iatrogenic open-angle 
glaucoma. Glaucoma is a group of eye diseases characterized by progressive optic nerve 
cupping with visual field loss leading to bilateral blindness. It has been reported that 
glaucoma is estimated to affect more than 50 million people worldwide as defined by the 
World Health Organization (WHO) [8].  
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1. Introduction 
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modulation of the cytosolic glucocorticoid receptor (GR) at the genomic level [1, 2]. The 
activated glucocorticoid-GR complex formed via binding of glucocorticoid with the GR in 
the cytoplasm, migrates to the nucleus, where it upregulates the expression of anti-
inflammatory proteins and repress the expression of pro-inflammatory proteins. In some 
recent work, it has been reported that the activated glucocorticoid-GR complex has also 
been found to initiate nongenomic effects like inhibition of vasodilation, vascular 
permeability and migration of leukocytes [1, 3]. Glucocorticoids also mediate anti-
inflammatory activity through membrane-bound GR-mediated nongenomic effects and also 
through direct non specific interaction with cellular membranes [3, 4]. Since GR is involved 
in a plethora of signalling pathways, more than 5000 genes are expressed or suppressed 
following glucocorticoid exposure [4, 5]. Therefore long term use or high dosages of 
glucocorticoids could result in adverse drug reactions (ADRs) like increased Intraocular 
Pressure (IOP) [6, 7] in ocular therapeutics. Glucocorticoids- induced ocular hypertension is 
of great concern in ophthalmic therapeutics as it can lead to secondary iatrogenic open-angle 
glaucoma. Glaucoma is a group of eye diseases characterized by progressive optic nerve 
cupping with visual field loss leading to bilateral blindness. It has been reported that 
glaucoma is estimated to affect more than 50 million people worldwide as defined by the 
World Health Organization (WHO) [8].  
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However, the use of corticosteroids has become more and more restricted and unacceptable 
because most of these agents are found to be associated with severe side effects, including 
percutaneous absorption and cutaneous atrophy [9]. Also allergic contact dermatitis is an 
unexpected adverse effect in most of these corticosteroids. On the other hand because of 
their high efficacy, their use is inevitable to give them the status of life saving drugs. The 
severe side effects associated with these glucocorticoids, has led to the pharmaceutical 
industry to make a productive effort towards the introduction of new generation of topical 
corticosteroids with specific substituents in their parent molecules to make them safer in 
comparison to the old generation glucocorticoids [10]. 
The effectiveness of hydrocortisone was first demonstrated by Sulzberger and Witten 
during 1950 [11] and soon after the new and more effective fluorinated hydrocortisones 
were introduced in the market during 1960 [12]. Further R&D works on these 
glucocorticoids led to introduction of super potent corticosteroids in the 1970s and 1980s. 
Cornell and Stoughton [13] had proposed a potency rating of these topically applied 
glucocorticoids in 1984, based primarily on the vasoconstrictor assay or skin-blanching of 
corticosteroid preparations. Again based upon the consensus of the United States 
Pharmacopoeia (USP) Dermatology Advisory Panel, a classification of the potency ranking 
for these glucocorticoids had been done as low, medium, high and very high [14]. New 
generation of glucocorticoids do not cause much cutaneous atrophy or systemic absorption 
in human body. Molecular configuration of these new corticosteroids tends to display a 
rapidly declining concentration gradient in the skin. Many of these new generation 
glucocorticoids are developed through the concept of prodrugs – a tool for improving 
physiochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically 
active agents. Thus prodrugs are bioreversible derivatives of drug molecules that undergo 
an enzymatic or chemical transformation in vivo to release the active parent drug, which 
could then exert the desired pharmacological effect. These new generation glucocorticoids 
primarily act in the top layers of the skin where the most important mediators of the 
inflammatory reactions are [10, 14] found. 
As for these new generation glucocorticoids, the action in the deeper layer is considerably 
diminished making them having less systemic side effects [14]. European and North 
American based clinical studies have shown that the new generation corticosteroids with 
their improved risk- benefit ratio are as effective as products currently available in the 
market [15]. These new generation glucocorticoids are highly effective in treating plethora of 
disease including psoriasis, allergies, asthma, rheumatoid arthritis and lupus [2-8, 14,15].  
Again the application of anti-inflammatory agents in ophthalmic therapeutic is a 
challenging task because of severe complications arising out of the currently used anti-
inflammatory agents. The eye is vulnerable to damage from low level of intraocular 
inflammation. The blood-aqueous and blood-retinal barriers generally limit penetration of 
protein and cells from peripheral circulation, while regulatory molecules and cells in the eye 
actively suppress immunological responses [16]. The fact that ocular inflammatory 
conditions and surgical trauma induce changes in the blood- aqueous and blood-retinal 
barriers [16-18], due to which immune cells and mediators of inflammation could enter the 
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eye, resulting in the development of symptoms of ocular inflammation such as redness, 
pain, swelling and itching [19]. Ocular inflammation is a serious problem, negligence of 
which may lead to temporary or permanent blindness [20].  
Clinical studies suggest that topical glucocorticoids are effective in the management of 
anterior segment inflammation. They impart a number of potent anti-inflammatory effects 
[21]. They are found to suppress cellular infiltration, capillary dilution, proliferation of 
fibroblasts, collagen deposition leading to scar formation; they also stabilize intracellular 
and extracellular membranes. Glucocorticoids increase the synthesis of lipocortins which 
block phospholipase A2 and also inhibit Histamine (A) synthesis in mast cells. A critical step in 
the inflammatory cascade is the inhibition of phospholipase A2 that inhibits the transformation 
of Phospholipids (B) to Arachidonic acid (C). Glucocorticoids are also found to increase the 
enzyme histaminase and modulate transcription factors present in mast cell nuclei [21, 22]. 
The formation of cataract is also one of the severe adverse drug reactions (ADRs) associated 




















It has been reported by Manabe et al [23] that the mechanism of steroid-induced cataract 
formation is chemically based and possibly not related to the downstream effects of 
glucocorticoid receptor (GR) activation. At present the most accepted hypothesis of this 
mechanism is likely to involve non-enzymatic formation of Schiff base intermediates 
between the steroid C-20 ketone group and nucleophilic groups such as  -amino groups of 
lysine residues of proteins (Figure 1). Schiff base formation is followed by a Heyns 
rearrangement [23] involving the nearby C-21 hydroxyl group of the glucocorticoid 
molecule furnishing stable amine-linked adducts. This covalent binding results in the 
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destabilization of the protein structure allowing further oxidation leading to steroid-induced 




























Figure 1. Mechanism of steroid-induced cataract formation due to the synthesis of the stable steroid- 
amine adduct between the C-20 carbonyl group of glucocorticoids and nucleophilic group such as - 
amino groups of lysine residues of proteins via formation Schiff Base  
R&D work in understanding the mechanism of action of steroids, both for their anti-
inflammatory effects and adverse drug reactions (ADRs) has lead to the development new 
generation glucocorticoids mainly through prodrug design approach to find use in treating 
plethora of diseases as mentioned earlier. All these new generation glucocorticoids are not 
designed for ophthalmic therapeutics. Hence a real breakthrough in the field of ophthalmic 
therapeutic could be achieved only by specifically designing new drug entities to 
incorporate the eye targeting possibility into their chemical structure [24,25]. Chemical 
Delivery Systems (CDSs) and Retrometabolic drug design principles have led to 
development of a new but unique class of glucocorticoids which are safe and effective in 
treating a wide variety of ocular inflammatory conditions including giant papillary 
conjunctivitis, seasonal allergic conjunctivitis, and uveities as well as in the treatment of 
ocular inflammation and pain following cataract surgery. This new and unique class of 
glucocorticoids are now known as soft glucocorticoids which are associated with highly 
minimized ADRs to justify terming them as `soft drugs’ [24, 26]. 
It is pertinent to note that, this important drug design based on Chemical Delivery Systems 
(CDSs) and Soft drug (SD) approaches integrate the specific pharmacological, metabolic, 
and targeting requirements for ophthalmic therapeutics. .A number of glucocorticoid soft 
drugs and soft  -blockers have been developed this way for clinical trials. Their potential is 
already documented by the results obtained with several soft drugs designed within this 
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framework. Glucocorticoid soft drugs such as Loteprednol Etabonate, and Etiprednol 
Dicloacetate and  -blockers such as Betaxoxime, and Adaprolol are some of the new 
chemical entities developed as soft drugs for ocular applications. Besides, many of these soft 
drugs have already reached the clinical development phase in various ophthalmic areas and 
one of them Loteprednol Etabonate has already been marketed [ 24]. Herein we review the 
important aspects of the development of new generation glucocorticoids through prodrug 
approach with special reference to the development of the first and second generation 
glucocorticoid soft drugs by the application chemical delivery systems (CDSs) and 
retrometabolic drug design approaches towards ophthalmic therapeutics. A few examples 
of soft ocular  –blockers have also been cited to know more about the retrometabolic drug 
design approach in depth as have been put forwarded by Bodor and his co-workers (24). 
2. New generation glucocorticoids: Prodrugs 
As discussed earlier several numbers of new entities of glucocorticoids have been developed 
during the last two decades. Many of them are already in market for their high efficacy and 
less systemic side effects. These new generation corticosteroids were developed with 
modifications made in the basic glucocorticoid molecules, viz., Betamethasone 1 or 
Dexamethasone 2 extensively used during early stage of glucocorticoids therapy. The main 
object of synthesizing these modified glucocorticoids was to get better skin penetration, 


















Dexamethasone (2)  
Even then in some cases it was observed that the changes that increased potency, also led 
sometimes to more systemic side effects. As per clinical investigations by various workers, 
these new generation glucocorticoids have been found to act via hepatic or extra hepatic 
biotransformation. These results in lesser systemic side effects and hence are much safer 
drugs to be used specially by adults and non- erythrodermic patients. However, while 
systemic side effects are of concern, cutaneous side effects are generally common involving 
problems such as striae formation, atrophy, purpura, peri-oral dermatitis, steroid rosacea, 
hypertrichosis and steroid acne [2,6]. Most of the side effects associated even with these new 
generation glucocorticoids are basically related to the duration and potency of the 
application, the manner of application, the presence of penetration-enhancing substances 
and the state of skin barrier. Besides these, the anatomic site and the age of the patient could 
also adversely influence the side effect profile [2, 6]. In both drug discovery and 
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destabilization of the protein structure allowing further oxidation leading to steroid-induced 
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development, prodrug design approach helped to maximize the amount of an active drug to 
reach its target through changing the physicochemical, pharmacokinetics or 
biopharmaceutical properties of the drug. Therefore the term prodrug refers to a 
pharmacologically inactive compound which is converted to an active drug by metabolic 
biotransformation which may occur prior, during or after absorption or at specific target 
sites within the body because of their specific molecular configurations [28-30]. The labile 
`prodrug’ corticosteroids such as 17-Prednicarbate, Alclometasone, Methylprednisolone 
aceponate, Fluticasone Propionate and Fluocortin butylester are some of these new 
generation glucocorticoids which are developed through prodrug approach [2,6]. Based on 
the molecular configuration of these new generation glucocorticoids, they are classified into 
several categories [Table1] [2, 6]. 
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Fluticasone propionate (11) 
Table 1. Classification of new generation glucocorticoids on the basis of their molecular configurations 
Chemical stability is another criteria for classification of these new generation corticosteroids. 
Based on this, most of these newer drugs can be regarded as prodrugs because immediately 
after application to the system, they undergo metabolization and acyl-exchanges to form the 
active molecule to fight the ailment in the system. As mentioned earlier, all these 
glucocorticoids have been developed through prodrugs design approach in order to maximize 
the amount of an active drug reaching its target through changing the physicochemical, 
biopharmaceutical or pharmacokinetic properties of drugs. Prodrugs are bioreversible 
derivatives of drug molecules that undergo an enzymatic or chemical transformation in vivo to 
release the active parent drug, which can then exert the desired pharmacological effect [28-30]. 
Most of the new generation corticosteroids have been found belonging to the class of molecules 
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having high potency. By introducing various substituents at different positions, changes or 
modifications were made on the parent hydrocortisone molecules, such as Betamethasone (1) 
and Dexamethasone (2) in order to get better skin penetration, slower enzymatic degradation 
and greater affinity for the cytosol receptor for these molecules to reduce or eliminate their 
systemic side effects [6]. The systemic side effects of these new corticosteroids are reduced due 
to rapid biotransformation while applying them for treatment of atopic dermatitis. However it 
is pertinent to note that there are still risks of having potential hypothalamus and pituitary axis 
(HPA) suppression with some of these new generation glucocorticoids while treating young 
children and erythrodermic patients. Clinical safety has been demonstrated in most of these 
newer corticosteroids with restricted duration of treatment up to six weeks [2, 6]. Even then skin 
atropy and some telangiectasia have been observed in some patients. A large number of reports 
of contact allergic reactions associated with these new generation glucocorticoids were still of 
great concern. To explain the increased allergenicity, data from clinical studies and literature 
were reviewed to define precisely some of the more important groups of cross-reacting 
molecules [31]. Table2 represents the various allergy groups of these newer glucocorticoids 
based on their molecular structures and configurations. Clinical studies have revealed that 
Tixocortol pivalate (19) has been identified as a good screening agent for the Group A [32]. 
Budesonide (3) is infact a 1:1 mixture of two diasteriomers (R- and S- isomer). The R-isomer has 
been found to be a marker for the Group B while the S-isomer for the Group D. Glucocorticoid 
members of Group C cause minimized contact sensitivity and do not cross react with other 
groups. As shown in Table2, Group D has been divided in two sub-groups D1 and D2 based on 
recent studies [2, 33] with respect to their mode of substitutions.  
 
Group Molecular configuration Characteristics of substituent
A Hydrocortisone (12) type No substitution in D ring, except a short chain ester on C-17 or C-21 or a thioester on C-21
B Triamcinolone (13 ) type C-16,C-17-cis-ketal or –diol structure 
C Betamethasone (1) type C-16 methyl substitution, no side chain on C-17; possible side chain at C-21. Fluocortin Butylester (4)
D Hydrocortisone-17α-butyrate(14) type





Long chain ester at C-17 and/or C-21 with C-16 methyl 
substitution; halogen substituent in ring B 
Betamethasone17α-Valerate 
(16)







Long chain ester at C-17; possibly a side chain at C-21; no methyl 
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To the Group D1, belong not only the old generation glucocorticoid molecules like 
Betamethasone dipropionate (15), Betamethasone-17α-valerate (16) and Clobetasol 17α 
propionate (17) but also new generation corticosteroids such as Mometasone furoate (10) and 
Fluticasone propionate (11). These glucocorticoids are found to possess very less systemic side 
effects and so can be used safely even in case of patients who are allergic to other 
corticosteroids. To the Group D2 belong Hydrocortisone-17α- valerate (18) and Hydrocortisone -
17α-butyrate (14 ) as well as the labile new generation glucocorticoids like 17-Prednicarbate (9) 
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S-isomer of Budesonide (3) is the marker for this Group D2, but they can cross react with the 
Group A. Table 3 illustrates the safety profile, potency , side effects and allergy groups of 
some of the new generation glucocorticoids along with their manufactures. 
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Table 3. Some of the marketed new generation glucocorticoids and their allergy groups: 
Continuous efforts are still being still sought after by pharmaceutical companies worldwide 
to develop and market more and more safer glucocorticoids as anti-inflammatory agents, 
because clinical investigations on some already marketed newer glucocorticoids have 
revealed that many of them are still prone to cause allergic reactions and other systemic side 
effects specially on prolonged use. However, glucocorticoids are still regarded as life saving 
drugs dominating over the other anti-inflammatory agents for the treatment of a number of 
diseases including psoriasis, allergies, acute asthma, rheumatoid arthritis and lupus.  
Eye–targeted Chemical Delivery Systems (CDSs) and retrometabolic drug design: Soft -Blockers 
and Soft Glucocorticoids 
Soft corticosteroids or Soft glucocorticoids can be termed as a unique class of new 
generation glucocorticoids that are designed specifically for ophthalmic therapeutics [24-
27]. The new generation glucocorticoids developed by prodrug approach as described 
earlier have brought revolution in treating a plethora of disease including psoriasis, 
allergies, asthma, rheumatoid arthritis and lupus because of their minimized systemic side 
effects. However, these new generation glucocorticoids are still not useful for ophthalmic 
applications due to their association with adverse drug reactions (ADRs) including 
elevation of intraocular pressure (IOP) and steroid-induced cataract formation [23] in 
ophthalmic applications. For the therapeutic treatment of most of ocular problems, topical 
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administration undoubtedly seems preferred mode, because for systemically administered 
drugs, only a very small fraction of the total dose will reach the eye from the general 
circulatory system. Even distribution for this fraction to the inside of the eye is further 
hindered by the blood-retinal barrier (BRB), which is almost as effective as blood-brain 
barrier (BBB) in restricting the passage of xenobiotics from the blood stream [34]. Therefore 
despite its apparent accessibility, the eye, in fact, is well protected against the absorption of 
foreign materials, including drug molecules, by the eyelids, by flow of tears, and also by 
the permeability barriers imposed by the cornea on one side and the blood-retinal barrier 
on the other side as mentioned above [24]. Because of this a significant portion of the 
applied drug is absorbed through nasolacrimal duct and the mucosal membranes of the 
nasal, oropharyngeal, and gastrointestinal tract to pass to the system. It has been found 
that no more than 2% of medication introduced topically to the eye is adsorbed [35-37]. 
Again clinical studies by various workers reveal that the main biological barrier for 
penetration to the eye is represented by the cornea. The relatively lipophilic corneal 
epithelium tissue having low porosity and high tortuosity due to tight annular junctions, 
is the primary barrier for hydrophilic drugs, where as the middle stromal layer 
consisting mainly of water interspersed with collagen fibrils( major thickness of cornea), 
is the main barrier for the lipophilic drugs [38-41]. All these facts result not only in a low 
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topical administration giving systemic side effects [42]. Moreover as mentioned earlier, 
existing ophthalmic drugs are actually not developed for ocular applications, they were 
intended for other therapeutic areas which were later converted to ocular applications 
following their high efficacy. This further has decreased the likelihood of achieving eye-
specific delivery along with reduced systemic side effects. In view of this, various drug 
Soft Glucocorticoids: Eye-Targeted Chemical Delivery  
Systems (CDSs) and Retrometabolic Drug Design: A Review 625 
design approaches have been tried to eliminate the problems of low ocular delivery and 
potential for substantial systemic side effects [6, 43]. It has been found that prodrug 
approach here had some limitations. Prodrugs are pharmacologically not active (or may be 
weakly active) compounds that results from transient chemical modifications of biologically 
active species, so that they are metabolically transformed into effective drugs following 
administration [28-30, 44-47]. Compared with the original structures, prodrug structures 
incorporate chemical modifications to get improvement in some deficient physiological 
properties, such as membrane permeability or water solubility or to overcome some other 
problems like rapid elimination, bad taste, a formulation difficulty etc. After administration, 
the prodrug because of its improved characteristics, is more systemically or locally available 
than the parent drug. However the prodrug must undergo chemical or biochemical 
conversion to the active form before exerting its biological effect. Some of the marketed 
ophthalmic prodrugs include Dipivefrine (21)-the dipivalate ester prodrug of epinephrine 
(20), latanoprost (22) and travoprost (23) -isopropyl ester prodrugs that are prostaglandin 
F2α (24) analogs [24]. 
Retrometabolic Drug Design: 
Because of the adverse drug reactions (ADRs) associated even with the new generation 
glucocorticoids in ocular treatment, the real breakthrough in the area of ophthalmic 
therapeutics could be achieved only by specifically designing new drugs with their 
ophthalmic applications in mind, so that the possibility of eye targeting with reduced 
systemic side effects is already incorporated in their chemical structures. In an effort to 
minimize ADRs and other complicacies associated with glucocorticoids, Bodor and his 
colleagues for the first time have developed the concept of retrometabolic drug design for 
ophthalmic therapeutics to introduce a new and unique class of glucocorticoids now known 
as soft corticosteroids or soft glucocorticoids that helped in developing glucocorticoid soft 
drugs for ophthalmic use [24, 48-50]. Soft -blockers are also falling in this soft drug 
category. The concept of soft drugs has been originated from the pioneer work of Prof. N 
Bodor and his co-workers at the Center for Drug Discovery, University of Florida, Health 
Science Center, Gainesville, FL 32610-0497, USA [24, 48-50]. The possibility of developing 
these soft drugs has been extensively studied along the lines of retro- metabolic drug design 
for two important classes of ophthalmic drugs, - blockers and glucocorticoids [24]. The 
underlying principle of retrometabolic drug design involves synthesizing analogs of lead 
molecules or reference molecules, starting from one of the known inactive metabolites of 
that lead compound. The inactive metabolite is then converted to an isosteric or isoelectronic 
analog with structural modifications designed for a rapid and predictable metabolism back 
to the original inactive metabolite after exerting the desired therapeutic effect at the site 
(Figure 2) [24, 26]. These analogs or soft drugs were predicted to have therapeutic potential 
similar to that of the lead compound, but because of the structural modifications provided 
by the design, any active drug remaining after attainment of the therapeutic effect would be 
metabolically deactivated, thus reducing adverse drug reactions (ADRs) [24, 26, 48-51]. 
According to Prof Bodor, in developing soft drugs the goal is not to avoid metabolism but 
rather to control and direct it. Inclusion of a metabolically sensitive moiety into the parent 
drug molecule can make possible the design and prediction of the major metabolic pathway 
 
Glucocorticoids – New Recognition of Our Familiar Friend 624 
administration undoubtedly seems preferred mode, because for systemically administered 
drugs, only a very small fraction of the total dose will reach the eye from the general 
circulatory system. Even distribution for this fraction to the inside of the eye is further 
hindered by the blood-retinal barrier (BRB), which is almost as effective as blood-brain 
barrier (BBB) in restricting the passage of xenobiotics from the blood stream [34]. Therefore 
despite its apparent accessibility, the eye, in fact, is well protected against the absorption of 
foreign materials, including drug molecules, by the eyelids, by flow of tears, and also by 
the permeability barriers imposed by the cornea on one side and the blood-retinal barrier 
on the other side as mentioned above [24]. Because of this a significant portion of the 
applied drug is absorbed through nasolacrimal duct and the mucosal membranes of the 
nasal, oropharyngeal, and gastrointestinal tract to pass to the system. It has been found 
that no more than 2% of medication introduced topically to the eye is adsorbed [35-37]. 
Again clinical studies by various workers reveal that the main biological barrier for 
penetration to the eye is represented by the cornea. The relatively lipophilic corneal 
epithelium tissue having low porosity and high tortuosity due to tight annular junctions, 
is the primary barrier for hydrophilic drugs, where as the middle stromal layer 
consisting mainly of water interspersed with collagen fibrils( major thickness of cornea), 
is the main barrier for the lipophilic drugs [38-41]. All these facts result not only in a low 






























Prostaglandin F2(24)  
topical administration giving systemic side effects [42]. Moreover as mentioned earlier, 
existing ophthalmic drugs are actually not developed for ocular applications, they were 
intended for other therapeutic areas which were later converted to ocular applications 
following their high efficacy. This further has decreased the likelihood of achieving eye-
specific delivery along with reduced systemic side effects. In view of this, various drug 
Soft Glucocorticoids: Eye-Targeted Chemical Delivery  
Systems (CDSs) and Retrometabolic Drug Design: A Review 625 
design approaches have been tried to eliminate the problems of low ocular delivery and 
potential for substantial systemic side effects [6, 43]. It has been found that prodrug 
approach here had some limitations. Prodrugs are pharmacologically not active (or may be 
weakly active) compounds that results from transient chemical modifications of biologically 
active species, so that they are metabolically transformed into effective drugs following 
administration [28-30, 44-47]. Compared with the original structures, prodrug structures 
incorporate chemical modifications to get improvement in some deficient physiological 
properties, such as membrane permeability or water solubility or to overcome some other 
problems like rapid elimination, bad taste, a formulation difficulty etc. After administration, 
the prodrug because of its improved characteristics, is more systemically or locally available 
than the parent drug. However the prodrug must undergo chemical or biochemical 
conversion to the active form before exerting its biological effect. Some of the marketed 
ophthalmic prodrugs include Dipivefrine (21)-the dipivalate ester prodrug of epinephrine 
(20), latanoprost (22) and travoprost (23) -isopropyl ester prodrugs that are prostaglandin 
F2α (24) analogs [24]. 
Retrometabolic Drug Design: 
Because of the adverse drug reactions (ADRs) associated even with the new generation 
glucocorticoids in ocular treatment, the real breakthrough in the area of ophthalmic 
therapeutics could be achieved only by specifically designing new drugs with their 
ophthalmic applications in mind, so that the possibility of eye targeting with reduced 
systemic side effects is already incorporated in their chemical structures. In an effort to 
minimize ADRs and other complicacies associated with glucocorticoids, Bodor and his 
colleagues for the first time have developed the concept of retrometabolic drug design for 
ophthalmic therapeutics to introduce a new and unique class of glucocorticoids now known 
as soft corticosteroids or soft glucocorticoids that helped in developing glucocorticoid soft 
drugs for ophthalmic use [24, 48-50]. Soft -blockers are also falling in this soft drug 
category. The concept of soft drugs has been originated from the pioneer work of Prof. N 
Bodor and his co-workers at the Center for Drug Discovery, University of Florida, Health 
Science Center, Gainesville, FL 32610-0497, USA [24, 48-50]. The possibility of developing 
these soft drugs has been extensively studied along the lines of retro- metabolic drug design 
for two important classes of ophthalmic drugs, - blockers and glucocorticoids [24]. The 
underlying principle of retrometabolic drug design involves synthesizing analogs of lead 
molecules or reference molecules, starting from one of the known inactive metabolites of 
that lead compound. The inactive metabolite is then converted to an isosteric or isoelectronic 
analog with structural modifications designed for a rapid and predictable metabolism back 
to the original inactive metabolite after exerting the desired therapeutic effect at the site 
(Figure 2) [24, 26]. These analogs or soft drugs were predicted to have therapeutic potential 
similar to that of the lead compound, but because of the structural modifications provided 
by the design, any active drug remaining after attainment of the therapeutic effect would be 
metabolically deactivated, thus reducing adverse drug reactions (ADRs) [24, 26, 48-51]. 
According to Prof Bodor, in developing soft drugs the goal is not to avoid metabolism but 
rather to control and direct it. Inclusion of a metabolically sensitive moiety into the parent 
drug molecule can make possible the design and prediction of the major metabolic pathway 
 
Glucocorticoids – New Recognition of Our Familiar Friend 626 
preventing the formation of undesired toxic, active, or high-energy intermediates. It is 
desired that, If possible, inactivation should take place as the result of a single, low- energy 
and high- capacity step that gives the inactive species subject to rapid elimination. Most 
critical metabolic pathways in a biological system are mediated by oxygenases, a consequence 
of the fact that the normal reaction of an organism to a foreign material is to burn it up as 
food [52]. However oxygenases exhibit not only interspecies, but also inter individual and are 
subject to inhibition and induction (24) and because the rates of hepatic mono-oxygenases 
reactions are at least two orders of magnitude lower than the slowest of the other enzymatic 
reactions [53,54], it is usually desirable to avoid oxidative pathways as well as these slow, 
easily saturable oxidases. In view of this, the design of soft drugs must be based on moieties 
activated by hydrolytic enzymes. Rapid metabolism could be more reliably performed by 
these ubiquitously distributed esterases. Bodor et al (26) suggested that it is desirable not to 
rely exclusively on metabolism by organs such as kidney or liver to have an additional 
advantage because blood flow and enzyme activities in these organs can be fatally damaged 
in critically ill patients. However, the increase in the therapeutic index can only be achieved 
if the drug is stable enough to reach its receptor site to deliver the desired effect, and any 
free drug remaining thereafter should be metabolized to minimize ADRs [24]. 
 
 
Figure 2. Retrometabolic drug design approach: Synthesis of new lead molecules (Soft drugs) based on 















Retrometabolic   
Drug Design Metabolism 
New Lead Molecules or 
Soft Drugs 











Soft Glucocorticoids: Eye-Targeted Chemical Delivery  






























29a  R=H, Oxime dvt.





































 (Stereospecific) in eye 
 tissues
































Figure 3. Site- and Stereospecific delivery of -adrenergic antagonists to the eye through sequential 
activation of their oximes and alkyl oximes.  
Soft- -Blockers: 
As because soft drug design is a general concept, topically applied soft drugs that show 
local activity with reduced systemic side effects could become potential therapeutics for any 
ocular diseases [24]. During the last three decades, Bodor and his colleagues have applied 
retrometabolic drug design to a variety of therapeutic agents such as - blockers, 
antimicrobials, analgesics, and acetyl cholinesterase (ACE) inhibitors and were successful in 
developing retrometabolically designed compounds with market potential. As for example, 
in addition to the oxime or methoxime  -blocker analogs, the development of soft  -
blockers could represent another possible route toward improved and safer antiglaucoma 
agents [54-62]. Several oxime and methoxime analogs of known  -Adrenergic blockers such 
as Alprenolol (25), Betaxolol (26)l, Timolol (27) etc. were synthesized from their respective 
ketone derivatives, viz., Alprenolone (28), Betaxolone (29), Timolone (30) and studied 
clinically [54-62]. They are potential drugs which have been developed applying general 
retrometabolic drug design principle and can be recognized as site-specific enzymatic 
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chemical delivery systems (CDSs) [54-62]. In these compounds, a  -amino oxime or 
alkyloxime function replaces the corresponding  -amino alcohol pharmacore part of the 
original molecules (Figure 3). These oxime or alkyloxime derivatives (31) are found to exist 
in Z (syn) or E (anti) configuration. They are hydrolyzed within the eye by enzymes located 
in the iris-cillary body and subsequently again by reductive enzymes present there 
producing only the active S- (-) stereoisomeric alcohol (32) of the corresponding -blockers 
[54]. For aryl  -amino alcohol-type  -adrenergic agonists and antagonists, most of the 

















































Figure 4. Inactive Metabolite-based Soft Drug Design: Comparison of the structure and metabolism of 
the soft  -blocker Adaprolol (23) with that of the traditional  -blocker Metoprolol(24).  
present with the S- (-) stereoisomer [63-65], possibly because this isomer allows better 
interaction of all three important functionalities (aromatic, amino and  -hydroxyl moieties) 
with the  -adrenoceptor. In fact these oxime and alkyloxime derivatives have been found to 
exhibit significant intraocular pressure (IOP) lowering activity, but even their intravenous 
administration did not produce the active  -blocker metabolically; as a result they are void 
of any cardiovascular activity, which has been found to be a major drawback of classical 
antiglaucoma agents [26].  
According to Bodor and his team [24], the oxime-type CDS approach clearly demonstrates 
the site- specific or site-enhanced drug delivery through sequential, multi-step enzymatic 
and/or chemical transformations through a targetor moiety that is converted into a 
biologically active function by enzymatic reactions which take place primarily at the site of 
action as a result of differential distribution of some enzymes found in the eye [24]. 
Soft Glucocorticoids: Eye-Targeted Chemical Delivery  
Systems (CDSs) and Retrometabolic Drug Design: A Review 629 
Again as Prof. Bodor and his team suggest [24,26], soft drugs (SDs) represent a different, 
conceptually opposite targeting concept; whereas eye-targeting CDSs, represented here by 
the above discussed oxime analogs, are inactive compounds designed to achieve the 
targeted effects via a multi-step activation process by enzymes found at their intended site of 
action. However soft drugs represented by -blockers or glucocorticoids are active 
compounds designed to achieve the targeted effects via a single-step inactivation process 
involving enzymes found ubiquitously in the systemic circulation. Because in this class, 
inactive metabolite based soft drugs can be achieved introducing the hydrolytically sensitive 
functionality at a flexible pharmacophore region, there is considerable freedom for 
structural modifications. As a result, transport and metabolism properties are easier to 
control. From the various soft -blockers developed along these lines by Bodor and 
Buchwald [24], Adaprolol (33), an adamantane ethyl ester was selected as a potential 
candidate for a new topical antiglaucoma agent [24 ]. The metabolism of the well-known  -
blocker Metoprolol (34) has been compared with that of the soft  -blocker Adaprolol which 
has been designed starting from one of Metoprolol`s inactive acid metabolite (35), viz., 
phenyl acetic acid (Figure 4). Its other metabolites include -hydroxymetoprolol (36) and O-
Dimethylmetoprolol (37) both of which are active. Another inactive metabolite includes the 
acid derivative 38. Adaprolol was chosen because of the fact that if membrane transport 
(lipophilicity) and relative stability are important for pharmacological activity as they are 
needed to achieve right corneal permeability, then the ester goup should be relatively 
lipophilic and should provide ester stability [66-70]. In clinical trials Adaprolol (33) indeed 
produced prolonged and significant IOP-reduction while hydrolyzed relatively fast [67, 68]. 
Therefore, it was possible to separate local activity from undesired systemic cardiovascular 
or pulmonary activity, a characteristic highly desirable in development of antiglaucoma 
therapy [24]. Adaprolol (33) could be now a potent antiglaucoma soft  -blocker to replace 
the traditional  -blocker Metoprolol (34). Further clinical studies confirmed that Adaprolol 
is not only effective in reducing intraocular pressure (IOP) but also has a safer 
cardiovascular profile than Timolol (27) because unlike Timolol, Adaprolol did not reduce 
the systolic blood pressure [24]. 
Glucocorticoid Soft Drugs: Ophthalmic Therapeutics 
Along the line of soft -blockers, development of soft anti-inflammatory glucocorticoids 
represents a promising and successful ophthalmic drug design area initiated by Bodor and 
his colleagues [24,26]. Inflammation in the eye could result from surgery, injury, infection, 
conjunctivitis, or uvitis-conditions that can cause severe discomfort even leading to loss of 
vision. As mentioned earlier, topical glucocorticoids represent an important class of 
molecules to treat ocular inflammations and allergies as they are the most effective anti-
inflammatory compounds offering the broadest range of treatment. However a number of 
contradictions limit their usefulness severely [12]. In addition to the general systemic side 
effects or adverse drug reactions (ADRs) associated with these glucocorticoids, they also 
cause several ocular complications such as IOP-elevation resulting steroid- induced 
glaucoma, induction of cataract formation and other secondary complications [12, 71]. In 
this context design of soft anti-inflammatory glucocorticoids has been one of the most active 
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chemical delivery systems (CDSs) [54-62]. In these compounds, a  -amino oxime or 
alkyloxime function replaces the corresponding  -amino alcohol pharmacore part of the 
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in the iris-cillary body and subsequently again by reductive enzymes present there 
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Glucocorticoid Soft Drugs: Ophthalmic Therapeutics 
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represents a promising and successful ophthalmic drug design area initiated by Bodor and 
his colleagues [24,26]. Inflammation in the eye could result from surgery, injury, infection, 
conjunctivitis, or uvitis-conditions that can cause severe discomfort even leading to loss of 
vision. As mentioned earlier, topical glucocorticoids represent an important class of 
molecules to treat ocular inflammations and allergies as they are the most effective anti-
inflammatory compounds offering the broadest range of treatment. However a number of 
contradictions limit their usefulness severely [12]. In addition to the general systemic side 
effects or adverse drug reactions (ADRs) associated with these glucocorticoids, they also 
cause several ocular complications such as IOP-elevation resulting steroid- induced 
glaucoma, induction of cataract formation and other secondary complications [12, 71]. In 
this context design of soft anti-inflammatory glucocorticoids has been one of the most active 
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and productive fields of soft drug design. Ophthalmic use of glucocorticoids usually causes 
increased intraocular pressure (IOP) as a result of increased resistance to aqueous humour 
outflow. The design of soft anti-inflammatory glucocorticoids has been one of the most 
important and most successful areas of Soft Drug design. Although the soft nature of such 
drugs are mainly associated with fast hydrolytic degradation, in fact it is not necessarily be 
so as Bodor and his co-workers suggested [24].Too much rapid hydrolysis may in fact result 
in weak activity. The desired increase of therapeutic index can be obtained only if the drug 
is sufficiently stable to reach the receptor sites at the target organ to produce the desired 
effect, but the free, non-protein-bound drug undergoes facile hydrolysis to avoid undesired 
systemic side effects. Therefore to develop a soft drug and hence separating successfully the 
desired local activity from systemic toxicity, an adequate balance between intrinsic activity, 
solubility/lipophilicity, tissue distribution, protein binding and rate of metabolic 
deactivation have to be achieved. In the case of slow, sustained release to the general 
circulatory system from delivery site, even a relatively slow hydrolysis could result in a very 
low, almost steady-state systemic concentration [24]. Based on these concepts of eye-
targeting chemical delivery systems (CDSs) and retrometabolic drug design approaches, 
Bodor and his group was successful in developing glucocorticoid soft drugs for ophthalmic 
therapeutics having potential market value.  
First Generation Cortienic Acid (39)-based Glucocorticoid Soft Drugs: Loteprednol Etabonate (41) 
and its Analogs (42): 
Synthesis of Dug molecules and Structure-Activity Studies: 
As already mentioned, Bodor and his colleagues [24, 26] have applied retrometabolic drug 
design approach to a variety of therapeutic agents such as - blockers, antimicrobials, 
analgesics, and acetyl cholinesterase (ACE) inhibitors and were successful in developing 
retrometabolically designed molecules reaching towards market application. They had 
designed a number of analogs starting with 1-cortienic acid (40), the primary metabolite of 
prednisolone that lacks corticosteroid activity [25]. Hydrocortisone can undergo a variety of 
oxidative and reductive metabolic conversions [72] by local esterases within the system. Thus 
oxidation of its dihydroxyacetone side chain leads to the formation of cortienic acid via 21-
dehydrocortisol (21-aldehyde) and cortisolic acid (21-acid) [Figure 5]. Cortienic acid (39) is 
an ideal lead molecule for the inactive metabolite soft drug (SD) approaches because it is 
lack of corticosteroid activity and therefore is major metabolite excreted in human urine. To 
get the new lead compounds, the pharmacophore moieties of the 17-hydroxyl and 17- 
carboxy substituents of the lead compound had to be restored by suitable 
isosteric/isoelectronic substitution containing esters or other types of functions that could 
restore the anti-inflammatory potency of the original corticosteroid while at the same time 
incorporating hydrolytic features to ensure metabolism. Other structural considerations 
included the presence or absence of double bond at C-1 position, presence of 6 or 9 
fluorine, and 16 & 16 –methyl group (Figure 6). More than hundred possible drug 
molecules were synthesized and tested in pre-clinical anti-inflammatory models [5]. 
Structure-activity studies by Bodor and his group [24] of these molecules have confirmed 
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that the best substituent for maximal therapeutic activity included a haloester at 17 
position and a carbonate or ether moiety at 17 position. Incorporation of 17 carbonates 
or ether was preferred over 17 esters to increase stability and to prevent potential 
formation of mixed anhydrides by reaction of a 17 ester with a 17 acid functionality and 
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Figure 5. Oxidative metabolism of hydrocortisone by local esterases into C-21 Aldehyde and C-21 Acid 
(Cortisolic Acid) 
Therefore in addition to the C-20 ketone functionality of prednisolone being replaced to 
eliminate the possibility of Schiff base intermediates, other chemical features associated with 
cataracterogenesis were also eliminated by the proposed design. The carbonates were 
expected to be less reactive than the corresponding esters due to the lower electrophilicity of 
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Loteprednol Etabonate (LE) namely chloromethyl- 17-[(ethoxycarbonyl) oxy]-11-hydroxy-
3-oxoandrosta-1, 4-diene-17 -carboxylate (41), was the most promising drug candidate 
among the various cortienic acid-based derivatives synthesized by Bodor and his group 
(Figure 6)]. In Loteprednol Elaborate (41), a metabolically labile ester function occupies 17 
- position, while a stable carbonate group occupies 17-position. The ester is hydrolyzed to 
an inactive carboxylic acid, Δ1-cortienic acid etabonate (43), and then into Δ1-cortienic acid 
(40) in biological systems after exerting the desired therapeutic effect, thereby minimizing 
the likelihood of toxicity [Figure 7]. As a result of the predictable conversion of Loteprednol 
Etabonate into an inactive metabolite in the eye following topical administration, this 
glucocorticoid has a low propensity for undesirable toxicity while possessing increased anti-
inflammatory activity. In fact Loteprednol Etabonate (41) has been found to be 1.5 times 
more potent than the parent anti-inflammatory agent dexamethasone [24].  
Loteprednol Etabonate (41) and its Clinical Investigations in Ophthalmic Therapeutics: 
Clinical study confirmed that Loteprednol Etabonate and some of the other soft 
glucocorticoids synthesized, provided a significant improvement of the therapeutic index, 
determined as the ratio between the anti-inflammatory activity and the thymus evolution 
activity [24]. In addition, binding studies using rat lung cytosolic corticosteroid receptors 
exhibited that the receptor binding affinity of LE and some of its analogs even exceeded that 
of the most potent glucocorticoids known[24]. Loteprednol Etabonate (41) is the one of the 
first-generation cortienic acid-based glucocorticoid soft drugs to get approved by Food and 
Drug Administration (FDA), USA for use in all inflammatory and allergy-related 
ophthalmic disorders, including inflammation after cataract surgery, uveitis, allergic 
conjunctivitis, and giant papillary conjunctivitis (GPC) [73-76]. Clinical tests on LE (41) by 
various groups of workers suggest it to be a potent glucocorticoid soft drug for ocular 
therapeutics. LE has also been selected for development as a potent glucocorticoid soft drug 
based on various considerations including the therapeutic index, availability, synthesis, and 
`softness’ (the rate and easiness of metabolic deactivation). LE is now the active ingredient 
of a number of ophthalmic preparations available in the market (Lotemax, Alrex, Zylet etc.) 
[73, 74, 76].  
Loteprednol Etabonate (41) has been found to be highly lipophilic which is 10 times greater 
than that of Dexamethasone (2), a characteristic that could increase its efficacy by enhancing 
penetration through biological membranes [24,26]. Competitive binding studies with rat 
lung type II GRs confirmed that binding affinity of LE was more than 4 times that of 
Dexamerhasone [77]. A vasoconstriction test in humans used to assess the bioavailability 
exhibited that LE could produce a blanching response similar to that of Betamethasone 17-
valerate (16) to confirm its good penetration properties and strong potency [11]. Bodor and 
his group, have reported the therapeutic index of LE having more than 20-fold better than 
that of other glucocorticoids including Hydrocortisone 17-butyrate (14), Betamethasone 
17-valerate (16) and Clobetasol 17-propionate (17) based on their cotton pellet glaucoma 
test and thymolysis potency [9]. LE (41) has been rightly selected on the basis of 
considerations including Therapeutic Index (TI) which is the ratio between the median toxic 
dose (TD50) and the median effective dose (ED50), availability, synthesis and the rate and 
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easiness of metabolic deactivation (Softness)[24]. In traditional glucocorticoids such as 
Hydrocortisone 17-butyrate (14), Betamethasone 17-valerate (16) and Clobetasol 17- 
propionate (17), efficacy and toxicity are closely correlated ( r2 =0.996) applying the 
relationship between the anti- inflammatory and thymus involution activities [24] 
determined in the cotton pellet granuloma test (Figure 8). In these glucocorticoids, the 
reported results [24] have shown that TI have been found to be almost similar regardless of 
their intrinsic activities; however glucocorticoid soft drug Loteprednol Etabonate (41) owing 
to its softness and improved toxicity profile, provides a significant improvement(24) (Table 













Figure 7. Metabolism of Loteprednol Etabonate (41) to 1-Cortienic acid etabonate (43) and then to 1-
Cortienic acid(40). 
Loteprednol Etabonate (LE) is predictably metabolized by local esterases into its inactive 
metabolite Δ1-cortienic acid (40) which has been confirmed through animal studies [20]. 
Clinical studies by Druzgala et al [78] have confirmed that the highest concentration of LE 
was found in cornea, followed by the iris/ciliary body and aqueous humour. The cornea also 
showed the highest ratio of metabolite to Loteprednol Etabonate (41), indicating that the 
cornea was the prime site of metabolism, while aqueous humour concentrations of LE were 
nearly 100-fold lower. This finding suggested that Loteprednol Etabonate may exert a 
decreased IOP effect as compared to other glucocorticoids [78]. Further a comparison of the 
IOP-elevating activity of Loteprednol Etabonate with that of Dexamethasone (2) in rabbits 
confirmed a lack of IOP effect with LE [79, 80]. LE was found to have a terminal half- life 
(t1/2) of 2.8 hrs in dogs following intravenous administration [81]. Further when absorbed 
systemically, LE was found to be metabolized to 1-cortienic acid etabonate (43) and then to 
1-cortienic acid (40) (Figure 7) and have been found to be eliminated rapidly through the 
bile and urine [26, 81, 82]. So far numerous preclinical tests were carried out on Loteprednol 
Etabonate (41) including more recent ones by Comstock and DeCory [20, 83]. Most of these 
clinical studies have confirmed that Loteprednol Etabonate achieves the required balance 
between the solubility/lipophilicity, ocular tissue distribution, receptor binding, and 
subsequent rate of metabolic deactivation as have been outlined by Bodor when he 
conceptualized for the first time the retrometabolic drug design. 
Since the design of this glucocorticoid soft drug LE by Bodor and his group, various 
ophthalmic suspension formulation of LE viz., a 0.2% suspension, a 0.5% suspension and a 
combination suspension of LE 0.5% plus tobramycin 0.3%, have been developed and clinically 
tested in various ocular inflammatory conditions and postoperative ocular inflammation.  
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Figure 8. Literature reported [24] graph showing the relationship between the Efficacy [log 1/ED50 
(μg/pellet)] and Toxicity [log 1/TD50 (μg/pellet) of Hydrocortisone-17 α-Butyrate (14: 0.1%), 
Betamethasone-17 α-Valerate (16: 0.12%), Clobetasone-17 α-Propionate (17: 0.1%) and Loteprednol 
Etabonate (41: 0.1%). Relative TI being computed with Betamethasone-17 α-Valerate (16) as reference. 
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(Rel TI) TI/TIBMV 
Loteprednol Etabonate (41) 56.2 22.5 
Clobetasone-17-Propionate (17) 3.8 1.5 




Table 4. Literature reported Therapeutic Index (TI) and Relative Therapeutic Index (Rel. TI) of some 
glucocorticoids and Loteprednol Etabonate (41). Relative Therapeutic Index was computed with 
Betamethasone-17 -Valerate (BMV)(16) as the reference. 
Ocular diseases against which LE formulations were clinically tested included Giant 
Papillary Conjunctivitis, Prophylaxis of Seasonal Allergic Conjunctivitis, Seasonal Allergic 
Conjunctivitis, Anterior Uveitis, Blepharokerato Conjunctivitis, and Keratoconjunctivitis 
sicca etc. All these studies confirmed the clinical anti-inflammatory potency of LE and lack 
of significant IOP after its use [20]. Again two identical placebo-controlled trials examined 
the safety and efficacy of LE in treating post operative inflammation following cataract 
surgery with intraocular lens implantation [92]. Ilyas et al [93] have studied the long term 
safety of LE 0.2% by conducting a retrospective review of more than 350 seasonal and 
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perennial conjunctivitis patients who used LE 0.2% on a daily basis for extended periods of 
time. The results showed the absence of significant ADRs as there were no reports of 
posterior subcapsular opacification with quite insignificant IOP in most of the patients. In 
fact there was no observation of IOP elevation greater than 4mm Hg over base line at any 
period of time.  
Besides, safety and efficacy of LE ophthalmic ointment 0.5% in the treatment of 
inflammation and pain following cataract surgery was studied in two randomized, 
multicentre, double-masked, parallel group, vehicle-controlled studies [20]. A very fewer LE 
ointment-treated patients needed rescue medication and most of them did not showed any 
ocular adverse event. Clinical trials on gel formulation of LE in treatment of ocular 
inflammation and pain after cataract surgery have been taken up more recently [20]. It is 
because of the high lipophilic nature of LE, gel formulation could provide improved 
product homogeneity over a suspension formulation to enhance its more consistent clinical 
response. 
LE has been designed by Bodor and his group with a C-20 ester rather than a C-20 ketone 
and so LE is unable to form covalent adduct with lens protein, the main reason behind 
steroid-induced cataract formation as discussed earlier. Global market research indicates 
that an estimated more than 20 million LE units have been distributed globally. Clinical 
studies suggest the rapid metabolism of LE into inactive metabolites in conjunction with the 
lack of C-20 carbonyl functionality have resulted in LE – to become a unique glucocorticoid 
soft drug with significantly less, if any, potential for promoting steroid-induced cataract 
formation.[20]. LE has now been proved as a safe and effective treatment for contact lens-
associated GPC, seasonal allergic conjunctivitis, postoperative inflammation or uveitis. 
Retrospective study established that even long time (>1 year) use of LE caused no reported 
adverse effects. .  
Synthesis of the Side Chain of Loteprednol Etabonate (41) directly from 20-Oxopregnane (44) to 
furnish an Analog (45) of LE: 
Based on promising results from animal studies, further clinical trials on Loteprednol 
Etabonate (41) are also going on for a safer treatment of gastrointestinal inflammation and 
other diseases such as asthma, rhinitis, and dermatological problems [76,82,84-86]. Success 
story of this retrometabolically designed glucocorticoid soft drug Loteprednol Etabonate has 
drawn attention to pharmaceutical industries as well as people working in steroid field 
worldwide. The authors of this chapter [87], recently, have reported a facile synthesis of the 
side chain of this potent ocular glucocorticoid soft drug, starting directly from 20-
oxopregnanes, viz., 3β-acetoxy-pregn-5(6),16(17)-diene-20-one (16- dehydropregnenolone 
acetate i.e. 16-DPA) (44)- a potent steroid drug intermediate, utilizing their recently 
developed metal mediated halogenation technique as a key reaction [88,89 ] to furnish the 
final product –an analog (45) of Loteprednol Etabonate (41) with the requisite side chain 
[Scheme 1]. 
The present methodology paves a useful and productive way to construct the side chain of 
this important glucocorticoid soft drug directly from 20-oxopregnanes via its C-21 
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glucocorticoids and Loteprednol Etabonate (41). Relative Therapeutic Index was computed with 
Betamethasone-17 -Valerate (BMV)(16) as the reference. 
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Conjunctivitis, Anterior Uveitis, Blepharokerato Conjunctivitis, and Keratoconjunctivitis 
sicca etc. All these studies confirmed the clinical anti-inflammatory potency of LE and lack 
of significant IOP after its use [20]. Again two identical placebo-controlled trials examined 
the safety and efficacy of LE in treating post operative inflammation following cataract 
surgery with intraocular lens implantation [92]. Ilyas et al [93] have studied the long term 
safety of LE 0.2% by conducting a retrospective review of more than 350 seasonal and 
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perennial conjunctivitis patients who used LE 0.2% on a daily basis for extended periods of 
time. The results showed the absence of significant ADRs as there were no reports of 
posterior subcapsular opacification with quite insignificant IOP in most of the patients. In 
fact there was no observation of IOP elevation greater than 4mm Hg over base line at any 
period of time.  
Besides, safety and efficacy of LE ophthalmic ointment 0.5% in the treatment of 
inflammation and pain following cataract surgery was studied in two randomized, 
multicentre, double-masked, parallel group, vehicle-controlled studies [20]. A very fewer LE 
ointment-treated patients needed rescue medication and most of them did not showed any 
ocular adverse event. Clinical trials on gel formulation of LE in treatment of ocular 
inflammation and pain after cataract surgery have been taken up more recently [20]. It is 
because of the high lipophilic nature of LE, gel formulation could provide improved 
product homogeneity over a suspension formulation to enhance its more consistent clinical 
response. 
LE has been designed by Bodor and his group with a C-20 ester rather than a C-20 ketone 
and so LE is unable to form covalent adduct with lens protein, the main reason behind 
steroid-induced cataract formation as discussed earlier. Global market research indicates 
that an estimated more than 20 million LE units have been distributed globally. Clinical 
studies suggest the rapid metabolism of LE into inactive metabolites in conjunction with the 
lack of C-20 carbonyl functionality have resulted in LE – to become a unique glucocorticoid 
soft drug with significantly less, if any, potential for promoting steroid-induced cataract 
formation.[20]. LE has now been proved as a safe and effective treatment for contact lens-
associated GPC, seasonal allergic conjunctivitis, postoperative inflammation or uveitis. 
Retrospective study established that even long time (>1 year) use of LE caused no reported 
adverse effects. .  
Synthesis of the Side Chain of Loteprednol Etabonate (41) directly from 20-Oxopregnane (44) to 
furnish an Analog (45) of LE: 
Based on promising results from animal studies, further clinical trials on Loteprednol 
Etabonate (41) are also going on for a safer treatment of gastrointestinal inflammation and 
other diseases such as asthma, rhinitis, and dermatological problems [76,82,84-86]. Success 
story of this retrometabolically designed glucocorticoid soft drug Loteprednol Etabonate has 
drawn attention to pharmaceutical industries as well as people working in steroid field 
worldwide. The authors of this chapter [87], recently, have reported a facile synthesis of the 
side chain of this potent ocular glucocorticoid soft drug, starting directly from 20-
oxopregnanes, viz., 3β-acetoxy-pregn-5(6),16(17)-diene-20-one (16- dehydropregnenolone 
acetate i.e. 16-DPA) (44)- a potent steroid drug intermediate, utilizing their recently 
developed metal mediated halogenation technique as a key reaction [88,89 ] to furnish the 
final product –an analog (45) of Loteprednol Etabonate (41) with the requisite side chain 
[Scheme 1]. 
The present methodology paves a useful and productive way to construct the side chain of 
this important glucocorticoid soft drug directly from 20-oxopregnanes via its C-21 
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functionalization in much simpler and easier way with their newly developed metal 
mediated halogenation technique, which avoids application of harsh and tedious reaction 














































































Scheme 1. Reagents and conditions: (i) H2,Pd-C, 95% (ii) MnO2-TMSCl/AcCl-AcOH, 81% (iii) 3% KOH, 
MeOH-H2O, 75% (iv) LiAlH4,THF, 88% (v) CAN, AcOH, 75% (vi) m-CPBA, CHCl3, 62% (vii) 
H2SO4,acetone-H2O, 48% (viii) Jones reagent, 57% (ix) OsO4 – H2O2, rt., 50% (x) NaIO4 , Ethyl 
chloroformate, 70% xi) Chloromethyl iodide, 75% .  
Second –generation Cortienic Acid (39)-based Glucocorticoid soft drugs: Etiprednol dicloacetate (46) 
and its Analogs (47): 
Synthesis of Drug molecules and Structure-Activity Studies: 
Based on their retrometabolic drug design approach, Nicholas Bodor [94] have more 
recently introduced another new class of soft glucocorticoids with 17-dicloroester 
substituent. These are now known as the second generation soft glucocorticoids (Figure 9). 
This is said to be a unique design as no known glucocorticoid has been found to contain a 
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halogen substituent at the 17 position. Nevertheless, the pharmacophore portions of these 
second- generation cortienic acid-based soft glucocorticoids, having the halogen atoms at 
17 position, can be positioned so as to provide excellent overlap with those of the 
traditional glucocorticoids [24, 95]. It has been conceived the idea that dichlorinated 
substituents seem required for activity and sufficiently soft nature. Molecular configuration 
suggests that with dicholrinated substituents, one of the chlorine atom would necessarily 
point in the direction needed for pharmacophore overlap, whereas with monochlorinated 
substituents, steric hindrance might force the lone chlorine atom to point away from this 
desired direction. Secondly experimentally it has been found that as compared with the 
unsubstituted ester, dichloro substituents could cause ~20 fold increase in the second-order 
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Figure 9. Design of 2nd Generation Cortienic Acid-based Soft Glucocorticoids Soft Drugs (47) and their 
Glucocorticoid Soft Drug representative Etiprednol Dicloacetate (ED)(46) 
substituent did not cause any change [96]. Unlike first generation soft glucocorticoids, in the 
second generation of this soft steroid series, hydrolysis primarily cleaves the 17- ester 
group and not the 17-ester group. The corresponding metabolites are also not active. From 
large no of compounds synthesized in this series, Etiprednol Dicloacetate (ED) (46) had been 
selected for development as a potent ocular glucocorticoid soft drug [24].  
Etiprednol Dicloacetate (46) and its Clinical Investigations in Ophthalmic Therapeutics: 
In animal and in human clinical trials, in accordance with its soft nature, Etiprednol 
Dicloacetate (46) was found to have low systemic toxicity [94, 97-99]. Etiprednol Dicloacetate 
had also shown better receptor binding capacity than Loteprednol Etabonate and was found 
to be more effective than Budesonide (3) in various asthma models [24]. Further No 
Observable Adverse Effect Level (NOAEL) of ED after oral administration for 28 days was 
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halogen substituent at the 17 position. Nevertheless, the pharmacophore portions of these 
second- generation cortienic acid-based soft glucocorticoids, having the halogen atoms at 
17 position, can be positioned so as to provide excellent overlap with those of the 
traditional glucocorticoids [24, 95]. It has been conceived the idea that dichlorinated 
substituents seem required for activity and sufficiently soft nature. Molecular configuration 
suggests that with dicholrinated substituents, one of the chlorine atom would necessarily 
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In animal and in human clinical trials, in accordance with its soft nature, Etiprednol 
Dicloacetate (46) was found to have low systemic toxicity [94, 97-99]. Etiprednol Dicloacetate 
had also shown better receptor binding capacity than Loteprednol Etabonate and was found 
to be more effective than Budesonide (3) in various asthma models [24]. Further No 
Observable Adverse Effect Level (NOAEL) of ED after oral administration for 28 days was 
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found to be 2mg/kg in rats and dogs, and about 40 times higher than that of Budesonide 
[97]. 
The comparison of the transrepressing and transactivating activity of Etiprednol 
Dicolacetate (46) and Budesonide(3) were done by measuring their inhibition in 
interleukin(IL)-1 production of a simulated human monocyte cell line and by evaluating 
glucocorticoid-induced increase in the activity of tyrosine-amino-transferase ( TAT) of a rat 
hepatoma cell line respectively [99] and the measured activities were expressed relative to 
Dexamethasone (2) From the results it was found that ED (46) possesses less transactivating 
activity with a preserved transrepressing acivity, and hence ED is to be called as a 
dissociated glucocorticoid. Dissociation of transactivating ( carbohydrate metabolism 
altering) and transrepressing ( anti-inflammatory) activity found in Etiprednol 
Dicloacetate(ED) is a fruitful advantage in subsequent help in separating the most beneficial 
anti-inflammatory activity from the undesired side effects or adverse drug reactions 
(ADRs).A comparison of transrepression ( anti-inflammatory effect) and transactivation 
(carbohydrate metabolism altering) effects of dexamethasone (2), used as 100% reference, 
Budesonide (3) and Etiprenol Dicloacette (46) determined on an average of two experiments 
for concentrations of 10 -7 (98) is depicted in Figure 10 [24]. Hence this productive effort in 
developing dissociated glucocorticoids can be termed as one of the novel and sought after 
mechanistic approaches towards the development of newer glucocorticoid soft drugs [24, 
100,101].  
 
Figure 10. Literature reported [24] tentative comparison of transrepression (anti-inflammatory effect) 
and transactivation (carbohydrate metabolism altering) effects of dexamethasone (2)(used as 100% 
reference), Budesonide (3) and Etiprednol Dicloacetate (46) 
3. Conclusion 
Since the introduction of glucocorticoids in drug industry more than a half century ago, new 
series of glucocorticoids have been introduced for site specificity as well as for minimizing 
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systemic side effects. At the initial stage, several new generation glucocorticoids were 
developed using prodrug design approach involving changes or modifications made in 
glucocorticoid molecules introducing specific substituents at various specific positions of the 
basic glucocorticoid skeletons to obtain better skin penetration, slower enzyme degradation 
and greater affinity for the cytosol receptor. The term prodrug refers to a pharmacologically 
inactive molecule that is converted to an active drug by metabolic biotransformations that 
may occur prior, during or after adsorption or at specific target sites within the body. This 
approach has given several potent new generation glucocorticoids such as Budesonide (3), 
17-Prednicarbate (9), Fluticasone propionate (11), Methyl prednisolone aceponate (5), 
Beclomethasone (7) etc towards successful treatment of plethora of diseases including 
psoriasis, allergies, asthma, rheumatoid arthritis and lupus, with significantly minimized 
systemic side effects. However, all these old and new generation glucocorticoids are 
effective in reducing anterior segment inflammation only and not suitable for ophthalmic 
therapeutics as they are found to be associated with Adverse Drug Reactions (ADRs) 
including elevation of Intraocular Pressure (IOP) and steroid-induced cataract formation in 
case of ophthalmic therapeutics as they were not designed for ocular treatment. Successful 
eye-specific therapeutic agents can only be achieved by suitable drug-design approaches 
which thoroughly can integrate the specific pharmacological, metabolic, and targeting 
requirements of ophthalmic drugs. Chemical Delivery Systems (CDSs) and Retrometabolic 
Soft Drug Design approaches initiated by Prof.Nicholas Bodor and his group at the Center 
for Drug Discovery, University of Florida, Health Science Center, USA, are found to be quite 
successful with a major break through for this purpose providing flexible and generally 
applicable solutions. Their potential is indeed well illustrated by the results obtained with a 
number of soft -blockers and glucocorticoid soft drugs designed within this framework 
towards ophthalmic therapeutics. Soft -blockers, viz., Betaxoxime (29a), Adaprolol (33) and 
Glucocorticoid Soft drugs viz.,, Loteprednol Etabonate (41) and Etiprednol Dicloacetate (46) 
are some of the soft drugs developed by this retrometabolic drug design approach which 
have already reached the clinical development phase in various ophthalmic areas and one of 
them Loteprednol Etabonate (LE) is already being in the market as a promising 
glucocorticoid soft drug in ophthalmic therapeutics. Not only that, based on clinical results 
from animal studies, LE now also finds place in safer treatment of gastrointestinal 
inflammations and other diseases such as asthma, rhinitis and dermatological problems. 
Moreover dissociation of transactivating and transrepressing activity found in the second 
generation glucocorticoid soft drug, viz., Etiprednol Dicloacetate (ED) could open up a 
novel and promising mechanistic pathways towards the development of more and more 
potent glucocorticoid soft drugs in future. 
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As one class of the most important steroid hormones, glucocorticoids have long been 
recognised and their therapeutic benefits have been widely used in clinical treatment, 
especially in anti-inflammation cases. Glucocorticoids regulate various processes 
in the body including the mobilization of energy stores, immune functions, gene 
expression, and maintenance of the homeostasis as well as the stress response, this is 
not surprising that the concept of “glucocorticoids” is mentioned in almost all medical 
text books that focus on specific organs or systems such as the cardiovascular system, 
the immune system, and the neuroendocrine system. The book of Glucocorticoids - 
New Recognition of Our Familiar Friend aims to introduce the latest findings relating 
to glucocorticoids, either freshly from the laboratory or from clinical case studies, and 
to open up a new angle of looking at the issue of balancing the therapeutic benefits and 
side effects brought up by glucocorticoids.
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